<SEC-DOCUMENT>0001274737-24-000022.txt : 20240318
<SEC-HEADER>0001274737-24-000022.hdr.sgml : 20240318
<ACCEPTANCE-DATETIME>20240318092649
ACCESSION NUMBER:		0001274737-24-000022
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		82
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240318
DATE AS OF CHANGE:		20240318

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXAGEN INC.
		CENTRAL INDEX KEY:			0001274737
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39049
		FILM NUMBER:		24757107

	BUSINESS ADDRESS:	
		STREET 1:		1261 LIBERTY WAY
		CITY:			VISTA
		STATE:			CA
		ZIP:			92081
		BUSINESS PHONE:		(760) 560-1501

	MAIL ADDRESS:	
		STREET 1:		1261 LIBERTY WAY
		CITY:			VISTA
		STATE:			CA
		ZIP:			92081

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXAGEN DIAGNOSTICS INC
		DATE OF NAME CHANGE:	20031230
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>exdx-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:6a8da8f2-df0f-4e69-99e5-93009f0ad924,g:882e5611-3f00-4664-b088-e8c5528fafa2,d:7d27a7d8e3c749dabb1f235100af8228-->
<html xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:exdx="http://www.exagen.com/20231231" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2023" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>exdx-20231231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-33">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-34">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-35">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-36">0001274737</ix:nonNumeric><ix:nonNumeric contextRef="c-43" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="f-288">P3Y</ix:nonNumeric><ix:nonFraction unitRef="unit" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="f-331">one</ix:nonFraction><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-332">one</ix:nonFraction><ix:nonNumeric contextRef="c-5" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-387">http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-388">http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-43" name="us-gaap:LesseeFinanceLeaseTermOfContract1" id="f-440">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-445">http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-450">http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-455">http://fasb.org/us-gaap/2023#OperatingLeaseLiabilityNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-456">http://fasb.org/us-gaap/2023#OperatingLeaseLiabilityNoncurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="exdx-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">exdx:TwoSuppliersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">exdx:TwoSuppliersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:Government1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:Government1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:ClientMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:ClientMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="installment"><xbrli:measure>exdx:installment</xbrli:measure></xbrli:unit><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>exdx:segment</xbrli:measure></xbrli:unit><xbrli:unit id="unit"><xbrli:measure>exdx:unit</xbrli:measure></xbrli:unit><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-24</xbrli:startDate><xbrli:endDate>2023-10-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-28</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-28</xbrli:startDate><xbrli:endDate>2023-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:EquipmentNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:EquipmentNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:EquipmentNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">exdx:OfficeAndLaboratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">exdx:OfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">exdx:OfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:PrometheusLaboratoriesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="supplier"><xbrli:measure>exdx:supplier</xbrli:measure></xbrli:unit><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:AlleghenyHealthNetworkResearchInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exdx:AHNCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exdx:AHNCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">exdx:USDepartmentOfJusticeCaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-23</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:A2017TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:DebtOtherThanAmendedLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">exdx:ShelfRegistrationStatementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">exdx:CowenEquityDistributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-15</xbrli:startDate><xbrli:endDate>2022-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationJan192026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationMar312026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationApr12026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationSep72024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationDec72025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:NoExpirationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:IncentiveAwardPlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:IncentiveAwardPlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exdx:CommonSharesAvailableForGrantUnderThe2019PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:IncentiveAwardPlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">exdx:TaxYearsThroughDecember312017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i7d27a7d8e3c749dabb1f235100af8228_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">(Mark One) </span></div><div><span style="font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:115%"></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:2.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.883%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-4"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-3">December 31</ix:nonNumeric>, 2023</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from     to     .</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-39049</ix:nonNumeric></span></div><div style="text-align:center"><img src="exdx-20231231_g1.jpg" alt="Image_0.jpg" style="height:56px;margin-bottom:5pt;vertical-align:text-bottom;width:153px"/></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">EXAGEN INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:0.1%"/><td style="width:1.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">20-0434866</ix:nonNumeric></span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">1261 Liberty Way</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Vista</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-12">California</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">92081</ix:nonNumeric></span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.766%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">(760)</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">560-1501</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Registrant's Telephone Number, Including Area Code)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">XGN</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(g) of the Act: None</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-19">No</ix:nonNumeric> &#9746;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744; <ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-20">No</ix:nonNumeric> &#9746;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-21">Yes</ix:nonNumeric> &#9746; No &#9744; </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-22">Yes</ix:nonNumeric> &#9746; No &#9744; </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Securities Exchange Act of 1934. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.959%"><tr><td style="width:1.0%"/><td style="width:20.521%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.521%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.962%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.973%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-23">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-24">&#9746;</ix:nonNumeric></span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="f-25">&#9746;</ix:nonNumeric></span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="f-26">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on the attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="f-27">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-28">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-29">&#9746;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of June 30, 2023 (the last business day of the registrant's most recently completed second fiscal quarter), the aggregate market value of the registrant's common stock held by non-affiliates of the registrant was approximately $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="f-30">37.3</ix:nonFraction> million, based on the closing price of the registrant's common stock on the Nasdaq Global Market of $2.90 per share.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total shares of common stock outstanding as of the close of business on March&#160;14, 2024 was <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-31">17,235,751</ix:nonFraction>.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-32" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain information required to be disclosed in Part III of this report is incorporated by reference from the registrant's definitive Proxy Statement for the 2024 Annual Meeting of Stockholders, which proxy statement will be filed not later than 120 days after the end of the fiscal year covered by this Form 10-K.</span></div></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i7d27a7d8e3c749dabb1f235100af8228_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:76.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.305%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part I</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_13">Business.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_13">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_16">Risk Factors.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_16">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_19">Unresolved Staff Comments.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_19">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_549755814585">Cybersecurity</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_549755814585">.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_549755814585">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_22">Properties.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_22">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_25">Legal Proceedings.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_25">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_28">Mine Safety Disclosures.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_28">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part II</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_34">Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_34">72</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_37">[Reserved].</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_37">72</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_40">Management's Discussion and Analysis of Financial Condition and Results of Operations.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_40">73</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_55">Quantitative and Qualitative Disclosures About Market Risk.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_55">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_58">Financial Statements and Supplementary Data.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_58">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_61">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_61">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_64">Controls and Procedures.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_64">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_67">Other Information.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_67">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_70">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_70">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part III</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_76">Directors, Executive Officers and Corporate Governance.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_76">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_79">Executive Compensation.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_79">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_82">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_82">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_85">Certain Relationships and Related Transactions, and Director Independence.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_85">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_88">Principal Accountant Fees and Services.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_88">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part IV</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_94">Exhibits and Financial Statement Schedules.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_94">87</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_97">Form 10-K Summary.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_97">87</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_103">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_103">92</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_106">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_106">F-1</a></span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i7d27a7d8e3c749dabb1f235100af8228_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Part I</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Forward-Looking Statements and Market Data</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Annual Report on Form 10-K (the Annual Report), contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). All statements other than statements of historical facts contained in this Annual Report, including statements regarding our future results of operations and financial position, business strategy, current and future product offerings, reimbursement and coverage, the expected benefits from our commercial arrangements with third parties, research and development costs, timing and likelihood of success and plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. This Annual Report also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In some cases, you can identify forward-looking statements by terms such as "believe," "may," "will," "should," "predict," "goal," "strategy," "potentially," "estimate," "continue," "anticipate," "intend," "could," "would," "project," "plan," "expect," "seek," and similar expressions that convey uncertainty of future events or outcomes, are intended to identify forward-looking statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The forward-looking statements in this Annual Report are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Annual Report and are subject to a number of risks, uncertainties and assumptions described under the sections &#8220;Risk Factors&#8221; and elsewhere in this Annual Report. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we undertake no obligation to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We use our trademarks in this Annual Report as well as trademarks, tradenames and service marks that are the property of other organizations. Solely for convenience, certain trademarks and tradenames referred to in this Annual Report may appear without the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and &#8482; symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not assert its rights, to these trademarks and tradenames. </span></div><div style="margin-top:9pt"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i7d27a7d8e3c749dabb1f235100af8228_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 1. Business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Company Overview </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exagen exists to provide clarity in autoimmune disease decision making with the goal of improving patients' clinical outcomes. We have developed and are commercializing a portfolio of innovative testing products, under our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> brand, which allow for the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases. We believe our strong focus and extensive background in the field of rheumatology, combined with our commitment to exceptional customer service and support, position us well to respond to the needs of rheumatologists and the patients they serve.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We commercially launched our lead testing product, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD, in 2012. AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD enables differential diagnosis for patients presenting with symptoms indicative of a wide variety of connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The comprehensive nature of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD allows for the testing of a number of relevant biomarkers in one convenient blood draw (as opposed to testing serially for individual biomarkers, which adds time and cost to the diagnostic process). We believe AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD may provide clinical utility for more than 41 million individuals in the United States, encompassing patients with conditions like systemic lupus erythematosus (SLE); rheumatoid arthritis (RA); Sj&#246;gren&#8217;s syndrome, antiphospholipid syndrome (APS); other autoimmune-related diseases, such as autoimmune thyroid; and disorders that mimic these diseases, such as fibromyalgia. There is an unmet need to add clarity for rheumatologists in their CTD clinical evaluations. As a result, we believe there is a significant market opportunity for our tests, which enable the differential diagnosis of these diseases, particularly, for potentially life-threatening diseases such as SLE.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Included in AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD is our proprietary AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test, which enables the diagnosis of SLE based on levels of erythrocyte bound C4d (EC4d) and B cell C4d (BC4d); along with anti-nuclear antibodies (ANA) and double-stranded DNA antibodies (ds-DNA). AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus provides rheumatologists and their patients with sensitive and specific results that allow for more accurate and potentially faster differential diagnosis of SLE, as compared to other currently-marketed testing methods. Beyond SLE, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD also allows rheumatologists to accurately diagnose other overlapping autoimmune and autoimmune-related diseases (including RA), with the same blood sample.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> SLE Monitor test leverages CB-CAPs technology to measure biomarkers that offer insight into a patient&#8217;s disease activity. This test is designed to enable rheumatologists to effectively assess and optimize therapeutic intervention in patients diagnosed with SLE. Depending on disease severity, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> SLE Monitor may be utilized by patients multiple times a year throughout their lives.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our RA testing products include AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> MTX and AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Anti-CarP. AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> MTX is a drug monitoring test designed to aid in the optimization of methotrexate therapy, the standard of care and first-line therapy for patients with RA. AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> MTX is based on our methotrexate polyglutamate (MTXPG) technology that measures blood levels of MTXPGs, the active metabolite of methotrexate linked to disease control in RA patients. Measuring MTXPGs allows rheumatologists to identify patients presenting with inadequate exposure to methotrexate, enabling them to optimize dosing and achieve therapeutic levels commensurate with adequate disease control. AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Anti-CarP was developed by the Leiden University Medical Center and measures anti-carbamylated protein antibody (anti-CarP). We introduced it as a biomarker-driven RA prognostic test, through a distribution agreement with Werfen USA, LLC, with the goal of identifying patients prone to more severe disease.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We market our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">testing products using our specialized sales force. Since the launch of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD in 2012 and through December&#160;31, 2023, we have delivered approximately 887,000 of these tests. For the year ended December&#160;31, 2023, 137,650 AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD tests were delivered, representing an approximate 2% increase over 2022. In the fourth quarter of 2023, the number of ordering healthcare providers reached 2,383 compared to 2,419 in the same period in 2022.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we continue to populate a growing proprietary database of de-identified patient test results from our clinical studies and our clinical laboratory. We believe the insights from these results have the potential to unlock value for pharmaceutical and biotechnology companies in the development and commercialization of therapeutics. We believe we also have the ability to further leverage our database to optimize patient selection in clinical trials for companies developing therapeutics for autoimmune and autoimmune-related diseases.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Our Strategy </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We address the unmet needs of those suffering from debilitating and chronic autoimmune disorders through aiding in differential diagnosis, prognosis, monitoring and therapeutic selection, to ultimately improve clinical outcomes for patients. The key tenets of our business strategy include:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.46pt">Focus on our flagship product, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"> CTD.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We have demonstrated a solid track record of commercial growth of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test. We believe we are uniquely positioned to continue expanding our commercial presence within the autoimmune disease market by leveraging our specialized sales force and expansive network of relationships with rheumatologists across the United States. Using our specialty laboratory focused on rheumatology, we plan to build upon industry-leading quality, service and technology to support strong AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD adoption and continue to grow our ordering physician base. </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.46pt">Continue developing innovative testing products, using clear criteria for R&amp;D projects and commercialization milestones. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We intend to leverage our protein and molecular assay development capabilities, bioinformatic team and proprietary technologies to pursue the development of additional testing products designed to have superior clinical utility for CTDs. We undertake research projects that have the potential for impactful results and address the top consumer needs in the rheumatology space. The research projects we support are those that we believe will have a competitive advantage (such as using proprietary technology), a pathway for reimbursement and an established evidence development plan with sufficient market size. Criteria for developed products that we ultimately commercialize include Medicare coverage (specific to patient population), proprietary value-based pricing, published clinical utility and a strategy for medical guideline inclusion.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.46pt">Maintain meaningful margin. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We seek to maintain meaningful margin by continuing to focus on increasing operating leverage through the implementation of certain internal initiatives, such as leveraging validation, utility and reimbursement-oriented clinical studies to facilitate payor coverage of our testing products. We center our efforts on long-term reimbursement and average sales price (ASP) growth. This strategy includes optimizing revenue cycle practices, focusing managed care efforts on medical policy expansion and continuing to educate insurance payors on the published, real-world evidence of the clinical utility of our testing products, demonstrating healthcare cost savings and reductions in time to diagnosis.</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We also seek to improve our per-test costs by focusing on profitable, core test offerings, minimizing fixed costs and overhead, and focusing our laboratory resources on AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD optimization. Additionally, we employ a streamlined salesforce covering territories which are designed to achieve the most efficient and effective reach and frequency for the promotion of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Autoimmune and Connective Tissue Diseases (CTDs)</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Autoimmune diseases encompass a broad range of serious, chronic and debilitating conditions in which a person&#8217;s immune system creates antibodies that mistakenly react against normal healthy tissues, causing inflammation and irreversible tissue damage. These antibodies are called autoantibodies and their detection through blood tests can help diagnose, prognose and monitor the course of autoimmune diseases. However, knowing when to test and which autoantibody to test for is challenging due to the vagueness of symptoms, the unexplained flaring and remission of symptoms, and the many conditions which can mimic autoimmune disease. Early and accurate diagnosis of the conditions causing these overlapping symptoms is critical, as an incorrect diagnosis can lead to toxicity from inappropriate medications, irreversible tissue damage and other comorbidities associated with uncontrolled disease. There is no known cause or cure for these chronic conditions and current treatment interventions are targeted at managing symptoms and limiting disease progression. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CTDs are a sub-category of autoimmune diseases involving inflammation of the joints, tissues and internal organs. Persons with CTDs often present to their rheumatologist with complaints of joint pain, fatigue, unexplained fever, inflammation, rash, stiffness and muscle aches. These symptoms overlap among numerous CTDs, including SLE, one of the most severe CTDs, which historically has been difficult to rule out, as well as other autoimmune-related diseases and other disorders that mimic these diseases, such as fibromyalgia. The National Institute of Environmental Health Sciences estimates that there are approximately 41 million patients in the United States with existing cases of autoimmune diseases. Of these patients, we estimate approximately seven million are potentially referable to rheumatologists and would be candidates for an AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test, representing a total addressable market of approximately $7.5 billion, based on the current Medicare allowable reimbursement rate. We estimate the total addressable market for our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products to be approximately $9.2 billion, based on estimated patient populations, the current Medicare allowable reimbursement rate and testing frequencies. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Systemic Lupus Erythematosus </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">SLE, the most common and severe form of lupus, is a chronic, inflammatory disorder that can damage any part of the body, including the skin, joints and internal organs. The blood of a person afflicted with SLE contains autoantibodies, which are the cause of the inflammation and organ damage and are one indicator of immune system abnormalities. SLE is characterized by a rise in symptoms and/or abnormal laboratory test results. SLE </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">varies in severity, from mild cases to those in which significant and potentially fatal damage occurs to vital organs such as the brain, heart, kidneys and lungs. Detection of these autoantibodies can assist rheumatologists in the diagnosis of SLE. Diagnosis of SLE allows rheumatologists to initiate the most appropriate therapy to minimize irreversible organ damage and reduce morbidity and mortality. Current treatment for SLE involves the use of antimalarials, corticosteroids, immunosuppressants and biologic agents to prevent or suppress active disease or flares. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Standard laboratory tests for diagnosing SLE include measuring immunological biomarkers, such as ANA, anti-double stranded DNA (anti-dsDNA) and other autoantibody tests. ANA are a group of autoantibodies produced by a person&#8217;s immune system when it fails to adequately distinguish between self and non-self. The ANA test detects these autoantibodies in the blood and is a useful screening tool for SLE and other autoimmune and autoimmune-related diseases. The vast majority of SLE patients test positive for ANA. However, the high sensitivity of ANA for SLE is counterbalanced by somewhat poor specificity. According to Dinse et al. (2022), who investigated the increasing prevalence of ANA in the United States using data from the National Health and Nutrition Examination Survey, approximately 0.7%&#8211;2.4% of individuals with a positive ANA test have SLE. This lack of specificity leads to many inappropriate non-autoimmune referrals to the rheumatologist from primary care physicians. For example, it has been reported that 30% of fibromyalgia patients may test positive for ANA, potentially generating as many as four million inappropriate rheumatology referrals. In addition, the Dinse et al. study reported the estimated prevalence of a positive ANA test in the normal, healthy, U.S. population to be 16.1% (approximately 41.5 million people), indicating a significant need for a highly specific test for this disease.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Anti-dsDNA are autoantibodies that target a person&#8217;s double-stranded DNA. The anti-dsDNA antibody test is a very specific test for SLE, as anti-dsDNA antibodies are rarely found in autoimmune diseases other than SLE. A strongly positive anti-dsDNA antibody test makes it very likely that a person has SLE, although if the test is negative it does not necessarily rule out SLE. Many people with SLE have a negative anti-dsDNA antibody test, reaffirming the need for an effective testing product which adds clarity to the rheumatologist&#8217;s clinical assessment.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Activation of the complement system is an integral part of the disease process of SLE. Thus, rheumatologists measure components of the complement system, including serum levels of C3 and C4, to help diagnose SLE and monitor SLE disease activity. In 2012, the Systemic Lupus Collaborating Clinics added low C3 and low C4 as immunologic criteria for classifying SLE. In active SLE, C3 and C4 complement proteins are consumed and broken down to fragments, known as complement activation products. Therefore, low levels of C3 and C4 suggest a diagnosis of SLE and that the disease is active. However, variability in the levels of C3 and C4 can occur due to factors unrelated to SLE disease presence or disease activity, making them less reliable as biomarkers for SLE. For example, C3 and C4 are acute-phase reactants and produced during inflammation. As a result, many SLE patients have normal complement levels even when the disease is active. Although relatively specific for SLE, low complement levels can also be seen in certain chronic infections, including non-lupus-related kidney inflammation, severe liver disease and other autoimmune diseases. CB-CAPs are formed when the fragments of complement activation products from C4 bind permanently to circulating cells such as red blood cells, b-cells and platelets. This binding lasts for the life of the cell and represents a more stable and reliable indicator of complement activation than measuring C3 and C4 alone.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2011, the first new biologic targeting treatment of SLE in over 50 years, GSK&#8217;s Benlysta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, was approved by the U.S. Food and Drug Administration (the FDA). In December 2020, the FDA approved this biologic drug for the treatment of adult patients with active lupus nephritis who are receiving standard therapy. Since Benlysta</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">'s approval, there have been a number of drug development programs that have failed in SLE, which may suggest that guidelines for classifying SLE patients and the endpoints used to determine clinical effectiveness have not adequately addressed the complexity of the disease process and its heterogeneous population.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Rheumatoid Arthritis </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">RA is a chronic, systemic autoimmune disease in which the immune system attacks the joints and can also affect other organ systems. The annual incidence and prevalence of RA in the United States is estimated to be 135,000 and 1.5 million, respectively. Patients suffering from RA develop joint damage that is associated with painful inflammation and often progresses to irreversible damage of cartilage and bone, leading to significant disability and a reduction in quality of life and the ability to work. Early diagnosis and effective treatment of RA is critically important to prevent erosive bone or joint damage and disability. Rheumatologists are compelled to reach a definitive diagnosis quickly and administer effective treatment. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Diagnosis of RA involves performing a complete medical history with physical and/or radiographic examination of the number and distribution of swollen, tender and painful joints that have persisted for more than six weeks. Laboratory testing for rheumatoid factor (RF), anti-cyclic citrullinated peptide (CCP) antibodies and testing for </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">general, nonspecific inflammation with erythrocyte sedimentation rate (the ESR) and C-reactive protein tests are used to assist in the diagnosis. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The standard of care for the treatment of RA involves the use of Disease Modifying Anti-Rheumatic Drugs (DMARDs) which have shown, in clinical studies, the ability to slow or stop disease progression. Methotrexate remains the most commonly used DMARD, due to its low cost and effectiveness, as well as the extensive clinical experience with its use. It is estimated that approximately 90% of RA patients in the United States, or 1.3 million patients, are treated with methotrexate, either as a monotherapy or in combination with another DMARD. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biologics DMARDs are proteins that have been genetically modified to target cellular components of the immune system that attack healthy tissues, causing the symptoms of RA. They are a targeted form of therapy, which makes them different from traditional RA treatments, such as methotrexate. The first FDA approved biologics for RA were the anti-TNFs. The anti-TNFs dominate the therapy for RA and generally are the first biologics chosen to augment methotrexate when patients are not achieving a satisfactory response. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Our Solution </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We market testing products under our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> brand that allow for the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and RA. We are focused on leveraging our sales channel targeting the approximately 4,500 rheumatologists across the United States to promote use of our product portfolio.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our Proprietary Technologies </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe the competitive advantage for our testing products is supported by core proprietary technology, namely our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Lupus Test </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test, which we offer as a stand-alone test and as part of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test panel, is a proprietary, clinically validated method to aid in the diagnosis of SLE that provides a significant improvement in sensitivity, relative to the current standard of care. The AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test leverages CB-CAPs technology, which determines the blood levels of complement activation proteins permanently deposited on hematopoietic cells. The determination of complement proteins in a patient&#8217;s blood is a mainstay in clinical laboratory science, and state-of-the-art methods traditionally rely on measurement of serum or plasma levels of soluble complements. C3 and C4 are the most commonly determined complement proteins in the blood and the precursors to activation of complement proteins into biologically active breakdown products. However, there are limitations with measuring C3 and C4 blood levels as indicators of complement activation. For example, increased synthesis of C3 and C4 by the liver can offset increased C3 and C4 breakdown during activation of the complement cascade, resulting in no change in serum levels. While the limitations and drawbacks of measuring standard components of the complement system, such as C3 and C4, are well recognized by the medical community, these laboratory biomarkers are part of international guidelines for the classification of SLE.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe the availability of novel complement biomarkers combined with algorithmic interpretations, as a support or replacement of standard C3 and C4 measures, is of great value for rheumatologists and their patients. CB-CAPs technology directly measures protein products of complement activation, such as C4d, the product of C4 activation. These complement activation products become stably attached to surfaces of circulating blood cells to become CB-CAPs. As such, the determination of CB-CAPs in the blood provides benefits when compared to the traditional complement measurement. These include the stable, accurate and unequivocal information of complement activation that enable consistent measurement and an improved ability to assess and monitor changes in biological activity related to activation of the complement system. In a clinical validation study published in 2014 by Chaim Putterman, et al. (the 2014 Study), EC4d and BC4d showed 22% higher sensitivity (66%) than C3 and C4 (44%) in diagnosing SLE, with specificity fixed at 91%.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our proprietary AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test integrates EC4d and BC4d with 8 autoantibodies to yield a quantitative and qualitative assessment of SLE risk. The AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test was designed to improve upon the diagnostic sensitivity of conventional biomarkers used to diagnose SLE while maintaining a high degree of specificity. In the aforementioned 2014 Study, the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test demonstrated 80% sensitivity for SLE (meaning 8 out of 10 diagnosed SLE patients tested positive) and 86% specificity for SLE (meaning 86% of non-SLE control subjects with other rheumatic conditions tested negative). A later study published in 2022 by Tyler O&#8217;Malley, et al., compared the clinical utility of the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test to the conventional biomarker strategy in the diagnosis of SLE, demonstrating 6-fold increased odds of SLE diagnosis and 3-fold increased odds of treatment initiation with a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">positive AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus result. We believe this patent-protected test gives us a significant advantage over our competitors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Testing Products </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since inception, we have been committed to developing and commercializing innovative testing products that address the challenges rheumatologists face in differentially diagnosing, prognosing and monitoring complex autoimmune and autoimmune-related diseases. We estimate the total addressable market for our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products to be approximately $9 billion, based on estimated patient populations, the current Medicare allowable reimbursement rate and testing frequencies. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Diagnosis </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"> CTD </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our lead testing product, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD, is a comprehensive test that aids in the differential diagnosis of SLE versus other common CTDs. AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD includes our proprietary AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test, which leverages CB-CAPs technology to specifically measure activation of the complement system. In addition to testing for SLE, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD tests for a series of biomarkers in one convenient blood draw to aid in the differential diagnosis of a wide variety of CTDs and other diseases which can be challenging to diagnose as a result of overlapping symptoms. These diseases include SLE; RA; Sj&#246;gren&#8217;s syndrome; APS; other autoimmune-related diseases, such as autoimmune thyroid; and other disorders that mimic these diseases, such as fibromyalgia. Use of our test significantly enhances the rheumatologist's ability to exclude SLE and differentiate other CTDs, resulting in a clearer assessment and ultimately increasing the efficiency and accuracy of the broader diagnostic process. The clinical performance of our proprietary AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test, combined with the convenience of a single blood draw, make AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD an attractive choice among rheumatologists.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"> Lupus </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our proprietary AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test is the cornerstone of the SLE assessment within our more comprehensive AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD testing product. AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient&#8217;s blood. These biomarkers are elevated in patients with SLE compared to patients with other CTDs. Next, the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test integrates these cell-bound complement products with 8 autoantibodies to yield a quantitative and qualitative assessment of SLE risk. Rheumatologists choose to order the comprehensive AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test or the more focused AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test based on medical necessity, which is determined by each patient&#8217;s symptoms and medical history. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"> APS </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">APS consists of a specialized panel of autoantibody tests. This test aids in both the diagnosis and management of APS, a hyper-coagulation state leading to thrombosis, pregnancy complications and even death. Rheumatologists would typically request the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> APS test in patients who initially tested positive for one or more APS biomarkers contained in AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD, or in the management of patients experiencing a high-risk pregnancy.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"> Vasculitis AAV </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Vasculitis AAV utilizes a testing panel of individual analytes designed to provide physicians with rapid and reliable results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV). AAV is a group of autoimmune diseases characterized by vascular inflammation and damage. Early signs and symptoms vary greatly and are not always indicative of the severity of the disease. Rapid and accurate testing is essential to prevent death and long-term disability.  </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Prognosis </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"> SLE Prognostic </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> SLE Prognostic is a panel of autoantibodies that have established predictive value for assessing the potential for complications affecting the kidney, brain and cardiovascular system, including lupus nephritis, lupus psychosis, strokes and heart attacks related to lupus. Rheumatologists rely on insights from the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> SLE Prognostic test to help tailor their treatment approach. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"> Anti-CarP </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Anti-CarP, developed by the Leiden University Medical Center, measures anti-CarP. We introduced it as a biomarker-driven RA prognostic test, through a distribution agreement with Werfen USA, LLC, with the goal of identifying patients prone to more severe disease. With the introduction of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Anti-CarP in 2018, we became the first commercial laboratory to make testing for anti-CarP available in the United States. This test uniquely addresses two major challenges facing rheumatologists today &#8211; (1) patients presenting with RA symptoms but lacking the common confirmatory blood tests for anti-RF or anti-CCP, known as sero-negative patients, and (2) the lack of a serologic indicator, which indicates a poor prognosis and helps guide treatment decisions. Anti-CarP can be positive in up to 26% of RA patients who are negative for anti-CCP. Furthermore, RA patients positive for Anti-CarP have an increased risk for more severe RA disease, including permanent joint damage</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Monitoring </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"> SLE Monitor</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> SLE Monitor is a blood test that employs CB-CAPs technology and is intended to assess the condition of a patient that has been diagnosed with SLE. It offers a unique combination of biomarkers that measure for EC4d, which has shown greater accuracy in tracking disease activity than C3 and C4, which is associated with thrombosis risk in SLE. AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> SLE Monitor offers additional insight into a patient&#8217;s disease activity as well as possible adverse events. Rheumatologists have limited methods for evaluating the extent of disease activity taking place inside the body of an SLE patient. They rely on imperfect biomarkers, overt symptoms or flares and patient reported history. All of these leave the rheumatologists looking for greater insights, especially in cases where patients under report their symptoms, a bias which healthcare providers may not fully appreciate. AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> SLE Monitor demonstrates correlation to SLE disease activity and is therefore designed to enable rheumatologists to effectively assess and optimize therapeutic intervention in patients diagnosed with SLE. Additionally, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> SLE Monitor measures EC4d, anti-C1q, C3, C4 and anti-dsDNA which can assist physicians with managing their lupus nephritis patients. Depending on disease severity, our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> SLE Monitor testing product may be utilized by patients multiple times a year and throughout their lives. We believe AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> SLE Monitor will play an increasingly important role in the management of SLE patients and further solidify the role and relationship of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products for these patients. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"> MTX </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">MTX is a patented and validated blood test that precisely measures blood levels of MTXPG, the active metabolite of methotrexate linked to disease control in RA patients. There is large variability in the way patients absorb and metabolize methotrexate, leaving rheumatologists unsure of what steps to take when a patient has an inadequate response. Methotrexate is the most widely prescribed drug by rheumatologists in the treatment of RA. Measuring MTXPGs allows rheumatologists to identify patients presenting with inadequate exposure to methotrexate, enabling them to optimize dosing and achieve therapeutic levels commensurate with adequate disease control. When faced with a patient who is not responding to methotrexate therapy, the options include increasing the dose, switching to a parenteral delivery method and/or advancing to a more costly biologic therapy. AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> MTX provides crucial information as to whether a patient has achieved MTXPG blood levels consistent with an appropriate response to methotrexate, also known as the therapeutic level, or if the MTXPG blood levels are too low to produce adequate effects. MTXPG blood levels are actionable clinical utility checkpoints and can help clinicians identify causes for a lack of response to methotrexate, such as poor activation to active metabolites, underexposure secondary to poor absorption or poor compliance, all of which are limiting factors to the achievement of a robust clinical response with this first-line treatment. AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> MTX can allow rheumatologists to make more informed therapeutic decisions in their efforts to optimize methotrexate therapy and give patients their best chance at achieving an optimal response. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"> HCQ </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> HCQ is a blood test designed to help rheumatologists objectively monitor levels of hydroxychloroquine (HCQ), in whole blood as they treat patients with SLE and other CTDs, including RA. HCQ is typically prescribed to patients to control SLE disease activity and prevent flares. However, there is large variability in the response to HCQ therapy, the drug can sometimes take weeks or months to have a therapeutic effect and compliance has been documented to be an issue in CTD patients. We believe measuring HCQ makes the patient accountable, and also helps to determine whether HCQ blood levels are adequate and consistent with clinical efficacy. The addition of new and costly biologic therapies approved for the treatment of SLE may drive interest by all healthcare stakeholders, especially payors, to adopt an approach that optimizes a generic drug before advancing to a costlier alternative. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Test Reports</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We provide the results of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products in a comprehensive and easy-to-understand test report, typically sent to rheumatologists within five business days following receipt of the blood specimen. As shown below, the result of the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus portion of the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD report displays a gradient illustrating the likelihood of the presence of lupus, which facilitates interpretation and discussion of the result with the patient versus only reporting a numerical value. In addition, all biomarker results for AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD are reported and organized by disease state, providing clarity and convenience for the rheumatologists. A sample of the full AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD report is shown below: </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CTD Report </span></div><div style="margin-top:9pt;text-align:center"><img src="exdx-20231231_g2.jpg" alt="CTD Test Report page 1.jpg" style="height:867px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:center"><img src="exdx-20231231_g3.jpg" alt="CTD Test Report page 2.jpg" style="height:890px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Our Pipeline and Growth Opportunities </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We regularly confer with national experts in the clinical management of rheumatic autoimmune diseases to help guide the organization&#8217;s leadership team on the design and execution of research projects, as well as weigh-in on known and anticipated advances in technologies affecting clinical management of autoimmune diseases. We believe there is significant potential to capitalize on our proprietary technologies by integrating with commercially validated biomarkers to develop testing products with superior clinical utility. The complement pathway is widely implicated in the pathogenesis of a variety of conditions, including autoimmune diseases and organ transplant rejection. We believe the stability and reliability of CB-CAPs technology, in combination with increased specificity provided by our patent-protected AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test, will allow us to produce meaningful and differentiated proprietary solutions for rheumatologists.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">TC4d, TIgG and TIgM Biomarkers</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our collaborative efforts with the Allegheny Health Network Research Institute (AHN) have resulted in further development of three innovative biomarkers (TC4d, TIgG, and TIgM), for which we obtained an exclusive, worldwide license from AHN in May 2021. These markers exhibit a high degree of specificity for lupus and are more sensitive for lupus compared to conventional biomarkers. The objective is to incorporate these three biomarkers into the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test in order to enhance the diagnostic sensitivity for lupus beyond its current 80% level. Additionally, TC4d represents a proprietary expansion of our existing CB-CAPs portfolio, involving a similar biochemical process wherein complement activation products are measured on T-cells. We believe the inclusion of these markers in our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test could further amplify its sensitivity, thus facilitating earlier detection of disease, and further differentiating our test in the market.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">CTD RA Sub-Profile</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Approximately 70-80% of RA patients show serological evidence of RA, identified by key biomarkers: anti-CCP and Rheumatoid Factor. The remaining 20-30% of patients, despite lacking these serological markers, are clinically diagnosed with RA; this subgroup is referred to as &#8220;seronegative RA.&#8221; These patients often face delays in diagnosis due to the absence of serological evidence. In cases of early inflammatory arthritis, differential diagnosis is broad, including conditions like reactive arthritis, crystal arthropathy, spondyloarthropathy, and other systemic rheumatic diseases such as SLE and Sjogren&#8217;s syndrome, alongside seronegative RA. Accordingly, identifying unique biomarkers specific to seronegative RA may bridge this diagnostic gap, enabling more timely and targeted treatment plans for these patients. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Lupus Nephritis Biomarkers</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lupus nephritis (LN) is an autoimmune disease and a frequent complication in people who have SLE. It causes the immune system to produce proteins called autoantibodies that attack the body's own tissues and organs, including the kidneys. If left untreated, LN can lead to significant health problems, permanent kidney damage and even death. Early diagnosis and treatment are key to managing LN and to preventing it from escalating. Although early onset of LN is not typically noticeable by patients, nearly 40% of SLE patients go on to develop LN. Currently, urinary protein to creatine ratio measurement is the standard means of assessing kidney involvement; however, it is not necessarily indicative of kidney prognosis or treatment response. We aim to leverage intellectual property licensed from Johns Hopkins University (JHU) to develop a test for detecting protein analytes in urine that can aid rheumatologists in the ongoing management and risk stratification of patients suffering from LN.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> SLE Monitor (2.0)</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">SLE is characterized by a chronic, systemic inflammatory burden, and disease progression is defined by the accumulation of irreversible organ damage typically resulting from chronic inflammation and/or chronic corticosteroid use. Among the challenges for rheumatologists responsible for the care of lupus patients is the unpredictability of the disease course defined by periods of waxing and waning episodes of inflammation. The unpredictable nature of SLE and the lack of reliable conventional biomarkers indicative of present and near-term disease activity results in a significant unmet need for a surrogate method to monitor disease activity. Our goal is to leverage clinical and laboratory data collected across multiple longitudinal SLE cohorts to identify a set of biomarkers that can inform an AI-developed algorithm aimed at guiding ongoing treatment decisions throughout the course of a lupus patient&#8217;s journey.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Sales and Marketing </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We employ a specialized sales force focused on targeting the approximately 4,500 rheumatologists across the United States. Our sales representatives generally have extensive experience in healthcare sales with backgrounds </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">in rheumatology, diagnostics and/or pharmaceutical sales. In addition, our sales representatives complete a comprehensive disease-level sales training program and are required to participate in regular, ongoing training activities and certifications. Our goal is for our sales representative to be viewed as a collaborative resource to the rheumatologists and their practice.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our field-based sales force is organized into 40 territories within the following four regions: West, Central, Northeast and Southeast. We also maintain an inside sales force that helps further our access to rheumatologists located in rural and outlying areas of the United States and works to increase our brand awareness with healthcare providers in these areas. We continually evaluate our sales force's reach and frequency of interactions with rheumatologists, including as we launch our pipeline products. Our specialized sales force and marketing activities are further augmented by our centralized, dedicated client services department. Our client services department uses its high level of technical training to enhance sales efficiency and customer satisfaction by providing personalized customer support.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Adoption and Growth through Quality Testing and Service</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our focus on quality allows for a dedicated sales approach based on a commitment to understanding the needs of both provider and patient. By raising awareness of the benefits AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing provides, our sales team is able to deliver quality testing and support services to providers, and ultimately, their patients. To ensure our marketing and sales efforts are reaching those that we believe could benefit most from AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, we emphasize execution in three core areas: targeting, messaging and call frequency. We strategically target the highest-potential practices by utilizing various data sources (e.g., market analytics, demographic data, historical therapeutic usage and diagnostic product trends). Furthermore, we believe the increased access afforded by our testing products will allow for patient-focused messaging</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and the increased accuracy of our testing products over current standard of care diagnostic methodologies. Finally, we execute a high-frequency promotional strategy for our top-targeted rheumatologists and their office personnel to build knowledge, understanding and retention of the benefits of our testing products. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We plan to leverage core channels for building awareness and adoption, including our participation with multiple patient advocacy organizations and medical societies, such as the American College of Rheumatology (ACR). We have also established strong relationships with multiple rheumatology care management organizations (Super Groups), which can be key in influencing favorable reimbursement. Our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> MTX testing product has been included in the clinical guidelines for two of these groups. We believe our experience with advancing a testing product from initial development through clinical adoption differentiates us and uniquely positions us to replicate success with our other testing products. Beyond working with these Super Groups, we intend to continue to augment field selling activity with a balanced marketing mix, including print and digital advertising, direct marketing, continuing medical education programs and working with key opinion leaders to support peer-to-peer educational events.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Reimbursement, Clinical Validation and Clinical Utility </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Reimbursement </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The primary source of revenue for our products is reimbursement from third-party payors and client bill arrangements. Third-party payors include government payors (such as Medicare and Medicaid) and commercial payors (such as insurance companies). Achieving and maintaining broad coverage and reimbursement from third-party payors, including Medicare, for our commercialized and pipeline products is a key determinant of our revenue, financial results and future growth.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are actively engaged in efforts to achieve broad commercial coverage and reimbursement for our current and future products, including contracting with commercial payors. Achieving positive coverage reduces the need for appeals and reduces failures to collect from the patient&#8217;s insurance. Additionally, achieving in-network contracts with commercial payors can shorten the time required to receive payments. Our approach to commercial payment is centered on working toward inclusion in clinical guidelines and individual payor medical policies. We seek to accomplish this through continued evidence development and publication, medical director engagement and individual claim-based appeal efforts, detailed as follows: </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt">Meet the evidence standards necessary to be consistent with leading clinical guidelines. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe inclusion in leading clinical guidelines plays a critical role in payors&#8217; coverage decisions. In order to change clinical guidelines, tests must carry a high level of published evidence demonstrating analytical validity, clinical validity, clinical utility and cost-effectiveness. When studies with such evidence are published in peer-reviewed journals, the authors of clinical guidelines may assess the level of evidence and determine whether modifying existing guidelines to include new technology is warranted.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt">Execute an internal managed care policy and claims adjudication function as part of our core business operations.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We employ a team of in-house claims processing and reimbursement specialists who work with patients and payors to obtain maximum reimbursement. In parallel, a managed care team collaborates with our reimbursement specialists to ensure our payor outreach strategy reacts to and anticipates the changing needs of our customer base. Overall, we work to address payors at the national level in addition to high-claim-volume regional payors we have identified based on our current territory coverage.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.46pt">Cultivate a network of key opinion leaders. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Key opinion leaders are able to influence clinical practice by publishing research and determining whether new tests should be integrated into clinical guidelines. We collaborate with key opinion leaders early in the development process to ensure our clinical studies are designed and executed in a way that clearly demonstrates the benefits of our testing products to healthcare providers and payors.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While we have contracts for reimbursement with a limited number of commercial payors, we are actively pursuing additional commercial payor contracts. When we contract to serve as a participating provider, reimbursements are made pursuant to a percentage of our charges or a negotiated fee schedule amount. For in-network and out-of-network claims for which we are not reimbursed in full (or receive a claim denial), we may elect to appeal the insurer&#8217;s underpayment (or denial of payment) or seek payment from the patient.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Clinical Validation </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We demonstrated the clinical validity of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus in a study of 794 patients conducted from 2010 to 2014 across multiple leading academic centers. The primary endpoint of the study was the specificity and sensitivity of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus compared to common autoantibodies used to diagnose SLE and other CTDs, such as ANA and anti-dsDNA. The final results of this study showed that AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus demonstrated 86% specificity and 80% sensitivity in distinguishing SLE from other CTDs and fibromyalgia. Additionally, the results showed that AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus was 33% more specific than ANA (53% specificity/89% sensitivity) and 48% more sensitive than anti-dsDNA (32% sensitivity/97% specificity). </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We further demonstrated the clinical validity of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus for detection of probable SLE (pSLE) in a 246 subject, multi-center, prospective, cross-sectional study, first published in the Arthritis &amp; Rheumatology Journal in September 2019. The objective of this study was to evaluate the frequency of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus and CB-CAPs as a marker of complement activation in patients with pSLE and the usefulness of the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test as a predictor of the evolution of pSLE into classified SLE by the ACR criteria. Of the 92 pSLE patients, more pSLE were positive for CB-CAPs (28%) or AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus (40%) than for low complement (9%) at the enrollment visit (p=0.0001, for each) and an AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus index score &gt;0.08 prospectively associated with the development from pSLE to SLE by ACR classification criteria within 18 months (hazard ratio = 3.11, p&lt;0.01).</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Clinical Utility </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have collaborated with both academic and community clinicians to demonstrate the clinical utility of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus versus standard diagnostic tests in physician diagnosis, impact on patient management decisions, patient reported outcomes and health economics.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We sponsored a longitudinal, case-control, retrospective review of medical charts in 2016 to assess the value and clinical utility of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus to rheumatologists. The results of this study were published in the Open Rheumatology Journal in 2016 and suggested that a positive AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test aids in the diagnosis of SLE versus standard diagnostic tests.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In early 2018, we initiated CARE for Lupus, a prospective, randomized, multi-site study to assess the performance of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus versus standard diagnostic laboratory tests (SDLT). A total of 145 patients were enrolled across 32 sites between July 2017 and December 2018, with 73 patients enrolled in the SDLT group and 72 patients in the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus group. The CARE study was published in September 2019 in Lupus Science &amp; Medicine. Results among patients who tested positive for AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus (n=9) showed 44% in the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus group had a higher likelihood of SLE, compared with 9% in the SDLT group (p=0.127). Among patients who tested negative for AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus (n=63), 60% in the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus group had a lower likelihood of SLE, compared with 37% in the SDLT group (p=0.012). In the group of patients randomized to the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus group, positive test results associated significantly with initiation of prednisone (p=0.03) and a similar trend was observed with HCQ therapy (p=0.11). Finally, in the group of patients randomized to the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus group, a positive test result associated with an increase in patient-reported outcomes measuring health-related quality of life using five-level EQ-5D (EQ5D-5L index score) from enrollment to visit 2 (p=0.028), and greater improvements were detectable when compared to the group of patients positive for AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus and randomized to the SDLT arm (p=0.049).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2021, a real-world retrospective analysis of patients tested with the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test was published in the journal Lupus Science &amp; Medicine, titled "A multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus clinical utility study summary." A cohort of 161 AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus tested patients from 12 rheumatology centers across the United States provided clinical outcome data on diagnosis and treatment decisions following AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus testing. The study findings revealed a 7 to 15-fold increased risk of Lupus diagnosis in AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus Positive and anti-dsDNA negative patients relative to patients negative for both tests. In addition, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus positive and anti-dsDNA negative patients were at 3 to 4-fold increased odds, relative to patients testing negative for both tests, of starting a new hydroxychloroquine (cornerstone therapy for Lupus) prescription following AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus testing. Collectively, the study results affirm earlier study findings demonstrating the superior clinical utility and actionability of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus vs. standard diagnostic testing for the differential diagnosis of Lupus.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2022, we announced new, real-world evidence illustrating that AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing can enable decisive clinical action in the differential diagnosis of lupus. The "Complement Activation Products vs Standard ANA Testing: Treatment Outcomes, Diagnosis, and Economic Impact in Systemic Lupus Erythematosus" (CAPSTONE) study was the largest comparative utility study in lupus diagnostics and was published in the Journal of Managed Care &amp; Specialty Pharmacy. The study leveraged multiple databases encompassing electronic health records and linked insurance claims data on nearly 50,000 patients tested with AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> or standard of care labs from hundreds of rheumatologists across the United States, comparing diagnosis, treatment and cost of care outcomes for new patients tested with AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus and those tested with a traditional ANA (tANA) approach, including specific autoantibodies. The CAPSTONE study supports that the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test is more clinically effective, both for patients who test positive and those who test negative, as compared to the current standard of care. Important key findings of the CAPSTONE study included, among other things, a: (i) 2x decrease in diagnostic testing costs in the first six-month follow-up period for AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus [-] vs. tANA[-]; (ii) 3.5x less frequent repeat testing overall when using AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus vs. tANA; (iii) 6x increased odds of establishing a new SLE diagnosis with AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus [+] vs. tANA[+]; and (iv) 3x increased odds of initiating one or more SLE treatments with AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus [+] vs. tANA[+]. The CAPSTONE study exemplifies the advantages of the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test for patients, providers and payors. Delayed diagnosis leads to increased disease burden and diminished quality of life for the patient relative to the current standard of care. By receiving conclusive results, providers are able to initiate treatment early, reducing the need for more aggressive approaches down the road that can lead to irreversible consequences for the patient. Additionally, a conclusive negative test allows providers to lower the number of repeat tests and follow-up visits which is a critical step for achieving diagnostic clarity for the patient.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Healthcare Economics</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2020, a study in collaboration with leading health economic experts was published in the journal ACR Open Rheumatology, titled "Evaluation of the Economic Benefit of Earlier SLE Diagnosis using a Multivariate Assay Panel (MAP)." This was the first ever evaluation of the economics of diagnosing SLE with AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus (MAP) compared to standard diagnostic laboratory tests in a hypothetical cohort of 1,000 suspected SLE patients. Over the four-year time horizon, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus demonstrated an estimated total direct cost savings of approximately $2.0 million ($1,991 per patient). In addition, the study findings from the economic model estimated a $0.7 million dollar savings in total cost of care with AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus versus a conventional SLE biomarker testing approach, as a result of the increased diagnostic sensitivity of the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test leading to fewer in-patient hospitalization costs. On a per tested basis, the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test is estimated to reduce total cost of care by $655 per eligible patient in the first year.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Laboratory Operations </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We perform all of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> tests in our approximately 13,000 square-foot laboratory located in Vista, California. Our laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). Our laboratory is certified for performance of high-complexity testing by the Centers for Medicare &amp; Medicaid Services (CMS) in accordance with CLIA and is licensed by California and all states requiring out-of-state licensure, including the New York State Department of Health (NYSDOH). Our clinical laboratory typically reports AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing product results within five business days. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that our existing laboratory facility is adequate to meet our business needs for at least the next 12 months and that additional laboratory space will be available on commercially reasonable terms, if required.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Quality Assurance </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our quality assurance function oversees the quality of our laboratory operations. We have established oversight for systems implementation and maintenance procedures, document control processes, supplier qualification, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">preventive or corrective actions and employee training processes that we believe achieves excellence in operations. We continuously monitor and improve our processes and procedures and believe this high-quality service leads to customer satisfaction and retention.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Competition </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The traditional methods used by healthcare providers to test patients with CTD-like symptoms are the main competitors of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. Such traditional methods include testing for a broad range of diagnostic, immunology and chemistry biomarkers, such as ANA and anti-dsDNA, and serum complement biomarkers, such as C3 and C4. We also face competition from commercial laboratories, such as Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, ARUP Laboratories, Inc. and the Mayo Clinic, all of which have existing infrastructures to support the commercialization of diagnostic services. Large, multispecialty group medical clinics, health systems and academic medical university-based clinics may provide in-house clinical laboratories offering autoimmune and autoimmune-related disease testing services. Additionally, we compete against regional clinical laboratories providing testing in the autoimmune and autoimmune-related disease field, including Rheumatology Diagnostics Laboratories, Inc. (acquired by Laboratory Corporation of America in June 2020). Other potential competitors include companies that might develop diagnostic, disease or drug monitoring products, such as Progentec Diagnostics Inc., Scipher Medicine Corporation, Genalyte Inc., Oncimmune plc, DxTerity Diagnostics Inc., AMPEL BioSolutions, and Immunovia AB. In the future, we may also face competition from companies developing new products or technologies. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe the principal competitive factors in our target market include: quality and strength of clinical and analytical validation data; confidence in diagnostic results; sales and marketing capabilities; the extent of reimbursement; inclusion in clinical guidelines; cost-effectiveness; and ease of use. We rely upon independent sources for phlebotomy to obtain patient samples; interruptions to this capability could dramatically impact patient access to our tests.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Many of our potential competitors have widespread brand recognition and substantially greater financial, technical and research and development resources; in addition to greater selling and marketing capabilities. Others may develop products with prices lower than ours or have preferred network status that could be viewed by rheumatologists and payors as functionally equivalent to our solution or offer solutions at prices designed to promote market penetration. This could force us to lower the list price of our products and affect our ability to achieve profitability. If we are unable to change clinical practice in a meaningful way or compete successfully against current and future competitors, we may be unable to increase market acceptance and sales of our products, which could prevent us from increasing our revenue or achieving profitability. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Intellectual Property Overview </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We strive to protect and enhance the proprietary technologies that we believe are important to our business and seek to obtain and maintain patents for any patentable aspects of our testing products or other inventions that are important to the development of our business. Our success will depend on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business. It will also depend on our ability to defend and enforce our patents, maintain our licenses to use intellectual property owned by third parties, preserve the confidentiality of our trade secrets and operate without infringing the valid and enforceable patents and other proprietary rights of third parties. We also rely on continuing technological innovation and in-licensing opportunities to develop, strengthen, and maintain our proprietary position in the fields targeted by our testing products and services. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are the owner or licensee of a portfolio of patents and patent applications and possess substantial know-how and trade secrets which protect various aspects of our business. The patent families comprising our patent portfolio are primarily focused on our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products for the diagnosis, prognosis and monitoring of autoimmune and autoimmune-related diseases, and red blood cell MTXPG exposure assessments. We intend to leverage the intellectual property surrounding our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products as an important component of our business strategy.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Patent Protection for our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"> Testing Products</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our portfolio of patents and patent applications related to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products generally relates to two aspects: the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lupus test and the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">MTX test. As of February 21, 2024, our portfolio primarily consisted of the following:</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Lupus Test</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We own five issued patents (US 10,132,813, US 11,360,099, US 11,531,033, US 11,761,965, and US 11,885,812), six U.S. nonprovisional patent applications, one US provisional patent application, and ten foreign patents that relate to our AVISE&#174; Lupus products. The foreign patents have issued in Europe (EP 2,673,644 and EP2972365), China (CN105229470), Japan (JP6453299) and Hong Kong (HK1192316). These patents cover the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus algorithm. The patent applications expire between 2032 and 2040. Any patent claiming priority to the U.S. provisional patent application will expire in 2044.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">MTX Exposure Assessment Products and Services</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We own two patents that relate to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> MTX product and methods for monitoring methotrexate therapy using red blood cell MTXPG exposure assessments. These patents include U.S. Patent Nos. 7,582,282 and 7,695,908, which are expected to expire between 2026 and 2027.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">CB-CAPs</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We previously held licenses to five patent families related to CB-CAPs technology from the University of Pittsburgh (UPitt). We have terminated these license agreements (related to U.S. Patent Nos. 7,361,517, 7,390,631, 7,585,640, 7,588,905, 8,080,382, 8,126,654, and foreign equivalents thereof), effective March 22, 2024. Our royalty obligations continue on cash collected in future periods for testing services provided prior to the royalty expiration date of March 23, 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Proprietary Rights and Processes</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may rely, in some circumstances, on proprietary technology and processes, including trade secrets, to protect our technology. However, these can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with those who have access to our confidential information, including our employees, consultants, scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of our proprietary technology and processes by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any such breach. In addition, our proprietary technology and processes may otherwise become known or be independently discovered by competitors. To the extent that our employees, consultants, scientific advisors, contractors or any future collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. For this and more comprehensive risks related to our proprietary technology and processes, please see &#8220;Risk Factors&#8212;Risks Related to our Intellectual Property.&#8221;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">License Agreements </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Amended and Restated Exclusive License Agreement with the University of Pittsburgh</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2011, we entered into an amended and restated exclusive license agreement with UPitt, to amend and restate the exclusive license agreement we obtained by our purchase of the medical diagnostics division of Cypress Bioscience, Inc. (Cypress) in 2010 (the Cypress Purchase) and to obtain an exclusive license to UPitt&#8217;s patent rights in certain inventions (the UPitt Patent Rights) related to the use of CB-CAPs technology in the diagnosis, prognosis and monitoring of diseases, including certain patents related to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the agreement, we are permitted to make, use and sell products and services utilizing the UPitt Patent Rights in the field of SLE and the field of monitoring of organ transplantation and organ rejection and to sublicense such rights. UPitt retained the right to practice under the UPitt Patent Rights and to use such rights for non-commercial education and research purposes. In addition, this agreement is subject to the rights of the U.S. government, if any, as set forth in 35 U.S.C. &#167;200, et seq. Pursuant to this law, the U.S. government may have acquired a nonexclusive, nontransferable, paid-up license to practice or have practiced for or on behalf of the U.S. government the inventions described in the UPitt Patent Rights throughout the world.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In consideration for the rights granted to us under the agreement, we made certain upfront payments to UPitt on the first and second anniversaries of the agreement that increased on the third and subsequent anniversaries of the agreement until the first sale of products or services utilizing the UPitt Patent Rights. We are required to pay UPitt a low single-digit royalty on net sales of products or services utilizing the UPitt Patent Rights sold by us or our affiliates, subject to minimum annual royalty payments and other adjustment in certain circumstances. We also made a $0.2 million milestone payment to UPitt with the achievement of certain levels of net sales which we met in 2014. Our royalty obligations continue for each licensed product or service on a country-by-country basis only until </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 23, 2024, which is the date of the expiration of the last licensed patent covering the applicable licensed product or service. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Exclusive License Agreement and Master Research Collaboration Agreement with Allegheny Health Network Research Institute </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2021, we entered into an exclusive license agreement with AHN, under which we obtained an exclusive, worldwide license to AHN's patent rights in certain inventions (the AHN Patent Rights) related to diagnostics for autoimmune rheumatic diseases.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the agreement, we are permitted to make, use and sell products and services utilizing the AHN Patent Rights and to sublicense such rights; provided, however, that any such sublicenses may only be granted with AHN's consent. AHN retained the right to practice under the AHN Patent Rights and to use such rights for teaching, research, education, public service, clinical and other research-related purposes. In addition, the agreement is subject to the rights of the U.S. government with respect to the AHN Patent Rights, including under a funding agreement between AHN and the U.S. government and under the Bayh-Dole Act (35 U.S.C. &#167;200, et seq.). Pursuant to the Bayh-Dole Act, the U.S. government may acquire a nonexclusive, nontransferable, paid-up license to practice or have practiced for or on behalf of the U.S. government the inventions described in the AHN Patent Rights throughout the world.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In consideration for the rights granted to us under the agreement, we paid an initial license fee to AHN to cover past patent expenses and agreed to pay future direct patent costs related to AHN Patent Rights. We are also required to pay AHN a low single-digit royalty on net sales of products utilizing the AHN Patent Rights through the first quarter of 2024 sold by us or our affiliates, subject to adjustment in certain circumstances. Beginning in the second quarter of 2024, we are required to pay AHN an increased low single-digit royalty or a flat annual minimum royalty amount, which royalty obligations continue for each licensed product on a country-by-country basis until the expiration of the last licensed patent covering the applicable licensed product in such country, pending approvals and commercialization, or the earlier termination of the agreement (excluding payment obligations accruing prior to such termination).</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event we sublicense any of the AHN Patent Rights, we are obligated to pay AHN a mid-double-digit percentage of any sublicense income, whether in the form of royalties or sub-license fees.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The agreement requires that we diligently develop and commercialize products that are covered by the AHN Patent Rights. If we elect not to pursue intellectual property rights or expand commercialization to certain territories within a commercially reasonable period, AHN may pursue other licenses and terminate our exclusive license with respect to such territories upon 30 days prior written notice.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may terminate the agreement upon 60-day written notice to AHN provided we pay a specified termination fee. AHN may terminate the agreement in the event of our nonperformance of any of our material obligations under the agreement if such nonperformance remains uncured for a certain period of time following our receipt of written notice of such nonperformance or in the event of insolvency. Absent early termination, the agreement will continue until expiration date of the longest-lived patent right included in the AHN Patent Rights.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we entered into a master research collaboration agreement with AHN, focused on the development of novel patented biomarkers for diagnosis, prognosis and monitoring of autoimmune diseases, including SLE. The agreement has a three-year initial term, expiring May 2024, with renewals thereafter for successive one-year terms upon mutual agreement with AHN. Each party may terminate the agreement upon 60 days' notice to the other party. We are required to pay AHN a collaboration fee of $0.4 million for each year of the agreement and AHN is required to make an in-kind contribution equivalent of $0.3 million for the initial term and each subsequent one-year term, if any.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Exclusive License Agreement and Collaboration Agreement with Queen Mary University of London </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2021, we entered into an exclusive license agreement with Queen Mary University of London (QMUL), under which we obtained an exclusive license to QMUL's patent-pending inventions (the QMUL Patent Rights), related to diagnosis and/or development of diagnostic or companion diagnostics for RA.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the agreement, we are permitted to make, use and sell products and services utilizing the QMUL Patent Rights and to sublicense such rights; provided, however, that any such sublicenses may only be granted with QMUL's consent. QMUL retained the right to practice under the QMUL Patent Rights and to use such rights for teaching, research, education, public service, clinical and other research-related purposes. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In consideration for the rights granted to us under the agreement, we paid an initial license fee to QMUL and payment of past patent expenses and ongoing patent expenses. We are required to make a $0.1 million milestone payment upon the first commercial sale of products utilizing the QMUL Patent Rights. In addition, after the first 18 months of commercial sales under the terms of the exclusive license agreement, we are required to pay royalties in the low to high single-digits on net sales of testing products using the assigned patents, pending approvals and commercialization.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event we sublicense any of the QMUL Patent Rights, we are obligated to pay QMUL a double-digit percentage of sublicensing income, whether in the form of royalties or sub-license fees.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The agreement requires that we diligently develop and commercialize products that are covered by the QMUL Patent Rights. QMUL may terminate the agreement if we fail to develop the QMUL Patent Rights in the field of diagnosis and/or development of diagnostic or companion diagnostics for rheumatoid arthritis, QMUL may convert our license to non-exclusive.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2023, we discontinued development of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> RADR platform, which was being developed using the QMUL Patent Rights. We also discontinued the associated clinical trials. We are permitted to terminate the license agreement upon six month written notice to QMUL. QMUL may terminate the agreement in the event of our nonperformance of any of our material obligations under the agreement if such nonperformance remains uncured for a certain period of time following our receipt of written notice of such nonperformance or in the event of insolvency. Absent early termination, the agreement will continue for a period of 20 years after the first commercial sale of any licensed product utilizing the QMUL Patent Rights.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we entered into a collaboration agreement with QMUL for a three-year term, expiring November 2024. We or QMUL may terminate the master research collaboration agreement upon 30-day written notice.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Exclusive License Agreement Johns Hopkins University</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2023, we entered into an exclusive license agreement with Johns Hopkins University, under which we obtained an exclusive, worldwide license to JHU&#8217;s patent rights in certain inventions (the JHU Patent Rights) related to methods of using urinary protein biomarkers as a means of risk stratifying lupus nephritis patients and predicting treatment response.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the agreement, we are permitted to make, use, import, export, offer and sell products and services utilizing the JHU Patent Rights and to sublicense such rights, subject to certain limitations. JHU retained the right to practice under the JHU Patent Rights and to use such rights for teaching, research, education, public service, clinical and other research related purposes; in addition to make, use and sell products and services to a qualified humanitarian organization for humanitarian purposes in so-called &#8220;least developed countries,&#8221; as defined by the United Nations Country Classification.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In consideration for the rights granted to us under the agreement, we paid an initial license fee and past patent expenses and agreed to pay future direct patent costs related to the JHU Patent Rights. Under the terms of the exclusive license agreement, we are required to pay royalties in the low single-digits on net sales of products using the assigned patents, subject to annual minimums, as well as certain milestone payments.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event we sublicense any of the JHU Patent Rights, we are obligated to pay JHU a double-digit percentage of sublicensing income; however, royalties we receive on sales made by sublicensees will be treated as if we made the sale.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The agreement requires that we diligently develop and commercialize products that are covered by the JHU Patent Rights, and we have agreed to meet certain development and commercial milestones. JHU may terminate the agreement if we fail to develop, commercialize and sell the licensed products. Additionally, JHU may terminate the agreement for cause upon 60-day written notice in the event of our nonperformance of any of our material obligations under the agreement if such nonperformance remains uncured for a certain period of time following our receipt of written notice of such nonperformance or in the event of insolvency. JHU may terminate the agreement immediately upon written notice to Exagen in the event of a material breach that is incapable of cure. Absent early termination, the agreement will continue for the longer of (i) expiration of the last to expire patent included in the license agreement, (ii) 10 years after the first commercial sale of any licensed product utilizing the JHU Patent Rights, or (iii) if no patents issue, 20 years from the effective date of the agreement (November 8, 2023). We may terminate the agreement upon ninety days&#8217; advance written notice to JHU.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Regulations </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Clinical Laboratory Improvement Amendments of 1988 </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a clinical laboratory, we are required to hold certain federal, state and local licenses, certifications and permits to conduct our business. Under CLIA, we are required to hold a certificate applicable to the categories of laboratory tests we perform and to comply with standards applicable to our operations, including test processes, personnel, facilities administration, equipment maintenance, recordkeeping, quality systems and proficiency testing. We must maintain CLIA certification to be eligible to bill for diagnostic services provided to Medicare beneficiaries. Many commercial third-party payors also require CLIA certification as a condition of payment. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our Vista facility holds a current CLIA certificate. To renew our CLIA certificate, we are subject to survey and inspection every two years to assess compliance with program standards. We elect to participate in the accreditation program of CAP. CMS has deemed CAP standards to be equally or more stringent than CLIA regulations and has approved CAP as a recognized accrediting organization. Inspection by CAP is performed in lieu of inspection by CMS for CAP-accredited laboratories. Because we are accredited by the CAP Laboratory Accreditation Program, we are deemed to also comply with CLIA. The regulatory and compliance standards applicable to the testing we perform may change over time, and any such changes could have a material effect on our business. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Penalties for non-compliance with CLIA or CAP requirements include suspension, limitation or revocation of the laboratory&#8217;s CLIA or CAP certificate, as well as a directed plan of correction, state on-site monitoring, civil money penalties, civil injunctive suit or criminal penalties, as applicable. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">State Laboratory Licensing </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our Vista facility also holds a state license issued by the California Department of Public Health (DPH). California law and regulations establish standards for the day-to-day operation of a clinical laboratory, including the training and skills required of laboratory personnel and quality control. In addition, California laws and regulations also mandate proficiency testing, which involves testing of specimens that have been specifically prepared for the laboratory for quality control purposes. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because we receive specimens from New York, our Vista facility is also required to be licensed by the NYSDOH New York laws and regulations establish standards in a variety of operational areas, including:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">day-to-day operation of the laboratory, including training, supervision and skill levels required of laboratory personnel;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">physical requirements of a facility;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">equipment; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">validation and quality control.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">New York law also mandates proficiency testing for laboratories licensed under New York state law, regardless of whether such laboratories are located in or outside of New York. If a laboratory is out of compliance with New York's statutory or regulatory standards, the NYSDOH, may suspend, limit, revoke or annul the laboratory&#8217;s New York license, censure the holder of the license or assess civil money penalties. Statutory or regulatory noncompliance may result in a laboratory&#8217;s operator being found guilty of a misdemeanor under New York law. New York's law and regulations are more stringent than CLIA in certain respects. For example, NYSDOH must approve a laboratory developed test (LDT) before it is offered in New York. We have received written approval from NYSDOH to offer our products in New York.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to New York and California, other states, including Maryland, Pennsylvania and Rhode Island, require licensing of out-of-state laboratories under certain circumstances. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Federal Oversight of Laboratory Developed Tests and Certain Devices</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The laws and regulations governing the marketing of diagnostic products are evolving, extremely complex, and in many instances, there are no significant regulatory or judicial interpretations of these laws and regulations. We perform our tests like AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> SLE Prognostic and AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> MTX assays in our Vista, California clinical laboratory, and they are currently primarily regulated under CLIA, as administered by CMS, as well as by applicable state laws, as described above. The FDA regulates any diagnostic tests that meet the definition of a medical device, except under specific, narrow circumstances. The Federal Food, Drug and Cosmetic Act (FDCA) defines a medical device as "an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including a component part, or accessory, which is, among other things: intended for use in the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals and which does not achieve its primary intended purposes through chemical action within or on the body of man or other animals and which is not dependent upon being metabolized for the achievement of any of its primary intended purposes." By this definition, in vitro reagents and diagnostic tests are considered medical devices. Specifically, the FDA defines an in vitro diagnostic test (IVD) as "reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including a determination of the state of health, in order to cure, mitigate, treat, or prevent disease or its sequelae." Therefore, the FDA generally considers diagnostic testing products like ours to be IVDs subject to the agency's regulatory requirements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Among other things, pursuant to the FDCA and its implementing regulations, the FDA regulates the research, testing, manufacturing, safety, labeling, storage, recordkeeping, pre-market clearance or approval, marketing and promotion and sales and distribution of medical devices, including IVDs, in the United States to ensure that medical products distributed domestically are safe and effective for their intended uses. In addition, the FDA regulates the export of medical devices manufactured in the United States to international markets. Many of the instruments, reagents, kits or other consumable products used within our laboratories are regulated as medical devices and therefore must comply with FDA quality system regulations and certain other device requirements. We have policies and procedures in place to ensure that we source such materials from suppliers that are in compliance with any applicable medical device regulatory requirements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FDCA classifies medical devices into one of three categories based on the risks associated with the device and the level of control necessary to provide reasonable assurance of safety and effectiveness. Devices deemed by the FDA to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices or devices deemed not substantially equivalent to a previously 510(k) cleared device, are categorized as Class III. These devices typically require submission and approval of a premarket approval application (PMA). Devices deemed to pose lower risk are categorized as either Class I or II. For most Class II devices, a manufacturer must submit to the FDA a 510(k) premarket notification submission requesting clearance of the device for commercial distribution in the United States. Some low-risk Class II devices are exempted from this requirement. When a 510(k) premarket notification submission is required, the manufacturer must submit to the FDA a premarket notification submission demonstrating that the device is "substantially equivalent" to a predicate device, which is: (i) a device that was legally marketed prior to May 28, 1976, for which PMA approval is not required, (ii) a legally marketed device that has been reclassified from Class III to Class II or Class I, or (iii) another legally marketed, similar device that has been cleared through the 510(k) clearance process. Class II devices may also be subject to special controls such as performance standards, post-market surveillance, FDA guidelines, or particularized labeling. Most Class I devices are exempt from 510(k) premarket notification requirements, but like Class II and Class III devices, are subject to general controls, such as registration and listing, quality system, labeling, and reporting requirements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">After the FDA permits a device to enter commercial distribution, numerous regulatory requirements apply. These include: the Quality System Regulation, which requires manufacturers to follow elaborate design, testing, control, documentation and other quality assurance procedures during the manufacturing process; labeling regulations; the FDA&#8217;s general prohibition against promoting products for unapproved or "off-label" uses; and the medical device reporting regulation, which requires that manufacturers report to the FDA if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction were to recur. The FDA has broad post-market and regulatory and enforcement powers. Failure to comply with the applicable U.S. medical device regulatory requirements could result in, among other things, warning letters, fines, injunctions, consent decrees, civil penalties, repairs, replacements, refunds, recalls or seizures of products, total or partial suspension of production, the FDA&#8217;s refusal to grant future premarket clearances or approvals, withdrawals or suspensions of current product applications, and criminal prosecution.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although the FDA has statutory authority to assure that medical devices, including IVDs, are safe and effective for their intended uses, the FDA has generally exercised its enforcement discretion and not enforced applicable device regulations with respect to IVDs that are designed, manufactured and used within a single high-complexity CLIA-certified laboratory for use only in that laboratory. Such tests are referred to as LDTs. We believe that all of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> test products are LDTs, as are our near-term pipeline candidate tests. However, in October 2023, the FDA issued a proposed rule aimed at regulating LDTs under the current medical device framework and proposing to phase out its existing enforcement discretion policy for this category of diagnostic tests; the public comment period ended in early December 2023. The proposal envisions that the LDT enforcement policy phase-out process would occur in gradual stages over a total period of four years, with pre-market approval applications for high-risk tests to be submitted by the 3.5-year mark, although more details are expected to be provided with the upcoming final rule. The likelihood of the FDA finalizing the proposed rule in April 2024 (as is currently projected), as well as potential litigation challenging the agency&#8217;s authority to take such action, is uncertain at this time. Affected stakeholders continue to press for a comprehensive legislative solution to create a harmonized paradigm for oversight of LDTs by </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">both the FDA and CMS, instead of implementation of the proposed FDA administrative action, which may be disruptive to the industry and to patient access to certain diagnostic tests. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Even though we presently commercialize our tests as LDTs, the FDA may disagree that our marketed tests are within the scope of its current enforcement discretion criteria for LDTs, our tests may in the future become subject to more onerous regulation by the FDA. For several years, members of Congress have been working with stakeholders on a possible bill to regulate in vitro clinical tests including LDTs. For example, as drafted and re-introduced for consideration by the current Congress, legislation called the Verifying Accurate, Leading-edge IVCT Development (VALID Act), has been garnering bipartisan and bicameral support. The VALID Act would codify into law the term "in vitro clinical test" (IVCT) to create a new medical product category separate from medical devices that includes products currently regulated as IVDs as well as LDTs. The VALID Act would also create a new system for labs and hospitals to use to submit their tests electronically to the FDA for approval, which is aimed at reducing the amount of time it takes for the agency to approve such tests, and establish a new program to expedite the development of diagnostic tests that can be used to address a current unmet need for patients.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">It is unclear whether the VALID Act would be passed by Congress in its current form or signed into law by the President. If the FDA finalizes its position on regulation of LDTs through the ongoing notice-and-comment rulemaking process, or the VALID Act or other federal legislation is passed reforming the government&#8217;s regulation of LDTs, or alternatively, if the FDA disagrees with our assessment that our tests fall within the definition of an LDT, we could, for the first time, be subject to enforcement of regulatory requirements such as registration and listing requirements, medical device reporting requirements and quality control requirements. Any new legislation or FDA regulations affecting LDTs may result in increased regulatory burdens on our ability to continue marketing our tests and to develop and introduce new tests in the future. Additionally, if and when the FDA begins to actively enforce its premarket submission regulations with respect to LDTs generally or our tests in particular, whether as a result of new legislative authority or culmination of the current notice-and-comment rulemaking process, we may be required to obtain premarket clearance for our tests under Section 510(k) of the FDCA or approval of a PMA. The process for submitting a 510(k) premarket notification and receiving FDA clearance usually takes from three to 12 months, but it can take significantly longer and clearance is never guaranteed. The process for submitting and obtaining FDA approval of a PMA generally takes from one to three years or even longer and approval is not guaranteed. PMA approval typically requires extensive clinical data and can be significantly longer, more expensive and more uncertain than the 510(k) clearance process. If premarket review is required for some or all of our tests, the FDA could require that we stop selling our products pending clearance or approval and conduct clinical testing prior to making submissions to the FDA to obtain premarket clearance or approval. The FDA could also require that we label our tests as investigational or limit the labeling claims we are permitted to make.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Regulation of Clinical Trials</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have also conducted and may in the future conduct research studies for our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> tests and our other tests in development that involve clinical investigators and human subjects (or stored specimens from human subjects) at sites in the United States. We may need to conduct additional clinical trials for the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> tests, as well as other tests we may offer in the future, to drive test adoption in the marketplace and reimbursement. Should we not be able to perform these studies, or should their results not provide clinically meaningful data and value for clinicians, adoption of our tests could be impaired and we may not be able to obtain reimbursement for them.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The conduct of clinical trials is also subject to extensive federal and institutional regulations intended to assure that the data and reported results are credible and accurate and that the rights, safety, and welfare of study participants are protected. Most studies involving human participants must be reviewed and approved by, and conducted under the auspices of, a duly-constituted institutional review board (IRB), which is a multi-disciplinary committee responsible for reviewing and evaluating the risks and benefits of a clinical trial for participating subjects and monitoring the trial on an ongoing basis. Companies sponsoring the clinical trials and investigators also must comply with, as applicable, regulations, guidelines and IRB requirements for obtaining informed consent from the study subjects, following the protocol and investigational plan, adequately monitoring the clinical trial, and timely reporting of adverse events. The sponsoring company or the IRB may suspend or terminate a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk. In addition, trials involving human subjects often require significant time and cash resources to complete and are subject to a high degree of risk, including risks of experiencing delays, failing to complete the trial or obtaining unexpected or negative results.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Advertising of Laboratory Services or LDTs</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Advertising for laboratory services and diagnostic testing products is subject to federal truth-in-advertising laws enforced by the Federal Trade Commission (FTC), as well as comparable state consumer protection laws, whether or not such services are regulated by the FDA as Class I or Class II devices or not directly subject to enforcement </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">discretion with respect to the FDA&#8217;s device requirements as LDTs. Under the Federal Trade Commission Act (FTC Act), the FTC is empowered, among other things, to (a) prevent unfair methods of competition and unfair or deceptive acts or practices in or affecting commerce; (b) seek monetary redress and other relief for conduct injurious to consumers; and (c) gather and compile information and conduct investigations relating to the organization, business, practices, and management of entities engaged in commerce. The FTC has very broad enforcement authority, and failure to abide by the substantive requirements of the FTC Act and other consumer protection laws can result in administrative or judicial penalties, including civil penalties, injunctions affecting the manner in which we would be able to market services or products in the future, or criminal prosecution.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Federal and State Physician Self-Referral Prohibitions</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to the federal physician self-referral prohibitions, commonly known as the Stark Law, and to similar state law restrictions, such as California&#8217;s Physician Ownership and Referral Act of 1933 (PORA), and other comparable state laws. The Stark Law generally prohibits us from billing Medicare or Medicaid for certain designated health services, including clinical laboratory services, when the physician ordering the service, or any member of such physician&#8217;s immediate family, has a financial relationship with us, unless the arrangement meets an exception to the prohibition. A financial relationship can be a compensation arrangement or an ownership or investment interest.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sanctions for a Stark Law violation include the following:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">denial of payment for the services provided in violation of the prohibition;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">refunds of amounts collected in violation of the Stark Law;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">significant civil penalties for each bill or claim for a service arising out of the prohibited referral, and additional penalties for each arrangement or scheme that the parties know (or should know) has the principal purpose of circumventing the Stark Law's prohibition;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">the imposition of penalties of up to three times the amounts assessed for each item or service wrongfully claimed; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">possible exclusion from federal healthcare programs, including Medicare and Medicaid.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Stark Law applies regardless of any intent by the parties to induce or reward referrals or the reasons for the financial relationship and the referral. In addition, violations of the Stark Law may also serve as the basis for liability under the federal False Claims Act, which can result in additional civil penalties. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Similarly, PORA makes it unlawful for a physician or certain other healing arts licensees to refer a person for certain healthcare services, including clinical laboratory services, if the licensee has a financial interest with the person or entity that receives the referral, unless an exemption is met. Unlike the Stark Law, PORA applies regardless of the source of payment. PORA also prohibits the submission of claims for services provided pursuant to a prohibited referral, and violation of this prohibition constitutes a public offense and is punishable upon conviction by a fine not exceeding fifteen thousand dollars ($15,000) for each violation and appropriate disciplinary action. Other states also have self-referral restrictions with which we have to comply, some of which differ from those imposed by the Stark Law or PORA. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Federal and State Anti-Kickback Laws </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Federal Anti-Kickback Statute makes it a felony for a person or entity, including a clinical laboratory, to knowingly and willfully offer, pay, solicit or receive any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, in order to induce or in return for the referral of an individual for the furnishing of, or the recommending or arranging for the furnishing of, purchasing, leasing, ordering or arranging for or recommending purchasing, leasing or ordering of any item or service that is reimbursable in whole or in part, under any federal healthcare program. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Courts have broadly interpreted the scope of the Anti-Kickback Statute and generally have held that the statute may be violated if merely one purpose of a payment arrangement is to induce referrals. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to statutory exceptions to the Anti-Kickback Statute, regulations provide for a number of safe harbors. If an arrangement meets the provisions of a safe harbor or exception, it is deemed not to violate the Anti-Kickback Statute, and the parties are immune from prosecution. An arrangement must fully comply with each element of an applicable safe harbor in order to qualify for protection. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Failure to meet the requirements of an exception or a safe harbor does not render an arrangement illegal. Rather, the government may evaluate such arrangements on a case-by-case basis, taking into account all facts and circumstances. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A violation of the Anti-Kickback Statute may result in imprisonment for up to ten years and significant fines for each violation and additional administrative civil money penalties, plus up to three times the amount of the remuneration paid. Convictions under the Anti-Kickback Statute result in mandatory exclusion from federal healthcare programs for a minimum of five years. In addition, a violation of the Anti-Kickback Statute can serve as the basis of liability under the federal False Claims Act, which is discussed in greater detail below.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although the Anti-Kickback Statute applies only to items and services reimbursable under any federal healthcare program, a number of states, including California, have passed statutes substantially similar to the Anti-Kickback Statute that apply to all third-party payors, including commercial insurers, and, in some states, to patients without insurance. The California Attorney General and courts have interpreted the California anti-kickback and fee-splitting laws in substantially the same way as the courts have interpreted the Anti-Kickback Statute. Penalties under such state laws include imprisonment and significant monetary fines. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, in October 2018, the Eliminating Kickbacks in Recovery Act of 2018 (EKRA) was enacted as part of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act. EKRA is an all-payor anti-kickback law that makes it a criminal offense to pay any remuneration to induce referrals to, or in exchange for, patients using the services of a recovery home, a substance use clinical treatment facility, or laboratory. However, unlike the Anti-Kickback Statute, EKRA is not limited to services covered by federal healthcare programs but applies more broadly to services covered by &#8220;healthcare benefit programs,&#8221; including commercial third-party payors. Although EKRA apparently was intended to reach patient brokering and similar arrangements to induce patronage of substance use recovery and treatment, the language in EKRA is broadly written. Further, certain of EKRA&#8217;s exceptions are inconsistent with the Anti-Kickback Statute and regulations. EKRA permits the U.S. Department of Justice to issue regulations clarifying EKRA&#8217;s exceptions or adding additional exceptions, but such regulations have not yet been issued.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other Federal and State Healthcare Laws </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the requirements discussed above, several other healthcare fraud and abuse laws could have an effect on our business. For example, federal law permits the U.S. Department of Health and Human Services (HHS) Office of Inspector General (OIG), to exclude an individual or entity from Medicare or Medicaid for charging federal healthcare programs, including Medicare or Medicaid, substantially in excess of its usual charges for its items or services absent a finding of good cause. The terms &#8220;usual charge&#8221; and &#8220;substantially in excess&#8221; are subject to varying interpretations, and the HHS OIG has withdrawn multiple versions of a proposed rule intended to implement the statute. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The federal False Claims Act prohibits, among other things, a person from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment to the federal government. In addition to actions initiated by the government itself, the statute authorizes actions to be brought on behalf of the federal government by a private party having knowledge of the alleged fraud pursuant to its </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> provisions. Because the complaint in a </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> action is initially filed under seal, the action may be pending for some time before the defendant is even aware of the action. Regardless of whether the government intervenes in the action, the relator, if successful, will receive a percentage of the recovery. In addition, providers and suppliers must report and return any overpayments received from the Medicare and Medicaid programs within 60 days of identification, and failure to identify and return such overpayments exposes the provider or supplier to federal False Claims Act liability. Violation of the federal False Claims Act may result payment of up to three times the actual damages sustained by the government, plus significant per-claim civil penalties, as well as mandatory exclusion from government healthcare programs. Several states, including California, have enacted comparable false claims laws that may apply regardless of payor.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The federal civil monetary penalties law (the CMP Law) prohibits, among other things, (1) the offering or transfer of remuneration (including a waiver of copayments and deductible amounts) to a Medicare or Medicaid beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or Medicaid, unless an exception applies; (2) employing or contracting with an individual or entity that the provider knows or should know is excluded from participation in a federal healthcare program; (3) billing for services requested by an unlicensed physician or an excluded provider; (4) billing for medically unnecessary services; and (5) presenting or causing to be presented a claim to a federal healthcare program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. The penalties for violating the CMP Law may include exclusion, substantial fines, and payment of up to three times the amount billed, depending on the nature of the offense. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As noted, a person who offers or provides to a Medicare or Medicaid beneficiary any remuneration, including waivers of co-payments, co-insurance and deductible amounts (or any part thereof), that the person knows or should know is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner or supplier of Medicare or Medicaid payable items or services may be held liable under the CMP Law. Moreover, in certain cases, providers who routinely waive amounts owed by federal healthcare program beneficiaries can also be held liable under the Anti-Kickback Statute and the federal False Claims Act. One of the exceptions to the prohibition under the CMP Law covers non-routine, unadvertised waivers of copayments or deductible amounts based on individualized determinations of financial need or exhaustion of reasonable collection efforts, and the Anti-Kickback Statute has a safe harbor. The HHS OIG, has emphasized in guidance documents that this exception should only be used on a case-by-case basis to address the financial needs of each particular patient. Although this prohibition applies only to federal healthcare program beneficiaries, applicable state laws related to, among other things, unlawful schemes to defraud, excessive fees for services, tortious interference with patient contracts and statutory or common law fraud, may also be implicated for similar practices offered to patients covered by commercial payors.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Federal criminal statutes prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including those administered by commercial payors, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Like the Anti-Kickback Statute, this federal criminal statute requires a showing of intent, but a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Physician Payments Sunshine Act imposes annual reporting requirements on manufacturers of certain devices, drugs and biologics for certain payments and transfers of value by them and in some cases their distributors to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other healthcare providers (such as nurse practitioners), and teaching hospitals, as well as ownership and investment interests held by physicians (as defined under the statute) and their immediate family members. Any failure to comply with these reporting requirements could result in significant fines and penalties. Because we manufacture our own in vitro diagnostic tests solely for use by or within our own laboratory, we believe that we are exempt from these reporting requirements. We may become subject to such reporting requirements under the terms of current CMS regulations, however, if enacted federal legislation renders our tests regulated by FDA, or if FDA finalizes its recently initiated notice-and-comment rulemaking to exercise authority over LDTs as medical devices or otherwise requires us to obtain premarket clearance or approval for one or more of our tests. A determination that we have violated these laws and regulations, or a public announcement that we are being investigated for possible violations, could adversely affect our business, prospects, results of operations or financial condition. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also subject to applicable state restrictions on laboratory billing. These laws vary from state to state but generally are intended to prevent a provider who ordered but did not perform the service from billing for that service at a markup. For example, California has an anti-markup statute with which we must comply, which prohibits a provider from charging for any laboratory test that it did not perform unless the provider (a) notifies the patient, client or customer of the name, address and charges of the laboratory performing the test, and (b) charges no more than what the provider was charged by the clinical laboratory that performed the test except for any other service actually rendered to the patient by the provider (for example, specimen collection, processing and handling). This provision applies, with certain limited exceptions, to licensed persons such as physicians and clinical laboratories regulated under California&#8217;s Business and Professions Code. A violation of this provision can lead to imprisonment and/or a fine of up to $10,000. Other states have similar anti-markup and other client billing restrictions with which we must comply. Many states also have "direct-bill" laws, which require the party that performed the service to bill for the service, with certain exceptions.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If our operations are found to be in violation of any of the fraud and abuse laws described above or any other healthcare regulatory laws that apply to us, we may be subject to penalties, including potentially significant criminal and civil and/or administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government healthcare programs, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">International Regulations </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Many countries in which we may offer any of our testing products in the future have anti-kickback regulations prohibiting providers from offering, paying, soliciting or receiving remuneration, directly or indirectly, in order to induce business that is reimbursable under any national healthcare program. In situations involving physicians employed by state-funded institutions or national healthcare agencies, violation of the local anti-kickback law may </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">also constitute a violation of the U.S. Foreign Corrupt Practices Act (FCPA), and/or other applicable anti-corruption laws. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FCPA prohibits any U.S. individual, business entity or employee of a U.S. business entity from offering or providing, directly or through a third party, including any potential distributors we may rely on in certain markets, anything of value to a foreign official with corrupt intent to influence an award or continuation of business or to gain an unfair advantage, whether or not such conduct violates local laws. In addition, it is illegal for a company that reports to the SEC to have false or inaccurate books or records or to fail to maintain a system of internal accounting controls. We will also be required to maintain accurate information and control over sales and distributors&#8217; activities that may fall within the purview of the FCPA, including its books and records provisions and its anti-bribery provisions. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The standard of intent and knowledge under the FCPA&#8217;s anti-bribery provisions is minimal intent and knowledge are usually inferred from the fact that bribery took place. The FCPA&#8217;s accounting provisions do not require intent. Violations of the FCPA&#8217;s anti-bribery provisions for corporations and other business entities are subject to a fine of up to $2.0 million and officers, directors, stockholders, employees and agents are subject to a fine of up to $100,000 and imprisonment for up to five years. Other countries, including the United Kingdom and other Organisation for Economic Co-Operation and Development Anti-Bribery Convention members, have similar anti-corruption regulations, such as the U.K. Bribery Act. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">When marketing our testing products outside of the United States, we may be subject to foreign regulatory requirements governing human clinical testing, prohibitions on the import of tissue necessary for us to perform our testing products or restrictions on the export of tissue imposed by countries outside of the United States or the import of tissue into the United States, and marketing approval. These requirements vary by jurisdiction, differ from those in the United States and may in some cases require us to perform additional pre-clinical or clinical testing. In many countries outside of the United States, coverage, pricing and reimbursement approvals are also required. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Privacy and Security Laws </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">U.S. Data Privacy and Security Laws</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HIPAA established comprehensive federal standards for the privacy and security of health information. In 2009, Congress enacted Subtitle D of the Health Information Technology for Economic and Clinical Health Act (HITECH) provisions of the American Recovery and Reinvestment Act of 2009. HITECH amended HIPAA and, among other things, expanded and strengthened HIPAA, created new targets for enforcement, imposed new penalties for noncompliance and established new breach notification requirements. HIPAA applies to health plans, healthcare clearing houses and healthcare providers that conduct certain healthcare transactions electronically (collectively, Covered Entities), as well as individuals or entities that perform services for them involving the use, or disclosure of, individually identifiable health information or "protected health information" (PHI) under HIPAA (Business Associates). Under HIPAA, as amended by the HITECH Act, HHS has issued regulations to protect the privacy and security of PHI used or disclosed by Covered Entities and Business Associates. HIPAA also regulates and standardizes the codes, formats and identifiers used in certain healthcare transactions and standardization of identifiers for health plans and providers, for example insurance billing. Any non-compliance with HIPAA and HITECH and related penalties, could adversely impact our business. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The HIPAA security standards require the adoption of administrative, physical and technical safeguards and the adoption of written security policies and procedures to maintain the security of protected health information. Also, federal agencies are increasing their focus on the importance of cybersecurity in protecting health information. For example, HHS outlined its cybersecurity strategy for the health care sector on December 6, 2023, which builds on a national strategy published by the White House on March 1, 2023, and on February 16, 2024, the HHS Office for Civil Rights (OCR) and the National Institute of Standards and Technology (NIST) announced the publication of a cybersecurity resource guide for implementing HIPAA.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The HIPAA privacy regulations address the privacy of PHI by limiting the use and release of such information. They also set forth certain rights that an individual has with respect to his or her PHI maintained by a covered entity, including the right to access or amend certain records containing PHI, request an accounting of disclosures of PHI or to request restrictions on the use or disclosure of PHI. The HIPAA breach notification regulations impose certain reporting requirements on Covered Entities and their Business Associates in the event of a breach of PHI. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Covered Entities must report breaches of PHI that has not been encrypted or otherwise secured in accordance with guidance from the Secretary of HHS (the Secretary). Breaches must be reported as soon as reasonably practicable, but no later than sixty days following discovery of the breach. Reports must be made to affected individuals, the Secretary, and depending on the size of the breach, the local and national media. Covered Entities like us are also </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">subject to the HHS HIPAA audit program and may be investigated in connection with a privacy or data security complaint.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Significant civil and criminal fines and other penalties may be imposed for violating HIPAA directly, and in connection with acts or omissions of any agents, including downstream business associates, as determined according to the federal common law of agency. Civil penalties are adjusted for inflation on an annual basis and can exceed one million dollars per year for failure to comply with a HIPAA requirement. A single breach incident can violate multiple requirements. Additionally, a person who knowingly obtains or discloses PHI in violation of HIPAA may face criminal penalties (including fines and imprisonment), which increase if the wrongful conduct involves false pretenses or the intent to sell, transfer or use PHI for commercial advantage, personal gain or malicious harm. Covered Entities are also subject to enforcement by state Attorneys General who were given authority to enforce HIPAA.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, while HIPAA does not create a private right of action allowing individuals to file suit against us in civil court for violations of HIPAA, its standards have been used as the basis for duty of care cases in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further, to the extent that we submit electronic healthcare claims and payment transactions that do not comply with the transaction standards established under HIPAA and HITECH, payments to us may be delayed or denied.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Even when HIPAA does not apply, according to the FTC, failing to take appropriate steps to keep consumers&#8217; personal information secure constitutes unfair acts or practices in or affecting commerce in violation of Section 5(a) of the FTC Act. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. The FTC and states' Attorneys General have also brought enforcement actions and prosecuted some data breach cases as unfair and/or deceptive acts or practices under the FTC Act and comparable state laws.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The HIPAA privacy and security regulations establish a uniform federal "floor" and do not preempt state laws that are more stringent or provide individuals with greater rights with respect to the privacy or security of, and access to, their records containing PHI or insofar as such state laws apply to personal information that is broader in scope than PHI. Certain state laws govern the privacy and security of health-related and other personal information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. The State of California, for example, has implemented comprehensive laws and regulations. The California Confidentiality of Medical Information Act (CMIA), imposes restrictive requirements regulating the use and disclosure of health information and other personally identifiable information. California has also recently adopted the California Consumer Privacy Act of 2018 (CCPA), which went into effect January 1, 2020. The CCPA, among other things, creates new data privacy obligations for covered companies and provides new privacy rights to California residents, including the right to opt out of certain disclosures of their information. It also creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Although the law includes limited exceptions, including for PHI maintained by a Covered Entity or Business Associate under HIPAA and medical information maintained by healthcare providers under the CMIA, it may regulate or impact our processing of personal information depending on the context. Further, the California Privacy Rights Act (CPRA) went into effect January 1, 2023 strengthening the CCPA. The CPRA imposes additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data and expands the application of the CCPA to all human resources personal information of our California-based employees. It also created a new California data protection agency authorized to issue substantive regulations and is expected to result in increased privacy and information security enforcement. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Various states such as Colorado, Connecticut, Delaware, Florida, Indiana, Iowa, Montana, Oregon, Tennessee, Texas, Utah and Virginia have enacted their own privacy laws similar to the CCPA, and other states are considering proposals for such laws, all of which increases the complexity of compliance and the risk of failures to comply.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Numerous other federal and state laws, including consumer protection laws and regulations, govern the collection, dissemination, use, access to, confidentiality and security of patient health information. In addition, Congress and some states are considering new laws and regulations that further protect the privacy and security of medical records or medical information. With the recent increase in publicity regarding data breaches resulting in improper dissemination of consumer information, all 50 states have passed laws regulating the actions that a business must take if it experiences a data breach, as defined by state law, including prompt disclosure within a specified amount </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of time to affected individuals. In addition to data breach notification laws, some states have enacted statutes and rules requiring businesses to reasonably protect certain types of personal information they hold or to otherwise comply with certain specified data security requirements for personal information. Congress has also been considering similar federal legislation relating to data privacy and data protection. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Many states, such as Massachusetts, have also implemented genetic testing and privacy laws imposing specific patient consent requirements and requirements for protecting test results. The interplay of federal and state laws regulating genetic information may be subject to varying interpretations by courts and government agencies, creating complex compliance issues for us and potentially exposing us to additional expense, adverse publicity and liability. Further, as regulatory focus on genetic privacy issues continues to increase and laws and regulations concerning the protection of personal information expand and become more complex, these potential risks to our business could intensify.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Information Blocking Rules</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Office of the National Coordinator for Health Information Technology (ONC), coordinates the ongoing development of standards to enable interoperable health information technology infrastructure nationwide in the healthcare sector. In May 2020, ONC released the final Information Blocking Rule to implement the interoperability and patient access provisions of the 21st Century Cures Act. We will need to continually review our practices for conduct that could be considered as likely to interfere with access, exchange or use of electronic health information, as those practices are prohibited by the Information Blocking Rule, unless one of the exceptions outlined in the Information Blocking Rule applies. Among other things, the Information Blocking Rule requires us to provide patients with on-demand access to laboratory test results. These requirements can be inconsistent with our obligations as a laboratory under state law and/or medical or ethical standards. It is currently unclear how the ONC will approach delays in providing patient access in these situations. Healthcare providers including laboratories will be subject to civil monetary penalties for violations of the Information Blocking Rule once the penalty regulations are finalized. The amount of such penalties for laboratories is unknown, but the regulations for health industry networks (HINs), health information exchanges (HIEs), and certified developers of health information technology allow for up to $1.0 million in penalties per violation.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">GDPR and Foreign Laws </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also subject to foreign privacy laws in the foreign jurisdictions in which we sell our testing products. The interpretation, application and interplay of consumer and health-related data protection laws in the United States, Europe and elsewhere are often uncertain, contradictory and in flux. In Europe, the General Data Protection Regulation (GDPR) went into full effect in May 2018. The GDPR implements stringent operational requirements for processors and controllers of personal data, including, for example, expanded disclosures about how personal information is collected and used, limitations on retention of information, increased requirements pertaining to health data and pseudonymized (i.e., key-coded) data, mandatory data breach notification requirements, more robust rights for individuals in regard to their personal data and higher standards for controllers to demonstrate that they have obtained valid consent for certain data processing activities. It provides that European Union (EU), and European Economic Area (EEA), member states may make their own further laws and regulations, which may impose further limitations, including in relation to the processing of biometric or health data, which may result in differences between member state laws, limit our ability to use and share personal data, cause our costs to increase and/or harm our business and/or financial condition.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Among other requirements, the GDPR also regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States, and the efficacy and longevity of current transfer mechanisms between the EU and the United States remains uncertain. For example, in 2016, the EU and the United States agreed to a transfer framework for data transferred from the EU to the United States, called the Privacy Shield, but the Court of Justice of the EU invalidated the Privacy Shield when it decided the case </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Maximilian Schrems vs. Facebook</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (Case C-311-18), known as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Schrems II</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. However, on July 10, 2023, the European Commission adopted an adequacy decision for a new mechanism for transferring data from the EU to the United States &#8211; the EU-US Data Privacy Framework, which provides EU individuals with several new rights, including the right to obtain access to their data, or obtain correction or deletion of incorrect or unlawfully handled data. The adequacy decision followed the signing of an executive order introducing new binding safeguards to address the points raised in the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Schrems II</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> decision. Notably, the new obligations were geared to ensure that data can be accessed by U.S. intelligence agencies only to the extent necessary and proportionate and to establish an independent and impartial redress mechanism to handle complaints from Europeans concerning the collection of their data for national security purposes. The European Commission will continually review developments in the United States along with its adequacy decision. Adequacy decisions can be adapted or even withdrawn in the event of developments affecting the level of protection in the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">applicable jurisdiction. Future actions of EU data protection authorities are difficult to predict. Some customers or other service providers may respond to these evolving laws and regulations by asking us to make certain privacy or data-related contractual commitments that we are unable or unwilling to make. This could lead to the loss of current or prospective customers or other business relationships.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Relatedly, following the United Kingdom&#8217;s withdrawal from the EU, the GDPR was implemented in the United Kingdom as the U.K. GDPR with the U.K. GDPR sits alongside the amended U.K. Data Protection Act 2018, retains the GDPR in U.K. national law. Under the U.K. GDPR, companies not established in the United Kingdom but who process personal data in relation to the offering of goods or services to individuals in the United Kingdom, or to monitor their behavior will be subject to the U.K. GDPR &#8211; the requirements of which are (at this time) largely aligned with those under the EU GDPR and as such, may lead to similar compliance and operational costs with potential fines of up to &#163;17.5 million or 4% of global turnover In June of 2021, the European Commission issued a decision, which will sunset on June 27, 2025 without further action, that the United Kingdom ensures an adequate level of protection for personal data transferred under the EU GDPR from the EU to the United Kingdom. The Parliament of the United Kingdom is currently considering the Data Protection and Digital Information Bill to harmonize the 2018 Data Protection Act, U.K. GDPR, and the Privacy and Electronic Communications Regulations under one legislative framework.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Billing and Government Reimbursement for Clinical Laboratory Services </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Medicare</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medicare coverage is limited to items and services, within the scope of a Medicare benefit category that are reasonable and necessary for the diagnosis or treatment of an illness or injury. With respect to Medicare coverage, Palmetto GBA, the Medicare Administrative Contractor (MAC) responsible for administering Medicare&#8217;s molecular diagnostic services program (MolDX Program), issued a Local Coverage Determination (LCD) that provides coverage for our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> MTX test. The MAC responsible for administering Medicare claims submitted by our laboratory, Noridian Healthcare Solutions (Noridian), has adopted Palmetto&#8217;s positive coverage policy, along with a related local coverage article that identifies a unique billing identifier for this test. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under Medicare, payment for our laboratory tests are generally made under the Clinical Laboratory Fee Schedule (CLFS) with payment amounts assigned to specific procedure billing codes. In April 2014, Congress passed the Protecting Access to Medicare Act (PAMA), which substantially changed the way in which Medicare sets the payment amounts for clinical laboratory services. Under PAMA, laboratories that receive the majority of their Medicare revenue from payments made under the CLFS or the Physician Fee Schedule (PFS) are required to report to CMS, beginning in 2017 and every three years thereafter (or annually for "advanced diagnostic laboratory tests" (ADLTs)), private payor payment rates and volumes for their tests. Laboratories that fail to report the required payment information may be subject to substantial civil monetary penalties. As required under PAMA, CMS uses the rates and volumes reported by laboratories to develop Medicare payment rates for laboratory tests equal to the volume-weighted median of the private payor payment rates for the tests. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June 23, 2016, CMS published the final rule implementing the reporting and rate-setting requirements under PAMA. For tests furnished on or after January 1, 2018, Medicare payments for clinical diagnostic laboratory tests (CDLTs) are based upon these reported private payor rates. For CDLTs assigned a new or substantially revised Current Procedural Terminology (CPT), because there is no comparable existing CDLT, CMS will set the initial payment rates using the gap-fill methodology, as under prior law. Initial payment rates for new ADLTs will be based on the actual list charge. Any reductions to payment rates resulting from the new methodology are limited to up to 10% per test per year in each of the years 2018 through 2020. As noted below, federal law has delayed implementation of further reductions until 2024, at which time the reduction cap will rise to 15% per test per year. PAMA did not impact Medicare reimbursement for AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD in 2022 compared to levels experienced in 2021. Additionally, PAMA and changes to the PFS will not have a significant impact to Medicare reimbursement for AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD in 2024 compared to levels experienced in 2023.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since December 2019, Congress has passed a series of laws to modify PAMA&#8217;s statutory requirements related to the data reporting period and phase-in of payment reductions under the CLFS or CDLTs that are not ADLTs Most recently, the Further Continuing Appropriations and Other Extensions Act of 2024 (Pub.L. 118-22, enacted on November 16, 2023) further delayed the reporting requirement as well as the application of the 15% phase-in reduction. Under these statutory provisions, the next data reporting period for CDLTs that are not ADLTs will be January 1, 2025 through March 31, 2025, and will be based on the most recent data collection period of January 1, 2019 through June 30, 2019. After this data reporting period, the three-year data reporting cycle for these tests will resume (e.g., 2028, 2031, etc.).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The same series of laws modified the phase-in of payment reductions resulting from private payor rate implementation so that a 0.0% reduction limit was applied for calendar years (CYs) 2021 through 2023, as compared to the payment amounts for a test the preceding year. The Further Continuing Appropriations and Other Extensions Act of 2024 further applied a 0.0% reduction limit for CY 2024. Consequently, payment may not be reduced by more than 15% per year for CYs 2025 through 2027 as compared to the payment amounts established for a test the prior year.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PAMA also authorized the adoption of new, temporary billing codes and unique test identifiers for FDA-cleared or approved tests, as well as ADLTs. The American Medical Association's (AMA) CPT Editorial Panel approved a proposal to create a new section of billing codes called Proprietary Laboratory Analyses (PLA) codes, to facilitate implementation of this section of PAMA. The AMA publishes approved codes on a quarterly basis. We requested a PLA code and in the quarter ended March 31, 2022, CMS agreed, effective April 1, 2022, to recognize a new PLA code for our protein-based test, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Billing for diagnostic testing can be complicated. Depending on the billing arrangement and applicable law, we must bill various parties, such as commercial payors, Medicare, Medicaid, physicians, hospitals, employer groups and patients, all of which have different billing requirements. Additionally, compliance with applicable laws and regulations as well as internal compliance policies and procedures adds further complexity to the billing process. Changes in laws and regulations could negatively impact our ability to bill our clients or increase our costs. CMS also establishes new procedures and continuously evaluates and implements changes to the reimbursement process for billing government healthcare programs. Missing or incorrect information on test requisitions adds complexity to and slows the billing process, creates backlogs of unbilled tests, and generally increases the aging of accounts receivable and bad debt expense. Failing to bill timely or correctly may have negative consequences for us, such as not being reimbursed for our services or experiencing an increase in the aging of our accounts receivable, which could adversely impact our results of operations and cash flows. Failure to comply with applicable laws relating to billing federal healthcare programs could also lead to various penalties, including:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">overpayments and recoupments of reimbursement received;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">exclusion from participation in Medicare/Medicaid programs;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">asset forfeitures;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">civil and criminal fines and penalties; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">the loss of various licenses, certificates and authorizations necessary to operate our business.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any of these penalties or sanctions could have a material adverse effect on our results of operations or cash flows. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Healthcare Reform </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2010, the Affordable Care Act (ACA) was enacted in the United States and made a number of substantial changes to the way healthcare is financed both by governmental and private payors. Although the ACA included a medical device tax, the tax never went into effect and was fully repealed by Congress with enactment of the 2019 federal spending package signed into law on December 20, 2019.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since the ACA&#8217;s enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and as a result, certain sections of the ACA have not been fully implemented or were effectively repealed. However, following several years of litigation in the federal courts, in June 2021, the U.S. Supreme Court (the Supreme Court) upheld the ACA when it dismissed a legal challenge to the ACA&#8217;s constitutionality. Further legislative and regulatory changes under the ACA remain possible, although the current Democrat-led presidential administration has been taking steps to strengthen the ACA. Future changes or additions to the ACA, the Medicare and Medicaid programs and changes stemming from other healthcare reform measures, especially with regard to healthcare access, financing or other legislation in individual states, could have a material adverse effect on the healthcare industry in the United States. The uncertainty around the future of the ACA, and in particular the impact to reimbursement levels and the number of insured individuals, may lead to delay in the purchasing decisions of our customers.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the ACA, there will likely continue to be proposals by legislators at both the federal and state levels, regulators and private third-party payors to reduce costs while expanding individual healthcare benefits.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Environmental and Other Regulatory Requirements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our laboratory is subject on an ongoing basis to federal, state and local laws and regulations governing the use, storage, handling and disposal of regulated medical waste, hazardous waste and biohazardous waste, including </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">chemicals, biological agents and compounds and blood and other tissue specimens. Typically, we use licensed or otherwise qualified outside vendors to dispose of this waste. However, many of these laws and regulations provide for strict liability, holding a party potentially liable without regard to fault or negligence. As a result, we could be held liable for damages and fines if our, or others', business operations or other actions result in contamination of the environment or personal injury due to exposure to hazardous materials. Our costs for complying with these laws and regulations cannot be estimated or predicted and depends on a number of factors, including the amount and nature of waste we produce (which depends in part on the number of tests we perform) and the terms we negotiate with our waste disposal vendors. Since inception, we have disposed of all hazardous and/or medical waste that we produced across our entire business through environmentally sound methods.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our operations are also subject to extensive requirements established by the U.S. Occupational Safety and Health Administration relating to workplace safety for healthcare employees, including requirements to develop and implement programs to protect workers from exposure to blood-borne pathogens by preventing or minimizing any exposure through needle stick or similar penetrating injuries.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Human Capital</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2023, we had a total of 179 employees: 174 full-time employees and 5 part-time employees. This includes 44 in laboratory operations, 9 in research and development, 49 in sales and marketing and 72 in general and administrative functions. All of our employees are located in the United States, none of which are represented by a labor union or covered by a collective bargaining agreement. We consider relations with our employees to be good.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recognize that attracting, motivating and retaining talent at all levels is vital to our continued success. Our employees are a significant asset and we aim to create an equitable, inclusive and empowering environment in which our employees can grow and advance their careers, with the overall goal of developing, retaining and expanding our workforce, as needed, to support our current pipeline and future business goals. By focusing on employee retention and engagement, we also improve our ability to support our business and operations, our pipeline, and also protect the long-term interests of our securityholders. Our success also depends on our ability to attract, engage and retain a diverse group of employees. Our efforts to recruit and retain a diverse and passionate workforce include providing competitive compensation and benefits packages and efforts to ensure our employees' voices are heard.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We value innovation, passion, data-driven decision making, persistence and honesty, and are building a diverse environment where our employees can thrive and be inspired to make exceptional contributions to bring novel testing products to patients.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, motivating and integrating our existing and future employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees and directors through grants of stock-based compensation awards and payments of cash-based performance bonus awards, in order to increase stockholder value and the success of our company by motivating our employees to perform to the best of their abilities and achieve our objectives. We are committed to providing a competitive and comprehensive benefits package to our employees. Our benefits package provides a balance of protection along with the flexibility to meet the individual health and wellness needs of our employees. We plan to continue to refine our efforts related to optimizing our use of human capital as we grow, including improvements in the way we hire, develop, motivate and retain employees.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We conduct periodic anonymous employee surveys aimed at measuring the overall satisfaction of our team and make efforts to address issues brought to our attention. The results consistently show that our employees consider their work valuable and meaningful.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Information About Our Directors and Executive Officers</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following persons currently serve as the directors and executive officers of Exagen:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:66.298%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Directors and Executive Officers</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Position</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Executive Officers</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Aballi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kamal Adawi</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Corporate Secretary</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tina Nova, Ph.D.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Chairman of the Board of Directors</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Directors</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brian Birk</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managing Partner, Co-Founder, Sun Mountain Capital</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ana Hooker</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Chief Laboratory Officer, Exact Sciences Corporation</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wendy Johnson</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Business Officer, Reneo Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paul Kim</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer, Fulgent Genetics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ebetual Pallares, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managing Member, Proficio Capital Management, LLC</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bruce Robertson, Ph.D.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managing Director, H.I.G Capital, LLC</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frank Stokes</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer, Castle Biosciences, Inc.</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Diversity and Inclusion</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our organization recognizes the importance of diversity and inclusion in recruiting, developing and retaining the best available talent. We are committed to further understanding and building upon our diversity and inclusion strengths and are continuing the process of identifying opportunities and developing initiatives.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2023, 58.6% of our employees identified as female, 33.9% identified as male and 7.5% of our employees identified as other or declined to self-identify. Additionally, 47.9% of our employees identified as White, 24.2% as Hispanic or Latino, 15.1% as Asian, 3.8% as Black or African-American, 3.2% as two or more races (not Hispanic or Latino), 0.6% as Native Hawaiian or other Pacific Islander, and 0.6% as American Indian or Alaska Native. 4.9% of our employees identified as other or declined to self-identify.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Environmental, Social and Governance Matters</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2020, we undertook a review of our environmental, social and governance (ESG), matters. In 2021, we released our initial Sustainability Report. In 2022, we created an Environmental, Social and Governance Committee (ESG Committee) with the purpose, duties and responsibility of reviewing and recommending our programs, policies and practices relating to ESG issues. The ESG Committee meets formally at least annually and plans to make recommendations to our President and Chief Executive Officer to be presented to the audit committee of our board of directors (the Audit Committee) when warranted. For more information regarding our ESG initiatives, please refer to www.exagen.com/investors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Suppliers </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We rely on sole suppliers for the critical supply of reagents, equipment and other materials that we use to perform the tests that comprise our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. We also purchase components used in our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing product transportation kits from sole-source suppliers. Some of these items are unique to these suppliers and vendors. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial Information </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We manage our operations and allocate resources as a single reporting segment. Financial information regarding our operations, assets and liabilities, including our net loss for the years ended December 31, 2023 and 2022 and our total assets as of December 31, 2023 and 2022, is included in our Financial Statements in Item 8 of this Annual Report.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Corporate Information</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We were incorporated under the laws of the state of New Mexico in 2002, under the name Exagen Corporation. In 2003, we changed our state of incorporation from New Mexico to Delaware by merging with and into Exagen Diagnostics, Inc., pursuant to which we changed our name to Exagen Diagnostics, Inc. In January 2019, we changed our name to Exagen Inc. Our principal executive offices are located at 1261 Liberty Way, Vista, California 92081. Our telephone number is (760) 560-1501. Our website address is www.exagen.com. The information </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">contained in, or accessible through, our website is not part of, and is not incorporated by reference into, this Annual Report. Investors should not rely on any such information in deciding whether to purchase our common stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Available Information</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We file Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, proxy and information statements and other information with the Securities and Exchange Commission (SEC). Our filings with the SEC are available free of charge on the SEC&#8217;s website and on the "Investors" section of our website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The SEC maintains an internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC at www.sec.gov.</span></div><div id="i7d27a7d8e3c749dabb1f235100af8228_16"></div><div style="margin-top:21pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 1A. Risk Factors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Investing in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties described below, together with all of the other information included in this Annual Report on Form 10-K, including our financial statements and related notes and "Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations," before making an investment decision to purchase or sell shares of our common stock. If any of the following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. In that event, the trading price of our common stock could decline, and you could lose part or all of your investment. The risks described below are not the only ones that we may face, and additional risks or uncertainties not known to us or that we currently deem immaterial may also impair our business and future prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Summary Risk Factors</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The risk factors described below are a summary of the principal risk factors associated with an investment in us. These are not the only risks we face. You should carefully consider these risk factors, together with the risk factors set forth in this Item 1A:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We have a history of losses, we expect to incur net losses in the future and we may not be able to generate sufficient revenue to achieve and maintain profitability;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If third-party payors do not provide coverage and adequate reimbursement for our testing products, or they breach, rescind or modify their contracts or reimbursement policies or delay payments for our testing products, or if we or our partners are unable to successfully negotiate payor contracts, our commercial success could be materially compromised;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">In the near-term, we expect that our financial results will depend primarily on sales of our testing products, and we will need to generate sufficient revenue from these testing products to grow our business;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We may be unable to manage our growth effectively, which could make it difficult to execute our business strategy;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our commercial success depends on attaining and maintaining significant market acceptance of our testing products among rheumatologists, patients, third-party payors and others in the medical community; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We rely on sole suppliers for some of the reagents, equipment and other materials used in our testing products, and we may not be able to fund replacements or transition to alternative suppliers;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we are unable to support demand for our current testing products or any of our future testing products or solutions, our business could suffer;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we are unable to compete successfully, we may be unable to increase or sustain our revenue or achieve profitability;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Developing new testing products involves a lengthy and complex process, and we may not be able to commercialize on a timely basis, or at all, other testing products we are developing;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If our sole clinical laboratory facility becomes damaged or inoperable, we are required to vacate our existing facility or we are unable to expand our existing facility as needed, we will be unable to perform our testing services and our business will be harmed;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We may require substantial additional capital to finance our planned operations, which may not be available to us on acceptable terms or at all. Our failure to obtain additional financing when needed on acceptable terms, or at all, could force us to delay, limit, reduce or eliminate our product development programs, commercialization efforts or other operations;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We conduct business in a heavily regulated industry. Complying with the numerous statutes and regulations pertaining to our business is expensive and time-consuming, and any failure by us, our consultants or commercial partners to comply could result in substantial penalties;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We have previously and may again in the future be required to modify our business practices, pay fines, incur significant expenses or experience losses due to litigation or governmental investigations;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The FDA may disagree with our assessment that our AVISE&#174; test products and any other tests we may develop are LDTs and determine that such test products are medical devices subject to the FDCA and FDA regulations;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we are unable to maintain intellectual property protection, our competitive position could be harmed; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Business and Strategy </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have a history of losses, we expect to incur net losses in the future and we may not be able to generate sufficient revenue to achieve and maintain profitability. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have incurred net losses since our inception. For the years ended December&#160;31, 2023 and 2022, we incurred net losses of $23.7 million and $47.4 million, respectively, and we expect to incur additional losses in 2024 and in future years. As of December&#160;31, 2023, we had an accumulated deficit of $279.2 million. Over the next several years, we expect to continue to devote substantially all of our resources to increase adoption of, and reimbursement for, our testing products and to develop future testing products. We may not be able to generate sufficient revenue to achieve and maintain profitability. Our failure to achieve and maintain profitability in the future could cause the market price of our common stock to decline and materially and adversely affect our prospects and business. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If third-party payors do not provide coverage and adequate reimbursement for our testing products, or they breach, rescind or modify their contracts or reimbursement policies or delay payments for our testing products, or if we or our partners are unable to successfully negotiate payor contracts, our commercial success could be compromised. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Successful commercialization of our testing products depends, in large part, on the availability of coverage and adequate reimbursement from third-party payors, including government payors, such as Medicare and Medicaid and commercial payors. For the testing products that we develop and commercialize, each third-party payor decides whether to cover the product, the amount it will reimburse for a covered product and the specific conditions for reimbursement. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reimbursement by third-party payors may depend on a number of factors, including the payor&#8217;s determination that tests using our technologies are: </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">not experimental or investigational; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">medically necessary; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">demonstrated to lead to improved patient outcomes; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">appropriate for the specific patient; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">cost-saving or cost-effective; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">supported by peer-reviewed medical journals; and </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">included in clinical guidelines. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are unable to provide third-party payors with sufficient evidence of the clinical utility and validity of our test, they may not provide coverage, or may provide limited coverage, which will adversely affect our revenue and our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ability to succeed. In addition, clinicians may be less likely to order a test unless third-party payors pay a substantial portion of the test price. Therefore, coverage determinations and reimbursement levels and conditions are critical to commercial success, and if we are not able to secure positive coverage determinations and reimbursement levels, our business will be materially adversely affected.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Third-party payors and other entities also conduct technology assessments of new medical tests and devices and provide and/or sell the results of their assessments to other parties. These assessments may be and have been used by third-party payors and healthcare providers as grounds to deny coverage for or refuse to use a test or procedure, including our tests. In addition, third-party payors have increased their efforts to control the cost, utilization and delivery of healthcare services. These measures have resulted in reduced payment rates and decreased utilization for the diagnostics industry. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Effective April 25, 2012, Palmetto GBA, the Medicare MolDx Program, assigned the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> MTX assay a unique identifier and determined that the test meets the applicable Medicare coverage criteria to support dose optimization and therapeutic decision making for patients diagnosed with RA on methotrexate. Our current Medicare Administrative Contractor, Noridian, has adopted this coverage policy. In addition, and effective April 1, 2022, CMS agreed to recognize a new PLA code for our protein-based test, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus. Noridian priced this PLA code at $1,085 per test. To determine pricing beyond 2022, CMS recommended crosswalking AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus (0312U) to Vectra (81490) at a rate of $840.65 per test. This pricing was finalized on the 2023 CLFS and is effective from January 1, 2023 through December 31, 2025. A pricing determination is not synonymous with a coverage determination. Having a price associated with the PLA code for any particular test does not secure coverage or reimbursement for that PLA code from Medicare or any other third-party payor. So, in an effort to improve transparency regarding Medicare support of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus, we submitted a formal request to Noridian for coverage of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test under the new PLA Code. On September 27, 2022, we received notice that Noridian has deemed our application for an LCD to be valid. Ultimately receiving a favorable LCD is uncertain and may be time-consuming, resource intensive and require multiple quarterly or annual periods to complete. We have faced and may again face or continue to face challenges relating to commercial payor claim processing and revenue with our tests.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other third-party payors make their own decisions as to whether to establish a policy to reimburse our testing products. Because approvals must be sought on a payor-by-payor basis, establishing broad coverage is a time-consuming and costly process. There are many third-party payors who have not yet established a coverage policy applicable to our testing products. In addition, several commercial payors issued non-coverage policies with respect to AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus, determining that AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus does not meet the medical criteria for coverage and is considered investigational and/or experimental. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While our testing products are reimbursed by a number of third-party payors, we do not currently have contracts with significant private payors. We have in the past, and will likely in the future, experience delays and temporary interruptions in the receipt of payments from third-party payors due to changes in their internal processes, documentation requirements and other issues, which could cause our revenue to fluctuate from period to period. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are not successful in reversing existing non-coverage policies, or if other third-party payors issue negative coverage policies, these policies could have a material adverse effect on our business and operations. Even if many third-party payors currently reimburse for our testing products, such payors have in the past and may again withdraw coverage at any time, review and adjust the rate of reimbursement, require co-payments from patients or stop paying for our testing products altogether, any of which could materially reduce our revenue. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">In the near-term, we expect that our financial results will depend primarily on sales of our testing products, and we will need to generate sufficient revenue from these testing products to grow our business. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A significant majority of our historical revenue has been derived from the sale of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD testing product, which we commercially launched in 2012. In the near term, we expect to continue to derive a majority of our revenue from sales of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD. We are in various stages of research and development with respect to other testing products that we may offer, but there can be no assurance that we will be able to commercialize these testing products. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The demand for our testing products may decrease or may not continue to increase at historical rates for a number of reasons. In addition, at any point in time we may decide to no longer commercialize any of our testing products for any number of reasons. While we have experienced revenue growth from the sale of our testing products, we may not be able to sustain this growth or maintain existing revenue levels. Further, we cannot ensure the continued availability of our testing products in commercial quantities at acceptable costs. If we are unable to increase sales of our testing products, expand reimbursement for our testing products, or successfully develop and commercialize </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">additional testing products, our revenue and our ability to achieve and sustain profitability would be impaired, and the market price of our common stock could decline.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our operations could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics, political instability, acts of war, including the current conflict in Ukraine and the Middle East, and other natural or manmade disasters (which may be exacerbated due to climate change) or business interruptions, for which we are predominantly self-insured. We rely on third-party manufacturers to produce our testing products. Our ability to obtain clinical supplies of our testing products could be disrupted if the operations of these suppliers were affected by a man-made or natural disaster or other business interruption. In addition, our corporate headquarters is located in Vista, California near major earthquake faults and fire zones, and the ultimate impact on us of being located near major earthquake faults and fire zones and being consolidated in a certain geographical area is unknown. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to Section 404 of Sarbanes-Oxley, our management is required to report upon the effectiveness of our internal control over financial reporting. When we lose our status as an &#8220;emerging growth company&#8221; and reach an accelerated filer threshold, our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the Exchange Act, we may need to upgrade our information technology systems; implement additional financial and management controls, reporting systems and procedures; and/or hire additional accounting and finance staff as we grow. If we or, if required, our auditors are unable to conclude that our internal control over financial reporting is effective, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On November 13, 2022, management and the Audit Committee determined that we made certain errors in revenue resulting from erroneous and duplicate billings related to changes in billing practices. The errors were due to the inadequate design, implementation and precision of internal controls and procedures to evaluate and monitor the accounting for revenue recognition. As a result, revenue and accounts receivable were overstated and other liabilities was understated for the quarter and year to date periods ended June 30, 2022.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We concluded that these were material errors in the financial statements requiring a restatement of the Form 10-Q for the three and six months ended June 30, 2022. Accordingly, management determined that this control deficiency constituted a material weakness as of December 31, 2022.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In response to the material weaknesses, and as previously disclosed in Item 9A of our annual report on Form 10-K for the year ended December 31, 2022, we implemented a remediation plan which included, but was not limited to, evaluating the staffing level, skills and qualification of accounting department personnel, enhancement of our existing control structure and processes for revenue recognition and improving the detailed review process of our revenue recognition models. The enhancements made to our control environment were in place as of December 31, 2023, and based on the evaluation of relevant internal controls, management has concluded that the material weaknesses previously identified have been remediated as of December 31, 2023.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting once that firm begin its Section 404 reviews, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may be unable to manage our growth effectively, which could make it difficult to execute our business strategy. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the need to scale our testing capacity, our future growth plans may also impose significant added responsibilities on management, including the need to identify, recruit, train and integrate additional employees and the need to manage additional relationships with various partners, suppliers and other third parties. In addition, if we were to experience rapid and significant growth, our administrative and operational infrastructure may be strained, requiring us to expand our financial, development, regulatory, manufacturing, marketing and sales capabilities or contract with third parties to provide these capabilities for us. Our ability to manage our business and growth, as well as function as a public company, will require us to continue to improve our operational, financial and management controls, reporting systems and procedures. The time and resources required to optimize these systems is uncertain, and failure to complete optimization in a timely and efficient manner could adversely affect our operations. If we are unable to manage our ongoing and future growth effectively, it may be difficult for us to execute our business strategy and our business could be harmed. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our commercial success depends upon attaining and maintaining significant market acceptance of our testing products among rheumatologists, patients, third-party payors and others in the medical community. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our success depends on our ability to continue to develop and market testing products that are recognized and accepted as safe, effective, reliable and cost effective, and any testing product that we offer may not gain or maintain market acceptance among rheumatologists, third-party payors, patients or the medical community. Market acceptance of our testing products depends on a number of factors, including: </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the perceived accuracy of our test results by rheumatologists and patients;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the potential and perceived advantages of our testing products over alternative products;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the demonstration of the performance and clinical validity of our testing products in clinical studies, the results of which, may not replicate the positive results from earlier studies; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the introduction of new tests that compete with our testing products;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the product cost in relation to alternative products;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">publicity concerning our testing products or competing products and treatments;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the availability of coverage and adequate reimbursement by third-party payors, including government authorities;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">relative convenience and ease of administration; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the effectiveness of our sales and marketing efforts.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, if we or our future partners have to withdraw a product from the market, it could harm our business and/or impact market acceptance of our other testing products. Further, our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products consist of various biomarkers, any of which could independently encounter issues with manufacturing, supply or overall quality. If any of the biomarkers in our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test were to encounter any issues, we may experience an impact in the overall success of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CTD as a whole, including a reduction in ASP or overall revenue, until such time as it can be remedied. Moreover, if our testing products do not achieve an adequate level of acceptance by rheumatologists, hospitals, third-party payors or patients, we may not generate sufficient revenue from that testing product and may not become or remain profitable. Our efforts to educate the medical community and third-party payors regarding the benefits of our testing products may require significant resources and may never be successful. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may experience limits on our revenue if rheumatologists decide not to order our testing products or if we are otherwise unable to create or maintain demand for our testing products. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are unable to create or maintain demand for our testing products in sufficient volume, we may not generate sufficient revenue to become profitable. To generate increased demand, we will need to continue to educate rheumatologists about the benefits of our testing products through publications in peer-reviewed medical journals, presentations at medical conferences and other similar means. For example, in the fourth quarter of 2023, we were featured in five scientific presentations at the 2023 ACR Annual Conference, ACR Convergence 2023. We will also need to generate demand for our testing products through one-on-one education by our sales force. We also plan to focus on educating patients about the benefits of these testing products, which we believe will be necessary to generate further demand. In addition, our inability to obtain and maintain coverage and adequate reimbursement </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">from third-party payors may limit adoption by rheumatologists, as well as third-party payors exerting pressure on rheumatologists and healthcare providers to order in-network testing products which could adversely affect our revenue.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Rheumatologists may rely on guidelines issued by industry groups regarding the diagnosis, prognosis, treatment and monitoring of autoimmune and autoimmune-related diseases, and the monitoring of the effectiveness of therapeutic drugs used to treat such diseases before utilizing any diagnostic test or monitoring solution. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The sizes of the markets for our testing products have not been established with precision and may be smaller than we estimate. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our estimates of the annual total addressable markets for our current and potential future testing products are based on a number of internal and third-party estimates. These include, without limitation, the number of patients with autoimmune and autoimmune-related diseases and the assumed prices at which we can sell testing products and our partners can sell therapeutics in markets that have not been established. While we believe our assumptions and the data underlying our estimates are reasonable, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors. As a result, our estimates of the annual total addressable market for our current and potential future testing products may prove to be incorrect. If the actual number of patients who would benefit from our testing products, the price at which we and our partners can sell future testing products, or the annual total addressable market for our testing products is smaller than we have estimated, it may impair our sales growth and have an adverse impact on our business. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may expend our limited resources to pursue a particular testing product and fail to capitalize on other testing products that may be more profitable or for which there is a greater likelihood of success. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because we have limited financial and managerial resources, we focus on specific testing products. As a result, we may forego or delay pursuit of opportunities with others that could have had greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. In addition, our spending on current and future research and development programs for testing products may not yield any commercially viable testing products. If we do not accurately evaluate the commercial potential or target market for a potential testing product, we may forego other similar arrangements which would have been more advantageous for us to pursue.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to: </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to successfully market and sell our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the extent to which our current testing and future testing products, if any, are eligible for coverage and reimbursement from third-party payors;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the timing and cost of, and level of investment in, research, development, regulatory approval and commercialization activities relating to our testing products, which may change from time to time, and our ability to successfully commercialize new testing products; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the cost of supplies, equipment and materials used for our testing products and laboratory operations, which may vary depending on the quantity of production and the terms of our agreements with third-party suppliers and manufacturers; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">expenditures that we may incur to acquire, develop or commercialize additional testing products and technologies; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the level of demand for our testing products, which may vary significantly; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the receipt, timing and mix of revenue for our testing products; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">future accounting pronouncements or changes in our accounting policies;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to collect timely reimbursement for our tests;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the rate and extent to which payors make an overpayment determination and require us to return all or some portion of payments which we received in a prior period; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the timing and success or failure of competing products, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. For instance during 2023, our operating results varied due, in part, to our efforts regarding revenue cycle management. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, it could have a material adverse effect on our business, financial condition and results of operations. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We rely on sole suppliers for some of the reagents, equipment and other materials used in our testing products, and a sole third-party fulfillment center used to supply healthcare providers with our testing products, and we may not be able to find replacements or transition to alternative suppliers or fulfillment centers.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We rely on sole suppliers for critical supply of reagents, equipment and other materials that we use to perform the tests that comprise our testing products. We also purchase components used in our specimen collection and transportation kits from sole-source suppliers. Some of these items are unique to these suppliers and vendors. While we have developed alternate sourcing strategies for many of these materials and vendors, we cannot be certain whether these strategies will be effective or the alternative sources will be available when we need them. We are not a major customer of some of our suppliers, and these suppliers may therefore give other customers&#8217; needs higher priority than ours. If our suppliers can no longer provide us with the materials we need to perform the tests that comprise our testing products, if the materials do not meet our quality specifications, or if we cannot obtain acceptable substitute materials, an interruption in test processing could occur and, in certain circumstances, we may be required to amend or cancel test results we have issued. Additionally, if we are unable to remedy future potential quality issues with unique reagent suppliers, or otherwise find a supplier for future biomarkers with issues, we may experience difficulties obtaining market acceptance for our products. Moreover, any issues with quality may result in a change from time to time of the composition of our tests, including our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CTD test, which could impact the average selling price and revenues received from sales of such test.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, if we should encounter delays or difficulties in securing the quality and quantity of equipment we require for our testing products, we may need to reconfigure our test processes, which could result in an interruption in sales. Any such interruption may significantly affect our future revenue and harm our customer relations and reputation. In addition, in order to mitigate these risks, we may need to maintain inventories of these supplies at higher levels than would be the case if multiple sources of supply were available.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We rely on a third party as our sole fulfillment center in Florida to supply healthcare providers with our testing products. Our sole fulfillment center could be harmed or rendered inoperable by natural or man-made disasters, including fire, earthquake, hurricane, flooding, pandemics or other disease outbreaks and power outages, which may render it difficult or impossible for us to supply healthcare providers with our testing products for some period of time. The inability to supply healthcare providers with our testing products or the backlog of tests that could develop if our sole fulfillment center is inoperable for even a short period of time, may result in the loss of customers or harm to our reputation or business relationships, and we may be unable to regain those customers or repair our reputation in the future. Furthermore, our sole fulfillment center could be costly and time-consuming to repair or replace. If our sole fulfillment center is destroyed or otherwise rendered inoperable, we may have difficulty replacing this fulfillment center and there can be no assurance we could do so in a timely manner, on terms favorable to us or at all.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we are unable to support demand for our current testing products or any of our future testing products or solutions, our business could suffer. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If demand for our testing products or any of our future testing products or solutions grows, we will need to continue to scale our testing capacity and processing technology, expand customer service, billing and systems processes and enhance our internal quality assurance program. We may also need additional certified laboratory scientists and other scientific and technical personnel to process higher volumes of our testing products. We cannot assure you that any increases in scale, related improvements and quality assurance will be successfully implemented or that appropriate personnel will be available. We will also need to purchase additional equipment, some of which can </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">take several months or more to procure, setup and validate, and increase our software and computing capacity to meet increased demand. Failure to implement necessary procedures, transition to new processes, hire the necessary personnel, obtain any necessary additional equipment and increase software and computing capacity could result in higher costs of processing tests or inability to meet demand. There can be no assurance that we will be able to perform our testing on a timely basis at a level consistent with demand, or that our efforts to scale our operations, expand our personnel, equipment, software and computing capacities, or implement process enhancements will be successfully implemented and will not negatively affect the quality of test results. In addition, there can be no assurance that we will have adequate space in our laboratory facility to accommodate such required expansion. We are also currently collaborating with third parties in an effort to implement multiplex technology in our laboratory. We may experience difficulties securing a partner for this technology and integrating such technology into our existing laboratory operations, which could affect our ability to meet demand for our testing products. If we encounter difficulty meeting market demand or quality standards, our reputation could be harmed and our future prospects and our business could suffer. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Billing for our testing products is complex, and we must dedicate substantial time and resources to the billing process to be paid for our testing products. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Billing for our testing products is complex, time consuming and expensive. Depending on the billing arrangement and applicable law, we bill various third-party payors, including Medicare and Medicaid, and commercial payors, as well as patients, all of which have different billing requirements. We generally bill third-party payors for our testing products and pursue reimbursement on a case-by-case basis where pricing contracts are not in place. We may also face increased risk in our collection efforts, including long collection cycles and potential delays in claims processing, which could adversely affect our business, results of operations and financial condition. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Several factors contribute to the complexity of the billing process, including: </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">differences between the list price for our testing products and the reimbursement rates of third-party payors; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">compliance with complex federal and state regulations related to billing Medicare and Medicaid; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">disputes among third-party payors as to which party is responsible for payment; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">differences in coverage among third-party payors; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the effect of patient deductibles, co-payments or co-insurance; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">differences in information and billing requirements among third-party payors; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">changes to billing codes used for our testing products; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">risk of government audits related to billing; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">incorrect or missing billing information; and </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the resources required to manage the billing and claims appeals process. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We use standard industry billing codes, known as CPT codes, to bill for our testing products. If these codes were to change, there is risk that errors could be made in the claim adjudication process. Such errors can occur with claims submission, third-party transmission or in the processing of the claim by the payor. Claim adjudication errors may result in a delay in payment processing or a reduction in the amount of the payment received. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As we introduce new testing products, we will need to add new codes to our billing process as well as our financial reporting systems. Failure or delays in effecting these changes in external billing and internal systems and processes could negatively affect our collection rates, revenue and cost of collecting. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our billing activities require us to implement compliance procedures and oversight, train and monitor our employees, and undertake internal audits to evaluate compliance with applicable laws and regulations as well as internal compliance policies and procedures. Payors also conduct external audits to evaluate payments, which add further complexity to the billing process. If the payor makes an overpayment determination, there is a risk that we may be required to return all or some portion of prior payments we have received. Additionally, providers and suppliers must report and return overpayments received from the Medicare and Medicaid programs within 60 days of identification. Failure to identify and return such overpayments exposes the provider or supplier to liability under the federal False Claims Act. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, from time to time, third-party payors change processes that may affect timely payment. These changes have in the past and may again result in uneven cash flow or impact the timing of revenue recognized with these payors. With respect to payments received from government healthcare programs, factors such as a prolonged government shutdown could cause significant regulatory delays or could result in attempts to reduce payments made to us by federal healthcare programs. In addition, third-party payors may refuse to ultimately make payment if their processes and requirements have not been met on a timely basis. These billing complexities, and the related uncertainty in obtaining payment for our testing products could negatively affect our revenue and cash flow, our ability to achieve profitability, and the consistency and comparability of our results of operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2023, Noridian posted the calendar year 2024 Medicare Physician Fee Schedule (MPFS), and CLFS, which establishes the reimbursement rates to be paid by Medicare for our jurisdiction for services performed on or after January 1, 2024. PAMA and changes to the PFS did not have a significant impact to Medicare reimbursement for AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD in 2024 compared to levels experienced in 2023. Revenue from Medicare comprised 34% and 39% of our revenue for the years ended December&#160;31, 2023 and 2022, respectively. Revenue from the sale of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD testing products comprised 88% and 84% of our revenue for the years ended December&#160;31, 2023 and 2022, respectively. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We also rely on a third-party provider to provide revenue cycle management software systems for certain processing and collection functions. In the past, we have experienced delays in claims processing as a result of our third-party provider making changes to its invoicing system, as well as not submitting claims to payors within the timeframe required. If claims for our testing products are not submitted to payors on a timely basis, or if we are required to switch to a different systems provider, it could have an adverse effect on our revenue and our business. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At times, we share our proprietary technology and confidential information, including trade secrets, with third parties that conduct studies and other services on our behalf. We seek to protect our proprietary technology, in part, by entering into confidentiality agreements, consulting agreements or other similar agreements with our advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are intentionally or inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets and despite our efforts to protect our trade secrets, a competitor&#8217;s discovery of our proprietary technology and confidential information or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we are unable to maintain or expand our sales and marketing force, as needed, to adequately address our customers&#8217; and future partners&#8217; needs, our business may be adversely affected. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We sell our testing products through our own specialized sales force. Our testing products compete in a concentrated specialty market of autoimmune and autoimmune-related diseases, and utilizing a specialized sales force is integral to our strategy. As such, we believe it is necessary to maintain a sales force that includes sales representatives with specific technical backgrounds and industry expertise and expect to continue to evaluate the reach and frequency with rheumatologists, including as we launch our pipeline products. We may be required to expand our specialized sales force as our company grows. Training of additional sales representatives can be costly and time consuming, particularly given the level of experience and sophistication we seek in our sales force. If we are unable to effectively retain, train and integrate additional sales representatives, as needed, it may adversely affect our ability to effectively market and sell our testing products. In addition, competition for highly specialized sales personnel is intense, and we may not be able to attract and retain personnel or be able to maintain an efficient and effective sales and marketing force. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our future sales will depend in large part on our ability to maintain an effective sales force. If we are unsuccessful in this regard, it could negatively impact our revenue growth and potential profitability. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we are unable to compete successfully, we may be unable to increase or sustain our revenue or achieve profitability. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our principal competition for our testing products is traditional methods used by healthcare providers to test patients with CTD-like symptoms. Such traditional methods include testing for a broad range of diagnostic, immunology and chemistry biomarkers, such as ANA and anti-dsDNA and serum complement biomarkers, such as C3 and C4. We </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">also face competition from commercial laboratories, such as ARUP Laboratories, Inc.; Laboratory Corporation of America Holdings; the Mayo Clinic; and Quest Diagnostics Incorporated, all of which have existing infrastructures to support the commercialization of diagnostic services. Large, multispecialty group medical clinics, health systems and academic medical university-based clinics may provide in-house clinical laboratories offering autoimmune and autoimmune-related disease testing services. Additionally, we compete against regional clinical laboratories providing testing in the autoimmune and autoimmune-related disease field, including Rheumatology Diagnostics Laboratories, Inc. (acquired by Laboratory Corporation of America in June 2020). Other potential competitors include companies that might develop diagnostic or disease or drug monitoring products, such as AMPEL BioSolutions, LLC; DxTerity Diagnostics Inc.; Genalyte Inc.; Immunovia AB; Oncimmune plc; Progentec Diagnostics Inc.; and Scipher Medicine Corporation. In the future, we may also face competition from companies developing new products or technologies.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe the principal competitive factors in our target market include: quality and strength of clinical and analytical validation data; confidence in diagnostic results; sales and marketing capabilities; the extent of reimbursement; inclusion in clinical guidelines; cost-effectiveness; and ease of use. We rely upon independent sources for phlebotomy to obtain patient samples; interruptions to this capability could dramatically impact patient access to our tests.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Many of our potential competitors have widespread brand recognition and substantially greater financial, technical and research and development resources and selling and marketing capabilities than we do. Others may develop products with prices lower than ours that could be viewed by rheumatologists and payors as functionally equivalent to our solution or offer solutions at prices designed to promote market penetration, which could force us to lower the list price of our products and affect our ability to achieve profitability. If we are unable to change clinical practice in a meaningful way or compete successfully against current and future competitors, we may be unable to increase market acceptance and sales of our products, which could prevent us from increasing our revenue or achieving profitability and could cause the market price of our common stock to decline. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To compete successfully we must be able to demonstrate, among other things, that our testing products are accurate and cost effective. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Developing new testing products involves a lengthy and complex process, and we may not be able to commercialize on a timely basis, or at all, other testing products we are developing. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may not be able to develop testing products with the clinical utility necessary to be useful and commercially successful. There are certain products for which a commercial launch would trigger additional payment obligations to licensors of the technology. In these cases, if the economic projections of the product do not outweigh the additional obligations, we may not launch these products. In order to develop and commercialize testing products, we need to: </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">expend significant funds to conduct substantial research and development; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">conduct successful verification, validation and utility studies; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">develop and scale our laboratory processes to accommodate different tests; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">achieve and maintain required regulatory certifications, including the hiring of appropriately licensed laboratory personnel; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">develop and scale our infrastructure to be able to analyze increasingly large amounts of data; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">build the commercial infrastructure to market and sell new testing products. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our testing product development process involves a high degree of risk and may take several years. Our testing product development efforts may fail for many reasons, including: </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">failure to identify additional biomarkers to incorporate into our testing products; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">failure or sub-optimal performance of the testing product at the research or development stage;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">obtaining patient consent inclusive of genetic analysis;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">difficulty in accessing archival patient specimens, especially specimens with known clinical results; or </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">failure of clinical validation, utility and outcome studies to support the effectiveness of the test. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Typically, few research and development projects result in commercial products, and success in early clinical studies often is not replicated in later studies. At any point, we may abandon development of a testing product candidate or we may be required to expend considerable resources repeating clinical studies, which would adversely affect the timing for generating potential revenue from a new testing product and our ability to invest in other products in our pipeline. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, as we develop testing products, we may have to make significant investments in product development, marketing and selling resources. If a clinical validation study fails to demonstrate the prospectively defined endpoints of the study, we might choose to abandon the development of the testing product or product feature that was the subject of the clinical study, which could harm our business. Additionally, competitors may develop and commercialize competing products or technologies faster than us or at a lower cost. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Developing new testing products and enhancements to our existing technologies is expensive and time consuming, and there is no assurance that such activities will result in significant new marketable testing products, enhancements to our current technologies, design improvements, cost savings, revenue or other expected benefits. If we spend significant resources on research and development and are unable to generate an adequate return on our investment or divert resources away from other, more attractive growth opportunities, our business and results of operations may be materially and adversely affected. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we cannot enter into new clinical study collaborations, our product development and subsequent commercialization could be delayed. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the past, we have entered into clinical study collaborations, and our success in the future depends in part on our ability to enter into additional collaborations with highly regarded institutions. This can be difficult due to internal and external constraints placed on these organizations. Some organizations may limit the number of collaborations they have with any one company so as to not be perceived as biased or conflicted. Organizations may also have insufficient administrative and related infrastructure to enable collaborations with many companies at once, which can extend the time it takes to develop, negotiate and implement a collaboration. Additionally, organizations often insist on retaining the rights to publish the clinical data resulting from the collaboration. The publication of clinical data in peer-reviewed medical journals is a crucial step in commercializing and obtaining reimbursement for testing products such as ours, and our inability to control when and if results are published may delay or limit our ability to derive sufficient revenue from any solution. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may acquire businesses or assets, form joint ventures or make investments in other companies or technologies that could harm our operating results, dilute our stockholders&#8217; ownership, increase our debt or cause us to incur significant expense. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of our business strategy, we may pursue acquisitions of complementary businesses or assets, as well as technology licensing arrangements and other strategic transactions or collaborations with third parties. We also may pursue strategic alliances that leverage our core technology and industry experience to expand our offerings or distribution, make investments in other companies or acquire ownership rights to therapeutics that are synergistic with our testing products. To date, other than our acquisition of the medical diagnostics division of Cypress Bioscience, Inc. in 2010, we have not acquired other companies or therapeutics and we have limited experience with respect to the formation of strategic alliances and joint ventures. If we make any acquisitions, we may not be able to integrate these acquisitions successfully into our existing business, and we could assume unknown or contingent liabilities. Any future acquisitions by us also could result in significant write-offs or the incurrence of debt and contingent liabilities, any of which could harm our operating results. Integration of an acquired company, business or assets also may require management resources that otherwise would be available for ongoing development of our existing business. We may not identify or complete these transactions in a timely manner, on a cost-effective basis, or at all, and we may not realize the anticipated benefits of any acquisition, technology license, strategic alliance, joint venture or investment. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To finance any acquisitions or investments, we may choose to issue shares of our stock as consideration, which would dilute the ownership of our stockholders. If the price of our common stock is low or volatile, we may not be able to acquire other companies for stock. Alternatively, it may be necessary for us to raise additional funds for these activities through public or private financings or through the issuance of debt. Additional funds may not be available on terms that are favorable to us, or at all, and any debt financing may involve covenants limiting or restricting our ability to take certain actions. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Also, the anticipated benefit of any strategic alliance, joint venture or acquisition may not materialize or such strategic alliance, joint venture or acquisition may be prohibited. In addition, our loan agreement restricts our ability to pursue certain mergers, acquisitions, amalgamations or consolidations that we may believe to be in our best interest. Additionally, future acquisitions or dispositions could result in potentially dilutive issuances of our equity </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">securities, the incurrence of debt, contingent liabilities or amortization expenses or write-offs of goodwill, any of which could harm our financial condition. We cannot predict the number, timing or size of future joint ventures or acquisitions, or the effect that any such transactions might have on our operating results. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The diagnostic industry is subject to rapidly changing technology, which could make our current and future testing products obsolete. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our industry is characterized by rapid technological changes, frequent new product introductions and enhancements and evolving industry standards. These advances require us to continuously develop our technology and work to develop new solutions to keep pace with evolving standards of care. Our testing products could become obsolete unless we continually innovate and expand our testing product offerings to include new clinical applications. If we are unable to develop new testing products or to demonstrate the applicability of our testing products for other diseases, our sales could decline and our competitive position could be harmed. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our failure to maintain relationships or build new relationships with key opinion leaders could materially adversely impact our business and prospects. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Key opinion leaders are able to influence clinical practice by publishing research and determining whether new tests should be integrated into clinical guidelines. We rely on key opinion leaders early in the development process to help ensure our clinical studies are designed and executed in a way that clearly demonstrates the benefits of our testing products to healthcare providers and payors. Our failure to maintain or build new relationships with such key opinion leaders could affect rheumatologist and patient perception of our testing products and result in a loss of existing and future customers and therefore materially adversely impact our business and prospects. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we are sued for errors and omissions or professional liability, we could face substantial liabilities that exceed our resources. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The marketing, sale and use of our testing products could lead to liability claims if someone were to allege that any such testing product failed to perform as it was designed. We may also be subject to liability for errors in the results we provide to rheumatologists or for a misunderstanding of, or inappropriate reliance upon, the information we provide. We may also be subject to similar types of claims related to testing products we may develop in the future. Any errors or omissions or professional liability claim could result in substantial damages and be costly and time consuming for us to defend. Although we maintain professional liability insurance, we cannot assure you that our insurance would fully protect us from the financial impact of defending against these types of claims or any judgments, fines or settlement costs arising out of any such claims. Any errors or omissions or professional liability claim brought against us, with or without merit, could increase our insurance rates or prevent us from securing insurance coverage in the future. Additionally, any product liability lawsuit could cause injury to our reputation or cause us to suspend sales of our testing products. Similarly, any product liability lawsuit affecting our partners could also cause injury to our reputation. We may also initiate a correction or removal for one of our testing products, issue a safety alert or undertake a field action or recall to reduce a risk to health posed by potential failure of our products to perform as designed, which could lead to increased costs and lead to increased scrutiny by regulatory authorities and our customers regarding the quality and safety of our testing products and to negative publicity, including safety alerts, press releases or administrative or judicial actions. The occurrence of any of these events could have an adverse effect on our business and results of operations. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The loss of members of our senior management team or our inability to attract and retain highly skilled scientists, technicians and salespeople could adversely affect our business. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our success depends largely on the skills, experience and performance of key members of our executive management team, including John Aballi, our President and Chief Executive Officer, and others in key management positions. The efforts of each of these persons will be critical to us as we continue to develop our technologies and test processes and focus on our growth. If we were to lose one or more of these key employees, we may experience difficulties in competing effectively, developing our technologies and implementing our business strategy. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, our research and development programs and commercial laboratory operations depend on our ability to attract and retain highly skilled scientists, including licensed clinical laboratory scientists and biostatisticians. We may not be able to attract or retain qualified scientists and technicians in the future due to the intense competition for qualified personnel among life science businesses, particularly in Southern California. Because it is expected that there will be a shortage of clinical laboratory scientists in coming years, it may become more difficult to hire sufficient numbers of qualified personnel. We also face competition from universities and public and private research institutions in recruiting and retaining highly qualified scientific personnel. Additionally, our success depends on our ability to attract and retain qualified and highly-specialized salespeople. We may have difficulties locating, recruiting or retaining qualified salespeople, which could cause a delay or decline in the rate of adoption of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">our testing products. If we are not able to attract and retain the necessary personnel to accomplish our business objectives, we may experience constraints that could adversely affect our ability to support our research and development, clinical laboratory and sales efforts. All of our employees are at-will, which means that either we or the employee may terminate their employment at any time.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If our sole clinical laboratory facility becomes damaged or inoperable, we are required to vacate our existing facility or we are unable to expand our existing facility as needed, we will be unable to perform our testing services and our business will be harmed.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We currently derive all of our revenue from tests conducted at a single laboratory facility located in Vista, California. Vista is situated on or near earthquake fault lines. Our facility and equipment could be harmed or rendered inoperable by natural or man-made disasters which may be exacerbated due to climate change, including earthquake, fire, flood, power loss, communications failure or terrorism, or public health crises. In particular, we store all of our flow cytometers, the instrument we use to detect CB-CAPs on cells, at our Vista facility. If all of our flow cytometers were rendered inoperable simultaneously pursuant to a natural or man-made disaster, we would be unable to perform these key tests as we do in the ordinary course of our business. The inability to perform the tests contained in our testing products or to reduce the backlog of analyses that could develop if our facility is inoperable, for even a short period of time, may result in the loss of customers or harm to our reputation, and we may be unable to regain those customers or repair our reputation in the future. Additionally, we store our bio-repository of specimens, which were collected in collaboration with leading academic institutions and help us to further validate our testing products, at our Vista facility. If these specimens were destroyed pursuant to a natural or man-made disaster or otherwise become unavailable, our ability to develop new testing products may be delayed. Furthermore, our facility and the equipment we use to perform our research and development work could be unavailable or costly and time-consuming to repair or replace. It would be difficult, time-consuming and expensive to rebuild our facility or license or transfer our proprietary technology to a third party, particularly in light of the licensure and accreditation requirements for a commercial laboratory like ours. Even in the unlikely event we are able to find a third party with such qualifications to enable us to conduct the tests contained in our testing products, we may be unable to negotiate commercially reasonable terms. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In order to rely on a third party to perform the tests contained in our testing products (even assuming we are able to do so in compliance with applicable regulations), we would need to engage another facility with established state licensure and CLIA certification under the scope of which tests could be performed following validation and other required procedures. We cannot assure you that we would be able to find another CLIA-certified facility willing to comply with the required procedures, that any such facility would be willing to perform the tests contained in our testing products for us on commercially reasonable terms, or that it would be able to meet our quality standards. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In order to establish additional clinical reference laboratory facilities, we have to spend considerable time and money securing adequate space, which may include constructing additional facilities, recruiting and training employees, and establishing the additional operational and administrative infrastructure necessary to support a second facility. We may not be able, or it may take considerable time, to replicate our testing processes or results in any new or converted facility. Additionally, any new clinical reference laboratory facility opened by us would be subject to certification under CLIA and licensing by several states, including, as applicable, California and New York, which could take a significant amount of time and result in delays in our ability to begin operations. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe we have the capacity to meet our projected needs for at least the next 12 months, although we may grow at a rate that is faster than we expect. We may need to further expand our laboratory space in the future. Any future expansion could disrupt laboratory operations, resulting in an inability to meet customer turnaround time expectations, and could be delayed, resulting in slower realization of laboratory efficiencies anticipated from the use of the expanded facilities. Adverse consequences resulting from a delay in the laboratory expansion could harm our relationships with our customers and our reputation, and could affect our ability to generate revenue. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We carry insurance for damage to our property and the disruption of our business, but this insurance may not cover all the risks associated with damage or disruption to our business, provide coverage in amounts sufficient to cover our potential losses or continue to be available to us on acceptable terms, if at all. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our testing process involves the use of sophisticated state-of-the-art equipment that requires precise calibration, and issues affecting such equipment may delay delivery or impact the quality of the test results to rheumatologists or otherwise adversely affect our operations. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of our process of determining CB-CAPs, the key biomarker detection and measurement technology incorporated into our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus and AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD products, we utilize a number of flow cytometers that require calibration and performance validation according to the requirements of the CAP at specified time intervals. While we believe we have implemented appropriate controls and metrics in our laboratory to meet such requirements, we </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">cannot provide any assurance that our instruments will not fall out of specification, in which case we would be required to re-calibrate them. Failure to timely re-calibrate our instruments could negatively impact the test results, which could result in liability and harm our reputation. Patient specimens degrade and become unusable generally within 48 hours of collection. Therefore, if we do not have other sufficient properly functioning flow cytometers due to failure to meet specifications or they otherwise become inoperable, our ability to process patient specimens in the required timeframe would be compromised and our business could be harmed. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Failure in our information technology, telephone or other systems could significantly disrupt our operations and adversely affect our business and financial condition. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Information technology and telephone systems are used extensively in virtually all aspects of our business, including laboratory testing, sales, billing, customer service, logistics and management of medical data. The success of our business depends on the ability to obtain, process, analyze, maintain and manage this data. Our management relies on our information systems because: </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">patient specimens must be received, tracked and processed on a timely basis; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">test results must be reported on a timely basis; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">billings and collections for all customers must be managed efficiently and accurately; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">third-party ancillary billing services require proper tracking and reporting; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">pricing and other information related to our services is needed by our sales force and other personnel in a timely manner to conduct business; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">patient-identifiable health information must be securely held and kept confidential; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">regulatory compliance requires proper tracking and reporting; and </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">proper recordkeeping is required for operating our business, managing employee compensation and other personnel matters. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our business, results of operations and financial condition may be adversely affected if, among other things: </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our information technology, telephone or other systems fail or are interrupted for any extended length of time; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">services relating to our information technology, telephone or other systems are not kept current; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our information technology, telephone or other systems do not have the capacity to support expanded operations and increased levels of business; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">data is lost or unable to be restored or processed; or </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">data is corrupted due to a breach of security. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Despite the precautionary measures we have taken to prevent breakdowns in our information technology, telephone and other systems, sustained or repeated system failures that interrupt our ability to process test orders, deliver test results or perform testing in a timely manner or that cause us to inadvertently disclose or lose patient information could adversely affect our business, results of operations and financial condition. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Security breaches, loss of data and other disruptions to us, our third-party service providers or our partners could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the ordinary course of our business, we and our partners, and our respective third-party service providers collect and store sensitive data, such as PHI (including test results), personally identifiable information and credit card information. We also store business and financial information, intellectual property, research and development information, trade secrets, and other proprietary and business critical information, including that of our customers, payors and third-party partners. We manage and maintain our applications and data utilizing a combination of on-site and vendor-owned systems. We face a number of risks related to our protection of, and our service providers&#8217; protection of, this critical information, including loss of access, unauthorized disclosure and unauthorized access, as well as risks associated with our ability to identify and audit such events and risks associated with the need to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">reconstruct any lost or stolen data. In addition, we have limited control over the storage of sensitive data by our third-party partners as well as risks related to the transfer and sale of de-identified data files to such partners. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The secure processing, storage, maintenance and transmission of this critical information is vital to our operations and business strategy, and we devote significant resources to protecting such information. Although we take measures to protect sensitive information from unauthorized access or disclosure, our information technology and infrastructure, and that of our third-party billing and collections provider, may be vulnerable to attacks by hackers or viruses or otherwise breached due to employee error, malfeasance or other activities. Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. Additionally, most of our employees have the ability to work remotely, which may increase the risk of security breaches, loss of data and other disruptions as a consequence of more employees accessing sensitive and critical information from remote locations. Because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. While we do not believe that we have experienced any such attack or breach, if such an event were to occur, our networks would be compromised and the information we store on those networks could be accessed by unauthorized parties, publicly disclosed, lost or stolen. A security breach or privacy violation that leads to unauthorized access, disclosure or modification of, or prevents access to, patient information, including PHI, could implicate state and federal breach notification laws. Any such access, disclosure or other loss of information could also result in legal claims or proceedings, and liability under laws that protect the privacy of personal information, such as HIPAA, as amended by the HITECH Act, and their implementing regulations and similar state data privacy and security laws and regulations including civil and criminal penalties. Unauthorized access, loss or dissemination could also disrupt our operations, including our ability to process tests, provide test results, bill payors or patients, process claims and appeals, provide customer assistance services, conduct research and development activities, collect, process and prepare company financial information, provide information about our products and other patient and rheumatologist education and outreach efforts through our website and manage the administrative aspects of our business and could damage our reputation, any of which could adversely affect our business. Any breach could also result in the compromise of our trade secrets and other proprietary information, which could adversely affect our competitive position.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the interpretation and application of federal and state consumer, health-related and data protection laws in the United States are often uncertain, contradictory and in flux. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices. If so, this could result in government-imposed fines or orders requiring that we change our practices, as well as private litigation, which could adversely affect our business. Moreover, these laws and their interpretations are constantly evolving and may become more stringent or inclusive over time. For example, increasing concerns about health information privacy have recently prompted the federal government to issue guidance taking a newly expansive view of the scope of the laws and regulations that they enforce. Complying with these various laws could cause us to incur substantial costs or require us to change our business practices, systems and compliance procedures in a manner adverse to our business.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are unable to prevent such security breaches or privacy violations or implement satisfactory remedial measures in connection with security incidents, we may suffer loss of reputation, financial loss, and civil or criminal fines or other penalties. In addition, these breaches and other forms of inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our financial condition, commercialization efforts and results of operations has been and may again in the future be adversely affected by outbreaks of contagious diseases.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any outbreak of a contagious disease, or other adverse public health developments, could have a material and adverse effect on our business operations. Such adverse effects could include disruptions or restrictions on the ability of our, our collaborators&#8217;, or our suppliers&#8217; personnel to travel, and could result in temporary closures of our facilities or the facilities of our collaborators or suppliers, including our sole laboratory. While the impact of the COVID-19 pandemic on our business, financial condition, results of operations and cash flows has subsided, the extent to which COVID-19 will affect our operations in the future will depend on future developments, which are highly uncertain and cannot be predicted with confidence.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Performance issues, service interruptions or price increases by our shipping carrier could adversely affect our business, results of operations and financial condition, and harm our reputation and ability to provide testing services on a timely basis. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expedited, reliable shipping is essential to our operations. We have been utilizing both United Parcel Service and Federal Express Corporation (Federal Express) for reliable and secure point-to-point transport of patient specimens </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to our laboratory and enhanced tracking of these patient specimens. Should Federal Express, United Parcel Service, or any other carrier we may use in the future, encounter delivery performance issues such as loss, damage or destruction of a specimen, it may be difficult to replace our patient specimens in a timely manner and such occurrences may damage our reputation and lead to decreased utilization from rheumatologists for our testing services and increased cost and expense to our business. In addition, any significant increase in shipping time or disruption to delivery service, whether due to bad weather, natural disaster (which may be exacerbated due to climate change), public health epidemics or pandemics, terrorist attacks or threats, labor strikes, work stoppages or boycotts, or for other reasons, could adversely affect our ability to receive and process patient specimens on a timely basis. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we, Federal Express, or United Parcel Service were to terminate our relationship, we would be required to find another party to provide expedited, reliable point-to-point transport of our patient specimens. There are only a few other providers of such nationwide transport services, and there can be no assurance that we will be able to enter into arrangements with such other providers on acceptable terms, if at all. Finding a new provider of transport services would be time-consuming and costly and result in delays in our ability to provide our testing services. Even if we were to enter into an arrangement with any such provider, there can be no assurance that they will provide the same level of quality in transport services currently provided to us by Federal Express and United Parcel Service. If any new provider does not provide, or if Federal Express or United Parcel Service does not continue to provide, the required quality and reliability of transport services at the same or similar costs, it could materially and adversely affect our business, reputation, results of operations and financial condition. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Inflation could adversely affect our business and financial results.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inflation increased significantly during 2022 and continued to increase through 2023. The current inflationary environment has resulted in higher prices, which have impacted our costs incurred to generate revenue from our laboratory testing services, costs to attract and retain personnel, and other operating costs. The severity and duration of the current inflationary environment remains uncertain and may continue to impact our financial condition and results of operations. Inflation may continue to adversely affect us by increasing the costs of products, materials (including reagents and laboratory supplies), and labor needed to operate our business in future periods. Actions by the government to stimulate the economy may increase the risk of significant inflation, which may have an adverse impact on our business or financial results. Moreover, we may not be able to pass those costs along in the products we sell. As such, inflationary pressures could have a material adverse effect on our performance and financial statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The failure of financial institutions or transactional counterparties could adversely affect our current and projected business operations and our financial condition and results of operations. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 10, 2023, Silicon Valley Bank (SVB) was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (FDIC) as receiver. Similarly, on March 12, 2023, Signature Bank and Silvergate Capital Corp. were each swept into receivership. A statement by the Department of the Treasury, the Federal Reserve and the FDIC stated that all depositors of SVB would have access to all of their money after only one business day of closure, including funds held in uninsured deposit accounts. Although we do not have any funds deposited with SVB and Signature Bank, we regularly maintain cash balances with other financial institutions in excess of the FDIC insurance limit. A failure of a depository institution to return deposits could impact access to our invested cash or cash equivalents and could adversely impact our operating liquidity and financial performance.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the Code), if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50 percentage-point change (by value) in its equity ownership by &#8220;5-percent shareholders,&#8221; as defined in the Code, over a rolling three-year period), the corporation&#8217;s ability to use its pre-change net operating loss (NOL), carryforwards and other pre-change tax attributes to offset its post-change federal taxable income and taxes, as applicable, may be limited. We previously completed a study to assess whether an ownership change, as defined by Section 382 of the Code, had occurred from our formation through December 31, 2019. Based upon this study, we determined that ownership changes had occurred in 2003, 2008, 2012, 2017 and 2019, and that our ability to use a significant portion of our NOL carryforwards is subject to limitation under Section 382 of the Code as a result of a prior ownership change. If we undergo an ownership change as a result of subsequent shifts in our stock ownership, our ability to utilize our NOL carryforwards and other pre-change tax attributes could be further limited by Sections 382 and 383 of the Code. Similar provisions of state tax law may also apply. In addition, federal NOL carryforwards generated in periods after December 31, 2017, may be carried forward indefinitely but, in taxable years beginning after December 31, 2020, may only be used to offset 80% of our taxable income. As a result of the foregoing, if we earn net taxable income, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">our ability to use NOL carryforwards and other tax attributes to offset taxable income and taxes, as applicable, may be limited. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our term loan contains restrictions that limit our flexibility in operating our business, and if we fail to comply with the covenants and other obligations under our loan agreement, the lenders may be able to accelerate amounts owed under the facility and may foreclose upon the assets securing our obligations. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2017, we entered into the loan and security agreement (the 2017 Term Loan) with Innovatus Life Sciences Lending Fund I, LP (Innovatus), which we subsequently amended in November 2019, November 2021 and April 2023 (the Amended Loan Agreement). The Amended Loan Agreement is collateralized by substantially all of our personal property, including our intellectual property. The Amended Loan Agreement also subjects us to certain affirmative and negative covenants, including limitations on our ability to transfer or dispose of assets, merge with or acquire other companies, make investments, pay dividends, incur additional indebtedness and liens and conduct transactions with affiliates. We are also subject to certain covenants that require us to maintain a minimum liquidity of at least $2.0 million, achieve certain minimum amounts of annual revenue, as measured on a rolling twelve-month basis, periodically deliver financial statements to Innovatus with an unqualified opinion (including no &#8220;going concern&#8221;) from our independent certified public accounting firm, and are required under certain conditions to make mandatory prepayments of outstanding principal. As a result of these covenants, we have certain limitations on the manner in which we can conduct our business, and we may be restricted from engaging in favorable business activities or financing future operations or capital needs until our current debt obligations are paid in full or we obtain the consent of Innovatus, which we may not be able to obtain. As of December&#160;31, 2023, there was $15.0 million in principal outstanding under the term loan and an additional $3.2 million outstanding representing interest payable in-kind by adding the paid in-kind interest amount to the outstanding principal balance of the term loans. Under the Amended Loan Agreement, we are required to repay any outstanding principal and capitalized interest in monthly installments over a ten-month period commencing on April 1, 2026. At December&#160;31, 2023, we were in compliance with all covenants of the Amended Loan Agreement. We cannot be certain that we will be able to generate sufficient cash flow or revenue to meet the financial covenants or pay the principal and accrued interest on our debt. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, upon the occurrence of an event of default, Innovatus, among other things, can declare all indebtedness due and payable immediately, which would adversely impact our liquidity and reduce the availability of our cash flows to fund working capital needs, capital expenditures and other general corporate purposes. An event of default includes, but is not limited to, our failure to pay any amount due and payable under the Amended Loan Agreement, the occurrence of a material adverse change in our business as defined in the Amended Loan Agreement, our breach of any representation or warranty in the Amended Loan Agreement, our breach of any covenant in the Amended Loan Agreement (subject to a cure period in some cases), a change in control as defined in the Amended Loan Agreement, our default on any debt payments to a third party in an amount exceeding $0.5 million or any voluntary or involuntary insolvency proceeding. If an event of default occurs and we are unable to repay amounts due under the Amended Loan Agreement, Innovatus could foreclose on substantially all of our personal property, including our intellectual property. We cannot be certain that future working capital, borrowings or equity financings will be available to repay or refinance our debt to Innovatus or any other debt we may incur in the future. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may require substantial additional capital to finance our planned operations, which may not be available to us on acceptable terms or at all. Our failure to obtain additional financing when needed on acceptable terms, or at all, could force us to delay, limit, reduce or eliminate our product development programs, commercialization efforts or other operations. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe, based on our current plan, that our current cash and cash equivalents and anticipated future revenue, will be sufficient to meet our anticipated cash requirements for at least the next 12 months. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our operating plans and other demands on our cash resources may change as a result of many factors currently unknown to us and we may need to seek additional funds sooner than planned, through public or private equity or debt financings or other sources, such as strategic collaborations. If our available cash balances and anticipated future revenue are insufficient to satisfy our liquidity requirements, including because of lower demand for our testing products or lower-than-expected rates of reimbursement from commercial payors and government payors, or other risks described in this &#8220;Risk Factors&#8221; section, we may seek to raise additional capital through equity offerings, debt financings, collaborations or licensing arrangements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On November 17, 2023, we filed a shelf registration statement on Form S-3, as amended by Amendment No. 1 to Form S-3 filed on November 27, 2023, that provides for aggregate offerings of up to $150.0 million of our securities subject to various limitations. We filed a prospectus on November 29, 2023 pursuant to this registration statement, registering sales of our common stock in an amount not to exceed $50.0 million, pursuant to a sales agreement by </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and between us and Cowen and Company, LLC (TD Cowen), as amended by Amendment No. 1 to Sales Agreement dated November 17, 2023 (the Amended Sales Agreement). Using a shelf registration statement to raise capital generally takes less time and is less expensive than other means, such as conducting an offering under a registration statement on Form S-1 and companies may be able to receive more favorable terms by raising capital pursuant to a shelf registration statement on Form S-3. Our ability to raise capital under our current shelf registration statement (and any future registration statement on Form S-3) is, and may again in the future be, limited by, among other things, current and future SEC rules and regulations impacting the eligibility of smaller companies to use Form S-3 without restrictions. As of the date of this Annual Report, we are subject to the "baby shelf rule" because the market value of our outstanding shares of common stock held by non-affiliates, or public float, was less than $75.0 million as of the date of this Annual Report. As a result, for sales following the date of this Annual Report and until we again have a public float with a value in excess of $75.0 million, if ever, we will be unable to use our shelf registration statement on Form S-3 or the Amended Sales Agreement to raise additional funds to the extent the aggregate market value of securities sold by us or on our behalf pursuant to Instruction I.B.6. of Form S-3 during the 12 calendar months immediately prior to, and including, any intended sale does not exceed one-third of the aggregate market value of our public float, calculated in accordance with the instructions to Form S-3.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the case of the incurrence of further indebtedness, the Amended Loan Agreement, subject to certain customary exceptions, restricts our ability to incur additional indebtedness or encumber any of our property without the prior consent of Innovatus. Under the Amended Loan Agreement, we are required to make monthly interest payments at a rate equal to the sum (the Basic Rate) of (a) the greater of 8.0% or The Wall Street Journal prime rate (the Prime Rate), plus (b) 2.0% (provided that 1.5% of the Basic Rate is payable in-kind by adding the amount to the outstanding principal balance of the term loans). We may also consider raising additional capital in the future to expand our business, pursue strategic investments, take advantage of financing opportunities, or for other reasons. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. The timing and amounts of our future capital requirements are difficult to forecast and will depend on numerous factors, including: our ability to maintain and grow sales of our testing products, as well as the costs associated with conducting clinical studies to demonstrate the utility of our testing products and support reimbursement efforts; fluctuations in working capital; the costs to expand our sales and marketing capabilities; the costs of developing our product pipeline, including the costs associated with conducting our ongoing and future validation studies; the additional costs we may incur as a result of operating as a public company and the extent to which we in-license, acquire or invest in complementary businesses or products.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additional funding may not be available to us on acceptable terms, or at all. If we raise funds by issuing equity securities, dilution to our stockholders could result, and the market price of our common stock could decline. Any equity securities issued also may provide for rights, preferences or privileges senior to those of holders of our common stock. The incurrence of additional indebtedness or the issuance of certain equity securities could result in increased fixed payment obligations and could also result in restrictive covenants (similar to our current obligations pursuant to the Amended Loan Agreement), such as limitations on our ability to incur additional debt or issue additional equity, limitations on our ability to acquire or license intellectual property rights, and other operating restrictions that could adversely affect our ability to conduct our business. In addition, our Amended Loan Agreement restricts our ability to incur additional indebtedness or encumber any of our property without the prior consent of Innovatus, subject to certain exceptions. In the event that we enter into collaborations or licensing arrangements to raise capital, we may be required to accept unfavorable terms. These agreements may require that we relinquish or license to a third party on unfavorable terms our rights to technologies or product candidates that we otherwise would seek to develop or commercialize ourselves or reserve certain opportunities for future potential arrangements when we might be able to achieve more favorable terms. If we are not able to secure additional funding when needed, we may have to delay, reduce the scope of or eliminate one or more research and development programs or selling and marketing initiatives. In addition, we may have to work with a partner on one or more of our testing products or market development programs, which could lower the economic value of those products or programs to our company.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are an emerging growth company and a smaller reporting company, and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS Act) and may remain an emerging growth company until the last day of the fiscal year following the fifth anniversary of the completion of our IPO, or December 31, 2024. However, if certain events occur prior to the end of such five-year period, including if we become a &#8220;large accelerated filer,&#8221; our annual gross revenue exceeds $1.235 billion or we issue more than $1.0 billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period. For so long as we remain an emerging growth company, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include: </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim condensed financial statements, with correspondingly reduced &#8220;Management&#8217;s discussion and analysis of financial condition and results of operations&#8221; disclosure; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">reduced disclosure obligations regarding executive compensation; and </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be reduced or more volatile. In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of these accounting standards until they would otherwise apply to private companies. We have elected to avail ourselves of this exemption and, therefore, we may not be subject to the same implementation timing for new or revised accounting standards as other public companies that are not emerging growth companies, which may make comparison of our financials to those of other public companies more difficult. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also a &#8220;smaller reporting company&#8221; as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Regulatory and Compliance Matters </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Healthcare policy changes, including recently enacted and proposed new legislation reforming the U.S. healthcare system, could cause significant harm to our business, operations and financial condition. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The ACA made a number of substantial changes to the way healthcare is financed both by governmental and commercial payors. The ACA also introduced mechanisms to reduce the per capita rate of growth in Medicare spending if expenditures exceed certain targets. Any such reductions could affect reimbursement payments for our tests.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2014, Congress passed PAMA, which included substantial changes to the way in which clinical laboratory services are paid under the CLFS. Under PAMA, certain clinical laboratories are required to periodically report to CMS private payor payment rates and volumes for their tests, and laboratories that fail to report the required payment information may be subject to substantial civil monetary penalties. Medicare reimbursement for CDLTs is based on the weighted-median of the payments made by private payors for these tests, rendering private payor payment levels even more significant than in the past. As a result, future Medicare payments may fluctuate more often and become subject to the willingness of private payors to recognize the value of diagnostic tests generally and any given test individually. The impact of this payment system on rates for our tests, including any current or future tests we may develop, is uncertain.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We cannot predict whether or when these or other recently enacted healthcare initiatives will be implemented at the federal or state level or how any such legislation or regulation may affect us. For instance, the payment reductions imposed by the ACA and the changes to reimbursement amounts paid by Medicare for tests such as ours based on the procedure set forth in PAMA, could limit the prices we will be able to charge or the amount of available reimbursement for our tests, which would reduce our revenue. Additionally, these healthcare laws, regulations and policies could be amended or additional healthcare initiatives could be implemented in the future.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further, the impact on our business of the expansion of the federal and state governments&#8217; role in the U.S. healthcare industry generally, including the social, governmental and other pressures to reduce healthcare costs while expanding individual benefits, is uncertain. Any future changes or initiatives could have a materially adverse effect on our business, financial condition, results of operations and cash flows.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Complying with numerous regulations pertaining to our business is an expensive and time-consuming process, and any failure to comply could result in substantial penalties. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to CLIA, a federal law that regulates clinical laboratories that perform testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease. CLIA regulations mandate specific standards in the areas of personnel qualifications, administration and participation in proficiency testing, patient test management, quality control, quality assurance and inspections. We have a current certificate of accreditation under CLIA because we are accredited to perform testing by CAP. To renew this certificate, we are subject to survey and inspection every two years. Moreover, inspectors from CMS or CAP may make random inspections of our clinical reference laboratory. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although we are required to hold a certificate of accreditation or compliance under CLIA that allows us to perform high complexity testing, we are not required to hold a certificate of accreditation through CAP. We could alternatively maintain a certificate of accreditation from another accrediting organization or a certificate of compliance through inspection by surveyors acting on behalf of the CLIA program. If our accreditation under CAP were to terminate, either voluntarily or involuntarily, we would need to convert our certification under CLIA to a certificate of compliance (or to a certificate of accreditation with another accreditation organization) in order to maintain our ability to perform clinical testing and to continue commercial operations. Whether we would be able to successfully maintain operations through either of these alternatives would depend upon the facts and circumstances surrounding termination of our CAP accreditation, such as whether any deficiencies were identified by CAP as the basis for termination and, if so, whether these were addressed to the satisfaction of the surveyors for the CLIA program (or another accrediting organization). </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The failure to comply with CLIA requirements can result in enforcement actions, including the revocation, suspension, or limitation of our CLIA certificate of accreditation, as well as a directed plan of correction, state on-site monitoring, civil money penalties, civil injunctive suit and/or criminal penalties. We must maintain CLIA compliance and certification to be eligible to bill for tests provided to Medicare beneficiaries. If we were to be found out of compliance with CLIA program requirements and subjected to sanctions, our business and reputation could be harmed. Even if it were possible for us to bring our laboratory back into compliance, we could incur significant expenses and potentially lose revenue in doing so. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also required to maintain a license to conduct testing in California. California laws establish standards for day-to-day operation of our clinical reference laboratory, including the training and skills required of personnel and quality control. In addition, our clinical reference laboratory is licensed on a product-specific basis by New York as an out of state laboratory and our testing products, as LDTs, must be approved by the NYSDOH on a product-by-product basis before they are offered in New York. We are also subject to periodic inspection by the NYSDOH and required to demonstrate ongoing compliance with NYSDOH regulations and standards. To the extent NYSDOH identified any non-compliance and we are unable to implement satisfactory corrective actions to remedy such non-compliance, the State of New York could withdraw approval for our testing products. New York law also mandates proficiency testing for laboratories licensed under New York state law, regardless of whether or not such laboratories are located in New York. Moreover, several other states require that we hold licenses to test specimens from patients in those states. Other states may have similar requirements or may adopt similar requirements in the future. Although we have obtained licenses from states where we believe we are required to be licensed, we may become aware of other states that require out-of-state laboratories to obtain licensure in order to accept specimens from the state, and it is possible that other states currently have such requirements or will have such requirements in the future. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we were to lose our CLIA accreditation or California license, whether as a result of a revocation, suspension or limitation, we would no longer be able to sell our testing products, which would limit our revenue and harm our business. If we were to lose our license or fail to obtain or maintain NYSDOH approval for our laboratory developed tests in New York or if we were to lose our license in other states where we are required to hold licenses, we would not be able to test specimens from those states, which would limit our revenue.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We conduct business in a heavily regulated industry. Complying with the numerous statutes and regulations pertaining to our business is expensive and time-consuming, and any failure by us, our consultants or commercial partners to comply could result in substantial penalties. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our industry and our operations are heavily regulated by various federal, state, local and foreign laws and regulations, and the regulatory environment in which we operate could change significantly and adversely in the future. These laws and regulations currently include, among others:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">CLIA&#8217;s and CAP&#8217;s regulation of our laboratory activities;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">FDA laws and regulations, including but not limited to requirements for offering LDTs;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">federal and state laws and standards affecting reimbursement by government payors, including certain coding requirements to obtain reimbursement and certain payment mechanisms for clinical laboratory services resulting from PAMA;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">HIPAA and HITECH, which establish comprehensive federal standards with respect to the privacy and security of PHI, and requirements for the use of certain standardized electronic transactions with respect to transmission of such information, as well as similar laws protecting other types of personal information;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">state laws governing the maintenance of personally identifiable information of state residents, including medical information, and which impose varying breach notification requirements, some of which allow private rights of action by individuals for violations and also impose penalties for such violations;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the federal Anti-Kickback Statute, which generally prohibits knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, in return for or to induce a person to refer to an individual any good, facility, item or service that is reimbursable under a federal healthcare program;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the federal Stark Law, which generally prohibits a physician from making a referral for certain designated health services covered by Medicare or Medicaid, including laboratory and pathology services, if the physician or an immediate family member has a financial relationship with the entity providing the designated health services;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the federal False Claims Act, which imposes civil penalties, and provides for civil whistleblower or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the federal Civil Monetary Penalties Law, which generally prohibits, among other things, the offering or transfer of remuneration to a Medicare or Medicaid beneficiary if it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner or supplier of services reimbursable by Medicare or Medicaid; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">EKRA, which imposes criminal penalties for knowing and willful payment or offer, or solicitation or receipt, of any remuneration, whether directly or indirectly, overtly or covertly, in cash or in kind, in exchange for the referral or inducement of laboratory testing (among other healthcare services) covered by healthcare benefit programs (including commercial insurers) unless a specific exception applies;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the ACA, which, among other things, establishes a requirement for providers and suppliers to report and return any overpayments received from the Medicare and Medicaid programs;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">other federal and state fraud and abuse laws, such as anti-kickback laws, prohibitions on self-referral, fee-splitting restrictions, insurance fraud laws, anti-markup laws, prohibitions on the provision of tests at no or discounted cost to induce physician or patient adoption and false claims acts, some of which may extend to services reimbursable by any third-party payor, including private payors;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the prohibition on reassignment of Medicare claims and other Medicare and Medicaid billing and coverage requirements;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">state laws that prohibit other specified healthcare practices, such as billing physicians for tests that they order, waiving coinsurance, copayments, deductibles and other amounts owed by patients, business corporations practicing medicine or employing or engaging physicians to practice medicine and billing a state Medicaid program at a price that is higher than what is charged to one or more other payors;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the FCPA, and applicable foreign anti-bribery laws;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">federal, state and local regulations relating to the handling and disposal of regulated medical waste, hazardous waste and biohazardous waste and workplace safety for healthcare employees;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">laws and regulations relating to health and safety, labor and employment, public reporting, taxation and other areas applicable to businesses generally, all of which are subject to change, including, for example, the significant changes to the taxation of business entities were enacted in December 2017; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">similar foreign laws and regulations that apply to us in the countries in which we operate or may operate in the future.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any future growth of our business, including, in particular, continued reliance on consultants, commercial partners and other third parties, may increase the potential for violating these laws. In some cases, our risk of violating these or other laws and regulations is further increased because of the lack of their complete interpretation by applicable regulatory authorities or courts, and their provisions are thus open to a variety of interpretations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have adopted policies and procedures designed to comply with these laws and regulations and, in the ordinary course of our business, we conduct internal reviews of our compliance with these laws. Our compliance is also subject to review by applicable government agencies. However, these laws and regulations are subject to change and additional interpretation and guidance from regulatory authorities. For instance, in April 2022, the HHS OIG issued a new advisory opinion indicating that a particular clinical laboratory&#8217;s practice of contracting with hospitals for the collection of samples for testing could, based on the facts provided and assuming the requisite intent, be a violation of the federal Anti-Kickback Statute. If this Advisory Opinion ultimately limits our ability to collect samples in a hospital setting, we may be required to contract for sample collection with other collection sites or sources, such as mobile phlebotomists, that could be more expensive and less convenient for patients, which could adversely affect both demand for our tests and the margins and profitability of our tests.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Given the complexity of these existing and changing rules and regulations, it is not always possible to identify and deter misconduct by employees, distributors, consultants and commercial partners and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with applicable laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. For additional information see the risk factor below entitled </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8220;We have previously and may again in the future be required to modify our business practices, pay fines, incur significant expenses or experience losses due to litigation or governmental investigations.&#8221;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Any action brought against us for violation of these or other laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses, divert our management&#8217;s attention from the operation of our business and harm our reputation. If our operations, including the conduct of our employees, consultants and commercial partners, are found to be in violation of any of these laws and regulations, we may be subject to applicable penalties associated with the violation, including administrative, civil and criminal penalties, damages, fines, individual imprisonment, exclusion from participation in federal healthcare programs, refunding of payments received by us and curtailment or cessation of our operations. Any of these consequences could seriously harm our business and our financial results.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">It is possible that some of our business activities could be subject to challenge under one or more of such laws. Such a challenge, regardless of the outcome, could have a material adverse effect on our business, business relationships, reputation, financial condition and results of operations. Although an effective compliance program can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. Moreover, achieving and sustaining compliance with these laws may prove costly. If we or our operations, or any of the rheumatologists or entities with whom we do business are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to significant penalties, including administrative, civil and/or criminal penalties, damages, fines, disgorgement, individual imprisonment, exclusion from participation in U.S. federal or state healthcare programs, such as Medicare and Medicaid, and similar programs outside the United States, a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could materially adversely affect our ability to operate our business and our financial results. To the extent that any of our testing products are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we use hazardous materials in a manner that causes contamination or injury, we could be liable for resulting damages. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to federal, state and local laws, rules and regulations governing the use, discharge, storage, handling and disposal of biological material, chemicals and waste. We cannot eliminate the risk of accidental contamination or injury to employees or third parties from the use, storage, handling or disposal of these materials. In the event of contamination or injury, we could be held liable for any resulting damages, remediation costs and any related penalties or fines, and any liability could exceed our resources or any applicable insurance coverage we may have. The cost of compliance with these laws and regulations may become significant, and our failure to comply may result in substantial fines or other consequences, either of which could negatively affect our operating results.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have previously and may again in the future be required to modify our business practices, pay fines, incur significant expenses or experience losses due to litigation or governmental investigations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time and in the ordinary course of our business, we have been and may be subject to litigation or governmental investigation on a variety of matters in the United States or foreign jurisdictions, including, without limitation, regulatory, intellectual property, product liability, antitrust, consumer, false claims, whistleblower, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, privacy, anti-kickback, anti-bribery, environmental, commercial, securities and employment litigation and claims and other legal proceedings that may arise from the conduct of our business. Our activities relating to our products and services are subject to extensive regulation in the United States and foreign jurisdictions. Like many companies in our industry, we have in the ordinary course of business received inquiries, subpoenas, civil investigative demands, and other types of information requests from government authorities. In addition, any litigation or government investigation generally, diverts the attention of our management team and resources from our core business and limits the time and attention of our management team otherwise available to devote to our business. Government investigation and litigation in general may cause us to incur significant expenses, to experience significant losses, and, as a result of such matters, we may also be required to materially alter the conduct of our operations or pay significant penalties. For example, pursuant to a settlement agreement, we made a single lump-sum remittance to the government in the amount of $0.7&#160;million plus interest in October 2023, the U.S. Attorney&#8217;s Office dismissed this &#8220;covered conduct&#8221; in the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> with prejudice, while non-covered conduct was dismissed without prejudice. In November 2023, the complaint was unsealed and served on Exagen. Exagen filed a motion to dismiss the complaint. In February 2024, the relator filed a motion for leave to amend the complaint. Exagen opposed this motion, and all motions are still pending. The Company intends to vigorously defend against the claims being asserted in the complaint.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any of these circumstances may adversely affect our business, prospects, reputation and results of operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, the FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties to sell our testing products outside the United States, to conduct clinical trials, and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The FDA may disagree with our assessment that our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"> test products and any other tests we may develop are LDTs and determine that such test products are medical devices subject to the FDCA and FDA regulations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FDA regulates any diagnostic test that meets the definition of a medical device, except under specific, narrow circumstances. The FDCA defines a medical device as &#8220;an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including a component part, or accessory which is , among other things: intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">treatment, or prevention of disease, in man or other animals and which does not achieve its primary intended purposes through chemical action within or on the body of man or other animals and which is not dependent upon being metabolized for the achievement of any of its primary intended purposes.&#8221; By this definition, in vitro reagents and diagnostic tests are considered medical devices. Specifically, the FDA defines an IVD as &#8220;reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including a determination of the state of health, in order to cure, mitigate, treat, or prevent disease or its sequelae.&#8221; Therefore, the FDA generally considers diagnostic testing products to be IVDs subject to the agency&#8217;s regulatory requirements for IVDs. However, the FDA has generally exercised its enforcement discretion and not enforced applicable regulations with respect to LDTs, which are IVDs that are designed, manufactured, and used within a single high-complexity CLIA-certified laboratory. We believe that all of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> test products are LDTs, as are our near-term pipeline candidate tests.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the FDA were to disagree with our conclusion that our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> test products fall within the scope of the agency&#8217;s LDT definition and determines that the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> tests are thus subject to FDA&#8217;s medical device authorities and implementing regulations, we would become subject to extensive regulatory requirements and may be required to stop selling our existing tests or refrain from launching any other tests we may develop. In particular, the FDA may require us to obtain PMAs or another type of device marketing authorization in order for us to commercialize our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> tests. The premarket review process for diagnostic testing products can be lengthy, expensive, time-consuming, and unpredictable. As part of the process to prepare regulatory submissions for FDA review, we may be required to conduct formal clinical trials before applying for commercial marketing authorization. Performing additional, new nonclinical studies or clinical trials in order to obtain product approval from the FDA, if any were to become necessary, would take a significant amount of time and would substantially delay our ability to commercialize our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> tests, all of which would adversely impact our business. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While we believe that we are currently in material compliance with applicable laws and regulations as historically enforced by the FDA with respect to LDTs, we cannot assure you that the FDA will agree with our determination. Any finding by the FDA or another regulatory authority that we have violated these laws and regulations, or a public announcement that we are being investigated for possible violations, could adversely affect our business, prospects, results of operations or financial condition.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The FDA may finalize its rulemaking to regulate LDTs or Congress may take action to reform the current legal requirements applicable to LDTs, and in either case, we may become subject to extensive regulatory requirements and may be required to conduct additional clinical trials prior to continuing to sell our existing tests or launching any other tests we may develop, which may increase the cost of conducting, or otherwise harm, our business.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We currently market our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> tests as LDTs and may, in the future, market other tests as LDTs. Although historically the FDA has applied a policy of enforcement discretion with respect to LDTs whereby the FDA does not generally actively enforce its regulatory requirements for such tests, in October 2023, the FDA issued a proposed rule to regulate LDTs under the current medical device framework. The agency&#8217;s proposal also includes a plan to phase out its current enforcement discretion policy over several years. This FDA rulemaking was initiated after years of failed congressional attempts to harmonize the regulatory paradigms applicable to LDTs and other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">in vitro </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">diagnostic tests, as discussed further below. The likelihood of the FDA finalizing the proposed rule following a public comment period, as well as potential litigation challenging its authority to take such action, is uncertain at this time as stakeholders continue to press for a comprehensive legislative solution instead of administrative agency action. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If there are changes in FDA regulations or legislative authorities such that the agency begins to exercise oversight over LDTs, or if the FDA disagrees that our marketed tests are within the scope of its criteria used for defining LDTs, we may become subject to extensive regulatory requirements and may be required to stop selling our existing tests or launching any other tests we may develop and to conduct additional clinical trials or take other actions prior to continuing to market our tests. If the FDA allows our tests to remain on the market but there is uncertainty about our tests, if they are labeled investigational by the FDA or if labeling claims the FDA allows us to make do not include the claims necessary or desirable for successful commercialization, orders from healthcare providers or reimbursement for our tests may decline.  </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, as noted above, Congress had been working on legislation to create an LDT and IVD, regulatory framework that would be separate and distinct from the existing medical device regulatory framework.  Reform legislation called the VALID Act garnered bipartisan and bicameral support in recent years but failed to move out of committee during the last congressional session. As drafted and re-introduced for consideration by the current Congress, the VALID Act would codify the term IVCT to create a new medical product category separate from medical devices to include products currently regulated as IVDs as well as LDTs, among other provisions. The VALID Act would also create a new system for laboratories to use to submit their tests electronically to the FDA for </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">approval, which is aimed at reducing the amount of time it would take for the agency to approve such tests and establish a new program to expedite the development of diagnostic tests that can be used to address a current unmet need for patients. The FDA&#8217;s October 2023 publication of an LDT proposed rule that would apply the existing medical device framework to laboratory-developed products has renewed stakeholder calls for a more targeted approach to modernizing the federal government&#8217;s oversight of clinical diagnostic tests. It remains possible that congressional action in this area could displace the need for the FDA to complete its recently proposed rulemaking.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If Congress were to pass the VALID Act or any other legislation applicable to the FDA&#8217;s regulation of LDTs, or if the FDA were to successfully promulgate new regulations for such products through the recently initiated notice-and-comment rulemaking or a future rulemaking proceeding, we will likely be subject to increased regulatory burdens such as registration and listing requirements, adverse event reporting requirements and quality control requirements. Any legislation or formal FDA regulatory framework affecting LDTs is also likely to have premarket application requirements prohibiting commercialization without FDA authorization and controls regarding modification to the tests that may require further FDA submissions. The premarket review process can be lengthy, expensive, time-consuming and unpredictable. Further, obtaining premarket clearance may involve, among other things, successfully completing clinical trials, which require significant time and cash resources and are subject to a high degree of risk, including risks of experiencing delays, failing to complete the trial or obtaining unexpected or negative results. If we are required to obtain premarket clearance or approval and/or conduct premarket clinical trials, our development costs could significantly increase, marketing of any new tests we may develop may be delayed, and sales of our existing tests could be interrupted or stopped. Any of these outcomes could reduce our revenue or increase our costs and materially adversely affect our business, prospects, results of operations or financial condition.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The outcome and ultimate impact on our business of any changes to the federal government&#8217;s regulation of LDTs is difficult to predict. Failure to comply with any applicable FDA requirements could trigger a range of enforcement actions, including warning letters, fines, penalties, suspension of operations, product recalls or seizures, denial of applications for clearance or approval, injunctions and other civil or criminal sanctions, which could have a material and adverse effect upon our business, operating results and financial condition.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furthermore, should it be required in the future, we cannot be sure that our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> tests, or any new tests that we may develop, will be reviewed and authorized for marketing by the FDA in a timely or cost-effective manner, if authorized at all. Even if such tests are authorized for marketing by the FDA, the agency could limit the test&#8217;s indications for use, which may significantly limit the market for that product and may adversely affect our business and financial condition.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The FTC and/or state enforcement or regulatory agencies may object to the methods and materials we use to promote our tests and initiate enforcement against us, which could adversely affect our business and financial condition.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FTC and/or state enforcement or regulatory agencies (including but not limited to the offices of state attorneys general) may object to the materials and methods we use to promote our current tests or other LDTs we may develop in the future, including with respect to the product claims in our promotional materials, and may initiate enforcement actions against us. Enforcement actions by the FTC may include, among others, injunctions, civil penalties and equitable monetary relief.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any failure or perceived failure by us to comply with federal or state laws or regulations, our internal policies and procedures or our contracts governing our use and disclosures of personal information could result in negative publicity, government investigations and enforcement actions including significant penalties, claims by third parties, and damage to our reputation, any of which could have a material adverse effect on our operations, financial performance and business.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Failure to comply with HIPAA, the HITECH Act, their implementing regulations and similar comparable state laws and regulations affecting the transmission, security and privacy of health information could result in significant penalties. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Numerous federal, state and foreign laws and regulations, including HIPAA and the HITECH Act, govern the collection, dissemination, disclosure, security, use and confidentiality of individually identifiable health information health-related and other personal information. HIPAA and the HITECH Act require us to comply with standards for the use and disclosure of PHI within our company and with third parties. The privacy, security and breach </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">notification rules promulgated under HIPAA, as amended by the HITECH Act, Standards for Privacy of Individually Identifiable Health Information (Privacy Standards) and the Security Standards for the Protection of Electronic Protected Health Information (Security Standards) under HIPAA establish a set of basic national privacy and security standards for the protection of individually identifiable health information by Covered Entities and their Business Associates. HIPAA requires Covered Entities, such as us, to develop and maintain policies and procedures with respect to individually identifiable health information that is used or disclosed, including the adoption of administrative, physical and technical safeguards to protect the privacy and security of such information. HIPAA also requires us to provide individuals with certain rights with respect to their PHI. If we engage a Business Associate to help us carry out healthcare activities and functions, we must have a written Business Associate contract or other arrangement with the Business Associate that establishes specifically what the Business Associate has been engaged to do and requires the Business Associate to comply with the requirements of HIPAA. Further, in the event of a breach of unsecured PHI we must notify each individual whose PHI is breached as well as federal regulators and in some cases, must publicize the breach in local or national media.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HIPAA also includes standards for common healthcare electronic transactions and code sets, such as claims information, plan eligibility, payment information and the use of electronic signatures, and privacy and electronic security of individually identifiable health information. Covered Entities, such as certain healthcare providers, are required to conform to such transaction set standards, known as the Standards for Electronic Transactions, pursuant to HIPAA. Submission of electronic healthcare claims and payment transactions that do not comply with the HIPAA electronic data transmission standards could result in delayed or denied payments.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the conduct of our business, we process, maintain, and transmit sensitive data, including PHI. There can be no assurance that a breach of privacy or security will not occur. If there is a breach, we could be subject to various lawsuits, penalties and damages and may be required to incur costs to mitigate the impact of the breach on affected individuals.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Penalties for failure to comply with HIPAA requirements are substantial and could include corrective action plans and/or the imposition of civil or criminal penalties. HIPAA also authorizes state attorneys general to file suit under HIPAA on behalf of state residents. Courts can award damages, costs and attorneys&#8217; fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to sue us in civil court for HIPAA violations, its standards have been used as the basis for a duty of care claim in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, certain states have adopted comparable privacy and security laws and regulations, some of which may apply more broadly or be more stringent than HIPAA. For example, the CCPA, which went into effect on January 1, 2020, gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Further, the CPRA went into effect in California amending the CCPA and may increase our compliance costs and potential liability, imposes additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data and adds opt outs for certain uses of sensitive data. It also created a new regulatory authority, the California Privacy Protection Agency (CPPA), which is authorized to issue substantive regulations and could result in increased privacy and information security enforcement. In the event that we are subject to or affected by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection laws (for example Virginia's Consumer Data Protection Act and other similar laws that recently went into effect in in other states, such as Utah, Colorado, Connecticut, Delaware, Florida, Indiana, Iowa, Montana, Oregon, Tennessee, and Texas), any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In Europe, the GDPR went into effect in May 2018 and imposes strict requirements for processing the personal data of individuals within the EEA. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States, and the efficacy and longevity of current transfer mechanisms between the EU and the United States remains uncertain. For example, in 2016, the EU and United States agreed to a transfer framework for data transferred from the EU to the United States, called the Privacy Shield, but the Privacy Shield was invalidated in July 2020 by the Court of Justice of the EU. In July 2023, however, the European Commission adopted an adequacy decision for a new mechanism for transferring data from the EU to the United States &#8211; the EU-US Data Privacy Framework, which provides EU individuals with several new rights, including the right to obtain access to their data, or obtain correction or deletion of incorrect or unlawfully handled data. The adequacy decision followed </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the signing of an executive order introducing new binding safeguards addressing the reasons behind the Court of Justice of the EU&#8217;s invalidation of the original Privacy Shield. The European Commission will continually review developments in the United States along with its adequacy decision. However, future actions of EU data protection authorities are difficult to predict.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Relatedly, following the United Kingdom&#8217;s withdrawal from the EU, the GDPR was implemented in the United Kingdom as the U.K. GDPR. The U.K. GDPR sits alongside the amended U.K. Data Protection Act 2018, which implements certain derogations in the EU GDPR into U.K. law. The U.K. GDPR mirrors the fines under the GDPR, i.e., fines up to the greater of &#8364;20 million (&#163;17.5 million) or 4% of global turnover. In June of 2021, the European Commission issued a decision, which will sunset on June 27, 2025 without further action, that the United Kingdom ensures an adequate level of protection for personal data transferred under the EU GDPR from the EU to the United Kingdom. The Parliament of the United Kingdom is currently considering the Data Protection and Digital Information Bill to harmonize the 2018 Data Protection Act, U.K. GDPR, and the Privacy and Electronic Communications Regulations under one legislative framework.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The regulatory framework governing the collection, storage, use and sharing of certain information, particularly financial and other personal information, is rapidly evolving and is likely to continue to be subject to uncertainty and varying interpretations. Additionally, increasing concerns about health information privacy have recently prompted the federal government to issue guidance taking a newly expansive view of the scope of the laws and regulations that they enforce. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our existing practices. Any failure or perceived failure by us, or any third parties with which we do business, to comply with our privacy policies, changing expectations, evolving laws, rules and regulations, industry standards or contractual obligations to which we or such third parties are or may become subject, may result in actions or other claims against us by governmental entities or private actors, the expenditure of substantial costs, time and other resources or the incurrence of significant fines, penalties or other liabilities. In addition, any such action, particularly to the extent we were found to be guilty of violations or otherwise liable for damages, would damage our reputation and adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another and may conflict with one another or other legal obligations with which we must comply. Any failure or perceived failure by us or our employees, representatives, contractors, consultants, collaborators, or other third parties to comply with such requirements or adequately address privacy and security concerns, even if unfounded, could result in additional cost and liability to us, damage our reputation and adversely affect our business and results of operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our future growth may depend, in part, on our ability to develop and commercialize our testing products in foreign markets. We are not permitted to market or promote any of our testing products before we receive regulatory approval from applicable regulatory authorities in foreign markets, and we may never receive such regulatory approvals for any of our testing products. To obtain separate regulatory approval in many other countries, we and our collaborators and service providers must comply with numerous and varying regulatory requirements regarding safety and efficacy and governing, among other things, clinical trials, commercial sales, pricing and distribution of our testing products. If we obtain regulatory approval of our testing products and ultimately commercialize our testing products in foreign markets, we would be subject to additional risks and uncertainties, including any or all of the following: </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">different regulatory requirements for approval of IVDs in foreign countries; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">reduced protection for intellectual property rights; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the existence of additional third-party patent rights of potential relevance to our business; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">unexpected changes in tariffs, trade barriers and regulatory requirements; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">economic weakness, including inflation, or political instability in particular foreign economies and markets; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue and other obligations incident to doing business in another country; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">inflationary pressures, such as those the global market is currently experiencing, which have and may increase costs for materials, supplies, and services;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">foreign reimbursement, pricing and insurance regimes; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">workforce uncertainty in countries where labor unrest is common; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">business interruptions resulting from geopolitical actions, including war and terrorism, such as current conflicts in Ukraine and the Middle East; natural disasters which may be exacerbated due to climate change, including earthquakes, typhoons, floods and fires; outbreak of disease; boycotts; or other business restrictions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to our Intellectual Property </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we are unable to maintain intellectual property protection, our competitive position could be harmed. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our ability to protect our technologies, such as the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test, affects our ability to compete and to achieve sustained profitability. We rely on a combination of U.S. and foreign patents and patent applications, copyrights, trademarks and trademark applications, and contractual restrictions to protect our intellectual property rights. We cannot be certain that the claims in our granted patents and pending patent applications covering our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products will be considered patentable or enforceable by the United States Patent and Trademark Office (the USPTO) courts in the United States, or by patent offices and courts in foreign countries. If we fail to protect our intellectual property, third parties may be able to compete more effectively against us and we may incur substantial litigation costs in our attempts to recover or restrict use of our intellectual property. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We apply for patents covering our testing products and technologies and uses thereof, as we deem appropriate, however we may fail to apply for patents on important testing products and technologies in a timely fashion or at all, or we may fail to apply for patents in potentially relevant jurisdictions, or we may cease our prosecution and maintenance of patents in potentially relevant jurisdictions. Currently, we have an exclusive license to 12 issued U.S. patents, one Patent Cooperation Treaty application, and certain corresponding foreign counterpart patents, relevant to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. We own five issued U.S. patents, six pending U.S. patent applications, one pending U.S. provisional patent application and certain corresponding foreign counterpart patents relevant to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. While we intend to pursue additional patent applications, it is possible that our pending patent applications and any future applications may not result in issued patents. Even if such patents do successfully issue, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. Any successful opposition to our patents could deprive us of exclusive rights necessary for the further development of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. Furthermore, even if they are unchallenged, our patents may not adequately protect our intellectual property, provide exclusivity for our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products or prevent others from designing around our claims. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We might not have been the first to make the inventions covered by each of our pending patent applications and we might not have been the first to file patent applications for these inventions. To determine the priority of these inventions, we may have to participate in interference proceedings, derivation proceedings or other post-grant proceedings declared by the USPTO that could result in substantial cost to us. No assurance can be given that our patent applications will have priority over other patent applications. In addition, recent changes to the patent laws of the United States allow for various post-grant opposition proceedings that have not been extensively tested, and their outcome is therefore uncertain. Furthermore, if third parties bring these proceedings against our patents, we could experience significant costs and management distraction. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We previously held licenses to five patent families related to CB-CAPs technology from the University of Pittsburgh (UPitt). We have terminated these license agreements (related to U.S. Patent Nos. 7,361,517, 7,390,631, 7,585,640, 7,588,905, 8,080,382, 8,126,654, and foreign equivalents thereof), effective March 22, 2024, and as a result may face increased competition with respect to the portion of our testing products previously protected by these patents.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable, or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect. While we use commercially reasonable efforts to protect our trade secrets, our licensors, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">employees, consultants, contractors and other advisors may unintentionally or willfully disclose such trade secret information to third parties and competitors. We attempt to protect our proprietary technology in large part by entering into confidentiality and non-disclosure agreements with our employees, consultants and other contractors. We cannot assure you, however, that these agreements will not be breached, that we will have adequate remedies for any breach or that competitors will not know of, or independently discover, our trade secrets. We cannot assure you that others will not independently develop substantially equivalent proprietary information or be issued patents that may prevent the sale of our testing products, technologies, services or know-how or require licensing and the payment of significant fees or royalties by us in order to produce our testing products, technologies or services. Further, we cannot be certain that the steps we have taken will prevent the misappropriation of our trade secrets and other confidential information. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Monitoring unauthorized disclosure is difficult, and we do not know whether the steps we have taken to prevent such disclosure are, or will be, adequate. If we were to enforce a claim that a third party had illegally obtained and was using our trade secrets, it would be expensive and time consuming, and the outcome would be unpredictable. In addition, courts outside the United States may be less willing to protect trade secrets. If we are unable to prevent unauthorized material disclosure of our trade secrets and other confidential information to third parties, and in particular in jurisdictions where we have not filed for patent protection, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results and financial condition. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Certain of our testing products utilize unpatented technology that is publicly available and can be used by our competitors. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products, such as AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD, utilize both patented technology and publicly available technology that is not protected by patents or other intellectual property rights. We believe that using certain publicly available technology allows us to offer a better and more comprehensive testing product. However, the publicly available technology which we rely upon is also used in, and may continue to be used in, products which compete with our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. Our competitors may independently develop competing diagnostic products and services that do not infringe our intellectual property. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"> testing products. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our success is heavily dependent on intellectual property, particularly on obtaining and enforcing patents. Obtaining and enforcing patents in the diagnostics industry involves both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. The United States has enacted and is currently implementing wide-ranging patent reform legislation. Recent Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. We may not develop additional proprietary products, methods and technologies that are patentable. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Some of our intellectual property has been discovered through government funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with non-U.S. manufacturers. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Some of the intellectual property rights we have acquired or licensed or may acquire or license in the future may have been generated through the use of U.S. government funding and may therefore be subject to certain federal regulations. For example, some of the research and development work related to our CB-CAPs technology was funded by government research grants. As a result, the U.S. government may have certain rights to intellectual property embodied in our testing products pursuant to the Bayh-Dole Act of 1980 (Bayh-Dole Act). These U.S. government rights include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require us to grant exclusive, partially exclusive or non-exclusive licenses to any of these inventions to a third party if it determines that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). The U.S. government also has the right to take title to these inventions if the grant recipient fails to disclose the invention to the government or fails to file an </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the United States. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. industry may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property. To the extent any of our future intellectual property is also generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may not be able to protect our intellectual property rights throughout the world. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Filing, prosecuting and defending patents on our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products in all countries throughout the world would be prohibitively expensive. Moreover, we believe that obtaining foreign patents may be more difficult than obtaining domestic patents because of differences in patent laws and, accordingly, our patent position may be stronger in the United States than abroad. In addition, the laws of some foreign countries do not protect intellectual property rights in the same manner and to the same extent as laws in the United States. Various countries limit the subject matter that can be patented and limit the ability of a patent owner to enforce patents in the medical and other related fields. This may limit our ability to obtain or utilize those patents internationally. In order to manage our foreign patent costs and focus on the U.S. market, we made the decision to cease the prosecution and maintenance of certain of our foreign patents and patent applications related to our CB-CAPs technology, which is used in our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement of such patent protection is not as strong as that in the United States. These products may compete with our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The patent protection and patent prosecution for some of our testing products may be dependent on third parties. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We or our licensors may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our patent position. It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope or requests for patent term adjustments. If we or our licensors, whether current or future, fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our licensors are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution or enforcement of our patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a licensee of third parties, we rely on third parties to file and prosecute patent applications and maintain patents and otherwise protect the licensed intellectual property under some of our license agreements. We have not had and do not have primary control over these activities for certain of our patents or patent applications and other intellectual property rights. We cannot be certain that such activities by third parties have been or will be conducted </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">in compliance with applicable laws and regulations or will result in valid and enforceable patents or other intellectual property rights. Pursuant to the terms of the license agreements with some of our licensors, the licensors may have the right to control enforcement of our licensed patents or defense of any claims asserting the invalidity of these patents and even if we are permitted to pursue such enforcement or defense, we will require the cooperation of our licensors. We cannot be certain that our licensors will allocate sufficient resources or prioritize their or our enforcement of such patents or defense of such claims to protect our interests in the licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it may permit other parties to compete with us. If any of our licensors or any of our future licensors or future collaborators fail to appropriately prosecute and maintain patent protection for patents covering any of our testing products, our ability to develop and commercialize those testing products may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, even where we have the right to control patent prosecution of patents and patent applications we have acquired or licensed from third parties, we may still be adversely affected or prejudiced by actions or inactions of our predecessors or licensors and their counsel that took place prior to us assuming control over patent prosecution. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our technology acquired or licensed from various third parties may be subject to retained rights. Our predecessors or licensors often retain certain rights under their agreements with us, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our predecessors or licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are limited in our ability to utilize acquired or licensed technologies, or if we lose our rights to critical in-licensed technology, we may be unable to successfully develop, out-license, market and sell our testing products, which could adversely affect our business. Our business strategy depends on the successful development of licensed and acquired technologies into commercial products. Therefore, any limitations on our ability to utilize these technologies may impair our ability to develop, out-license or market and sell our testing products. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are a party to a number of license agreements under which we are granted intellectual property rights that are important to our business. For example, we license certain patent rights from AHN, QMUL and JHU. Our existing license agreements impose various regulatory and/or commercial diligence obligations, payment of milestones and/or royalties and other obligations. If we fail to comply with our obligations under a license agreement, the license agreement may be terminated, in which event we would not be able to further develop or market certain AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. Additionally, we may not always have the first right to maintain, enforce or defend our licensed intellectual property rights and, although we would likely have the right to assume the maintenance, enforcement and defense of such intellectual property rights if our licensors do not, our ability to do so may be compromised by our licensors&#8217; acts or omissions. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Licensing of intellectual property rights is of critical importance to our business and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property rights subject to a license agreement, including the scope of rights granted under the license agreement and other interpretation-related issues, and whether and the extent to which our technology and processes infringe on intellectual property rights of the licensor that are not subject to the licensing agreement. If disputes over intellectual property rights that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, our business, results of operations, financial condition and prospects may be adversely affected. We may enter into additional licenses in the future and if we fail to comply with obligations under those agreements, we could suffer adverse consequences. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent process. Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on any issued patents and/or applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patents and/or applications. Our outside counsel has systems in place to monitor deadlines to pay these fees and to remind us of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">these fees, and our outside counsel employs an outside firm to pay these fees due to the USPTO and to foreign patent agencies based on our instructions. In the aggregate, these fees can be cost prohibitive for an early-stage company. Accordingly, we made a financially-driven decision to prioritize our payment of these fees and to allow certain of our applications to lapse, particularly with respect to our ex-U.S. rights licensed from UPitt related to our CB-CAPs technology. The permanent lapse of certain of these ex-U.S. rights may result in our patent position being stronger in the United States than abroad, such as in countries that are part of the European Patent Convention, and third parties may be able to compete more effectively against us in countries outside the United States, including in those countries that belong to the European Patent Convention. Additionally, while an inadvertent lapse may sometimes be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market earlier than should otherwise have been the case, which would have a material adverse effect on our business. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Presently we have intellectual property rights, through licenses from third parties and under patents that we own, related to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. Because our programs may involve additional products that require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights. We may be unable to acquire or in-license proprietary rights that we identify as being necessary for our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. Even if we are able to obtain a license to such proprietary rights, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The licensing and acquisition of third-party proprietary rights is a competitive area, and companies, which may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party proprietary rights that we may consider necessary or attractive in order to further develop our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us, either on reasonable terms, or at all. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment, or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights on commercially reasonable terms, our ability to further develop our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products and our business, financial condition and prospects for growth could suffer. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Third-party claims alleging intellectual property infringement may prevent or delay our development efforts. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patents and other intellectual property rights in the diagnostics industry, as well as administrative proceedings for challenging patents, including interference and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. The Leahy-Smith America Invents Act introduced new procedures including inter partes review and post grant review. The implementation of these procedures brings the possibility of third-party challenges to our patents and the outcome of such challenges could result in a loss or narrowing of our patent rights. In such an event, our competitors might be able to enter the market earlier than should otherwise have been the case, which would have a material adverse effect on our business. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. As the diagnostics industry expands and more patents are issued, the risk increases that our activities related to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products may give rise to claims of infringement of the patent rights of others. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We cannot assure you that any of our current or future AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products will not infringe existing or future patents. Although we are not aware of any issued patents that will prevent us from marketing our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products, there may be third-party patents of which we are currently unaware with claims to materials or methods of manufacture related to the use or manufacture of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. If a third party that owns such a patent asserts it successfully against one of our current or future AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products, we may be unable to market our product, which could materially harm our business and because patent applications can take many years to issue and may be confidential for 18 months or more after filing, there may be currently pending third-party </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">patent applications which may later result in issued patents that our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products or our technologies may infringe, or which such third parties claim are infringed by the use of our technologies. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Parties making claims against us for infringement or misappropriation of their intellectual property rights may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop one or more of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. Defense of these claims, regardless of their merit, would involve substantial expenses and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees if we are found to be willfully infringing a third party&#8217;s patents, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or development of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products, which could harm our business significantly. Even if we were able to obtain a license, the rights may be nonexclusive, which may give our competitors access to the same intellectual property. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to infringement claims against us, if third parties have prepared and filed patent applications in the United States that also claim technology to which we have rights, we may have to participate in interference proceedings in the USPTO to determine the priority of invention. Third parties may also attempt to initiate reexamination, post grant review or inter partes review of our patents in the USPTO. We may also become involved in similar proceedings in the patent offices in other jurisdictions regarding our intellectual property rights with respect to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products and technology. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may be involved in proceedings to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Third parties may infringe, misappropriate or otherwise violate our existing patents, patents that may be issued to us in the future, or the patents of our licensors that are licensed to us. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, if we or one of our licensors initiated legal proceedings against a third party to enforce a patent covering one of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products, the defendant could counterclaim that the patent covering such AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing product is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Such proceedings could result in an invalidation of our patents. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. Such a loss of patent protection could have a material adverse impact on our business. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Litigation proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because of the expense and uncertainty of litigation, we may conclude that even if a third party is infringing our patents or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our stockholders. We are not aware of any third-party infringement of our intellectual property rights that would have a materially adverse impact on our business. In addition, there can be no assurance that our licensors will be willing to bring and enforce claims to prevent third parties from infringing intellectual property that is licensed to us, particularly if the affected intellectual property is less important to the licensor&#8217;s business than to ours. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have received confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed at other companies in our industry. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise improperly used or disclosed confidential information of these third parties or our employees&#8217; former employers. Further, we may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. We may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to defend against these and other claims challenging our right to and use of confidential and proprietary information. If we fail in defending any such claims, in addition to paying monetary damages, we may lose our rights therein. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Common Stock </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our stock price may be volatile, and you may not be able to sell shares of our common stock at or above the price you paid. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The public trading price for our common stock is affected by a number of factors, including: </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">actual or anticipated variations in our and our competitors&#8217; financial condition and results of operations; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">announcements by us or our competitors of new products, strategic partnerships or capital commitments; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">changes in reimbursement by current or potential third-party payors; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">issuance of new securities analysts&#8217; reports or changed recommendations for our stock; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">actual or anticipated changes in regulatory oversight of our testing products; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">developments or disputes concerning our intellectual property or other proprietary rights; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">commencement of, or our involvement in, litigation; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">announced or completed acquisitions of businesses or technologies by us or our competitors; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">any major change in our management; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">changes in accounting principles; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">announcement or expectation of additional financing efforts; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">future sales of our common stock by our executive officers, directors and other stockholders; and </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">general economic conditions and slow or negative growth of our markets, including as a result of the current conflict in the Ukraine and the Middle East. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the stock market in general, and the market for stock of life sciences companies in particular, has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors, as well as general economic, political and market conditions such as recessions or interest rate changes, may seriously affect the market price of our common stock, regardless of our actual operating performance. As a result of this volatility, you may not realize any return on your investment in us and may lose some or all of your investment. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, in the past, following periods of volatility in the overall market and the market price of a particular company&#8217;s securities, securities class action litigation has often been instituted against these companies. This litigation, if instituted against us, could result in substantial costs and a diversion of our management&#8217;s attention and resources. Any adverse determination in any such litigation or any amounts paid to settle any such actual or threatened litigation could require that we make significant payments. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Future sales of shares by existing stockholders could cause our stock price to decline. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sales of a substantial number of shares of our common stock in the public market or the perception that these sales might occur could significantly reduce the trading price of our common stock and impair our ability to raise adequate capital through the sale of additional equity securities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, our directors and executive officers have and may continue to establish programmed selling plans under Rule 10b5-1 of the Exchange Act for the purpose of effecting sales of our common stock. Any sales of securities by directors and executive officers, or the perception that those sales may occur, including the entry into such programmed selling plans, could have a material adverse effect on the trading price of our common stock, particularly if the trading volume of our common stock is relatively low at the time of these sales.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could significantly reduce the value of our shares to a potential acquiror or delay or prevent changes in control or changes in our management without the consent of our board of directors. The provisions in our charter documents include the following: </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the exclusive right of our board of directors, unless the board of directors grants such right to the stockholders, to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the required approval of at least 66-2/3% of the shares entitled to vote to remove a director for cause, and the prohibition on removal of directors without cause; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the ability of our board of directors to alter our amended and restated bylaws without obtaining stockholder approval; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the required approval of at least 66-2/3% of the shares entitled to vote to adopt, amend or repeal our amended and restated bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">an exclusive forum provision providing that the Court of Chancery of the State of Delaware will be the exclusive forum for certain actions and proceedings; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the requirement that a special meeting of stockholders may be called only by the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s own slate of directors or otherwise attempting to obtain control of us. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also subject to the anti-takeover provisions contained in Section 203 of the Delaware General Corporation Law. Under Section 203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the board of directors has approved the transaction. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our amended and restated certificate of incorporation provide that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation, or any action asserting a claim against us that is governed by the internal affairs doctrine; provided, that, this provision would not apply to suits brought to enforce a duty or liability created by the Securities Act or the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. To the extent that any such claims may be based upon federal law claims, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. By agreeing to this provision, however, the stockholders will not be deemed to have waived our compliance with the Federal Securities laws and rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find the choice of forum provisions in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our executive officers, directors and principal stockholders, if they choose to act together, have the ability to control or significantly influence all matters submitted to stockholders for approval. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on their most recent publicly filed beneficial ownership reports, our greater than 5% stockholders collectively own approximately 64% of our outstanding capital stock and our greater than 5% stockholders, directors and executive officers collectively own (without duplication) approximately 65% of our outstanding capital stock as of February 15, 2024. As a result, such persons, acting together, have the ability to control or significantly influence all matters submitted to our stockholders for approval, including the election and removal of directors and approval of any significant transaction, as well as our management and business affairs. This concentration of ownership may have the effect of delaying, deferring or preventing a change in control, impeding a merger, consolidation, takeover or other business combination involving us, or discouraging a potential acquiror from making a tender offer or otherwise attempting to obtain control of our business, even if such a transaction would benefit other stockholders. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have never paid dividends on our capital stock, and we do not anticipate paying dividends in the foreseeable future. Your ability to achieve a return on your investment will depend on appreciation, if any, in the price of our common stock. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have never declared or paid any cash dividends on our common stock and do not intend to pay any cash dividends in the foreseeable future. We currently intend to retain any future earnings to fund the growth of our business. In addition, our Amended Loan Agreement restricts our ability to pay cash dividends on our common stock and we may also enter into credit agreements or other borrowing arrangements in the future that will restrict our ability to declare or pay cash dividends on our common stock. Any determination to pay dividends in the future will be at the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for the foreseeable future. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">An active, liquid trading market for our common stock may not be maintained.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prior to our initial public offering (IPO), there had been no public market for our common stock. Our common stock began trading on The Nasdaq Global Market (Nasdaq) relatively recently, but we can provide no assurance that we will be able to develop and sustain an active trading market for our common stock. Even if an active trading market is developed, it may not be sustained. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. An inactive market may also impair our ability to raise capital by selling shares and may impair our ability to acquire other businesses or technologies using our shares as consideration, which, in turn, could materially adversely affect our business. During 2023, our average daily trading volume has been approximately 25,040 shares.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our failure to meet the continued listing requirements of Nasdaq or The Nasdaq Stock Market LLC could result in a delisting of our common stock. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we fail to satisfy the continued listing requirements of Nasdaq, such as the corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement or prevent future non-compliance with Nasdaq&#8217;s listing requirements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If securities or industry analysts downgrade our common stock or otherwise issue adverse opinions or commentary regarding our stock or do not publish research or reports about our company, our stock price and trading volume could decline. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The trading market for our common stock depends in part on the research and reports that equity research analysts publish about us and our business. Currently, we have limited analyst coverage and we do not have any control over such analysts or the content and opinions included in their reports. Securities analysts may elect not to provide research coverage of our company, and such lack of research coverage may adversely affect the market price of our common stock. The price of our common stock could also decline if one or more equity research analysts downgrade our common stock or if those analysts issue other unfavorable commentary or cease publishing reports about us or our business. If one or more equity research analysts cease coverage of our company, we could lose visibility in the market, which in turn could cause our stock price to decline. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We could be subject to securities class action litigation. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because life sciences and diagnostics companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business.</span></div><div id="i7d27a7d8e3c749dabb1f235100af8228_19"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 1B. Unresolved Staff Comments.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable.</span></div><div><span><br/></span></div><div id="i7d27a7d8e3c749dabb1f235100af8228_549755814585"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 1C. Cybersecurity.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recognize the critical importance of maintaining the trust and confidence of physicians, patients, business partners and employees toward our business and are committed to protecting the confidentiality, integrity and availability of our business operations and systems. Our board of directors is actively involved in oversight of our risk management activities, and cybersecurity represents an important element of our overall approach to risk management. Our cybersecurity policies, standards, processes and practices are based on recognized frameworks established by NIST and other applicable industry standards, as well as the HIPAA Security Rule and other recognized frameworks. In general, we seek to address cybersecurity risks through a comprehensive, cross-functional approach that is focused on preserving the confidentiality, security and availability of the information that we collect and store by identifying, preventing and mitigating cybersecurity threats and effectively responding to cybersecurity incidents when they occur.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cybersecurity Risk Management and Strategy; Effect of Risk</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We face risks related to cybersecurity such as unauthorized access, cybersecurity attacks and other security incidents, including as perpetrated by hackers and unintentional damage or disruption to hardware and software systems, loss of data, and misappropriation of confidential information. To identify and assess material risks from cybersecurity threats, we maintain a comprehensive cybersecurity program to ensure our systems are effective and prepared for information security risks, including regular oversight of our programs for security monitoring for internal and external threats to ensure the confidentiality and integrity of our information assets. We consider risks from cybersecurity threats in addition to other company risks as part of our overall risk assessment process. We employ a range of tools and services, including regular network and endpoint monitoring, audits, vulnerability assessments, and penetration testing to inform our risk identification and assessment. As discussed in more detail under &#8220;Cybersecurity Governance&#8221; below, our Audit Committee provides oversight of our cybersecurity risk management and strategy processes, which are led by our Vice President of Information Services.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We also identify our cybersecurity threat risks by comparing our processes to standards set by NIST, as well as  performing intrusion detection and prevention. To provide for the availability of critical data and systems, maintain </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">regulatory compliance, manage our material risks from cybersecurity threats, and protect against and respond to cybersecurity incidents, we undertake the following activities:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">a.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.67pt">monitor emerging data protection laws and implement changes to our processes that are designed to comply with such laws;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">b.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.67pt">through our policies, practices and contracts (as applicable), require employees, as well as third parties that provide services on our behalf, to treat confidential information and data with care;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">c.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.23pt">employ technical safeguards that are designed to protect our information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti-malware functionality and access controls, which are evaluated and improved through vulnerability assessments and cybersecurity threat intelligence;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">d.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.67pt">provide regular, mandatory training for our employees regarding cybersecurity threats as a means to equip them with effective tools to address cybersecurity threats, and to communicate our evolving information security policies, standards, processes and practices;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">e.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.67pt">conduct regular phishing email simulations for all employees with access to our email systems to enhance awareness and responsiveness to possible threats;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">f.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.46pt">conduct monthly cybersecurity management and incident training for employees involved in our systems and processes that handle sensitive data;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">g.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.67pt">leverage internal and external resources to help us identify, protect, detect, respond and recover when there is an actual or potential cybersecurity incident; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">h.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:9.67pt">carry information security risk insurance that provides protection against the potential losses arising from a cybersecurity incident</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our incident response plan coordinates the activities we take to prepare for, detect, respond to and recover from cybersecurity incidents, which include processes to triage, assess severity for, escalate, contain, investigate and remediate the incident, as well as to comply with potentially applicable legal obligations and mitigate damage to our business and reputation. As part of the above processes, we rely on internal resources rather than consultants, auditors or other third parties, to review our cybersecurity program.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our processes also address cybersecurity threat risks associated with our use of third-party service providers, including our suppliers and manufacturers or who have access to patient and employee data or our systems. In addition, cybersecurity considerations affect the selection and oversight of our third-party service providers. We perform diligence on third parties that have access to our systems, data or facilities that house such systems or data.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We describe whether and how risks from identified cybersecurity threats, including as a result of any previous cybersecurity incidents, have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition, under the heading &#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Failure in our information technology, telephone or other systems could significantly disrupt our operations and adversely affect our business and financial condition</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">,&#8221; which disclosures are incorporated by reference herein. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cybersecurity Governance; Management</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cybersecurity is an important part of our risk management processes and an area of focus for our board of directors and management. In general, our board of directors oversees risk management activities designed and implemented by our management, and considers specific risks, including, for example, risks associated with our strategic plan, business operations, and capital structure. Our board of directors executes its oversight responsibility for risk management both directly and through delegating oversight of certain of these risks to its committees, and our board of directors has authorized our Audit Committee to oversee risks from cybersecurity threats. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Upon detection of a material cybersecurity threat, our Audit Committee receives an update from management of the cybersecurity threat, risk management and strategy processes, as well as the steps management has taken to respond to such risks. In such sessions, our Audit Committee generally receives materials that include cybersecurity materials discussing current material cybersecurity threat risks, and describing our ability to mitigate those risks, and discusses such matters with our Chief Executive Officer. Our Audit Committee and board of directors receive prompt and timely information regarding any cybersecurity incident that meets established reporting thresholds. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our cybersecurity risk management and strategy processes, which are discussed in greater detail above, are led by our Vice President of Information Services, with support from our entire Information Services department. Such individuals have collectively over 10 years of prior work experience in various roles involving managing information security, developing cybersecurity strategy, implementing effective information and cybersecurity programs, as well as several relevant degrees and certifications. These Information Services team members are informed about and monitor the prevention, mitigation, detection, and remediation of cybersecurity incidents through their management of, and participation in, the cybersecurity risk management and strategy processes described above, including the operation of our incident response plan. As discussed above, these Information Services team members report to our Chief Executive Officer, and ultimately to the Audit Committee of our board of directors about material cybersecurity threats.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="i7d27a7d8e3c749dabb1f235100af8228_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 2. Properties.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our corporate headquarters are located in Vista, California, where we lease approximately 27,000 square feet of office and laboratory space under a lease that expires in 2027, with an option to extend a portion of the lease for an additional five-year period. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We also lease approximately 28,000 square feet of additional office space in Carlsbad, California, under a sublease that is co-terminus with our other lease expiring in 2027. We believe that our current facilities are adequate for our current needs and that suitable additional or alternative spaces will be available in the future on commercially reasonable terms, if required.</span></div><div id="i7d27a7d8e3c749dabb1f235100af8228_25"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 3. Legal Proceedings.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, we may be involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2023, we resolved an investigation with the U.S. Attorney&#8217;s Office for the District of Massachusetts that was initiated by a </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> lawsuit. Pursuant to a Settlement Agreement, we made a single lump-sum remittance to the government in the amount of $0.7 million plus interest in connection with specimen processing arrangements that we historically had with physicians. The U.S. Attorney&#8217;s Office dismissed this &#8220;covered conduct&#8221; in the qui tam with prejudice, while non-covered conduct was dismissed without prejudice. In November 2023, the complaint was unsealed and served on us. We filed a motion to dismiss the complaint. In February 2024, the relator filed a motion for leave to amend the complaint. We opposed this motion, and all motions are still pending. The Company intends to vigorously defend against the claims being asserted in the complaint.</span></div><div id="i7d27a7d8e3c749dabb1f235100af8228_28"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Items 4. Mine Safety Disclosures.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><div id="i7d27a7d8e3c749dabb1f235100af8228_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part II</span></div><div style="text-align:center"><span><br/></span></div><div id="i7d27a7d8e3c749dabb1f235100af8228_34"></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Market Information</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our common stock began trading on The Nasdaq Global Market on September 19, 2019 under the symbol "XGN." Prior to September 19, 2019, there was no public market for our common stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Holders of Record</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;14, 2024, there were approximately 31 stockholders of record of our common stock. This number was derived from our shareholder records and does not include beneficial owners of our common stock whose shares are held in "street" name with various dealers, clearing agencies, banks, brokers and other fiduciaries.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Dividend Policy</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have never declared or paid any cash dividends on our capital stock. We intend to retain future earnings, if any, to finance the operation of our business and do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors after considering our financial condition, results of operations, capital requirements, business prospects and other factors the board of directors deems relevant, and subject to the restrictions contained in any future financing instruments. In addition, our ability to pay cash dividends is currently prohibited by the terms of our Amended Loan Agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Securities Authorized for Issuance under Equity Compensation Plans</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See Part III, Item 12 of this Annual Report under the section titled "Security Ownership of Certain Beneficial Owners and Management" for information about our equity compensation plans, which is incorporated by reference herein.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Performance Graph</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recent Sales of Unregistered Securities</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">None.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Purchases of Equity Securities by the Issuer</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">None.</span></div><div style="margin-top:9pt"><span><br/></span></div><div id="i7d27a7d8e3c749dabb1f235100af8228_37"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. [Reserved.]</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><div id="i7d27a7d8e3c749dabb1f235100af8228_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">You should read the following discussion of our financial condition and results of operations in conjunction with the financial statements and the notes thereto included elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business and financial performance, includes forward-looking statements that are based on current beliefs, plans and expectations and involve risks, uncertainties and assumptions. You should read the "Special note regarding forward-looking statements" and "Risk Factors" section of this Annual Report on Form 10-K for a discussion of important factors that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</span></div><div id="i7d27a7d8e3c749dabb1f235100af8228_43"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Overview</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We exist to provide clarity in autoimmune disease decision making with the goal of improving patients' clinical outcomes. We have developed and are commercializing a portfolio of innovative testing products under our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> brand, which allow for the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases. There is an unmet need for rheumatologists to add clarity in their CTD clinical evaluation, and we believe there is a significant opportunity for our tests in this market, particularly for potentially life-threatening diseases such as SLE.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since inception we have devoted substantially all of our efforts to developing and marketing products for the diagnosis, prognosis and monitoring of autoimmune diseases. We commercially launched our lead testing product, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD, in 2012. Our proprietary AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lupus test is included as part of the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD panel and employs a patent-protected method for diagnosing patients with SLE based on levels of CB-CAPs (e.g. EC4d and BC4d), ANA, and ds-DNA. The AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lupus test also employs patent-protected algorithms used to generate risk scores to diagnose patients with SLE based on the levels of the biomarkers. These proprietary, patent-protected methods vastly improve the diagnostic sensitivity of our test compared to the current standard of care. AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD enables differential diagnosis for patients presenting with symptoms indicative of a wide variety of CTDs and other related diseases with overlapping symptoms. Revenue from this product comprised 88% and 84% of our revenue for the years ended December&#160;31, 2023 and 2022, respectively. For the years ended December&#160;31, 2023 and 2022, we incurred net losses of $23.7&#160;million and $47.4 million, respectively, and we expect to continue to incur operating losses in the near term. Our operations have been funded primarily through equity financings, debt financings and revenue from product sales. We have never been profitable and, as of December&#160;31, 2023, we had $36.5&#160;million of cash and cash equivalents and an accumulated deficit of $279.2&#160;million.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reimbursement for our testing services comes from several sources, including commercial payors (such as insurance companies and health maintenance organizations), government payors (such as Medicare and Medicaid), and patients. Reimbursement rates vary by product and payor.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> tests are performed in our approximately 13,000 square foot laboratory located in Vista, California, which is certified under the CLIA and accredited by CAP. Our laboratory is certified for performance of high-complexity testing by CMS in accordance with CLIA and is licensed by all states requiring out-of-state licensure. Our clinical laboratory typically reports all AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">testing product results within five business days.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We market our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products using our specialized sales force covering 40 territories in the United States. Many diagnostic sales forces are trained only to understand the comparative benefits of the tests they promote. In contrast, the specialized backgrounds of our sales personnel, coupled with our comprehensive training, enables our sales representatives to interpret results from our de-identified patient test reports and provide unique insights in a highly tailored discussion with rheumatologists. We believe our focus on and experience in the field of rheumatology, combined with our commitment to excellent customer service and support, position us very well to respond to the needs of rheumatologists and the patients they serve.</span></div><div id="i7d27a7d8e3c749dabb1f235100af8228_46"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Factors Affecting Our Performance</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe there are several important factors that have impacted, and that we expect will impact, our operating performance and results of operations, including:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.46pt">Reimbursement for Our Testing Products</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Our revenue depends on achieving broad coverage and reimbursement for our tests from third-party payors, including both commercial payors and government payors. Payment from third-party payors differs depending on whether we are considered a "participating provider" (have entered into a contract with the payors as a participating provider) or a "non-participating provider" (do not have a contract and are considered a "non-participating provider"). Payors will often </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">reimburse non-participating providers at a lower amount than participating providers, if at all. We have received a substantial portion of our revenue from a limited number of commercial payors, most of which have not contracted with us to be a participating provider. Historically, we have experienced situations where commercial payors proactively reduced the amounts they were willing to reimburse for our tests, and in other situations, commercial payors have determined that the amounts they previously paid were too high and have sought to recover those perceived excess payments by deducting such amounts from payments otherwise being made. When we contract to serve as a participating provider, reimbursements are made pursuant to a negotiated fee schedule and are limited to only covered indications.&#160;If we are not able to obtain or maintain coverage and adequate reimbursement from third-party payors, we may not be able to effectively increase our testing volume and revenue as expected. Additionally, changes in our estimated reimbursements for tests performed in prior periods can positively or negatively impact our revenue in the current period and cause our financial results to fluctuate. In addition, in connection with our revenue cycle management initiatives, we plan to hold claims in the first half of the year which will likely result in increases in our accounts receivable and an accelerated decrease in our cash in the first half of the year which we would expect to return to typical levels by the end of our fiscal year.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.46pt">Continued Growth of Our Testing Products. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since the launch of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD in 2012 and through December&#160;31, 2023, we have delivered approximately 887,000 of these tests. 137,650 AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD tests were delivered in the year ended December&#160;31, 2023, representing approximately 2% growth over the same period in 2022. The number of ordering healthcare providers in the quarter ended December&#160;31, 2023 was 2,383, representing an approximate 2% decrease over the same period in 2022. Revenue growth for our testing products will depend, in part, on our ability to continue to expand our base of ordering healthcare providers and increase our penetration with existing healthcare providers.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.46pt">Development of Additional Testing Products. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We rely on sales of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test to generate the significant majority of our revenue. We expect to continue to invest in research and development in order to develop additional testing products. Our success in developing new testing products will be important in our efforts to grow our business by expanding the potential market for our products and diversifying our sources of revenue.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.46pt">Maintain Meaningful Margin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. We seek to maintain meaningful margin through a continued focus on increasing operating leverage through the implementation of certain internal initiatives, such as leveraging validation, utility and reimbursement oriented clinical studies to facilitate payor coverage of our testing products. We plan to center our efforts around long-term reimbursement and ASP growth and seek to improve our per test costs by focusing on profitable, core test offerings and limiting fixed costs and overhead.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.46pt">Timing of Our Research and Development Expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. We conduct clinical studies to validate our new testing products, as well as ongoing clinical and outcome studies to further expand the published evidence that supports our commercialized AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> testing products. We also expend funds to secure clinical samples that can be used in discovery, product development, clinical validation, utility and outcome studies. Our spending on experiments and clinical studies may vary substantially from quarter to quarter, and the timing of these research and development activities is difficult to predict. If a substantial number of clinical samples are obtained in a given quarter or if a high-cost experiment is conducted in one quarter versus the next, the timing of these expenses will affect our financial results.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.46pt">How We Recognize Revenue</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. We record revenue on an accrual basis, using an estimate of the amount that we will ultimately realize, as determined based on a historical analysis of amounts collected by test and by payor, among other factors. Changes to such estimates may increase or decrease revenue recognized in future periods.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While each of these areas present significant opportunities for us, they also pose significant risks and challenges that we must address. We discuss many of these risks, uncertainties and other factors in the section entitled "Risk Factors."</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Seasonality</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on our experience to date, we expect some seasonal variations in our financial results due to a variety of factors, such as: the year-end holiday period and other major holidays, vacation patterns of both patients and healthcare providers (including medical conferences), climate and weather conditions in our markets (for example, excess sun exposure can cause flares in SLE), seasonal conditions that may affect medical practices and provider activity (for example, influenza outbreaks that may reduce the percentage of patients that can be seen) and other factors relating to the timing of patient benefit changes, as well as patient deductibles and co-insurance limits.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Inflationary Environment</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The current inflationary environment has resulted in higher prices, which have impacted our costs incurred to generate revenue from our laboratory testing services, costs to attract and retain personnel, and other operating costs. The severity and duration of the current inflationary environment remains uncertain and may continue to impact our financial condition and results of operations.</span></div><div id="i7d27a7d8e3c749dabb1f235100af8228_49"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial Overview</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recognize revenue in accordance with the provisions of ASC Topic 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue from Contracts with Customers.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We record revenue on an accrual basis, using an estimate of the amount we will ultimately receive, as determined based on a historical analysis of amounts collected by test and by payor, among other factors. These assessments require significant judgment by management.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To date, we have derived nearly all of our revenue from the sale of our testing products, most of which is attributable to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test. We primarily market our testing products to rheumatologists in the United States. The rheumatologists who order our testing products, and to whom results are reported, are generally not responsible for payment for these products. The parties that pay for these services (payors) consist of commercial payors (insurance companies, health maintenance organizations, etc.), government payors (primarily Medicare and Medicaid), client payors (hospitals, other laboratories, etc.), and patient self-pay. Our service is completed upon the delivery of test results to the prescribing rheumatologists which triggers billing for the service.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our ability to increase our revenue will depend on our ability to further penetrate the market for our current and future testing products and increase our reimbursement and collection rates for tests delivered.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the quarter ended March 31, 2022, CMS agreed, effective April 1, 2022, to recognize a new PLA code for our protein-based test, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus. Noridian, our MAC, priced this PLA code at $1,085 per test. To determine pricing beyond 2022, CMS recommended crosswalking AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus (0312U) to Vectra (81490) at a rate of $840.65 per test. This pricing was finalized on the 2023 CLFS and is effective from January 1, 2023 through December 31, 2025. The process for obtaining and maintaining consistent reimbursement for new tests can be uncertain, lengthy and time consuming. A pricing determination is not synonymous with a coverage determination. Having a price associated with the PLA code for any particular test does not secure coverage or reimbursement for that PLA code from Medicare or any other third-party payor.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In an effort to improve transparency regarding Medicare support of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lupus, on July 29, 2022, we submitted a formal request to Noridian for coverage of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test under the new PLA Code. On September 27, 2022, we received notice that Noridian has deemed our application for an LCD to be valid. Ultimately receiving a favorable LCD is uncertain and may be time-consuming, resource intensive and require multiple quarterly or annual periods to complete. In the meantime, we have continued to submit Medicare claims for AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus, appeal denials and respond to requests for additional information. On January 31, 2024, CMS released a coverage article under which all multi-analyte proteomic testing will be considered within the scope of MolDX and reviewed through their technology assessment process. The article requires all laboratories furnishing multi-analyte proteomics testing in MolDX jurisdictions to register with the DEX</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Diagnostics Exchange Registry and obtain a Z-Code</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> identifier. To determine if the submitted tests are compliant with relevant policy requirements, these tests will undergo technical assessment by Palmetto GBA as part of the MolDX program. The article listed several such tests, including the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Lupus test.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We face challenges relating to commercial payor claim processing and revenue. Now that we are billing under our PLA code, we are experiencing denials due to unfavorable medical policy with certain plans, and we expect this situation to persist.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">During the year ended December 31, 2023, we implemented several revenue cycle management initiatives, including among others, withholding the submission of commercial payor claims for reimbursement until subsequent quarters, increasing appeals efforts and implementing increases to our patient payment rates. Additionally, in November 2023, we increased the list price billed for our tests. These ongoing revenue cycle management initiatives aim to optimize our appeals process and the potential for cash collections. We experienced moderate declines in test volume in the second half of 2023, as rheumatologists and patients adjust to these changes; however, we delivered 137,650 tests for our flagship product, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> CTD, in the year ended December&#160;31, 2023 as compared to 135,210 tests for the year ended December&#160;31, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Operating Expenses</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Costs of Revenue</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs of revenue represents the expenses associated with obtaining and testing patient specimens. The components of our costs of revenue include materials costs, direct labor, equipment, infrastructure expenses, shipping charges to transport specimens, blood specimen collections fees, royalties, depreciation and allocated overhead (including rent and utilities).</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Each payor, whether commercial, government, or individual, reimburses us at different amounts. These differences can be significant. As a result, our costs of revenue as a percentage of revenue may vary significantly from period to period due to the composition of payors for each period's billings. We expect that our costs of revenue will remain relatively consistent year-over-year in the near-term.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Selling, General and Administrative Expenses</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Selling, general and administrative expenses consist of personnel costs (including stock-based compensation expense), direct marketing expenses, accounting and legal expenses, consulting costs, and allocated overhead (including rent, information technology, depreciation and utilities). We expect that our selling, general and administrative expenses will remain relatively consistent year-over-year in the near-term.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Research and Development Expenses</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development expenses include costs incurred to develop our technology, test products and product candidates, in addition to costs incurred to collect clinical specimens and conduct clinical studies to develop and support those products and product candidates. These costs consist of personnel-related expenses (including stock-based compensation expense), materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead (including rent and utilities). We expense all research and development costs in the periods in which they are incurred. We expect that our research and development expenses will increase year-over-year in the near-term as a result of ongoing clinical studies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Interest Expense</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest expense consists of cash and non-cash interest expense associated with our financing arrangements, including the borrowings under our Amended Loan Agreement with Innovatus. We expect interest expense to remain relatively consistent in the year ending December 31, 2024 as compared to the year ended December 31, 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Interest Income</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest income consists of interest income earned on our cash and cash equivalents.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Income Tax (Expense) Benefit</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income taxes include federal and state income taxes in the United States.</span></div><div id="i7d27a7d8e3c749dabb1f235100af8228_52"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Years Ended December&#160;31, 2023 and 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.284%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Costs of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,122)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,590)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,865&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,011)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,506)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75,385&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,229)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22,837)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46,051)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,214&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,335)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,448)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23,656)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47,669)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,013&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(315)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23,689)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47,387)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,698&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue increased $7.0&#160;million, or 15.3%, for the year ended December&#160;31, 2023 compared to the year ended December&#160;31, 2022, primarily due to improved commercial payor ASP, increased AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD year-over-year volume and cash collections from tests performed in prior periods, partially offset by decreased Medicare ASP. The number of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD tests delivered increased to 137,650 in the year ended December&#160;31, 2023 compared to 135,210 tests delivered in the same 2022 period. The AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test accounted for 88% and 84% of revenue for the years ended December&#160;31, 2023 and 2022, respectively. The number of ordering healthcare providers decreased to 2,383 for the three months ended December&#160;31, 2023 compared to 2,419 in the same 2022 period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Costs of Revenue</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs of revenue decreased $1.1&#160;million, or 4.6%, for the year ended December&#160;31, 2023 compared to the year ended December&#160;31, 2022. This decrease was primarily due to decreases of $0.9 million in materials and supplies expenses resulting from price improvements related to transition of biomarkers to suppliers with favorable pricing, and $0.2 million in shipping and handling costs. Gross margin as a percentage of revenue increased to 56.1% for the year ended December&#160;31, 2023 compared to 46.9% for the year ended December&#160;31, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Selling, General and Administrative Expenses</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Selling, general and administrative expenses decreased $4.6&#160;million, or 8.8%, for the year ended December&#160;31, 2023 compared to the year ended December&#160;31, 2022. This decrease was primarily due to decreases of $6.1 million of personnel costs, including salaries, benefits, stock-based compensation, severance expenses and other reimbursable employee expenses, as a result of lower headcount, in addition to decreases of $1.5 million in marketing expenses related to advertising expenses, speaker programs and trade show expenses, $0.3 million in insurance expenses, $0.2 million in third-party billing expenses and $0.1 million in legal expenses. These decreases were partially offset by the recognition of a $1.5 million loss on the disposal of assets primarily related to an assignment of a lease, in addition to an increases in expenses related to bonuses of $1.3 million, facilities and allocated overhead expenses of $0.5 million and commissions of 0.3 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Research and Development Expenses</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development expenses decreased $5.0 million, or 50.7%, for the year ended December&#160;31, 2023 compared to the year ended December&#160;31, 2022. This decrease was primarily due to decreases of $2.7 million of personnel costs, including salaries, benefits and stock-based compensation, as a result of lower headcount, decreases related to lab supplies expenses of $1.0 million, collaboration expenses of $0.5 million, clinical study expenses of $0.3 million, and professional service fees of $0.2 million, in addition to a long-lived assets impairment charge of $0.4 million for the year ended December 31, 2022.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Goodwill Impairment</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of our annual goodwill impairment assessment in the fourth quarter of 2022, we determined that the sustained decrease in our market capitalization constituted an indicator of impairment and as a result, a quantitative goodwill impairment test was completed as of December 31, 2022. This analysis identified an impairment of $5.5&#160;million related to our goodwill.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Interest Expense</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest expense decreased $0.1 million for the year ended December&#160;31, 2023 compared to the year ended December&#160;31, 2022 due to a lower principal balance on the company's Amended Loan Agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Interest Income</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest income increased $0.7 million for the year ended December&#160;31, 2023 compared to the year ended December&#160;31, 2022 due to higher money market and certificate of deposit interest rates in 2023 compared to 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Income Tax (Expense) Benefit</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income tax benefit increased $0.3 million for the year ended December&#160;31, 2023 compared to the year ended December&#160;31, 2022, primarily due to the release of a valuation allowance. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Liquidity and Capital Resources</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have incurred net losses since our inception. For the years ended December&#160;31, 2023 and 2022, we incurred a net loss of $23.7 million and $47.4&#160;million, respectively, and we expect to incur additional losses in future periods. To date, we have generated only limited revenue, and we may never achieve revenue sufficient to offset our expenses. As of December&#160;31, 2023, we had an accumulated deficit of $279.2&#160;million and cash and cash equivalents of $36.5 million. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. Currently, our funds are held in cash, money market funds and certificates of deposit.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since becoming a public company, our primary sources of capital have been cash inflows from product sales, sales of our common stock and, to a lesser extent, borrowings under our 2017 Term Loan. In April 2023, we further amended the 2017 Term Loan, pursuant to which we prepaid $10.0 million of principal and amended additional terms of the agreement. See Note 4, Borrowings, to our audited financial statements included in this Annual Report on Form 10-K for additional information.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our obligations under the Amended Loan Agreement are secured by a security interest in substantially all of our assets, including our intellectual property. The Amended Loan Agreement contains customary conditions to borrowing, events of default, and covenants, including covenants requiring us to maintain minimum liquidity of $2.0 million, covenants to achieve certain minimum amounts of revenue, and covenants limiting our ability to dispose of assets, undergo a change in control, merge with or acquire other entities, incur debt, incur liens, pay dividends or other distributions to holders of our capital stock, repurchase stock and make investments, in each case subject to certain exceptions. Per the Amended Loan Agreement, we are not required to comply with the revenue covenant for any quarter during which we maintain a minimum aggregate cash balance equal to fifty percent of the aggregate principal amount of the 2017 Term Loan funded (excluding any capitalized interest paid-in-kind) at all times during such quarter. The consequences of failing to achieve the performance covenants, when applicable, will be cured if (i) within thirty days of failing to achieve the performance covenant, we submit a new Board approved financial plan to Innovatus under which we are expected to break even on a cash flow basis prior to the maturity date, and (ii) within thirty days of the submission of such financial plan, we issue additional equity securities or subordinated debt with net proceeds sufficient to fund any cash flow deficiency generated from operations, as defined in the Amended Loan Agreement. As of December&#160;31, 2023, we were in compliance with all covenants of the Amended Loan Agreement with Innovatus. In addition, upon the occurrence of an event of default, Innovatus, among other things, can declare all indebtedness due and payable immediately, which would adversely impact our liquidity and reduce the availability of our cash flows to fund working capital needs, capital expenditures and other general corporate purposes.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On November 17, 2023, we filed a registration statement on Form S-3 (Shelf Registration Statement) covering the offering, from time to time, of up to $150.0 million of common stock, preferred stock, debt securities, warrants and units, all of which remain available for sale at December 31, 2023.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 15, 2022, the Company entered into a sales agreement (the Sales Agreement) with TD Cowen as sales agent, pursuant to which the Company may offer and sell, from time to time, shares of Company common stock having an aggregate offering price of up to $50.0 million. The Sales Agreement was amended in November 2023 in connection with the filing of the Form S-3 discussed above. The Company is not obligated to sell any shares of Company common stock in the offering and, as of December&#160;31, 2023, the Company had not sold any shares of its common stock pursuant to the Sales Agreement.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our ability to utilize the $150&#160;million of capacity remaining under our Shelf Registration Statement, including the $50.0&#160;million of capacity remaining under our at the market offering sales agreement is limited by our compliance with the baby shelf rules (as defined below). As of the filing of this Annual Report on Form 10-K, our public float is less than $75 million, and under SEC regulations, for so long as our public float remains less than $75 million, the amount we can raise through primary public offerings of securities in any twelve-month period using shelf registration statements subject to Instruction I.B.6. to Form S-3 is limited to an aggregate of one-third of our public float, which is referred to as the &#8220;baby shelf rules.&#8221; As of February 15, 2024, our public float was approximately $29.7 million, based on 12,916,064 shares of outstanding common stock held by non-affiliates and at a price of $2.30 per share, which was the last reported sale price of our common stock on the Nasdaq Capital Market on January&#160;30, 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Funding Requirements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our primary use of cash is to fund our operations as we continue to grow our business. We expect to continue to incur operating losses in the near term. In the short-term, we expect costs of revenue and selling, general and administrative expenses to remain relatively consistent. We expect research and development expenses to increase in the short-term as a result of ongoing clinical studies. We believe we have sufficient laboratory capacity to support increased test volume. Cash used to fund operating expenses is impacted by the timing of when we pay expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect that our near- and longer-term liquidity requirements will continue to consist of working capital and general corporate expenses associated with the growth of our business, including payments we may be required to make upon the achievement of previously negotiated milestones associated with intellectual property we have licensed, payments related to non-cancelable purchase obligations with one supplier for reagents, payments related to our principal and interest under our long term borrowing arrangements, payments for operating leases related to our office and laboratory space in Vista, California and our office space in Carlsbad, California, and payments for finance leases related to our laboratory equipment (see Note 4, Borrowings, and Note 6, Commitments and Contingencies, to our audited financial statements included in this Annual Report on Form 10-K). Based on our current business plan, we believe that our existing cash and cash equivalents and our anticipated future revenue, will be sufficient to meet our anticipated cash requirements for at least the next 12&#160;months from the date of this filing.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our estimate of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties. Actual results could vary as a result of a number of factors, including:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for our testing products;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to maintain and grow sales of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;testing products, as well as the costs associated with conducting clinical studies to demonstrate the utility of our products and support reimbursement efforts;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">fluctuations in working capital;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">the costs of developing our product pipeline, including the costs associated with conducting our ongoing and future validation, utility and outcome studies as well as the success of our development efforts; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.46pt">the extent to which we establish additional partnerships or in-license, acquire or invest in complementary businesses or products as well as the success of our existing partnerships and/or in-licenses.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Until such time, if ever, as we can generate revenue to support our costs structure, we expect to finance our operations through equity offerings, debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders may be diluted, and the terms of these </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. If additional funding is required or desired, there can be no assurance that additional funds will be available to us on acceptable terms on a timely basis, if at all, or that we will generate sufficient cash from operations to adequately fund our operating needs or achieve or sustain profitability. If we are unable to raise additional capital or generate sufficient cash from operations to adequately fund our operations, we will need to delay, reduce or eliminate some or all of our research and development programs, product portfolio expansion plans or commercialization efforts. Doing so will likely have an unfavorable effect on our ability to execute on our business plan and could have a negative impact on our commercial and strategic relationships. If we cannot expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital, our business, financial condition, and results of operations could be adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cash Flows</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes our cash flows for the periods indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14,462)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32,144)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(804)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,318)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,632)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(489)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net change in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25,898)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36,951)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash Flows from Operating Activities</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net cash used in operating activities for the year ended December&#160;31, 2023 was $14.5 million and primarily resulted from (i) our net loss of $23.7 million adjusted for non-cash charges of $8.9 million primarily related to stock-based compensation, depreciation, amortization, loss on disposal of assets primarily related to the assignment of a lease, non-cash lease expenses and non-cash interest and (ii) changes in our net operating assets of $0.3&#160;million primarily related to net increases in prepaid expenses and other current assets and accounts receivable, and net decreases in operating lease liabilities, partially offset by net increases in accrued and other current liabilities. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net cash used in operating activities for the year ended December 31, 2022 was $32.1&#160;million and primarily resulted from (i) our net loss of $47.4&#160;million adjusted for non-cash charges of $13.6&#160;million related to stock-based compensation, depreciation, amortization, non-cash interest and deferred income taxes and (ii) changes in our net operating assets of $1.7&#160;million primarily related to net increases in accounts receivable and net decreases in accounts payable, partially offset by net decreases in prepaid expenses and other current assets and net increases in accrued liabilities and other current liabilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash Flows from Investing Activities</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net cash used in investing activities for the year ended December&#160;31, 2023 and 2022 was $0.8&#160;million and $4.3 million, respectively, and was primarily due to net purchases of property and equipment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash Flows from Financing Activities</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net cash used in financing activities for the year ended December&#160;31, 2023 was $10.6 million, primarily consisting of principal payments on the Amended Loan Agreement, finance lease obligations and notes payable, partially offset by the proceeds from the Exagen Inc. 2019 Employee Stock Purchase Plan (the ESPP) purchases.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Critical Accounting Estimates</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our audited financial statements, which have been prepared in accordance with accounting principles generally accepted in United States of America (GAAP). The preparation of these audited financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the audited financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material. We believe the following accounting estimates are the most critical to us, in that they require our most difficult, subjective or complex judgments in the preparation of our financial statements. For further information, see Note 2, Summary of Significant Accounting Policies, to our Financial Statements, which outlines our application of significant accounting policies. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue Recognition</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To date, substantially all of our revenue has been derived from sales of our testing products. We primarily market our testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order our services and to whom test results are reported are generally not responsible for payment for these services. The parties that pay for these services consist of commercial payors, government payors (primarily Medicare and Medicaid), client payors (hospitals, other laboratories, etc.) and patient self-pays.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Payors are billed at our list price. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration we expect to receive from such payors. We follow a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions, recording adjustments in the current period as changes in estimates. Further adjustments to the allowances, based on actual receipts, are recorded upon settlement. The transaction price is estimated using an expected value method on a portfolio basis. Our portfolios are grouped per payor (each individual third-party insurance, Medicare, Medicaid, client payors, patient self-pay, etc.) and per test basis.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Collection of our net revenues from payors is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation by management. We continually assess the state of our cash collections in order to identify areas of risk and opportunity that allow us to appropriately estimate receivables and revenue. Should we later determine the judgements underlying estimated collections change, our financial results could be impacted in future periods. Included in revenues for the years ended December&#160;31, 2023 and 2022 was a net revenue increase of $3.4 million and a net revenue decrease of $2.4 million, respectively, associated with changes in estimated variable consideration related to performance obligations satisfied in previous periods.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Stock-Based Compensation</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recorded stock-based compensation expense of approximately $3.6 million and $4.7 million for the years ended December&#160;31, 2023 and 2022, respectively. We expect to continue to grant stock options, restricted stock units (RSUs) and other equity-based awards in the future and to the extent that we do, our stock-based compensation expense recognized in future periods will likely increase. For stock options and purchase rights granted under the ESPP, we estimate the grant date fair value using the Black-Scholes option-pricing valuation model. For RSUs, we use the closing price of our common stock on the date of grant to determine the fair value.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Black-Scholes option pricing model requires the use of assumptions, which determine the fair value of stock-based awards. If we had made different assumptions, our stock-based compensation expense, net loss and net loss per share attributable to common stockholders could have been significantly different. See Note 2, Summary of Significant Accounting Policies, and Note 9, Stock Option Plan, to our audited financial statements in this Annual Report on Form 10-K for information concerning certain of the specific assumptions we used in applying the Black-Scholes option pricing model to determine the estimated fair value of our stock options granted and purchases under our ESPP rights in the years ended December&#160;31, 2023 and 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recent Accounting Pronouncements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See Note 2, Recent Accounting Pronouncements, of our annual financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">JOBS Act Accounting Election</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The JOBS Act contains provisions that, among other things, reduce certain reporting requirements for an "emerging growth company." The JOBS Act permits an "emerging growth company" like us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We have elected to use this extended transition period under the JOBS Act until the earlier of the date we (i)&#160;are no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opt out of the extended transition period provided in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the JOBS Act. As a result, our audited financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We will remain an emerging growth company until the last day of our fiscal year following the fifth anniversary of the date of the first sale of our common equity securities pursuant to an effective registration statement under the Securities Act, which will occur in 2024. However, if certain events occur prior to the end of this five-year period, including if we become a "large accelerated filer" as defined in Rule&#160;12b-2 under the Exchange Act, our annual gross revenues exceed $1.235&#160;billion or we issue more than $1.0&#160;billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to this anniversary.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><div id="i7d27a7d8e3c749dabb1f235100af8228_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable.</span></div><div id="i7d27a7d8e3c749dabb1f235100af8228_58"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. Financial Statements and Supplementary Data.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements and supplemental data required by this item are set forth at the pages indicated in Part IV, Item 15(a)(1) of this Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div id="i7d27a7d8e3c749dabb1f235100af8228_61"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">None.</span></div><div id="i7d27a7d8e3c749dabb1f235100af8228_64"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 9A. Controls and Procedures.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that the information required to be disclosed by us in such reports is accumulated and communicated to our management, including our principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, control may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our management, with the participation of our principal executive officer and our principal financial officer, evaluated, as of the end of the period covered by this Annual Report on Form 10-K, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our principal executive officer and principal financial officer have concluded that as of December&#160;31, 2023, our disclosure controls and procedures were effective at the reasonable assurance level. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgement in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Management's Report on Internal Control over Financial Reporting</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Internal control over financial reporting is a process designed under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. Our internal control over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets, (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors, and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements. Because of its inherent limitations, internal controls over financial reporting may not prevent or detect all misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2023, our management assessed the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Internal Control-Integrated Framework (2013 framework)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Based on this assessment, our management concluded that, as of December&#160;31, 2023, our internal control over financial reporting was effective.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Remediation of Previously Disclosed Material Weaknesses</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On November 13, 2022, management and the Audit Committee determined that we made certain errors in revenue resulting from erroneous and duplicate billings related to changes in billing practices. The errors were due to the inadequate design, implementation and precision of internal controls and procedures to evaluate and monitor the accounting for revenue recognition. As a result, revenue and accounts receivable were overstated and other liabilities was understated for the quarter and year to date periods ended June 30, 2022.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We concluded that these were material errors in the financial statements requiring a restatement of the Form 10-Q for the three and six months ended June 30, 2022. Accordingly, management determined that this control deficiency constituted a material weakness as of December 31, 2022.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In response to the material weaknesses, and as previously disclosed in Item 9A of our annual report on Form 10-K for the year ended December 31, 2022, we implemented a remediation plan which included, but was not limited to, evaluating the staffing level, skills and qualification of accounting department personnel, enhancement of our existing control structure and processes for revenue recognition and improving the detailed review process of our revenue recognition models. The enhancements made to our control environment were in place as of December 31, 2023, and based on the evaluation of relevant internal controls, management has concluded that the material weaknesses previously identified have been remediated as of December 31, 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Attestation Report of the Registered Public Accounting Firm</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Annual Report on Form 10-K does not include an attestation report of our registered public accounting firm due to an exemption provided by the JOBS Act for "emerging growth companies."</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other than the remediation of the material weakness discussed above, there have been no changes in our internal control over financial reporting during the three months ended December&#160;31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Inherent Limitations on Effectiveness of Controls and Procedures</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><div id="i7d27a7d8e3c749dabb1f235100af8228_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable.</span></div><div style="margin-top:9pt"><span><br/></span></div><div id="i7d27a7d8e3c749dabb1f235100af8228_70"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable.</span></div><div style="margin-top:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><div id="i7d27a7d8e3c749dabb1f235100af8228_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part III</span></div><div style="text-align:center"><span><br/></span></div><div id="i7d27a7d8e3c749dabb1f235100af8228_76"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers and Corporate Governance.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information required by this item is incorporated herein by reference to our Proxy Statement with respect to our 2023 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.</span></div><div id="i7d27a7d8e3c749dabb1f235100af8228_79"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. Executive Compensation.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information required by this item is incorporated herein by reference to our Proxy Statement with respect to our 2023 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.</span></div><div id="i7d27a7d8e3c749dabb1f235100af8228_82"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information required by this item is incorporated herein by reference to our Proxy Statement with respect to our 2023 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.</span></div><div id="i7d27a7d8e3c749dabb1f235100af8228_85"></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Transactions, and Director Independence.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information required by this item is incorporated herein by reference to our Proxy Statement with respect to our 2023 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.</span></div><div id="i7d27a7d8e3c749dabb1f235100af8228_88"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Principal Accountant Fees and Services.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our independent registered public accounting firm is BDO USA, P.C., San Diego, California, PCAOB ID #<ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-37">243</ix:nonNumeric>.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The information required by this item is incorporated herein by reference to our Proxy Statement with respect to our 2023 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><div id="i7d27a7d8e3c749dabb1f235100af8228_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part IV</span></div><div style="text-align:center"><span><br/></span></div><div id="i7d27a7d8e3c749dabb1f235100af8228_94"></div><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 15. Exhibits and Financial Statement Schedules.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial Statements and Financial Statement Schedules</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(1) Exhibits</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A list of exhibits is set forth on the Exhibit Index immediately preceding the signature page of this Annual Report on Form 10-K and is incorporated herein by reference.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(2) All financial statements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The financial statements of Exagen Inc., together with the report thereon of BDO USA, P.C., an independent registered public accounting firm, are included in this Annual Report on Form 10-K beginning on page F-2.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(3) Financial statement schedules</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto.</span></div><div id="i7d27a7d8e3c749dabb1f235100af8228_97"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. Form 10-K Summary.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">None.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><div id="i7d27a7d8e3c749dabb1f235100af8228_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index to Exhibits</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.109%"><tr><td style="width:1.0%"/><td style="width:7.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.286%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.049%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.028%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Filing Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed/Furnished Herewith</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519252366/d769261dex31.htm">Amended and Restated Certificate of Incorporation.</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/23/2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473721000017/ex31-amendedandrestatedbyl.htm">Amended and Restated Bylaws.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/22/2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473723000004/exhibit-exagenxamendmentto.htm">A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473723000004/exhibit-exagenxamendmentto.htm">mendment to A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473723000004/exhibit-exagenxamendmentto.htm">mended and Restated Bylaws, dated January 19, 2023.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1/23/2023</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex41.htm">Specimen stock certificate evidencing the shares of common stock.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex42.htm">Amended and Restated Investors&#8217; Rights Agreement, dated July 12, 2019, by and among the Company and certain of its stockholders.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex43.htm">Amended and Restated Stockholders' Agreement, dated July 12, 2019, by and among the Company and certain of its stockholders.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex44.htm">Form of Common Stock Purchase Warrant issued to investors by the Company in connection with private placement financings.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex48.htm">Form of Common Stock Purchase Warrant to purchase common stock issued to investors by the Company in 2016.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex49.htm">Form of Warrant to Purchase Stock issued to Innovatus Life Sciences Lending Fund I, LP in connection with the Company's 2018 loan agreement.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473721000094/ex45-formofprexfundedwarra.htm">Form of Exchange Warrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/9/2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="xgn-descriptionofsecurities.htm">Description of Securities</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex101.htm">Exagen Corporation 2002 Stock Option Plan, as amended, and form of option agreement thereunder.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex102.htm">Exagen Diagnostics, Inc. 2013 Stock Option Plan, as amended, and form of option agreement thereunder.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex103.htm">Exagen Inc. 2019 Incentive Award Plan.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.4#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex104.htm">Form of Option Agreement under Exagen Inc. 2019 Incentive Award Plan.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473721000015/ex105-formofrsuagreement20.htm">Form of Restricted Stock Unit Agreement under Exagen Inc. 2019 Incentive Award Plan.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/16/2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex105.htm">Exagen Inc. 2019 Employee Stock Purchase Plan.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.7 &#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1010.htm">Asset Purchase Agreement, dated October 8, 2010, by and between Cypress Bioscience, Inc., Proprius, Inc. and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.8&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1011.htm">Amendment No. One to Asset Purchase Agreement, dated March 10, 2011, by and between Cypress Bioscience, Inc., Proprius, Inc. and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1012.htm">Amendment No. Two to Asset Purchase Agreement, dated August 21, 2012, by and between Royalty Pharma Collection Trust, Proprius, Inc. and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.10&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1013.htm">Amendment No. Three to Asset Purchase Agreement, dated February 6, 2013, by and between Royalty Pharma Collection Trust, Proprius, Inc. and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.109%"><tr><td style="width:1.0%"/><td style="width:7.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.286%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.049%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.028%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1014.htm">Amendment No. Four to Asset Purchase Agreement, dated October 8, 2013, by and between Royalty Pharma Collection Trust, Proprius, Inc. and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1015.htm">Amendment No. Five to Asset Purchase Agreement, dated January 26, 2016, by and between Royalty Pharma Collection Trust, Proprius, Inc. and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.13&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1016.htm">Amendment No. Six to Asset Purchase Agreement, dated February 16, 2017, by and between Royalty Pharma Collection Trust, Proprius, Inc. and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.14&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1017.htm">Amended and Restated Exclusive License Agreement, dated August 2, 2011, by and between the University of Pittsburgh-Of the Commonwealth System of Higher Education and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.15&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1018.htm">First Amendment to Amended and Restated Exclusive License Agreement, dated May 17, 2012, by and between the University of Pittsburgh-Of the Commonwealth System of Higher Education and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.16&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1019.htm">Second Amendment to Amended and Restated Exclusive License Agreement, dated September 30, 2013, by and between the University of Pittsburgh-Of the Commonwealth System of Higher Education and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1020.htm">Third Amendment to Amended and Restated Exclusive License Agreement, dated June 24, 2016, by and between the University of Pittsburgh-Of the Commonwealth System of Higher Education and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.18&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1021.htm">Exclusive License Agreement, dated September 30, 2013, by and between the University of Pittsburgh-Of the Commonwealth System of Higher Education and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.22</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.19&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1022.htm">Exclusive License Agreement, dated September 5, 2011, by and between Thierry Dervieux, Ph.D. and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.23</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1024.htm">Standard Industrial/Commercial Multi-Tenant Lease, dated January 13, 2012, by and between RGS Properties and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/28/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1025.htm">First Amendment to Standard Industrial/Commercial Multi-Tenant Lease, dated December 1, 2013, by and between RGS Properties and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/28/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.22</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473720000026/secondamend1261suitebc.htm">Second Amendment to Standard Industrial/Commercial Multi-Tenant Lease, dated April 29, 2016, by and between RGS Properties and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.27</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/25/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.23</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473720000026/thirdamend1261suitebc.htm">Third Amendment to Standard Industrial/Commercial Multi-Tenant Lease, dated June 16, 2017, by and between RGS Properties and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.28</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/25/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.24</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473720000026/fourthamendmenttolease.htm">Fourth Amendment to Standard Industrial/Commercial Multi-Tenant Lease, dated March 16, 2020, by and between RGS Properties and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.29</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/25/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.25</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473721000115/ex103-fifthaddendumtolease.htm">Fifth Amendment to Standard Industrial/Commercial Multi-Tenant Lease, dated October 19, 2021, by and between RGS Properties and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/10/2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.26</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1030.htm">Standard Industrial/Commercial Single-Tenant Lease, dated September 4, 2014, by and between Geiger Court, LLC and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.109%"><tr><td style="width:1.0%"/><td style="width:7.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.286%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.049%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.028%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.27</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473720000026/firstamend1221lease.htm">First Amendment to Standard Industrial/Commercial Single-Tenant Lease, dated August 2, 2017, by and between Geiger Court, LLC and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/25/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.28</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473720000026/a1221libertyway-leasea.htm">Extension of Lease to Standard Industrial/Commercial Single-Tenant Lease, dated March 12, 2020, by and between Liberty Vista and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.32</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/25/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.29</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473721000015/ex1034-amend1to1221liberty.htm">First Amendment to Standard Industrial/Commercial Single-Tenant Lease, dated January 6, 2021, by and between Liberty Vista and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.34</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/16/2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.30</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473721000115/ex102-amend2to1221libertyw.htm">Second Amendment to Standard Industrial/Commercial Single-Tenant Lease, dated October 11, 2021, by and between Liberty Vista and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/10/2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.31</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473720000026/ex10331261suitealeasev2.htm">Standard Industrial/Commercial Multi-Tenant Lease, dated March 17, 2020 by and between RGS Properties and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.33</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/25/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.32</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473721000115/ex104-firstaddendumtolease.htm">First Amendment to Standard Industrial/Commercial Multi-Tenant Lease, dated October 19, 2021, by and between RGS Properties and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/10/2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.33&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473721000115/ex101-subleaseagreement819.htm">Sublease Agreement, dated August 19, 2021, by and between Plum Healthcare Group, LLC and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/10/2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.34</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1031.htm">Master Lease Agreement, dated February 1, 2018, by and between Celtic Commercial Finance, a division of MB Equipment Finance, LLC and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.32</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.35</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1032.htm">Loan and Security Agreement, dated September 7, 2017, by and between Innovatus Life Sciences Lending Fund I, LP and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.33</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.36</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473720000026/ex1036-innovatusxexage.htm">First Amendment to Loan and Security Agreement, dated November 19, 2019, by and between Innovatus Life Sciences Lending I, LP and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.36</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/25/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.37</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473720000097/ex101-innovatusacknowl.htm">Acknowledgement Letter to Loan and Security Agreement, dated October 7, 2020, by and between Innovatus Life Sciences Lending Fund I, LP and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/10/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.38</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473721000115/ex105-secondamendmentloana.htm">Second Amendment to Loan and Security Agreement, dated November 1, 2021, by and among Innovatus Life Sciences Lending Fund I, LP, other lenders and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/10/2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.39#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex1034.htm">Offer Letter, dated October 12, 2010, by and between Thierry Dervieux, Ph.D. and the Company, as amended on September 9, 2011 and September 6, 2019.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.34</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.40</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex1034.htm">Form of Indemnification Agreement for Directors and Officers.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.35</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.41#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex1036.htm">Offer Letter, dated October 7, 2011, by and between Fortunato Ron Rocca and the Company, as amended on September 4, 2019.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.36</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.42#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex1037.htm">Offer Letter, dated May 16, 2017, by and between Kamal Adawi and the Company, as amended on September 4, 2019.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.37</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.43#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473720000026/ex1041-zackofferletter.htm">Offer Letter dated February 21, 2020, by and between Debra Zack, MD Ph.D. and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.41</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/25/2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.44#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex1038.htm">Non-Employee Director Compensation Program.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.38</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.45#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473721000015/ex1046-executivecicseveran.htm">Executive Change in Control Severance Plan.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.46</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/16/2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.46#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473722000067/johnaballiceoemploymentagr.htm">Employment Agreement, dated as of October 16, 2022, by and between the Company and John Aballi</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/16/2022</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.109%"><tr><td style="width:1.0%"/><td style="width:7.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.286%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.049%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.028%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.47#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473722000067/exagenseveranceagreement-r.htm">Severance Agreement, dated as of October 14, 2022, by and between the Company and Ron Rocca</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/16/2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.48</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473722000064/ex11-xgnxsalesagreement.htm">Sales Agreement, dated as of September 15, 2022, by and between the Company and Cowen and Company, LLC</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/15/2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.49</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473722000080/debzackconsultingagreement.htm">Consulting Agreement, dated as of December 5, 2022, by and between the Company and Debra Zack, M.D., Ph.D.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/5/2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.50&#x5E;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001274737/000127473723000041/exdx-20230428.htm">Third Amendment to Loan and Security Agreement dated April 28, 2023, by and among Innovatus Life Sciences Lending I, LP, other lenders and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/4/2023</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.51</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473723000103/a1221libertywayassignmenta.htm">Assignment and Assumption Agreement, by and among Liberty Vista, L.P., Mindera Corporation and the Company.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/13/2023</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.52</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001274737/000127473723000116/exdx-20231206.htm">Consulting Agreement, dated as of December 6, 2023, by and between the Company and Mark Hazeltine.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/11/2023</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex231-2023bdoconsent.htm">Consent of Independent Registered Public Accounting Firm.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_103">Power of Attorney (included on signature page).</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="xgn311-123123.htm">Certificate of Principal Executive Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="xgn312-123123.htm">Certificate of Principal Financial Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="xgn321-123123.htm">Certifications Pursuant to U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Public Company Accounting Reform and Investor Protection Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.1#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1274737/000127473723000103/exagen-clawbackpolicy.htm">Exagen Inc. Clawback Policy.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/13/2023</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Labels Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The cover page from the Company's Annual Report on Form 10-K for the year ended December 31, 2021, has been formatted in Inline XBRL.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:76.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">* &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification is deemed not filed for purpose of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.</span></div><div style="padding-left:76.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#&#160;&#160;&#160;&#160;Indicates management contract or compensatory plan.</span></div><div style="padding-left:76.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;Portions of this exhibit (indicated by asterisks) have been omitted for confidentiality purposes.</span></div><div style="padding-left:76.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#x5E;&#160;&#160;&#160;&#160;Certain schedules to this exhibit have been omitted pursuant to Item 601(a)(5) of Regulation S-K. Copies of the omitted schedules will be furnished to the SEC upon request.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><div id="i7d27a7d8e3c749dabb1f235100af8228_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signatures</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"/><td style="width:56.762%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXAGEN INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: March&#160;18, 2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">by:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ John Aballi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Aballi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Power of Attorney</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints John Aballi and Kamal Adawi as his or her true and lawful attorneys-in-fact, and each of them, with full power of substitution, for him or her in any and all capacities, to sign any amendments to this Annual Report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact, and either of them, or his or their substitute or substitutes may do or cause to be done by virtue hereof.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"><tr><td style="width:1.0%"/><td style="width:5.507%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.007%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.007%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.473%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ John Aballi</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March&#160;18, 2024</span></div></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">John Aballi</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Kamal Adawi</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chief Financial Officer and Corporate Secretary</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March&#160;18, 2024</span></div></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kamal Adawi</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Tina S. Nova, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Executive Chairman of the Board</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March&#160;18, 2024</span></div></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tina S. Nova, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Brian Birk</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March&#160;18, 2024</span></div></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brian Birk</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Ana Hooker</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March&#160;18, 2024</span></div></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ana Hooker</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Wendy S. Johnson</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March&#160;18, 2024</span></div></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Wendy S. Johnson</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Paul Kim</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March&#160;18, 2024</span></div></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Paul Kim</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Ebetuel Pallares, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March&#160;18, 2024</span></div></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ebetuel Pallares, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Bruce C. Robertson, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March&#160;18, 2024</span></div></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bruce C. Robertson, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Frank Stokes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March&#160;18, 2024</span></div></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Frank Stokes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><div id="i7d27a7d8e3c749dabb1f235100af8228_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Index to Financial Statements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_109">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (PCAOB ID No. 243)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_109">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_112">Balance Sheets as of December 31, 202</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_112">3</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_112"> and 202</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_112">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_112">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_115">Statements of Operations for the Years Ended December 31, 202</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_115">3</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_115"> and 202</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_115">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_115">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_118">Statements of Stockholders' Equity for the Years Ended December 31, 202</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_118">3</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_118"> and 20</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_118">2</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_118">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_118">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_121">Statements of Cash Flows for the Years Ended December 31, 202</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_121">3</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_121"> and 20</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_121">2</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_121">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_121">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_124">Notes to Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d27a7d8e3c749dabb1f235100af8228_124">7</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="i7d27a7d8e3c749dabb1f235100af8228_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Shareholders and Board of Directors</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exagen Inc.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Vista, California</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Opinion on the Financial Statements </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have audited the accompanying balance sheets of Exagen Inc. (the "Company&#8221;) as of December 31, 2023 and 2022, the related statements of operations, stockholders&#8217; equity, and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Basis for Opinion</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-38">BDO USA, P.C.</ix:nonNumeric></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have served as the Company&#8217;s auditor since 2017.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-39">San Diego, California</ix:nonNumeric></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March&#160;18, 2024</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><div id="i7d27a7d8e3c749dabb1f235100af8228_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.800%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.868%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-40">36,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-41">62,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-42">6,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-43">6,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-44">4,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-45">4,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-46">47,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-47">72,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-48">5,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-49">8,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-50">3,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-51">4,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-52">616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-53">528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-54">56,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-55">86,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and Stockholders' Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-56">3,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-57">3,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-58">976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">1,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings-current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="f-60">264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="f-61">190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">7,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">5,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-64">11,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-65">9,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings-non-current portion, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-66">19,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-67">28,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-68">2,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-69">4,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-70">357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-71">867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-72">34,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-73">43,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 6)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-74"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-75"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-76"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-77">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-78"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-79">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-80"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-81"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-82"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-83">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding at December 31, 2023 and December 31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-84">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-86"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-87">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-88"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-89">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized at December 31, 2023 and December 31, 2022; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-90"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-91">17,045,954</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-92"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-93">16,549,984</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-94">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-95">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Additional paid-in capital</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-96">301,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-97">297,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-98">279,216</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-99">255,527</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-100">22,694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-101">42,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-102">56,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-103">86,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="i7d27a7d8e3c749dabb1f235100af8228_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.184%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="12" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-104">52,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-105">45,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Costs of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-106">23,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-107">24,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-108">47,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-109">52,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-110">4,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-111">9,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="f-112">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="f-113">5,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-114">75,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-115">91,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-116">22,837</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-117">46,051</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-118">2,335</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-119">2,448</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-120">1,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-121">830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-122">23,656</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-123">47,669</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-124">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-125">282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-126">23,689</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-127">47,387</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted (Note 2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-128"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-129">1.34</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-130"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-131">2.77</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average number of shares used to compute net loss per share, basic and diluted (Note 2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-132"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-133">17,679,467</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-134"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-135">17,082,348</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements</span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="i7d27a7d8e3c749dabb1f235100af8228_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Statements of Stockholders' Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.358%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-136">16,164,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-137">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-138">293,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-139">208,140</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-140">84,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock from vested restricted stock units and payment of employees' taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="exdx:IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares" format="ixt:num-dot-decimal" scale="0" id="f-141">64,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="exdx:IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue" scale="3" id="f-142">239</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="exdx:IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue" scale="3" id="f-143">239</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-144">245,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-145">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-146">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-147">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock under Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-148">75,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-149">385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-150">385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-151">4,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-152">4,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-153">47,387</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-154">47,387</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-155">16,549,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-156">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-157">297,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-158">255,527</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-159">42,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock from vested restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-160">273,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-161">93,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-162">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-163">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock under Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-164">129,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-165">279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-166">279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-167">3,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-168">3,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-169">23,689</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-170">23,689</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-171">17,045,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-172">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-173">301,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-174">279,216</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-175">22,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="i7d27a7d8e3c749dabb1f235100af8228_121"></div><hr style="page-break-after:always"/><div style="min-height:24.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.950%"><tr><td style="width:1.0%"/><td style="width:75.190%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.497%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.497%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.059%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-176">23,689</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-177">47,387</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-178">2,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-179">1,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of debt discount and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="f-180">156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="f-181">161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash interest expense</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="f-182">363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="f-183">551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:fixed-zero" scale="3" id="f-184">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="3" id="f-185">306</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on disposal of assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="f-186">189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:fixed-zero" scale="3" id="f-187">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on lease assignment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="exdx:GainLossOnDispositionOfLeaseAssignment" format="ixt:num-dot-decimal" scale="3" id="f-188">1,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="exdx:GainLossOnDispositionOfLeaseAssignment" format="ixt:fixed-zero" scale="3" id="f-189">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="exdx:NonCashLeaseExpense" scale="3" id="f-190">939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="exdx:NonCashLeaseExpense" scale="3" id="f-191">967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-lived assets impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="3" id="f-192">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="3" id="f-193">397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="f-194">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="f-195">5,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-196">3,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-197">4,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:fixed-zero" scale="3" id="f-198">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="f-199">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="f-200">474</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-201">3,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" scale="3" id="f-202">654</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" scale="3" id="f-203">505</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="f-204">101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="f-205">47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-206">1,010</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-207">854</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-208">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-209">901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-210">2,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-211">1,402</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-212">14,462</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-213">32,144</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-214">828</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-215">4,318</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from disposal of property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="f-216">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-217">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-218">804</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-219">4,318</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-220">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-221">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments of taxes withheld on vested restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="f-222">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-223">239</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from common stock issued under Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="f-224">279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="f-225">385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal payment on finance lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="f-226">697</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="f-227">667</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal payment on note payable obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="f-228">241</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="f-229">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal payment on long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-230">10,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-231">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-232">10,632</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-233">489</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net change in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-234">25,898</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-235">36,951</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-236">62,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-237">99,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-238">36,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-239">62,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-240">1,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-241">1,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of non-cash items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equipment purchased under finance lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-242">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="f-243">741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equipment purchased under notes payable obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="exdx:EquipmentPurchasedUnderNotesPayableObligations" scale="3" id="f-244">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="exdx:EquipmentPurchasedUnderNotesPayableObligations" scale="3" id="f-245">807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Costs incurred, but not paid, in connection with capital expenditures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-246">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-247">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements</span></div><div style="height:24.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="i7d27a7d8e3c749dabb1f235100af8228_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i7d27a7d8e3c749dabb1f235100af8228_127"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exagen Inc.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Notes to Financial Statements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 1. <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" id="f-248" continuedAt="f-248-1" escape="true">Organization</ix:nonNumeric></span></div><ix:continuation id="f-248-1"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Description of Business</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Exagen Inc. (the Company) is a commercial-stage diagnostics company which exists to provide clarity in autoimmune disease decision making with the goal of improving patients' clinical outcomes.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Liquidity</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has incurred recurring losses and negative cash flows from operating activities since inception. The Company anticipates that it will continue to incur net losses into the foreseeable future. At December&#160;31, 2023, the Company had cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-249">36.5</ix:nonFraction> million and had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="f-250">279.2</ix:nonFraction> million. Since inception, the Company has financed its operations primarily through a combination of equity financings, debt financing arrangements, and revenue from sales of the Company's products. Based on the Company's current business plan, management believes that its existing capital resources will be sufficient to fund the Company's obligations for at least twelve months following the issuance of these financial statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To execute its business plans, the Company may need additional funding to support its continuing operations and pursue its growth strategy. Until such time as the Company can achieve significant cash flows from operations, if ever, it expects to finance its operations through the sale of its stock, debt financings or other strategic transactions. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its programs, product portfolio expansion plans or commercialization efforts, which could have a material adverse effect on the Company's business, operating results and financial condition and the Company's ability to achieve its intended business objectives.</span></div></ix:continuation><div id="i7d27a7d8e3c749dabb1f235100af8228_130"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 2. <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-251" continuedAt="f-251-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-251-1" continuedAt="f-251-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Basis of Presentation and Use of Estimates</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of the accompanying financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Significant estimates and assumptions made in the accompanying financial statements include, but are not limited to revenue recognition, the estimated incremental borrowing rate for the determination of the Company's operating lease right-of-use (ROU) assets and the recoverability of its long-lived assets and net deferred tax assets (and related valuation allowance). The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-252" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Concentration of Credit Risk and Other Risk and Uncertainties</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its cash or cash equivalents.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Significant payors and customers are those which represent more than 10% of the Company's total revenue or accounts receivable balance at each respective balance sheet date. <ix:nonNumeric contextRef="c-1" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="f-253" continuedAt="f-253-1" escape="true">For each significant payor and customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-251-2" continuedAt="f-251-3"><ix:continuation id="f-253-1"><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-23" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-254">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-24" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-255">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-25" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-256">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-26" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-257">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accounts Receivable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-27" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-258">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-28" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-259">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-29" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-260">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-30" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-261">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the years ended December&#160;31, 2023 and 2022, approximately <ix:nonFraction unitRef="number" contextRef="c-31" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-262">88</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-32" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-263">84</ix:nonFraction>%, respectively, of the Company's revenue was related to the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is dependent on key suppliers for certain laboratory materials. For each of the years ended December&#160;31, 2023 and 2022, approximately <ix:nonFraction unitRef="number" contextRef="c-33" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-264"><ix:nonFraction unitRef="number" contextRef="c-34" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-265">96</ix:nonFraction></ix:nonFraction>% of the Company's diagnostic testing supplies were purchased from two suppliers. An interruption in the supply of these materials would impact the Company's ability to perform testing services.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Disaggregation of Revenue</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-266" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table includes the Company's revenues as disaggregated by payor and customer category (in&#160;thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-267">23,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-268">18,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-269">18,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-270">17,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Client(1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-271">9,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-272">7,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other(2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-273">612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-274">973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-275">52,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-276">45,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes hospitals, other laboratories, etc.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes patient self-pay.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-277" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company considers all highly-liquid investments purchased with a remaining maturity date of three months or less upon acquisition to be cash equivalents. These investments are stated at cost, which approximates fair value.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has an arrangement with a financial institution with which it has an existing banking relationship, whereby in exchange for the issuance of corporate credit cards, the Company agreed to obtain a certificate of deposit with this financial institution in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="f-278">0.2</ix:nonFraction> million as collateral for the balances borrowed on these cards. The Company has classified the value of this certificate of deposit (including all interest earned thereon) within other assets in the accompanying balance sheets. The Company has the right to terminate the credit card program at any time. Upon termination of the credit card program and repayment of all outstanding balances owed, the Company may redeem the certificate of deposit (and all interest earned thereon).</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="f-280" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="f-279" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash, cash equivalents and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-281">36,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-282">62,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="f-283">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="f-284">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-285">36,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-286">62,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-251-3" continuedAt="f-251-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-287" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Property and Equipment</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment are stated at cost, net of depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between <span style="-sec-ix-hidden:f-288">three</span> and <ix:nonNumeric contextRef="c-44" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-289">five years</ix:nonNumeric>. Leasehold improvements are amortized on a straight-line basis over the lesser of the estimated useful life or the remaining term of the related lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operating expenses in the statements of operations in the period realized.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="f-290" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Long-lived Assets</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s long-lived assets are comprised principally of its property and equipment and operating lease assets. The Company amortizes all finite lived intangible assets over their respective estimated useful lives. Operating lease assets are amortized over the term of the leases. In considering whether long-lived assets are impaired, the Company combines its intangible assets and other long-lived assets into groupings, a determination which is made principally on the basis of whether the assets are specific to a particular test offered or technology being developed. If the Company identifies a change in the circumstances related to its long-lived assets that indicates the carrying value of any such asset may not be recoverable, the Company will perform an impairment analysis. A long-lived asset is deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset&#8217;s carrying amount. Management&#8217;s estimates of future cash flows are impacted by projected test volume and levels of reimbursement, as well as expectations related to the future cost structure of the entity. Any required impairment loss would be measured as the amount by which the asset&#8217;s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="f-291" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Goodwill</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company operates in a single operating segment and reporting unit for the measurement of goodwill. Goodwill was reviewed for impairment annually (during the fourth quarter) or more frequently if indicators of impairment existed. The Company would first assess qualitative factors to determine whether it was more likely than not that the fair value of the reporting unit was less than its carrying amount as a basis for determining whether it was necessary to perform a quantitative assessment. If, after assessing qualitative factors, the Company determined it was not more likely than not that the fair value of a reporting unit was less than its carrying amount, then performing a quantitative assessment was unnecessary. If deemed necessary, a quantitative assessment compared the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeded its carrying amount, goodwill was not considered impaired; otherwise, an impairment loss was recorded.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-292" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Leases</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company categorizes leases at their commencement as either operating or finance leases. The Company recognizes operating lease ROU assets and operating lease liabilities for each lease arrangement identified. Lease liabilities are recorded at the present value of future lease payments discounted using the Company's incremental borrowing rate for the lease established at the commencement date. The incremental borrowing rate is the rate of interest the Company would have to pay to borrow, on a collateralized basis over a similar term and in a similar economic environment, an amount equal to the total lease payments. The Company primarily considers industry data, its credit rating and the lease term to determine its incremental borrowing rate. ROU assets are measured at the amount of the lease liability plus any initial direct costs, less any lease incentives received before commencement. Lease expense is recognized as a single lease cost over the lease term on a straight-line basis. The Company has elected not to apply the recognition requirements to short-term leases and not to separate non-lease components from lease components for its leases.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="exdx:ClinicalStudyPolicyPolicyTextBlock" id="f-293" continuedAt="f-293-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Clinical Studies</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, the Company engages in efforts to scientifically measure and document the application and efficacy of its various testing products. These arrangements typically require the Company to pay a fee to a third-party scientific investigator (usually a physician or research institution) for each subject enrolled in a clinical study, and the Company accrues expenses based on estimated progress of services performed, including actual level of subjects enrolled and progress of the clinical studies. Payments made prior to the completion of clinical study services are capitalized as a prepaid expense. The prepaid amounts are expensed as the related goods are delivered or the services are performed, or when it is no longer expected that the goods will be delivered or the </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-251-4" continuedAt="f-251-5"><ix:continuation id="f-293-1"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">services rendered. Expenses associated with clinical study activities are recorded in research and development expenses in the accompanying statement of operations.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="f-294" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue Recognition</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (each, a payor) consist of commercial payors (healthcare insurers), government payors (primarily Medicare and Medicaid), client payors (i.e., hospitals, other laboratories, etc.) and patient self-pay. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes revenue in accordance with Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (ASC 606) and follows a five-step process to determine the amount and timing of revenue recognized: (1) identify the contract with the customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to performance obligations in the contract, and (5) recognize revenue when (or as) the performance obligation is satisfied. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Payors are generally billed at the Company's list price, unless a separate pricing contract is in place. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions. Adjustments are recorded in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, are recorded upon settlement. Included in revenues for the years ended December&#160;31, 2023 and 2022 was a net revenue increase of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="f-295">3.4</ix:nonFraction> million and a net revenue decrease of $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" sign="-" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="f-296">2.4</ix:nonFraction> million, respectively, associated with changes in estimated variable consideration related to performance obligations satisfied in previous periods. The transaction price is estimated using an expected value method on a portfolio basis.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Variable consideration is included in the transaction price only to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainties with respect to the amount are resolved. The Company's portfolios are grouped per payor (i.e. each individual commercial payor, Medicare, Medicaid, client payors, patient self-pay, etc.) and per test. Consideration may be constrained and excluded from the transaction price in situations where there is no contractually agreed upon reimbursement coverage or in absence of a predictable pattern and history of collectability with a payor. Accordingly, in such situations revenues are recognized on the basis of actual cash collections. Additionally, from time to time, the Company may issue refunds to payors for overpayments or amounts billed in error. Any refunds are accounted for as reductions in revenues in the statement of operations as an element of variable consideration. The estimated expected refunds are accrued as a liability on the Company&#8217;s balance sheet.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information, along with any requested medical or other claims-related information to the healthcare insurers. This generally occurs within 30 to 90 days of billing, however, the amount and timing of any reimbursements or collections for our billed tests may vary by payor and other circumstances. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ReceivablesPolicyTextBlock" id="f-297" continuedAt="f-297-1" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounts Receivable and Allowance for Credit Losses</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-297-1">We accrue an allowance for credit losses against our accounts receivable based on management&#8217;s current estimate of amounts that will not be collected. Management&#8217;s estimates are typically based on historical loss information adjusted for current conditions. We generally do not perform evaluations of the financial condition of our customers and generally do not require collateral. The allowance for credit losses was <ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest" format="ixt-sec:numwordsen" scale="6" id="f-298"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest" format="ixt-sec:numwordsen" scale="6" id="f-299">zero</ix:nonFraction></ix:nonFraction> as of December&#160;31, 2023. There was <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest" format="ixt:fixed-zero" scale="0" id="f-300">no</ix:nonFraction> allowance for credit losses recognized as of December 31, 2022. Adjustments for implicit price concessions attributable to variable consideration, as discussed above, are incorporated into the measurement of the accounts receivable balances and are not part of the allowance for credit losses.</ix:continuation>  Accounts receivable was $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-301">6.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-302">6.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-303">9.7</ix:nonFraction> million for the years ended December&#160;31, 2023, 2022 and 2021, respectively.  </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-304" continuedAt="f-304-1" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Research and Development</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-251-5" continuedAt="f-251-6"><ix:continuation id="f-304-1"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense; materials; laboratory supplies; consulting costs; costs associated with setting up and conducting clinical studies; depreciation; amortization and allocated overhead, including rent and utilities.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="f-305" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Advertising and Marketing Costs</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AdvertisingExpense" scale="6" id="f-306">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:AdvertisingExpense" scale="6" id="f-307">3.0</ix:nonFraction> million for the years ended December&#160;31, 2023 and 2022, respectively, and are included in selling, general and administrative expenses in the accompanying statements of operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CostOfSalesPolicyTextBlock" id="f-308" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Shipping and Handling Costs</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs incurred for shipping and handling are included in costs of revenue in the accompanying statements of operations and were approximately $<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-5" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="6" id="f-309">2.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-5" name="us-gaap:CostOfRevenue" scale="6" id="f-310">2.7</ix:nonFraction> million for the years ended December&#160;31, 2023 and 2022, respectively.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:EmployeeStockOwnershipPlanESOPPolicy" id="f-311" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Stock-Based Compensation</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The fair value of stock options and purchases under the Company's 2019 Employee Stock Purchase Plan (ESPP) rights is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The BSM option pricing model incorporates various inputs, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. Volatility is based on the Company's historical calculated volatility since being publicly traded. The weighted-average expected term of options was calculated using the simplified method, as we have concluded that our stock option exercise history does not provide a reasonable basis upon which to estimate the expected term. The risk-free interest rate for periods within the contractual term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-312">zero</ix:nonFraction>, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of each restricted stock unit (RSU) is determined on the grant date using the closing price of the Company's common stock on that date. The Company's RSUs generally vest in equal annual installments over <ix:nonFraction unitRef="installment" contextRef="c-1" decimals="INF" name="exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" format="ixt-sec:numwordsen" scale="0" id="f-313">four</ix:nonFraction> years from the date of grant or, for grants to new hires, date of hire. Vesting of RSUs is subject to the holder's continued service with the Company. The Company issues new shares to satisfy RSUs upon vesting.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-314" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Comprehensive Loss</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-315" continuedAt="f-315-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Income Taxes</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized as an expense in the period that includes the enactment date. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would adjust the deferred tax asset valuation allowance, which would reduce the provision for income taxes. </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-251-6" continuedAt="f-251-7"><ix:continuation id="f-315-1"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company records uncertain tax positions on the basis of a two-step process whereby (i) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-316" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Net Loss Per Share</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. The weighted-average number of shares used to compute basic and diluted shares includes shares issuable upon the exercise of pre-funded warrants at a nominal price. Potentially dilutive common stock equivalents are comprised of warrants for the purchase of common stock, stock options, RSUs outstanding under the Company's 2019 Incentive Award Plan (the 2019 Plan) and shares of the Company's common stock pursuant to the ESPP. For each of the years ended December&#160;31, 2023 and 2022, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as the inclusion of the potentially dilutive securities would be antidilutive.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-317" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-47" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-318">409,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-48" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-319">409,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-49" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-320">986,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-50" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-321">1,421,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-51" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-322">1,387,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-52" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-323">1,036,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-53" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-324">44,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-54" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-325">58,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-326">2,828,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-327">2,925,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-328" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Segment Reporting</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-329">one</ix:nonFraction> operating segment.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-330" continuedAt="f-330-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent Accounting Pronouncements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012 (JOBS Act), the Company meets the definition of an emerging growth company. The Company has elected to use the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Unless otherwise discussed, Accounting Standards Updates (ASU) not included in the Company&#8217;s disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on the Company&#8217;s financial statements or disclosures.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2023, the FASB issued ASU No. 2023-07, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (ASU 2023-07), which requires public entities to disclose significant segment expenses that are regularly provided to the Chief Operating Decision Maker (CODM) and details of how the CODM uses financial reporting to assess the performance of a segment. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. This ASU will likely result in additional required disclosure when adopted. The Company is currently evaluating the provisions of this ASU and the impact on its financial statements and related disclosures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In December 2023, the FASB issued ASU 2023-09,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"> Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> (ASU 2023-09), which requires additional income tax disclosures in the rate reconciliation table for federal, state and foreign income taxes, in addition to more details about the reconciling items in some categories </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-330-1"><ix:continuation id="f-251-7"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">when items meet a certain quantitative threshold. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 with early adoption permitted. The Company is currently evaluating the impact of this standard, but does not expect that it will have a material impact on its financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Recently Adopted Accounting Standards</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which requires the measurement of expected credit losses (based on historical experience, current conditions and reasonable forecasts) for financial instruments (such as accounts receivable) held at the reporting date which are carried at amortized cost. The main objective of this ASU is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. In November 2018, the FASB issued ASU 2018-19, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Codification Improvements to Topic 326, Financing Instruments-Credit Losses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which included an amendment of the effective date for nonpublic entities. The Company adopted this pronouncement on January 1, 2023. The adoption did not have material impact on its financial statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in ASU 2020-06 are effective for smaller reporting companies as defined by the SEC for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. The Company early adopted ASU 2020-06 as of January 1, 2023. The adoption did not have an impact on its financial statements.</span></div></ix:continuation></ix:continuation><div id="i7d27a7d8e3c749dabb1f235100af8228_133"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 3. <ix:nonNumeric contextRef="c-1" name="exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" id="f-333" continuedAt="f-333-1" escape="true">Other Financial Information</ix:nonNumeric></span></div><ix:continuation id="f-333-1" continuedAt="f-333-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Prepaid Expenses and Other Current Assets</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="f-334" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diagnostic&#160;testing&#160;supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-335">2,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-336">1,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid product royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidRoyalties" scale="3" id="f-337">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidRoyalties" scale="3" id="f-338">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid maintenance and insurance contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="exdx:PrepaidMaintenanceAndInsuranceContracts" format="ixt:num-dot-decimal" scale="3" id="f-339">1,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="exdx:PrepaidMaintenanceAndInsuranceContracts" format="ixt:num-dot-decimal" scale="3" id="f-340">2,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="f-341">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="f-342">236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-343">4,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-344">4,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Property and Equipment</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-345" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment consist of the following (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture&#160;and&#160;fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="f-346">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="f-347">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-348">5,312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-349">5,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-350">2,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-351">1,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-352">3,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-353">5,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="f-354">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-355">1,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-356">10,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-357">13,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-358">5,769</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-359">5,124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-360">5,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-361">8,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Depreciation and amortization expense for the years ended December&#160;31, 2023 and 2022, was approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-362">2.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-363">1.6</ix:nonFraction> million, respectively. At December&#160;31, 2023 and 2022, the gross book value of assets under finance leases was $<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" scale="6" id="f-364">2.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" scale="6" id="f-365">2.8</ix:nonFraction> million, respectively, and is classified in "Laboratory equipment" in the table above.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-333-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Loss on Lease Assignment</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 24, 2023, the Company entered into an assignment and assumption (the Assignment and Assumption Agreement) of the Company&#8217;s previously executed lease agreement with Liberty Vista, LP (formerly known as Geiger Court, LLC) and Mindera Corporation (Mindera), pursuant to which the Company assigned to Mindera the lease of a building located adjacent to the Company's headquarters in Vista, CA. Under the terms of the Assignment and Assumption Agreement, Mindera assumed all obligations under the lease, effective October 31, 2023. As a result of the lease assignment, the Company derecognized the remaining balances related to the associated operating lease ROU asset of $<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-366">0.7</ix:nonFraction>&#160;million, operating lease liability of $<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-367">0.8</ix:nonFraction>&#160;million and leasehold improvements of $<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-5" name="us-gaap:LeaseholdImprovementsGross" format="ixt:num-dot-decimal" scale="6" id="f-368">1.6</ix:nonFraction>&#160;million, resulting in a $<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-5" sign="-" name="exdx:GainLossOnDispositionOfLeaseAssignment" format="ixt:num-dot-decimal" scale="6" id="f-369">1.5</ix:nonFraction>&#160;million loss on lease assignment. The loss was classified within selling, general and administrative expenses in the accompanying statements of operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Impairment of Long-Lived Assets and Goodwill</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December 31, 2022, the Company recorded an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="6" id="f-370">0.4</ix:nonFraction>&#160;million related to previously capitalized equipment used in research and development activities that were halted in the fourth quarter of 2022. The impairment charge was classified within research and development expenses in the accompanying statements of operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December 31, 2022, the Company also determined that a sustained decrease in its market capitalization constituted an indicator of impairment of goodwill and as a result, instead of performing a qualitative test, the Company chose to proceed directly to performing a quantitative test during the fourth quarter. The Company determined the fair value of the reporting unit using the discounted cash flow (DCF) method, which is considered a Level 3 measurement. In applying the DCF method, cash flows are estimated for a five-year financial forecast developed by management. A terminal value, which represents the value of additional cash flows into perpetuity, is also calculated. Cash flows are then discounted to present value at a discount rate commensurate with their risk. Based on this analysis, the carrying value of the reporting unit was in excess of the fair value and the goodwill was fully impaired. During the year ended December 31, 2022, the Company recorded a goodwill impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-371">5.5</ix:nonFraction>&#160;million.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfGoodwillTextBlock" id="f-372" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents details of the Company's goodwill for the year ended December 31, 2022 (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-373">5,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Goodwill impairment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="f-374">5,506</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="3" id="f-375">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued and Other Current Liabilities</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-376" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued and other current liabilities consist of the following (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued&#160;payroll&#160;and&#160;related&#160;expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedSalariesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-377">4,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedSalariesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-378">2,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InterestPayableCurrent" scale="3" id="f-379">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestPayableCurrent" scale="3" id="f-380">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued purchases of goods and services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="exdx:AccruedPurchaseGoodsAndServicesCurrent" scale="3" id="f-381">720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="exdx:AccruedPurchaseGoodsAndServicesCurrent" scale="3" id="f-382">803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="f-383">463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="f-384">514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued clinical study activity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="exdx:AccruedLiabilitiesClinicalStudyCurrent" scale="3" id="f-385">118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="exdx:AccruedLiabilitiesClinicalStudyCurrent" scale="3" id="f-386">162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-387"><span style="-sec-ix-hidden:f-388">Finance lease obligations, current portion</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-389">490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-390">700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Refund liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CustomerRefundLiabilityCurrent" scale="3" id="f-391">302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CustomerRefundLiabilityCurrent" scale="3" id="f-392">445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-393">561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-394">226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-395">7,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-396">5,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i7d27a7d8e3c749dabb1f235100af8228_136"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 4. <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-397" continuedAt="f-397-1" escape="true">Borrowings</ix:nonNumeric></span></div><ix:continuation id="f-397-1" continuedAt="f-397-2"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">2017 Term Loan</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-397-2" continuedAt="f-397-3"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2017, the Company executed a term loan agreement (the 2017 Term Loan) with Innovatus Life Sciences Lending Fund I, LP (Innovatus), as amended (the Amended Loan Agreement), pursuant to which the Company borrowed $<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-398">25.0</ix:nonFraction>&#160;million. At December&#160;31, 2023, <ix:nonFraction unitRef="usd" contextRef="c-68" decimals="0" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" format="ixt:fixed-zero" scale="0" id="f-399">no</ix:nonFraction> additional amounts remained available to borrow under the Amended Loan Agreement. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 28, 2023, the Company entered into the Amended Loan Agreement. The Amended Loan Agreement was treated as a modification. In connection with the Amended Loan Agreement, the Company repaid $<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-400">10.0</ix:nonFraction>&#160;million of the principal balance outstanding, for which the prepayment premium was waived. Pursuant to the Amended Loan Agreement, the interest rate on all borrowings under the Amended Loan Agreement is the sum (the Basic Rate) of (a) the greater of <ix:nonFraction unitRef="number" contextRef="c-70" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-401">8.0</ix:nonFraction>% or The Wall Street Journal prime rate (the Prime Rate), plus (b) <ix:nonFraction unitRef="number" contextRef="c-71" decimals="2" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-402">2.0</ix:nonFraction>%, which is paid-in-kind in the form of additional term loans (PIK Loans). Under the Amended Loan Agreement, an amount equal to <ix:nonFraction unitRef="number" contextRef="c-71" decimals="3" name="exdx:DebtInstrumentStatedInterestRatePaidInKind" scale="-2" id="f-403">1.5</ix:nonFraction>% of the Basic Rate will be payable in-kind and capitalized to the principal amount of the outstanding term loan on a monthly basis until April 1, 2026, after which interest is scheduled to accrue at the Basic Rate. The maturity date of the loan was extended to December 31, 2026. The Company estimated the effective interest rate of this loan to be approximately <ix:nonFraction unitRef="number" contextRef="c-68" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-404">11.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-72" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-405">8.5</ix:nonFraction>% as of December&#160;31, 2023 and 2022, respectively. Accrued interest is due and payable monthly, unless the Company elects to pay paid-in-kind interest. The outstanding principal and accrued interest under the Amended Loan Agreement is to be repaid in <ix:nonFraction unitRef="installment" contextRef="c-73" decimals="INF" name="exdx:DebtInstrumentNumberOfMonthlyInstallments" format="ixt-sec:numwordsen" scale="0" id="f-406">ten</ix:nonFraction> equal monthly installments commencing in April 2026. Upon repayment of the final installment under the Amended Loan Agreement, the Company is required to pay an additional fee of $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-5" name="us-gaap:DebtInstrumentFeeAmount" format="ixt:num-dot-decimal" scale="6" id="f-407">1.0</ix:nonFraction>&#160;million. This obligation is being accreted into interest expense over the term of the loan using the effective interest method. For the years ended December&#160;31, 2023 and 2022, the Company issued PIK Loans totaling $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" name="exdx:DebtInstrumentPaidInKindLoansIssued" format="ixt:num-dot-decimal" scale="6" id="f-408">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-5" name="exdx:DebtInstrumentPaidInKindLoansIssued" format="ixt:num-dot-decimal" scale="6" id="f-409">0.6</ix:nonFraction> million, respectively. At December&#160;31, 2023, $<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-410">18.2</ix:nonFraction> million in principal and PIK loans are outstanding, all of which is included in borrowings-non-current portion on the accompanying balance sheet.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Amended Loan Agreement currently requires a prepayment premium of <ix:nonFraction unitRef="number" contextRef="c-68" decimals="INF" name="exdx:DebtInstrumentPrepaymentPremiumPercentage" scale="-2" id="f-411">1</ix:nonFraction>% of the aggregate outstanding principal for any prepayments made prior to November 1, 2024.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Loan Agreement is collateralized by a first priority security interest in substantially all of the Company's assets, including intellectual property. The affirmative covenants of the Amended Loan Agreement require that the Company timely file taxes, maintain good standing and government compliance, maintain liability and other insurance, provide prompt notification of significant corporate events, and furnish audited financial statements within 150 days of fiscal year end without qualification as to the scope of the audit or as to going concern and without any other similar qualification.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The affirmative covenants require that the Company achieve a specified level of revenue, as measured quarterly on a rolling <ix:nonNumeric contextRef="c-73" name="exdx:DebtInstrumentCovenantRevenuePerformancePeriod" format="ixt-sec:durwordsen" id="f-412">twelve-month</ix:nonNumeric> basis, however the Company is not required to comply with the revenue covenant for any quarter during which it maintains a minimum aggregate cash balance equal to <ix:nonFraction unitRef="number" contextRef="c-73" decimals="2" name="exdx:DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant" format="ixt-sec:numwordsen" scale="-2" id="f-413">fifty</ix:nonFraction> percent of the aggregate principal amount of the Amended Loan Agreement (excluding any capitalized interest paid-in-kind) at all times during such quarter. The consequences of failing to achieve the performance covenants, when applicable, will be cured if, (i) within <ix:nonNumeric contextRef="c-73" name="exdx:DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" format="ixt-sec:durwordsen" id="f-414">thirty days</ix:nonNumeric> of failing to achieve the performance covenant, the Company submits a new Board approved financial plan to Innovatus under which the Company is expected to break even on a cash flow basis prior to the maturity date, and (ii) within <ix:nonNumeric contextRef="c-73" name="exdx:DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" format="ixt-sec:durwordsen" id="f-415">thirty days</ix:nonNumeric> of the submission of such financial plan, the Company issues additional equity securities or subordinated debt with net proceeds sufficient to fund any cash flow deficiency generated from operations, as defined in the Amended Loan Agreement. The Amended Loan Agreement requires that the Company maintain certain levels of minimum liquidity and maintains an unrestricted cash balance of $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-5" name="exdx:DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" format="ixt:num-dot-decimal" scale="6" id="f-416">2.0</ix:nonFraction> million.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The negative covenants provide, among other things, that without the prior consent of Innovatus, subject to certain exceptions, the Company may not dispose of certain assets, engage in certain business combinations or acquisitions, incur additional indebtedness or encumber any of the Company's property, pay dividends on the Company's capital stock or make prohibited investments. The Amended Loan Agreement provides that an event of default will occur if, among other triggers, (i)&#160;the Company defaults in the payment of any amount payable under the agreement when due, (ii)&#160;there occurs any circumstance(s) that could reasonably be expected to result in a material adverse effect on the Company's business, operations or condition, or on the Company's ability to perform its obligations under the agreement, (iii)&#160;the Company becomes insolvent, (iv)&#160;the Company undergoes a change in control or (v)&#160;the Company breaches any negative covenants or certain affirmative covenants in the agreement or, subject to a cure period, otherwise neglects to perform or observe any material item in the agreement.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023, the Company was in compliance with all covenants of the Amended Loan Agreement. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-397-3"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon an event of default in any of the Amended Loan Agreement covenants, the repayment of the 2017 Term Loan may be accelerated, and the applicable interest rate will be increased by <ix:nonFraction unitRef="number" contextRef="c-77" decimals="3" name="exdx:DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" scale="-2" id="f-417">4.0</ix:nonFraction>% until the default is cured. Although repayment of the 2017 Term Loan can be accelerated under certain circumstances, the Company believes acceleration of this loan is not probable as of the date of these financial statements. Accordingly, the Company has reflected the amounts of the Third Loan Amendment due beyond twelve months of the balance sheet date as non-current.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">2022 Equipment Notes Payable</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2022, the Company purchased laboratory equipment using notes payable. At December&#160;31, 2023, the total notes payable balance related to this financed equipment was $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-418">0.8</ix:nonFraction>&#160;million, with $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="us-gaap:NotesPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-419">0.3</ix:nonFraction>&#160;million classified within borrowings-current portion and $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="us-gaap:LongTermNotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-420">0.5</ix:nonFraction>&#160;million within borrowings-non-current portion, net of discounts and debt issuance costs in the accompanying balance sheets. At December 31, 2022, the total notes payable balance related to this financed equipment was $<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-421">0.8</ix:nonFraction>&#160;million, with $<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-5" name="us-gaap:NotesPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-422">0.2</ix:nonFraction>&#160;million classified within borrowings-current portion and $<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-5" name="us-gaap:LongTermNotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-423">0.6</ix:nonFraction>&#160;million within borrowings-non-current portion, net of discounts and debt issuance costs in the accompanying balance sheets. The financed equipment is subject to a <ix:nonFraction unitRef="number" contextRef="c-80" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-424">5.28</ix:nonFraction>% effective interest rate and will mature on October 1, 2026.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Future Minimum Payments on Outstanding Borrowings</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="f-425" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2023, future minimum aggregate payments, including interest, for outstanding borrowings are as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-426">1,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-427">1,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="3" id="f-428">21,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="exdx:LongTermDebtIncludingUndiscountedInterest" format="ixt:num-dot-decimal" scale="3" id="f-429">25,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="f-430">113</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="exdx:LongTermDebtUndiscountedInterestAmount" format="ixt:num-dot-decimal" scale="3" id="f-431">5,558</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total borrowings, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-432">19,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Borrowings-current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="f-433">264</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings-non-current portion, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-434">19,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i7d27a7d8e3c749dabb1f235100af8228_139"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 5. <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeFinanceLeasesTextBlock" id="f-436" continuedAt="f-436-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-435" continuedAt="f-435-1" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="f-436-1" continuedAt="f-436-2"><ix:continuation id="f-435-1" continuedAt="f-435-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Leases</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Operating Leases</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company leases office and laboratory space located in Vista, California. The lease expires in April 2027, with an option to extend portions of the lease for additional <ix:nonNumeric contextRef="c-81" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-437">5-year</ix:nonNumeric> periods. The Company has not included the optional renewal periods in the measurement of the lease liability, because it is not reasonably certain that the Company will exercise these renewal options. The Company's payments under the lease are subject to escalation clauses.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company leases additional office space in Carlsbad, California, under a sub-lease which commenced in October 2021 and expires in April 2027. Monthly base rent under the sub-lease agreement is $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="0" name="exdx:OperatingLeaseMonthlyBaseRent" format="ixt:num-dot-decimal" scale="0" id="f-438">70,042</ix:nonFraction>. The monthly base rent increases by approximately <ix:nonFraction unitRef="number" contextRef="c-83" decimals="2" name="exdx:OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent" scale="-2" id="f-439">3</ix:nonFraction>% annually, each October 1, through the remainder of the lease term.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Finance Leases</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has entered into various finance lease agreements to obtain laboratory equipment. The terms of the Company's finance leases generally range from <span style="-sec-ix-hidden:f-440">three</span> to <ix:nonNumeric contextRef="c-44" name="us-gaap:LesseeFinanceLeaseTermOfContract1" format="ixt-sec:durwordsen" id="f-441">five years</ix:nonNumeric> and are typically secured by the underlying equipment. The portion of the future payments designated as principal repayments were classified as finance lease liabilities on the Company's balance sheet.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Operating and Finance Leases Balances and Costs</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-442" continuedAt="f-442-1" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating and finance leases consist of the following (in thousands):</span></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-436-2" continuedAt="f-436-3"><ix:continuation id="f-435-2" continuedAt="f-435-3"><ix:continuation id="f-442-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.786%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Balance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-443">3,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-444">4,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-445">Property and equipment, net</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="f-446">810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-447">1,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-448">976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-449">1,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-450">Accrued and other current liabilities</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-451">490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-452">700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-453">2,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-454">4,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-455"><span style="-sec-ix-hidden:f-456">Other non-current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="f-457">358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="f-458">848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs associated with the Company's leases were included in the statements of operations as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease cost</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-459">1,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-460">1,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="f-461">556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="f-462">679</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest on finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="f-463">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="f-464">80</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-465">2,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-466">2,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(1) Includes variable lease cost of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="0" id="f-467">129,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="0" id="f-468">165,000</ix:nonFraction> for the years ended December&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Supplemental cash flow information on leases is as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash out flows from operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-469">1,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-470">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash out flows from interest paid on finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="f-471">128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="f-472">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financing cash out flows from finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="f-473">697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="f-474">667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Information regarding the weighted-average lease term and weighted average discount rate are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-475">3.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-5" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-476">4.3</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-4" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-477">2.06</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-5" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-478">1.94</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-479">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-480">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-481">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-482">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-484" continuedAt="f-484-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="f-483" continuedAt="f-483-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Future payments under operating and finance leases as of December&#160;31, 2023 are as follows (in thousands):</span></div></ix:nonNumeric></ix:nonNumeric></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-484-1"><ix:continuation id="f-483-1"><ix:continuation id="f-436-3"><ix:continuation id="f-435-3"><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-485">1,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="f-486">574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-487">1,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="f-488">248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-489">1,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="f-490">147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="f-491">445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="3" id="f-492">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-493">4,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="f-494">997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="f-495">541</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="f-496">149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-497">3,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiability" scale="3" id="f-498">848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-499">976</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-500">490</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease obligations, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-501">2,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="f-502">358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation></ix:continuation></ix:continuation><div id="i7d27a7d8e3c749dabb1f235100af8228_719"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 6. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-503" continuedAt="f-503-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-503-1" continuedAt="f-503-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Acquisition-related liabilities</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the acquisition of the medical diagnostics division of Royalty Pharma Collection Trust (Royalty Pharma) (formerly known as Cypress Bioscience, Inc.) in 2010, the Company had royalty payment obligations of <ix:nonFraction unitRef="number" contextRef="c-84" decimals="3" name="exdx:RoyaltyObligationPercentageOfSales" scale="-2" id="f-504">2.5</ix:nonFraction>% on net sales of products which incorporate certain acquired technologies through December 31, 2023. These obligations no longer exist for products sold after December 31, 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Licensing Agreements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has licensed technology for use in its diagnostic tests. In addition to the milestone payments required by these agreements, individual license agreements generally provide for ongoing royalty payments ranging from <ix:nonFraction unitRef="number" contextRef="c-85" decimals="INF" name="exdx:RoyaltyObligationPercentageOfSales" scale="-2" id="f-505">1.5</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-86" decimals="INF" name="exdx:RoyaltyObligationPercentageOfSales" scale="-2" id="f-506">7.0</ix:nonFraction>% on net sales of products which incorporate licensed technology, as defined in such agreements. Royalties are accrued when incurred and recorded in costs of revenue in the accompanying statements of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Supply Agreements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2021, the Company amended a supply agreement with <ix:nonFraction unitRef="supplier" contextRef="c-87" decimals="INF" name="exdx:PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers" format="ixt-sec:numwordsen" scale="0" id="f-507">one</ix:nonFraction> supplier for reagents which includes minimum annual purchase commitments of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:PurchaseObligationDueInNextTwelveMonths" scale="6" id="f-508">8.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:PurchaseObligationDueInSecondYear" scale="6" id="f-509">9.2</ix:nonFraction> million for the years ended December 31, 2024 and 2025, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Collaboration Obligations</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2021, the Company entered into a master research collaboration agreement with Allegheny Health Network Research Institute (AHN), pursuant to which the Company is required to pay AHN a collaboration fee of $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="exdx:CollaborationAgreementAnnualCollaborationFee" scale="6" id="f-510">0.4</ix:nonFraction> million per year. Collaboration expenses under the master research collaboration agreement were $<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="exdx:CollaborationAgreementCollaborationExpenses" scale="6" id="f-511"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="exdx:CollaborationAgreementCollaborationExpenses" scale="6" id="f-512">0.3</ix:nonFraction></ix:nonFraction> million for each of the years ended December&#160;31, 2023 and 2022. Collaboration expenses under the AHN collaboration are included in research and development expenses in the accompanying statements of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Contingencies</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications; including for subpoenas and other civil investigative demands, from governmental agencies, Medicare or Medicaid and managed care organizations reviewing billing practices or requesting comment on allegations of billing irregularities that are brought to their attention through billing audits or third parties. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made or that the Company believes to be immaterial. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Litigation</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, the Company may be subject to various legal proceedings that arise in the ordinary course of business activities. The Company does not believe the outcome of any such matters as of December&#160;31, 2023 will have a material effect on its financial position or results of operations.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-503-2"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2023, the Company resolved an investigation with the U.S. Attorney&#8217;s Office for the District of Massachusetts that was initiated by a </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">lawsuit. Pursuant to a Settlement Agreement, the Company made a single lump-sum remittance to the government in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="6" id="f-513">0.7</ix:nonFraction>&#160;million in connection with specimen processing arrangements that Exagen historically had with physicians. The U.S. Attorney&#8217;s Office dismissed this &#8220;covered conduct&#8221; in the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">lawsuit with prejudice, while non-covered conduct was dismissed without prejudice. In November 2023 the complaint was unsealed and served on Exagen. Exagen filed a motion to dismiss the complaint. In December 2023, the Company's insurance carrier provided reimbursement for certain defense costs the Company incurred in the October 2023 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">lawsuit. In February 2024, the relator filed a motion for leave to amend the complaint. Exagen opposed this motion, and all motions are still pending. The Company intends to vigorously defend against the claims being asserted in the complaint.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's participation in federal healthcare programs is not affected by the Settlement Agreement.</span></div></ix:continuation><div style="text-indent:24.75pt"><span><br/></span></div><div id="i7d27a7d8e3c749dabb1f235100af8228_142"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 7. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-514" continuedAt="f-514-1" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="f-514-1" continuedAt="f-514-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-515" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The carrying values of the Company's cash, cash equivalents and restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued and other current liabilities approximate their fair values due to their short-term nature and are considered to be Level 1 measurements. The estimated fair value of the Company's long-term borrowings is determined by Level 2 inputs and based primarily on quoted market prices for the same or similar issues. As of December&#160;31, 2023, the Amended Loan Agreement had a carrying value of $<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-516">18.7</ix:nonFraction> million and a fair value of $<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="f-517">19.7</ix:nonFraction> million. As of December 31, 2022, the 2017 Term Loan had a carrying value of $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-518">28.3</ix:nonFraction>&#160;million and a fair value of $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="f-519">26.9</ix:nonFraction>&#160;million. The estimated fair value of the Amended Loan Agreement was determined based on a discounted cash flow approach using available market information on discount and borrowing rates with similar terms, maturities, and credit ratings. The carrying value of the Company's other long-term borrowing as of December&#160;31, 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-520">0.8</ix:nonFraction>&#160;million, which approximated its fair value.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The three-levels of the valuation hierarchy for disclosure of fair value measurements are defined as follows:</span></div><div style="margin-top:9pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 1 -&#160;&#160;&#160;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:9pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 2 -&#160;&#160;&#160;&#160;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span></div><div style="margin-top:9pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 3 -&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-521" continuedAt="f-521-1" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.432%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-522">14,386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-523">14,386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-524">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-525">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-521-1"><ix:continuation id="f-514-2" continuedAt="f-514-3"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-526">29,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-527">29,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-528">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-529">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certificate of deposit, included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-530">30,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-531">30,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-532">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-533">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-534">59,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-535">59,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-536">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-537">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="margin-top:9pt"><ix:continuation id="f-514-3"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of the Company's money market funds is based on quoted market prices.</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;</span></div><div id="i7d27a7d8e3c749dabb1f235100af8228_145"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 8. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-538" continuedAt="f-538-1" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><ix:continuation id="f-538-1"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Common Stock</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Shelf Registration Statement</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On November 17, 2023, the Company filed a registration statement on Form S-3, as amended (the 2023 Shelf Registration Statement), covering the offering, from time to time, of up to $<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="exdx:SaleOfStockAuthorizedAmount" scale="6" id="f-539">150.0</ix:nonFraction> million of common stock, preferred stock, debt securities, warrants and units. The 2023 Shelf Registration Statement became effective on November 29, 2023, and all $<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="exdx:SaleOfStockRemainingAuthorizedAmount" format="ixt:num-dot-decimal" scale="6" id="f-540">150.0</ix:nonFraction>&#160;million remain available for sale as of December&#160;31, 2023.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">At The Market Sales Agreement</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 15, 2022, the Company entered into a sales agreement, as amended on November 17, 2023 (the Sales Agreement) with Cowen and Company, LLC as sales agent, pursuant to which the Company may offer and sell, from time to time, shares of Company common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-541">50.0</ix:nonFraction>&#160;million. The Company is not obligated to sell any shares of Company common stock in the offering. As of December&#160;31, 2023, the Company has not sold any shares of its common stock pursuant to the Sales Agreement</span><span style="color:#008080;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Outstanding Warrants</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="f-542" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following equity classified warrants to purchase common stock were outstanding as of December&#160;31, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-113" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-543">237,169</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-113" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-544">1.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-114" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-545">67,086</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-114" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-546">1.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-115" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="f-547">131</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-115" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-548">1.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-116" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-549">83,778</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-116" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-550">14.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-117" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-551">20,944</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-117" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-552">14.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants (Exchange Warrants)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-118" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-553">804,951</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-118" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-554">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 22, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">None</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-555">1,214,059</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet" format="ixt:fixed-zero" scale="0" id="f-556"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet" format="ixt:fixed-zero" scale="0" id="f-557">No</ix:nonFraction></ix:nonFraction> warrants to purchase common stock were exercised during the years ended December&#160;31, 2023 and 2022.</span></div></ix:continuation><div id="i7d27a7d8e3c749dabb1f235100af8228_151"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 9. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-558" continuedAt="f-558-1" escape="true">Stock Option Plan</ix:nonNumeric></span></div><ix:continuation id="f-558-1" continuedAt="f-558-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">2019 Incentive Award Plan</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2019, the Company's board of directors adopted, and the Company's stockholders approved, the 2019 Plan. Under the 2019 Plan, which expires in September 2029, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. The options generally expire <ix:nonNumeric contextRef="c-119" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-559">ten years</ix:nonNumeric> after the date of grant and are exercisable to the extent vested. Vesting is established by the Company's board of directors and is generally <ix:nonNumeric contextRef="c-119" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-560">four years</ix:nonNumeric> from the date of grant or, for grants to new hires, date of hire. The 2019 Plan contains an "evergreen provision" that allows annual increases in the number of shares available for issuance on the first day of each calendar year through January 1, 2029 in an amount equal to the lesser of: (i) <ix:nonFraction unitRef="number" contextRef="c-120" decimals="2" name="exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" scale="-2" id="f-561">4</ix:nonFraction>% of the outstanding capital stock on each December 31st, or (ii) such lesser amount determined by the Company's board of directors. As of December&#160;31, 2023, <ix:nonFraction unitRef="shares" contextRef="c-121" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-562">1,831,107</ix:nonFraction> shares of common stock remained available for future awards. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-558-2" continuedAt="f-558-3"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the evergreen provision, on January 1, 2024, an additional <ix:nonFraction unitRef="shares" contextRef="c-122" decimals="INF" name="exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-563">681,838</ix:nonFraction> shares of common stock became available for issuance under the 2019 Plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="f-564" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">RSU activity under the Company's 2019 Plan is set forth below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-123" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-565">1,036,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-123" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-566">7.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-567">2,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-124" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-568">857,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-124" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-569">2.39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards released</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-124" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-570">273,319</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-124" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-571">7.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-124" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-572">232,730</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-124" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-573">6.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-125" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-574">1,387,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-125" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-575">4.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-576">2,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2023, all of the outstanding RSUs are unvested. The fair value of RSUs vested in the years ended December&#160;31, 2023 and 2022 was $<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="6" id="f-577">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="6" id="f-578">0.7</ix:nonFraction>&#160;million, respectively. The weighted average grant date fair value for RSUs granted during the years ended December&#160;31, 2023 and 2022 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-124" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-579">2.39</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-126" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-580">5.89</ix:nonFraction>, respectively. As of December&#160;31, 2023, total unrecognized compensation cost related to RSUs was $<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-581">4.4</ix:nonFraction> million, which is expected to be recognized over a remaining weighted-average vesting period of <ix:nonNumeric contextRef="c-124" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-582">2.8</ix:nonNumeric> years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Stock Options</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-583" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock option activity under the Company's 2019 Plan is set forth below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-584">1,421,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-585">12.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-586">7.09</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="f-587">483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-588">73,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-589">3.04</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-590">93,335</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-591">0.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-592">43,895</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-593">13.83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-594">370,686</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-595">16.88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-596">986,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-597">11.87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-598">6.44</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="f-599">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest, December&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-600">986,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-601">11.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-602">6.44</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="f-603">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options exercisable, December&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-604">877,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="f-605">12.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-606">6.18</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" id="f-607">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The weighted-average grant date fair value per share of options granted during the years ended December&#160;31, 2023 and 2022 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-608">2.17</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-609">2.74</ix:nonFraction>, respectively. The aggregate intrinsic value of options exercised during the years ended December&#160;31, 2023 and 2022 was $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="6" id="f-610">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="f-611">0.6</ix:nonFraction> million, respectively. The intrinsic value is calculated as the difference between the fair value of the Company's common stock and the exercise price of the stock options. The fair value of the Company's common stock was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-612">1.99</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-613">2.40</ix:nonFraction> per share at December&#160;31, 2023 and 2022, respectively. As of December&#160;31, 2023, total unrecognized compensation cost related to option awards was $<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-614">0.3</ix:nonFraction> million, which is expected to be recognized over a remaining weighted-average vesting period of <ix:nonNumeric contextRef="c-128" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-615">0.8</ix:nonNumeric> years.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">2019 Employee Stock Purchase Plan</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2019, the Company's board of directors adopted, and the Company's stockholders approved, the ESPP. The ESPP became effective on the day the ESPP was adopted by the Company's board of directors. The ESPP permits participants to purchase common stock through payroll deductions of up to <ix:nonFraction unitRef="number" contextRef="c-129" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="f-616">20</ix:nonFraction>% of their eligible compensation. The number of shares of common stock available for issuance under the ESPP will be annually increased on the first day of each calendar year during the term of the ESPP through January 1, 2029 in an amount equal to the lesser of (i) <ix:nonFraction unitRef="number" contextRef="c-129" decimals="2" name="exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" scale="-2" id="f-617">1</ix:nonFraction>% of the outstanding capital stock on each December 31st, or (ii) such lesser amount determined by the Company's board of directors. During the year ended December&#160;31, 2023, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-130" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-618">129,593</ix:nonFraction> shares of common stock pursuant to scheduled purchases under the ESPP. As of December&#160;31, 2023, <ix:nonFraction unitRef="shares" contextRef="c-129" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-619">449,332</ix:nonFraction> shares of common stock remained available for issuance. Pursuant to the evergreen provision, on January 1, 2024, an additional <ix:nonFraction unitRef="shares" contextRef="c-131" decimals="INF" name="exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-620">170,460</ix:nonFraction> shares became available for issuance under the ESPP.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-558-3"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock-based compensation expense related to the ESPP for each of the years ended December&#160;31, 2023 and 2022 was less than $<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-621"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-622">0.1</ix:nonFraction></ix:nonFraction> million. As of December&#160;31, 2023, total unrecognized compensation cost related to stock purchase rights granted under the ESPP was less than $<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="f-623">0.1</ix:nonFraction> million, which is expected to be recognized over a remaining weighted-average vesting period of <ix:nonNumeric contextRef="c-130" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-624">0.2</ix:nonNumeric> years.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Stock-Based Compensation Expense</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-625" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total non-cash stock-based compensation expense recorded related to options, RSUs and stock purchase rights granted under the ESPP in the statement of operations is as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-626">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-627">213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-628">3,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-629">3,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-630">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-631">631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-632">3,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-633">4,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="f-634" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Common stock reserved for future issuance consists of the following at December&#160;31, 2023:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.408%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-139" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-635">1,214,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock option grants issued and outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-127" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-636">986,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock reserved for issuance upon vesting of outstanding restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-125" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-637">1,387,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common shares available for grant under the 2019 Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-121" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-638">1,831,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common shares available for future issuance under ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-129" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-639">449,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-640">5,868,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i7d27a7d8e3c749dabb1f235100af8228_154"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 10. <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-641" continuedAt="f-641-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="f-641-1" continuedAt="f-641-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-642" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The provision for income taxes consists of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-643">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-644">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-645">33</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-646">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-647">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-648">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-649">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="f-650">137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-651">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="f-652">169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-653">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="f-654">306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-655">33</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-656">282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-657" continuedAt="f-657-1" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The effective tax rate of our provision for income taxes differs from the federal statutory rate as follows:</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-641-2" continuedAt="f-641-3"><ix:continuation id="f-657-1"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal statutory tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-658">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-659">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State income taxes, net of federal tax benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-660">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-661">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-662">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-663">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-664">3.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-665">1.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="f-666">1.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="f-667">0.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-668">18.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-669">23.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="f-670">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" format="ixt:fixed-zero" scale="-2" id="f-671">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-672">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-673">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Significant components of the Company&#8217;s deferred tax assets at December&#160;31, 2023 and 2022 are shown below (in thousands). A valuation allowance has been established as realization of the Company&#8217;s deferred tax assets has not met the more likely-than-not threshold requirement. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-674" continuedAt="f-674-1" escape="true">If the Company&#8217;s judgment changes and it is determined that the Company will be able to realize these deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on deferred tax assets will be accounted for as a reduction to income tax expense.</ix:nonNumeric></span></div><ix:continuation id="f-674-1"><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-675">32,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-676">29,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-677">2,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-678">2,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accruals, reserves and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" format="ixt:num-dot-decimal" scale="3" id="f-679">1,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" scale="3" id="f-680">349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-681">2,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-682">2,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="f-683">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="f-684">362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-685">1,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-686">1,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="exdx:DeferredTaxAssetsLeaseLiability" scale="3" id="f-687">925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="exdx:DeferredTaxAssetsLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-688">1,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalization of research and experimentation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="exdx:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts" format="ixt:num-dot-decimal" scale="3" id="f-689">2,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="exdx:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts" format="ixt:num-dot-decimal" scale="3" id="f-690">2,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-691">44,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-692">39,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-693">42,942</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-694">38,567</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-695">1,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-696">1,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Right of use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="exdx:DeferredTaxLiabilitiesRightOfUseAssets" scale="3" id="f-697">814</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="exdx:DeferredTaxLiabilitiesRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="f-698">1,206</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basis differences in fixed and intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="exdx:DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" scale="3" id="f-699">287</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="exdx:DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" scale="3" id="f-700">206</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-701">1,101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-702">1,412</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-703">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-704">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="f-705" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the valuation allowance for deferred tax assets during the years ended December&#160;31, 2023 and 2022, which related primarily to increases in net operating loss (NOL) carryforwards, research and development tax credits, capitalization of research and experimentation costs, and impairment of goodwill were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation allowance at the beginning of the year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-706">38,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-707">27,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increases recorded to income tax provision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="3" id="f-708">4,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="3" id="f-709">11,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation allowance at the end of the year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-710">42,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-711">38,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-641-3"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At December&#160;31, 2023 and 2022, the Company had federal NOL carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="6" id="f-712">129.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="6" id="f-713">118.4</ix:nonFraction> million, respectively. At December&#160;31, 2023 and 2022, the Company had state NOL carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="6" id="f-714">91.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="6" id="f-715">87.0</ix:nonFraction> million, respectively. Approximately $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="6" id="f-716">43.5</ix:nonFraction> million of the federal tax loss carryforwards will begin to expire in 2024, unless previously utilized. The federal NOL carryforwards generated after December 31, 2017 of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" scale="6" id="f-717">86.3</ix:nonFraction> million will carryforward indefinitely. The Company&#8217;s state tax loss carryforwards will begin to expire in 2030, unless previously utilized. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At December&#160;31, 2023, the Company's deferred tax assets are primarily comprised of federal and state tax NOL carryforwards. The Company completed a formal study through the year ended December 31, 2019 and determined ownership changes within the meaning of Internal Revenue Code (IRC), Section 382 had occurred in 2003, 2008, 2012, 2017 and 2019. Based on the analysis, $<ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="f-718">61.1</ix:nonFraction> million of the Company's tax attribute carryforwards through December 31, 2017 cannot be utilized under IRC Section 382. The Company's ability to utilize NOL carryforwards generated after December 31, 2017 will not expire under the Tax Cuts and Jobs Act of 2017. The Company adjusted tax attribute carry forwards and deferred tax assets accordingly. As the deferred tax assets associated with the tax attribute carry forwards were fully offset by a valuation allowance, a corresponding reduction in the Company's valuation allowance was also recorded, resulting in no income tax impact.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is subject to taxation in the U.S. and in various state jurisdictions. The Company&#8217;s tax years for 2004 and forward are subject to examination by the U.S. and state tax authorities due to the carryforward of unutilized net operating losses and research and development credits. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes interest and/or penalties related to income tax matters in its provision for income taxes. The Company does not have any material accruals for, and did not recognize any, material interest or penalties in these financial statements in any period presented. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Uncertain Tax Positions </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At December&#160;31, 2023 and 2022, the Company had <ix:nonFraction unitRef="usd" contextRef="c-4" decimals="INF" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="0" id="f-719"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="INF" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="0" id="f-720">no</ix:nonFraction></ix:nonFraction> unrecognized tax benefits. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company does not believe that the balance of unrecognized tax benefits will materially change within the next twelve months.</span></div></ix:continuation><div id="i7d27a7d8e3c749dabb1f235100af8228_157"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 11. <ix:nonNumeric contextRef="c-1" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="f-721" continuedAt="f-721-1" escape="true">401(k) Plan</ix:nonNumeric></span></div><ix:continuation id="f-721-1"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company sponsors an employee savings plan that qualifies as a deferred salary arrangement under Section 401(k) of the Code. Participating employees may defer up to the Internal Revenue Service annual contribution limit. Additionally, the Company may elect to make contributions into the savings plan at its sole discretion. For each of the years ended December&#160;31, 2023 and 2022, the Company made contributions to the 401(k) Plan at <ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="f-722">4</ix:nonFraction>% of qualified employee compensation. For the years ended December&#160;31, 2023 and 2022, these contributions totaled approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="f-723">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="f-724">0.9</ix:nonFraction> million, respectively.</span></div></ix:continuation><div style="text-indent:24.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.8
<SEQUENCE>2
<FILENAME>xgn-descriptionofsecurities.htm
<DESCRIPTION>EX-4.8
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="id05eda46f36f478dbc7cc3572533800d_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 4.8</font></div></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DESCRIPTION OF SECURITIES </font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGISTERED PURSUANT TO SECTION 12 OF </font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="margin-bottom:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following description summarizes some of the terms of our capital stock. Because it is only a summary, it does not contain all the information that may be important to you and is subject to and qualified in its entirety by reference to our amended and restated certificate of incorporation (the Certificate of Incorporation) and amended and restated bylaws (the Bylaws) which are filed as exhibits to our Annual Report on Form 10-K and are incorporated by reference herein. We encourage you to read our Certificate of Incorporation and our Bylaws for additional information.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our authorized capital stock consists of 200,000,000 shares of common stock, $0.001 par value per share, and 10,000,000 shares of preferred stock, $0.001 par value per share.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Voting Rights </font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders, including the election of directors, and do not have cumulative voting rights. Accordingly, the holders of a majority of the outstanding shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they so choose, other than any directors that holders of any preferred stock we may issue may be entitled to elect. Subject to the supermajority votes for some matters, other matters shall be decided by the affirmative vote of our stockholders having a majority in voting power of the votes cast by the stockholders present or represented and voting on such matter. Our Certificate of Incorporation and Bylaws also provide that our directors may be removed only for cause and only by the affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares of capital stock entitled to vote thereon. In addition, the affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares of capital stock entitled to vote thereon is required to amend or repeal, or to adopt any provision inconsistent with, several of the provisions of our Certificate of Incorporation.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Dividends </font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subject to preferences that may be applicable to any then outstanding preferred stock, holders of common stock are entitled to receive ratably those dividends, if any, as may be declared by the board of directors out of legally available funds. </font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Liquidation Rights</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In the event of our liquidation, dissolution or winding up, the holders of common stock will be entitled to share ratably in the assets legally available for distribution to stockholders after the payment of or provision for all of our debts and other liabilities, subject to the prior rights of any preferred stock then outstanding. Holders of common stock have no preemptive or conversion rights or other subscription rights and there are no redemption or sinking funds provisions applicable to the common stock. All outstanding shares of common stock are, and the common stock to be outstanding upon the closing of this offering will be, duly authorized, validly issued, fully paid and nonassessable. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Preferred Stock</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under the terms of our Certificate of Incorporation, our board of directors has the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the dividend, voting and other rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon, and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of the common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in our control and may adversely affect the market price of the common stock and the voting and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">other rights of the holders of common stock. We have no current plans to issue any shares of preferred stock.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior to the issuance of shares of each series, the board of directors is required by the General Corporation Law of the State of Delaware (the DGCL) and our Certificate of Incorporation to adopt resolutions and file a certificate of designation with the Secretary of State of the State of Delaware. The certificate of designation fixes for each class or series the designations, powers, preferences, rights, qualifications, limitations and restrictions, including dividend rights, conversion rights, redemption privileges and liquidation preferences.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Some provisions of Delaware law, our Certificate of Incorporation and our Bylaws contain provisions that could make the following transactions more difficult&#58; an acquisition of us by means of a tender offer&#59; an acquisition of us by means of a proxy contest or otherwise&#59; or the removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions which provide for payment of a premium over the market price for our shares.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">These provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of the increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Undesignated Preferred Stock</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The ability of our board of directors, without action by the stockholders, to issue up to 10,000,000 shares of undesignated preferred stock with voting or other rights or preferences as designated by our board of directors could impede the success of any attempt to change control of us. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of our company.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Stockholder Meetings</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our Bylaws provide that a special meeting of stockholders may be called only by our chairman of the board, chief executive officer or president (in the absence of a chief executive officer), or by a resolution adopted by a majority of our board of directors.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Requirements for Advance Notification of Stockholder Nominations and Proposals</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our Bylaws establish advance notice procedures with respect to stockholder proposals to be brought before a stockholder meeting and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Elimination of Stockholder Action by Written Consent</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our Certificate of Incorporation and Bylaws eliminate the right of stockholders to act by written consent without a meeting.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Staggered Board</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our board of directors is divided into three classes&#58; Class I, Class II and Class III. The directors in each class will serve for a three-year term, one class being elected each year by our stockholders. This system of electing and removing directors may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Removal of Directors</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our Certificate of Incorporation provides that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two thirds of the total voting power of all of our outstanding voting stock then entitled to vote in the election of directors.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Stockholders Not Entitled to Cumulative Voting</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our Certificate of Incorporation does not permit stockholders to cumulate their votes in the election of directors. Accordingly, the holders of a majority of the outstanding shares of our common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they choose, other than any directors that holders of our preferred stock may be entitled to elect.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Delaware Anti-Takeover Statute</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">are subject to Section 203 of the Delaware General Corporation Law, which prohibits persons deemed to be &#8220;interested stockholders&#8221; from engaging in a &#8220;business combination&#8221; with a publicly held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#8217;s voting stock. Generally, a &#8220;business combination&#8221; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Choice of Forum</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our Certificate of Incorporation provides that, unless we consent in writing to the selection of an alternative form, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for&#58; (i) any derivative action or proceeding brought on our behalf&#59; (ii) any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders, creditors or other constituents&#59; (iii) any action asserting a claim against us arising pursuant to any provision of the General Corporation Law of the State of Delaware or our Certificate of Incorporation or Bylaws&#59; (iv) any action to interpret, apply, enforce or determine the validity of our Certificate of Incorporation or Bylaws&#59; or (v) any action asserting a claim governed by the internal affairs doctrine. This exclusive forum provision would not apply to suits brought to enforce any liability or duty created by the Securities Act or the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. Our Bylaws provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. To the extent that any such claims may be based upon federal law claims, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. The enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. Our Certificate of Incorporation and Bylaws also provide that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to this choice of forum provision.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Amendment of Charter Provisions</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The amendment of any of the above provisions, except for the provision making it possible for our board of directors to issue preferred stock, would require approval by holders of at least two thirds of the total voting power of all of our outstanding voting stock.</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The provisions of Delaware law, our Certificate of Incorporation and our Bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the composition of our board and management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Transfer Agent and Registrar</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. The transfer agent and registrar&#8217;s address is 6200 S. Quebec St., Greenwood Village, CO 80111.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Exchange Listing</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our common stock is listed for trading on Nasdaq under the symbol &#8220;XGN.&#8221;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ex231-2023bdoconsent.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ie94cecfa2e7e4dd6989df75637c54027_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Consent of Independent Registered Public Accounting Firm</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-275632) and Form S-8 (Nos. 333-272038, 333-264867, 333-256014 and 333-233878) of Exagen Inc. of our report dated March&#160;18, 2024, relating to the financial statements, which appears in this Annual Report on Form 10-K. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; BDO USA, P.C.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;18, 2024</font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-4.3pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.3pt"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>xgn311-123123.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ie5e92d48af7e4a028a6564e44f8e004b_1"></div><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:242%">Exhibit 31.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">EXAGEN INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:242%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:167%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">I, John Aballi, certify that&#58;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">I have reviewed this Annual Report on Form 10-K of Exagen Inc.&#59;</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:168%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%"> Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:168%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%"> Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:168%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%"> Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt;text-indent:18pt"><font><br></font></div><div style="margin-bottom:21pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.648%"><tr><td style="width:1.0%"></td><td style="width:49.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March&#160;18, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John Aballi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Aballi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:3pt"><font><br></font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>xgn312-123123.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i40cfbe932b5945eeb3c4d02e02995b00_1"></div><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:242%">Exhibit 31.2</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">EXAGEN INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:242%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:167%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">I, Kamal Adawi, certify that&#58;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">I have reviewed this Annual Report on Form 10-K of Exagen Inc.&#59;</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt;text-indent:18pt"><font><br></font></div><div style="margin-bottom:21pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.648%"><tr><td style="width:1.0%"></td><td style="width:49.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March&#160;18, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kamal Adawi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kamal Adawi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="margin-top:3pt"><font><br></font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>xgn321-123123.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i1f4f5e731bf749a88409384fbfc4f7c3_1"></div><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:201%">Exhibit 32.1</font></div><div style="text-align:right"><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:167%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">Pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Exagen Inc. (the &#34;Company&#34;) hereby certifies, to such officer's knowledge, that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The accompanying annual report on Form 10-K of the Company for the fiscal year ended December 31, 2023 (the &#34;Report&#34;) fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Dated&#58; March&#160;18, 2024</font></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.066%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John Aballi</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Aballi</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</font></div><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="margin-top:16pt"><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:167%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">Pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Exagen Inc. (the &#34;Company&#34;) hereby certifies, to such officer's knowledge, that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The accompanying annual report on Form 10-K of the Company for the fiscal year ended December 31, 2023 (the &#34;Report&#34;) fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Dated&#58; March&#160;18, 2024</font></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.066%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kamal Adawi</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kamal Adawi</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer (Principal Financial and Accounting Officer)</font></div></td></tr></table></div><div style="margin-top:16pt"><font><br></font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>exdx-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:6a8da8f2-df0f-4e69-99e5-93009f0ad924,g:882e5611-3f00-4664-b088-e8c5528fafa2-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exdx="http://www.exagen.com/20231231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exagen.com/20231231">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exdx-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exdx-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exdx-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exdx-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.exagen.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.exagen.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheets" roleURI="http://www.exagen.com/role/BalanceSheets">
        <link:definition>0000003 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetsParenthetical" roleURI="http://www.exagen.com/role/BalanceSheetsParenthetical">
        <link:definition>0000004 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofOperations" roleURI="http://www.exagen.com/role/StatementsofOperations">
        <link:definition>0000005 - Statement - Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofStockholdersEquity" roleURI="http://www.exagen.com/role/StatementsofStockholdersEquity">
        <link:definition>0000006 - Statement - Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofCashFlows" roleURI="http://www.exagen.com/role/StatementsofCashFlows">
        <link:definition>0000007 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organization" roleURI="http://www.exagen.com/role/Organization">
        <link:definition>0000008 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformation" roleURI="http://www.exagen.com/role/OtherFinancialInformation">
        <link:definition>0000010 - Disclosure - Other Financial Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Borrowings" roleURI="http://www.exagen.com/role/Borrowings">
        <link:definition>0000011 - Disclosure - Borrowings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.exagen.com/role/Leases">
        <link:definition>0000012 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingencies" roleURI="http://www.exagen.com/role/CommitmentandContingencies">
        <link:definition>0000013 - Disclosure - Commitment and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.exagen.com/role/FairValueMeasurements">
        <link:definition>0000014 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.exagen.com/role/StockholdersEquity">
        <link:definition>0000015 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlan" roleURI="http://www.exagen.com/role/StockOptionPlan">
        <link:definition>0000016 - Disclosure - Stock Option Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.exagen.com/role/IncomeTaxes">
        <link:definition>0000017 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="A401kPlan" roleURI="http://www.exagen.com/role/A401kPlan">
        <link:definition>0000018 - Disclosure - 401(k) Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationTables" roleURI="http://www.exagen.com/role/OtherFinancialInformationTables">
        <link:definition>9954473 - Disclosure - Other Financial Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsTables" roleURI="http://www.exagen.com/role/BorrowingsTables">
        <link:definition>9954474 - Disclosure - Borrowings (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.exagen.com/role/LeasesTables">
        <link:definition>9954475 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.exagen.com/role/FairValueMeasurementsTables">
        <link:definition>9954476 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.exagen.com/role/StockholdersEquityTables">
        <link:definition>9954477 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanTables" roleURI="http://www.exagen.com/role/StockOptionPlanTables">
        <link:definition>9954478 - Disclosure - Stock Option Plan (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.exagen.com/role/IncomeTaxesTables">
        <link:definition>9954479 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationDetails" roleURI="http://www.exagen.com/role/OrganizationDetails">
        <link:definition>9954480 - Disclosure - Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails">
        <link:definition>9954481 - Disclosure - Summary of Significant Accounting Policies - Revenue by Major Payers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>9954482 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails">
        <link:definition>9954483 - Disclosure - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>9954484 - Disclosure - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSecuritiesDetails" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails">
        <link:definition>9954485 - Disclosure - Summary of Significant Accounting Policies - Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationPrepaidExpensesDetails" roleURI="http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails">
        <link:definition>9954486 - Disclosure - Other Financial Information - Prepaid Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationPropertyandEquipmentDetails" roleURI="http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails">
        <link:definition>9954487 - Disclosure - Other Financial Information - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationNarrativeDetails" roleURI="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails">
        <link:definition>9954488 - Disclosure - Other Financial Information - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationGoodwillDetails" roleURI="http://www.exagen.com/role/OtherFinancialInformationGoodwillDetails">
        <link:definition>9954489 - Disclosure - Other Financial Information - Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationAccruedLiabilitiesDetails" roleURI="http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails">
        <link:definition>9954490 - Disclosure - Other Financial Information - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsNarrativeDetails" roleURI="http://www.exagen.com/role/BorrowingsNarrativeDetails">
        <link:definition>9954491 - Disclosure - Borrowings - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsFutureMinimumPaymentsDetails" roleURI="http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails">
        <link:definition>9954492 - Disclosure - Borrowings - Future Minimum Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.exagen.com/role/LeasesNarrativeDetails">
        <link:definition>9954493 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseBalancesDetails" roleURI="http://www.exagen.com/role/LeasesLeaseBalancesDetails">
        <link:definition>9954494 - Disclosure - Leases - Lease Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesCostsAssociatedwiththeCompanysLeasesDetails" roleURI="http://www.exagen.com/role/LeasesCostsAssociatedwiththeCompanysLeasesDetails">
        <link:definition>9954495 - Disclosure - Leases - Costs Associated with the Company's Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails" roleURI="http://www.exagen.com/role/LeasesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails">
        <link:definition>9954496 - Disclosure - Leases - Supplemental Cash Flow Information On Leases And Weighted-Average Lease Term (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails" roleURI="http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails">
        <link:definition>9954497 - Disclosure - Leases - Future Payments Under Operating And Finance Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1" roleURI="http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1">
        <link:definition>9954497 - Disclosure - Leases - Future Payments Under Operating And Finance Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesNarrativeDetails" roleURI="http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails">
        <link:definition>9954498 - Disclosure - Commitment and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.exagen.com/role/FairValueMeasurementsDetails">
        <link:definition>9954499 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.exagen.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>9954500 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails" roleURI="http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails">
        <link:definition>9954501 - Disclosure - Stockholders' Equity - Warrants to Purchase Common Stock Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanNarrativeDetails" roleURI="http://www.exagen.com/role/StockOptionPlanNarrativeDetails">
        <link:definition>9954502 - Disclosure - Stock Option Plan - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanRestrictedStockUnitsDetails" roleURI="http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails">
        <link:definition>9954503 - Disclosure - Stock Option Plan - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanStockOptionActivityDetails" roleURI="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails">
        <link:definition>9954504 - Disclosure - Stock Option Plan - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanStockBasedCompensationExpenseDetails" roleURI="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails">
        <link:definition>9954505 - Disclosure - Stock Option Plan - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanCommonStockReservedForFutureIssuanceDetails" roleURI="http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails">
        <link:definition>9954506 - Disclosure - Stock Option Plan - Common Stock Reserved For Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" roleURI="http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails">
        <link:definition>9954507 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" roleURI="http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails">
        <link:definition>9954508 - Disclosure - Income Taxes - Reconciliation of Effective Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>9954509 - Disclosure - Income Taxes - Reconciliation of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesChangeInValuationAllowanceDetails" roleURI="http://www.exagen.com/role/IncomeTaxesChangeInValuationAllowanceDetails">
        <link:definition>9954510 - Disclosure - Income Taxes - Change In Valuation Allowance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.exagen.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>9954511 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="A401kPlanDetails" roleURI="http://www.exagen.com/role/A401kPlanDetails">
        <link:definition>9954512 - Disclosure - 401(k) Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" abstract="false" name="DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_NoExpirationMember" abstract="true" name="NoExpirationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_TwoSuppliersMember" abstract="true" name="TwoSuppliersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts" abstract="false" name="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_DebtOtherThanAmendedLoanAgreementMember" abstract="true" name="DebtOtherThanAmendedLoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_DebtInstrumentPrepaymentPremiumPercentage" abstract="false" name="DebtInstrumentPrepaymentPremiumPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="exdx_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" abstract="false" name="DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract" abstract="true" name="CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exdx_WeightedAverageRemainingLeaseTermAbstract" abstract="true" name="WeightedAverageRemainingLeaseTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exdx_LongTermDebtIncludingUndiscountedInterest" abstract="false" name="LongTermDebtIncludingUndiscountedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_ExpirationDec72025Member" abstract="true" name="ExpirationDec72025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_GainLossOnDispositionOfLeaseAssignment" abstract="false" name="GainLossOnDispositionOfLeaseAssignment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_DeferredTaxAssetsLeaseLiability" abstract="false" name="DeferredTaxAssetsLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" abstract="false" name="IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_AmendedLoanAgreementMember" abstract="true" name="AmendedLoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_DebtInstrumentStatedInterestRatePaidInKind" abstract="false" name="DebtInstrumentStatedInterestRatePaidInKind" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="exdx_ShelfRegistrationStatementMember" abstract="true" name="ShelfRegistrationStatementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward" abstract="true" name="ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exdx_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_SaleOfStockRemainingAuthorizedAmount" abstract="false" name="SaleOfStockRemainingAuthorizedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_ClientMember" abstract="true" name="ClientMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" abstract="false" name="DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue" abstract="false" name="IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_InnovatusLifeSciencesLendingFundMember" abstract="true" name="InnovatusLifeSciencesLendingFundMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercisedNet" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exdx_RentalPropertyByTypeDomain" abstract="true" name="RentalPropertyByTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent" abstract="false" name="OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="exdx_ExpirationApr12026Member" abstract="true" name="ExpirationApr12026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_DeferredTaxLiabilitiesRightOfUseAssets" abstract="false" name="DeferredTaxLiabilitiesRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_AccruedPurchaseGoodsAndServicesCurrent" abstract="false" name="AccruedPurchaseGoodsAndServicesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_LongTermDebtUndiscountedInterestAmount" abstract="false" name="LongTermDebtUndiscountedInterestAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" abstract="false" name="PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers" abstract="false" name="PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exdx_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_DebtInstrumentPaidInKindLoansIssued" abstract="false" name="DebtInstrumentPaidInKindLoansIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember" abstract="true" name="CommonSharesAvailableForGrantUnderThe2019PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_ExpirationJan192026Member" abstract="true" name="ExpirationJan192026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_AHNCollaborationMember" abstract="true" name="AHNCollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_NonCashLeaseExpense" abstract="false" name="NonCashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_OperatingLeaseMonthlyBaseRent" abstract="false" name="OperatingLeaseMonthlyBaseRent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_AccruedLiabilitiesClinicalStudyCurrent" abstract="false" name="AccruedLiabilitiesClinicalStudyCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant" abstract="false" name="DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exdx_EquipmentNotesPayableMember" abstract="true" name="EquipmentNotesPayableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exdx_ComputerEquipmentAndSoftwareMember" abstract="true" name="ComputerEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_RentalPropertyByTypeAxis" abstract="true" name="RentalPropertyByTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="exdx_TaxYearsThroughDecember312017Member" abstract="true" name="TaxYearsThroughDecember312017Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_OtherFinancialInformationAbstract" abstract="true" name="OtherFinancialInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="exdx_OfficeAndLaboratoryMember" abstract="true" name="OfficeAndLaboratoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_MedicareAdvantageMember" abstract="true" name="MedicareAdvantageMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_ExpirationSep72024Member" abstract="true" name="ExpirationSep72024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_RoyaltyObligationPercentageOfSales" abstract="false" name="RoyaltyObligationPercentageOfSales" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="exdx_Term2017Member" abstract="true" name="Term2017Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_CowenEquityDistributionAgreementMember" abstract="true" name="CowenEquityDistributionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_WeightedAverageDiscountRateAbstract" abstract="true" name="WeightedAverageDiscountRateAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exdx_EquipmentPurchasedUnderNotesPayableObligations" abstract="false" name="EquipmentPurchasedUnderNotesPayableObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_IncentiveAwardPlan2019Member" abstract="true" name="IncentiveAwardPlan2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_ClinicalStudyPolicyPolicyTextBlock" abstract="false" name="ClinicalStudyPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="exdx_CommercialMember" abstract="true" name="CommercialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_AVISECTDTestMember" abstract="true" name="AVISECTDTestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_SaleOfStockAuthorizedAmount" abstract="false" name="SaleOfStockAuthorizedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_DebtInstrumentNumberOfMonthlyInstallments" abstract="false" name="DebtInstrumentNumberOfMonthlyInstallments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exdx_CollaborationAgreementAnnualCollaborationFee" abstract="false" name="CollaborationAgreementAnnualCollaborationFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares" abstract="false" name="IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exdx_OfficeMember" abstract="true" name="OfficeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_PrometheusLaboratoriesIncMember" abstract="true" name="PrometheusLaboratoriesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" abstract="false" name="DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_DebtInstrumentCovenantRevenuePerformancePeriod" abstract="false" name="DebtInstrumentCovenantRevenuePerformancePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exdx_PrepaidMaintenanceAndInsuranceContracts" abstract="false" name="PrepaidMaintenanceAndInsuranceContracts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_AlleghenyHealthNetworkResearchInstituteMember" abstract="true" name="AlleghenyHealthNetworkResearchInstituteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exdx_ExpirationMar312026Member" abstract="true" name="ExpirationMar312026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_USDepartmentOfJusticeCaseMember" abstract="true" name="USDepartmentOfJusticeCaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_Government1Member" abstract="true" name="Government1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="exdx_CollaborationAgreementCollaborationExpenses" abstract="false" name="CollaborationAgreementCollaborationExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_A2017TermLoanMember" abstract="true" name="A2017TermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>exdx-20231231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:6a8da8f2-df0f-4e69-99e5-93009f0ad924,g:882e5611-3f00-4664-b088-e8c5528fafa2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exagen.com/role/BalanceSheets" xlink:type="simple" xlink:href="exdx-20231231.xsd#BalanceSheets"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_acdca048-723d-49ce-bc5f-9ebde320189a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_7570453a-629a-45e6-8bed-47b07719eefe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_acdca048-723d-49ce-bc5f-9ebde320189a" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_7570453a-629a-45e6-8bed-47b07719eefe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_e2684fb5-a020-4bfa-af77-dd5f095f22e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_acdca048-723d-49ce-bc5f-9ebde320189a" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_e2684fb5-a020-4bfa-af77-dd5f095f22e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7105d1b8-dab6-4816-bee0-0d5daeb85fde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_acdca048-723d-49ce-bc5f-9ebde320189a" xlink:to="loc_us-gaap_LiabilitiesCurrent_7105d1b8-dab6-4816-bee0-0d5daeb85fde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_85f4838f-aa9b-43a3-af2a-cd0cd17169dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_acdca048-723d-49ce-bc5f-9ebde320189a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_85f4838f-aa9b-43a3-af2a-cd0cd17169dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a496621f-0d84-4850-a09c-1ec1f2b163c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b93ac859-ed6c-424b-8444-f455d048a4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a496621f-0d84-4850-a09c-1ec1f2b163c0" xlink:to="loc_us-gaap_AccountsPayableCurrent_b93ac859-ed6c-424b-8444-f455d048a4b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_fb2b2490-e53e-4039-9edb-e4e704ebb4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a496621f-0d84-4850-a09c-1ec1f2b163c0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_fb2b2490-e53e-4039-9edb-e4e704ebb4e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b0c4d927-1b5f-412e-9b73-4e5affe1139c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a496621f-0d84-4850-a09c-1ec1f2b163c0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b0c4d927-1b5f-412e-9b73-4e5affe1139c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_cd37315b-37fd-4f6a-b03d-664e049f9d43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a496621f-0d84-4850-a09c-1ec1f2b163c0" xlink:to="loc_us-gaap_LongTermDebtCurrent_cd37315b-37fd-4f6a-b03d-664e049f9d43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ddb78578-a2e8-4c19-b14e-5c47b02804f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c4e0c4c9-1fcd-40c0-a016-029a1f233131" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ddb78578-a2e8-4c19-b14e-5c47b02804f0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c4e0c4c9-1fcd-40c0-a016-029a1f233131" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_25a96a16-4f92-4b65-afec-df2b209d401a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ddb78578-a2e8-4c19-b14e-5c47b02804f0" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_25a96a16-4f92-4b65-afec-df2b209d401a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_003d41a0-d686-4c8a-8c11-9f8eba98bfb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ddb78578-a2e8-4c19-b14e-5c47b02804f0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_003d41a0-d686-4c8a-8c11-9f8eba98bfb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1536cb77-f778-436f-ae70-bfd246c5059b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2147e50f-7227-4d0d-9927-8ee7f4df4565" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1536cb77-f778-436f-ae70-bfd246c5059b" xlink:to="loc_us-gaap_StockholdersEquity_2147e50f-7227-4d0d-9927-8ee7f4df4565" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_79be44e7-4869-43c2-9f6e-74a604a778f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1536cb77-f778-436f-ae70-bfd246c5059b" xlink:to="loc_us-gaap_Liabilities_79be44e7-4869-43c2-9f6e-74a604a778f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e647dbe0-c19e-4cc4-99db-b9a14a625c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1536cb77-f778-436f-ae70-bfd246c5059b" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e647dbe0-c19e-4cc4-99db-b9a14a625c3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0bf5a2fd-78df-40aa-9f65-cd03a55fbd0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_8c3b7ebe-9cd0-4130-805f-989d6b89c380" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0bf5a2fd-78df-40aa-9f65-cd03a55fbd0f" xlink:to="loc_us-gaap_PreferredStockValue_8c3b7ebe-9cd0-4130-805f-989d6b89c380" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_c54d9512-9394-4352-8379-a006d63c7510" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0bf5a2fd-78df-40aa-9f65-cd03a55fbd0f" xlink:to="loc_us-gaap_AdditionalPaidInCapital_c54d9512-9394-4352-8379-a006d63c7510" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_766583e6-9e7a-49ad-beba-89422e1b2cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0bf5a2fd-78df-40aa-9f65-cd03a55fbd0f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_766583e6-9e7a-49ad-beba-89422e1b2cc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ff91d9c3-e400-4641-b9b6-7d52d0e67dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0bf5a2fd-78df-40aa-9f65-cd03a55fbd0f" xlink:to="loc_us-gaap_CommonStockValue_ff91d9c3-e400-4641-b9b6-7d52d0e67dbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_da4f56fb-22b7-4de6-a9c3-5b979ac080f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_dd1a8339-f828-4228-b022-86b224f9c9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_da4f56fb-22b7-4de6-a9c3-5b979ac080f8" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_dd1a8339-f828-4228-b022-86b224f9c9b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a517f900-c7b0-442e-8744-569d40901d66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_da4f56fb-22b7-4de6-a9c3-5b979ac080f8" xlink:to="loc_us-gaap_AssetsCurrent_a517f900-c7b0-442e-8744-569d40901d66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_923f0102-0660-4aca-a539-293c91a8d7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_da4f56fb-22b7-4de6-a9c3-5b979ac080f8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_923f0102-0660-4aca-a539-293c91a8d7dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_dba03c30-a213-4a2b-9195-cd87fd3f9777" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_da4f56fb-22b7-4de6-a9c3-5b979ac080f8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_dba03c30-a213-4a2b-9195-cd87fd3f9777" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StatementsofOperations" xlink:type="simple" xlink:href="exdx-20231231.xsd#StatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/StatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1ee45e2a-48d9-48a4-b40b-4605378b27d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b9384110-7775-41d4-9867-c62feb18de7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_1ee45e2a-48d9-48a4-b40b-4605378b27d9" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b9384110-7775-41d4-9867-c62feb18de7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_d260e892-9393-4ce1-a52a-21a948fc73a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_1ee45e2a-48d9-48a4-b40b-4605378b27d9" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_d260e892-9393-4ce1-a52a-21a948fc73a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_95fda13f-225e-46a5-8e06-4b0aeb7fded3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_7b436a4a-6a11-41e1-945e-e88344c23518" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_95fda13f-225e-46a5-8e06-4b0aeb7fded3" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_7b436a4a-6a11-41e1-945e-e88344c23518" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f244b52a-bf6f-454f-9ae3-46156f65e059" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_95fda13f-225e-46a5-8e06-4b0aeb7fded3" xlink:to="loc_us-gaap_OperatingIncomeLoss_f244b52a-bf6f-454f-9ae3-46156f65e059" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_4fd6f0d8-cc38-4c9d-b5fb-a27c725f2ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_95fda13f-225e-46a5-8e06-4b0aeb7fded3" xlink:to="loc_us-gaap_InterestExpense_4fd6f0d8-cc38-4c9d-b5fb-a27c725f2ec7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9311ffb6-80d5-4ada-bbc9-54212845fde7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_a4704d4d-a146-4e56-9244-be7ab1642c12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9311ffb6-80d5-4ada-bbc9-54212845fde7" xlink:to="loc_us-gaap_CostsAndExpenses_a4704d4d-a146-4e56-9244-be7ab1642c12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fb9a745b-4a6e-4d39-8c4c-d3fa7b18a4e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9311ffb6-80d5-4ada-bbc9-54212845fde7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fb9a745b-4a6e-4d39-8c4c-d3fa7b18a4e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0038e0ff-c090-4be0-a916-ed616426707d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9d232bcb-50e9-4d4c-b297-e41ebd3aa27a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0038e0ff-c090-4be0-a916-ed616426707d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9d232bcb-50e9-4d4c-b297-e41ebd3aa27a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0c4bcf76-dc05-4281-9fb0-d99a52e9ce3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0038e0ff-c090-4be0-a916-ed616426707d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0c4bcf76-dc05-4281-9fb0-d99a52e9ce3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_08b4b8fb-3937-4200-bc67-316097972df9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0038e0ff-c090-4be0-a916-ed616426707d" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_08b4b8fb-3937-4200-bc67-316097972df9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_03aa631b-c25d-4e9b-b0d0-1ffb36cac5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0038e0ff-c090-4be0-a916-ed616426707d" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_03aa631b-c25d-4e9b-b0d0-1ffb36cac5ac" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StatementsofCashFlows" xlink:type="simple" xlink:href="exdx-20231231.xsd#StatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/StatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cfc2ca63-da7d-41da-bd7a-8f0142530abe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_11d3d108-d4e3-46f4-8252-b9417872b466" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cfc2ca63-da7d-41da-bd7a-8f0142530abe" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_11d3d108-d4e3-46f4-8252-b9417872b466" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5ae9b24d-75eb-45dc-88a0-7054d8cbdc1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cfc2ca63-da7d-41da-bd7a-8f0142530abe" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5ae9b24d-75eb-45dc-88a0-7054d8cbdc1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d2d2eaa1-4e08-45d1-b549-53f98535a4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cfc2ca63-da7d-41da-bd7a-8f0142530abe" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d2d2eaa1-4e08-45d1-b549-53f98535a4c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ee3fa1a1-3139-401e-81ce-1b503af99c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_c291160a-062a-443e-bc43-6ebdf923edc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ee3fa1a1-3139-401e-81ce-1b503af99c4e" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_c291160a-062a-443e-bc43-6ebdf923edc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_96209980-93bd-4971-8da8-39b8b5a4f91e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ee3fa1a1-3139-401e-81ce-1b503af99c4e" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_96209980-93bd-4971-8da8-39b8b5a4f91e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_13cc9ce9-3488-4a81-932b-e5efe1b35e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ee3fa1a1-3139-401e-81ce-1b503af99c4e" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_13cc9ce9-3488-4a81-932b-e5efe1b35e7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_249e8a66-250d-480b-834e-fb6b52078abc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ee3fa1a1-3139-401e-81ce-1b503af99c4e" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_249e8a66-250d-480b-834e-fb6b52078abc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7e849376-47ea-4815-8bf8-ccd6fc77dfc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ee3fa1a1-3139-401e-81ce-1b503af99c4e" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7e849376-47ea-4815-8bf8-ccd6fc77dfc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_05d611c7-d10e-410a-a417-b94717fdff69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ee3fa1a1-3139-401e-81ce-1b503af99c4e" xlink:to="loc_us-gaap_ProceedsFromStockPlans_05d611c7-d10e-410a-a417-b94717fdff69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f1a7d45c-7a5b-4b70-af2c-2240277cd14b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ea969647-d823-4cb7-890a-d20d5c0d3d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f1a7d45c-7a5b-4b70-af2c-2240277cd14b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ea969647-d823-4cb7-890a-d20d5c0d3d0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_4eb0a4ea-c211-4685-ab62-0c660fb85d35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f1a7d45c-7a5b-4b70-af2c-2240277cd14b" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_4eb0a4ea-c211-4685-ab62-0c660fb85d35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_05960318-d455-4ab9-8c52-f0b34adcfaea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_d73f3f29-04c7-47a7-ad7d-3007c71d7e50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_05960318-d455-4ab9-8c52-f0b34adcfaea" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_d73f3f29-04c7-47a7-ad7d-3007c71d7e50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_NonCashLeaseExpense_56e41a59-c4b4-4638-b150-a719a11602cf" xlink:href="exdx-20231231.xsd#exdx_NonCashLeaseExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_05960318-d455-4ab9-8c52-f0b34adcfaea" xlink:to="loc_exdx_NonCashLeaseExpense_56e41a59-c4b4-4638-b150-a719a11602cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_9ea88a04-499f-4e3a-8cc6-1386a83630f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_05960318-d455-4ab9-8c52-f0b34adcfaea" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_9ea88a04-499f-4e3a-8cc6-1386a83630f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_56271bec-6a5e-4889-9a1c-4b15eb8c0ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaidInKindInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_05960318-d455-4ab9-8c52-f0b34adcfaea" xlink:to="loc_us-gaap_PaidInKindInterest_56271bec-6a5e-4889-9a1c-4b15eb8c0ef6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9563a8d9-3f45-4f00-9b75-99d1cf233cda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_05960318-d455-4ab9-8c52-f0b34adcfaea" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9563a8d9-3f45-4f00-9b75-99d1cf233cda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1da47a7b-1d97-4fbb-9587-f76b68680607" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_05960318-d455-4ab9-8c52-f0b34adcfaea" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1da47a7b-1d97-4fbb-9587-f76b68680607" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4363e9e4-ccd9-426c-a212-4fc97603475d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_05960318-d455-4ab9-8c52-f0b34adcfaea" xlink:to="loc_us-gaap_ShareBasedCompensation_4363e9e4-ccd9-426c-a212-4fc97603475d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_ffcaa914-f8a1-4ff3-8959-c99b8426fba0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_05960318-d455-4ab9-8c52-f0b34adcfaea" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_ffcaa914-f8a1-4ff3-8959-c99b8426fba0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_acc21040-e56e-4496-b988-14a57f3a7cad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_05960318-d455-4ab9-8c52-f0b34adcfaea" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_acc21040-e56e-4496-b988-14a57f3a7cad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a4137cbe-a5e0-4708-a0e6-7d65df67a5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_05960318-d455-4ab9-8c52-f0b34adcfaea" xlink:to="loc_us-gaap_NetIncomeLoss_a4137cbe-a5e0-4708-a0e6-7d65df67a5dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_35c87a04-f917-4452-b9d9-6a0e33c51a24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_05960318-d455-4ab9-8c52-f0b34adcfaea" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_35c87a04-f917-4452-b9d9-6a0e33c51a24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_d982578b-9dbe-457a-ab32-cda166866181" xlink:href="exdx-20231231.xsd#exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_05960318-d455-4ab9-8c52-f0b34adcfaea" xlink:to="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_d982578b-9dbe-457a-ab32-cda166866181" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0d257ba4-144f-4c72-a21b-0907f8e956b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_05960318-d455-4ab9-8c52-f0b34adcfaea" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0d257ba4-144f-4c72-a21b-0907f8e956b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_4dfcce7a-7b52-4906-b624-2dff95ad0fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_05960318-d455-4ab9-8c52-f0b34adcfaea" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_4dfcce7a-7b52-4906-b624-2dff95ad0fb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_68477688-ad3b-4c97-90ce-eac4b6e892a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_05960318-d455-4ab9-8c52-f0b34adcfaea" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_68477688-ad3b-4c97-90ce-eac4b6e892a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_daecfdc8-296a-4918-bac3-89a45bab40e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_05960318-d455-4ab9-8c52-f0b34adcfaea" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_daecfdc8-296a-4918-bac3-89a45bab40e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_GainLossOnDispositionOfLeaseAssignment_26fbdeb8-0818-41fa-a20c-e911b82bef90" xlink:href="exdx-20231231.xsd#exdx_GainLossOnDispositionOfLeaseAssignment"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_05960318-d455-4ab9-8c52-f0b34adcfaea" xlink:to="loc_exdx_GainLossOnDispositionOfLeaseAssignment_26fbdeb8-0818-41fa-a20c-e911b82bef90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_c2c4ca09-f320-4dc9-b146-b432d7c59873" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="18" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_05960318-d455-4ab9-8c52-f0b34adcfaea" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_c2c4ca09-f320-4dc9-b146-b432d7c59873" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0ddbaec7-ec0c-483a-808f-b0a61764804a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_f39222da-50bf-407a-a9f9-9b335860cb01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0ddbaec7-ec0c-483a-808f-b0a61764804a" xlink:to="loc_us-gaap_RestrictedCash_f39222da-50bf-407a-a9f9-9b335860cb01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a130a54c-5820-4d7e-80b5-3d4c1c65f311" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0ddbaec7-ec0c-483a-808f-b0a61764804a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a130a54c-5820-4d7e-80b5-3d4c1c65f311" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#OtherFinancialInformationPrepaidExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6a0aa6e1-ceae-455f-a723-7cd506e2fd47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_6b0ab4e7-2b5c-4ab6-95d6-23361d0f27cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6a0aa6e1-ceae-455f-a723-7cd506e2fd47" xlink:to="loc_us-gaap_OtherAssetsCurrent_6b0ab4e7-2b5c-4ab6-95d6-23361d0f27cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRoyalties_8c54d5fa-3b7d-4d45-a15c-2494386eeb92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidRoyalties"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6a0aa6e1-ceae-455f-a723-7cd506e2fd47" xlink:to="loc_us-gaap_PrepaidRoyalties_8c54d5fa-3b7d-4d45-a15c-2494386eeb92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidMaintenanceAndInsuranceContracts_479607e1-9eda-4abd-acbb-2dbe04c58d51" xlink:href="exdx-20231231.xsd#exdx_PrepaidMaintenanceAndInsuranceContracts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6a0aa6e1-ceae-455f-a723-7cd506e2fd47" xlink:to="loc_exdx_PrepaidMaintenanceAndInsuranceContracts_479607e1-9eda-4abd-acbb-2dbe04c58d51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_9aac45a0-ab38-4faa-87c7-f20c5c224597" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6a0aa6e1-ceae-455f-a723-7cd506e2fd47" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_9aac45a0-ab38-4faa-87c7-f20c5c224597" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#OtherFinancialInformationPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_54fbe055-f198-4091-a2d1-0ae6892fa737" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_65c60215-b186-4601-8259-bd366399d020" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_54fbe055-f198-4091-a2d1-0ae6892fa737" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_65c60215-b186-4601-8259-bd366399d020" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_aa61e76a-ad1d-472f-975f-07734410d589" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_54fbe055-f198-4091-a2d1-0ae6892fa737" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_aa61e76a-ad1d-472f-975f-07734410d589" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#OtherFinancialInformationAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_37aee158-d21d-4ab7-9c2e-fe2759a153f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_0e83b712-bb02-44cd-aff6-9398b4270b10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_37aee158-d21d-4ab7-9c2e-fe2759a153f7" xlink:to="loc_us-gaap_AccruedSalariesCurrent_0e83b712-bb02-44cd-aff6-9398b4270b10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent_ca8b0bda-1269-4c1b-a098-d1a6d0e4ba30" xlink:href="exdx-20231231.xsd#exdx_AccruedLiabilitiesClinicalStudyCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_37aee158-d21d-4ab7-9c2e-fe2759a153f7" xlink:to="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent_ca8b0bda-1269-4c1b-a098-d1a6d0e4ba30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_489c0539-9e54-4fd9-8f0f-28a8f427d18e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_37aee158-d21d-4ab7-9c2e-fe2759a153f7" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_489c0539-9e54-4fd9-8f0f-28a8f427d18e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent_aa373300-e20e-44a9-8fe5-9689d2d59ee6" xlink:href="exdx-20231231.xsd#exdx_AccruedPurchaseGoodsAndServicesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_37aee158-d21d-4ab7-9c2e-fe2759a153f7" xlink:to="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent_aa373300-e20e-44a9-8fe5-9689d2d59ee6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_e3d53621-1773-472e-b983-203be0e58288" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_37aee158-d21d-4ab7-9c2e-fe2759a153f7" xlink:to="loc_us-gaap_InterestPayableCurrent_e3d53621-1773-472e-b983-203be0e58288" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_ace592c3-8625-4fcd-95d3-549bac12baa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_37aee158-d21d-4ab7-9c2e-fe2759a153f7" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_ace592c3-8625-4fcd-95d3-549bac12baa5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_de552b70-7430-4a30-8739-50fe8dc4844d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_37aee158-d21d-4ab7-9c2e-fe2759a153f7" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_de552b70-7430-4a30-8739-50fe8dc4844d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_630a3315-f2aa-454a-99a9-517f9e721515" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_37aee158-d21d-4ab7-9c2e-fe2759a153f7" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_630a3315-f2aa-454a-99a9-517f9e721515" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#BorrowingsFutureMinimumPaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtIncludingUndiscountedInterest_c767fe7c-1818-4f24-8762-d0738c329d11" xlink:href="exdx-20231231.xsd#exdx_LongTermDebtIncludingUndiscountedInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_12bcbb19-70e1-4c07-85c3-2db6b3e0d44f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest_c767fe7c-1818-4f24-8762-d0738c329d11" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_12bcbb19-70e1-4c07-85c3-2db6b3e0d44f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_71933fb7-221a-4e43-8179-263106a31152" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest_c767fe7c-1818-4f24-8762-d0738c329d11" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_71933fb7-221a-4e43-8179-263106a31152" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_ef14d297-c8fd-48c3-a68e-1e67193040d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest_c767fe7c-1818-4f24-8762-d0738c329d11" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_ef14d297-c8fd-48c3-a68e-1e67193040d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_52b359cb-6717-4b58-8d8b-55258ad02dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_9a0e26d6-d3a7-433e-852e-3f8e400e20a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_52b359cb-6717-4b58-8d8b-55258ad02dc8" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_9a0e26d6-d3a7-433e-852e-3f8e400e20a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtUndiscountedInterestAmount_49ad50cf-cac6-4508-88ce-f14b185ebc40" xlink:href="exdx-20231231.xsd#exdx_LongTermDebtUndiscountedInterestAmount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_52b359cb-6717-4b58-8d8b-55258ad02dc8" xlink:to="loc_exdx_LongTermDebtUndiscountedInterestAmount_49ad50cf-cac6-4508-88ce-f14b185ebc40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtIncludingUndiscountedInterest_036b4fc8-a1b2-4f6a-a410-9954a0a35d6f" xlink:href="exdx-20231231.xsd#exdx_LongTermDebtIncludingUndiscountedInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_52b359cb-6717-4b58-8d8b-55258ad02dc8" xlink:to="loc_exdx_LongTermDebtIncludingUndiscountedInterest_036b4fc8-a1b2-4f6a-a410-9954a0a35d6f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/LeasesCostsAssociatedwiththeCompanysLeasesDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#LeasesCostsAssociatedwiththeCompanysLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/LeasesCostsAssociatedwiththeCompanysLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_c79666cb-e528-494b-a131-0fc7d08a3ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_7d5c7d62-4dd3-4f54-bd09-0ff87a082a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_c79666cb-e528-494b-a131-0fc7d08a3ad5" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_7d5c7d62-4dd3-4f54-bd09-0ff87a082a7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_f33f2cb7-e6bd-4673-9bb6-8dfee0d0346f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_c79666cb-e528-494b-a131-0fc7d08a3ad5" xlink:to="loc_us-gaap_OperatingLeaseCost_f33f2cb7-e6bd-4673-9bb6-8dfee0d0346f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_29603bc9-5e0a-4acc-9a05-8068a0bddb4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_c79666cb-e528-494b-a131-0fc7d08a3ad5" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_29603bc9-5e0a-4acc-9a05-8068a0bddb4e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_eba3d5f0-fb6e-464a-9b7e-7c11f7ccbd40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_238bc6f2-0999-4a3d-9d1d-3004cc86b751" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_eba3d5f0-fb6e-464a-9b7e-7c11f7ccbd40" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_238bc6f2-0999-4a3d-9d1d-3004cc86b751" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f1f762e2-7c89-4a62-b832-25a0d72a43da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_eba3d5f0-fb6e-464a-9b7e-7c11f7ccbd40" xlink:to="loc_us-gaap_OperatingLeaseLiability_f1f762e2-7c89-4a62-b832-25a0d72a43da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_31addd75-8765-4a4e-bbf8-2252c6f2d7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_36cad652-1910-4069-95da-5195d248b531" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_31addd75-8765-4a4e-bbf8-2252c6f2d7f2" xlink:to="loc_us-gaap_FinanceLeaseLiability_36cad652-1910-4069-95da-5195d248b531" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_84ead4a2-2807-4dad-9922-9efd2feb6de4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_31addd75-8765-4a4e-bbf8-2252c6f2d7f2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_84ead4a2-2807-4dad-9922-9efd2feb6de4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_48b89e28-dbee-44b8-bf87-d5937d83d40b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_bde2d100-b958-4d93-904d-bcc959e934e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_48b89e28-dbee-44b8-bf87-d5937d83d40b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_bde2d100-b958-4d93-904d-bcc959e934e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7e54ec7c-c982-429a-a22c-cc8518d7345e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_48b89e28-dbee-44b8-bf87-d5937d83d40b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7e54ec7c-c982-429a-a22c-cc8518d7345e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_19ee1cb9-190e-4487-8c73-90d478802563" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_e8c2160d-4504-4b27-9974-afb91cca7760" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_19ee1cb9-190e-4487-8c73-90d478802563" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_e8c2160d-4504-4b27-9974-afb91cca7760" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_6ec9b0b9-d348-41a8-a67d-b9e5e9824956" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_19ee1cb9-190e-4487-8c73-90d478802563" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_6ec9b0b9-d348-41a8-a67d-b9e5e9824956" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1" xlink:type="simple" xlink:href="exdx-20231231.xsd#LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_68ff58e7-6bd7-493d-8687-d12a7fab069f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_eda39eb4-6447-4edc-b1b1-e7092e47600f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_68ff58e7-6bd7-493d-8687-d12a7fab069f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_eda39eb4-6447-4edc-b1b1-e7092e47600f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_a94f472f-4c49-4ab3-91c3-17984536936d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_68ff58e7-6bd7-493d-8687-d12a7fab069f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_a94f472f-4c49-4ab3-91c3-17984536936d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_98f93981-1f62-42f4-bc4f-ffd267648429" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_68ff58e7-6bd7-493d-8687-d12a7fab069f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_98f93981-1f62-42f4-bc4f-ffd267648429" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_2c655034-0928-49ee-ad90-bdc2bbd10b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_68ff58e7-6bd7-493d-8687-d12a7fab069f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_2c655034-0928-49ee-ad90-bdc2bbd10b3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ffb65fc1-8565-4720-8bb9-9c7952cdbdba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6f77669f-a0bd-4730-9529-a90ce9aff55b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ffb65fc1-8565-4720-8bb9-9c7952cdbdba" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6f77669f-a0bd-4730-9529-a90ce9aff55b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a6093ca8-a9b4-42df-b046-73c358a338e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ffb65fc1-8565-4720-8bb9-9c7952cdbdba" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a6093ca8-a9b4-42df-b046-73c358a338e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d7cf31b4-5a7e-49c9-8dc0-333a2fef1151" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ffb65fc1-8565-4720-8bb9-9c7952cdbdba" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d7cf31b4-5a7e-49c9-8dc0-333a2fef1151" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f704fc44-be93-49e2-9ee3-d0d03008624b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ffb65fc1-8565-4720-8bb9-9c7952cdbdba" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f704fc44-be93-49e2-9ee3-d0d03008624b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_65c36e83-978a-4f50-baaa-da972871bf62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1610a8e3-f089-4f29-86d3-68859ba1ebe5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_65c36e83-978a-4f50-baaa-da972871bf62" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1610a8e3-f089-4f29-86d3-68859ba1ebe5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_0428743e-7e76-4f63-9c1a-c3cf6c6911a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_65c36e83-978a-4f50-baaa-da972871bf62" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_0428743e-7e76-4f63-9c1a-c3cf6c6911a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d4bff1b4-ca67-4586-893e-5186a736f8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_f64c3029-5f82-4897-9cd5-5e48a1217b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d4bff1b4-ca67-4586-893e-5186a736f8d3" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_f64c3029-5f82-4897-9cd5-5e48a1217b7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_d4ae65bc-759c-4817-9385-79fe26a79bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d4bff1b4-ca67-4586-893e-5186a736f8d3" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_d4ae65bc-759c-4817-9385-79fe26a79bdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f95f1a4f-2220-4994-8bb5-f8ca43602146" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_25e6e041-29e6-4c84-8bf2-5537a35ff355" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f95f1a4f-2220-4994-8bb5-f8ca43602146" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_25e6e041-29e6-4c84-8bf2-5537a35ff355" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e7ee1076-1e4a-4fe8-98e5-650c60764819" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f95f1a4f-2220-4994-8bb5-f8ca43602146" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e7ee1076-1e4a-4fe8-98e5-650c60764819" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_db3132a6-1b1a-4dc2-bb17-baf35fe47584" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_a60f87e5-57b3-401c-9642-7d061212f1fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_db3132a6-1b1a-4dc2-bb17-baf35fe47584" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_a60f87e5-57b3-401c-9642-7d061212f1fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_b72c80cb-f09a-4651-acda-f9a846fe6c96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_db3132a6-1b1a-4dc2-bb17-baf35fe47584" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_b72c80cb-f09a-4651-acda-f9a846fe6c96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_d0206970-3ddc-4743-a1a0-e53eaff047fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_db3132a6-1b1a-4dc2-bb17-baf35fe47584" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_d0206970-3ddc-4743-a1a0-e53eaff047fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_38c2baa2-199d-4e9d-837e-9e8d3e0d15fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_db3132a6-1b1a-4dc2-bb17-baf35fe47584" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_38c2baa2-199d-4e9d-837e-9e8d3e0d15fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_27617fd8-fb7a-4f39-adfa-89899dcb91b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_db3132a6-1b1a-4dc2-bb17-baf35fe47584" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_27617fd8-fb7a-4f39-adfa-89899dcb91b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_3ba5460d-51a0-470d-8c6b-596728e8b5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_db3132a6-1b1a-4dc2-bb17-baf35fe47584" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_3ba5460d-51a0-470d-8c6b-596728e8b5c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_683795c3-a06e-47e6-81b8-6e99f16301bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_db3132a6-1b1a-4dc2-bb17-baf35fe47584" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_683795c3-a06e-47e6-81b8-6e99f16301bf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_1f60e6db-cd5c-425d-bafb-54b475697c32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_edc8aba7-2372-4966-babd-5ca903a2adee" xlink:href="exdx-20231231.xsd#exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_1f60e6db-cd5c-425d-bafb-54b475697c32" xlink:to="loc_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_edc8aba7-2372-4966-babd-5ca903a2adee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredTaxLiabilitiesRightOfUseAssets_154867d7-db2d-43c1-842d-53d143cbaf0e" xlink:href="exdx-20231231.xsd#exdx_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_1f60e6db-cd5c-425d-bafb-54b475697c32" xlink:to="loc_exdx_DeferredTaxLiabilitiesRightOfUseAssets_154867d7-db2d-43c1-842d-53d143cbaf0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_106e6783-3cc7-4af2-bb15-72d5c3990ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_ccf1aea2-c7ba-4af6-a0ba-886e701fa2a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_106e6783-3cc7-4af2-bb15-72d5c3990ccb" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_ccf1aea2-c7ba-4af6-a0ba-886e701fa2a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_32e0d82b-6596-4806-b911-dd966a1a2682" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_106e6783-3cc7-4af2-bb15-72d5c3990ccb" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_32e0d82b-6596-4806-b911-dd966a1a2682" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts_f62f2c79-2976-4ad1-babd-8d18abc470fe" xlink:href="exdx-20231231.xsd#exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_106e6783-3cc7-4af2-bb15-72d5c3990ccb" xlink:to="loc_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts_f62f2c79-2976-4ad1-babd-8d18abc470fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_45b49a79-c1f4-4a47-86ef-5ba4c2277a95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_106e6783-3cc7-4af2-bb15-72d5c3990ccb" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_45b49a79-c1f4-4a47-86ef-5ba4c2277a95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_3f42d004-c3ac-4b41-b009-6a11933c7051" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_106e6783-3cc7-4af2-bb15-72d5c3990ccb" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_3f42d004-c3ac-4b41-b009-6a11933c7051" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_65a23919-4120-4939-b9bd-00a45f6c54aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_106e6783-3cc7-4af2-bb15-72d5c3990ccb" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_65a23919-4120-4939-b9bd-00a45f6c54aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_dcd7b648-9ddc-4245-8b13-8d4d30b00674" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_106e6783-3cc7-4af2-bb15-72d5c3990ccb" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_dcd7b648-9ddc-4245-8b13-8d4d30b00674" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredTaxAssetsLeaseLiability_b1950ec6-8ac7-4da8-8cec-2ec033db241f" xlink:href="exdx-20231231.xsd#exdx_DeferredTaxAssetsLeaseLiability"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_106e6783-3cc7-4af2-bb15-72d5c3990ccb" xlink:to="loc_exdx_DeferredTaxAssetsLeaseLiability_b1950ec6-8ac7-4da8-8cec-2ec033db241f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_fa515e4b-f1e5-4203-9fc3-2eb6634a3308" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_4165af5f-f381-46b1-99b6-71ead2d110a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_fa515e4b-f1e5-4203-9fc3-2eb6634a3308" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_4165af5f-f381-46b1-99b6-71ead2d110a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_d71b3520-f98e-4892-bf7c-348386eb6d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_fa515e4b-f1e5-4203-9fc3-2eb6634a3308" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_d71b3520-f98e-4892-bf7c-348386eb6d8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_e8450f1a-cdbf-4f30-89a0-4a7cd91722ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_21e6c50e-b7b7-4f46-a8ff-27853c28c8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_e8450f1a-cdbf-4f30-89a0-4a7cd91722ad" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_21e6c50e-b7b7-4f46-a8ff-27853c28c8a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_a9153073-2c16-4b75-99c7-5e116204bbbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_e8450f1a-cdbf-4f30-89a0-4a7cd91722ad" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_a9153073-2c16-4b75-99c7-5e116204bbbd" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>exdx-20231231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:6a8da8f2-df0f-4e69-99e5-93009f0ad924,g:882e5611-3f00-4664-b088-e8c5528fafa2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.exagen.com/role/StatementsofStockholdersEquity" xlink:type="simple" xlink:href="exdx-20231231.xsd#StatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_aa1ef10e-7b96-414f-ad86-3e0ba2585f39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_60294d3c-5782-4a5c-b6a8-a6df5ac7f011" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_aa1ef10e-7b96-414f-ad86-3e0ba2585f39" xlink:to="loc_us-gaap_StatementTable_60294d3c-5782-4a5c-b6a8-a6df5ac7f011" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1f0d7e23-06e0-4f21-aa62-53851f49f1ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_60294d3c-5782-4a5c-b6a8-a6df5ac7f011" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1f0d7e23-06e0-4f21-aa62-53851f49f1ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1f0d7e23-06e0-4f21-aa62-53851f49f1ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1f0d7e23-06e0-4f21-aa62-53851f49f1ff" xlink:to="loc_us-gaap_EquityComponentDomain_1f0d7e23-06e0-4f21-aa62-53851f49f1ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_49b53a48-7214-462d-944a-1e8ed057a80a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1f0d7e23-06e0-4f21-aa62-53851f49f1ff" xlink:to="loc_us-gaap_EquityComponentDomain_49b53a48-7214-462d-944a-1e8ed057a80a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_16427fe6-7492-4e06-87bc-3756ad025476" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_49b53a48-7214-462d-944a-1e8ed057a80a" xlink:to="loc_us-gaap_CommonStockMember_16427fe6-7492-4e06-87bc-3756ad025476" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_df9c059d-f75e-45aa-a93d-daf594652926" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_49b53a48-7214-462d-944a-1e8ed057a80a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_df9c059d-f75e-45aa-a93d-daf594652926" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_24a93d6d-7835-4092-8bcf-7352167ef1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_49b53a48-7214-462d-944a-1e8ed057a80a" xlink:to="loc_us-gaap_RetainedEarningsMember_24a93d6d-7835-4092-8bcf-7352167ef1e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c570e2e-ca8a-443c-8c7a-dfb100ea068c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aa1ef10e-7b96-414f-ad86-3e0ba2585f39" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c570e2e-ca8a-443c-8c7a-dfb100ea068c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6cfa81cb-6565-4092-9584-eb37fa8146d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c570e2e-ca8a-443c-8c7a-dfb100ea068c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6cfa81cb-6565-4092-9584-eb37fa8146d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8c65f80a-8718-4a31-b0de-eced66e2d161" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c570e2e-ca8a-443c-8c7a-dfb100ea068c" xlink:to="loc_us-gaap_StockholdersEquity_8c65f80a-8718-4a31-b0de-eced66e2d161" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares_0ebda5e2-b8d1-41d2-b556-f2b0f694fda5" xlink:href="exdx-20231231.xsd#exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c570e2e-ca8a-443c-8c7a-dfb100ea068c" xlink:to="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares_0ebda5e2-b8d1-41d2-b556-f2b0f694fda5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue_c5fb100f-e54e-478b-b770-2920fc800e60" xlink:href="exdx-20231231.xsd#exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c570e2e-ca8a-443c-8c7a-dfb100ea068c" xlink:to="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue_c5fb100f-e54e-478b-b770-2920fc800e60" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_08978e2c-32e6-4795-ae93-5aba41a3fbfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c570e2e-ca8a-443c-8c7a-dfb100ea068c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_08978e2c-32e6-4795-ae93-5aba41a3fbfd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8e5f579d-38e3-4d17-b34d-e84a16cec17b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c570e2e-ca8a-443c-8c7a-dfb100ea068c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8e5f579d-38e3-4d17-b34d-e84a16cec17b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_20cdd94c-366b-4bfa-b856-d8b115508c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c570e2e-ca8a-443c-8c7a-dfb100ea068c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_20cdd94c-366b-4bfa-b856-d8b115508c1b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_26cfb9d2-6c14-44bc-8882-90a631abdf9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c570e2e-ca8a-443c-8c7a-dfb100ea068c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_26cfb9d2-6c14-44bc-8882-90a631abdf9e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_314cd0ee-241a-431f-8f7f-d0d8fae1a1a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c570e2e-ca8a-443c-8c7a-dfb100ea068c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_314cd0ee-241a-431f-8f7f-d0d8fae1a1a7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_82a726d4-b3ef-4c42-9dcf-1020e26faa06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c570e2e-ca8a-443c-8c7a-dfb100ea068c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_82a726d4-b3ef-4c42-9dcf-1020e26faa06" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3eb865f7-71c8-4955-a0ae-31a29179e5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c570e2e-ca8a-443c-8c7a-dfb100ea068c" xlink:to="loc_us-gaap_NetIncomeLoss_3eb865f7-71c8-4955-a0ae-31a29179e5e3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3c3b45be-937b-4b42-81d1-0960a864c85d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_db8d14f2-2ece-45d8-ba0d-19ff524b53f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_4e9cfa3b-9fcb-4f7c-aa77-d38e236b84ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_75139919-08e7-413c-9b06-7d2ea99be02b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4e9cfa3b-9fcb-4f7c-aa77-d38e236b84ae" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_75139919-08e7-413c-9b06-7d2ea99be02b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_ddd4ebf5-b95d-4f60-9b2e-b2ddeb04901f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_75139919-08e7-413c-9b06-7d2ea99be02b" xlink:to="loc_srt_MajorCustomersAxis_ddd4ebf5-b95d-4f60-9b2e-b2ddeb04901f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ddd4ebf5-b95d-4f60-9b2e-b2ddeb04901f_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_ddd4ebf5-b95d-4f60-9b2e-b2ddeb04901f" xlink:to="loc_srt_NameOfMajorCustomerDomain_ddd4ebf5-b95d-4f60-9b2e-b2ddeb04901f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_eb5d47f1-99c9-4c9b-88a5-7f56fae59753" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_ddd4ebf5-b95d-4f60-9b2e-b2ddeb04901f" xlink:to="loc_srt_NameOfMajorCustomerDomain_eb5d47f1-99c9-4c9b-88a5-7f56fae59753" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareMember_3735fe49-ed00-48d5-89ad-45758056196a" xlink:href="exdx-20231231.xsd#exdx_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_eb5d47f1-99c9-4c9b-88a5-7f56fae59753" xlink:to="loc_exdx_MedicareMember_3735fe49-ed00-48d5-89ad-45758056196a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareAdvantageMember_ba9084ca-7c25-42ca-8c9a-a6cc12dfbd5f" xlink:href="exdx-20231231.xsd#exdx_MedicareAdvantageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_eb5d47f1-99c9-4c9b-88a5-7f56fae59753" xlink:to="loc_exdx_MedicareAdvantageMember_ba9084ca-7c25-42ca-8c9a-a6cc12dfbd5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_40df6f9d-69cc-4c6f-bc15-8bc610a9f45e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_75139919-08e7-413c-9b06-7d2ea99be02b" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_40df6f9d-69cc-4c6f-bc15-8bc610a9f45e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_40df6f9d-69cc-4c6f-bc15-8bc610a9f45e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_40df6f9d-69cc-4c6f-bc15-8bc610a9f45e" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_40df6f9d-69cc-4c6f-bc15-8bc610a9f45e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5d7425a1-a225-440b-b95c-0b53d772a6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_40df6f9d-69cc-4c6f-bc15-8bc610a9f45e" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5d7425a1-a225-440b-b95c-0b53d772a6ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_021d078c-7d09-49a4-9ae4-4dfc2b8423e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5d7425a1-a225-440b-b95c-0b53d772a6ff" xlink:to="loc_us-gaap_SalesRevenueNetMember_021d078c-7d09-49a4-9ae4-4dfc2b8423e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_aa84b715-34b1-4112-9c19-60be3b5ac773" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5d7425a1-a225-440b-b95c-0b53d772a6ff" xlink:to="loc_us-gaap_AccountsReceivableMember_aa84b715-34b1-4112-9c19-60be3b5ac773" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_b85975ab-ead0-4ad8-a96f-530b27e1ed9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_75139919-08e7-413c-9b06-7d2ea99be02b" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_b85975ab-ead0-4ad8-a96f-530b27e1ed9d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_b85975ab-ead0-4ad8-a96f-530b27e1ed9d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b85975ab-ead0-4ad8-a96f-530b27e1ed9d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_b85975ab-ead0-4ad8-a96f-530b27e1ed9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_86b70236-ed1e-4ba5-8f13-64383396fd1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b85975ab-ead0-4ad8-a96f-530b27e1ed9d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_86b70236-ed1e-4ba5-8f13-64383396fd1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_b76c1a85-1e99-4944-9d85-cc4ea495fec0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_86b70236-ed1e-4ba5-8f13-64383396fd1a" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_b76c1a85-1e99-4944-9d85-cc4ea495fec0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_90ac7dfd-94bf-42b4-a04c-298fff513b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4e9cfa3b-9fcb-4f7c-aa77-d38e236b84ae" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_90ac7dfd-94bf-42b4-a04c-298fff513b0c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_260dc148-6774-4dac-a4f6-d38236917ead" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_e24730bf-4786-4ae0-b708-ee772792520b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_260dc148-6774-4dac-a4f6-d38236917ead" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_e24730bf-4786-4ae0-b708-ee772792520b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_35dd194c-7a2d-4c03-89cd-0565948a76b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_e24730bf-4786-4ae0-b708-ee772792520b" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_35dd194c-7a2d-4c03-89cd-0565948a76b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_35dd194c-7a2d-4c03-89cd-0565948a76b2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_35dd194c-7a2d-4c03-89cd-0565948a76b2" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_35dd194c-7a2d-4c03-89cd-0565948a76b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_56f0da9a-8be4-4a78-93d6-7a4bfa47a404" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_35dd194c-7a2d-4c03-89cd-0565948a76b2" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_56f0da9a-8be4-4a78-93d6-7a4bfa47a404" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_1e73f145-5aa9-4e8d-abfb-086746a14840" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_56f0da9a-8be4-4a78-93d6-7a4bfa47a404" xlink:to="loc_us-gaap_SalesRevenueNetMember_1e73f145-5aa9-4e8d-abfb-086746a14840" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a3305396-f354-4625-a79b-6ab514d397e5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_e24730bf-4786-4ae0-b708-ee772792520b" xlink:to="loc_srt_ProductOrServiceAxis_a3305396-f354-4625-a79b-6ab514d397e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a3305396-f354-4625-a79b-6ab514d397e5_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a3305396-f354-4625-a79b-6ab514d397e5" xlink:to="loc_srt_ProductsAndServicesDomain_a3305396-f354-4625-a79b-6ab514d397e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_03436841-8634-42f0-b86a-f23cacb5dda7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a3305396-f354-4625-a79b-6ab514d397e5" xlink:to="loc_srt_ProductsAndServicesDomain_03436841-8634-42f0-b86a-f23cacb5dda7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AVISECTDTestMember_cc3f0eb8-4285-4355-ad96-e94d10734d1a" xlink:href="exdx-20231231.xsd#exdx_AVISECTDTestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_03436841-8634-42f0-b86a-f23cacb5dda7" xlink:to="loc_exdx_AVISECTDTestMember_cc3f0eb8-4285-4355-ad96-e94d10734d1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember_316cb6c4-f250-4014-b4fa-998cab04c0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_03436841-8634-42f0-b86a-f23cacb5dda7" xlink:to="loc_us-gaap_ShippingAndHandlingMember_316cb6c4-f250-4014-b4fa-998cab04c0e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_b9953fb3-e9dd-46e1-a63f-3e1d563c7e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_e24730bf-4786-4ae0-b708-ee772792520b" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_b9953fb3-e9dd-46e1-a63f-3e1d563c7e4c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_b9953fb3-e9dd-46e1-a63f-3e1d563c7e4c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b9953fb3-e9dd-46e1-a63f-3e1d563c7e4c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_b9953fb3-e9dd-46e1-a63f-3e1d563c7e4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_86c77500-0d6f-40fc-8361-249dc4c36815" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b9953fb3-e9dd-46e1-a63f-3e1d563c7e4c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_86c77500-0d6f-40fc-8361-249dc4c36815" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_d78433d4-e67d-4d4b-aca5-01e2b0a5539b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_86c77500-0d6f-40fc-8361-249dc4c36815" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_d78433d4-e67d-4d4b-aca5-01e2b0a5539b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember_8c19216a-bb9c-48ba-a897-c67b6977b56a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_86c77500-0d6f-40fc-8361-249dc4c36815" xlink:to="loc_us-gaap_SupplierConcentrationRiskMember_8c19216a-bb9c-48ba-a897-c67b6977b56a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_ff2f63c0-dc2d-47f1-b47d-bd700b02c964" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_e24730bf-4786-4ae0-b708-ee772792520b" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_ff2f63c0-dc2d-47f1-b47d-bd700b02c964" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_ff2f63c0-dc2d-47f1-b47d-bd700b02c964_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_ff2f63c0-dc2d-47f1-b47d-bd700b02c964" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_ff2f63c0-dc2d-47f1-b47d-bd700b02c964_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_07e512fa-8245-47dc-93c1-db75cea0f13b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_ff2f63c0-dc2d-47f1-b47d-bd700b02c964" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_07e512fa-8245-47dc-93c1-db75cea0f13b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TwoSuppliersMember_dfd38594-d1fb-40fe-8ceb-7debac1266ea" xlink:href="exdx-20231231.xsd#exdx_TwoSuppliersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_07e512fa-8245-47dc-93c1-db75cea0f13b" xlink:to="loc_exdx_TwoSuppliersMember_dfd38594-d1fb-40fe-8ceb-7debac1266ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b5617d96-7a26-4c26-b549-4ee4d785f6eb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_e24730bf-4786-4ae0-b708-ee772792520b" xlink:to="loc_srt_RangeAxis_b5617d96-7a26-4c26-b549-4ee4d785f6eb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b5617d96-7a26-4c26-b549-4ee4d785f6eb_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b5617d96-7a26-4c26-b549-4ee4d785f6eb" xlink:to="loc_srt_RangeMember_b5617d96-7a26-4c26-b549-4ee4d785f6eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dab15490-e38a-4674-be08-f09f7a2a6d5e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b5617d96-7a26-4c26-b549-4ee4d785f6eb" xlink:to="loc_srt_RangeMember_dab15490-e38a-4674-be08-f09f7a2a6d5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a0b723cc-e748-43b6-be51-fbe132aedc71" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_dab15490-e38a-4674-be08-f09f7a2a6d5e" xlink:to="loc_srt_MinimumMember_a0b723cc-e748-43b6-be51-fbe132aedc71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9f8f8636-f359-4cd5-b289-8745f5624354" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_dab15490-e38a-4674-be08-f09f7a2a6d5e" xlink:to="loc_srt_MaximumMember_9f8f8636-f359-4cd5-b289-8745f5624354" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_43afd688-efb7-4521-ac17-e1b1151dd0a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_260dc148-6774-4dac-a4f6-d38236917ead" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_43afd688-efb7-4521-ac17-e1b1151dd0a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_f63525af-bbdb-4710-822e-531a52ea7cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_260dc148-6774-4dac-a4f6-d38236917ead" xlink:to="loc_us-gaap_RestrictedCash_f63525af-bbdb-4710-822e-531a52ea7cfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_09e97fe7-0b3b-42d8-a439-3ecf7502e0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_260dc148-6774-4dac-a4f6-d38236917ead" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_09e97fe7-0b3b-42d8-a439-3ecf7502e0d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_4b6c3ece-4ec5-48eb-8ec3-4c7c21459a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_260dc148-6774-4dac-a4f6-d38236917ead" xlink:to="loc_us-gaap_NumberOfOperatingSegments_4b6c3ece-4ec5-48eb-8ec3-4c7c21459a5a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_a9328da2-ce88-4401-b234-ca122fbe896b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_260dc148-6774-4dac-a4f6-d38236917ead" xlink:to="loc_us-gaap_NumberOfReportingUnits_a9328da2-ce88-4401-b234-ca122fbe896b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_c0d5b95f-4cc5-4424-8e2d-dd53831b639a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_260dc148-6774-4dac-a4f6-d38236917ead" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_c0d5b95f-4cc5-4424-8e2d-dd53831b639a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest_3542c996-3533-4f73-9833-f9e34607fff1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_260dc148-6774-4dac-a4f6-d38236917ead" xlink:to="loc_us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest_3542c996-3533-4f73-9833-f9e34607fff1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_250fbc72-db07-4882-87b8-737685576e53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_260dc148-6774-4dac-a4f6-d38236917ead" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_250fbc72-db07-4882-87b8-737685576e53" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_6e68c835-ea13-4d23-8e2a-1adc8f7d21b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_260dc148-6774-4dac-a4f6-d38236917ead" xlink:to="loc_us-gaap_AdvertisingExpense_6e68c835-ea13-4d23-8e2a-1adc8f7d21b0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_0f602453-c3f1-4b9f-b668-882c30e73c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_260dc148-6774-4dac-a4f6-d38236917ead" xlink:to="loc_us-gaap_CostOfRevenue_0f602453-c3f1-4b9f-b668-882c30e73c8e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8d63acb8-970e-4fca-a7c6-51b49fc1ac97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_260dc148-6774-4dac-a4f6-d38236917ead" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8d63acb8-970e-4fca-a7c6-51b49fc1ac97" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_5d9554c9-167c-4b48-98ba-db069d5b20b1" xlink:href="exdx-20231231.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_260dc148-6774-4dac-a4f6-d38236917ead" xlink:to="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_5d9554c9-167c-4b48-98ba-db069d5b20b1" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_57575f04-6dcf-42aa-98b5-96197feeb950" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_d48cd8af-a42c-41b8-86e4-5eca760cbc52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_57575f04-6dcf-42aa-98b5-96197feeb950" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_d48cd8af-a42c-41b8-86e4-5eca760cbc52" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_051a867f-355c-4941-8e29-e3ff30a82c25" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d48cd8af-a42c-41b8-86e4-5eca760cbc52" xlink:to="loc_srt_MajorCustomersAxis_051a867f-355c-4941-8e29-e3ff30a82c25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_051a867f-355c-4941-8e29-e3ff30a82c25_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_051a867f-355c-4941-8e29-e3ff30a82c25" xlink:to="loc_srt_NameOfMajorCustomerDomain_051a867f-355c-4941-8e29-e3ff30a82c25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e341cd28-d3ac-447b-89fd-71edd7f4dff2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_051a867f-355c-4941-8e29-e3ff30a82c25" xlink:to="loc_srt_NameOfMajorCustomerDomain_e341cd28-d3ac-447b-89fd-71edd7f4dff2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CommercialMember_032d31d0-0745-436d-8ce3-96f22b27d20e" xlink:href="exdx-20231231.xsd#exdx_CommercialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_e341cd28-d3ac-447b-89fd-71edd7f4dff2" xlink:to="loc_exdx_CommercialMember_032d31d0-0745-436d-8ce3-96f22b27d20e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Government1Member_6ebca207-bdec-4617-9199-647482c665d9" xlink:href="exdx-20231231.xsd#exdx_Government1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_e341cd28-d3ac-447b-89fd-71edd7f4dff2" xlink:to="loc_exdx_Government1Member_6ebca207-bdec-4617-9199-647482c665d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClientMember_5b26ff30-2a8c-46e6-af2a-d8f3606694bc" xlink:href="exdx-20231231.xsd#exdx_ClientMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_e341cd28-d3ac-447b-89fd-71edd7f4dff2" xlink:to="loc_exdx_ClientMember_5b26ff30-2a8c-46e6-af2a-d8f3606694bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCustomerMember_a7e2b4ce-6e2a-4742-83cd-f110109be7d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_e341cd28-d3ac-447b-89fd-71edd7f4dff2" xlink:to="loc_us-gaap_OtherCustomerMember_a7e2b4ce-6e2a-4742-83cd-f110109be7d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6b102dd6-45e3-46b7-9ed5-5cce1f785060" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_57575f04-6dcf-42aa-98b5-96197feeb950" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6b102dd6-45e3-46b7-9ed5-5cce1f785060" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#SummaryofSignificantAccountingPoliciesSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_94e0246a-b023-45ae-9bb8-29b11365b6e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_f42e4301-60d3-4c45-9906-4efcae6ad8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_94e0246a-b023-45ae-9bb8-29b11365b6e7" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_f42e4301-60d3-4c45-9906-4efcae6ad8d0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ba368db8-399d-473e-81df-e7365ae43e44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f42e4301-60d3-4c45-9906-4efcae6ad8d0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ba368db8-399d-473e-81df-e7365ae43e44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ba368db8-399d-473e-81df-e7365ae43e44_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ba368db8-399d-473e-81df-e7365ae43e44" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ba368db8-399d-473e-81df-e7365ae43e44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6efeb938-376d-4620-a874-da5567013891" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ba368db8-399d-473e-81df-e7365ae43e44" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6efeb938-376d-4620-a874-da5567013891" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_1c7bcab3-f492-4368-a47a-29c4af5fe216" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6efeb938-376d-4620-a874-da5567013891" xlink:to="loc_us-gaap_WarrantMember_1c7bcab3-f492-4368-a47a-29c4af5fe216" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_14bcb0d9-7fa0-46e7-bc40-f20126fe4c27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6efeb938-376d-4620-a874-da5567013891" xlink:to="loc_us-gaap_StockOptionMember_14bcb0d9-7fa0-46e7-bc40-f20126fe4c27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0136fc92-e230-4822-94e9-ce6f8a0f2b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6efeb938-376d-4620-a874-da5567013891" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0136fc92-e230-4822-94e9-ce6f8a0f2b3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_24d99201-36be-4334-8074-d17c892beb6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6efeb938-376d-4620-a874-da5567013891" xlink:to="loc_us-gaap_EmployeeStockMember_24d99201-36be-4334-8074-d17c892beb6d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9425df88-8dc3-4c11-abdd-b8f356ec788b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_94e0246a-b023-45ae-9bb8-29b11365b6e7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9425df88-8dc3-4c11-abdd-b8f356ec788b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#OtherFinancialInformationPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fb2bca64-1e3c-4c2c-a1fb-94c5ff83d84f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_101927fd-bfae-4ed6-9fbd-e086f74ac2b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fb2bca64-1e3c-4c2c-a1fb-94c5ff83d84f" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_101927fd-bfae-4ed6-9fbd-e086f74ac2b8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_945c371a-5f49-40e2-a433-95a2dbaf79e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_101927fd-bfae-4ed6-9fbd-e086f74ac2b8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_945c371a-5f49-40e2-a433-95a2dbaf79e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_945c371a-5f49-40e2-a433-95a2dbaf79e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_945c371a-5f49-40e2-a433-95a2dbaf79e5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_945c371a-5f49-40e2-a433-95a2dbaf79e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_11d71b98-fc6f-47ad-b9ce-8e58748ea5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_945c371a-5f49-40e2-a433-95a2dbaf79e5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_11d71b98-fc6f-47ad-b9ce-8e58748ea5cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_9f0f0a02-0f37-49c4-b95b-a44c2fded006" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_11d71b98-fc6f-47ad-b9ce-8e58748ea5cf" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_9f0f0a02-0f37-49c4-b95b-a44c2fded006" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LaboratoryEquipmentMember_f97bea8a-f30b-427c-bf50-28044e14837b" xlink:href="exdx-20231231.xsd#exdx_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_11d71b98-fc6f-47ad-b9ce-8e58748ea5cf" xlink:to="loc_exdx_LaboratoryEquipmentMember_f97bea8a-f30b-427c-bf50-28044e14837b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ComputerEquipmentAndSoftwareMember_7f8074d7-697b-47d0-888e-757a28b2fc5e" xlink:href="exdx-20231231.xsd#exdx_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_11d71b98-fc6f-47ad-b9ce-8e58748ea5cf" xlink:to="loc_exdx_ComputerEquipmentAndSoftwareMember_7f8074d7-697b-47d0-888e-757a28b2fc5e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_766006cc-768c-4a5e-8516-d6219bdcb3eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_11d71b98-fc6f-47ad-b9ce-8e58748ea5cf" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_766006cc-768c-4a5e-8516-d6219bdcb3eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_e3a0c74a-c881-4436-9dd4-7f528e7f405a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_11d71b98-fc6f-47ad-b9ce-8e58748ea5cf" xlink:to="loc_us-gaap_ConstructionInProgressMember_e3a0c74a-c881-4436-9dd4-7f528e7f405a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_effd902f-08ad-4c23-a006-defc156a8347" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fb2bca64-1e3c-4c2c-a1fb-94c5ff83d84f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_effd902f-08ad-4c23-a006-defc156a8347" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_cc76db24-926f-4def-9619-d42f4e7b8eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fb2bca64-1e3c-4c2c-a1fb-94c5ff83d84f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_cc76db24-926f-4def-9619-d42f4e7b8eb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_7fa04131-14a6-404a-9cb9-39cd7823d573" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fb2bca64-1e3c-4c2c-a1fb-94c5ff83d84f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_7fa04131-14a6-404a-9cb9-39cd7823d573" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#OtherFinancialInformationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a77b7989-f268-41ba-8a56-459693d5c1d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7bb9d684-1c60-49ad-95c5-7f194f4526a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a77b7989-f268-41ba-8a56-459693d5c1d8" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7bb9d684-1c60-49ad-95c5-7f194f4526a2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_50890ca8-a32d-472a-9ff7-04b68a021f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7bb9d684-1c60-49ad-95c5-7f194f4526a2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_50890ca8-a32d-472a-9ff7-04b68a021f9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_50890ca8-a32d-472a-9ff7-04b68a021f9b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_50890ca8-a32d-472a-9ff7-04b68a021f9b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_50890ca8-a32d-472a-9ff7-04b68a021f9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a7d39df5-fa8e-44d4-b19a-9f3e2ab31297" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_50890ca8-a32d-472a-9ff7-04b68a021f9b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a7d39df5-fa8e-44d4-b19a-9f3e2ab31297" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LaboratoryEquipmentMember_b85bfbee-eaaa-40ce-bc98-7642fabd2bad" xlink:href="exdx-20231231.xsd#exdx_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a7d39df5-fa8e-44d4-b19a-9f3e2ab31297" xlink:to="loc_exdx_LaboratoryEquipmentMember_b85bfbee-eaaa-40ce-bc98-7642fabd2bad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_a4a03f2e-3ea3-47e0-94e8-70c8236dd881" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a7d39df5-fa8e-44d4-b19a-9f3e2ab31297" xlink:to="loc_us-gaap_BuildingMember_a4a03f2e-3ea3-47e0-94e8-70c8236dd881" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_51ef2914-4e28-4101-834d-ab38e026a100" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a77b7989-f268-41ba-8a56-459693d5c1d8" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_51ef2914-4e28-4101-834d-ab38e026a100" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_561c8006-809c-471d-bed6-7438d0dee88b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a77b7989-f268-41ba-8a56-459693d5c1d8" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_561c8006-809c-471d-bed6-7438d0dee88b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_04254c19-1c15-4d34-8edb-6ecf658cab13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a77b7989-f268-41ba-8a56-459693d5c1d8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_04254c19-1c15-4d34-8edb-6ecf658cab13" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8b1b293e-bb15-44f6-93e1-a83921e065ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a77b7989-f268-41ba-8a56-459693d5c1d8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8b1b293e-bb15-44f6-93e1-a83921e065ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_5e956213-e312-44d5-997c-1f3673ac0634" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a77b7989-f268-41ba-8a56-459693d5c1d8" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_5e956213-e312-44d5-997c-1f3673ac0634" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_GainLossOnDispositionOfLeaseAssignment_701eec7a-b004-4b94-8492-cee5344193d3" xlink:href="exdx-20231231.xsd#exdx_GainLossOnDispositionOfLeaseAssignment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a77b7989-f268-41ba-8a56-459693d5c1d8" xlink:to="loc_exdx_GainLossOnDispositionOfLeaseAssignment_701eec7a-b004-4b94-8492-cee5344193d3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_5595a903-5d83-449c-986d-71d80d722ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a77b7989-f268-41ba-8a56-459693d5c1d8" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_5595a903-5d83-449c-986d-71d80d722ffa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_46972c59-c726-467d-8b19-553a602942e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a77b7989-f268-41ba-8a56-459693d5c1d8" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_46972c59-c726-467d-8b19-553a602942e0" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#BorrowingsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c25e87c1-3992-484a-81e1-9e41cb6a4e45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:to="loc_us-gaap_DebtInstrumentTable_c25e87c1-3992-484a-81e1-9e41cb6a4e45" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ff50a05b-e967-4f3e-ac78-58ba1874ef4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c25e87c1-3992-484a-81e1-9e41cb6a4e45" xlink:to="loc_us-gaap_DebtInstrumentAxis_ff50a05b-e967-4f3e-ac78-58ba1874ef4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ff50a05b-e967-4f3e-ac78-58ba1874ef4a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ff50a05b-e967-4f3e-ac78-58ba1874ef4a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ff50a05b-e967-4f3e-ac78-58ba1874ef4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_44cb3282-41ce-4064-928d-5dc545452742" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ff50a05b-e967-4f3e-ac78-58ba1874ef4a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_44cb3282-41ce-4064-928d-5dc545452742" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AmendedLoanAgreementMember_b8cc33a6-b6c7-47bb-80c2-dffc22529def" xlink:href="exdx-20231231.xsd#exdx_AmendedLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_44cb3282-41ce-4064-928d-5dc545452742" xlink:to="loc_exdx_AmendedLoanAgreementMember_b8cc33a6-b6c7-47bb-80c2-dffc22529def" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Term2017Member_2c59ed7d-7af8-456b-97aa-5248ec0e8c87" xlink:href="exdx-20231231.xsd#exdx_Term2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_44cb3282-41ce-4064-928d-5dc545452742" xlink:to="loc_exdx_Term2017Member_2c59ed7d-7af8-456b-97aa-5248ec0e8c87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_EquipmentNotesPayableMember_35727683-5682-4b01-b999-3e793b63fc48" xlink:href="exdx-20231231.xsd#exdx_EquipmentNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_44cb3282-41ce-4064-928d-5dc545452742" xlink:to="loc_exdx_EquipmentNotesPayableMember_35727683-5682-4b01-b999-3e793b63fc48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_be74f14c-29a8-4a95-b85e-85ee12863fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c25e87c1-3992-484a-81e1-9e41cb6a4e45" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_be74f14c-29a8-4a95-b85e-85ee12863fa0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_be74f14c-29a8-4a95-b85e-85ee12863fa0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_be74f14c-29a8-4a95-b85e-85ee12863fa0" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_be74f14c-29a8-4a95-b85e-85ee12863fa0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_ea2a0e75-eb76-4154-a8a1-578f10276dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_be74f14c-29a8-4a95-b85e-85ee12863fa0" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_ea2a0e75-eb76-4154-a8a1-578f10276dbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_InnovatusLifeSciencesLendingFundMember_47c54579-475a-4cfd-baa5-7b5d50e5f44b" xlink:href="exdx-20231231.xsd#exdx_InnovatusLifeSciencesLendingFundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_ea2a0e75-eb76-4154-a8a1-578f10276dbf" xlink:to="loc_exdx_InnovatusLifeSciencesLendingFundMember_47c54579-475a-4cfd-baa5-7b5d50e5f44b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4986cfae-a92e-470e-ae83-2038cbf9a5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c25e87c1-3992-484a-81e1-9e41cb6a4e45" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4986cfae-a92e-470e-ae83-2038cbf9a5ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4986cfae-a92e-470e-ae83-2038cbf9a5ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4986cfae-a92e-470e-ae83-2038cbf9a5ab" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4986cfae-a92e-470e-ae83-2038cbf9a5ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cc03927b-f95f-46bc-945f-f0b395f1374a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4986cfae-a92e-470e-ae83-2038cbf9a5ab" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cc03927b-f95f-46bc-945f-f0b395f1374a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_e962d077-10c9-42c2-a381-ef8b6a776490" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cc03927b-f95f-46bc-945f-f0b395f1374a" xlink:to="loc_us-gaap_LoansPayableMember_e962d077-10c9-42c2-a381-ef8b6a776490" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentInKindPIKNoteMember_835b5913-de98-4dad-b24d-1bc21b1e0ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentInKindPIKNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cc03927b-f95f-46bc-945f-f0b395f1374a" xlink:to="loc_us-gaap_PaymentInKindPIKNoteMember_835b5913-de98-4dad-b24d-1bc21b1e0ee4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_9363f53a-4ade-4875-895e-9118bb92922d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c25e87c1-3992-484a-81e1-9e41cb6a4e45" xlink:to="loc_us-gaap_VariableRateAxis_9363f53a-4ade-4875-895e-9118bb92922d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_9363f53a-4ade-4875-895e-9118bb92922d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_9363f53a-4ade-4875-895e-9118bb92922d" xlink:to="loc_us-gaap_VariableRateDomain_9363f53a-4ade-4875-895e-9118bb92922d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_e0e01adf-edee-4bae-97cd-2ed067dfa10c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_9363f53a-4ade-4875-895e-9118bb92922d" xlink:to="loc_us-gaap_VariableRateDomain_e0e01adf-edee-4bae-97cd-2ed067dfa10c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_3fde93e2-7ab3-4087-b0b2-6485aeb79b70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_e0e01adf-edee-4bae-97cd-2ed067dfa10c" xlink:to="loc_us-gaap_PrimeRateMember_3fde93e2-7ab3-4087-b0b2-6485aeb79b70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_30558997-6878-4139-8131-47c21adb19e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_30558997-6878-4139-8131-47c21adb19e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_7f2f6002-f777-4b62-873c-596423e3bdc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_7f2f6002-f777-4b62-873c-596423e3bdc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_bb5b20ba-c149-4ad7-8244-8bd561602b10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_bb5b20ba-c149-4ad7-8244-8bd561602b10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_38e51e03-d4e3-4e83-b180-31e51221b8a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_38e51e03-d4e3-4e83-b180-31e51221b8a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f2072faa-7877-4d97-8ea2-b31a36429771" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f2072faa-7877-4d97-8ea2-b31a36429771" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_348ee653-3ed1-4f60-a187-4ca86a7022ef" xlink:href="exdx-20231231.xsd#exdx_DebtInstrumentStatedInterestRatePaidInKind"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:to="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_348ee653-3ed1-4f60-a187-4ca86a7022ef" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0a7bac9f-e4a7-4dff-8244-aa6cf6e6a572" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0a7bac9f-e4a7-4dff-8244-aa6cf6e6a572" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentNumberOfMonthlyInstallments_5497a19a-0957-465f-831f-a69c485421ab" xlink:href="exdx-20231231.xsd#exdx_DebtInstrumentNumberOfMonthlyInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:to="loc_exdx_DebtInstrumentNumberOfMonthlyInstallments_5497a19a-0957-465f-831f-a69c485421ab" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_46306923-2319-4544-b723-47e270b7fe47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_46306923-2319-4544-b723-47e270b7fe47" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPaidInKindLoansIssued_85eb58e8-41bd-486d-a194-0c9565a9eb5a" xlink:href="exdx-20231231.xsd#exdx_DebtInstrumentPaidInKindLoansIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:to="loc_exdx_DebtInstrumentPaidInKindLoansIssued_85eb58e8-41bd-486d-a194-0c9565a9eb5a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_3a67b621-f99d-4cd1-aabd-e15dc3aa62cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_3a67b621-f99d-4cd1-aabd-e15dc3aa62cd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage_c099cecb-f7d3-4374-afc9-481ef8a2aeff" xlink:href="exdx-20231231.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:to="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage_c099cecb-f7d3-4374-afc9-481ef8a2aeff" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantRevenuePerformancePeriod_db1741af-9f7d-4dae-9833-31d17921338c" xlink:href="exdx-20231231.xsd#exdx_DebtInstrumentCovenantRevenuePerformancePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:to="loc_exdx_DebtInstrumentCovenantRevenuePerformancePeriod_db1741af-9f7d-4dae-9833-31d17921338c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant_6fd5d805-a361-4b97-b19c-a706ed346a0f" xlink:href="exdx-20231231.xsd#exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:to="loc_exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant_6fd5d805-a361-4b97-b19c-a706ed346a0f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet_aa3660f8-e2f1-4f74-a7b0-df9e259b54b1" xlink:href="exdx-20231231.xsd#exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:to="loc_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet_aa3660f8-e2f1-4f74-a7b0-df9e259b54b1" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_fc8876e5-978b-40e3-abc0-e98c6aa494df" xlink:href="exdx-20231231.xsd#exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:to="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_fc8876e5-978b-40e3-abc0-e98c6aa494df" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_29846138-5719-4447-bdfc-44639d373f0f" xlink:href="exdx-20231231.xsd#exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:to="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_29846138-5719-4447-bdfc-44639d373f0f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_434482ed-cb76-4f84-85c2-5b03dcfc7a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:to="loc_us-gaap_NotesPayable_434482ed-cb76-4f84-85c2-5b03dcfc7a7b" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_6bfd6def-6fc3-4fd3-bd7a-101c66c55da6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:to="loc_us-gaap_NotesPayableCurrent_6bfd6def-6fc3-4fd3-bd7a-101c66c55da6" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_2fe505da-6873-44e2-9e4b-2b24894a02d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:to="loc_us-gaap_LongTermNotesPayable_2fe505da-6873-44e2-9e4b-2b24894a02d4" xlink:type="arc" order="19"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_c1687ef9-370a-42da-aae8-0aff1f117ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_03eab5f6-120e-4d24-9424-96ffb71ce980" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_c1687ef9-370a-42da-aae8-0aff1f117ffc" xlink:to="loc_us-gaap_LossContingenciesTable_03eab5f6-120e-4d24-9424-96ffb71ce980" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeAxis_912e4154-a562-492b-b269-d816b9fcc65b" xlink:href="exdx-20231231.xsd#exdx_RentalPropertyByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_03eab5f6-120e-4d24-9424-96ffb71ce980" xlink:to="loc_exdx_RentalPropertyByTypeAxis_912e4154-a562-492b-b269-d816b9fcc65b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeDomain_912e4154-a562-492b-b269-d816b9fcc65b_default" xlink:href="exdx-20231231.xsd#exdx_RentalPropertyByTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exdx_RentalPropertyByTypeAxis_912e4154-a562-492b-b269-d816b9fcc65b" xlink:to="loc_exdx_RentalPropertyByTypeDomain_912e4154-a562-492b-b269-d816b9fcc65b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeDomain_049bd3c2-173d-4e0d-ac39-081622261f47" xlink:href="exdx-20231231.xsd#exdx_RentalPropertyByTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exdx_RentalPropertyByTypeAxis_912e4154-a562-492b-b269-d816b9fcc65b" xlink:to="loc_exdx_RentalPropertyByTypeDomain_049bd3c2-173d-4e0d-ac39-081622261f47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeAndLaboratoryMember_4074b9ba-b1c4-4731-81e0-fbee353fdb94" xlink:href="exdx-20231231.xsd#exdx_OfficeAndLaboratoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exdx_RentalPropertyByTypeDomain_049bd3c2-173d-4e0d-ac39-081622261f47" xlink:to="loc_exdx_OfficeAndLaboratoryMember_4074b9ba-b1c4-4731-81e0-fbee353fdb94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeMember_8fad9003-ee7e-4e6c-a774-c1b0744a8e46" xlink:href="exdx-20231231.xsd#exdx_OfficeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exdx_RentalPropertyByTypeDomain_049bd3c2-173d-4e0d-ac39-081622261f47" xlink:to="loc_exdx_OfficeMember_8fad9003-ee7e-4e6c-a774-c1b0744a8e46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6ed56dfd-56dd-47da-8dd1-a4a2ebf6fa6c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_03eab5f6-120e-4d24-9424-96ffb71ce980" xlink:to="loc_srt_RangeAxis_6ed56dfd-56dd-47da-8dd1-a4a2ebf6fa6c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6ed56dfd-56dd-47da-8dd1-a4a2ebf6fa6c_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6ed56dfd-56dd-47da-8dd1-a4a2ebf6fa6c" xlink:to="loc_srt_RangeMember_6ed56dfd-56dd-47da-8dd1-a4a2ebf6fa6c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fdc732fb-ca65-4b5e-bade-47447a0fbb64" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6ed56dfd-56dd-47da-8dd1-a4a2ebf6fa6c" xlink:to="loc_srt_RangeMember_fdc732fb-ca65-4b5e-bade-47447a0fbb64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_645fae5d-a210-465f-b6e0-87761f65b48c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fdc732fb-ca65-4b5e-bade-47447a0fbb64" xlink:to="loc_srt_MinimumMember_645fae5d-a210-465f-b6e0-87761f65b48c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5916ebc1-fbb2-4aac-96fa-81b54c7abfc9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fdc732fb-ca65-4b5e-bade-47447a0fbb64" xlink:to="loc_srt_MaximumMember_5916ebc1-fbb2-4aac-96fa-81b54c7abfc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_137e10e4-2770-4883-b3ab-a7bce8fd62bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_03eab5f6-120e-4d24-9424-96ffb71ce980" xlink:to="loc_us-gaap_LeaseContractualTermAxis_137e10e4-2770-4883-b3ab-a7bce8fd62bf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_137e10e4-2770-4883-b3ab-a7bce8fd62bf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_137e10e4-2770-4883-b3ab-a7bce8fd62bf" xlink:to="loc_us-gaap_LeaseContractualTermDomain_137e10e4-2770-4883-b3ab-a7bce8fd62bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_ce3680f8-72ab-4251-bab4-57fc2376541b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_137e10e4-2770-4883-b3ab-a7bce8fd62bf" xlink:to="loc_us-gaap_LeaseContractualTermDomain_ce3680f8-72ab-4251-bab4-57fc2376541b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeAndLaboratoryMember_2f95aeeb-c125-4b27-8061-c03802b666d2" xlink:href="exdx-20231231.xsd#exdx_OfficeAndLaboratoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_ce3680f8-72ab-4251-bab4-57fc2376541b" xlink:to="loc_exdx_OfficeAndLaboratoryMember_2f95aeeb-c125-4b27-8061-c03802b666d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeMember_a6922863-f047-4933-bd76-01a16df69e1a" xlink:href="exdx-20231231.xsd#exdx_OfficeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_ce3680f8-72ab-4251-bab4-57fc2376541b" xlink:to="loc_exdx_OfficeMember_a6922863-f047-4933-bd76-01a16df69e1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_b9e7a88b-adcd-4c7c-be0d-0f9d40d62ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c1687ef9-370a-42da-aae8-0aff1f117ffc" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_b9e7a88b-adcd-4c7c-be0d-0f9d40d62ffe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeaseMonthlyBaseRent_2f831440-f880-4a63-8cb8-2db3d74113e3" xlink:href="exdx-20231231.xsd#exdx_OperatingLeaseMonthlyBaseRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c1687ef9-370a-42da-aae8-0aff1f117ffc" xlink:to="loc_exdx_OperatingLeaseMonthlyBaseRent_2f831440-f880-4a63-8cb8-2db3d74113e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent_8d7c2a4f-04d3-4424-b00b-8118e4fc1e3c" xlink:href="exdx-20231231.xsd#exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c1687ef9-370a-42da-aae8-0aff1f117ffc" xlink:to="loc_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent_8d7c2a4f-04d3-4424-b00b-8118e4fc1e3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_54f70bf6-3e89-4559-83e7-6dbd4a9284cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c1687ef9-370a-42da-aae8-0aff1f117ffc" xlink:to="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_54f70bf6-3e89-4559-83e7-6dbd4a9284cf" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#CommitmentandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_7ec4f607-7fdb-4e44-8a42-71f0d9c7ad4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_8ae3ee8d-5d8a-429e-9a5c-72d8cb53afaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_7ec4f607-7fdb-4e44-8a42-71f0d9c7ad4a" xlink:to="loc_us-gaap_OtherCommitmentsTable_8ae3ee8d-5d8a-429e-9a5c-72d8cb53afaf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_467a1985-530f-4635-8137-7b55a20f62b8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_8ae3ee8d-5d8a-429e-9a5c-72d8cb53afaf" xlink:to="loc_srt_CounterpartyNameAxis_467a1985-530f-4635-8137-7b55a20f62b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_467a1985-530f-4635-8137-7b55a20f62b8_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_467a1985-530f-4635-8137-7b55a20f62b8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_467a1985-530f-4635-8137-7b55a20f62b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b91b0dcc-5e22-47c2-9d66-ccab23575098" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_467a1985-530f-4635-8137-7b55a20f62b8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b91b0dcc-5e22-47c2-9d66-ccab23575098" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrometheusLaboratoriesIncMember_d20750c7-8672-4a87-839a-fae13573081c" xlink:href="exdx-20231231.xsd#exdx_PrometheusLaboratoriesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b91b0dcc-5e22-47c2-9d66-ccab23575098" xlink:to="loc_exdx_PrometheusLaboratoriesIncMember_d20750c7-8672-4a87-839a-fae13573081c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember_b93f3847-650f-4591-a635-5757dc5c0595" xlink:href="exdx-20231231.xsd#exdx_AlleghenyHealthNetworkResearchInstituteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b91b0dcc-5e22-47c2-9d66-ccab23575098" xlink:to="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember_b93f3847-650f-4591-a635-5757dc5c0595" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3c50cb9c-3569-475a-8e67-88c69b83ce20" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_8ae3ee8d-5d8a-429e-9a5c-72d8cb53afaf" xlink:to="loc_srt_RangeAxis_3c50cb9c-3569-475a-8e67-88c69b83ce20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3c50cb9c-3569-475a-8e67-88c69b83ce20_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3c50cb9c-3569-475a-8e67-88c69b83ce20" xlink:to="loc_srt_RangeMember_3c50cb9c-3569-475a-8e67-88c69b83ce20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a86534a3-18ca-4c85-87fb-346ad8c820c9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3c50cb9c-3569-475a-8e67-88c69b83ce20" xlink:to="loc_srt_RangeMember_a86534a3-18ca-4c85-87fb-346ad8c820c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_af42e305-cd8d-40fb-98a7-0ccc108cf713" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a86534a3-18ca-4c85-87fb-346ad8c820c9" xlink:to="loc_srt_MinimumMember_af42e305-cd8d-40fb-98a7-0ccc108cf713" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0c64eda4-f3bd-4424-b3ba-377a2012a82d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a86534a3-18ca-4c85-87fb-346ad8c820c9" xlink:to="loc_srt_MaximumMember_0c64eda4-f3bd-4424-b3ba-377a2012a82d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_84aaf646-f57c-4f7f-8de0-ab7fbe4604c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_8ae3ee8d-5d8a-429e-9a5c-72d8cb53afaf" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_84aaf646-f57c-4f7f-8de0-ab7fbe4604c7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_84aaf646-f57c-4f7f-8de0-ab7fbe4604c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_84aaf646-f57c-4f7f-8de0-ab7fbe4604c7" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_84aaf646-f57c-4f7f-8de0-ab7fbe4604c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_81529265-fd9c-4488-914a-8bb62a795055" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_84aaf646-f57c-4f7f-8de0-ab7fbe4604c7" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_81529265-fd9c-4488-914a-8bb62a795055" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_2647f083-bbf1-4467-bd9a-c37002f50c29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_81529265-fd9c-4488-914a-8bb62a795055" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_2647f083-bbf1-4467-bd9a-c37002f50c29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f64e7a49-f9e8-48d0-9c84-4de126f60bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_8ae3ee8d-5d8a-429e-9a5c-72d8cb53afaf" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f64e7a49-f9e8-48d0-9c84-4de126f60bd7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f64e7a49-f9e8-48d0-9c84-4de126f60bd7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f64e7a49-f9e8-48d0-9c84-4de126f60bd7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f64e7a49-f9e8-48d0-9c84-4de126f60bd7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_00c3c6e5-5459-4f4e-869c-c30e764e0eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f64e7a49-f9e8-48d0-9c84-4de126f60bd7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_00c3c6e5-5459-4f4e-869c-c30e764e0eb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AHNCollaborationMember_8fca517d-c384-43a9-9367-12933bcfc96b" xlink:href="exdx-20231231.xsd#exdx_AHNCollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_00c3c6e5-5459-4f4e-869c-c30e764e0eb4" xlink:to="loc_exdx_AHNCollaborationMember_8fca517d-c384-43a9-9367-12933bcfc96b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_4a29893d-b5c5-43f3-a98f-2b803e1da88a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_8ae3ee8d-5d8a-429e-9a5c-72d8cb53afaf" xlink:to="loc_srt_LitigationCaseAxis_4a29893d-b5c5-43f3-a98f-2b803e1da88a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_4a29893d-b5c5-43f3-a98f-2b803e1da88a_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_4a29893d-b5c5-43f3-a98f-2b803e1da88a" xlink:to="loc_srt_LitigationCaseTypeDomain_4a29893d-b5c5-43f3-a98f-2b803e1da88a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_57acf0ea-81c8-4250-af32-821cc6be663f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_4a29893d-b5c5-43f3-a98f-2b803e1da88a" xlink:to="loc_srt_LitigationCaseTypeDomain_57acf0ea-81c8-4250-af32-821cc6be663f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_USDepartmentOfJusticeCaseMember_bffdb6d7-76fb-40f7-af56-a9a555a5e62c" xlink:href="exdx-20231231.xsd#exdx_USDepartmentOfJusticeCaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_57acf0ea-81c8-4250-af32-821cc6be663f" xlink:to="loc_exdx_USDepartmentOfJusticeCaseMember_bffdb6d7-76fb-40f7-af56-a9a555a5e62c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_80bc60cb-ebfa-44a1-8ab8-bebc3034df09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_8ae3ee8d-5d8a-429e-9a5c-72d8cb53afaf" xlink:to="loc_us-gaap_LitigationStatusAxis_80bc60cb-ebfa-44a1-8ab8-bebc3034df09" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_80bc60cb-ebfa-44a1-8ab8-bebc3034df09_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_80bc60cb-ebfa-44a1-8ab8-bebc3034df09" xlink:to="loc_us-gaap_LitigationStatusDomain_80bc60cb-ebfa-44a1-8ab8-bebc3034df09_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_365098e9-24a2-4cd0-ae2a-928f32ddf49f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_80bc60cb-ebfa-44a1-8ab8-bebc3034df09" xlink:to="loc_us-gaap_LitigationStatusDomain_365098e9-24a2-4cd0-ae2a-928f32ddf49f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_423a0aa2-769a-41f1-a830-69c7da25cdce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_365098e9-24a2-4cd0-ae2a-928f32ddf49f" xlink:to="loc_us-gaap_SettledLitigationMember_423a0aa2-769a-41f1-a830-69c7da25cdce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RoyaltyObligationPercentageOfSales_effc1edf-0b11-412c-bcb2-1eb2364d2f69" xlink:href="exdx-20231231.xsd#exdx_RoyaltyObligationPercentageOfSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_7ec4f607-7fdb-4e44-8a42-71f0d9c7ad4a" xlink:to="loc_exdx_RoyaltyObligationPercentageOfSales_effc1edf-0b11-412c-bcb2-1eb2364d2f69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers_5a3de18a-2a48-4405-ae20-bf1ea10c6654" xlink:href="exdx-20231231.xsd#exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_7ec4f607-7fdb-4e44-8a42-71f0d9c7ad4a" xlink:to="loc_exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers_5a3de18a-2a48-4405-ae20-bf1ea10c6654" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_dfb889f3-a534-40bf-a5e5-9e0a64df7f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_7ec4f607-7fdb-4e44-8a42-71f0d9c7ad4a" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_dfb889f3-a534-40bf-a5e5-9e0a64df7f8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_941a9dd9-ec4c-4202-808d-bc61e7699a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_7ec4f607-7fdb-4e44-8a42-71f0d9c7ad4a" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_941a9dd9-ec4c-4202-808d-bc61e7699a8b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CollaborationAgreementAnnualCollaborationFee_8e9d9f7d-12fd-4a8f-8626-c2cb23b6250c" xlink:href="exdx-20231231.xsd#exdx_CollaborationAgreementAnnualCollaborationFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_7ec4f607-7fdb-4e44-8a42-71f0d9c7ad4a" xlink:to="loc_exdx_CollaborationAgreementAnnualCollaborationFee_8e9d9f7d-12fd-4a8f-8626-c2cb23b6250c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CollaborationAgreementCollaborationExpenses_a5b377c0-a1cb-47c7-83ee-b56505ee6048" xlink:href="exdx-20231231.xsd#exdx_CollaborationAgreementCollaborationExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_7ec4f607-7fdb-4e44-8a42-71f0d9c7ad4a" xlink:to="loc_exdx_CollaborationAgreementCollaborationExpenses_a5b377c0-a1cb-47c7-83ee-b56505ee6048" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_61566d5c-6e5b-4f38-aa6b-8780224b1656" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_7ec4f607-7fdb-4e44-8a42-71f0d9c7ad4a" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_61566d5c-6e5b-4f38-aa6b-8780224b1656" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_f18487f4-1bf0-46d1-9f56-ffd1af4fa552" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_cfa18816-4c57-4e30-981c-f3a49332aec9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_f18487f4-1bf0-46d1-9f56-ffd1af4fa552" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_cfa18816-4c57-4e30-981c-f3a49332aec9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e8c2803a-caed-44c5-8d81-f9c9b5595195" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_cfa18816-4c57-4e30-981c-f3a49332aec9" xlink:to="loc_us-gaap_DebtInstrumentAxis_e8c2803a-caed-44c5-8d81-f9c9b5595195" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e8c2803a-caed-44c5-8d81-f9c9b5595195_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e8c2803a-caed-44c5-8d81-f9c9b5595195" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e8c2803a-caed-44c5-8d81-f9c9b5595195_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8005e153-2d84-40d7-b110-18f221463df1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e8c2803a-caed-44c5-8d81-f9c9b5595195" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8005e153-2d84-40d7-b110-18f221463df1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AmendedLoanAgreementMember_9be74320-e5f5-4de9-afb6-5e9e592cf9fc" xlink:href="exdx-20231231.xsd#exdx_AmendedLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8005e153-2d84-40d7-b110-18f221463df1" xlink:to="loc_exdx_AmendedLoanAgreementMember_9be74320-e5f5-4de9-afb6-5e9e592cf9fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_A2017TermLoanMember_bcf2fef6-540d-4d03-bce3-fdb1737d8ff9" xlink:href="exdx-20231231.xsd#exdx_A2017TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8005e153-2d84-40d7-b110-18f221463df1" xlink:to="loc_exdx_A2017TermLoanMember_bcf2fef6-540d-4d03-bce3-fdb1737d8ff9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtOtherThanAmendedLoanAgreementMember_d2d28dfd-867f-468a-8261-0b2b61c8a94d" xlink:href="exdx-20231231.xsd#exdx_DebtOtherThanAmendedLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8005e153-2d84-40d7-b110-18f221463df1" xlink:to="loc_exdx_DebtOtherThanAmendedLoanAgreementMember_d2d28dfd-867f-468a-8261-0b2b61c8a94d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_844d10e4-f4ef-4daf-9a93-46ce15adefde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_cfa18816-4c57-4e30-981c-f3a49332aec9" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_844d10e4-f4ef-4daf-9a93-46ce15adefde" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_844d10e4-f4ef-4daf-9a93-46ce15adefde_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_844d10e4-f4ef-4daf-9a93-46ce15adefde" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_844d10e4-f4ef-4daf-9a93-46ce15adefde_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2c9caa9f-b40f-403b-aba2-4978a47786a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_844d10e4-f4ef-4daf-9a93-46ce15adefde" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2c9caa9f-b40f-403b-aba2-4978a47786a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_62596fde-a941-4e48-b0a3-91766b59a43f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_2c9caa9f-b40f-403b-aba2-4978a47786a8" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_62596fde-a941-4e48-b0a3-91766b59a43f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_454d0f4d-d781-43de-a113-369e3e51b302" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_cfa18816-4c57-4e30-981c-f3a49332aec9" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_454d0f4d-d781-43de-a113-369e3e51b302" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_454d0f4d-d781-43de-a113-369e3e51b302_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_454d0f4d-d781-43de-a113-369e3e51b302" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_454d0f4d-d781-43de-a113-369e3e51b302_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_90d9248a-d145-4d71-a5ae-bbb7231348cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_454d0f4d-d781-43de-a113-369e3e51b302" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_90d9248a-d145-4d71-a5ae-bbb7231348cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c8a928b1-ffc5-453e-9179-9613bb3aabdc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_90d9248a-d145-4d71-a5ae-bbb7231348cc" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c8a928b1-ffc5-453e-9179-9613bb3aabdc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ac3f0ca8-6c52-49bb-a49a-c2669ffe3e03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_90d9248a-d145-4d71-a5ae-bbb7231348cc" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ac3f0ca8-6c52-49bb-a49a-c2669ffe3e03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_38c4ac64-e6fc-4f6c-91a6-b01b6b370dec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_90d9248a-d145-4d71-a5ae-bbb7231348cc" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_38c4ac64-e6fc-4f6c-91a6-b01b6b370dec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_30122bff-9657-4208-b9ed-d85a813f7139" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_cfa18816-4c57-4e30-981c-f3a49332aec9" xlink:to="loc_us-gaap_FinancialInstrumentAxis_30122bff-9657-4208-b9ed-d85a813f7139" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_30122bff-9657-4208-b9ed-d85a813f7139_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_30122bff-9657-4208-b9ed-d85a813f7139" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_30122bff-9657-4208-b9ed-d85a813f7139_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ea1cb4aa-5d03-461a-9f86-bc720677f2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_30122bff-9657-4208-b9ed-d85a813f7139" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ea1cb4aa-5d03-461a-9f86-bc720677f2ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2c93821f-b822-4b00-a042-3d99c5ce90f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ea1cb4aa-5d03-461a-9f86-bc720677f2ee" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2c93821f-b822-4b00-a042-3d99c5ce90f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_44fe85d6-1fc1-4680-928a-40655965e054" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ea1cb4aa-5d03-461a-9f86-bc720677f2ee" xlink:to="loc_us-gaap_CertificatesOfDepositMember_44fe85d6-1fc1-4680-928a-40655965e054" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_361165db-befe-48ee-b8dc-2ec5d55b7379" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_f18487f4-1bf0-46d1-9f56-ffd1af4fa552" xlink:to="loc_us-gaap_LongTermDebt_361165db-befe-48ee-b8dc-2ec5d55b7379" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_4412d3f8-22b9-454e-944f-3287886b82a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_f18487f4-1bf0-46d1-9f56-ffd1af4fa552" xlink:to="loc_us-gaap_DebtInstrumentFairValue_4412d3f8-22b9-454e-944f-3287886b82a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_23ef32ac-c139-414c-9055-23a1e042d1ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_f18487f4-1bf0-46d1-9f56-ffd1af4fa552" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_23ef32ac-c139-414c-9055-23a1e042d1ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5434cf24-7a8b-41dc-8467-20631baf918e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_23ef32ac-c139-414c-9055-23a1e042d1ce" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5434cf24-7a8b-41dc-8467-20631baf918e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_61785bb0-6bda-4eb5-90f8-8c9a37277ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_23ef32ac-c139-414c-9055-23a1e042d1ce" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_61785bb0-6bda-4eb5-90f8-8c9a37277ae1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_0f10c3e1-a3c5-44db-8fdc-e165e9b0face" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ade2e508-da50-4f22-b351-dd65c97cc877" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_0f10c3e1-a3c5-44db-8fdc-e165e9b0face" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ade2e508-da50-4f22-b351-dd65c97cc877" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_551c16f9-67bf-47ee-bc6b-d89006608c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ade2e508-da50-4f22-b351-dd65c97cc877" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_551c16f9-67bf-47ee-bc6b-d89006608c4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_551c16f9-67bf-47ee-bc6b-d89006608c4b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_551c16f9-67bf-47ee-bc6b-d89006608c4b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_551c16f9-67bf-47ee-bc6b-d89006608c4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20c54d94-e480-40cc-8a3b-5dfb28ca520b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_551c16f9-67bf-47ee-bc6b-d89006608c4b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20c54d94-e480-40cc-8a3b-5dfb28ca520b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShelfRegistrationStatementMember_97205ef6-0e2d-4a52-965c-5c0cf15ec14d" xlink:href="exdx-20231231.xsd#exdx_ShelfRegistrationStatementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20c54d94-e480-40cc-8a3b-5dfb28ca520b" xlink:to="loc_exdx_ShelfRegistrationStatementMember_97205ef6-0e2d-4a52-965c-5c0cf15ec14d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CowenEquityDistributionAgreementMember_e67fdeb3-3c04-4c3b-90c6-2854476a8b07" xlink:href="exdx-20231231.xsd#exdx_CowenEquityDistributionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20c54d94-e480-40cc-8a3b-5dfb28ca520b" xlink:to="loc_exdx_CowenEquityDistributionAgreementMember_e67fdeb3-3c04-4c3b-90c6-2854476a8b07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_SaleOfStockAuthorizedAmount_41646017-7b72-49e1-9693-b7fd2cf96d2b" xlink:href="exdx-20231231.xsd#exdx_SaleOfStockAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_0f10c3e1-a3c5-44db-8fdc-e165e9b0face" xlink:to="loc_exdx_SaleOfStockAuthorizedAmount_41646017-7b72-49e1-9693-b7fd2cf96d2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_SaleOfStockRemainingAuthorizedAmount_287f37ca-9003-4fdc-bab5-258619eb839e" xlink:href="exdx-20231231.xsd#exdx_SaleOfStockRemainingAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_0f10c3e1-a3c5-44db-8fdc-e165e9b0face" xlink:to="loc_exdx_SaleOfStockRemainingAuthorizedAmount_287f37ca-9003-4fdc-bab5-258619eb839e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_33ed3a16-1c07-4988-9399-6678b985a131" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_0f10c3e1-a3c5-44db-8fdc-e165e9b0face" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_33ed3a16-1c07-4988-9399-6678b985a131" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_f1475933-488e-4859-8f39-dd60da0814c6" xlink:href="exdx-20231231.xsd#exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_0f10c3e1-a3c5-44db-8fdc-e165e9b0face" xlink:to="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_f1475933-488e-4859-8f39-dd60da0814c6" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_6f7ca751-ff21-4bbd-a413-b300dbbc446d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_4db21fdf-77fe-4a36-af3f-f16447bfe28a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_6f7ca751-ff21-4bbd-a413-b300dbbc446d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_4db21fdf-77fe-4a36-af3f-f16447bfe28a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_7830d6b9-6e8c-452f-b4ef-ba20faa5dff6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4db21fdf-77fe-4a36-af3f-f16447bfe28a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_7830d6b9-6e8c-452f-b4ef-ba20faa5dff6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_7830d6b9-6e8c-452f-b4ef-ba20faa5dff6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_7830d6b9-6e8c-452f-b4ef-ba20faa5dff6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_7830d6b9-6e8c-452f-b4ef-ba20faa5dff6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_c51fd92b-7adc-4c88-b1f3-0cd3153ad441" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_7830d6b9-6e8c-452f-b4ef-ba20faa5dff6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_c51fd92b-7adc-4c88-b1f3-0cd3153ad441" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationJan192026Member_67edc897-3ff5-44a0-8e07-145f3093ca41" xlink:href="exdx-20231231.xsd#exdx_ExpirationJan192026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_c51fd92b-7adc-4c88-b1f3-0cd3153ad441" xlink:to="loc_exdx_ExpirationJan192026Member_67edc897-3ff5-44a0-8e07-145f3093ca41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationMar312026Member_2c640f76-53d3-4afc-bd40-7b8b6635bb84" xlink:href="exdx-20231231.xsd#exdx_ExpirationMar312026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_c51fd92b-7adc-4c88-b1f3-0cd3153ad441" xlink:to="loc_exdx_ExpirationMar312026Member_2c640f76-53d3-4afc-bd40-7b8b6635bb84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationApr12026Member_4e94c430-95bd-49cd-a9bf-a625f943eb5f" xlink:href="exdx-20231231.xsd#exdx_ExpirationApr12026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_c51fd92b-7adc-4c88-b1f3-0cd3153ad441" xlink:to="loc_exdx_ExpirationApr12026Member_4e94c430-95bd-49cd-a9bf-a625f943eb5f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationSep72024Member_cb350605-fac4-4f40-b430-623b10477aea" xlink:href="exdx-20231231.xsd#exdx_ExpirationSep72024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_c51fd92b-7adc-4c88-b1f3-0cd3153ad441" xlink:to="loc_exdx_ExpirationSep72024Member_cb350605-fac4-4f40-b430-623b10477aea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationDec72025Member_d58a341f-efee-4c35-be93-7bfad64da54d" xlink:href="exdx-20231231.xsd#exdx_ExpirationDec72025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_c51fd92b-7adc-4c88-b1f3-0cd3153ad441" xlink:to="loc_exdx_ExpirationDec72025Member_d58a341f-efee-4c35-be93-7bfad64da54d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_NoExpirationMember_3735ebcd-28db-4965-a481-317e54b1e21a" xlink:href="exdx-20231231.xsd#exdx_NoExpirationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_c51fd92b-7adc-4c88-b1f3-0cd3153ad441" xlink:to="loc_exdx_NoExpirationMember_3735ebcd-28db-4965-a481-317e54b1e21a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_f180720a-7129-4f9e-9e1e-8f0df378f042" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6f7ca751-ff21-4bbd-a413-b300dbbc446d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_f180720a-7129-4f9e-9e1e-8f0df378f042" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7c107c64-39fb-400e-8abe-81e152e26540" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6f7ca751-ff21-4bbd-a413-b300dbbc446d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7c107c64-39fb-400e-8abe-81e152e26540" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#StockOptionPlanNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1568a821-a345-483e-ae58-6922b40353a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6e2026e-78cf-4a10-a491-593efa613a56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1568a821-a345-483e-ae58-6922b40353a6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6e2026e-78cf-4a10-a491-593efa613a56" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4c0e0322-957a-41f1-80fa-0257b51f0c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6e2026e-78cf-4a10-a491-593efa613a56" xlink:to="loc_us-gaap_PlanNameAxis_4c0e0322-957a-41f1-80fa-0257b51f0c4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4c0e0322-957a-41f1-80fa-0257b51f0c4c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_4c0e0322-957a-41f1-80fa-0257b51f0c4c" xlink:to="loc_us-gaap_PlanNameDomain_4c0e0322-957a-41f1-80fa-0257b51f0c4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4f0dc311-574a-4ff7-95a7-04c8231116c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_4c0e0322-957a-41f1-80fa-0257b51f0c4c" xlink:to="loc_us-gaap_PlanNameDomain_4f0dc311-574a-4ff7-95a7-04c8231116c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncentiveAwardPlan2019Member_20742303-c6a6-4262-baaf-8e7e5e39e6e9" xlink:href="exdx-20231231.xsd#exdx_IncentiveAwardPlan2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4f0dc311-574a-4ff7-95a7-04c8231116c8" xlink:to="loc_exdx_IncentiveAwardPlan2019Member_20742303-c6a6-4262-baaf-8e7e5e39e6e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7270bc04-bf76-4c41-b892-2cf5250899ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6e2026e-78cf-4a10-a491-593efa613a56" xlink:to="loc_us-gaap_AwardTypeAxis_7270bc04-bf76-4c41-b892-2cf5250899ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7270bc04-bf76-4c41-b892-2cf5250899ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7270bc04-bf76-4c41-b892-2cf5250899ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7270bc04-bf76-4c41-b892-2cf5250899ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e20c9644-a6e2-4527-8b01-5d6d35ef7afe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7270bc04-bf76-4c41-b892-2cf5250899ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e20c9644-a6e2-4527-8b01-5d6d35ef7afe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_89d5cb9e-4e55-4eb3-bac1-4ac3059f30f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e20c9644-a6e2-4527-8b01-5d6d35ef7afe" xlink:to="loc_us-gaap_EmployeeStockOptionMember_89d5cb9e-4e55-4eb3-bac1-4ac3059f30f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_7f39161d-8dab-4214-b3a6-943183306bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e20c9644-a6e2-4527-8b01-5d6d35ef7afe" xlink:to="loc_us-gaap_EmployeeStockMember_7f39161d-8dab-4214-b3a6-943183306bbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3108d026-c2fb-4b8a-a1c2-98f3ebe1dafb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e20c9644-a6e2-4527-8b01-5d6d35ef7afe" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3108d026-c2fb-4b8a-a1c2-98f3ebe1dafb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2b7f29c7-ad7b-477d-b68d-c030e4d2bc1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6e2026e-78cf-4a10-a491-593efa613a56" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2b7f29c7-ad7b-477d-b68d-c030e4d2bc1f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2b7f29c7-ad7b-477d-b68d-c030e4d2bc1f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2b7f29c7-ad7b-477d-b68d-c030e4d2bc1f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2b7f29c7-ad7b-477d-b68d-c030e4d2bc1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_452f28d9-d083-42d4-b7b7-7f72ed0baa40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2b7f29c7-ad7b-477d-b68d-c030e4d2bc1f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_452f28d9-d083-42d4-b7b7-7f72ed0baa40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_422f29d2-c0f3-4cb7-9c61-c307759644fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_452f28d9-d083-42d4-b7b7-7f72ed0baa40" xlink:to="loc_us-gaap_SubsequentEventMember_422f29d2-c0f3-4cb7-9c61-c307759644fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_259f1818-9dd6-4fdb-9980-0c75cc9929ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1568a821-a345-483e-ae58-6922b40353a6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_259f1818-9dd6-4fdb-9980-0c75cc9929ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9be41fd4-e128-4ea9-aa3d-a141a5d32ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1568a821-a345-483e-ae58-6922b40353a6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9be41fd4-e128-4ea9-aa3d-a141a5d32ae9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_e6df59f6-b7bd-4927-914f-03fd4d02ded4" xlink:href="exdx-20231231.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1568a821-a345-483e-ae58-6922b40353a6" xlink:to="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_e6df59f6-b7bd-4927-914f-03fd4d02ded4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_431eecca-1093-48b5-855c-41a135baf4c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1568a821-a345-483e-ae58-6922b40353a6" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_431eecca-1093-48b5-855c-41a135baf4c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized_69883133-af4e-4248-b5ae-3c0e43a6a032" xlink:href="exdx-20231231.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1568a821-a345-483e-ae58-6922b40353a6" xlink:to="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized_69883133-af4e-4248-b5ae-3c0e43a6a032" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_884fe3e4-d5c6-4edf-ba7a-da0ba87bd133" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1568a821-a345-483e-ae58-6922b40353a6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_884fe3e4-d5c6-4edf-ba7a-da0ba87bd133" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5c743f3a-63f7-443d-8713-3816c13eee25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1568a821-a345-483e-ae58-6922b40353a6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5c743f3a-63f7-443d-8713-3816c13eee25" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1395f7d3-950d-4f16-b1b0-f6fe9efe3220" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1568a821-a345-483e-ae58-6922b40353a6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1395f7d3-950d-4f16-b1b0-f6fe9efe3220" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_97d48c5a-3ce4-4114-ba93-534cd9b5ee4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1568a821-a345-483e-ae58-6922b40353a6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_97d48c5a-3ce4-4114-ba93-534cd9b5ee4e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_75cc11c2-bec4-4516-9425-64339cadc9bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1568a821-a345-483e-ae58-6922b40353a6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_75cc11c2-bec4-4516-9425-64339cadc9bd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_eced8ff8-2d7f-48df-b30f-0a6d0284de8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1568a821-a345-483e-ae58-6922b40353a6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_eced8ff8-2d7f-48df-b30f-0a6d0284de8f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fe253bc1-d30d-4dc6-9186-f00754e3b2c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1568a821-a345-483e-ae58-6922b40353a6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fe253bc1-d30d-4dc6-9186-f00754e3b2c1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_09ace6bb-704c-49f5-b7d3-363862edd9db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1568a821-a345-483e-ae58-6922b40353a6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_09ace6bb-704c-49f5-b7d3-363862edd9db" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a20c7f1d-ae95-4fb7-846e-7fa92b191d39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1568a821-a345-483e-ae58-6922b40353a6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a20c7f1d-ae95-4fb7-846e-7fa92b191d39" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_cdcfb794-e491-4baf-b78e-5f27442245fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1568a821-a345-483e-ae58-6922b40353a6" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_cdcfb794-e491-4baf-b78e-5f27442245fa" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_7b2aaadc-b9de-445e-bee7-8feb0c478322" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1568a821-a345-483e-ae58-6922b40353a6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_7b2aaadc-b9de-445e-bee7-8feb0c478322" xlink:type="arc" order="15"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#StockOptionPlanRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e6dbc0c-7935-43f9-9f2c-eecb132c13df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c66a164f-2d43-4611-a86d-70a2ebb74610" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e6dbc0c-7935-43f9-9f2c-eecb132c13df" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c66a164f-2d43-4611-a86d-70a2ebb74610" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_16e0a6c8-7fe5-4767-bbff-ea6a608fcb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c66a164f-2d43-4611-a86d-70a2ebb74610" xlink:to="loc_us-gaap_AwardTypeAxis_16e0a6c8-7fe5-4767-bbff-ea6a608fcb3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16e0a6c8-7fe5-4767-bbff-ea6a608fcb3b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_16e0a6c8-7fe5-4767-bbff-ea6a608fcb3b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16e0a6c8-7fe5-4767-bbff-ea6a608fcb3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9fec5382-3a5f-4246-bb71-12cf819629ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_16e0a6c8-7fe5-4767-bbff-ea6a608fcb3b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9fec5382-3a5f-4246-bb71-12cf819629ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7ecac239-30c1-40af-835d-5e42897eb07b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9fec5382-3a5f-4246-bb71-12cf819629ac" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7ecac239-30c1-40af-835d-5e42897eb07b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e5e44be7-f982-4306-9a4f-39b8580f6855" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e6dbc0c-7935-43f9-9f2c-eecb132c13df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e5e44be7-f982-4306-9a4f-39b8580f6855" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_058aa268-cb42-4650-94d3-2d834623d43c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e5e44be7-f982-4306-9a4f-39b8580f6855" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_058aa268-cb42-4650-94d3-2d834623d43c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d32991c8-16f5-4585-8606-86171da07ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e5e44be7-f982-4306-9a4f-39b8580f6855" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d32991c8-16f5-4585-8606-86171da07ebf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f8ad98f3-3fc5-4289-9060-f1ebfa234c97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e5e44be7-f982-4306-9a4f-39b8580f6855" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f8ad98f3-3fc5-4289-9060-f1ebfa234c97" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_bf3be328-3ea2-43dc-865d-b109d58cd91a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e5e44be7-f982-4306-9a4f-39b8580f6855" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_bf3be328-3ea2-43dc-865d-b109d58cd91a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1cc68185-8ce0-4d38-8c91-581bf1a66e93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_18d6e4d0-9e93-4aa1-823c-60be1890c6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e6dbc0c-7935-43f9-9f2c-eecb132c13df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_18d6e4d0-9e93-4aa1-823c-60be1890c6cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_04d2110f-85d5-402f-989d-266a89994def" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_18d6e4d0-9e93-4aa1-823c-60be1890c6cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_04d2110f-85d5-402f-989d-266a89994def" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_524df391-db54-4e17-bb9a-89f2509fff18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_18d6e4d0-9e93-4aa1-823c-60be1890c6cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_524df391-db54-4e17-bb9a-89f2509fff18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_62b9116c-bcbf-4128-ad16-c2a31355acf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_18d6e4d0-9e93-4aa1-823c-60be1890c6cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_62b9116c-bcbf-4128-ad16-c2a31355acf4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8049d72d-4d12-4424-920b-2d09a906330e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_18d6e4d0-9e93-4aa1-823c-60be1890c6cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8049d72d-4d12-4424-920b-2d09a906330e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_789b3ceb-f80e-4a6d-9e7e-b5e64509a20e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_dff79855-695d-40ff-96b2-d535e1815f25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e6dbc0c-7935-43f9-9f2c-eecb132c13df" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_dff79855-695d-40ff-96b2-d535e1815f25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_f2e2bc29-640f-4050-8f7f-bbb663cf7dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_dff79855-695d-40ff-96b2-d535e1815f25" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_f2e2bc29-640f-4050-8f7f-bbb663cf7dfe" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#StockOptionPlanStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d7176be8-719b-4188-a7f8-c4355d64f09d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d80ed6c7-bee5-4163-b03c-533191a3dafe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d7176be8-719b-4188-a7f8-c4355d64f09d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d80ed6c7-bee5-4163-b03c-533191a3dafe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_bb267017-107a-41b3-938f-f17b7f4488ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d80ed6c7-bee5-4163-b03c-533191a3dafe" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_bb267017-107a-41b3-938f-f17b7f4488ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_bb267017-107a-41b3-938f-f17b7f4488ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bb267017-107a-41b3-938f-f17b7f4488ab" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_bb267017-107a-41b3-938f-f17b7f4488ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_42500afe-6e5f-4a61-be92-e94d3830d3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bb267017-107a-41b3-938f-f17b7f4488ab" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_42500afe-6e5f-4a61-be92-e94d3830d3b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_c712a89f-418d-4faa-b90c-e6cf5833b93e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_42500afe-6e5f-4a61-be92-e94d3830d3b4" xlink:to="loc_us-gaap_CostOfSalesMember_c712a89f-418d-4faa-b90c-e6cf5833b93e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_df6d98f9-fada-4a10-9c69-fae38e199dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_42500afe-6e5f-4a61-be92-e94d3830d3b4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_df6d98f9-fada-4a10-9c69-fae38e199dc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_426ea85d-b5cb-4582-a851-6e48e7b7a529" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_42500afe-6e5f-4a61-be92-e94d3830d3b4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_426ea85d-b5cb-4582-a851-6e48e7b7a529" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_e32b7716-d654-4a7f-aa3a-822197365a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d7176be8-719b-4188-a7f8-c4355d64f09d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_e32b7716-d654-4a7f-aa3a-822197365a0e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#StockOptionPlanCommonStockReservedForFutureIssuanceDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a05dc3e-b331-4232-92ef-c831e2f39abc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_55e1c30c-4c1e-4d92-90e8-b4f43a0374b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a05dc3e-b331-4232-92ef-c831e2f39abc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_55e1c30c-4c1e-4d92-90e8-b4f43a0374b7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2c9458a3-a9ca-4052-a1eb-dd67e14f5ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_55e1c30c-4c1e-4d92-90e8-b4f43a0374b7" xlink:to="loc_us-gaap_AwardTypeAxis_2c9458a3-a9ca-4052-a1eb-dd67e14f5ab0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2c9458a3-a9ca-4052-a1eb-dd67e14f5ab0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2c9458a3-a9ca-4052-a1eb-dd67e14f5ab0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2c9458a3-a9ca-4052-a1eb-dd67e14f5ab0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dc31e046-7401-45da-95d8-8bf84b71b756" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2c9458a3-a9ca-4052-a1eb-dd67e14f5ab0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dc31e046-7401-45da-95d8-8bf84b71b756" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_8fceb7e5-c1ae-47c7-8671-6cbb490a8064" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dc31e046-7401-45da-95d8-8bf84b71b756" xlink:to="loc_us-gaap_WarrantMember_8fceb7e5-c1ae-47c7-8671-6cbb490a8064" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_db6874f0-1045-4072-a343-23be7c3e1227" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dc31e046-7401-45da-95d8-8bf84b71b756" xlink:to="loc_us-gaap_EmployeeStockOptionMember_db6874f0-1045-4072-a343-23be7c3e1227" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_77b51425-b163-4ad9-91df-947d7148c498" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dc31e046-7401-45da-95d8-8bf84b71b756" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_77b51425-b163-4ad9-91df-947d7148c498" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember_619c4577-ae67-401b-8ecf-905ee00a44d5" xlink:href="exdx-20231231.xsd#exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dc31e046-7401-45da-95d8-8bf84b71b756" xlink:to="loc_exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember_619c4577-ae67-401b-8ecf-905ee00a44d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_ec775fe3-c450-4254-a15d-c57bba8e8ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dc31e046-7401-45da-95d8-8bf84b71b756" xlink:to="loc_us-gaap_EmployeeStockMember_ec775fe3-c450-4254-a15d-c57bba8e8ba9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8392c50a-2107-4a7f-b2ab-80acd59a3ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a05dc3e-b331-4232-92ef-c831e2f39abc" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8392c50a-2107-4a7f-b2ab-80acd59a3ad5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_fa3962bb-ab42-43e6-b9a9-ff2e7f972140" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_7b3d3602-aad1-46d7-ab68-1eb46cc3dd44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_fa3962bb-ab42-43e6-b9a9-ff2e7f972140" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_7b3d3602-aad1-46d7-ab68-1eb46cc3dd44" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_38781b52-05ba-4e75-96af-8f8751cb4730" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_7b3d3602-aad1-46d7-ab68-1eb46cc3dd44" xlink:to="loc_us-gaap_TaxPeriodAxis_38781b52-05ba-4e75-96af-8f8751cb4730" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_38781b52-05ba-4e75-96af-8f8751cb4730_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_38781b52-05ba-4e75-96af-8f8751cb4730" xlink:to="loc_us-gaap_TaxPeriodDomain_38781b52-05ba-4e75-96af-8f8751cb4730_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_1dbd121b-c84d-4659-903b-6c96e8e06521" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_38781b52-05ba-4e75-96af-8f8751cb4730" xlink:to="loc_us-gaap_TaxPeriodDomain_1dbd121b-c84d-4659-903b-6c96e8e06521" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TaxYearsThroughDecember312017Member_e277c6e4-a375-4cf2-895f-80e07cc8ce54" xlink:href="exdx-20231231.xsd#exdx_TaxYearsThroughDecember312017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_1dbd121b-c84d-4659-903b-6c96e8e06521" xlink:to="loc_exdx_TaxYearsThroughDecember312017Member_e277c6e4-a375-4cf2-895f-80e07cc8ce54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_1159b48b-bb78-448c-aae2-0793faaddd09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_fa3962bb-ab42-43e6-b9a9-ff2e7f972140" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_1159b48b-bb78-448c-aae2-0793faaddd09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_d8117ca1-22d6-4bda-bab9-8f77b264fd90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_fa3962bb-ab42-43e6-b9a9-ff2e7f972140" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_d8117ca1-22d6-4bda-bab9-8f77b264fd90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_14a2aaa7-37e9-4546-8da3-1951d78fd013" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_fa3962bb-ab42-43e6-b9a9-ff2e7f972140" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_14a2aaa7-37e9-4546-8da3-1951d78fd013" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_56259d70-f246-4e06-ba65-1934c55442ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_fa3962bb-ab42-43e6-b9a9-ff2e7f972140" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_56259d70-f246-4e06-ba65-1934c55442ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_a47a8c64-8e6e-4537-be12-caef670a1660" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_fa3962bb-ab42-43e6-b9a9-ff2e7f972140" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_a47a8c64-8e6e-4537-be12-caef670a1660" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>exdx-20231231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:6a8da8f2-df0f-4e69-99e5-93009f0ad924,g:882e5611-3f00-4664-b088-e8c5528fafa2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_c4761b38-5eb2-44db-9ae9-17dff1c65f64_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_7a551970-b6b9-4e6e-aea4-e06aaff3b76d_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_3c932e9b-b39b-4da4-80b1-d35b70fd47db_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6f3f0330-34b1-4dcb-8dfd-6841eb088e52_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_ced8f4e9-638f-4cae-a2cd-0e0226436b2b_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_1522d849-e08e-43e9-ae11-4c469aa7147e_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_0c252679-d2b1-4131-96d1-931feed3db48_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_10867c1e-afd3-4d57-b446-1a53589667e4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d1f686e4-729b-4612-8aba-6aedf8d95eac_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1b2e3a4c-031d-4ff5-b13c-e782a2cd26ef_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options, expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_0065ab66-bcca-4c15-9ce2-fcde2bc516ad_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued royalties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_367d410b-a923-477f-9033-d83d85c8b0d5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_InnovatusLifeSciencesLendingFundMember_d3c0d811-61e0-4828-834a-13ba6c6369c0_terseLabel_en-US" xlink:label="lab_exdx_InnovatusLifeSciencesLendingFundMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Innovatus Life Sciences Lending Fund</link:label>
    <link:label id="lab_exdx_InnovatusLifeSciencesLendingFundMember_label_en-US" xlink:label="lab_exdx_InnovatusLifeSciencesLendingFundMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Innovatus Life Sciences Lending Fund [Member]</link:label>
    <link:label id="lab_exdx_InnovatusLifeSciencesLendingFundMember_documentation_en-US" xlink:label="lab_exdx_InnovatusLifeSciencesLendingFundMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Innovatus Life Sciences Lending Fund</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_InnovatusLifeSciencesLendingFundMember" xlink:href="exdx-20231231.xsd#exdx_InnovatusLifeSciencesLendingFundMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_InnovatusLifeSciencesLendingFundMember" xlink:to="lab_exdx_InnovatusLifeSciencesLendingFundMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8a42b99c-9e2b-4b35-b5c8-95553c235760_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a6cb2db2-6425-4b38-9da1-36374b934f52_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_9651014b-af7f-4870-8610-522199702df8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_RentalPropertyByTypeAxis_a7e6880d-5c0f-4d82-b27f-3c4c2b269e76_terseLabel_en-US" xlink:label="lab_exdx_RentalPropertyByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rental Property, by Type [Axis]</link:label>
    <link:label id="lab_exdx_RentalPropertyByTypeAxis_label_en-US" xlink:label="lab_exdx_RentalPropertyByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rental Property, by Type [Axis]</link:label>
    <link:label id="lab_exdx_RentalPropertyByTypeAxis_documentation_en-US" xlink:label="lab_exdx_RentalPropertyByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rental Property, by Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeAxis" xlink:href="exdx-20231231.xsd#exdx_RentalPropertyByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_RentalPropertyByTypeAxis" xlink:to="lab_exdx_RentalPropertyByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_05c4d8f8-e19b-4bb2-9a68-38b70ff0052c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_ba69660a-d8bd-42c5-beaa-009ef778dcfa_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentNumberOfMonthlyInstallments_8b08fafa-76a1-4958-bb55-4ef2718297b0_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentNumberOfMonthlyInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of monthly installments</link:label>
    <link:label id="lab_exdx_DebtInstrumentNumberOfMonthlyInstallments_label_en-US" xlink:label="lab_exdx_DebtInstrumentNumberOfMonthlyInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number Of Monthly Installments</link:label>
    <link:label id="lab_exdx_DebtInstrumentNumberOfMonthlyInstallments_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentNumberOfMonthlyInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number Of Monthly Installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentNumberOfMonthlyInstallments" xlink:href="exdx-20231231.xsd#exdx_DebtInstrumentNumberOfMonthlyInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentNumberOfMonthlyInstallments" xlink:to="lab_exdx_DebtInstrumentNumberOfMonthlyInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_a9dee507-7f08-48e5-928a-573f384b680d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_311497fa-0185-471f-8167-3ff8a54eb3e9_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_7d6165ab-992e-41e5-acae-3727a7a5cc93_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Federal statutory tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_4a39d247-275c-4527-8f33-f0a70c9f54e1_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_2fd54c8e-c9ba-4c49-ad6e-70cc5375da7a_negatedLabel_en-US" xlink:label="lab_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Basis differences in fixed and intangible assets</link:label>
    <link:label id="lab_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_label_en-US" xlink:label="lab_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Fixed Assets And Intangible Assets</link:label>
    <link:label id="lab_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_documentation_en-US" xlink:label="lab_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Fixed Assets And Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" xlink:href="exdx-20231231.xsd#exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" xlink:to="lab_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b0342183-1021-4bf3-883a-e630eb263835_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_ef52ed57-5cac-4271-8a00-69916607cd20_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplier [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_be2f2b2d-0074-46fa-bf53-ec9903f2574f_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_c265bd29-637b-4c6d-b5f2-1808dd2538de_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_f6b0cdca-69d3-4e13-bc9b-4730c288dec5_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2b448737-5096-4ace-a9ed-73da86d2de7f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_85ff2d31-669f-426a-88ad-4ca6225c46e2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_89acf74a-b016-4b64-96b4-c18969441b5c_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_de5e3ba1-5cc7-4b72-8ff0-52d9911fc3d4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from common stock issued under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_c1716877-7a35-4ea0-8497-cfbd2901dc7b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_658f10d4-8b0a-476e-a1e6-489cbbc6fa8b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_RoyaltyObligationPercentageOfSales_49ed652c-33e7-416f-91cb-a4b3f77e3d26_terseLabel_en-US" xlink:label="lab_exdx_RoyaltyObligationPercentageOfSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty obligation, percent of net sales</link:label>
    <link:label id="lab_exdx_RoyaltyObligationPercentageOfSales_label_en-US" xlink:label="lab_exdx_RoyaltyObligationPercentageOfSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Obligation, Percentage of Sales</link:label>
    <link:label id="lab_exdx_RoyaltyObligationPercentageOfSales_documentation_en-US" xlink:label="lab_exdx_RoyaltyObligationPercentageOfSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Obligation, Percentage of Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RoyaltyObligationPercentageOfSales" xlink:href="exdx-20231231.xsd#exdx_RoyaltyObligationPercentageOfSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_RoyaltyObligationPercentageOfSales" xlink:to="lab_exdx_RoyaltyObligationPercentageOfSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_ddef18ce-c092-4c49-b86e-32226341f62b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_d9e2b4f8-95a9-41e3-ae1b-cb8b237ade50_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_c0f02609-7684-442b-8f64-699bddc72229_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_603ac1a2-9389-4b1f-a15f-6b8c4c21bac9_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_c8b1c31c-becf-4b03-b224-2f494def4602_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_35861feb-3dec-4775-b062-64a84ece6320_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_3c020f43-1f5d-4cb3-81c7-915c288f8156_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_a43e3648-abf2-450e-8d27-a7c546e2942d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.001 par value per share; 10,000,000 shares authorized, no shares issued or outstanding at December 31, 2023 and December 31, 2022</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_81eade27-10d0-45de-80ad-2ce32aa7af62_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_72d94bba-ec5e-4c0d-9029-7cf944a25553_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_f2910c7d-e6ab-4c25-83f6-1ef3f95c13ad_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-lived assets impairment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_f0b3fa79-20e1-4d5d-83e4-2ec0a8433ef6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_be73746e-2c2a-4d07-bcd9-60bd05355f94_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_3c993564-0a2a-4c5d-8f9b-b79789ef5f1d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_fc508c48-357e-4df2-8872-4d3d21d081a4_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Refund liability</link:label>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Refund Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRefundLiabilityCurrent" xlink:to="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_ec05ba1d-5aac-4804-9881-1b1b0de95ec5_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_8970e9c9-d77f-448e-bfd2-73f60a16a05d_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of non-cash items:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_e1296175-7c18-4aef-a14f-37e84f8c6768_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_2775c73d-5864-4d08-9c73-f379554b9ebe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_497c73bd-2784-4352-9367-6c217a7a9b84_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f41b7f01-907e-4297-8e34-59cd0d880561_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_b61b4cb1-eaf5-40c7-9017-ff9535be7bc8_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d799ef0b-85a6-4415-892c-fad3c72b4d81_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_66f1aa11-5e15-41ae-9a5c-0e515618dacf_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_15a77716-5d41-4ee8-97ab-1b360d7a73e8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d5c9299d-dac6-42f9-89ea-9bee2995d7ba_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee options, weighted-average grant date fair value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_1ae69f5e-2849-4f3e-ab0b-d6b9ad21aeda_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_9fa05a46-4639-48ec-868f-d20b49a8cfb0_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_95b31903-795f-4d37-b99e-b4a66e22b19f_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_73fc0d79-11b7-43a2-8d0d-5bff2a84293c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentInKindPIKNoteMember_f226ce4a-7c3c-4ebf-8722-f2ff5c7c1e51_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentInKindPIKNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Paid in-kind note</link:label>
    <link:label id="lab_us-gaap_PaymentInKindPIKNoteMember_label_en-US" xlink:label="lab_us-gaap_PaymentInKindPIKNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment in Kind (PIK) Note [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentInKindPIKNoteMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentInKindPIKNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentInKindPIKNoteMember" xlink:to="lab_us-gaap_PaymentInKindPIKNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_b36522a0-7ef9-4f48-aa6a-740e97b3a061_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a930aa14-d368-4a46-99a2-9de89995e443_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update and change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_543cd67a-aedc-4e33-85a4-3668a6924971_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent_149d3823-d5b6-445f-a437-30f842203d31_terseLabel_en-US" xlink:label="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued purchases of goods and services</link:label>
    <link:label id="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent_label_en-US" xlink:label="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Purchase, Goods and Services, Current</link:label>
    <link:label id="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent_documentation_en-US" xlink:label="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Purchase, Goods and Services, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:href="exdx-20231231.xsd#exdx_AccruedPurchaseGoodsAndServicesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:to="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_146418ca-27c8-45fe-b5f5-b02007c87770_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_0561faf6-d3f6-49b7-998d-914ca3d7feaf_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_5ac1b95c-dc8d-4968-8c1f-f031b9f76133_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_b6e59786-a0b7-4187-8670-518abbc03837_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ef9629d3-c1dd-4304-9d46-8d2bfd2ff912_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_14dcdf86-d21d-4297-930e-60871291f96d_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_4b184f3a-33c5-4f7f-a716-6b8fcda3d182_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_3e57cca7-2fb5-415b-8e19-fc9aa0c395a2_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common shares available for future issuance under ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_870461c8-4b30-438b-84c0-fcb99194d5b0_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_0b176a48-7400-47f9-8a49-f8f058486aa8_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e934f646-9317-4c2a-bfa5-b6791564c332_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_17b8f13e-3882-433b-91c6-544670baef91_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_RentalPropertyByTypeDomain_3c598dd4-6131-4317-bd12-4c1c1a87a24d_terseLabel_en-US" xlink:label="lab_exdx_RentalPropertyByTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rental Property, by Type [Domain]</link:label>
    <link:label id="lab_exdx_RentalPropertyByTypeDomain_label_en-US" xlink:label="lab_exdx_RentalPropertyByTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rental Property, by Type [Domain]</link:label>
    <link:label id="lab_exdx_RentalPropertyByTypeDomain_documentation_en-US" xlink:label="lab_exdx_RentalPropertyByTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rental Property, by Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeDomain" xlink:href="exdx-20231231.xsd#exdx_RentalPropertyByTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_RentalPropertyByTypeDomain" xlink:to="lab_exdx_RentalPropertyByTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_da63656b-e9a2-41b3-ab65-df3223e9cfdd_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable and Allowance for Credit Losses</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_bc187684-a895-4fd8-b277-d8fcb87d5558_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0061ac6b-3509-450d-a81f-1524188cb539_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options, vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentPaidInKindLoansIssued_b649718d-3436-42f1-a0b4-94d3dccef09b_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan, paid in-kind loans issued</link:label>
    <link:label id="lab_exdx_DebtInstrumentPaidInKindLoansIssued_label_en-US" xlink:label="lab_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Paid In Kind Loans Issued</link:label>
    <link:label id="lab_exdx_DebtInstrumentPaidInKindLoansIssued_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Paid In Kind Loans Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:href="exdx-20231231.xsd#exdx_DebtInstrumentPaidInKindLoansIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:to="lab_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_2887246e-5679-4a0a-a98f-bceecff73e51_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_175a7b92-33c8-43e3-91cc-604b791ed96a_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Common Stock Reserved For Future Issuance</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_91c25596-7515-4898-bd08-864a1395988c_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationSep72024Member_317aaddb-8873-4867-a1e8-6e718ad7d1f0_terseLabel_en-US" xlink:label="lab_exdx_ExpirationSep72024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant expiration September 7, 2024</link:label>
    <link:label id="lab_exdx_ExpirationSep72024Member_label_en-US" xlink:label="lab_exdx_ExpirationSep72024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expiration Sep 7, 2024 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationSep72024Member_documentation_en-US" xlink:label="lab_exdx_ExpirationSep72024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expiration Sep 7, 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationSep72024Member" xlink:href="exdx-20231231.xsd#exdx_ExpirationSep72024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationSep72024Member" xlink:to="lab_exdx_ExpirationSep72024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermNotesPayable_0a576146-9924-48e0-a2e5-1a6b81e91ba0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes payable noncurrent</link:label>
    <link:label id="lab_us-gaap_LongTermNotesPayable_label_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable" xlink:to="lab_us-gaap_LongTermNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_09fdc0f9-6cd3-491c-bdce-1d0195d12954_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f882007a-0b75-4536-96fe-6fb8dbefe48d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number&#160;of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_6bde4fe1-5119-4fcc-88f8-921a4d3a138b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_d4a817b2-1e18-4ad3-91cd-2ed27a76e1c8_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2538b833-e7b1-483e-96a1-7140770b96f7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_ac200d76-425d-43ee-a70f-d752dad661df_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_1d2dcd65-f5c7-4d6c-bdc2-1869ae44e8c4_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_TaxYearsThroughDecember312017Member_8773cfbf-4ca8-423b-a294-fb7cb6302794_terseLabel_en-US" xlink:label="lab_exdx_TaxYearsThroughDecember312017Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Years Through December 31, 2017</link:label>
    <link:label id="lab_exdx_TaxYearsThroughDecember312017Member_label_en-US" xlink:label="lab_exdx_TaxYearsThroughDecember312017Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Years Through December 31, 2017 [Member]</link:label>
    <link:label id="lab_exdx_TaxYearsThroughDecember312017Member_documentation_en-US" xlink:label="lab_exdx_TaxYearsThroughDecember312017Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Years Through December 31, 2017</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TaxYearsThroughDecember312017Member" xlink:href="exdx-20231231.xsd#exdx_TaxYearsThroughDecember312017Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_TaxYearsThroughDecember312017Member" xlink:to="lab_exdx_TaxYearsThroughDecember312017Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_b6080824-df5a-4ed1-bba3-fcb4f68892dc_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_080c8827-101c-437c-a6b2-dcb92f9c2daa_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_224ee1e1-c61b-412f-a76d-1526e6b54166_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_8a37549c-4d12-4a22-9032-b4ad6362456f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_068bbcad-cc58-46e7-8262-2a2a74f889f7_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, exercise price of warrants or rights (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_070d3b18-edc9-46ce-9fc1-1f0142c81f1d_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_ae1769cb-f90a-49d4-a5eb-5aa6c5b5cb74_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certificate of deposit, included in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OfficeMember_6d24e60c-7e86-494d-a1a2-3959a3c77ad5_terseLabel_en-US" xlink:label="lab_exdx_OfficeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office</link:label>
    <link:label id="lab_exdx_OfficeMember_label_en-US" xlink:label="lab_exdx_OfficeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office [Member]</link:label>
    <link:label id="lab_exdx_OfficeMember_documentation_en-US" xlink:label="lab_exdx_OfficeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Office</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeMember" xlink:href="exdx-20231231.xsd#exdx_OfficeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OfficeMember" xlink:to="lab_exdx_OfficeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_ea8917f1-9b05-4cdb-bb72-01575e03d2b4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest_04cb38af-a909-47c0-ae02-66b57ef7ffb7_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for credit loss</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest" xlink:to="lab_us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_516717e3-955b-4079-97b3-4460f30bfbf4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_4a576bfa-072c-41f1-91bd-9286412d6684_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationMar312026Member_8c3d77ca-cf8b-4479-bcd7-1dde189a5af7_terseLabel_en-US" xlink:label="lab_exdx_ExpirationMar312026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant expiration March 31, 2026</link:label>
    <link:label id="lab_exdx_ExpirationMar312026Member_label_en-US" xlink:label="lab_exdx_ExpirationMar312026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expiration Mar 31, 2026 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationMar312026Member_documentation_en-US" xlink:label="lab_exdx_ExpirationMar312026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expiration Mar 31, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationMar312026Member" xlink:href="exdx-20231231.xsd#exdx_ExpirationMar312026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationMar312026Member" xlink:to="lab_exdx_ExpirationMar312026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_dc35178e-f5b5-4bd6-aafc-f48972df6010_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_b29f037c-793a-4821-84b0-e7c041acbe74_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_10d981ab-a6b7-4514-81bd-a793b018d3b8_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_85823f1c-f602-44c7-8b8c-78090b8927bc_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_a7b7bdd3-1628-46b8-922e-444416c903e7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_52eb95e4-5f2f-4d23-90c8-2da819480071_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants to purchase common stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0cea6b11-b976-44f5-8393-95aa9e0494e5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_ac0e9a4d-9a1a-4706-83ed-8764cfa1c502_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Lease obligations, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_0d9c8bf9-1639-4323-8dcc-5d0ff9747fbb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_22ae42d2-dcab-4aa9-ae23-74dd453d0458_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_c27afa6b-8875-44b4-84c5-a9d87db2289e_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock reserved for issuance upon vesting of outstanding restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_ca7bcca5-9023-4013-95d6-d1b7812b231a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_8a07a7f1-bfef-4c4d-b08c-740675bea1c4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_MedicareMember_7a44d877-e464-4e9e-a51e-e90a83bb8c54_terseLabel_en-US" xlink:label="lab_exdx_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_exdx_MedicareMember_label_en-US" xlink:label="lab_exdx_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_exdx_MedicareMember_documentation_en-US" xlink:label="lab_exdx_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medicare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareMember" xlink:href="exdx-20231231.xsd#exdx_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_MedicareMember" xlink:to="lab_exdx_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_9210daa0-4297-4dd6-87a6-294a94e48b12_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_01b45fd3-39a6-4db4-9806-aec4a6e7745e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research and development tax credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6c524895-7bb1-44b7-8961-88574c28be1f_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_599a5d33-73a1-4512-b4a4-b9728e38e0b7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unamortized debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_e8f31835-681e-43f1-833f-f17ef4b25cb3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Lessee, Operating Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ClinicalStudyPolicyPolicyTextBlock_75f670ae-3f81-407a-a1a1-82224c23c037_terseLabel_en-US" xlink:label="lab_exdx_ClinicalStudyPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical Studies</link:label>
    <link:label id="lab_exdx_ClinicalStudyPolicyPolicyTextBlock_label_en-US" xlink:label="lab_exdx_ClinicalStudyPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Study, Policy [Policy Text Block]</link:label>
    <link:label id="lab_exdx_ClinicalStudyPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_exdx_ClinicalStudyPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Study, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClinicalStudyPolicyPolicyTextBlock" xlink:href="exdx-20231231.xsd#exdx_ClinicalStudyPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ClinicalStudyPolicyPolicyTextBlock" xlink:to="lab_exdx_ClinicalStudyPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationDec72025Member_63a99432-c628-4c79-8d32-85ba2cfe9b2a_terseLabel_en-US" xlink:label="lab_exdx_ExpirationDec72025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant expiration December 7, 2025</link:label>
    <link:label id="lab_exdx_ExpirationDec72025Member_label_en-US" xlink:label="lab_exdx_ExpirationDec72025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expiration Dec 7, 2025 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationDec72025Member_documentation_en-US" xlink:label="lab_exdx_ExpirationDec72025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expiration Dec 7, 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationDec72025Member" xlink:href="exdx-20231231.xsd#exdx_ExpirationDec72025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationDec72025Member" xlink:to="lab_exdx_ExpirationDec72025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_d5c680ee-8129-4bd1-ada4-759741c7109f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_WeightedAverageRemainingLeaseTermAbstract_2f2402a8-3f7c-4427-aba2-ed22f13e796d_terseLabel_en-US" xlink:label="lab_exdx_WeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining lease term (years)</link:label>
    <link:label id="lab_exdx_WeightedAverageRemainingLeaseTermAbstract_label_en-US" xlink:label="lab_exdx_WeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted-Average Remaining Lease Term [Abstract]</link:label>
    <link:label id="lab_exdx_WeightedAverageRemainingLeaseTermAbstract_documentation_en-US" xlink:label="lab_exdx_WeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted-Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_WeightedAverageRemainingLeaseTermAbstract" xlink:href="exdx-20231231.xsd#exdx_WeightedAverageRemainingLeaseTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_WeightedAverageRemainingLeaseTermAbstract" xlink:to="lab_exdx_WeightedAverageRemainingLeaseTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_24adf594-736e-44dc-9def-0b575a3594c3_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shipping and Handling Costs</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_7fcd45dc-c17c-4870-a228-b98a1f9ee30e_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_d92a2391-f777-441d-a733-497a86ca3adc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_6e1916d0-0b7f-45d9-846d-0119fa2625fa_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Lease Costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_aae4b2f8-b6c7-434d-823f-8facf2fd9d37_negatedLabel_en-US" xlink:label="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_label_en-US" xlink:label="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Current Other Assets</link:label>
    <link:label id="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_documentation_en-US" xlink:label="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Current Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:href="exdx-20231231.xsd#exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:to="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_4ab92004-13b0-453a-bbc1-502d2ca743d7_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_8e4c2337-e9a3-4f16-a550-e70905528bf0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_e57a1495-33c6-4fad-971d-8077457e49c5_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_c3a4e50a-53c1-4eed-ac05-d53384501245_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_948974a5-c278-4292-a146-f5362401fc96_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anti-dilutive securities excluded from computation (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c50b3d83-1f8a-400c-b498-14130612278d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_ffd56dea-203c-4201-9785-2ff4c9dc5007_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_199bc0dd-4ae1-4ef7-bd9a-70184a99003f_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_6fb880be-b599-4485-b19d-0da5811db07c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost related to stock purchase</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8ccdbf39-fa62-422b-b343-ed03054a7e60_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs incurred, but not paid, in connection with capital expenditures</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3f9b8970-1baf-41a4-a240-153e1c80e31b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_0ade33a8-dc87-467b-be05-98356030414d_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_76ea86b2-bd2e-4248-93b7-9163a24475ca_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3a49304f-235e-484b-a6ee-66e44c6c4d79_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_1b99686b-eda2-433a-ab86-a45bcfd355e2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_a77408f7-d5d8-4ce9-a56e-ff4432838fa9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_967012e5-a330-42db-aa2d-f1c65a58cdd4_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_3f6565e4-22a0-4679-af13-e5552cbbda77_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_b69c7f2d-7520-4148-8d70-6388e9316840_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_5a101195-fbab-4c6b-8178-65b8ba4bba41_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Arrangement, Restricted Stock Unit, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_89a525f3-06ef-48a4-a53d-98ee4593a3be_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_fb4a7440-8adc-4718-a906-5975c161ec12_negatedLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_0018208d-2b1d-4dee-87c7-41f75c11db42_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_24ba8a92-22f6-4f74-a539-1cf762f91045_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest on finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f8fd6ee0-308f-488b-a9c7-40592907beb9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of stock under Employee Stock Purchase Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_SaleOfStockRemainingAuthorizedAmount_021e5e2c-f343-4469-ad68-6432f84f7dd2_terseLabel_en-US" xlink:label="lab_exdx_SaleOfStockRemainingAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock offering, remaining authorized amount</link:label>
    <link:label id="lab_exdx_SaleOfStockRemainingAuthorizedAmount_label_en-US" xlink:label="lab_exdx_SaleOfStockRemainingAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Remaining Authorized Amount</link:label>
    <link:label id="lab_exdx_SaleOfStockRemainingAuthorizedAmount_documentation_en-US" xlink:label="lab_exdx_SaleOfStockRemainingAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Remaining Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_SaleOfStockRemainingAuthorizedAmount" xlink:href="exdx-20231231.xsd#exdx_SaleOfStockRemainingAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_SaleOfStockRemainingAuthorizedAmount" xlink:to="lab_exdx_SaleOfStockRemainingAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_b1b730ae-2417-45b4-bc1a-db01b0198a5b_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_13818a89-0660-4bf4-89a0-ae43e8c30248_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0d4fad67-8b45-4d89-a225-b22241913fea_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant_3c2f6029-5c7b-4934-b1fd-054f61923e2f_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, minimum cash balance</link:label>
    <link:label id="lab_exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant_label_en-US" xlink:label="lab_exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Minimum Cash Balance Required, Not Required To Comply With Covenant</link:label>
    <link:label id="lab_exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Minimum Cash Balance Required, Not Required To Comply With Covenant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant" xlink:href="exdx-20231231.xsd#exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant" xlink:to="lab_exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_90088bab-c813-4d44-bb70-26bd4328240a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a22cccf9-add3-45c6-a187-c8a40f28061b_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements and Recently Adopted Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_d612a8d7-cb5d-47dd-b021-69bd72b6a13b_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_31e286c4-7836-417e-a4a4-c74146359092_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c3bb2a5c-e6ff-4c8b-a0ce-b70bf24dfe1d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c3fd6dfa-ced0-4fb0-92bd-f3dcfd625e5b_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_bd1a1189-9b5e-472a-9264-3f1e11f0d60c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_d41ead3d-c8e1-4e72-9804-a786b4afb3b0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_bc8babd0-2900-4a91-afdd-6a091269a850_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_0be530d4-90a5-467d-a500-1fbd419c7f20_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loan payable</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_PrometheusLaboratoriesIncMember_2c4a8a37-85f8-42c9-bab5-81bc60129a1a_terseLabel_en-US" xlink:label="lab_exdx_PrometheusLaboratoriesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prometheus Laboratories</link:label>
    <link:label id="lab_exdx_PrometheusLaboratoriesIncMember_label_en-US" xlink:label="lab_exdx_PrometheusLaboratoriesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prometheus Laboratories, Inc. [Member]</link:label>
    <link:label id="lab_exdx_PrometheusLaboratoriesIncMember_documentation_en-US" xlink:label="lab_exdx_PrometheusLaboratoriesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prometheus Laboratories, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrometheusLaboratoriesIncMember" xlink:href="exdx-20231231.xsd#exdx_PrometheusLaboratoriesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_PrometheusLaboratoriesIncMember" xlink:to="lab_exdx_PrometheusLaboratoriesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_5008f793-edc6-4181-ae55-dc2e9f0be49d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_9788b208-b652-4289-be62-4b9fc4dbc896_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_317bd602-bddf-432b-ba09-213d2787271e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b92864aa-401d-4b0c-b112-7ad4b10a82f9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of stock from vested restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d0a411e5-b5c6-4a24-9006-6bff1d9b3aa6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Awards released (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_bc87211b-f140-4f13-9e06-32e5d6a48fb9_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_SaleOfStockAuthorizedAmount_46f030ed-9f77-4d70-80fe-54eef4b4927c_terseLabel_en-US" xlink:label="lab_exdx_SaleOfStockAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock offering, authorized amount</link:label>
    <link:label id="lab_exdx_SaleOfStockAuthorizedAmount_label_en-US" xlink:label="lab_exdx_SaleOfStockAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Authorized Amount</link:label>
    <link:label id="lab_exdx_SaleOfStockAuthorizedAmount_documentation_en-US" xlink:label="lab_exdx_SaleOfStockAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_SaleOfStockAuthorizedAmount" xlink:href="exdx-20231231.xsd#exdx_SaleOfStockAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_SaleOfStockAuthorizedAmount" xlink:to="lab_exdx_SaleOfStockAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_07387aa2-40ba-4085-a61e-d89b7a8a6e82_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_262e52ae-738c-4421-81d7-af0b06b31a8b_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total borrowings, net of discounts and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_7f2f59a0-a57c-4502-a6d1-eaebda155fe8_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total borrowings, net of discounts and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_26a8301a-5057-4159-a094-2f7422c0beaa_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration received on transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_ff4df6a2-f11a-4cd3-8861-b99e3c779ad3_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_IncentiveAwardPlan2019Member_6609766e-1a1e-48aa-9064-75a42fde9b95_terseLabel_en-US" xlink:label="lab_exdx_IncentiveAwardPlan2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019 Incentive Award Plan</link:label>
    <link:label id="lab_exdx_IncentiveAwardPlan2019Member_label_en-US" xlink:label="lab_exdx_IncentiveAwardPlan2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incentive Award Plan, 2019 [Member]</link:label>
    <link:label id="lab_exdx_IncentiveAwardPlan2019Member_documentation_en-US" xlink:label="lab_exdx_IncentiveAwardPlan2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Incentive Award Plan, 2019</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncentiveAwardPlan2019Member" xlink:href="exdx-20231231.xsd#exdx_IncentiveAwardPlan2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_IncentiveAwardPlan2019Member" xlink:to="lab_exdx_IncentiveAwardPlan2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_f302e2d7-313c-4c4c-9d91-820575ba5265_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_ca2fd190-2118-4b34-b3cf-2b5e0171bca2_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock option grants issued and outstanding</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b61fd832-f0c5-4e91-97b2-487d1532f82b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options, cost not yet recognized, remaining weighted average vesting period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_93b337ea-32be-4e66-9f96-b35c987a9f15_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_LongTermDebtUndiscountedInterestAmount_cf117bc2-8bfc-40e5-ae79-60d95e89df61_negatedTerseLabel_en-US" xlink:label="lab_exdx_LongTermDebtUndiscountedInterestAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_exdx_LongTermDebtUndiscountedInterestAmount_label_en-US" xlink:label="lab_exdx_LongTermDebtUndiscountedInterestAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Undiscounted Interest Amount</link:label>
    <link:label id="lab_exdx_LongTermDebtUndiscountedInterestAmount_documentation_en-US" xlink:label="lab_exdx_LongTermDebtUndiscountedInterestAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-term Debt, Undiscounted Interest Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtUndiscountedInterestAmount" xlink:href="exdx-20231231.xsd#exdx_LongTermDebtUndiscountedInterestAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_LongTermDebtUndiscountedInterestAmount" xlink:to="lab_exdx_LongTermDebtUndiscountedInterestAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_4602256f-df68-45a1-98a9-f8e0468cad77_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3828a3d4-3bb1-4f0e-869e-ac3796bdb720_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options, unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ee65d02e-36fd-4572-9f0d-31e15a180d27_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_e172f743-7e5e-4492-bd81-cf3a9d2add38_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant date fair value of RSUs vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_USDepartmentOfJusticeCaseMember_1786df35-e3ac-40f3-a27d-8a8eac573b82_terseLabel_en-US" xlink:label="lab_exdx_USDepartmentOfJusticeCaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Department Of Justice Case</link:label>
    <link:label id="lab_exdx_USDepartmentOfJusticeCaseMember_label_en-US" xlink:label="lab_exdx_USDepartmentOfJusticeCaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">U.S. Department Of Justice Case [Member]</link:label>
    <link:label id="lab_exdx_USDepartmentOfJusticeCaseMember_documentation_en-US" xlink:label="lab_exdx_USDepartmentOfJusticeCaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">U.S. Department Of Justice Case</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_USDepartmentOfJusticeCaseMember" xlink:href="exdx-20231231.xsd#exdx_USDepartmentOfJusticeCaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_USDepartmentOfJusticeCaseMember" xlink:to="lab_exdx_USDepartmentOfJusticeCaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_8d9ca929-bdf0-4c1a-a827-e8c0023729cb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_0992554c-c1d1-4bf5-8208-7e5b202a7d03_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal tax loss carryforwards, subject to expiration</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_858cfba9-6dca-4dc7-aaa4-5459cb1f5c2a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract_439eb803-c9c3-4d14-97d6-ef751a9d9a85_terseLabel_en-US" xlink:label="lab_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract_label_en-US" xlink:label="lab_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow Information, Operating and Finance Lease Payments [Abstract]</link:label>
    <link:label id="lab_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract_documentation_en-US" xlink:label="lab_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Flow Information, Operating and Finance Lease Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract" xlink:href="exdx-20231231.xsd#exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract" xlink:to="lab_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_15f41bdb-b88e-4031-a90f-8f5768e1fcd4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind_035a0693-a4f6-4f5c-a71d-9b4e7d326194_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan, paid in-kind, interest rate</link:label>
    <link:label id="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind_label_en-US" xlink:label="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Stated Interest Rate, Paid In-Kind</link:label>
    <link:label id="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Stated Interest Rate, Paid In-Kind</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:href="exdx-20231231.xsd#exdx_DebtInstrumentStatedInterestRatePaidInKind"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:to="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_412621c6-1c7a-4ba4-9c3c-833939260a1b_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Option Plan</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_3f09aa90-03b6-48be-990c-00734eba5aae_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_e127978a-48ce-4a44-ba34-8a7ed5370a11_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares_a48608b8-d105-472a-b4e3-058b55313b7d_terseLabel_en-US" xlink:label="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of stock from vested restricted stock units and payment of employees' taxes (in shares)</link:label>
    <link:label id="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares_label_en-US" xlink:label="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance Of Stock From Vested Restricted Stock Units And Payment Of Employees Taxes, Shares</link:label>
    <link:label id="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares_documentation_en-US" xlink:label="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issuance Of Stock From Vested Restricted Stock Units And Payment Of Employees Taxes, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares" xlink:href="exdx-20231231.xsd#exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares" xlink:to="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_d8e59ebe-0a83-4c47-a53c-b57aee533d1e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_46fbb0a5-4f88-4266-a9f2-387fa158a743_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Exercise&#160;Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_28db7e14-de20-4a44-bfb7-9718d0ae35c8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_931bc521-223a-4996-973a-7eafd39c597f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum Employee payroll deduction percentage</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_e2398348-3ab5-4b57-b176-5fc4ea13fb0d_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_bccd2834-88df-4b1d-b3de-2d04b6268d0b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_b41f9191-8cc6-4028-a313-8419efde30d8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_4694c372-9958-4e3a-a00c-0c3a2ef46b38_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_774676b8-e74f-47ed-9348-f1f44f7619fa_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCustomerMember_77f3ce04-5c8b-4f7f-a91f-b031da25eed4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherCustomerMember_label_en-US" xlink:label="lab_us-gaap_OtherCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Customer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCustomerMember" xlink:to="lab_us-gaap_OtherCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_b5023514-6113-4bae-9c2c-21db439bd4b9_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4e2cdadd-cfb7-4f4b-a918-e58b19b55f2e_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_78e4efb1-08d2-43cf-b37b-70bd9395eca4_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsGross" xlink:to="lab_us-gaap_LeaseholdImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_4a3896ca-d701-4450-8cfb-602f6617c7c9_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_344d4b59-e667-4a31-b618-fbc760f9ac32_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, fair value disclosure</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_PrepaidMaintenanceAndInsuranceContracts_f64d2287-8a8a-4725-8296-83d1930c63c4_terseLabel_en-US" xlink:label="lab_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid maintenance and insurance contracts</link:label>
    <link:label id="lab_exdx_PrepaidMaintenanceAndInsuranceContracts_label_en-US" xlink:label="lab_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Maintenance and Insurance Contracts</link:label>
    <link:label id="lab_exdx_PrepaidMaintenanceAndInsuranceContracts_documentation_en-US" xlink:label="lab_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid Maintenance and Insurance Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:href="exdx-20231231.xsd#exdx_PrepaidMaintenanceAndInsuranceContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:to="lab_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_b52d87c8-543b-4828-8ae5-774d83ad421d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease, term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Finance Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:to="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_9e2793f7-fd1e-4567-a3a8-f60fdd81b6eb_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3d831867-17bd-47a3-87bc-4178b884c39d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, fair value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9ca9e7bc-8144-4577-9ecb-3945330a7900_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_53857409-187b-455f-822c-b0500176f9d1_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_42ffc4cb-bd39-40ea-94ef-f6f17270d2ed_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diagnostic&#160;testing&#160;supplies</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_ef047321-77a5-457c-bd63-f3bbd5d18a35_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_9ba553db-689a-4e13-ae37-245789c44d81_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_59cc7efc-85ad-4c1f-9efb-9a5e9b40ef87_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_f1ebdb1d-870a-4d32-8674-417c55da0bf6_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_4723bba9-f697-4625-a71f-ee577d263411_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_b24a6d11-2e8d-4d40-82f5-bfc16ada106d_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_5df64ceb-6c20-4629-92f8-ac54bb6e5669_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_145c2313-47ec-4141-8f77-fa7d98b17049_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CollaborationAgreementCollaborationExpenses_3fa23a98-2fda-4b58-b38b-3a05b62bbe4a_terseLabel_en-US" xlink:label="lab_exdx_CollaborationAgreementCollaborationExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreement, collaboration expenses</link:label>
    <link:label id="lab_exdx_CollaborationAgreementCollaborationExpenses_label_en-US" xlink:label="lab_exdx_CollaborationAgreementCollaborationExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Collaboration Expenses</link:label>
    <link:label id="lab_exdx_CollaborationAgreementCollaborationExpenses_documentation_en-US" xlink:label="lab_exdx_CollaborationAgreementCollaborationExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Collaboration Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CollaborationAgreementCollaborationExpenses" xlink:href="exdx-20231231.xsd#exdx_CollaborationAgreementCollaborationExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CollaborationAgreementCollaborationExpenses" xlink:to="lab_exdx_CollaborationAgreementCollaborationExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_4319b74a-1d14-4885-b9ac-ea1fce82fbe7_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_d896e3c4-5d8c-4adc-9b86-46fe74a196d8_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising and Marketing Costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized_a79e6606-2c6e-4c06-8e93-5dc6ddb00832_terseLabel_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in number of shares authorized (in shares)</link:label>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized_label_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase (Decrease) In Number Of Shares Authorized</link:label>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized_documentation_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase (Decrease) In Number Of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized" xlink:href="exdx-20231231.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized" xlink:to="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_a021f31f-33d1-4201-826c-1cfc46cc82a2_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_c5b2e513-6dfe-43f5-a062-2b2cc884cef3_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OfficeAndLaboratoryMember_594c0e0b-c2bf-4f48-b316-e5797727f1d5_terseLabel_en-US" xlink:label="lab_exdx_OfficeAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office and Laboratory</link:label>
    <link:label id="lab_exdx_OfficeAndLaboratoryMember_label_en-US" xlink:label="lab_exdx_OfficeAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office and Laboratory [Member]</link:label>
    <link:label id="lab_exdx_OfficeAndLaboratoryMember_documentation_en-US" xlink:label="lab_exdx_OfficeAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Office and Laboratory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeAndLaboratoryMember" xlink:href="exdx-20231231.xsd#exdx_OfficeAndLaboratoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OfficeAndLaboratoryMember" xlink:to="lab_exdx_OfficeAndLaboratoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_46461f5a-857e-4e37-9dbc-4b6d6122afb8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_aa9fa8a5-73a3-49dc-8241-e6111e6b1186_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_4af4bd44-3ae0-416f-b6b2-3a6dda318ed2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_d8254d55-9bcd-4ab5-a3d3-6c1491ea82e8_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_77ebc18a-5f5d-4473-8eaa-e359c55607cf_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_5bc63689-bd50-473a-a995-e0f7634afcdd_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_d060e2e8-28bb-4958-abaa-c367328ec4da_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_8fac2f9b-21ef-4b1c-b486-7b41b07b4f54_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_73d0fe35-3d5e-45c0-bb63-3807b2225a7e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_11754fcf-1ab9-4159-a4b0-1dd7b492da79_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising and marketing costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_7cf16bfa-c483-4077-ae34-ccf4f0b885e0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_2e9b7d81-362b-4571-a6c9-b8b2ccc416c3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_3154bb6e-ace5-46ae-a5de-f46977b78633_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_f3092c8e-3aac-4b4e-987b-f676e16b994d_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_f5a7fa4a-63b8-4783-add2-f843530314de_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_d9c86602-9383-4080-a2cf-3a91f7d67426_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase obligation, due in next twelve months</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:to="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_0b7e60e1-f042-42df-92f2-1ac45c33c094_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating cash out flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_8667415e-7844-4a13-97a7-b58b386ae6dc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_70732212-85a5-4cee-bea2-ba6fc99f6d17_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_7811283a-cee8-4c01-8d30-b7a9029bafca_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_c8f77c42-6c4c-4b4c-85c9-a284b91b7a88_terseLabel_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of common stock warrants (in shares)</link:label>
    <link:label id="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_label_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised, Net</link:label>
    <link:label id="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_documentation_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:href="exdx-20231231.xsd#exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:to="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent_95bebc8b-ccf7-4551-b3db-93f584073cf2_terseLabel_en-US" xlink:label="lab_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, annual increase in base rent payment percentage</link:label>
    <link:label id="lab_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent_label_en-US" xlink:label="lab_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Annual Increase In Base Rent Payment, Percent</link:label>
    <link:label id="lab_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent_documentation_en-US" xlink:label="lab_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Annual Increase In Base Rent Payment, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent" xlink:href="exdx-20231231.xsd#exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent" xlink:to="lab_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_a873c52d-74d9-4a97-9376-f9765352d6ea_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk and Other Risk and Uncertainties</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_492c71ce-2180-47be-a643-5447607f4c80_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_f7807c4f-6c89-437b-be8c-616a93e212c1_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">401(k) Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayable_6fc13011-28cd-4820-9d82-4cde4f26ef18_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayable_label_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable" xlink:to="lab_us-gaap_NotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_a06a6a4a-1be8-4783-9ebc-54ab2a2626f9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_33840e9a-5a9f-48ab-ade1-c4840c742342_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ComputerEquipmentAndSoftwareMember_d771dedf-db0d-41e2-a951-ae61fdf47b8d_terseLabel_en-US" xlink:label="lab_exdx_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_exdx_ComputerEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_exdx_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment and Software [Member]</link:label>
    <link:label id="lab_exdx_ComputerEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_exdx_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Computer Equipment and Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ComputerEquipmentAndSoftwareMember" xlink:href="exdx-20231231.xsd#exdx_ComputerEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ComputerEquipmentAndSoftwareMember" xlink:to="lab_exdx_ComputerEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AuditInformationAbstract_label_en-US" xlink:label="lab_exdx_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_exdx_AuditInformationAbstract_documentation_en-US" xlink:label="lab_exdx_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AuditInformationAbstract" xlink:href="exdx-20231231.xsd#exdx_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AuditInformationAbstract" xlink:to="lab_exdx_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_f7a3974b-380f-4b2d-8fa7-59a95b400693_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_3d47b850-bc46-4605-b4cb-d4f041627d9b_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1933cf15-59f7-41ef-b2e6-26463bd6c7ef_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number&#160;of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_9e91451b-4bc6-4f1d-8552-195b3205c406_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DeferredTaxAssetsLeaseLiability_1ca9c267-7260-49db-81b9-faef62f59be9_terseLabel_en-US" xlink:label="lab_exdx_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_exdx_DeferredTaxAssetsLeaseLiability_label_en-US" xlink:label="lab_exdx_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Lease Liability</link:label>
    <link:label id="lab_exdx_DeferredTaxAssetsLeaseLiability_documentation_en-US" xlink:label="lab_exdx_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredTaxAssetsLeaseLiability" xlink:href="exdx-20231231.xsd#exdx_DeferredTaxAssetsLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DeferredTaxAssetsLeaseLiability" xlink:to="lab_exdx_DeferredTaxAssetsLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_190cba66-34f8-4de9-9d05-e59b05160aba_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_5980734b-51c2-4502-b566-9ee6c4d772be_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_f63565cb-fc97-4099-8bc5-af2618b5977b_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_ce8ee680-18c8-4d1e-950c-539b76a0315a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidRoyalties_53883417-d9ec-4aab-91d8-4cd823815d83_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid product royalties</link:label>
    <link:label id="lab_us-gaap_PrepaidRoyalties_label_en-US" xlink:label="lab_us-gaap_PrepaidRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRoyalties" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidRoyalties" xlink:to="lab_us-gaap_PrepaidRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_aecba524-18c9-45fc-8453-2c83b1b87b0e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Aggregate Payments for Outstanding Borrowings</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_305d11c8-d21c-44d0-b3cd-1b5db2f204a3_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_1ab460cb-9799-4352-a0c2-17d3256f0af3_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_a79b3248-3225-41de-8f47-c5114acd0725_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_13d4ac11-b958-4c7a-92dc-5297882d66ec_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Qualified employee compensation contribution, amount</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e6894c67-36d3-4d75-9e9c-d5d040819d89_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_86d42e57-fbae-4741-8a17-644bbaae76e4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SettledLitigationMember_5415135f-b5ec-4ae3-a86e-2edc4dc45e6b_terseLabel_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settled Litigation</link:label>
    <link:label id="lab_us-gaap_SettledLitigationMember_label_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SettledLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettledLitigationMember" xlink:to="lab_us-gaap_SettledLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_64cc249a-6c7e-46a5-97d9-196f730a4c04_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember_70e3acbd-3f8f-4b4b-959a-6ef1fc25ab4d_terseLabel_en-US" xlink:label="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allegheny Health Network Research Institute</link:label>
    <link:label id="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember_label_en-US" xlink:label="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allegheny Health Network Research Institute [Member]</link:label>
    <link:label id="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember_documentation_en-US" xlink:label="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Allegheny Health Network Research Institute</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:href="exdx-20231231.xsd#exdx_AlleghenyHealthNetworkResearchInstituteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:to="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_35529cd0-0fa4-4bca-83a6-925f9110b5b6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_WeightedAverageDiscountRateAbstract_7b9e1dfe-0a94-44f5-a379-86a1dd4f9c8a_terseLabel_en-US" xlink:label="lab_exdx_WeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_exdx_WeightedAverageDiscountRateAbstract_label_en-US" xlink:label="lab_exdx_WeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted-Average Discount Rate [Abstract]</link:label>
    <link:label id="lab_exdx_WeightedAverageDiscountRateAbstract_documentation_en-US" xlink:label="lab_exdx_WeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted-Average Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_WeightedAverageDiscountRateAbstract" xlink:href="exdx-20231231.xsd#exdx_WeightedAverageDiscountRateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_WeightedAverageDiscountRateAbstract" xlink:to="lab_exdx_WeightedAverageDiscountRateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_a70ba031-e2bd-4eff-8781-315a858ecd67_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value per share; 200,000,000 shares authorized at December 31, 2023 and December 31, 2022; 17,045,954 and 16,549,984 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CommercialMember_0db9f885-9cd9-42b0-80cf-5fd8f9fc4232_terseLabel_en-US" xlink:label="lab_exdx_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial</link:label>
    <link:label id="lab_exdx_CommercialMember_label_en-US" xlink:label="lab_exdx_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial [Member]</link:label>
    <link:label id="lab_exdx_CommercialMember_documentation_en-US" xlink:label="lab_exdx_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CommercialMember" xlink:href="exdx-20231231.xsd#exdx_CommercialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CommercialMember" xlink:to="lab_exdx_CommercialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_Term2017Member_7ed87802-c131-41f3-b044-99d2f724716b_terseLabel_en-US" xlink:label="lab_exdx_Term2017Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Term loan</link:label>
    <link:label id="lab_exdx_Term2017Member_label_en-US" xlink:label="lab_exdx_Term2017Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term 2017 [Member]</link:label>
    <link:label id="lab_exdx_Term2017Member_documentation_en-US" xlink:label="lab_exdx_Term2017Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term 2017</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Term2017Member" xlink:href="exdx-20231231.xsd#exdx_Term2017Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_Term2017Member" xlink:to="lab_exdx_Term2017Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_02c19fcc-9f52-4fb8-8c06-91b6fc4b3aa2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_3b8f4253-7e3f-42ed-9885-3f33885bcbaa_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_5f9d634d-fb66-408a-8ebf-095af4f2a9a9_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_43ae0336-666f-4641-a3de-7a8cb34214db_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_f7d089c9-17e5-4f54-98d7-ceb0ee5d4001_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_38f9c1fc-f00e-4002-b6c4-505e4e0aa5db_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Principal payment on finance lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_a2ccb53d-1e5d-4bc2-9946-220c6d351551_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing cash out flows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_bb1b4cb7-b615-485d-8a3a-f64c75061598_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finance Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_0dbf734d-e522-4d40-af86-1eb6f3894764_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_fc97cedf-4f48-46b6-a70f-ea76133ca012_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Concentration of Risk, by Risk Factor and Significant Payer</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_eeb13878-8609-43c6-a74b-50464932fec5_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_51357299-b9a2-42bd-8206-b2ace044f7a0_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_e6b9e2f8-4b29-4f67-b7b5-6fe8d330da53_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_a64b76ae-2383-4cab-9c56-788b5510ea8b_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease, right-of-use asset, statement of financial position</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_5265ffa0-3d22-482b-ada4-5f573e105bee_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_b3f5e57a-08e2-4a2d-946a-5177923a1bd2_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost, Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_1ca15544-67ea-4a74-be09-3678624b78a6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_4301f4d4-56ed-4ae7-9cf7-51ad720d8ca5_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_f3e476a1-5e5a-4e7b-82f9-fd2d27c6547d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_d772adf0-e977-4195-acc3-6d984d11b496_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet_b6924b53-5355-4491-82dd-45a74f5683db_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan, covenant, number of days to cure covenant if performance measure is not met</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet_label_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Number Of Days To Cure If Performance Measure Is Not Met</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Number Of Days To Cure If Performance Measure Is Not Met</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" xlink:href="exdx-20231231.xsd#exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" xlink:to="lab_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_d1fee7bf-1517-45ae-bc37-7ce685b83ed9_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_4638b0c7-0c61-425d-93df-246f056a334a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_8099ddb1-e479-404c-be41-e580593809a0_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants issued to purchase redeemable convertible preferred stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_c7c31047-2763-4f9f-afc2-96aca7807102_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_b57ed135-c5b1-4a53-b05b-11df53b45e7d_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">State income taxes, net of federal tax benefits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_565f79c6-6366-4ed6-a23a-a71d7d57c16d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_bf8f8514-bbd4-4aa8-b1e6-3dcba892fa36_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_07e0a621-83cf-43e1-8edd-bcb0a4d0c239_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_5fd3437c-0021-4119-979b-ed49e605821b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_f3fcb3d1-8493-4461-a1d5-fa676f487e14_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_e6c7b134-d5e9-4c39-800a-dc28f3964177_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_39458f8a-b037-44fd-9da4-d4f04d46f675_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_876c6ff7-5d8d-453c-a973-4c3383e275b8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_d753ce65-ebab-4b0e-95fd-f619bf5b602f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a2a4b773-00e8-4a1f-85dc-e5ff8715a3aa_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers_4b6f84e3-75f0-45fc-b933-d09b96e583c3_terseLabel_en-US" xlink:label="lab_exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of suppliers in amended supply agreement</link:label>
    <link:label id="lab_exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers_label_en-US" xlink:label="lab_exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation, Amended Supply Agreement, Number Of Suppliers</link:label>
    <link:label id="lab_exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers_documentation_en-US" xlink:label="lab_exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Obligation, Amended Supply Agreement, Number Of Suppliers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers" xlink:href="exdx-20231231.xsd#exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers" xlink:to="lab_exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_27c854cb-edf4-47c8-9d5a-c6c3fe60d295_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_478923f4-adc9-4021-9449-76498e93b2e2_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_b2942979-ff30-4574-bc1e-110808abae2a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan, fee incurred upon payment of final installment</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_9f76bf98-cd02-4044-9fb3-f766ac23439e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued&#160;payroll&#160;and&#160;related&#160;expenses</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Salaries, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_1aa6cfe4-3340-4e75-add8-53fba97beada_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_a7851af6-8957-4780-82f6-4a3fdce25b75_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_e9a0e2aa-1435-4931-a4ae-eb3849b95b11_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture&#160;and&#160;fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_515aba81-b4d6-4d9b-afd5-644e5a4c1b8f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan, interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_93a22246-5993-4fd5-9bea-e13b3a1870fd_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accruals, reserves and other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Loss Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_80eb97d6-1eec-4c7d-988b-b7336061685a_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_02de89f5-d94a-4617-b8f4-09b2f7c32a27_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_26e4afa7-e21b-4d5f-b068-0fb85c79d0e4_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_10a04816-501d-4ec4-8b1d-3bbc001be27e_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_1ef1efb3-5b0f-4d4e-800a-2ebcb0221b58_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_fa3adc15-bbe9-48e6-804f-72931afdd161_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_ea32c1c4-6bd7-4361-bcab-6b871d62048a_negatedLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_643f2aba-bae7-4341-92d9-d0f96225f124_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_c152c1cf-3ec0-4c34-8b38-95509123e9aa_periodStartLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance at the beginning of the year</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_858ad0d1-13b1-468e-a2e1-d20840f4a533_periodEndLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance at the end of the year</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68b8e949-b60d-450e-9587-bedb7715588f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_1cbf82fb-d6f6-4f5b-ad5b-9f17eb6b0c7a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_5c6b098b-7408-4bce-ba2e-65803a34950a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AHNCollaborationMember_39b4da7a-65d9-4c00-b1cd-da873bf510f5_terseLabel_en-US" xlink:label="lab_exdx_AHNCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AHN Collaboration</link:label>
    <link:label id="lab_exdx_AHNCollaborationMember_label_en-US" xlink:label="lab_exdx_AHNCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AHN Collaboration [Member]</link:label>
    <link:label id="lab_exdx_AHNCollaborationMember_documentation_en-US" xlink:label="lab_exdx_AHNCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AHN Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AHNCollaborationMember" xlink:href="exdx-20231231.xsd#exdx_AHNCollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AHNCollaborationMember" xlink:to="lab_exdx_AHNCollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_52ec9c7b-c7f4-469d-b889-6c9df170a5c8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_b3e99be5-aa98-4ae2-a4a5-71c0fa63dbbd_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1ddf01a2-51e8-4774-9c11-26fbc0ac9444_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e88b1487-8f32-4eea-b1d6-ffe123ef5a41_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_ca57cc7f-9410-42bf-a2ca-669c279fa787_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_f9700daa-d2a3-4ca3-be1f-fb157582f3b5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_fbb8eb28-4eac-4926-ae52-2a978f194859_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_6ff25066-7d7f-4781-890f-9156803352f6_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_665479f8-7795-4c99-9f95-3c217ef95286_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan covenant, minimum unrestricted cash balance</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_label_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:href="exdx-20231231.xsd#exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:to="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0155154d-9e51-4214-a5de-8577a4b5ecb3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan, effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_85521176-14ab-45ac-9dc5-f50604a0700e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_6f0b0218-5122-4ff0-9984-9c624ba1fe06_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d5d0a6cc-c99f-4621-b3b8-80a30b167adc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_9408b42b-8cac-4738-8307-43939ad25f2d_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_7dd4f56d-a2be-4387-ac9c-8be7702bbdff_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6a8763fe-41de-440b-a545-c22605f22bfd_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_40e7983a-4ed5-4486-a8a8-98661f91d74e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_31cda858-7318-4590-a663-25b57210d1f2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5038bc63-a3e4-4db9-9fa3-c97744eabe75_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_95b41ac0-1f0f-4fb7-be86-5c0019f6a6fb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaidInKindInterest_fc7d24bb-ff15-4f8a-b4c4-78568cb05225_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaidInKindInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest" xlink:to="lab_us-gaap_PaidInKindInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_d8aa3a24-cf9d-4f1e-94f5-bd1fe774b053_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_87a01e26-fa3f-4844-b2f6-655d1bd0d017_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross book value of assets under finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, before Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_c2ea1413-4115-4536-8a25-6c60b835ae0f_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_b761e813-20b3-4843-a3e4-4901551d9bf3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_5b5400b4-7619-42e7-b343-d607d5e5e6ed_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_966330cb-1e24-4c2a-ba83-408405c9d4b6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_Government1Member_0b405927-f91d-45e7-abd6-3fa343528f93_terseLabel_en-US" xlink:label="lab_exdx_Government1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government</link:label>
    <link:label id="lab_exdx_Government1Member_label_en-US" xlink:label="lab_exdx_Government1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government1 [Member]</link:label>
    <link:label id="lab_exdx_Government1Member_documentation_en-US" xlink:label="lab_exdx_Government1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Government1Member" xlink:href="exdx-20231231.xsd#exdx_Government1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_Government1Member" xlink:to="lab_exdx_Government1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_76f67c60-d23f-42f3-97b3-50379084a47a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_8b52a814-6bca-40f7-9119-d60b71ee5385_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplier [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_EquipmentPurchasedUnderNotesPayableObligations_ce22ce94-8842-4efb-88ac-0ce30bd9811f_terseLabel_en-US" xlink:label="lab_exdx_EquipmentPurchasedUnderNotesPayableObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equipment purchased under notes payable obligations</link:label>
    <link:label id="lab_exdx_EquipmentPurchasedUnderNotesPayableObligations_label_en-US" xlink:label="lab_exdx_EquipmentPurchasedUnderNotesPayableObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment Purchased Under Notes Payable Obligations</link:label>
    <link:label id="lab_exdx_EquipmentPurchasedUnderNotesPayableObligations_documentation_en-US" xlink:label="lab_exdx_EquipmentPurchasedUnderNotesPayableObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equipment Purchased Under Notes Payable Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_EquipmentPurchasedUnderNotesPayableObligations" xlink:href="exdx-20231231.xsd#exdx_EquipmentPurchasedUnderNotesPayableObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_EquipmentPurchasedUnderNotesPayableObligations" xlink:to="lab_exdx_EquipmentPurchasedUnderNotesPayableObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_98171ada-32a6-465d-96c8-618c26679705_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_4b7649ae-4e0f-4198-9aef-918dfb7fc929_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9e9a5756-0bb8-4f39-a651-20ce2c35d4ef_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_cf446842-01c3-4e1a-a675-69f46880c326_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Outstanding Warrants</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_d4bd1081-a4d9-487c-813f-46a3612ef9cf_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_b2a7410f-8568-4d22-93be-c61b7dcb756f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_cce1ac0d-6c06-44ef-9c26-a5a5a9eff426_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_fc19f8c6-c2ff-4662-8427-6bf31c83ea8d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_GainLossOnDispositionOfLeaseAssignment_437df5d1-edeb-4870-ab65-16ef48b81b0a_negatedTerseLabel_en-US" xlink:label="lab_exdx_GainLossOnDispositionOfLeaseAssignment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on lease assignment</link:label>
    <link:label id="lab_exdx_GainLossOnDispositionOfLeaseAssignment_label_en-US" xlink:label="lab_exdx_GainLossOnDispositionOfLeaseAssignment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Lease Assignment</link:label>
    <link:label id="lab_exdx_GainLossOnDispositionOfLeaseAssignment_documentation_en-US" xlink:label="lab_exdx_GainLossOnDispositionOfLeaseAssignment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Lease Assignment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_GainLossOnDispositionOfLeaseAssignment" xlink:href="exdx-20231231.xsd#exdx_GainLossOnDispositionOfLeaseAssignment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_GainLossOnDispositionOfLeaseAssignment" xlink:to="lab_exdx_GainLossOnDispositionOfLeaseAssignment" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_69592d45-5f31-4679-9f43-3974a77230ce_terseLabel_en-US" xlink:label="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Financial Information</link:label>
    <link:label id="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_label_en-US" xlink:label="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities [Text Block]</link:label>
    <link:label id="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_documentation_en-US" xlink:label="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:href="exdx-20231231.xsd#exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:to="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0cf5387b-6a73-43f7-991a-17d55e37b7d2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments of taxes withheld on vested restricted stock units</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_ba656f7f-11fa-4167-abf1-55d19d864ada_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_fdc60c1a-54a6-42b2-99a9-96d2b393e6c8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_301c3661-6ecc-4366-9725-896659e7e2cc_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_60408c09-2f2c-4148-8879-3740a18dd6b0_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_TwoSuppliersMember_903027c4-aa2c-4c16-94ae-827691e58589_terseLabel_en-US" xlink:label="lab_exdx_TwoSuppliersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Two Suppliers</link:label>
    <link:label id="lab_exdx_TwoSuppliersMember_label_en-US" xlink:label="lab_exdx_TwoSuppliersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Suppliers [Member]</link:label>
    <link:label id="lab_exdx_TwoSuppliersMember_documentation_en-US" xlink:label="lab_exdx_TwoSuppliersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Suppliers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TwoSuppliersMember" xlink:href="exdx-20231231.xsd#exdx_TwoSuppliersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_TwoSuppliersMember" xlink:to="lab_exdx_TwoSuppliersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_85c97618-b19d-4a0b-a5de-25d9970d70a0_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ShelfRegistrationStatementMember_6a0d617f-e21f-4672-8676-64be2552990b_terseLabel_en-US" xlink:label="lab_exdx_ShelfRegistrationStatementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shelf Registration Statement</link:label>
    <link:label id="lab_exdx_ShelfRegistrationStatementMember_label_en-US" xlink:label="lab_exdx_ShelfRegistrationStatementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shelf Registration Statement [Member]</link:label>
    <link:label id="lab_exdx_ShelfRegistrationStatementMember_documentation_en-US" xlink:label="lab_exdx_ShelfRegistrationStatementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shelf Registration Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShelfRegistrationStatementMember" xlink:href="exdx-20231231.xsd#exdx_ShelfRegistrationStatementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ShelfRegistrationStatementMember" xlink:to="lab_exdx_ShelfRegistrationStatementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_f6ce9ba1-e5df-4973-bc5b-a08ece9c873d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings-current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_95de7ee0-d5c2-4344-b2bb-5c8d1c529d4a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Borrowings-current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0881220a-31ca-4802-b586-1c24840a79d4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Non-cash Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_4f7470ac-2993-4aeb-8035-0ab49c912fdd_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_53998651-38bc-4a12-bf47-8ea17a66db12_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2fd1d75a-97d5-4ece-9fb9-176991891c27_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_a0608740-fea5-4982-a12b-4e595a7b220b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_2556397f-8091-4cbb-ab4c-cfee41606531_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_8dd2928d-02e6-4f47-98f8-76126a9f5637_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_b898dcde-3669-42bd-865e-d85741ebbe24_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of stock under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_3f97d3e2-b8da-4c51-be6c-aabe27f1db9d_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock options</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_2458c1ac-28dc-45ad-a61f-1ae726c32225_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_4ae946d2-8893-47bc-a053-136df40fb7de_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on disposal of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_MedicareAdvantageMember_a80fa663-57cc-4ada-99da-933e5d7be36f_terseLabel_en-US" xlink:label="lab_exdx_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medicare Advantage</link:label>
    <link:label id="lab_exdx_MedicareAdvantageMember_label_en-US" xlink:label="lab_exdx_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medicare Advantage [Member]</link:label>
    <link:label id="lab_exdx_MedicareAdvantageMember_documentation_en-US" xlink:label="lab_exdx_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medicare Advantage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareAdvantageMember" xlink:href="exdx-20231231.xsd#exdx_MedicareAdvantageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_MedicareAdvantageMember" xlink:to="lab_exdx_MedicareAdvantageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_8308f62f-7a5c-4093-ade5-b346c269eb85_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_6ce76b2f-0de6-41b7-9ef8-7afaa63f1b59_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease, liability, current, statement of financial position</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember_f90feed7-9777-4e11-bb14-bfaeadcdeb43_terseLabel_en-US" xlink:label="lab_exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common shares available for grant under the 2019 Plan</link:label>
    <link:label id="lab_exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember_label_en-US" xlink:label="lab_exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Shares Available For Grant Under The 2019 Plan [Member]</link:label>
    <link:label id="lab_exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember_documentation_en-US" xlink:label="lab_exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Shares Available For Grant Under The 2019 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember" xlink:href="exdx-20231231.xsd#exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember" xlink:to="lab_exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentCovenantRevenuePerformancePeriod_de6b2df1-a42c-4e90-8952-fe592e20fc12_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantRevenuePerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan, covenant, revenue performance period</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantRevenuePerformancePeriod_label_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantRevenuePerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Revenue Performance Period</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantRevenuePerformancePeriod_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantRevenuePerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Revenue Performance Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantRevenuePerformancePeriod" xlink:href="exdx-20231231.xsd#exdx_DebtInstrumentCovenantRevenuePerformancePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentCovenantRevenuePerformancePeriod" xlink:to="lab_exdx_DebtInstrumentCovenantRevenuePerformancePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_5b10ac40-4309-4821-9bd2-1147f38cda3f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_4c1f3596-f799-4e5d-8b52-f513ccf02801_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restricted Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage_f11e9d6d-453b-4771-a5dd-0d6bd93d2414_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan, prepayment premium percentage</link:label>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage_label_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Premium Percentage</link:label>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Premium Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:href="exdx-20231231.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:to="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInSecondYear_0f0c4a32-c767-40bb-8b02-ee23981da396_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase obligation, due in second year</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInSecondYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInSecondYear" xlink:to="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_99b51021-6a93-477c-b0e4-20c6ebe22421_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_006ebf67-e3c1-45ac-a840-6250b0b34435_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable (in Shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_25aa3360-37f5-4d4b-aa96-8e236622da6a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal net operating loss carryforwards, carryforward indefinitely</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_4f58d690-a424-4b80-9a43-d93e51eaca3a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_eb7d7e4e-da5e-4684-a553-b48344aea126_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_1a4c588a-f664-44bb-ade3-3a2eb47b86fc_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_0aec6463-db44-4be4-9191-f774bc84854f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_b21b171a-8140-4a16-b1be-b78645e5b559_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_3a0b710b-5ca6-4597-a489-def5e67b3d0c_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AmendedLoanAgreementMember_e353a940-bbd6-4e02-9da5-55c7dbc622c2_terseLabel_en-US" xlink:label="lab_exdx_AmendedLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amended Loan Agreement</link:label>
    <link:label id="lab_exdx_AmendedLoanAgreementMember_label_en-US" xlink:label="lab_exdx_AmendedLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amended Loan Agreement [Member]</link:label>
    <link:label id="lab_exdx_AmendedLoanAgreementMember_documentation_en-US" xlink:label="lab_exdx_AmendedLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amended Loan Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AmendedLoanAgreementMember" xlink:href="exdx-20231231.xsd#exdx_AmendedLoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AmendedLoanAgreementMember" xlink:to="lab_exdx_AmendedLoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_8eced3cb-8cd7-4f64-b927-5c43b30dab3e_terseLabel_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of annual vesting installments</link:label>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_label_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Annual Installments</link:label>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_documentation_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Annual Installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:href="exdx-20231231.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:to="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_ae341bab-78bb-4da5-a156-d85db19d0ca4_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases recorded to income tax provision</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e2920531-6cea-432c-87fd-b313191e5dc8_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplierConcentrationRiskMember_a7ad91d3-1951-49de-a83b-61b1a3e4b682_terseLabel_en-US" xlink:label="lab_us-gaap_SupplierConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplier Concentration Risk</link:label>
    <link:label id="lab_us-gaap_SupplierConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_SupplierConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierConcentrationRiskMember" xlink:to="lab_us-gaap_SupplierConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrent_cf0a0f57-bdb7-45c0-8b91-8078d6003524_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes payable current</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_NonCashLeaseExpense_76af5d35-3eaa-4aab-bfa1-525c87195725_terseLabel_en-US" xlink:label="lab_exdx_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_exdx_NonCashLeaseExpense_label_en-US" xlink:label="lab_exdx_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Lease Expense</link:label>
    <link:label id="lab_exdx_NonCashLeaseExpense_documentation_en-US" xlink:label="lab_exdx_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Cash Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_NonCashLeaseExpense" xlink:href="exdx-20231231.xsd#exdx_NonCashLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_NonCashLeaseExpense" xlink:to="lab_exdx_NonCashLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_8fadac99-96ec-4e75-86f3-b214182a3ae5_negatedLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AVISECTDTestMember_aaeedfaf-be96-49e9-a8f3-741d311e798d_terseLabel_en-US" xlink:label="lab_exdx_AVISECTDTestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AVISE CTD Test</link:label>
    <link:label id="lab_exdx_AVISECTDTestMember_label_en-US" xlink:label="lab_exdx_AVISECTDTestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AVISE CTD Test [Member]</link:label>
    <link:label id="lab_exdx_AVISECTDTestMember_documentation_en-US" xlink:label="lab_exdx_AVISECTDTestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AVISE CTD Test</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AVISECTDTestMember" xlink:href="exdx-20231231.xsd#exdx_AVISECTDTestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AVISECTDTestMember" xlink:to="lab_exdx_AVISECTDTestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_fe2c1cba-9980-4f66-96d1-15222aa39c39_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_79aa1b9d-9428-428c-955f-7e411bac92ec_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_LaboratoryEquipmentMember_d95daddf-a7ac-4d3c-89b2-fae182eb0aec_terseLabel_en-US" xlink:label="lab_exdx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_exdx_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_exdx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_exdx_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_exdx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Laboratory Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LaboratoryEquipmentMember" xlink:href="exdx-20231231.xsd#exdx_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_LaboratoryEquipmentMember" xlink:to="lab_exdx_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b6727ff8-cda0-4a14-a389-dff664ed81dc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_247f80be-490b-44da-9cd2-bacdef79e4b6_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_89f2059f-5c72-4059-ad1a-dad5d4063494_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_950c7158-d429-45d2-9734-3b15dd4cc3ec_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationJan192026Member_2ef2f400-495a-4292-a6df-0c4b146e345a_terseLabel_en-US" xlink:label="lab_exdx_ExpirationJan192026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant expiration January 19, 2026</link:label>
    <link:label id="lab_exdx_ExpirationJan192026Member_label_en-US" xlink:label="lab_exdx_ExpirationJan192026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expiration Jan 19, 2026 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationJan192026Member_documentation_en-US" xlink:label="lab_exdx_ExpirationJan192026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expiration Jan 19, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationJan192026Member" xlink:href="exdx-20231231.xsd#exdx_ExpirationJan192026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationJan192026Member" xlink:to="lab_exdx_ExpirationJan192026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_8db7f529-29f2-4741-90a4-7a7bc7470462_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_72506fe5-1553-4264-8956-e28abcd89ced_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_25020904-8412-4992-8919-d62a4940cc89_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_11d712f2-895b-4cf2-8581-050f3683d053_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_604e3015-d367-4bf9-a67e-ba36801cdd37_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_862cf3e4-2c22-4ae3-b14d-29ca85339b3a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_276449f4-baa1-4be9-9520-817f03bcfd86_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Awards canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_e8413137-484b-4f85-8398-548479055d50_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Qualified employee compensation, employer matching contribution, percent of employees' gross pay</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_a64b400d-7d45-4740-9a10-251aff2ffa9d_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_label_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="lab_us-gaap_IncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_3a31cc0a-14e8-4438-91b3-088e90eb6af3_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_cb7063c8-c333-4be5-8577-2de3d762ad94_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_EquipmentNotesPayableMember_c0b0dca1-0cd0-4838-ab15-87b0990b2346_terseLabel_en-US" xlink:label="lab_exdx_EquipmentNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equipment Notes Payable</link:label>
    <link:label id="lab_exdx_EquipmentNotesPayableMember_label_en-US" xlink:label="lab_exdx_EquipmentNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment Notes Payable [Member]</link:label>
    <link:label id="lab_exdx_EquipmentNotesPayableMember_documentation_en-US" xlink:label="lab_exdx_EquipmentNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equipment Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_EquipmentNotesPayableMember" xlink:href="exdx-20231231.xsd#exdx_EquipmentNotesPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_EquipmentNotesPayableMember" xlink:to="lab_exdx_EquipmentNotesPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPPolicy_efb064f5-5002-4393-bf5c-bfca6a0fa0c1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPPolicy_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_ef68c852-34f9-4e61-861a-6321c7ea5d38_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent_94506dca-4da7-4c12-8228-6f6a69196d71_terseLabel_en-US" xlink:label="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical study activity</link:label>
    <link:label id="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent_label_en-US" xlink:label="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Clinical Study, Current</link:label>
    <link:label id="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent_documentation_en-US" xlink:label="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Clinical Study, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:href="exdx-20231231.xsd#exdx_AccruedLiabilitiesClinicalStudyCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:to="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_5382edef-c408-494b-95eb-b124bd344ce0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_d004f00c-b5cf-4033-ad64-bed2a310c308_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_c1d2e467-9f08-47ab-8007-4d86a94e384d_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_fb7c6525-c493-471a-b51b-3f0bb97d3861_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_76e182e4-c527-47e0-817d-5abf81ed68af_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_32e3e024-fdf2-4233-add7-9775f631747c_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_c7f57446-a5ba-4545-8db3-7e1f1ea493b4_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan covenant, increase to interest rate</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_label_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:href="exdx-20231231.xsd#exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:to="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_f31a63e7-e39e-4513-ab4c-512f7bdd859b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Financial Instrument Measured on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DeferredTaxLiabilitiesRightOfUseAssets_80643ac8-5a1b-4106-8960-4a873de36131_negatedTerseLabel_en-US" xlink:label="lab_exdx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Right of use assets</link:label>
    <link:label id="lab_exdx_DeferredTaxLiabilitiesRightOfUseAssets_label_en-US" xlink:label="lab_exdx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Right Of Use Assets</link:label>
    <link:label id="lab_exdx_DeferredTaxLiabilitiesRightOfUseAssets_documentation_en-US" xlink:label="lab_exdx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Right Of Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:href="exdx-20231231.xsd#exdx_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:to="lab_exdx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_0673f5b3-6c57-423f-a5d8-99318ce4c142_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal payment on long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_b3bf1f55-b41a-4691-aacc-c5870fbcc311_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment of principal</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_f42036c9-d393-4791-9857-e1df2bc7834f_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_34e49fcb-5840-4014-8f9f-1dcd2d29590e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease obligations, net of current portion</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_3be63c32-6a63-49e9-9fa4-b511283b4153_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_9eda7b86-6b94-40f8-841e-b52c6e168d6a_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt discount and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_NoExpirationMember_b466f87a-f97d-4393-ae20-fe4ccabc7032_terseLabel_en-US" xlink:label="lab_exdx_NoExpirationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">No expiration</link:label>
    <link:label id="lab_exdx_NoExpirationMember_label_en-US" xlink:label="lab_exdx_NoExpirationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">No expiration [Member]</link:label>
    <link:label id="lab_exdx_NoExpirationMember_documentation_en-US" xlink:label="lab_exdx_NoExpirationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">No expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_NoExpirationMember" xlink:href="exdx-20231231.xsd#exdx_NoExpirationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_NoExpirationMember" xlink:to="lab_exdx_NoExpirationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_a0d43c58-47a5-4220-9da6-5ab2d8b6ab8a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_ed6ba999-81fa-4997-92cd-5df88cf19b3c_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ClientMember_ad789c18-3b1a-423a-8863-3f31a9963275_terseLabel_en-US" xlink:label="lab_exdx_ClientMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Client</link:label>
    <link:label id="lab_exdx_ClientMember_label_en-US" xlink:label="lab_exdx_ClientMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Client [Member]</link:label>
    <link:label id="lab_exdx_ClientMember_documentation_en-US" xlink:label="lab_exdx_ClientMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Client</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClientMember" xlink:href="exdx-20231231.xsd#exdx_ClientMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ClientMember" xlink:to="lab_exdx_ClientMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_880fb0dc-2dec-439a-9238-9208fbe0aba6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_c6026387-14fc-4394-ac68-21e887877d9b_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Income tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_c91580ab-ee2a-4a3a-8d52-5a4bf9efa1a4_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-deductible expenses</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_0d7cdcbc-7bc6-4ecc-8f28-8b8fb801b77e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease, right-of-use asset, after accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_e8208ec4-f6e0-4413-8bae-8abe5e26749d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_cad53de8-1740-4863-b416-0d73204c8e2b_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_label_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Terms [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAgreementTermsMember" xlink:to="lab_us-gaap_LicenseAgreementTermsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_7cb792a7-d56a-4fc4-b83c-0958e60e4d59_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_00e5ba89-cd2e-4743-81c3-aca84ce732e6_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts_e496407a-d2b2-4676-92e3-2d4ce46f0a07_terseLabel_en-US" xlink:label="lab_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalization of research and experimentation costs</link:label>
    <link:label id="lab_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts_label_en-US" xlink:label="lab_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Capitalization Of Research And Experimentation Costs</link:label>
    <link:label id="lab_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts_documentation_en-US" xlink:label="lab_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Capitalization Of Research And Experimentation Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts" xlink:href="exdx-20231231.xsd#exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts" xlink:to="lab_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_7ab52b2a-5dc0-4ccf-9847-3e96a6d6c214_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_A2017TermLoanMember_a36533dd-5801-4d82-a8ca-2c14e919d1e0_terseLabel_en-US" xlink:label="lab_exdx_A2017TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Term Loan</link:label>
    <link:label id="lab_exdx_A2017TermLoanMember_label_en-US" xlink:label="lab_exdx_A2017TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2017 Term Loan [Member]</link:label>
    <link:label id="lab_exdx_A2017TermLoanMember_documentation_en-US" xlink:label="lab_exdx_A2017TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2017 Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_A2017TermLoanMember" xlink:href="exdx-20231231.xsd#exdx_A2017TermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_A2017TermLoanMember" xlink:to="lab_exdx_A2017TermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_28d9ae60-7fa3-4c7a-9572-326588ab1811_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlement payment</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_2650b8bb-08e2-4f27-b134-b7cd5782706d_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_f2eadafc-8c3c-4075-bc3c-f1a3b91593e7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0cbc4b19-da7b-4db9-8cc9-8f2ea4e73bee_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward_c458be55-5755-4e29-8d08-788f4e06f2e3_terseLabel_en-US" xlink:label="lab_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes In The Valuation Allowance For Deferred Tax Assets [Roll Forward]</link:label>
    <link:label id="lab_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward_label_en-US" xlink:label="lab_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes In The Valuation Allowance For Deferred Tax Assets [Roll Forward]</link:label>
    <link:label id="lab_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward_documentation_en-US" xlink:label="lab_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Changes In The Valuation Allowance For Deferred Tax Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward" xlink:href="exdx-20231231.xsd#exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward" xlink:to="lab_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OperatingLeaseMonthlyBaseRent_98d4bcd6-de19-4cf4-b93e-e09b534a7c8a_terseLabel_en-US" xlink:label="lab_exdx_OperatingLeaseMonthlyBaseRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, monthly base rent</link:label>
    <link:label id="lab_exdx_OperatingLeaseMonthlyBaseRent_label_en-US" xlink:label="lab_exdx_OperatingLeaseMonthlyBaseRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Monthly Base Rent</link:label>
    <link:label id="lab_exdx_OperatingLeaseMonthlyBaseRent_documentation_en-US" xlink:label="lab_exdx_OperatingLeaseMonthlyBaseRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Monthly Base Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeaseMonthlyBaseRent" xlink:href="exdx-20231231.xsd#exdx_OperatingLeaseMonthlyBaseRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OperatingLeaseMonthlyBaseRent" xlink:to="lab_exdx_OperatingLeaseMonthlyBaseRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_c6bcadd8-3ad0-481c-bba5-beb525eac562_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_a05b4b02-5799-4341-896e-944fad9389be_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_687d1f93-67d1-4bf0-b44c-0ef892b8f3b9_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds, included in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_LongTermDebtIncludingUndiscountedInterest_ef85d8fc-ddb7-4e39-9579-3017126a97f3_totalLabel_en-US" xlink:label="lab_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_exdx_LongTermDebtIncludingUndiscountedInterest_label_en-US" xlink:label="lab_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Including Undiscounted Interest</link:label>
    <link:label id="lab_exdx_LongTermDebtIncludingUndiscountedInterest_documentation_en-US" xlink:label="lab_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-term Debt, Including Undiscounted Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:href="exdx-20231231.xsd#exdx_LongTermDebtIncludingUndiscountedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:to="lab_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_3a32f4cf-8afb-4e9f-9d93-5625137b81aa_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite lived assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_31fad10d-094a-439a-8a99-11638c4214b8_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_d21efc0e-7830-49ca-89cf-5f6ca4560f97_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal payment on note payable obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_7bc21f07-436b-44f3-8b22-b7ba63958547_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CollaborationAgreementAnnualCollaborationFee_635d9fdf-c8b5-4800-ae59-96801ebe9eb4_terseLabel_en-US" xlink:label="lab_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration fee</link:label>
    <link:label id="lab_exdx_CollaborationAgreementAnnualCollaborationFee_label_en-US" xlink:label="lab_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Annual Collaboration Fee</link:label>
    <link:label id="lab_exdx_CollaborationAgreementAnnualCollaborationFee_documentation_en-US" xlink:label="lab_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Annual Collaboration Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:href="exdx-20231231.xsd#exdx_CollaborationAgreementAnnualCollaborationFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:to="lab_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5a6fd04c-aa56-4af1-9942-8a16d6d5c98a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OtherFinancialInformationAbstract_label_en-US" xlink:label="lab_exdx_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Financial Information [Abstract]</link:label>
    <link:label id="lab_exdx_OtherFinancialInformationAbstract_documentation_en-US" xlink:label="lab_exdx_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Financial Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract" xlink:href="exdx-20231231.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OtherFinancialInformationAbstract" xlink:to="lab_exdx_OtherFinancialInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_7eb5d34e-5e3b-4101-9ce0-473f496b88b0_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest expense</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtOtherThanAmendedLoanAgreementMember_a3bb1d92-7c52-41b8-adb5-174685371bbc_terseLabel_en-US" xlink:label="lab_exdx_DebtOtherThanAmendedLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Other Than Amended Loan Agreement</link:label>
    <link:label id="lab_exdx_DebtOtherThanAmendedLoanAgreementMember_label_en-US" xlink:label="lab_exdx_DebtOtherThanAmendedLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Other Than Amended Loan Agreement [Member]</link:label>
    <link:label id="lab_exdx_DebtOtherThanAmendedLoanAgreementMember_documentation_en-US" xlink:label="lab_exdx_DebtOtherThanAmendedLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Other Than Amended Loan Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtOtherThanAmendedLoanAgreementMember" xlink:href="exdx-20231231.xsd#exdx_DebtOtherThanAmendedLoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtOtherThanAmendedLoanAgreementMember" xlink:to="lab_exdx_DebtOtherThanAmendedLoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_93cc83be-46b6-4f02-8c6f-ce19cae2701f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_844b3ce9-68a9-44f5-a0e1-75d2cd4631e9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_39e6106d-8d0d-4f5d-bddd-c40547fa9e66_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_dda54399-9040-4a7f-8d05-2d131b44681b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings-non-current portion, net of discounts and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_96283660-3146-4e4e-b17e-73052c047595_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_590e94d5-5ddb-473d-b30b-621151b9f8ba_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_ac25115d-60df-47c8-9bc9-2b382b83ec8d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease, liability, noncurrent, statement of financial position</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_3df274bc-b0d5-4ada-b451-5b30ccf245b4_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2a9ba039-5d08-428d-a552-876346a6523f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average number of shares used to compute net loss per share, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_0206d7e7-5546-484a-911d-d70fe0abce3a_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_42d9997b-4343-4bdc-bc9b-9d071d61164f_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equipment purchased under finance lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_83f7d223-97e8-4277-8c58-8d28342ea59b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_f09ea309-4ab4-4bc8-a3e3-579f6cd61cc2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cc6518d8-0ac5-45bc-9ba8-c47158945a68_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_6b6428fd-aca8-4797-a478-22ccd89db70a_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_309d34e2-e46b-4958-96c5-2bbdc24ea489_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_5ea5a09d-77f6-4a3a-99d2-fa06fa9f6fc3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_ac040626-de44-4b67-80aa-7dc7bed37c9f_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CowenEquityDistributionAgreementMember_18a73fcd-c21e-4793-9f78-da168f559a02_terseLabel_en-US" xlink:label="lab_exdx_CowenEquityDistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cowen Equity Distribution Agreement</link:label>
    <link:label id="lab_exdx_CowenEquityDistributionAgreementMember_label_en-US" xlink:label="lab_exdx_CowenEquityDistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cowen Equity Distribution Agreement [Member]</link:label>
    <link:label id="lab_exdx_CowenEquityDistributionAgreementMember_documentation_en-US" xlink:label="lab_exdx_CowenEquityDistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cowen Equity Distribution Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CowenEquityDistributionAgreementMember" xlink:href="exdx-20231231.xsd#exdx_CowenEquityDistributionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CowenEquityDistributionAgreementMember" xlink:to="lab_exdx_CowenEquityDistributionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_7c8ba950-c6fe-4c13-ab60-97a6af65c2cd_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_a0d950a6-2142-4981-a9ac-273f92d9cf52_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7d6b6f23-f44a-4ceb-a51e-c923e9c74013_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_67ce2587-92fa-4574-9c1d-1953e9bc17e3_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_ea67c5d9-a994-4ce2-875e-17fcecaacc22_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_701a21a4-3a7c-41c9-bcf8-fd12fed62564_terseLabel_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual percentage increase in shares available for issuance under the Plan</link:label>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_label_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Percentage</link:label>
    <link:label id="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_documentation_en-US" xlink:label="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" xlink:href="exdx-20231231.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" xlink:to="lab_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_bdfbb710-4d88-4d55-a8a5-cfea3f6be9d5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_3a413c14-3509-421e-8ee8-3c92a76ea612_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_9deae77c-70a3-4c95-95e0-445fda443749_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating cash out flows from interest paid on finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_4b769d59-ba8b-46b1-9347-2e0ded073ed3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_32255a1c-e13a-43bd-8206-2651826ed46f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards released (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0cc4af6d-11bf-4073-8565-2e9bce3fd4e7_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_74180d7c-3cfa-4718-9928-fb0e2e93134c_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationApr12026Member_8408b22b-06e4-4924-aeda-e98111296134_terseLabel_en-US" xlink:label="lab_exdx_ExpirationApr12026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant expiration April 1, 2026</link:label>
    <link:label id="lab_exdx_ExpirationApr12026Member_label_en-US" xlink:label="lab_exdx_ExpirationApr12026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expiration Apr 1, 2026 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationApr12026Member_documentation_en-US" xlink:label="lab_exdx_ExpirationApr12026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expiration Apr 1, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationApr12026Member" xlink:href="exdx-20231231.xsd#exdx_ExpirationApr12026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationApr12026Member" xlink:to="lab_exdx_ExpirationApr12026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_dbe8b728-3d05-478c-bc74-a0436f22e73f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_069da6ae-6aa6-442b-bebf-abe7dc31d255_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of lease assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrimeRateMember_2bd5df62-d5a0-4011-aa53-5c33dcf1253d_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prime Rate</link:label>
    <link:label id="lab_us-gaap_PrimeRateMember_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prime Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember" xlink:to="lab_us-gaap_PrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fc5cf105-c7fa-455e-86ff-30fa17491b35_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_44e9cdcc-2415-4c6c-94af-d580cb518afc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_62b372dd-4016-4662-a0e0-03788d73f105_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_48e94d36-e6d9-4d8c-bc88-e3270ecc816b_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease obligations, current portion</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_5ef59f04-d6e1-47a8-952b-e2f1cea0152b_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_6bb25160-5ed8-41d6-a428-15e6253d6c47_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0abbae08-d3b8-47cd-9d62-b48205e98fcb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_86842926-6ed6-425e-9686-5aa9c39b48cf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2dcfdd53-151a-4ce3-96e4-50787def47e5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average number of shares used to compute net loss per share, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_7fbc1820-fb4e-447d-8e72-c43e8885777c_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_796b1d15-e0db-4edf-8e45-925b42eaaf28_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_ea5c7449-5ff8-475d-a14a-f60cdd80a049_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_d0dd5024-92ec-457b-93b2-d5d8364bc4c3_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue_93fc300f-e70d-4b7c-b216-6e73c684643c_negatedTerseLabel_en-US" xlink:label="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Issuance of stock from vested restricted stock units and payment of employees' taxes</link:label>
    <link:label id="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue_label_en-US" xlink:label="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance Of Stock From Vested Restricted Stock Units And Payment Of Employees Taxes, Value</link:label>
    <link:label id="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue_documentation_en-US" xlink:label="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issuance Of Stock From Vested Restricted Stock Units And Payment Of Employees Taxes, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue" xlink:href="exdx-20231231.xsd#exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue" xlink:to="lab_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_d5859013-162b-4cfe-abac-7e1e130a1a4f_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShippingAndHandlingMember_606a1d0a-e99b-4bbf-8196-b8d9aacf7d77_terseLabel_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shipping and Handling</link:label>
    <link:label id="lab_us-gaap_ShippingAndHandlingMember_label_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shipping and Handling [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShippingAndHandlingMember" xlink:to="lab_us-gaap_ShippingAndHandlingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_7649ce90-9059-4b20-b3c4-2ff8f8228ec6_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_faf73af8-e5cd-4f66-a8db-abed926038fc_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_bd394f44-eec5-4ef3-872d-adabd8773b16_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_4f8b4b76-ed3a-4fa8-b79b-9e256f9df5e4_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_a6634911-562c-4e63-9957-efdec122aa4f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_a62dc573-9062-46ec-af19-638820e08429_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_e4bebc0f-2528-4d45-96d5-4c4569b7d4a6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3a9eed2b-23fe-4436-850c-7ec1790b1917_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Remaining Contractual Term&#160;(Years) and Aggregate Instrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>exdx-20231231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:6a8da8f2-df0f-4e69-99e5-93009f0ad924,g:882e5611-3f00-4664-b088-e8c5528fafa2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exagen.com/role/Cover" xlink:type="simple" xlink:href="exdx-20231231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_bb6d0242-43eb-4282-abb3-27eb01c1f85e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_862193c8-d1b3-4130-8cea-8c3258cd4c30" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb6d0242-43eb-4282-abb3-27eb01c1f85e" xlink:to="loc_dei_DocumentType_862193c8-d1b3-4130-8cea-8c3258cd4c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_ce429d91-4b87-429c-a61a-27acda501d37" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb6d0242-43eb-4282-abb3-27eb01c1f85e" xlink:to="loc_dei_DocumentAnnualReport_ce429d91-4b87-429c-a61a-27acda501d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_57af4f14-88a2-4ea2-92bf-4a5bafd65892" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb6d0242-43eb-4282-abb3-27eb01c1f85e" xlink:to="loc_dei_DocumentPeriodEndDate_57af4f14-88a2-4ea2-92bf-4a5bafd65892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_ccd3abe2-babf-4838-b8d0-6061d936b2e6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb6d0242-43eb-4282-abb3-27eb01c1f85e" xlink:to="loc_dei_CurrentFiscalYearEndDate_ccd3abe2-babf-4838-b8d0-6061d936b2e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_92ecc3b8-1083-4324-a582-2b066a49e241" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb6d0242-43eb-4282-abb3-27eb01c1f85e" xlink:to="loc_dei_DocumentTransitionReport_92ecc3b8-1083-4324-a582-2b066a49e241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_0261d9aa-3535-4eca-8dde-60f26e9cb0f9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb6d0242-43eb-4282-abb3-27eb01c1f85e" xlink:to="loc_dei_EntityFileNumber_0261d9aa-3535-4eca-8dde-60f26e9cb0f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_cfbe7a76-93cd-4443-a7dc-b9af212f8113" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb6d0242-43eb-4282-abb3-27eb01c1f85e" xlink:to="loc_dei_EntityRegistrantName_cfbe7a76-93cd-4443-a7dc-b9af212f8113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_54d40537-0dbf-4280-93ca-499c30cf2872" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb6d0242-43eb-4282-abb3-27eb01c1f85e" xlink:to="loc_dei_EntityIncorporationStateCountryCode_54d40537-0dbf-4280-93ca-499c30cf2872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_eadfd0a7-f96a-4d08-9c7e-a7512dfd5cb2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb6d0242-43eb-4282-abb3-27eb01c1f85e" xlink:to="loc_dei_EntityTaxIdentificationNumber_eadfd0a7-f96a-4d08-9c7e-a7512dfd5cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_8756e2d4-e85f-49c3-9fe0-2c2dc9c841fc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb6d0242-43eb-4282-abb3-27eb01c1f85e" xlink:to="loc_dei_EntityAddressAddressLine1_8756e2d4-e85f-49c3-9fe0-2c2dc9c841fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_9c459de8-98cf-4eff-977e-48e683771dca" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb6d0242-43eb-4282-abb3-27eb01c1f85e" xlink:to="loc_dei_EntityAddressCityOrTown_9c459de8-98cf-4eff-977e-48e683771dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_614defa2-ca5d-4dd0-8b04-f4702435b050" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb6d0242-43eb-4282-abb3-27eb01c1f85e" xlink:to="loc_dei_EntityAddressStateOrProvince_614defa2-ca5d-4dd0-8b04-f4702435b050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_e4a3158a-33ca-4ba9-8512-d1eba383f0ee" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb6d0242-43eb-4282-abb3-27eb01c1f85e" xlink:to="loc_dei_EntityAddressPostalZipCode_e4a3158a-33ca-4ba9-8512-d1eba383f0ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_af6b051c-d773-40cb-bba0-4712d9e5cd32" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb6d0242-43eb-4282-abb3-27eb01c1f85e" xlink:to="loc_dei_CityAreaCode_af6b051c-d773-40cb-bba0-4712d9e5cd32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_aef0fef3-9c96-4374-bbd8-ac306ec6a873" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb6d0242-43eb-4282-abb3-27eb01c1f85e" xlink:to="loc_dei_LocalPhoneNumber_aef0fef3-9c96-4374-bbd8-ac306ec6a873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_26635731-0bdb-40a8-8fe8-c63eefa46218" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb6d0242-43eb-4282-abb3-27eb01c1f85e" xlink:to="loc_dei_Security12bTitle_26635731-0bdb-40a8-8fe8-c63eefa46218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ce4898e8-c57d-4aba-8c2f-869fae3e4bdc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb6d0242-43eb-4282-abb3-27eb01c1f85e" xlink:to="loc_dei_TradingSymbol_ce4898e8-c57d-4aba-8c2f-869fae3e4bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_57f7bf25-2c67-4b68-8037-cf1bfdea4f4a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb6d0242-43eb-4282-abb3-27eb01c1f85e" xlink:to="loc_dei_SecurityExchangeName_57f7bf25-2c67-4b68-8037-cf1bfdea4f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_83e365f7-5af6-4ea8-880d-67eb63fdf0c2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb6d0242-43eb-4282-abb3-27eb01c1f85e" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_83e365f7-5af6-4ea8-880d-67eb63fdf0c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_eec1e99a-7a46-469d-9534-68b941913933" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb6d0242-43eb-4282-abb3-27eb01c1f85e" xlink:to="loc_dei_EntityVoluntaryFilers_eec1e99a-7a46-469d-9534-68b941913933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_847d6c06-c334-4301-9d29-38103890c96b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb6d0242-43eb-4282-abb3-27eb01c1f85e" xlink:to="loc_dei_EntityCurrentReportingStatus_847d6c06-c334-4301-9d29-38103890c96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_bce6008a-6929-494b-955c-5055cc5884dc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb6d0242-43eb-4282-abb3-27eb01c1f85e" xlink:to="loc_dei_EntityInteractiveDataCurrent_bce6008a-6929-494b-955c-5055cc5884dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_aa908282-19a8-41ad-927d-0418fae4a174" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb6d0242-43eb-4282-abb3-27eb01c1f85e" xlink:to="loc_dei_EntityFilerCategory_aa908282-19a8-41ad-927d-0418fae4a174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_6e1b5fab-2e80-4ba3-98f6-90f337c30be6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb6d0242-43eb-4282-abb3-27eb01c1f85e" xlink:to="loc_dei_EntitySmallBusiness_6e1b5fab-2e80-4ba3-98f6-90f337c30be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_21634968-8dd0-466e-baf3-526c54b00e8c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb6d0242-43eb-4282-abb3-27eb01c1f85e" xlink:to="loc_dei_EntityEmergingGrowthCompany_21634968-8dd0-466e-baf3-526c54b00e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_e5f795b6-cfda-43a3-ae00-0951e2f08bc0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb6d0242-43eb-4282-abb3-27eb01c1f85e" xlink:to="loc_dei_EntityExTransitionPeriod_e5f795b6-cfda-43a3-ae00-0951e2f08bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_c5bd064b-3005-41c8-9b17-a2b3c8f1338d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb6d0242-43eb-4282-abb3-27eb01c1f85e" xlink:to="loc_dei_IcfrAuditorAttestationFlag_c5bd064b-3005-41c8-9b17-a2b3c8f1338d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_8af8d200-7d96-4142-a42e-6a8ba004f442" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb6d0242-43eb-4282-abb3-27eb01c1f85e" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_8af8d200-7d96-4142-a42e-6a8ba004f442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_d13401d8-46af-4303-be8c-c364381f2d5f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb6d0242-43eb-4282-abb3-27eb01c1f85e" xlink:to="loc_dei_EntityShellCompany_d13401d8-46af-4303-be8c-c364381f2d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_e2f9d77e-8fb0-4013-bf25-4ca8ec03f273" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb6d0242-43eb-4282-abb3-27eb01c1f85e" xlink:to="loc_dei_EntityPublicFloat_e2f9d77e-8fb0-4013-bf25-4ca8ec03f273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_3585761d-3f42-4a48-8b58-2d522a5b70c1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb6d0242-43eb-4282-abb3-27eb01c1f85e" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_3585761d-3f42-4a48-8b58-2d522a5b70c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_3109df4a-e3df-46f1-8ae5-599af8ead954" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb6d0242-43eb-4282-abb3-27eb01c1f85e" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_3109df4a-e3df-46f1-8ae5-599af8ead954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_b4ff1493-45f7-4d0a-b553-e493e25ba0ac" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb6d0242-43eb-4282-abb3-27eb01c1f85e" xlink:to="loc_dei_DocumentFiscalYearFocus_b4ff1493-45f7-4d0a-b553-e493e25ba0ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_72e96647-629a-4b60-97bc-9ca7c4da1537" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb6d0242-43eb-4282-abb3-27eb01c1f85e" xlink:to="loc_dei_DocumentFiscalPeriodFocus_72e96647-629a-4b60-97bc-9ca7c4da1537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_ca0f9d7f-828c-4819-962c-4e8c365ff3c6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb6d0242-43eb-4282-abb3-27eb01c1f85e" xlink:to="loc_dei_AmendmentFlag_ca0f9d7f-828c-4819-962c-4e8c365ff3c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_5db69836-3632-41c8-acfc-8ee6975e1165" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb6d0242-43eb-4282-abb3-27eb01c1f85e" xlink:to="loc_dei_EntityCentralIndexKey_5db69836-3632-41c8-acfc-8ee6975e1165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/AuditInformation" xlink:type="simple" xlink:href="exdx-20231231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AuditInformationAbstract_7cc4a2c8-c6a2-4d38-b22d-df8baf5bb39b" xlink:href="exdx-20231231.xsd#exdx_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_249c06c7-a5ee-46ec-a87a-d195170adf5a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_AuditInformationAbstract_7cc4a2c8-c6a2-4d38-b22d-df8baf5bb39b" xlink:to="loc_dei_AuditorName_249c06c7-a5ee-46ec-a87a-d195170adf5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_670d29f0-e3f8-4521-8d3d-dd19b63c8f39" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_AuditInformationAbstract_7cc4a2c8-c6a2-4d38-b22d-df8baf5bb39b" xlink:to="loc_dei_AuditorLocation_670d29f0-e3f8-4521-8d3d-dd19b63c8f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_a9a17069-c154-4a42-b32e-5d0a4b6e28d9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_AuditInformationAbstract_7cc4a2c8-c6a2-4d38-b22d-df8baf5bb39b" xlink:to="loc_dei_AuditorFirmId_a9a17069-c154-4a42-b32e-5d0a4b6e28d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BalanceSheets" xlink:type="simple" xlink:href="exdx-20231231.xsd#BalanceSheets"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_aff4233f-25e6-4a69-8ad2-3cdf2d689039" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_e8a2309c-62da-4cef-886e-c79d6506696c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_aff4233f-25e6-4a69-8ad2-3cdf2d689039" xlink:to="loc_us-gaap_AssetsAbstract_e8a2309c-62da-4cef-886e-c79d6506696c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_bf21d0fe-99db-4025-a51f-a3b27becb1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e8a2309c-62da-4cef-886e-c79d6506696c" xlink:to="loc_us-gaap_AssetsCurrentAbstract_bf21d0fe-99db-4025-a51f-a3b27becb1f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6b8e9491-7463-4597-8595-706c4bdece7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bf21d0fe-99db-4025-a51f-a3b27becb1f2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6b8e9491-7463-4597-8595-706c4bdece7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5d66b902-d15b-4990-b0ea-3a937acfd1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bf21d0fe-99db-4025-a51f-a3b27becb1f2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5d66b902-d15b-4990-b0ea-3a937acfd1bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_937eeb60-64a0-452d-8cad-4748469716e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bf21d0fe-99db-4025-a51f-a3b27becb1f2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_937eeb60-64a0-452d-8cad-4748469716e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1b63dfe3-53cd-4de4-a3a2-856409fa9708" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bf21d0fe-99db-4025-a51f-a3b27becb1f2" xlink:to="loc_us-gaap_AssetsCurrent_1b63dfe3-53cd-4de4-a3a2-856409fa9708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_4e4c672a-1de5-4d21-af54-795db34ccefb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e8a2309c-62da-4cef-886e-c79d6506696c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_4e4c672a-1de5-4d21-af54-795db34ccefb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6b8f81ae-d94a-4b05-9b3e-d156740cace3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e8a2309c-62da-4cef-886e-c79d6506696c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6b8f81ae-d94a-4b05-9b3e-d156740cace3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_15a1a193-28b3-46e6-8324-81a367c40015" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e8a2309c-62da-4cef-886e-c79d6506696c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_15a1a193-28b3-46e6-8324-81a367c40015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_250cd589-1ecd-4793-b70e-0a8d68008b94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e8a2309c-62da-4cef-886e-c79d6506696c" xlink:to="loc_us-gaap_Assets_250cd589-1ecd-4793-b70e-0a8d68008b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dbdd56dd-88d2-4d5c-b518-629db0ca4c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_aff4233f-25e6-4a69-8ad2-3cdf2d689039" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dbdd56dd-88d2-4d5c-b518-629db0ca4c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_df106acf-b01d-403d-94a0-43cf39efb318" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dbdd56dd-88d2-4d5c-b518-629db0ca4c0a" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_df106acf-b01d-403d-94a0-43cf39efb318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_47a72117-bd5f-413c-9567-2156d0d28cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_df106acf-b01d-403d-94a0-43cf39efb318" xlink:to="loc_us-gaap_AccountsPayableCurrent_47a72117-bd5f-413c-9567-2156d0d28cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_518faec6-a6c8-4af1-9fa4-ad678222501d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_df106acf-b01d-403d-94a0-43cf39efb318" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_518faec6-a6c8-4af1-9fa4-ad678222501d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_d9070668-473c-4721-bb4d-d0a126aba643" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_df106acf-b01d-403d-94a0-43cf39efb318" xlink:to="loc_us-gaap_LongTermDebtCurrent_d9070668-473c-4721-bb4d-d0a126aba643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_46cee893-66e3-4931-a881-31643d323b03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_df106acf-b01d-403d-94a0-43cf39efb318" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_46cee893-66e3-4931-a881-31643d323b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6c26f97e-6ec9-4c41-a390-fb9620bcb1ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_df106acf-b01d-403d-94a0-43cf39efb318" xlink:to="loc_us-gaap_LiabilitiesCurrent_6c26f97e-6ec9-4c41-a390-fb9620bcb1ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_5e4a2757-3ac7-4c51-b61c-becbc9f80dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dbdd56dd-88d2-4d5c-b518-629db0ca4c0a" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_5e4a2757-3ac7-4c51-b61c-becbc9f80dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_273c423f-8d7e-47f7-bf87-a9374e8f28fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dbdd56dd-88d2-4d5c-b518-629db0ca4c0a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_273c423f-8d7e-47f7-bf87-a9374e8f28fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_cd5f90f9-250b-4afe-aef3-09ec88eab03b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dbdd56dd-88d2-4d5c-b518-629db0ca4c0a" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_cd5f90f9-250b-4afe-aef3-09ec88eab03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_09e4f3f9-e659-44cb-b4a3-a18f9f222ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dbdd56dd-88d2-4d5c-b518-629db0ca4c0a" xlink:to="loc_us-gaap_Liabilities_09e4f3f9-e659-44cb-b4a3-a18f9f222ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_6673170b-f11c-4062-b8dd-5b0264fe2fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dbdd56dd-88d2-4d5c-b518-629db0ca4c0a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_6673170b-f11c-4062-b8dd-5b0264fe2fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_6e804914-198b-4136-b8e5-82fd3b087ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dbdd56dd-88d2-4d5c-b518-629db0ca4c0a" xlink:to="loc_us-gaap_StockholdersEquityAbstract_6e804914-198b-4136-b8e5-82fd3b087ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_bf256321-752e-43c5-b1ef-7491657f7a72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6e804914-198b-4136-b8e5-82fd3b087ad4" xlink:to="loc_us-gaap_PreferredStockValue_bf256321-752e-43c5-b1ef-7491657f7a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_30b73ccb-448b-45a4-b306-86941bbc1b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6e804914-198b-4136-b8e5-82fd3b087ad4" xlink:to="loc_us-gaap_CommonStockValue_30b73ccb-448b-45a4-b306-86941bbc1b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_811e9887-171f-47f3-8716-45cdd5ac183f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6e804914-198b-4136-b8e5-82fd3b087ad4" xlink:to="loc_us-gaap_AdditionalPaidInCapital_811e9887-171f-47f3-8716-45cdd5ac183f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a21bb141-78db-4a82-bf98-f65ee2900867" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6e804914-198b-4136-b8e5-82fd3b087ad4" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a21bb141-78db-4a82-bf98-f65ee2900867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6cbf6ae3-17db-462f-b91b-cf2d224a44ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6e804914-198b-4136-b8e5-82fd3b087ad4" xlink:to="loc_us-gaap_StockholdersEquity_6cbf6ae3-17db-462f-b91b-cf2d224a44ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4d07d87d-0d36-4581-a313-4cb82d24394b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dbdd56dd-88d2-4d5c-b518-629db0ca4c0a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_4d07d87d-0d36-4581-a313-4cb82d24394b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BalanceSheetsParenthetical" xlink:type="simple" xlink:href="exdx-20231231.xsd#BalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/BalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_a45cc0c2-1c46-4a66-9f91-9081a830f2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_521c6b3d-ed33-4243-88e8-f739e63c9ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a45cc0c2-1c46-4a66-9f91-9081a830f2b2" xlink:to="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_521c6b3d-ed33-4243-88e8-f739e63c9ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_eed0b424-2097-4190-b945-9cab2b38c67d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_521c6b3d-ed33-4243-88e8-f739e63c9ed9" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_eed0b424-2097-4190-b945-9cab2b38c67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_6c937ed8-55d2-4173-bb3a-f9700b513a43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_521c6b3d-ed33-4243-88e8-f739e63c9ed9" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_6c937ed8-55d2-4173-bb3a-f9700b513a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_ed92024c-9aac-4727-bbb3-b067a1ea3899" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_521c6b3d-ed33-4243-88e8-f739e63c9ed9" xlink:to="loc_us-gaap_PreferredStockSharesIssued_ed92024c-9aac-4727-bbb3-b067a1ea3899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_5b85b16e-3f37-47d9-b2a6-c329fb739ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_521c6b3d-ed33-4243-88e8-f739e63c9ed9" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_5b85b16e-3f37-47d9-b2a6-c329fb739ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_ecd64361-4916-433a-af47-acad61b4e12e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a45cc0c2-1c46-4a66-9f91-9081a830f2b2" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_ecd64361-4916-433a-af47-acad61b4e12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f66ff727-e2ab-4511-831d-13c9c18efa68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_ecd64361-4916-433a-af47-acad61b4e12e" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f66ff727-e2ab-4511-831d-13c9c18efa68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_772f5b10-87e9-412d-9f0f-910fdfe58a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_ecd64361-4916-433a-af47-acad61b4e12e" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_772f5b10-87e9-412d-9f0f-910fdfe58a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_7ba3ce58-c558-48a5-938b-95fb4cb92b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_ecd64361-4916-433a-af47-acad61b4e12e" xlink:to="loc_us-gaap_CommonStockSharesIssued_7ba3ce58-c558-48a5-938b-95fb4cb92b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b24f1cf0-9517-47af-ad1c-791d6a55928e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_ecd64361-4916-433a-af47-acad61b4e12e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b24f1cf0-9517-47af-ad1c-791d6a55928e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StatementsofOperations" xlink:type="simple" xlink:href="exdx-20231231.xsd#StatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_dc801374-4a40-4020-91f1-730ea8c1e7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e8e36822-4d52-451c-a99f-140a1da57372" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dc801374-4a40-4020-91f1-730ea8c1e7b1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e8e36822-4d52-451c-a99f-140a1da57372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_1d67ca10-2634-4530-a12f-b564851d70f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dc801374-4a40-4020-91f1-730ea8c1e7b1" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_1d67ca10-2634-4530-a12f-b564851d70f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_da09f065-377a-46d3-9187-5ef37232b658" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1d67ca10-2634-4530-a12f-b564851d70f8" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_da09f065-377a-46d3-9187-5ef37232b658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_5c9cdb1d-8db4-448f-a649-0d46d3af16c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1d67ca10-2634-4530-a12f-b564851d70f8" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_5c9cdb1d-8db4-448f-a649-0d46d3af16c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_20a87fc6-d95c-47b5-9758-49a921eaffdc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1d67ca10-2634-4530-a12f-b564851d70f8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_20a87fc6-d95c-47b5-9758-49a921eaffdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_3cac0e22-64b1-482f-8624-fcc71eb5cf6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1d67ca10-2634-4530-a12f-b564851d70f8" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_3cac0e22-64b1-482f-8624-fcc71eb5cf6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0793a840-ac6f-4f19-a5b6-ddd735472cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1d67ca10-2634-4530-a12f-b564851d70f8" xlink:to="loc_us-gaap_CostsAndExpenses_0793a840-ac6f-4f19-a5b6-ddd735472cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d3bc64ef-0189-478a-b239-9e64b9bfb6a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dc801374-4a40-4020-91f1-730ea8c1e7b1" xlink:to="loc_us-gaap_OperatingIncomeLoss_d3bc64ef-0189-478a-b239-9e64b9bfb6a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_81455679-8687-47c6-b83e-020e04a69db9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dc801374-4a40-4020-91f1-730ea8c1e7b1" xlink:to="loc_us-gaap_InterestExpense_81455679-8687-47c6-b83e-020e04a69db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_7030602b-a4c3-4d2c-a9d2-4f05341c8685" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dc801374-4a40-4020-91f1-730ea8c1e7b1" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_7030602b-a4c3-4d2c-a9d2-4f05341c8685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_625abeb6-e2f0-47d9-9731-909e82a87c00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dc801374-4a40-4020-91f1-730ea8c1e7b1" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_625abeb6-e2f0-47d9-9731-909e82a87c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_26f6eb8e-172b-41fe-a420-65fa945ad8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dc801374-4a40-4020-91f1-730ea8c1e7b1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_26f6eb8e-172b-41fe-a420-65fa945ad8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8ffe0da1-6bc2-4576-a5aa-f725c07569be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dc801374-4a40-4020-91f1-730ea8c1e7b1" xlink:to="loc_us-gaap_NetIncomeLoss_8ffe0da1-6bc2-4576-a5aa-f725c07569be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_63d034b9-0bef-4140-825f-a69f2d352ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dc801374-4a40-4020-91f1-730ea8c1e7b1" xlink:to="loc_us-gaap_EarningsPerShareBasic_63d034b9-0bef-4140-825f-a69f2d352ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5da5e2a4-b640-4741-924e-d98313bd3f44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dc801374-4a40-4020-91f1-730ea8c1e7b1" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5da5e2a4-b640-4741-924e-d98313bd3f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_80b17f5b-1ed3-4cf4-9e95-9f33972e41ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dc801374-4a40-4020-91f1-730ea8c1e7b1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_80b17f5b-1ed3-4cf4-9e95-9f33972e41ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b63b0d4b-5a37-4623-a902-8c7662f5e22d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_dc801374-4a40-4020-91f1-730ea8c1e7b1" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b63b0d4b-5a37-4623-a902-8c7662f5e22d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StatementsofStockholdersEquity" xlink:type="simple" xlink:href="exdx-20231231.xsd#StatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_ccdcb0f5-c7f7-4136-8621-aff80ffb2442" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_60294d3c-5782-4a5c-b6a8-a6df5ac7f011" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_ccdcb0f5-c7f7-4136-8621-aff80ffb2442" xlink:to="loc_us-gaap_StatementTable_60294d3c-5782-4a5c-b6a8-a6df5ac7f011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1f0d7e23-06e0-4f21-aa62-53851f49f1ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_60294d3c-5782-4a5c-b6a8-a6df5ac7f011" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1f0d7e23-06e0-4f21-aa62-53851f49f1ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_49b53a48-7214-462d-944a-1e8ed057a80a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1f0d7e23-06e0-4f21-aa62-53851f49f1ff" xlink:to="loc_us-gaap_EquityComponentDomain_49b53a48-7214-462d-944a-1e8ed057a80a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_16427fe6-7492-4e06-87bc-3756ad025476" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_49b53a48-7214-462d-944a-1e8ed057a80a" xlink:to="loc_us-gaap_CommonStockMember_16427fe6-7492-4e06-87bc-3756ad025476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_df9c059d-f75e-45aa-a93d-daf594652926" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_49b53a48-7214-462d-944a-1e8ed057a80a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_df9c059d-f75e-45aa-a93d-daf594652926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_24a93d6d-7835-4092-8bcf-7352167ef1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_49b53a48-7214-462d-944a-1e8ed057a80a" xlink:to="loc_us-gaap_RetainedEarningsMember_24a93d6d-7835-4092-8bcf-7352167ef1e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_aa1ef10e-7b96-414f-ad86-3e0ba2585f39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_60294d3c-5782-4a5c-b6a8-a6df5ac7f011" xlink:to="loc_us-gaap_StatementLineItems_aa1ef10e-7b96-414f-ad86-3e0ba2585f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c570e2e-ca8a-443c-8c7a-dfb100ea068c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aa1ef10e-7b96-414f-ad86-3e0ba2585f39" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c570e2e-ca8a-443c-8c7a-dfb100ea068c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6cfa81cb-6565-4092-9584-eb37fa8146d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c570e2e-ca8a-443c-8c7a-dfb100ea068c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6cfa81cb-6565-4092-9584-eb37fa8146d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8c65f80a-8718-4a31-b0de-eced66e2d161" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c570e2e-ca8a-443c-8c7a-dfb100ea068c" xlink:to="loc_us-gaap_StockholdersEquity_8c65f80a-8718-4a31-b0de-eced66e2d161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares_0ebda5e2-b8d1-41d2-b556-f2b0f694fda5" xlink:href="exdx-20231231.xsd#exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c570e2e-ca8a-443c-8c7a-dfb100ea068c" xlink:to="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares_0ebda5e2-b8d1-41d2-b556-f2b0f694fda5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue_c5fb100f-e54e-478b-b770-2920fc800e60" xlink:href="exdx-20231231.xsd#exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c570e2e-ca8a-443c-8c7a-dfb100ea068c" xlink:to="loc_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue_c5fb100f-e54e-478b-b770-2920fc800e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_08978e2c-32e6-4795-ae93-5aba41a3fbfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c570e2e-ca8a-443c-8c7a-dfb100ea068c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_08978e2c-32e6-4795-ae93-5aba41a3fbfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8e5f579d-38e3-4d17-b34d-e84a16cec17b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c570e2e-ca8a-443c-8c7a-dfb100ea068c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8e5f579d-38e3-4d17-b34d-e84a16cec17b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_20cdd94c-366b-4bfa-b856-d8b115508c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c570e2e-ca8a-443c-8c7a-dfb100ea068c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_20cdd94c-366b-4bfa-b856-d8b115508c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_26cfb9d2-6c14-44bc-8882-90a631abdf9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c570e2e-ca8a-443c-8c7a-dfb100ea068c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_26cfb9d2-6c14-44bc-8882-90a631abdf9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_314cd0ee-241a-431f-8f7f-d0d8fae1a1a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c570e2e-ca8a-443c-8c7a-dfb100ea068c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_314cd0ee-241a-431f-8f7f-d0d8fae1a1a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_82a726d4-b3ef-4c42-9dcf-1020e26faa06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c570e2e-ca8a-443c-8c7a-dfb100ea068c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_82a726d4-b3ef-4c42-9dcf-1020e26faa06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3eb865f7-71c8-4955-a0ae-31a29179e5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c570e2e-ca8a-443c-8c7a-dfb100ea068c" xlink:to="loc_us-gaap_NetIncomeLoss_3eb865f7-71c8-4955-a0ae-31a29179e5e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3c3b45be-937b-4b42-81d1-0960a864c85d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c570e2e-ca8a-443c-8c7a-dfb100ea068c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3c3b45be-937b-4b42-81d1-0960a864c85d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_db8d14f2-2ece-45d8-ba0d-19ff524b53f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c570e2e-ca8a-443c-8c7a-dfb100ea068c" xlink:to="loc_us-gaap_StockholdersEquity_db8d14f2-2ece-45d8-ba0d-19ff524b53f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StatementsofCashFlows" xlink:type="simple" xlink:href="exdx-20231231.xsd#StatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_945b0551-2788-4f4d-a8bc-d99aaaa6b969" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_089961b2-9972-44d5-9bf6-5b3a7ee233d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_945b0551-2788-4f4d-a8bc-d99aaaa6b969" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_089961b2-9972-44d5-9bf6-5b3a7ee233d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c2969237-3d06-496e-8327-5208ead23d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_089961b2-9972-44d5-9bf6-5b3a7ee233d7" xlink:to="loc_us-gaap_NetIncomeLoss_c2969237-3d06-496e-8327-5208ead23d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2dbe7a7e-1bd6-417c-bacc-85e119c2b831" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_089961b2-9972-44d5-9bf6-5b3a7ee233d7" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2dbe7a7e-1bd6-417c-bacc-85e119c2b831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_0a1de364-f34d-48a4-9a81-9b5713c3b434" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2dbe7a7e-1bd6-417c-bacc-85e119c2b831" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_0a1de364-f34d-48a4-9a81-9b5713c3b434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_ab7847c8-5c0a-4713-be71-02537ec510db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2dbe7a7e-1bd6-417c-bacc-85e119c2b831" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_ab7847c8-5c0a-4713-be71-02537ec510db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_34f990fc-6cc0-4c56-a610-edfe8a359d51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaidInKindInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2dbe7a7e-1bd6-417c-bacc-85e119c2b831" xlink:to="loc_us-gaap_PaidInKindInterest_34f990fc-6cc0-4c56-a610-edfe8a359d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_a018ca28-bdcd-4b93-aa09-56953af21f74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2dbe7a7e-1bd6-417c-bacc-85e119c2b831" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_a018ca28-bdcd-4b93-aa09-56953af21f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_303d93ad-2ac1-418b-ad90-94e901a9bb6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2dbe7a7e-1bd6-417c-bacc-85e119c2b831" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_303d93ad-2ac1-418b-ad90-94e901a9bb6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_GainLossOnDispositionOfLeaseAssignment_8465d188-9a8a-41d1-a31b-db1ff988f613" xlink:href="exdx-20231231.xsd#exdx_GainLossOnDispositionOfLeaseAssignment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2dbe7a7e-1bd6-417c-bacc-85e119c2b831" xlink:to="loc_exdx_GainLossOnDispositionOfLeaseAssignment_8465d188-9a8a-41d1-a31b-db1ff988f613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_NonCashLeaseExpense_4715cf2d-66b5-4334-9148-4af5c45ba07d" xlink:href="exdx-20231231.xsd#exdx_NonCashLeaseExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2dbe7a7e-1bd6-417c-bacc-85e119c2b831" xlink:to="loc_exdx_NonCashLeaseExpense_4715cf2d-66b5-4334-9148-4af5c45ba07d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_ab1a755f-9bf9-4f4c-8fc0-1020ee6b294b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2dbe7a7e-1bd6-417c-bacc-85e119c2b831" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_ab1a755f-9bf9-4f4c-8fc0-1020ee6b294b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_7d297f73-8d2f-43ae-98fa-7fe2bee69b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2dbe7a7e-1bd6-417c-bacc-85e119c2b831" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_7d297f73-8d2f-43ae-98fa-7fe2bee69b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_5f9bde3f-7c1b-426d-8bbb-34cfa36bcd23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2dbe7a7e-1bd6-417c-bacc-85e119c2b831" xlink:to="loc_us-gaap_ShareBasedCompensation_5f9bde3f-7c1b-426d-8bbb-34cfa36bcd23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_98043d46-52b6-4b8c-97e9-594e39e047a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2dbe7a7e-1bd6-417c-bacc-85e119c2b831" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_98043d46-52b6-4b8c-97e9-594e39e047a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c7e8a7cd-6842-467a-b02f-0e5874cde2c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2dbe7a7e-1bd6-417c-bacc-85e119c2b831" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c7e8a7cd-6842-467a-b02f-0e5874cde2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2e393101-f451-475f-a076-18689945e81b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c7e8a7cd-6842-467a-b02f-0e5874cde2c1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2e393101-f451-475f-a076-18689945e81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_c6698ecd-15ec-4f51-ae05-2166bee55da8" xlink:href="exdx-20231231.xsd#exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c7e8a7cd-6842-467a-b02f-0e5874cde2c1" xlink:to="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_c6698ecd-15ec-4f51-ae05-2166bee55da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1214f2ca-150c-4117-a101-72cbe1d55def" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c7e8a7cd-6842-467a-b02f-0e5874cde2c1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1214f2ca-150c-4117-a101-72cbe1d55def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2820a9fa-4737-4a95-bd97-4f16255f496e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c7e8a7cd-6842-467a-b02f-0e5874cde2c1" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2820a9fa-4737-4a95-bd97-4f16255f496e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_eb27814e-cb57-43db-a900-7ee2762ef0af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c7e8a7cd-6842-467a-b02f-0e5874cde2c1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_eb27814e-cb57-43db-a900-7ee2762ef0af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_60f8d820-5970-4b03-bcf7-f646c0ddd94c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c7e8a7cd-6842-467a-b02f-0e5874cde2c1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_60f8d820-5970-4b03-bcf7-f646c0ddd94c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1fa68735-f256-47aa-8167-8dd73f569c49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_089961b2-9972-44d5-9bf6-5b3a7ee233d7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1fa68735-f256-47aa-8167-8dd73f569c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_07fa3214-49f4-482f-9af0-7aafe7c13411" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_945b0551-2788-4f4d-a8bc-d99aaaa6b969" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_07fa3214-49f4-482f-9af0-7aafe7c13411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_03eff9ea-500a-4f3c-a189-0713dcc3250b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_07fa3214-49f4-482f-9af0-7aafe7c13411" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_03eff9ea-500a-4f3c-a189-0713dcc3250b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2c669807-5b46-48ef-87c5-eeb702cd5b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_07fa3214-49f4-482f-9af0-7aafe7c13411" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2c669807-5b46-48ef-87c5-eeb702cd5b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5279d4af-41b7-4af8-8c6c-df68c57ec0db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_07fa3214-49f4-482f-9af0-7aafe7c13411" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5279d4af-41b7-4af8-8c6c-df68c57ec0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_cb4cc61d-7aa2-4c90-9664-b0a74615dc96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_945b0551-2788-4f4d-a8bc-d99aaaa6b969" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_cb4cc61d-7aa2-4c90-9664-b0a74615dc96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_38f11c40-28ee-4917-87ec-71d54fbf52bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_cb4cc61d-7aa2-4c90-9664-b0a74615dc96" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_38f11c40-28ee-4917-87ec-71d54fbf52bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c944ca5e-a968-48c3-9c6a-fd857c69a940" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_cb4cc61d-7aa2-4c90-9664-b0a74615dc96" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c944ca5e-a968-48c3-9c6a-fd857c69a940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_3ddb344f-87a5-4445-bcf0-7b618156e33b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_cb4cc61d-7aa2-4c90-9664-b0a74615dc96" xlink:to="loc_us-gaap_ProceedsFromStockPlans_3ddb344f-87a5-4445-bcf0-7b618156e33b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_c5dae759-dba1-4af2-96e4-eb3815df2170" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_cb4cc61d-7aa2-4c90-9664-b0a74615dc96" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_c5dae759-dba1-4af2-96e4-eb3815df2170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_ee139737-b557-4e7d-9652-e997e24dfa05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_cb4cc61d-7aa2-4c90-9664-b0a74615dc96" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_ee139737-b557-4e7d-9652-e997e24dfa05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_a2c4353e-4acc-45e4-ab86-0696d3baea7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_cb4cc61d-7aa2-4c90-9664-b0a74615dc96" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_a2c4353e-4acc-45e4-ab86-0696d3baea7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_caf5ec48-53fe-4f84-9626-50aaae0604cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_cb4cc61d-7aa2-4c90-9664-b0a74615dc96" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_caf5ec48-53fe-4f84-9626-50aaae0604cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6b482c96-3c74-4c9e-859c-7a61ba54e2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_945b0551-2788-4f4d-a8bc-d99aaaa6b969" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6b482c96-3c74-4c9e-859c-7a61ba54e2cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_601d0dc8-979d-4349-9b37-86f516820a55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_945b0551-2788-4f4d-a8bc-d99aaaa6b969" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_601d0dc8-979d-4349-9b37-86f516820a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ace0cda9-b703-40e5-81f5-e50fcd9eadc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_945b0551-2788-4f4d-a8bc-d99aaaa6b969" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ace0cda9-b703-40e5-81f5-e50fcd9eadc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_01b9c602-07b4-4435-a563-f613be07c321" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_945b0551-2788-4f4d-a8bc-d99aaaa6b969" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_01b9c602-07b4-4435-a563-f613be07c321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_0765a046-b4c2-4388-99e6-5045c21bcb26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_01b9c602-07b4-4435-a563-f613be07c321" xlink:to="loc_us-gaap_InterestPaidNet_0765a046-b4c2-4388-99e6-5045c21bcb26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_b84d962b-5df3-4213-bc0a-8cac8afe99a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_945b0551-2788-4f4d-a8bc-d99aaaa6b969" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_b84d962b-5df3-4213-bc0a-8cac8afe99a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_75b94778-f67e-45d6-8948-cfab1f1c20ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_b84d962b-5df3-4213-bc0a-8cac8afe99a5" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_75b94778-f67e-45d6-8948-cfab1f1c20ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_EquipmentPurchasedUnderNotesPayableObligations_5d996816-477a-499d-b76f-e89097eaa4eb" xlink:href="exdx-20231231.xsd#exdx_EquipmentPurchasedUnderNotesPayableObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_b84d962b-5df3-4213-bc0a-8cac8afe99a5" xlink:to="loc_exdx_EquipmentPurchasedUnderNotesPayableObligations_5d996816-477a-499d-b76f-e89097eaa4eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_6a33adf9-106c-4d62-b4be-a11350283135" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_b84d962b-5df3-4213-bc0a-8cac8afe99a5" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_6a33adf9-106c-4d62-b4be-a11350283135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/Organization" xlink:type="simple" xlink:href="exdx-20231231.xsd#Organization"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/Organization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fdcfbdbe-b5cb-46c3-8499-d40472826691" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_298d095b-7417-4347-a3e6-a5b3c718511d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fdcfbdbe-b5cb-46c3-8499-d40472826691" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_298d095b-7417-4347-a3e6-a5b3c718511d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="exdx-20231231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5c2594d4-6e10-42e2-90a1-6177d3829240" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_45ef56af-8f63-4988-8595-f7807c5c1f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5c2594d4-6e10-42e2-90a1-6177d3829240" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_45ef56af-8f63-4988-8595-f7807c5c1f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformation" xlink:type="simple" xlink:href="exdx-20231231.xsd#OtherFinancialInformation"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_8a2158f6-aa44-4c79-b921-615e5a6ec1f9" xlink:href="exdx-20231231.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_9bbb0581-205a-4340-bcf0-e272866a968b" xlink:href="exdx-20231231.xsd#exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_8a2158f6-aa44-4c79-b921-615e5a6ec1f9" xlink:to="loc_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_9bbb0581-205a-4340-bcf0-e272866a968b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/Borrowings" xlink:type="simple" xlink:href="exdx-20231231.xsd#Borrowings"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/Borrowings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_63e3274b-f15d-4864-8742-c00c9d25c656" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_a8396571-f961-48e2-9c62-63ab77af8d59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_63e3274b-f15d-4864-8742-c00c9d25c656" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_a8396571-f961-48e2-9c62-63ab77af8d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/Leases" xlink:type="simple" xlink:href="exdx-20231231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_07c6af6e-2c58-41f6-a363-cabee48e934b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_ccc32bc7-6335-4f34-b84e-221c5f7a3fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07c6af6e-2c58-41f6-a363-cabee48e934b" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_ccc32bc7-6335-4f34-b84e-221c5f7a3fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_bb585a9e-efa9-4a49-a950-24fd47cfee3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07c6af6e-2c58-41f6-a363-cabee48e934b" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_bb585a9e-efa9-4a49-a950-24fd47cfee3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingencies" xlink:type="simple" xlink:href="exdx-20231231.xsd#CommitmentandContingencies"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/CommitmentandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c457c05f-dc7a-4db6-84e8-6aadd0a1a841" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_bb32a0c3-a931-43f3-89be-9862cd04db99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c457c05f-dc7a-4db6-84e8-6aadd0a1a841" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_bb32a0c3-a931-43f3-89be-9862cd04db99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="exdx-20231231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_54f5fcc1-7d95-44ac-ae0f-e7b24cc56ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_f3824929-1dbf-432d-956a-7bf911fa8ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_54f5fcc1-7d95-44ac-ae0f-e7b24cc56ef2" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_f3824929-1dbf-432d-956a-7bf911fa8ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquity" xlink:type="simple" xlink:href="exdx-20231231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8a30b4b1-457b-43e1-a4c5-19b541a940ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_e3c3d608-a41f-42e7-8491-f2417fec9f01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8a30b4b1-457b-43e1-a4c5-19b541a940ec" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_e3c3d608-a41f-42e7-8491-f2417fec9f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlan" xlink:type="simple" xlink:href="exdx-20231231.xsd#StockOptionPlan"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b8d54df5-2409-42d4-8632-6870df83c99d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_01e961c2-d27c-4930-9cf7-5c25e74b6636" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b8d54df5-2409-42d4-8632-6870df83c99d" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_01e961c2-d27c-4930-9cf7-5c25e74b6636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxes" xlink:type="simple" xlink:href="exdx-20231231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1756dcbf-d420-401e-80e4-3ae98a8dc942" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_40f8e8da-bdbc-4c0f-90e7-f24bcba3087e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1756dcbf-d420-401e-80e4-3ae98a8dc942" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_40f8e8da-bdbc-4c0f-90e7-f24bcba3087e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/A401kPlan" xlink:type="simple" xlink:href="exdx-20231231.xsd#A401kPlan"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/A401kPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_5bbef733-0cff-4307-970e-b4a56cc0cc63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_c33590d3-4224-4cc0-baa0-4a46de133c45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_5bbef733-0cff-4307-970e-b4a56cc0cc63" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_c33590d3-4224-4cc0-baa0-4a46de133c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="exdx-20231231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a356af52-7b29-46df-8735-53cc7dd09623" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_50feb125-c3b4-4cdb-a398-771405c8426f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a356af52-7b29-46df-8735-53cc7dd09623" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_50feb125-c3b4-4cdb-a398-771405c8426f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_092eafb6-f3b1-4f46-a594-a4bb72bcba38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a356af52-7b29-46df-8735-53cc7dd09623" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_092eafb6-f3b1-4f46-a594-a4bb72bcba38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_8dd8c50e-a73a-4940-acc4-f5c4c3278fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a356af52-7b29-46df-8735-53cc7dd09623" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_8dd8c50e-a73a-4940-acc4-f5c4c3278fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_89b9c9aa-4854-4871-9e49-63052e7575f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a356af52-7b29-46df-8735-53cc7dd09623" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_89b9c9aa-4854-4871-9e49-63052e7575f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_680bd8d4-60bf-4f9e-a516-ef253ec3c47f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a356af52-7b29-46df-8735-53cc7dd09623" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_680bd8d4-60bf-4f9e-a516-ef253ec3c47f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_b906847a-48d5-4545-98dc-54c54ca878e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a356af52-7b29-46df-8735-53cc7dd09623" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_b906847a-48d5-4545-98dc-54c54ca878e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClinicalStudyPolicyPolicyTextBlock_25930edb-3d70-4197-ba6e-a7752e81b15e" xlink:href="exdx-20231231.xsd#exdx_ClinicalStudyPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a356af52-7b29-46df-8735-53cc7dd09623" xlink:to="loc_exdx_ClinicalStudyPolicyPolicyTextBlock_25930edb-3d70-4197-ba6e-a7752e81b15e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_0817048e-d11d-4053-b034-00ee11a94ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a356af52-7b29-46df-8735-53cc7dd09623" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_0817048e-d11d-4053-b034-00ee11a94ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_a1904bfb-4c62-4f87-83d0-d20d8b21267b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a356af52-7b29-46df-8735-53cc7dd09623" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_a1904bfb-4c62-4f87-83d0-d20d8b21267b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_0d9656f2-cb73-4318-ae5a-1540c370ed46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a356af52-7b29-46df-8735-53cc7dd09623" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_0d9656f2-cb73-4318-ae5a-1540c370ed46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_bda45641-df65-42e6-af37-9ce2fe933ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a356af52-7b29-46df-8735-53cc7dd09623" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_bda45641-df65-42e6-af37-9ce2fe933ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_e14c8fb8-f301-4199-9024-e7d54b8c1e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a356af52-7b29-46df-8735-53cc7dd09623" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_e14c8fb8-f301-4199-9024-e7d54b8c1e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPolicy_a50b6003-f4c5-4972-a3c3-939389613f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a356af52-7b29-46df-8735-53cc7dd09623" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPPolicy_a50b6003-f4c5-4972-a3c3-939389613f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_0cf92ed4-297a-4143-a217-e566cbcc4b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a356af52-7b29-46df-8735-53cc7dd09623" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_0cf92ed4-297a-4143-a217-e566cbcc4b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_fcc203ce-56a5-49e8-a679-52cc8434e8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a356af52-7b29-46df-8735-53cc7dd09623" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_fcc203ce-56a5-49e8-a679-52cc8434e8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_aae870a5-f397-400e-af98-0bd9899688ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a356af52-7b29-46df-8735-53cc7dd09623" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_aae870a5-f397-400e-af98-0bd9899688ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_c7628aa8-80e6-4bd7-b407-1ebe64989352" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a356af52-7b29-46df-8735-53cc7dd09623" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_c7628aa8-80e6-4bd7-b407-1ebe64989352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_77c211ec-18cc-4288-a6cf-883a4274a0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a356af52-7b29-46df-8735-53cc7dd09623" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_77c211ec-18cc-4288-a6cf-883a4274a0d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_97b2bdbe-f102-4705-a276-dbba2b32166e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a356af52-7b29-46df-8735-53cc7dd09623" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_97b2bdbe-f102-4705-a276-dbba2b32166e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="exdx-20231231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8f023f0a-f2d9-4088-af0c-c3cf283d49ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_ea34cc2d-3c2c-4f8e-a06a-9cce7b54d494" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8f023f0a-f2d9-4088-af0c-c3cf283d49ae" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_ea34cc2d-3c2c-4f8e-a06a-9cce7b54d494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_b64dca64-f628-4e9b-8b2d-2d23167f7618" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8f023f0a-f2d9-4088-af0c-c3cf283d49ae" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_b64dca64-f628-4e9b-8b2d-2d23167f7618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_2f110c0f-45c5-4182-8e6e-3be34a0a7f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8f023f0a-f2d9-4088-af0c-c3cf283d49ae" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_2f110c0f-45c5-4182-8e6e-3be34a0a7f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_d7f65e64-81fb-4899-807c-414e7f61a477" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8f023f0a-f2d9-4088-af0c-c3cf283d49ae" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_d7f65e64-81fb-4899-807c-414e7f61a477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1cf547db-a010-49b0-81e5-a7c5c3a7c5b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8f023f0a-f2d9-4088-af0c-c3cf283d49ae" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1cf547db-a010-49b0-81e5-a7c5c3a7c5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationTables" xlink:type="simple" xlink:href="exdx-20231231.xsd#OtherFinancialInformationTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_4f9f3ead-3e56-44e6-b2aa-19647f7b0679" xlink:href="exdx-20231231.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_0e5cfa2c-e892-4e5a-b261-f223eb20b73c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_4f9f3ead-3e56-44e6-b2aa-19647f7b0679" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_0e5cfa2c-e892-4e5a-b261-f223eb20b73c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_ea44db44-c121-49d2-a32e-aea88fdcc19d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_4f9f3ead-3e56-44e6-b2aa-19647f7b0679" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_ea44db44-c121-49d2-a32e-aea88fdcc19d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_372a0a16-cf3c-4561-957c-93287b5cb033" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_4f9f3ead-3e56-44e6-b2aa-19647f7b0679" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_372a0a16-cf3c-4561-957c-93287b5cb033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_08279c03-3868-49df-a3a1-00f381cb9f12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_4f9f3ead-3e56-44e6-b2aa-19647f7b0679" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_08279c03-3868-49df-a3a1-00f381cb9f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsTables" xlink:type="simple" xlink:href="exdx-20231231.xsd#BorrowingsTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/BorrowingsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_768cbefa-cfbe-4ee3-9361-a1acd16c4ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_3db3e47c-2ce5-4f8f-88f2-2360d41fd579" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_768cbefa-cfbe-4ee3-9361-a1acd16c4ebe" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_3db3e47c-2ce5-4f8f-88f2-2360d41fd579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/LeasesTables" xlink:type="simple" xlink:href="exdx-20231231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_33b03c77-0058-40f8-a702-206e0b70d088" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_0375052a-ebbe-4e13-b930-94b6fa660357" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_33b03c77-0058-40f8-a702-206e0b70d088" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_0375052a-ebbe-4e13-b930-94b6fa660357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d0551cf9-8672-4c27-bb3f-09bac31c94e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_33b03c77-0058-40f8-a702-206e0b70d088" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d0551cf9-8672-4c27-bb3f-09bac31c94e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_980efb8d-fd51-438e-9ad8-7ba6b221d3d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_33b03c77-0058-40f8-a702-206e0b70d088" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_980efb8d-fd51-438e-9ad8-7ba6b221d3d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="exdx-20231231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_be438f20-c795-4c19-8458-54c65ace552e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_54ece574-710f-4fb2-b5b3-29a5943516c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_be438f20-c795-4c19-8458-54c65ace552e" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_54ece574-710f-4fb2-b5b3-29a5943516c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="exdx-20231231.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4bf67c01-2dc4-46ce-b0ba-5417a6cf8cea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_d8f3f7f9-b6e3-4a17-9f9f-5ed9236afa15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4bf67c01-2dc4-46ce-b0ba-5417a6cf8cea" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_d8f3f7f9-b6e3-4a17-9f9f-5ed9236afa15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanTables" xlink:type="simple" xlink:href="exdx-20231231.xsd#StockOptionPlanTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9f3c7625-7620-4657-821e-aa1c2e8a4c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_63237448-ac6e-4c5e-a883-ab1564af5e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9f3c7625-7620-4657-821e-aa1c2e8a4c2f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_63237448-ac6e-4c5e-a883-ab1564af5e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8d8be5f9-4426-465c-a675-2c47fd6934d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9f3c7625-7620-4657-821e-aa1c2e8a4c2f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8d8be5f9-4426-465c-a675-2c47fd6934d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_48ec4aba-e475-4f04-b485-f93ab2a2ac28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9f3c7625-7620-4657-821e-aa1c2e8a4c2f" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_48ec4aba-e475-4f04-b485-f93ab2a2ac28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_d67535ac-f1be-460f-be42-d5d1f80e51cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9f3c7625-7620-4657-821e-aa1c2e8a4c2f" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_d67535ac-f1be-460f-be42-d5d1f80e51cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="exdx-20231231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_61b31afb-8380-4a11-b9c8-4983e350b042" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_5cd67c43-08ed-4427-b4dd-a5da21335079" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_61b31afb-8380-4a11-b9c8-4983e350b042" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_5cd67c43-08ed-4427-b4dd-a5da21335079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_e662489b-99b8-4d2d-b876-31a28d6ad257" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_61b31afb-8380-4a11-b9c8-4983e350b042" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_e662489b-99b8-4d2d-b876-31a28d6ad257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_d4fdd904-6b76-47e4-9089-93c5a68b05e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_61b31afb-8380-4a11-b9c8-4983e350b042" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_d4fdd904-6b76-47e4-9089-93c5a68b05e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_bf831505-ef80-415f-a3a6-e8511706d462" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_61b31afb-8380-4a11-b9c8-4983e350b042" xlink:to="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_bf831505-ef80-415f-a3a6-e8511706d462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OrganizationDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#OrganizationDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OrganizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d6e900a0-486f-460c-a967-428e5a354036" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_71084637-61ef-4a48-8a49-e7973fb54160" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d6e900a0-486f-460c-a967-428e5a354036" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_71084637-61ef-4a48-8a49-e7973fb54160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a8e889d5-d08d-4987-8ef1-9a8045f5bc69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d6e900a0-486f-460c-a967-428e5a354036" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a8e889d5-d08d-4987-8ef1-9a8045f5bc69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4272d1c3-be54-4ff6-a5e9-07a8db77fb73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_75139919-08e7-413c-9b06-7d2ea99be02b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4272d1c3-be54-4ff6-a5e9-07a8db77fb73" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_75139919-08e7-413c-9b06-7d2ea99be02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_ddd4ebf5-b95d-4f60-9b2e-b2ddeb04901f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_75139919-08e7-413c-9b06-7d2ea99be02b" xlink:to="loc_srt_MajorCustomersAxis_ddd4ebf5-b95d-4f60-9b2e-b2ddeb04901f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_eb5d47f1-99c9-4c9b-88a5-7f56fae59753" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_ddd4ebf5-b95d-4f60-9b2e-b2ddeb04901f" xlink:to="loc_srt_NameOfMajorCustomerDomain_eb5d47f1-99c9-4c9b-88a5-7f56fae59753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareMember_3735fe49-ed00-48d5-89ad-45758056196a" xlink:href="exdx-20231231.xsd#exdx_MedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_eb5d47f1-99c9-4c9b-88a5-7f56fae59753" xlink:to="loc_exdx_MedicareMember_3735fe49-ed00-48d5-89ad-45758056196a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareAdvantageMember_ba9084ca-7c25-42ca-8c9a-a6cc12dfbd5f" xlink:href="exdx-20231231.xsd#exdx_MedicareAdvantageMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_eb5d47f1-99c9-4c9b-88a5-7f56fae59753" xlink:to="loc_exdx_MedicareAdvantageMember_ba9084ca-7c25-42ca-8c9a-a6cc12dfbd5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_40df6f9d-69cc-4c6f-bc15-8bc610a9f45e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_75139919-08e7-413c-9b06-7d2ea99be02b" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_40df6f9d-69cc-4c6f-bc15-8bc610a9f45e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5d7425a1-a225-440b-b95c-0b53d772a6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_40df6f9d-69cc-4c6f-bc15-8bc610a9f45e" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5d7425a1-a225-440b-b95c-0b53d772a6ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_021d078c-7d09-49a4-9ae4-4dfc2b8423e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5d7425a1-a225-440b-b95c-0b53d772a6ff" xlink:to="loc_us-gaap_SalesRevenueNetMember_021d078c-7d09-49a4-9ae4-4dfc2b8423e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_aa84b715-34b1-4112-9c19-60be3b5ac773" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5d7425a1-a225-440b-b95c-0b53d772a6ff" xlink:to="loc_us-gaap_AccountsReceivableMember_aa84b715-34b1-4112-9c19-60be3b5ac773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_b85975ab-ead0-4ad8-a96f-530b27e1ed9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_75139919-08e7-413c-9b06-7d2ea99be02b" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_b85975ab-ead0-4ad8-a96f-530b27e1ed9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_86b70236-ed1e-4ba5-8f13-64383396fd1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b85975ab-ead0-4ad8-a96f-530b27e1ed9d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_86b70236-ed1e-4ba5-8f13-64383396fd1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_b76c1a85-1e99-4944-9d85-cc4ea495fec0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_86b70236-ed1e-4ba5-8f13-64383396fd1a" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_b76c1a85-1e99-4944-9d85-cc4ea495fec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_4e9cfa3b-9fcb-4f7c-aa77-d38e236b84ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_75139919-08e7-413c-9b06-7d2ea99be02b" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_4e9cfa3b-9fcb-4f7c-aa77-d38e236b84ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_90ac7dfd-94bf-42b4-a04c-298fff513b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4e9cfa3b-9fcb-4f7c-aa77-d38e236b84ae" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_90ac7dfd-94bf-42b4-a04c-298fff513b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d4b25e02-368a-41a9-888b-bc355c196512" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_e24730bf-4786-4ae0-b708-ee772792520b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d4b25e02-368a-41a9-888b-bc355c196512" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_e24730bf-4786-4ae0-b708-ee772792520b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_35dd194c-7a2d-4c03-89cd-0565948a76b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_e24730bf-4786-4ae0-b708-ee772792520b" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_35dd194c-7a2d-4c03-89cd-0565948a76b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_56f0da9a-8be4-4a78-93d6-7a4bfa47a404" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_35dd194c-7a2d-4c03-89cd-0565948a76b2" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_56f0da9a-8be4-4a78-93d6-7a4bfa47a404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_1e73f145-5aa9-4e8d-abfb-086746a14840" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_56f0da9a-8be4-4a78-93d6-7a4bfa47a404" xlink:to="loc_us-gaap_SalesRevenueNetMember_1e73f145-5aa9-4e8d-abfb-086746a14840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a3305396-f354-4625-a79b-6ab514d397e5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_e24730bf-4786-4ae0-b708-ee772792520b" xlink:to="loc_srt_ProductOrServiceAxis_a3305396-f354-4625-a79b-6ab514d397e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_03436841-8634-42f0-b86a-f23cacb5dda7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a3305396-f354-4625-a79b-6ab514d397e5" xlink:to="loc_srt_ProductsAndServicesDomain_03436841-8634-42f0-b86a-f23cacb5dda7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AVISECTDTestMember_cc3f0eb8-4285-4355-ad96-e94d10734d1a" xlink:href="exdx-20231231.xsd#exdx_AVISECTDTestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_03436841-8634-42f0-b86a-f23cacb5dda7" xlink:to="loc_exdx_AVISECTDTestMember_cc3f0eb8-4285-4355-ad96-e94d10734d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember_316cb6c4-f250-4014-b4fa-998cab04c0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_03436841-8634-42f0-b86a-f23cacb5dda7" xlink:to="loc_us-gaap_ShippingAndHandlingMember_316cb6c4-f250-4014-b4fa-998cab04c0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_b9953fb3-e9dd-46e1-a63f-3e1d563c7e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_e24730bf-4786-4ae0-b708-ee772792520b" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_b9953fb3-e9dd-46e1-a63f-3e1d563c7e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_86c77500-0d6f-40fc-8361-249dc4c36815" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b9953fb3-e9dd-46e1-a63f-3e1d563c7e4c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_86c77500-0d6f-40fc-8361-249dc4c36815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_d78433d4-e67d-4d4b-aca5-01e2b0a5539b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_86c77500-0d6f-40fc-8361-249dc4c36815" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_d78433d4-e67d-4d4b-aca5-01e2b0a5539b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember_8c19216a-bb9c-48ba-a897-c67b6977b56a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_86c77500-0d6f-40fc-8361-249dc4c36815" xlink:to="loc_us-gaap_SupplierConcentrationRiskMember_8c19216a-bb9c-48ba-a897-c67b6977b56a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_ff2f63c0-dc2d-47f1-b47d-bd700b02c964" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_e24730bf-4786-4ae0-b708-ee772792520b" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_ff2f63c0-dc2d-47f1-b47d-bd700b02c964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_07e512fa-8245-47dc-93c1-db75cea0f13b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_ff2f63c0-dc2d-47f1-b47d-bd700b02c964" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_07e512fa-8245-47dc-93c1-db75cea0f13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TwoSuppliersMember_dfd38594-d1fb-40fe-8ceb-7debac1266ea" xlink:href="exdx-20231231.xsd#exdx_TwoSuppliersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_07e512fa-8245-47dc-93c1-db75cea0f13b" xlink:to="loc_exdx_TwoSuppliersMember_dfd38594-d1fb-40fe-8ceb-7debac1266ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b5617d96-7a26-4c26-b549-4ee4d785f6eb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_e24730bf-4786-4ae0-b708-ee772792520b" xlink:to="loc_srt_RangeAxis_b5617d96-7a26-4c26-b549-4ee4d785f6eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dab15490-e38a-4674-be08-f09f7a2a6d5e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b5617d96-7a26-4c26-b549-4ee4d785f6eb" xlink:to="loc_srt_RangeMember_dab15490-e38a-4674-be08-f09f7a2a6d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a0b723cc-e748-43b6-be51-fbe132aedc71" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_dab15490-e38a-4674-be08-f09f7a2a6d5e" xlink:to="loc_srt_MinimumMember_a0b723cc-e748-43b6-be51-fbe132aedc71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9f8f8636-f359-4cd5-b289-8745f5624354" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_dab15490-e38a-4674-be08-f09f7a2a6d5e" xlink:to="loc_srt_MaximumMember_9f8f8636-f359-4cd5-b289-8745f5624354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_260dc148-6774-4dac-a4f6-d38236917ead" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_e24730bf-4786-4ae0-b708-ee772792520b" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_260dc148-6774-4dac-a4f6-d38236917ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_43afd688-efb7-4521-ac17-e1b1151dd0a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_260dc148-6774-4dac-a4f6-d38236917ead" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_43afd688-efb7-4521-ac17-e1b1151dd0a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_f63525af-bbdb-4710-822e-531a52ea7cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_260dc148-6774-4dac-a4f6-d38236917ead" xlink:to="loc_us-gaap_RestrictedCash_f63525af-bbdb-4710-822e-531a52ea7cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_09e97fe7-0b3b-42d8-a439-3ecf7502e0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_260dc148-6774-4dac-a4f6-d38236917ead" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_09e97fe7-0b3b-42d8-a439-3ecf7502e0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_4b6c3ece-4ec5-48eb-8ec3-4c7c21459a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_260dc148-6774-4dac-a4f6-d38236917ead" xlink:to="loc_us-gaap_NumberOfOperatingSegments_4b6c3ece-4ec5-48eb-8ec3-4c7c21459a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_a9328da2-ce88-4401-b234-ca122fbe896b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_260dc148-6774-4dac-a4f6-d38236917ead" xlink:to="loc_us-gaap_NumberOfReportingUnits_a9328da2-ce88-4401-b234-ca122fbe896b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_c0d5b95f-4cc5-4424-8e2d-dd53831b639a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_260dc148-6774-4dac-a4f6-d38236917ead" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_c0d5b95f-4cc5-4424-8e2d-dd53831b639a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest_3542c996-3533-4f73-9833-f9e34607fff1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_260dc148-6774-4dac-a4f6-d38236917ead" xlink:to="loc_us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest_3542c996-3533-4f73-9833-f9e34607fff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_250fbc72-db07-4882-87b8-737685576e53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_260dc148-6774-4dac-a4f6-d38236917ead" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_250fbc72-db07-4882-87b8-737685576e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_6e68c835-ea13-4d23-8e2a-1adc8f7d21b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_260dc148-6774-4dac-a4f6-d38236917ead" xlink:to="loc_us-gaap_AdvertisingExpense_6e68c835-ea13-4d23-8e2a-1adc8f7d21b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_0f602453-c3f1-4b9f-b668-882c30e73c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_260dc148-6774-4dac-a4f6-d38236917ead" xlink:to="loc_us-gaap_CostOfRevenue_0f602453-c3f1-4b9f-b668-882c30e73c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8d63acb8-970e-4fca-a7c6-51b49fc1ac97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_260dc148-6774-4dac-a4f6-d38236917ead" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8d63acb8-970e-4fca-a7c6-51b49fc1ac97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_5d9554c9-167c-4b48-98ba-db069d5b20b1" xlink:href="exdx-20231231.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_260dc148-6774-4dac-a4f6-d38236917ead" xlink:to="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_5d9554c9-167c-4b48-98ba-db069d5b20b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f96c3caa-48bf-4505-bea9-a16bfe3b14b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_d48cd8af-a42c-41b8-86e4-5eca760cbc52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f96c3caa-48bf-4505-bea9-a16bfe3b14b4" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_d48cd8af-a42c-41b8-86e4-5eca760cbc52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_051a867f-355c-4941-8e29-e3ff30a82c25" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d48cd8af-a42c-41b8-86e4-5eca760cbc52" xlink:to="loc_srt_MajorCustomersAxis_051a867f-355c-4941-8e29-e3ff30a82c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e341cd28-d3ac-447b-89fd-71edd7f4dff2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_051a867f-355c-4941-8e29-e3ff30a82c25" xlink:to="loc_srt_NameOfMajorCustomerDomain_e341cd28-d3ac-447b-89fd-71edd7f4dff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CommercialMember_032d31d0-0745-436d-8ce3-96f22b27d20e" xlink:href="exdx-20231231.xsd#exdx_CommercialMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_e341cd28-d3ac-447b-89fd-71edd7f4dff2" xlink:to="loc_exdx_CommercialMember_032d31d0-0745-436d-8ce3-96f22b27d20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Government1Member_6ebca207-bdec-4617-9199-647482c665d9" xlink:href="exdx-20231231.xsd#exdx_Government1Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_e341cd28-d3ac-447b-89fd-71edd7f4dff2" xlink:to="loc_exdx_Government1Member_6ebca207-bdec-4617-9199-647482c665d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClientMember_5b26ff30-2a8c-46e6-af2a-d8f3606694bc" xlink:href="exdx-20231231.xsd#exdx_ClientMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_e341cd28-d3ac-447b-89fd-71edd7f4dff2" xlink:to="loc_exdx_ClientMember_5b26ff30-2a8c-46e6-af2a-d8f3606694bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCustomerMember_a7e2b4ce-6e2a-4742-83cd-f110109be7d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCustomerMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_e341cd28-d3ac-447b-89fd-71edd7f4dff2" xlink:to="loc_us-gaap_OtherCustomerMember_a7e2b4ce-6e2a-4742-83cd-f110109be7d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_57575f04-6dcf-42aa-98b5-96197feeb950" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d48cd8af-a42c-41b8-86e4-5eca760cbc52" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_57575f04-6dcf-42aa-98b5-96197feeb950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6b102dd6-45e3-46b7-9ed5-5cce1f785060" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_57575f04-6dcf-42aa-98b5-96197feeb950" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6b102dd6-45e3-46b7-9ed5-5cce1f785060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_358d3142-8f98-4615-9ea9-04f3cb9d4da1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_eb3224cd-a217-474b-86e1-ec84460357a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_358d3142-8f98-4615-9ea9-04f3cb9d4da1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_eb3224cd-a217-474b-86e1-ec84460357a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_cfb563dc-a112-4a51-b7de-5c3d43dcaa27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_358d3142-8f98-4615-9ea9-04f3cb9d4da1" xlink:to="loc_us-gaap_RestrictedCash_cfb563dc-a112-4a51-b7de-5c3d43dcaa27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_79874fc3-18a7-48df-994e-19973a76a9ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_358d3142-8f98-4615-9ea9-04f3cb9d4da1" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_79874fc3-18a7-48df-994e-19973a76a9ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#SummaryofSignificantAccountingPoliciesSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_82d4e94c-875b-439d-814d-17f8645cbec1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_f42e4301-60d3-4c45-9906-4efcae6ad8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82d4e94c-875b-439d-814d-17f8645cbec1" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_f42e4301-60d3-4c45-9906-4efcae6ad8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ba368db8-399d-473e-81df-e7365ae43e44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f42e4301-60d3-4c45-9906-4efcae6ad8d0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ba368db8-399d-473e-81df-e7365ae43e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6efeb938-376d-4620-a874-da5567013891" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ba368db8-399d-473e-81df-e7365ae43e44" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6efeb938-376d-4620-a874-da5567013891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_1c7bcab3-f492-4368-a47a-29c4af5fe216" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6efeb938-376d-4620-a874-da5567013891" xlink:to="loc_us-gaap_WarrantMember_1c7bcab3-f492-4368-a47a-29c4af5fe216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_14bcb0d9-7fa0-46e7-bc40-f20126fe4c27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6efeb938-376d-4620-a874-da5567013891" xlink:to="loc_us-gaap_StockOptionMember_14bcb0d9-7fa0-46e7-bc40-f20126fe4c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0136fc92-e230-4822-94e9-ce6f8a0f2b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6efeb938-376d-4620-a874-da5567013891" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0136fc92-e230-4822-94e9-ce6f8a0f2b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_24d99201-36be-4334-8074-d17c892beb6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6efeb938-376d-4620-a874-da5567013891" xlink:to="loc_us-gaap_EmployeeStockMember_24d99201-36be-4334-8074-d17c892beb6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_94e0246a-b023-45ae-9bb8-29b11365b6e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f42e4301-60d3-4c45-9906-4efcae6ad8d0" xlink:to="loc_us-gaap_ClassOfStockLineItems_94e0246a-b023-45ae-9bb8-29b11365b6e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9425df88-8dc3-4c11-abdd-b8f356ec788b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_94e0246a-b023-45ae-9bb8-29b11365b6e7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9425df88-8dc3-4c11-abdd-b8f356ec788b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#OtherFinancialInformationPrepaidExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_04368c47-cf75-4388-9378-085ba233657d" xlink:href="exdx-20231231.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_138f4777-2aac-437d-af58-28d16a5ed372" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_04368c47-cf75-4388-9378-085ba233657d" xlink:to="loc_us-gaap_OtherAssetsCurrent_138f4777-2aac-437d-af58-28d16a5ed372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRoyalties_78a5d5c6-0403-4dee-bae5-652dae8cfb67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_04368c47-cf75-4388-9378-085ba233657d" xlink:to="loc_us-gaap_PrepaidRoyalties_78a5d5c6-0403-4dee-bae5-652dae8cfb67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidMaintenanceAndInsuranceContracts_4cbf9b04-e57d-47bf-8559-17a75879095a" xlink:href="exdx-20231231.xsd#exdx_PrepaidMaintenanceAndInsuranceContracts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_04368c47-cf75-4388-9378-085ba233657d" xlink:to="loc_exdx_PrepaidMaintenanceAndInsuranceContracts_4cbf9b04-e57d-47bf-8559-17a75879095a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_5f630584-c3d6-4629-b048-f7244ccbee4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_04368c47-cf75-4388-9378-085ba233657d" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_5f630584-c3d6-4629-b048-f7244ccbee4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_830e7626-5a23-4c12-a44e-860099cd1e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_04368c47-cf75-4388-9378-085ba233657d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_830e7626-5a23-4c12-a44e-860099cd1e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#OtherFinancialInformationPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_b8df4b7b-4aa9-463c-96e7-84a2c53d2111" xlink:href="exdx-20231231.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_101927fd-bfae-4ed6-9fbd-e086f74ac2b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_b8df4b7b-4aa9-463c-96e7-84a2c53d2111" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_101927fd-bfae-4ed6-9fbd-e086f74ac2b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_945c371a-5f49-40e2-a433-95a2dbaf79e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_101927fd-bfae-4ed6-9fbd-e086f74ac2b8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_945c371a-5f49-40e2-a433-95a2dbaf79e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_11d71b98-fc6f-47ad-b9ce-8e58748ea5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_945c371a-5f49-40e2-a433-95a2dbaf79e5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_11d71b98-fc6f-47ad-b9ce-8e58748ea5cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_9f0f0a02-0f37-49c4-b95b-a44c2fded006" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_11d71b98-fc6f-47ad-b9ce-8e58748ea5cf" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_9f0f0a02-0f37-49c4-b95b-a44c2fded006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LaboratoryEquipmentMember_f97bea8a-f30b-427c-bf50-28044e14837b" xlink:href="exdx-20231231.xsd#exdx_LaboratoryEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_11d71b98-fc6f-47ad-b9ce-8e58748ea5cf" xlink:to="loc_exdx_LaboratoryEquipmentMember_f97bea8a-f30b-427c-bf50-28044e14837b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ComputerEquipmentAndSoftwareMember_7f8074d7-697b-47d0-888e-757a28b2fc5e" xlink:href="exdx-20231231.xsd#exdx_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_11d71b98-fc6f-47ad-b9ce-8e58748ea5cf" xlink:to="loc_exdx_ComputerEquipmentAndSoftwareMember_7f8074d7-697b-47d0-888e-757a28b2fc5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_766006cc-768c-4a5e-8516-d6219bdcb3eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_11d71b98-fc6f-47ad-b9ce-8e58748ea5cf" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_766006cc-768c-4a5e-8516-d6219bdcb3eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_e3a0c74a-c881-4436-9dd4-7f528e7f405a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_11d71b98-fc6f-47ad-b9ce-8e58748ea5cf" xlink:to="loc_us-gaap_ConstructionInProgressMember_e3a0c74a-c881-4436-9dd4-7f528e7f405a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fb2bca64-1e3c-4c2c-a1fb-94c5ff83d84f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_101927fd-bfae-4ed6-9fbd-e086f74ac2b8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fb2bca64-1e3c-4c2c-a1fb-94c5ff83d84f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_effd902f-08ad-4c23-a006-defc156a8347" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fb2bca64-1e3c-4c2c-a1fb-94c5ff83d84f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_effd902f-08ad-4c23-a006-defc156a8347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_cc76db24-926f-4def-9619-d42f4e7b8eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fb2bca64-1e3c-4c2c-a1fb-94c5ff83d84f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_cc76db24-926f-4def-9619-d42f4e7b8eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_7fa04131-14a6-404a-9cb9-39cd7823d573" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fb2bca64-1e3c-4c2c-a1fb-94c5ff83d84f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_7fa04131-14a6-404a-9cb9-39cd7823d573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#OtherFinancialInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_789d7d3e-b7de-4ec8-848d-55d2871e3d35" xlink:href="exdx-20231231.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7bb9d684-1c60-49ad-95c5-7f194f4526a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_789d7d3e-b7de-4ec8-848d-55d2871e3d35" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7bb9d684-1c60-49ad-95c5-7f194f4526a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_50890ca8-a32d-472a-9ff7-04b68a021f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7bb9d684-1c60-49ad-95c5-7f194f4526a2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_50890ca8-a32d-472a-9ff7-04b68a021f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a7d39df5-fa8e-44d4-b19a-9f3e2ab31297" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_50890ca8-a32d-472a-9ff7-04b68a021f9b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a7d39df5-fa8e-44d4-b19a-9f3e2ab31297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LaboratoryEquipmentMember_b85bfbee-eaaa-40ce-bc98-7642fabd2bad" xlink:href="exdx-20231231.xsd#exdx_LaboratoryEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a7d39df5-fa8e-44d4-b19a-9f3e2ab31297" xlink:to="loc_exdx_LaboratoryEquipmentMember_b85bfbee-eaaa-40ce-bc98-7642fabd2bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_a4a03f2e-3ea3-47e0-94e8-70c8236dd881" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a7d39df5-fa8e-44d4-b19a-9f3e2ab31297" xlink:to="loc_us-gaap_BuildingMember_a4a03f2e-3ea3-47e0-94e8-70c8236dd881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a77b7989-f268-41ba-8a56-459693d5c1d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7bb9d684-1c60-49ad-95c5-7f194f4526a2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a77b7989-f268-41ba-8a56-459693d5c1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_51ef2914-4e28-4101-834d-ab38e026a100" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a77b7989-f268-41ba-8a56-459693d5c1d8" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_51ef2914-4e28-4101-834d-ab38e026a100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_561c8006-809c-471d-bed6-7438d0dee88b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a77b7989-f268-41ba-8a56-459693d5c1d8" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_561c8006-809c-471d-bed6-7438d0dee88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_04254c19-1c15-4d34-8edb-6ecf658cab13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a77b7989-f268-41ba-8a56-459693d5c1d8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_04254c19-1c15-4d34-8edb-6ecf658cab13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8b1b293e-bb15-44f6-93e1-a83921e065ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a77b7989-f268-41ba-8a56-459693d5c1d8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8b1b293e-bb15-44f6-93e1-a83921e065ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_5e956213-e312-44d5-997c-1f3673ac0634" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a77b7989-f268-41ba-8a56-459693d5c1d8" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_5e956213-e312-44d5-997c-1f3673ac0634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_GainLossOnDispositionOfLeaseAssignment_701eec7a-b004-4b94-8492-cee5344193d3" xlink:href="exdx-20231231.xsd#exdx_GainLossOnDispositionOfLeaseAssignment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a77b7989-f268-41ba-8a56-459693d5c1d8" xlink:to="loc_exdx_GainLossOnDispositionOfLeaseAssignment_701eec7a-b004-4b94-8492-cee5344193d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_5595a903-5d83-449c-986d-71d80d722ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a77b7989-f268-41ba-8a56-459693d5c1d8" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_5595a903-5d83-449c-986d-71d80d722ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_46972c59-c726-467d-8b19-553a602942e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a77b7989-f268-41ba-8a56-459693d5c1d8" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_46972c59-c726-467d-8b19-553a602942e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationGoodwillDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#OtherFinancialInformationGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_60f7aeb3-0b4b-4a07-af04-77bebee27721" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_24bee893-5c43-44d5-846a-9f5b98f26f69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_60f7aeb3-0b4b-4a07-af04-77bebee27721" xlink:to="loc_us-gaap_GoodwillRollForward_24bee893-5c43-44d5-846a-9f5b98f26f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_756891ac-1ff0-4c06-950b-c568904120d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_24bee893-5c43-44d5-846a-9f5b98f26f69" xlink:to="loc_us-gaap_Goodwill_756891ac-1ff0-4c06-950b-c568904120d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_b874205c-7b2e-427f-a034-adbf417a397b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_24bee893-5c43-44d5-846a-9f5b98f26f69" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_b874205c-7b2e-427f-a034-adbf417a397b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3dd357de-43ef-4fa3-bb60-2d1b760662c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_24bee893-5c43-44d5-846a-9f5b98f26f69" xlink:to="loc_us-gaap_Goodwill_3dd357de-43ef-4fa3-bb60-2d1b760662c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#OtherFinancialInformationAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_c798c5cb-84e2-4782-88a5-e5f8a765d028" xlink:href="exdx-20231231.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_b63b51ee-5dee-4c55-8266-e4815f075106" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_c798c5cb-84e2-4782-88a5-e5f8a765d028" xlink:to="loc_us-gaap_AccruedSalariesCurrent_b63b51ee-5dee-4c55-8266-e4815f075106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_78222c58-490b-4704-8e03-2d15d41a6341" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_c798c5cb-84e2-4782-88a5-e5f8a765d028" xlink:to="loc_us-gaap_InterestPayableCurrent_78222c58-490b-4704-8e03-2d15d41a6341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent_09fa216b-8309-4e11-9a8a-64f7be8e2fe6" xlink:href="exdx-20231231.xsd#exdx_AccruedPurchaseGoodsAndServicesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_c798c5cb-84e2-4782-88a5-e5f8a765d028" xlink:to="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent_09fa216b-8309-4e11-9a8a-64f7be8e2fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_58b5d100-01b9-4dad-bdcb-ddc9e3da43b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_c798c5cb-84e2-4782-88a5-e5f8a765d028" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_58b5d100-01b9-4dad-bdcb-ddc9e3da43b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent_5cb3bffe-48b6-4475-8752-6e3fd1bb52ea" xlink:href="exdx-20231231.xsd#exdx_AccruedLiabilitiesClinicalStudyCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_c798c5cb-84e2-4782-88a5-e5f8a765d028" xlink:to="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent_5cb3bffe-48b6-4475-8752-6e3fd1bb52ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_49f3c46f-6593-4056-9173-7032c92ed355" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_c798c5cb-84e2-4782-88a5-e5f8a765d028" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_49f3c46f-6593-4056-9173-7032c92ed355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_1561f423-d684-4567-b4cf-6ce9f802d226" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_c798c5cb-84e2-4782-88a5-e5f8a765d028" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_1561f423-d684-4567-b4cf-6ce9f802d226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_0f550a67-570d-47c7-8fcb-c0cd150bda13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_c798c5cb-84e2-4782-88a5-e5f8a765d028" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_0f550a67-570d-47c7-8fcb-c0cd150bda13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_9e72b1d7-19b3-4bb7-9058-4153de5c869b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_c798c5cb-84e2-4782-88a5-e5f8a765d028" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_9e72b1d7-19b3-4bb7-9058-4153de5c869b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5734b157-c3b0-4ddb-9c61-67091df00cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_c798c5cb-84e2-4782-88a5-e5f8a765d028" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_5734b157-c3b0-4ddb-9c61-67091df00cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#BorrowingsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_05ed5f7a-0483-4fe3-8258-16c278ffb7c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c25e87c1-3992-484a-81e1-9e41cb6a4e45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_05ed5f7a-0483-4fe3-8258-16c278ffb7c4" xlink:to="loc_us-gaap_DebtInstrumentTable_c25e87c1-3992-484a-81e1-9e41cb6a4e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ff50a05b-e967-4f3e-ac78-58ba1874ef4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c25e87c1-3992-484a-81e1-9e41cb6a4e45" xlink:to="loc_us-gaap_DebtInstrumentAxis_ff50a05b-e967-4f3e-ac78-58ba1874ef4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_44cb3282-41ce-4064-928d-5dc545452742" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ff50a05b-e967-4f3e-ac78-58ba1874ef4a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_44cb3282-41ce-4064-928d-5dc545452742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AmendedLoanAgreementMember_b8cc33a6-b6c7-47bb-80c2-dffc22529def" xlink:href="exdx-20231231.xsd#exdx_AmendedLoanAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_44cb3282-41ce-4064-928d-5dc545452742" xlink:to="loc_exdx_AmendedLoanAgreementMember_b8cc33a6-b6c7-47bb-80c2-dffc22529def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Term2017Member_2c59ed7d-7af8-456b-97aa-5248ec0e8c87" xlink:href="exdx-20231231.xsd#exdx_Term2017Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_44cb3282-41ce-4064-928d-5dc545452742" xlink:to="loc_exdx_Term2017Member_2c59ed7d-7af8-456b-97aa-5248ec0e8c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_EquipmentNotesPayableMember_35727683-5682-4b01-b999-3e793b63fc48" xlink:href="exdx-20231231.xsd#exdx_EquipmentNotesPayableMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_44cb3282-41ce-4064-928d-5dc545452742" xlink:to="loc_exdx_EquipmentNotesPayableMember_35727683-5682-4b01-b999-3e793b63fc48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_be74f14c-29a8-4a95-b85e-85ee12863fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c25e87c1-3992-484a-81e1-9e41cb6a4e45" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_be74f14c-29a8-4a95-b85e-85ee12863fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_ea2a0e75-eb76-4154-a8a1-578f10276dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_be74f14c-29a8-4a95-b85e-85ee12863fa0" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_ea2a0e75-eb76-4154-a8a1-578f10276dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_InnovatusLifeSciencesLendingFundMember_47c54579-475a-4cfd-baa5-7b5d50e5f44b" xlink:href="exdx-20231231.xsd#exdx_InnovatusLifeSciencesLendingFundMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_ea2a0e75-eb76-4154-a8a1-578f10276dbf" xlink:to="loc_exdx_InnovatusLifeSciencesLendingFundMember_47c54579-475a-4cfd-baa5-7b5d50e5f44b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4986cfae-a92e-470e-ae83-2038cbf9a5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c25e87c1-3992-484a-81e1-9e41cb6a4e45" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4986cfae-a92e-470e-ae83-2038cbf9a5ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cc03927b-f95f-46bc-945f-f0b395f1374a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4986cfae-a92e-470e-ae83-2038cbf9a5ab" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cc03927b-f95f-46bc-945f-f0b395f1374a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_e962d077-10c9-42c2-a381-ef8b6a776490" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cc03927b-f95f-46bc-945f-f0b395f1374a" xlink:to="loc_us-gaap_LoansPayableMember_e962d077-10c9-42c2-a381-ef8b6a776490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentInKindPIKNoteMember_835b5913-de98-4dad-b24d-1bc21b1e0ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentInKindPIKNoteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cc03927b-f95f-46bc-945f-f0b395f1374a" xlink:to="loc_us-gaap_PaymentInKindPIKNoteMember_835b5913-de98-4dad-b24d-1bc21b1e0ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_9363f53a-4ade-4875-895e-9118bb92922d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c25e87c1-3992-484a-81e1-9e41cb6a4e45" xlink:to="loc_us-gaap_VariableRateAxis_9363f53a-4ade-4875-895e-9118bb92922d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_e0e01adf-edee-4bae-97cd-2ed067dfa10c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_9363f53a-4ade-4875-895e-9118bb92922d" xlink:to="loc_us-gaap_VariableRateDomain_e0e01adf-edee-4bae-97cd-2ed067dfa10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_3fde93e2-7ab3-4087-b0b2-6485aeb79b70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_e0e01adf-edee-4bae-97cd-2ed067dfa10c" xlink:to="loc_us-gaap_PrimeRateMember_3fde93e2-7ab3-4087-b0b2-6485aeb79b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c25e87c1-3992-484a-81e1-9e41cb6a4e45" xlink:to="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_30558997-6878-4139-8131-47c21adb19e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_30558997-6878-4139-8131-47c21adb19e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_7f2f6002-f777-4b62-873c-596423e3bdc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_7f2f6002-f777-4b62-873c-596423e3bdc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_bb5b20ba-c149-4ad7-8244-8bd561602b10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_bb5b20ba-c149-4ad7-8244-8bd561602b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_38e51e03-d4e3-4e83-b180-31e51221b8a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_38e51e03-d4e3-4e83-b180-31e51221b8a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f2072faa-7877-4d97-8ea2-b31a36429771" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f2072faa-7877-4d97-8ea2-b31a36429771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_348ee653-3ed1-4f60-a187-4ca86a7022ef" xlink:href="exdx-20231231.xsd#exdx_DebtInstrumentStatedInterestRatePaidInKind"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:to="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_348ee653-3ed1-4f60-a187-4ca86a7022ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0a7bac9f-e4a7-4dff-8244-aa6cf6e6a572" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0a7bac9f-e4a7-4dff-8244-aa6cf6e6a572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentNumberOfMonthlyInstallments_5497a19a-0957-465f-831f-a69c485421ab" xlink:href="exdx-20231231.xsd#exdx_DebtInstrumentNumberOfMonthlyInstallments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:to="loc_exdx_DebtInstrumentNumberOfMonthlyInstallments_5497a19a-0957-465f-831f-a69c485421ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_46306923-2319-4544-b723-47e270b7fe47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_46306923-2319-4544-b723-47e270b7fe47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPaidInKindLoansIssued_85eb58e8-41bd-486d-a194-0c9565a9eb5a" xlink:href="exdx-20231231.xsd#exdx_DebtInstrumentPaidInKindLoansIssued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:to="loc_exdx_DebtInstrumentPaidInKindLoansIssued_85eb58e8-41bd-486d-a194-0c9565a9eb5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_3a67b621-f99d-4cd1-aabd-e15dc3aa62cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_3a67b621-f99d-4cd1-aabd-e15dc3aa62cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage_c099cecb-f7d3-4374-afc9-481ef8a2aeff" xlink:href="exdx-20231231.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:to="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage_c099cecb-f7d3-4374-afc9-481ef8a2aeff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantRevenuePerformancePeriod_db1741af-9f7d-4dae-9833-31d17921338c" xlink:href="exdx-20231231.xsd#exdx_DebtInstrumentCovenantRevenuePerformancePeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:to="loc_exdx_DebtInstrumentCovenantRevenuePerformancePeriod_db1741af-9f7d-4dae-9833-31d17921338c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant_6fd5d805-a361-4b97-b19c-a706ed346a0f" xlink:href="exdx-20231231.xsd#exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:to="loc_exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant_6fd5d805-a361-4b97-b19c-a706ed346a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet_aa3660f8-e2f1-4f74-a7b0-df9e259b54b1" xlink:href="exdx-20231231.xsd#exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:to="loc_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet_aa3660f8-e2f1-4f74-a7b0-df9e259b54b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_fc8876e5-978b-40e3-abc0-e98c6aa494df" xlink:href="exdx-20231231.xsd#exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:to="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_fc8876e5-978b-40e3-abc0-e98c6aa494df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_29846138-5719-4447-bdfc-44639d373f0f" xlink:href="exdx-20231231.xsd#exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:to="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_29846138-5719-4447-bdfc-44639d373f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_434482ed-cb76-4f84-85c2-5b03dcfc7a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:to="loc_us-gaap_NotesPayable_434482ed-cb76-4f84-85c2-5b03dcfc7a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_6bfd6def-6fc3-4fd3-bd7a-101c66c55da6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:to="loc_us-gaap_NotesPayableCurrent_6bfd6def-6fc3-4fd3-bd7a-101c66c55da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_2fe505da-6873-44e2-9e4b-2b24894a02d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermNotesPayable"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fbfe6daa-fbeb-4142-94bd-22420fcf4448" xlink:to="loc_us-gaap_LongTermNotesPayable_2fe505da-6873-44e2-9e4b-2b24894a02d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#BorrowingsFutureMinimumPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_966455ee-e427-4a59-90e4-21a346c56f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_11eea206-690f-4933-a5b4-7a6fe86b250e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_966455ee-e427-4a59-90e4-21a346c56f1a" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_11eea206-690f-4933-a5b4-7a6fe86b250e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_d2226061-d6f2-4d93-bc3f-a44ea69f41f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_966455ee-e427-4a59-90e4-21a346c56f1a" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_d2226061-d6f2-4d93-bc3f-a44ea69f41f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_d3930df2-45d2-412d-a15f-164f92b3db11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_966455ee-e427-4a59-90e4-21a346c56f1a" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_d3930df2-45d2-412d-a15f-164f92b3db11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtIncludingUndiscountedInterest_8a99d667-694a-4a9d-8b5d-9010b0735d36" xlink:href="exdx-20231231.xsd#exdx_LongTermDebtIncludingUndiscountedInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_966455ee-e427-4a59-90e4-21a346c56f1a" xlink:to="loc_exdx_LongTermDebtIncludingUndiscountedInterest_8a99d667-694a-4a9d-8b5d-9010b0735d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_2d9ff3ac-bd9b-462d-a050-64571815742a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_966455ee-e427-4a59-90e4-21a346c56f1a" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_2d9ff3ac-bd9b-462d-a050-64571815742a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtUndiscountedInterestAmount_71f8d9cb-7312-4956-a361-6299f9635a2d" xlink:href="exdx-20231231.xsd#exdx_LongTermDebtUndiscountedInterestAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_966455ee-e427-4a59-90e4-21a346c56f1a" xlink:to="loc_exdx_LongTermDebtUndiscountedInterestAmount_71f8d9cb-7312-4956-a361-6299f9635a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d8267350-d864-4e2f-940a-3c525a7cf9de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_966455ee-e427-4a59-90e4-21a346c56f1a" xlink:to="loc_us-gaap_LongTermDebt_d8267350-d864-4e2f-940a-3c525a7cf9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_34eee7fc-bab4-4e60-8b5a-1efc9de6bfa1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_966455ee-e427-4a59-90e4-21a346c56f1a" xlink:to="loc_us-gaap_LongTermDebtCurrent_34eee7fc-bab4-4e60-8b5a-1efc9de6bfa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_87375c62-54c3-4018-aeba-e18898713ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_966455ee-e427-4a59-90e4-21a346c56f1a" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_87375c62-54c3-4018-aeba-e18898713ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e08df98b-f5be-4223-aca8-69b386956d33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_03eab5f6-120e-4d24-9424-96ffb71ce980" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e08df98b-f5be-4223-aca8-69b386956d33" xlink:to="loc_us-gaap_LossContingenciesTable_03eab5f6-120e-4d24-9424-96ffb71ce980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeAxis_912e4154-a562-492b-b269-d816b9fcc65b" xlink:href="exdx-20231231.xsd#exdx_RentalPropertyByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_03eab5f6-120e-4d24-9424-96ffb71ce980" xlink:to="loc_exdx_RentalPropertyByTypeAxis_912e4154-a562-492b-b269-d816b9fcc65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeDomain_049bd3c2-173d-4e0d-ac39-081622261f47" xlink:href="exdx-20231231.xsd#exdx_RentalPropertyByTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_RentalPropertyByTypeAxis_912e4154-a562-492b-b269-d816b9fcc65b" xlink:to="loc_exdx_RentalPropertyByTypeDomain_049bd3c2-173d-4e0d-ac39-081622261f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeAndLaboratoryMember_4074b9ba-b1c4-4731-81e0-fbee353fdb94" xlink:href="exdx-20231231.xsd#exdx_OfficeAndLaboratoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_RentalPropertyByTypeDomain_049bd3c2-173d-4e0d-ac39-081622261f47" xlink:to="loc_exdx_OfficeAndLaboratoryMember_4074b9ba-b1c4-4731-81e0-fbee353fdb94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeMember_8fad9003-ee7e-4e6c-a774-c1b0744a8e46" xlink:href="exdx-20231231.xsd#exdx_OfficeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_RentalPropertyByTypeDomain_049bd3c2-173d-4e0d-ac39-081622261f47" xlink:to="loc_exdx_OfficeMember_8fad9003-ee7e-4e6c-a774-c1b0744a8e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6ed56dfd-56dd-47da-8dd1-a4a2ebf6fa6c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_03eab5f6-120e-4d24-9424-96ffb71ce980" xlink:to="loc_srt_RangeAxis_6ed56dfd-56dd-47da-8dd1-a4a2ebf6fa6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fdc732fb-ca65-4b5e-bade-47447a0fbb64" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6ed56dfd-56dd-47da-8dd1-a4a2ebf6fa6c" xlink:to="loc_srt_RangeMember_fdc732fb-ca65-4b5e-bade-47447a0fbb64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_645fae5d-a210-465f-b6e0-87761f65b48c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fdc732fb-ca65-4b5e-bade-47447a0fbb64" xlink:to="loc_srt_MinimumMember_645fae5d-a210-465f-b6e0-87761f65b48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5916ebc1-fbb2-4aac-96fa-81b54c7abfc9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fdc732fb-ca65-4b5e-bade-47447a0fbb64" xlink:to="loc_srt_MaximumMember_5916ebc1-fbb2-4aac-96fa-81b54c7abfc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_137e10e4-2770-4883-b3ab-a7bce8fd62bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_03eab5f6-120e-4d24-9424-96ffb71ce980" xlink:to="loc_us-gaap_LeaseContractualTermAxis_137e10e4-2770-4883-b3ab-a7bce8fd62bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_ce3680f8-72ab-4251-bab4-57fc2376541b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_137e10e4-2770-4883-b3ab-a7bce8fd62bf" xlink:to="loc_us-gaap_LeaseContractualTermDomain_ce3680f8-72ab-4251-bab4-57fc2376541b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeAndLaboratoryMember_2f95aeeb-c125-4b27-8061-c03802b666d2" xlink:href="exdx-20231231.xsd#exdx_OfficeAndLaboratoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_ce3680f8-72ab-4251-bab4-57fc2376541b" xlink:to="loc_exdx_OfficeAndLaboratoryMember_2f95aeeb-c125-4b27-8061-c03802b666d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeMember_a6922863-f047-4933-bd76-01a16df69e1a" xlink:href="exdx-20231231.xsd#exdx_OfficeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_ce3680f8-72ab-4251-bab4-57fc2376541b" xlink:to="loc_exdx_OfficeMember_a6922863-f047-4933-bd76-01a16df69e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_c1687ef9-370a-42da-aae8-0aff1f117ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_03eab5f6-120e-4d24-9424-96ffb71ce980" xlink:to="loc_us-gaap_LossContingenciesLineItems_c1687ef9-370a-42da-aae8-0aff1f117ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_b9e7a88b-adcd-4c7c-be0d-0f9d40d62ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c1687ef9-370a-42da-aae8-0aff1f117ffc" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_b9e7a88b-adcd-4c7c-be0d-0f9d40d62ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeaseMonthlyBaseRent_2f831440-f880-4a63-8cb8-2db3d74113e3" xlink:href="exdx-20231231.xsd#exdx_OperatingLeaseMonthlyBaseRent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c1687ef9-370a-42da-aae8-0aff1f117ffc" xlink:to="loc_exdx_OperatingLeaseMonthlyBaseRent_2f831440-f880-4a63-8cb8-2db3d74113e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent_8d7c2a4f-04d3-4424-b00b-8118e4fc1e3c" xlink:href="exdx-20231231.xsd#exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c1687ef9-370a-42da-aae8-0aff1f117ffc" xlink:to="loc_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent_8d7c2a4f-04d3-4424-b00b-8118e4fc1e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_54f70bf6-3e89-4559-83e7-6dbd4a9284cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c1687ef9-370a-42da-aae8-0aff1f117ffc" xlink:to="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_54f70bf6-3e89-4559-83e7-6dbd4a9284cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/LeasesLeaseBalancesDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#LeasesLeaseBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/LeasesLeaseBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2b11596a-1184-42e4-8cd5-dae10be08869" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b287f904-b269-4280-a2ee-46ca6bf19df5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2b11596a-1184-42e4-8cd5-dae10be08869" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b287f904-b269-4280-a2ee-46ca6bf19df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_00e8c393-66f3-4460-bbb2-7e843bd5bd48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2b11596a-1184-42e4-8cd5-dae10be08869" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_00e8c393-66f3-4460-bbb2-7e843bd5bd48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_198f709e-b9b6-4958-bbf5-0121803aac60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2b11596a-1184-42e4-8cd5-dae10be08869" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_198f709e-b9b6-4958-bbf5-0121803aac60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_63e496b4-83d9-4699-ad38-d9b5b3edf2bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2b11596a-1184-42e4-8cd5-dae10be08869" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_63e496b4-83d9-4699-ad38-d9b5b3edf2bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_e6426a93-5599-4fb6-acc5-b2294b69ffb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2b11596a-1184-42e4-8cd5-dae10be08869" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_e6426a93-5599-4fb6-acc5-b2294b69ffb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_0654fbe5-ea86-4f6a-9887-d5eaa286d0c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2b11596a-1184-42e4-8cd5-dae10be08869" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_0654fbe5-ea86-4f6a-9887-d5eaa286d0c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4a30151f-5659-4005-8c60-6ed858fe6ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2b11596a-1184-42e4-8cd5-dae10be08869" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4a30151f-5659-4005-8c60-6ed858fe6ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_8bb639c5-4f5e-4290-8f23-75cb85374896" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2b11596a-1184-42e4-8cd5-dae10be08869" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_8bb639c5-4f5e-4290-8f23-75cb85374896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_0eee38f4-9605-4265-b396-904e6ef196e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2b11596a-1184-42e4-8cd5-dae10be08869" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_0eee38f4-9605-4265-b396-904e6ef196e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/LeasesCostsAssociatedwiththeCompanysLeasesDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#LeasesCostsAssociatedwiththeCompanysLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/LeasesCostsAssociatedwiththeCompanysLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ea495055-310a-4f19-9fa8-f3e824c52eb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_699db025-e2ca-4e53-8f3b-aa2018c3fa1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ea495055-310a-4f19-9fa8-f3e824c52eb6" xlink:to="loc_us-gaap_OperatingLeaseCost_699db025-e2ca-4e53-8f3b-aa2018c3fa1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_5e8869aa-e9ca-4120-829c-a5edfbde65f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ea495055-310a-4f19-9fa8-f3e824c52eb6" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_5e8869aa-e9ca-4120-829c-a5edfbde65f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_d67b7a51-e920-4be3-9135-e29cb830ab77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ea495055-310a-4f19-9fa8-f3e824c52eb6" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_d67b7a51-e920-4be3-9135-e29cb830ab77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_13c89ed8-e1e9-4573-a13d-d9194b63263b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ea495055-310a-4f19-9fa8-f3e824c52eb6" xlink:to="loc_us-gaap_LeaseCost_13c89ed8-e1e9-4573-a13d-d9194b63263b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_adb5878e-ba08-4fdd-a9c9-0a7ba17fd065" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ea495055-310a-4f19-9fa8-f3e824c52eb6" xlink:to="loc_us-gaap_VariableLeaseCost_adb5878e-ba08-4fdd-a9c9-0a7ba17fd065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/LeasesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#LeasesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/LeasesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_510f331c-59c6-430c-81b7-4e3d58d3cf56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract_b5095b94-8417-4780-80b6-abd6c767fc4b" xlink:href="exdx-20231231.xsd#exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_510f331c-59c6-430c-81b7-4e3d58d3cf56" xlink:to="loc_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract_b5095b94-8417-4780-80b6-abd6c767fc4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_ee1da6a1-13f6-42ae-b096-5ec842723fec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract_b5095b94-8417-4780-80b6-abd6c767fc4b" xlink:to="loc_us-gaap_OperatingLeasePayments_ee1da6a1-13f6-42ae-b096-5ec842723fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_acfdc41e-4af8-40e9-bb6a-7c046a52d521" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract_b5095b94-8417-4780-80b6-abd6c767fc4b" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_acfdc41e-4af8-40e9-bb6a-7c046a52d521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_6f6645f3-9f24-42d4-a6a5-d2b88322c63e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract_b5095b94-8417-4780-80b6-abd6c767fc4b" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_6f6645f3-9f24-42d4-a6a5-d2b88322c63e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_WeightedAverageRemainingLeaseTermAbstract_2a889c25-2570-4bc0-8042-2f733252ad3e" xlink:href="exdx-20231231.xsd#exdx_WeightedAverageRemainingLeaseTermAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_510f331c-59c6-430c-81b7-4e3d58d3cf56" xlink:to="loc_exdx_WeightedAverageRemainingLeaseTermAbstract_2a889c25-2570-4bc0-8042-2f733252ad3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_60f454b7-94d8-4138-b3ce-3159e7b69f18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_WeightedAverageRemainingLeaseTermAbstract_2a889c25-2570-4bc0-8042-2f733252ad3e" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_60f454b7-94d8-4138-b3ce-3159e7b69f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_40901bfe-4ac3-4ae3-87de-240fbd1ea213" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_WeightedAverageRemainingLeaseTermAbstract_2a889c25-2570-4bc0-8042-2f733252ad3e" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_40901bfe-4ac3-4ae3-87de-240fbd1ea213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_WeightedAverageDiscountRateAbstract_1018abe4-e714-48b3-8e65-d83b46e8951e" xlink:href="exdx-20231231.xsd#exdx_WeightedAverageDiscountRateAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_510f331c-59c6-430c-81b7-4e3d58d3cf56" xlink:to="loc_exdx_WeightedAverageDiscountRateAbstract_1018abe4-e714-48b3-8e65-d83b46e8951e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_79b6bbbc-2ef6-4a58-b2c7-3bcb44c1423c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_WeightedAverageDiscountRateAbstract_1018abe4-e714-48b3-8e65-d83b46e8951e" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_79b6bbbc-2ef6-4a58-b2c7-3bcb44c1423c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_28b99781-13a7-468a-9deb-c3e757eb47e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_WeightedAverageDiscountRateAbstract_1018abe4-e714-48b3-8e65-d83b46e8951e" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_28b99781-13a7-468a-9deb-c3e757eb47e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_bd38ba55-e34b-4486-907c-f7ca9e6de8e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3f29e263-62fc-4d1d-b1dc-99962891672e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bd38ba55-e34b-4486-907c-f7ca9e6de8e8" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3f29e263-62fc-4d1d-b1dc-99962891672e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ce638b6e-d12d-4961-b086-8cde044b4a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3f29e263-62fc-4d1d-b1dc-99962891672e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ce638b6e-d12d-4961-b086-8cde044b4a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4d3372b6-44f0-411e-94c4-89992ab7493f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3f29e263-62fc-4d1d-b1dc-99962891672e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4d3372b6-44f0-411e-94c4-89992ab7493f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e9fa385d-01dc-4349-8599-251b045f92bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3f29e263-62fc-4d1d-b1dc-99962891672e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e9fa385d-01dc-4349-8599-251b045f92bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5349f913-021c-46d4-a5ff-dcf6dfdbf7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3f29e263-62fc-4d1d-b1dc-99962891672e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5349f913-021c-46d4-a5ff-dcf6dfdbf7f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fe311419-3b4a-4aab-b098-6681376906ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3f29e263-62fc-4d1d-b1dc-99962891672e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fe311419-3b4a-4aab-b098-6681376906ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_17e4b33c-5242-4046-a498-b1400e9be1cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3f29e263-62fc-4d1d-b1dc-99962891672e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_17e4b33c-5242-4046-a498-b1400e9be1cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_74394f2c-a591-4b58-92b4-eb8eda5c89e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3f29e263-62fc-4d1d-b1dc-99962891672e" xlink:to="loc_us-gaap_OperatingLeaseLiability_74394f2c-a591-4b58-92b4-eb8eda5c89e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_d4c7f9e1-1cd2-4035-88a4-af11b990de82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3f29e263-62fc-4d1d-b1dc-99962891672e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_d4c7f9e1-1cd2-4035-88a4-af11b990de82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0c16a407-465a-4fa8-883d-49d7708824c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3f29e263-62fc-4d1d-b1dc-99962891672e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0c16a407-465a-4fa8-883d-49d7708824c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_61abcdeb-b7b5-4d64-9e7a-88688922e002" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bd38ba55-e34b-4486-907c-f7ca9e6de8e8" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_61abcdeb-b7b5-4d64-9e7a-88688922e002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_c6d4bea2-db57-4574-8ae8-baf52a3b13f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_61abcdeb-b7b5-4d64-9e7a-88688922e002" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_c6d4bea2-db57-4574-8ae8-baf52a3b13f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_7ec7ec65-5d47-43fa-a2fb-baa134e32013" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_61abcdeb-b7b5-4d64-9e7a-88688922e002" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_7ec7ec65-5d47-43fa-a2fb-baa134e32013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_14f643b3-5d87-4eb7-8ff4-02b6d1f51a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_61abcdeb-b7b5-4d64-9e7a-88688922e002" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_14f643b3-5d87-4eb7-8ff4-02b6d1f51a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_02231293-01a5-4e55-b948-7e5edd79a23a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_61abcdeb-b7b5-4d64-9e7a-88688922e002" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_02231293-01a5-4e55-b948-7e5edd79a23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_fb8fed5d-0eab-4c7f-a577-a23ffb37c735" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_61abcdeb-b7b5-4d64-9e7a-88688922e002" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_fb8fed5d-0eab-4c7f-a577-a23ffb37c735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_96b86ac3-5c3b-4208-9667-e01c7593683f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_61abcdeb-b7b5-4d64-9e7a-88688922e002" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_96b86ac3-5c3b-4208-9667-e01c7593683f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_9a704481-5ad5-4597-92a5-f82635fcfcb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_61abcdeb-b7b5-4d64-9e7a-88688922e002" xlink:to="loc_us-gaap_FinanceLeaseLiability_9a704481-5ad5-4597-92a5-f82635fcfcb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_e968c721-7ff3-4f55-8c2a-88004f9e5f94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_61abcdeb-b7b5-4d64-9e7a-88688922e002" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_e968c721-7ff3-4f55-8c2a-88004f9e5f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_c773887b-a657-41f2-871b-4e5ece669bda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_61abcdeb-b7b5-4d64-9e7a-88688922e002" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_c773887b-a657-41f2-871b-4e5ece669bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1" xlink:type="simple" xlink:href="exdx-20231231.xsd#LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#CommitmentandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_44b45e2e-9cf4-45c9-8fe4-6afd1a8a0c32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_8ae3ee8d-5d8a-429e-9a5c-72d8cb53afaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_44b45e2e-9cf4-45c9-8fe4-6afd1a8a0c32" xlink:to="loc_us-gaap_OtherCommitmentsTable_8ae3ee8d-5d8a-429e-9a5c-72d8cb53afaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_467a1985-530f-4635-8137-7b55a20f62b8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_8ae3ee8d-5d8a-429e-9a5c-72d8cb53afaf" xlink:to="loc_srt_CounterpartyNameAxis_467a1985-530f-4635-8137-7b55a20f62b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b91b0dcc-5e22-47c2-9d66-ccab23575098" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_467a1985-530f-4635-8137-7b55a20f62b8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b91b0dcc-5e22-47c2-9d66-ccab23575098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrometheusLaboratoriesIncMember_d20750c7-8672-4a87-839a-fae13573081c" xlink:href="exdx-20231231.xsd#exdx_PrometheusLaboratoriesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b91b0dcc-5e22-47c2-9d66-ccab23575098" xlink:to="loc_exdx_PrometheusLaboratoriesIncMember_d20750c7-8672-4a87-839a-fae13573081c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember_b93f3847-650f-4591-a635-5757dc5c0595" xlink:href="exdx-20231231.xsd#exdx_AlleghenyHealthNetworkResearchInstituteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b91b0dcc-5e22-47c2-9d66-ccab23575098" xlink:to="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember_b93f3847-650f-4591-a635-5757dc5c0595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3c50cb9c-3569-475a-8e67-88c69b83ce20" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_8ae3ee8d-5d8a-429e-9a5c-72d8cb53afaf" xlink:to="loc_srt_RangeAxis_3c50cb9c-3569-475a-8e67-88c69b83ce20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a86534a3-18ca-4c85-87fb-346ad8c820c9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3c50cb9c-3569-475a-8e67-88c69b83ce20" xlink:to="loc_srt_RangeMember_a86534a3-18ca-4c85-87fb-346ad8c820c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_af42e305-cd8d-40fb-98a7-0ccc108cf713" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a86534a3-18ca-4c85-87fb-346ad8c820c9" xlink:to="loc_srt_MinimumMember_af42e305-cd8d-40fb-98a7-0ccc108cf713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0c64eda4-f3bd-4424-b3ba-377a2012a82d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a86534a3-18ca-4c85-87fb-346ad8c820c9" xlink:to="loc_srt_MaximumMember_0c64eda4-f3bd-4424-b3ba-377a2012a82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_84aaf646-f57c-4f7f-8de0-ab7fbe4604c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_8ae3ee8d-5d8a-429e-9a5c-72d8cb53afaf" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_84aaf646-f57c-4f7f-8de0-ab7fbe4604c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_81529265-fd9c-4488-914a-8bb62a795055" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_84aaf646-f57c-4f7f-8de0-ab7fbe4604c7" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_81529265-fd9c-4488-914a-8bb62a795055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_2647f083-bbf1-4467-bd9a-c37002f50c29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_81529265-fd9c-4488-914a-8bb62a795055" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_2647f083-bbf1-4467-bd9a-c37002f50c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f64e7a49-f9e8-48d0-9c84-4de126f60bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_8ae3ee8d-5d8a-429e-9a5c-72d8cb53afaf" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f64e7a49-f9e8-48d0-9c84-4de126f60bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_00c3c6e5-5459-4f4e-869c-c30e764e0eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f64e7a49-f9e8-48d0-9c84-4de126f60bd7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_00c3c6e5-5459-4f4e-869c-c30e764e0eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AHNCollaborationMember_8fca517d-c384-43a9-9367-12933bcfc96b" xlink:href="exdx-20231231.xsd#exdx_AHNCollaborationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_00c3c6e5-5459-4f4e-869c-c30e764e0eb4" xlink:to="loc_exdx_AHNCollaborationMember_8fca517d-c384-43a9-9367-12933bcfc96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_4a29893d-b5c5-43f3-a98f-2b803e1da88a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_8ae3ee8d-5d8a-429e-9a5c-72d8cb53afaf" xlink:to="loc_srt_LitigationCaseAxis_4a29893d-b5c5-43f3-a98f-2b803e1da88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_57acf0ea-81c8-4250-af32-821cc6be663f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_4a29893d-b5c5-43f3-a98f-2b803e1da88a" xlink:to="loc_srt_LitigationCaseTypeDomain_57acf0ea-81c8-4250-af32-821cc6be663f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_USDepartmentOfJusticeCaseMember_bffdb6d7-76fb-40f7-af56-a9a555a5e62c" xlink:href="exdx-20231231.xsd#exdx_USDepartmentOfJusticeCaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_57acf0ea-81c8-4250-af32-821cc6be663f" xlink:to="loc_exdx_USDepartmentOfJusticeCaseMember_bffdb6d7-76fb-40f7-af56-a9a555a5e62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_80bc60cb-ebfa-44a1-8ab8-bebc3034df09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_8ae3ee8d-5d8a-429e-9a5c-72d8cb53afaf" xlink:to="loc_us-gaap_LitigationStatusAxis_80bc60cb-ebfa-44a1-8ab8-bebc3034df09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_365098e9-24a2-4cd0-ae2a-928f32ddf49f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_80bc60cb-ebfa-44a1-8ab8-bebc3034df09" xlink:to="loc_us-gaap_LitigationStatusDomain_365098e9-24a2-4cd0-ae2a-928f32ddf49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_423a0aa2-769a-41f1-a830-69c7da25cdce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_365098e9-24a2-4cd0-ae2a-928f32ddf49f" xlink:to="loc_us-gaap_SettledLitigationMember_423a0aa2-769a-41f1-a830-69c7da25cdce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_7ec4f607-7fdb-4e44-8a42-71f0d9c7ad4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_8ae3ee8d-5d8a-429e-9a5c-72d8cb53afaf" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_7ec4f607-7fdb-4e44-8a42-71f0d9c7ad4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RoyaltyObligationPercentageOfSales_effc1edf-0b11-412c-bcb2-1eb2364d2f69" xlink:href="exdx-20231231.xsd#exdx_RoyaltyObligationPercentageOfSales"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_7ec4f607-7fdb-4e44-8a42-71f0d9c7ad4a" xlink:to="loc_exdx_RoyaltyObligationPercentageOfSales_effc1edf-0b11-412c-bcb2-1eb2364d2f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers_5a3de18a-2a48-4405-ae20-bf1ea10c6654" xlink:href="exdx-20231231.xsd#exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_7ec4f607-7fdb-4e44-8a42-71f0d9c7ad4a" xlink:to="loc_exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers_5a3de18a-2a48-4405-ae20-bf1ea10c6654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_dfb889f3-a534-40bf-a5e5-9e0a64df7f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_7ec4f607-7fdb-4e44-8a42-71f0d9c7ad4a" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_dfb889f3-a534-40bf-a5e5-9e0a64df7f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_941a9dd9-ec4c-4202-808d-bc61e7699a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_7ec4f607-7fdb-4e44-8a42-71f0d9c7ad4a" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_941a9dd9-ec4c-4202-808d-bc61e7699a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CollaborationAgreementAnnualCollaborationFee_8e9d9f7d-12fd-4a8f-8626-c2cb23b6250c" xlink:href="exdx-20231231.xsd#exdx_CollaborationAgreementAnnualCollaborationFee"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_7ec4f607-7fdb-4e44-8a42-71f0d9c7ad4a" xlink:to="loc_exdx_CollaborationAgreementAnnualCollaborationFee_8e9d9f7d-12fd-4a8f-8626-c2cb23b6250c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CollaborationAgreementCollaborationExpenses_a5b377c0-a1cb-47c7-83ee-b56505ee6048" xlink:href="exdx-20231231.xsd#exdx_CollaborationAgreementCollaborationExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_7ec4f607-7fdb-4e44-8a42-71f0d9c7ad4a" xlink:to="loc_exdx_CollaborationAgreementCollaborationExpenses_a5b377c0-a1cb-47c7-83ee-b56505ee6048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_61566d5c-6e5b-4f38-aa6b-8780224b1656" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_7ec4f607-7fdb-4e44-8a42-71f0d9c7ad4a" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_61566d5c-6e5b-4f38-aa6b-8780224b1656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f5006d44-06c2-4182-bf00-d8dcf0b2e083" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_cfa18816-4c57-4e30-981c-f3a49332aec9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f5006d44-06c2-4182-bf00-d8dcf0b2e083" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_cfa18816-4c57-4e30-981c-f3a49332aec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e8c2803a-caed-44c5-8d81-f9c9b5595195" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_cfa18816-4c57-4e30-981c-f3a49332aec9" xlink:to="loc_us-gaap_DebtInstrumentAxis_e8c2803a-caed-44c5-8d81-f9c9b5595195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8005e153-2d84-40d7-b110-18f221463df1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e8c2803a-caed-44c5-8d81-f9c9b5595195" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8005e153-2d84-40d7-b110-18f221463df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AmendedLoanAgreementMember_9be74320-e5f5-4de9-afb6-5e9e592cf9fc" xlink:href="exdx-20231231.xsd#exdx_AmendedLoanAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8005e153-2d84-40d7-b110-18f221463df1" xlink:to="loc_exdx_AmendedLoanAgreementMember_9be74320-e5f5-4de9-afb6-5e9e592cf9fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_A2017TermLoanMember_bcf2fef6-540d-4d03-bce3-fdb1737d8ff9" xlink:href="exdx-20231231.xsd#exdx_A2017TermLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8005e153-2d84-40d7-b110-18f221463df1" xlink:to="loc_exdx_A2017TermLoanMember_bcf2fef6-540d-4d03-bce3-fdb1737d8ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtOtherThanAmendedLoanAgreementMember_d2d28dfd-867f-468a-8261-0b2b61c8a94d" xlink:href="exdx-20231231.xsd#exdx_DebtOtherThanAmendedLoanAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8005e153-2d84-40d7-b110-18f221463df1" xlink:to="loc_exdx_DebtOtherThanAmendedLoanAgreementMember_d2d28dfd-867f-468a-8261-0b2b61c8a94d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_844d10e4-f4ef-4daf-9a93-46ce15adefde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_cfa18816-4c57-4e30-981c-f3a49332aec9" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_844d10e4-f4ef-4daf-9a93-46ce15adefde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2c9caa9f-b40f-403b-aba2-4978a47786a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_844d10e4-f4ef-4daf-9a93-46ce15adefde" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2c9caa9f-b40f-403b-aba2-4978a47786a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_62596fde-a941-4e48-b0a3-91766b59a43f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_2c9caa9f-b40f-403b-aba2-4978a47786a8" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_62596fde-a941-4e48-b0a3-91766b59a43f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_454d0f4d-d781-43de-a113-369e3e51b302" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_cfa18816-4c57-4e30-981c-f3a49332aec9" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_454d0f4d-d781-43de-a113-369e3e51b302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_90d9248a-d145-4d71-a5ae-bbb7231348cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_454d0f4d-d781-43de-a113-369e3e51b302" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_90d9248a-d145-4d71-a5ae-bbb7231348cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c8a928b1-ffc5-453e-9179-9613bb3aabdc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_90d9248a-d145-4d71-a5ae-bbb7231348cc" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c8a928b1-ffc5-453e-9179-9613bb3aabdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ac3f0ca8-6c52-49bb-a49a-c2669ffe3e03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_90d9248a-d145-4d71-a5ae-bbb7231348cc" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ac3f0ca8-6c52-49bb-a49a-c2669ffe3e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_38c4ac64-e6fc-4f6c-91a6-b01b6b370dec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_90d9248a-d145-4d71-a5ae-bbb7231348cc" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_38c4ac64-e6fc-4f6c-91a6-b01b6b370dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_30122bff-9657-4208-b9ed-d85a813f7139" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_cfa18816-4c57-4e30-981c-f3a49332aec9" xlink:to="loc_us-gaap_FinancialInstrumentAxis_30122bff-9657-4208-b9ed-d85a813f7139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ea1cb4aa-5d03-461a-9f86-bc720677f2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_30122bff-9657-4208-b9ed-d85a813f7139" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ea1cb4aa-5d03-461a-9f86-bc720677f2ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2c93821f-b822-4b00-a042-3d99c5ce90f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ea1cb4aa-5d03-461a-9f86-bc720677f2ee" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2c93821f-b822-4b00-a042-3d99c5ce90f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_44fe85d6-1fc1-4680-928a-40655965e054" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ea1cb4aa-5d03-461a-9f86-bc720677f2ee" xlink:to="loc_us-gaap_CertificatesOfDepositMember_44fe85d6-1fc1-4680-928a-40655965e054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_f18487f4-1bf0-46d1-9f56-ffd1af4fa552" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_cfa18816-4c57-4e30-981c-f3a49332aec9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_f18487f4-1bf0-46d1-9f56-ffd1af4fa552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_361165db-befe-48ee-b8dc-2ec5d55b7379" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_f18487f4-1bf0-46d1-9f56-ffd1af4fa552" xlink:to="loc_us-gaap_LongTermDebt_361165db-befe-48ee-b8dc-2ec5d55b7379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_4412d3f8-22b9-454e-944f-3287886b82a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_f18487f4-1bf0-46d1-9f56-ffd1af4fa552" xlink:to="loc_us-gaap_DebtInstrumentFairValue_4412d3f8-22b9-454e-944f-3287886b82a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_23ef32ac-c139-414c-9055-23a1e042d1ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_f18487f4-1bf0-46d1-9f56-ffd1af4fa552" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_23ef32ac-c139-414c-9055-23a1e042d1ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5434cf24-7a8b-41dc-8467-20631baf918e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_23ef32ac-c139-414c-9055-23a1e042d1ce" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5434cf24-7a8b-41dc-8467-20631baf918e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_61785bb0-6bda-4eb5-90f8-8c9a37277ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_23ef32ac-c139-414c-9055-23a1e042d1ce" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_61785bb0-6bda-4eb5-90f8-8c9a37277ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_cc109db0-b042-4504-a6d4-48d706a4958a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ade2e508-da50-4f22-b351-dd65c97cc877" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_cc109db0-b042-4504-a6d4-48d706a4958a" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ade2e508-da50-4f22-b351-dd65c97cc877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_551c16f9-67bf-47ee-bc6b-d89006608c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ade2e508-da50-4f22-b351-dd65c97cc877" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_551c16f9-67bf-47ee-bc6b-d89006608c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20c54d94-e480-40cc-8a3b-5dfb28ca520b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_551c16f9-67bf-47ee-bc6b-d89006608c4b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20c54d94-e480-40cc-8a3b-5dfb28ca520b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShelfRegistrationStatementMember_97205ef6-0e2d-4a52-965c-5c0cf15ec14d" xlink:href="exdx-20231231.xsd#exdx_ShelfRegistrationStatementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20c54d94-e480-40cc-8a3b-5dfb28ca520b" xlink:to="loc_exdx_ShelfRegistrationStatementMember_97205ef6-0e2d-4a52-965c-5c0cf15ec14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CowenEquityDistributionAgreementMember_e67fdeb3-3c04-4c3b-90c6-2854476a8b07" xlink:href="exdx-20231231.xsd#exdx_CowenEquityDistributionAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20c54d94-e480-40cc-8a3b-5dfb28ca520b" xlink:to="loc_exdx_CowenEquityDistributionAgreementMember_e67fdeb3-3c04-4c3b-90c6-2854476a8b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_0f10c3e1-a3c5-44db-8fdc-e165e9b0face" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ade2e508-da50-4f22-b351-dd65c97cc877" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_0f10c3e1-a3c5-44db-8fdc-e165e9b0face" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_SaleOfStockAuthorizedAmount_41646017-7b72-49e1-9693-b7fd2cf96d2b" xlink:href="exdx-20231231.xsd#exdx_SaleOfStockAuthorizedAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_0f10c3e1-a3c5-44db-8fdc-e165e9b0face" xlink:to="loc_exdx_SaleOfStockAuthorizedAmount_41646017-7b72-49e1-9693-b7fd2cf96d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_SaleOfStockRemainingAuthorizedAmount_287f37ca-9003-4fdc-bab5-258619eb839e" xlink:href="exdx-20231231.xsd#exdx_SaleOfStockRemainingAuthorizedAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_0f10c3e1-a3c5-44db-8fdc-e165e9b0face" xlink:to="loc_exdx_SaleOfStockRemainingAuthorizedAmount_287f37ca-9003-4fdc-bab5-258619eb839e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_33ed3a16-1c07-4988-9399-6678b985a131" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_0f10c3e1-a3c5-44db-8fdc-e165e9b0face" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_33ed3a16-1c07-4988-9399-6678b985a131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_f1475933-488e-4859-8f39-dd60da0814c6" xlink:href="exdx-20231231.xsd#exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_0f10c3e1-a3c5-44db-8fdc-e165e9b0face" xlink:to="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_f1475933-488e-4859-8f39-dd60da0814c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_34d6449d-f153-4f55-bfc3-291f7c52c3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_4db21fdf-77fe-4a36-af3f-f16447bfe28a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_34d6449d-f153-4f55-bfc3-291f7c52c3d0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_4db21fdf-77fe-4a36-af3f-f16447bfe28a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_7830d6b9-6e8c-452f-b4ef-ba20faa5dff6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4db21fdf-77fe-4a36-af3f-f16447bfe28a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_7830d6b9-6e8c-452f-b4ef-ba20faa5dff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_c51fd92b-7adc-4c88-b1f3-0cd3153ad441" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_7830d6b9-6e8c-452f-b4ef-ba20faa5dff6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_c51fd92b-7adc-4c88-b1f3-0cd3153ad441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationJan192026Member_67edc897-3ff5-44a0-8e07-145f3093ca41" xlink:href="exdx-20231231.xsd#exdx_ExpirationJan192026Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_c51fd92b-7adc-4c88-b1f3-0cd3153ad441" xlink:to="loc_exdx_ExpirationJan192026Member_67edc897-3ff5-44a0-8e07-145f3093ca41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationMar312026Member_2c640f76-53d3-4afc-bd40-7b8b6635bb84" xlink:href="exdx-20231231.xsd#exdx_ExpirationMar312026Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_c51fd92b-7adc-4c88-b1f3-0cd3153ad441" xlink:to="loc_exdx_ExpirationMar312026Member_2c640f76-53d3-4afc-bd40-7b8b6635bb84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationApr12026Member_4e94c430-95bd-49cd-a9bf-a625f943eb5f" xlink:href="exdx-20231231.xsd#exdx_ExpirationApr12026Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_c51fd92b-7adc-4c88-b1f3-0cd3153ad441" xlink:to="loc_exdx_ExpirationApr12026Member_4e94c430-95bd-49cd-a9bf-a625f943eb5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationSep72024Member_cb350605-fac4-4f40-b430-623b10477aea" xlink:href="exdx-20231231.xsd#exdx_ExpirationSep72024Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_c51fd92b-7adc-4c88-b1f3-0cd3153ad441" xlink:to="loc_exdx_ExpirationSep72024Member_cb350605-fac4-4f40-b430-623b10477aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationDec72025Member_d58a341f-efee-4c35-be93-7bfad64da54d" xlink:href="exdx-20231231.xsd#exdx_ExpirationDec72025Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_c51fd92b-7adc-4c88-b1f3-0cd3153ad441" xlink:to="loc_exdx_ExpirationDec72025Member_d58a341f-efee-4c35-be93-7bfad64da54d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_NoExpirationMember_3735ebcd-28db-4965-a481-317e54b1e21a" xlink:href="exdx-20231231.xsd#exdx_NoExpirationMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_c51fd92b-7adc-4c88-b1f3-0cd3153ad441" xlink:to="loc_exdx_NoExpirationMember_3735ebcd-28db-4965-a481-317e54b1e21a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_6f7ca751-ff21-4bbd-a413-b300dbbc446d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4db21fdf-77fe-4a36-af3f-f16447bfe28a" xlink:to="loc_us-gaap_ClassOfStockLineItems_6f7ca751-ff21-4bbd-a413-b300dbbc446d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_f180720a-7129-4f9e-9e1e-8f0df378f042" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6f7ca751-ff21-4bbd-a413-b300dbbc446d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_f180720a-7129-4f9e-9e1e-8f0df378f042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7c107c64-39fb-400e-8abe-81e152e26540" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6f7ca751-ff21-4bbd-a413-b300dbbc446d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7c107c64-39fb-400e-8abe-81e152e26540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#StockOptionPlanNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_35662b86-76ab-4811-8f81-817580fa1fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6e2026e-78cf-4a10-a491-593efa613a56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_35662b86-76ab-4811-8f81-817580fa1fd6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6e2026e-78cf-4a10-a491-593efa613a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4c0e0322-957a-41f1-80fa-0257b51f0c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6e2026e-78cf-4a10-a491-593efa613a56" xlink:to="loc_us-gaap_PlanNameAxis_4c0e0322-957a-41f1-80fa-0257b51f0c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4f0dc311-574a-4ff7-95a7-04c8231116c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_4c0e0322-957a-41f1-80fa-0257b51f0c4c" xlink:to="loc_us-gaap_PlanNameDomain_4f0dc311-574a-4ff7-95a7-04c8231116c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncentiveAwardPlan2019Member_20742303-c6a6-4262-baaf-8e7e5e39e6e9" xlink:href="exdx-20231231.xsd#exdx_IncentiveAwardPlan2019Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4f0dc311-574a-4ff7-95a7-04c8231116c8" xlink:to="loc_exdx_IncentiveAwardPlan2019Member_20742303-c6a6-4262-baaf-8e7e5e39e6e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7270bc04-bf76-4c41-b892-2cf5250899ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6e2026e-78cf-4a10-a491-593efa613a56" xlink:to="loc_us-gaap_AwardTypeAxis_7270bc04-bf76-4c41-b892-2cf5250899ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e20c9644-a6e2-4527-8b01-5d6d35ef7afe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7270bc04-bf76-4c41-b892-2cf5250899ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e20c9644-a6e2-4527-8b01-5d6d35ef7afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_89d5cb9e-4e55-4eb3-bac1-4ac3059f30f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e20c9644-a6e2-4527-8b01-5d6d35ef7afe" xlink:to="loc_us-gaap_EmployeeStockOptionMember_89d5cb9e-4e55-4eb3-bac1-4ac3059f30f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_7f39161d-8dab-4214-b3a6-943183306bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e20c9644-a6e2-4527-8b01-5d6d35ef7afe" xlink:to="loc_us-gaap_EmployeeStockMember_7f39161d-8dab-4214-b3a6-943183306bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3108d026-c2fb-4b8a-a1c2-98f3ebe1dafb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e20c9644-a6e2-4527-8b01-5d6d35ef7afe" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3108d026-c2fb-4b8a-a1c2-98f3ebe1dafb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2b7f29c7-ad7b-477d-b68d-c030e4d2bc1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6e2026e-78cf-4a10-a491-593efa613a56" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2b7f29c7-ad7b-477d-b68d-c030e4d2bc1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_452f28d9-d083-42d4-b7b7-7f72ed0baa40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2b7f29c7-ad7b-477d-b68d-c030e4d2bc1f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_452f28d9-d083-42d4-b7b7-7f72ed0baa40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_422f29d2-c0f3-4cb7-9c61-c307759644fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_452f28d9-d083-42d4-b7b7-7f72ed0baa40" xlink:to="loc_us-gaap_SubsequentEventMember_422f29d2-c0f3-4cb7-9c61-c307759644fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1568a821-a345-483e-ae58-6922b40353a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6e2026e-78cf-4a10-a491-593efa613a56" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1568a821-a345-483e-ae58-6922b40353a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_259f1818-9dd6-4fdb-9980-0c75cc9929ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1568a821-a345-483e-ae58-6922b40353a6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_259f1818-9dd6-4fdb-9980-0c75cc9929ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9be41fd4-e128-4ea9-aa3d-a141a5d32ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1568a821-a345-483e-ae58-6922b40353a6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9be41fd4-e128-4ea9-aa3d-a141a5d32ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_e6df59f6-b7bd-4927-914f-03fd4d02ded4" xlink:href="exdx-20231231.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1568a821-a345-483e-ae58-6922b40353a6" xlink:to="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage_e6df59f6-b7bd-4927-914f-03fd4d02ded4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_431eecca-1093-48b5-855c-41a135baf4c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1568a821-a345-483e-ae58-6922b40353a6" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_431eecca-1093-48b5-855c-41a135baf4c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized_69883133-af4e-4248-b5ae-3c0e43a6a032" xlink:href="exdx-20231231.xsd#exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1568a821-a345-483e-ae58-6922b40353a6" xlink:to="loc_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized_69883133-af4e-4248-b5ae-3c0e43a6a032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_884fe3e4-d5c6-4edf-ba7a-da0ba87bd133" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1568a821-a345-483e-ae58-6922b40353a6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_884fe3e4-d5c6-4edf-ba7a-da0ba87bd133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5c743f3a-63f7-443d-8713-3816c13eee25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1568a821-a345-483e-ae58-6922b40353a6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5c743f3a-63f7-443d-8713-3816c13eee25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1395f7d3-950d-4f16-b1b0-f6fe9efe3220" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1568a821-a345-483e-ae58-6922b40353a6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1395f7d3-950d-4f16-b1b0-f6fe9efe3220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_97d48c5a-3ce4-4114-ba93-534cd9b5ee4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1568a821-a345-483e-ae58-6922b40353a6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_97d48c5a-3ce4-4114-ba93-534cd9b5ee4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_75cc11c2-bec4-4516-9425-64339cadc9bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1568a821-a345-483e-ae58-6922b40353a6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_75cc11c2-bec4-4516-9425-64339cadc9bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_eced8ff8-2d7f-48df-b30f-0a6d0284de8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1568a821-a345-483e-ae58-6922b40353a6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_eced8ff8-2d7f-48df-b30f-0a6d0284de8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fe253bc1-d30d-4dc6-9186-f00754e3b2c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1568a821-a345-483e-ae58-6922b40353a6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fe253bc1-d30d-4dc6-9186-f00754e3b2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_09ace6bb-704c-49f5-b7d3-363862edd9db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1568a821-a345-483e-ae58-6922b40353a6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_09ace6bb-704c-49f5-b7d3-363862edd9db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a20c7f1d-ae95-4fb7-846e-7fa92b191d39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1568a821-a345-483e-ae58-6922b40353a6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a20c7f1d-ae95-4fb7-846e-7fa92b191d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_cdcfb794-e491-4baf-b78e-5f27442245fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1568a821-a345-483e-ae58-6922b40353a6" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_cdcfb794-e491-4baf-b78e-5f27442245fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_7b2aaadc-b9de-445e-bee7-8feb0c478322" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1568a821-a345-483e-ae58-6922b40353a6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_7b2aaadc-b9de-445e-bee7-8feb0c478322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#StockOptionPlanRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ff167a35-21e9-4ccc-935f-bbfb962927c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c66a164f-2d43-4611-a86d-70a2ebb74610" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ff167a35-21e9-4ccc-935f-bbfb962927c7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c66a164f-2d43-4611-a86d-70a2ebb74610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_16e0a6c8-7fe5-4767-bbff-ea6a608fcb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c66a164f-2d43-4611-a86d-70a2ebb74610" xlink:to="loc_us-gaap_AwardTypeAxis_16e0a6c8-7fe5-4767-bbff-ea6a608fcb3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9fec5382-3a5f-4246-bb71-12cf819629ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_16e0a6c8-7fe5-4767-bbff-ea6a608fcb3b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9fec5382-3a5f-4246-bb71-12cf819629ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7ecac239-30c1-40af-835d-5e42897eb07b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9fec5382-3a5f-4246-bb71-12cf819629ac" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7ecac239-30c1-40af-835d-5e42897eb07b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e6dbc0c-7935-43f9-9f2c-eecb132c13df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c66a164f-2d43-4611-a86d-70a2ebb74610" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e6dbc0c-7935-43f9-9f2c-eecb132c13df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e5e44be7-f982-4306-9a4f-39b8580f6855" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e6dbc0c-7935-43f9-9f2c-eecb132c13df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e5e44be7-f982-4306-9a4f-39b8580f6855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_058aa268-cb42-4650-94d3-2d834623d43c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e5e44be7-f982-4306-9a4f-39b8580f6855" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_058aa268-cb42-4650-94d3-2d834623d43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d32991c8-16f5-4585-8606-86171da07ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e5e44be7-f982-4306-9a4f-39b8580f6855" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d32991c8-16f5-4585-8606-86171da07ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f8ad98f3-3fc5-4289-9060-f1ebfa234c97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e5e44be7-f982-4306-9a4f-39b8580f6855" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f8ad98f3-3fc5-4289-9060-f1ebfa234c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_bf3be328-3ea2-43dc-865d-b109d58cd91a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e5e44be7-f982-4306-9a4f-39b8580f6855" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_bf3be328-3ea2-43dc-865d-b109d58cd91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1cc68185-8ce0-4d38-8c91-581bf1a66e93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e5e44be7-f982-4306-9a4f-39b8580f6855" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1cc68185-8ce0-4d38-8c91-581bf1a66e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_18d6e4d0-9e93-4aa1-823c-60be1890c6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e6dbc0c-7935-43f9-9f2c-eecb132c13df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_18d6e4d0-9e93-4aa1-823c-60be1890c6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_04d2110f-85d5-402f-989d-266a89994def" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_18d6e4d0-9e93-4aa1-823c-60be1890c6cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_04d2110f-85d5-402f-989d-266a89994def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_524df391-db54-4e17-bb9a-89f2509fff18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_18d6e4d0-9e93-4aa1-823c-60be1890c6cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_524df391-db54-4e17-bb9a-89f2509fff18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_62b9116c-bcbf-4128-ad16-c2a31355acf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_18d6e4d0-9e93-4aa1-823c-60be1890c6cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_62b9116c-bcbf-4128-ad16-c2a31355acf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8049d72d-4d12-4424-920b-2d09a906330e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_18d6e4d0-9e93-4aa1-823c-60be1890c6cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8049d72d-4d12-4424-920b-2d09a906330e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_789b3ceb-f80e-4a6d-9e7e-b5e64509a20e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_18d6e4d0-9e93-4aa1-823c-60be1890c6cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_789b3ceb-f80e-4a6d-9e7e-b5e64509a20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_dff79855-695d-40ff-96b2-d535e1815f25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e6dbc0c-7935-43f9-9f2c-eecb132c13df" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_dff79855-695d-40ff-96b2-d535e1815f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_f2e2bc29-640f-4050-8f7f-bbb663cf7dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_dff79855-695d-40ff-96b2-d535e1815f25" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_f2e2bc29-640f-4050-8f7f-bbb663cf7dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#StockOptionPlanStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_67c537ad-c653-4f1c-b38c-a4c82ee26f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5c14fa11-e504-4251-a0f2-63313d6b9900" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_67c537ad-c653-4f1c-b38c-a4c82ee26f0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5c14fa11-e504-4251-a0f2-63313d6b9900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4d9e3f8c-b5ae-4763-8b36-801f2d727348" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5c14fa11-e504-4251-a0f2-63313d6b9900" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4d9e3f8c-b5ae-4763-8b36-801f2d727348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_925ce903-efde-4da2-b341-7409c860a495" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5c14fa11-e504-4251-a0f2-63313d6b9900" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_925ce903-efde-4da2-b341-7409c860a495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f46fd8f8-a6ec-4c3b-9cdc-c00843ed4e12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5c14fa11-e504-4251-a0f2-63313d6b9900" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f46fd8f8-a6ec-4c3b-9cdc-c00843ed4e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0977e111-90ac-45d7-be0e-384d83163863" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5c14fa11-e504-4251-a0f2-63313d6b9900" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0977e111-90ac-45d7-be0e-384d83163863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c14e62fb-6a37-4581-8ad5-cb4c30fe460f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5c14fa11-e504-4251-a0f2-63313d6b9900" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c14e62fb-6a37-4581-8ad5-cb4c30fe460f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fb0a0dcb-a5e6-4049-80c4-c14af59f32d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5c14fa11-e504-4251-a0f2-63313d6b9900" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fb0a0dcb-a5e6-4049-80c4-c14af59f32d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0d031a83-cc88-4fd7-a583-8d0df7905839" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_67c537ad-c653-4f1c-b38c-a4c82ee26f0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0d031a83-cc88-4fd7-a583-8d0df7905839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_74c70e6a-016a-4706-a620-3d57f8ac4eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_67c537ad-c653-4f1c-b38c-a4c82ee26f0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_74c70e6a-016a-4706-a620-3d57f8ac4eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cfcd777e-6d17-44d2-b86c-f4a37ae56168" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_67c537ad-c653-4f1c-b38c-a4c82ee26f0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cfcd777e-6d17-44d2-b86c-f4a37ae56168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_88b6ca3d-b8b8-47d8-ba04-08d58fc0cc5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cfcd777e-6d17-44d2-b86c-f4a37ae56168" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_88b6ca3d-b8b8-47d8-ba04-08d58fc0cc5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_05959ceb-72ec-41e7-bca9-52a5d286e2d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cfcd777e-6d17-44d2-b86c-f4a37ae56168" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_05959ceb-72ec-41e7-bca9-52a5d286e2d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c44b49af-6ef9-4d58-bab1-89a752f12aac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cfcd777e-6d17-44d2-b86c-f4a37ae56168" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c44b49af-6ef9-4d58-bab1-89a752f12aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_6407f90a-5a95-4cdb-b5a3-25512fa4aadc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cfcd777e-6d17-44d2-b86c-f4a37ae56168" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_6407f90a-5a95-4cdb-b5a3-25512fa4aadc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_d377de28-fcaf-42dd-8531-a3657c9aca60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cfcd777e-6d17-44d2-b86c-f4a37ae56168" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_d377de28-fcaf-42dd-8531-a3657c9aca60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9aaa54f7-e86b-49bc-8018-dec463e05af7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cfcd777e-6d17-44d2-b86c-f4a37ae56168" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9aaa54f7-e86b-49bc-8018-dec463e05af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_b96f2489-7853-41fe-8a1c-2ca0d15cc563" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_67c537ad-c653-4f1c-b38c-a4c82ee26f0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_b96f2489-7853-41fe-8a1c-2ca0d15cc563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_4b41ddf3-e7c4-4be4-bbb5-498c1b942502" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_67c537ad-c653-4f1c-b38c-a4c82ee26f0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_4b41ddf3-e7c4-4be4-bbb5-498c1b942502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2ca89ce7-287f-41b0-8e4b-6d25061d56b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_67c537ad-c653-4f1c-b38c-a4c82ee26f0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2ca89ce7-287f-41b0-8e4b-6d25061d56b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_bc05d34b-7039-4928-96eb-5b4b716ce0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2ca89ce7-287f-41b0-8e4b-6d25061d56b7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_bc05d34b-7039-4928-96eb-5b4b716ce0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_785a65be-33f0-4123-95c4-5fe8cad813fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2ca89ce7-287f-41b0-8e4b-6d25061d56b7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_785a65be-33f0-4123-95c4-5fe8cad813fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_d418915c-3a0e-48e0-85b0-15586e9aa503" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2ca89ce7-287f-41b0-8e4b-6d25061d56b7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_d418915c-3a0e-48e0-85b0-15586e9aa503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b0398644-8d01-4c48-9704-5034dbcf18b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2ca89ce7-287f-41b0-8e4b-6d25061d56b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b0398644-8d01-4c48-9704-5034dbcf18b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_7e31946a-f36f-4006-bc07-f700fc7f788e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2ca89ce7-287f-41b0-8e4b-6d25061d56b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_7e31946a-f36f-4006-bc07-f700fc7f788e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_4d3822e4-643d-4f8d-8588-1ca3327afd26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2ca89ce7-287f-41b0-8e4b-6d25061d56b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_4d3822e4-643d-4f8d-8588-1ca3327afd26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#StockOptionPlanStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5ea2f6b4-0b86-4816-8964-6d8d8fd82717" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d80ed6c7-bee5-4163-b03c-533191a3dafe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5ea2f6b4-0b86-4816-8964-6d8d8fd82717" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d80ed6c7-bee5-4163-b03c-533191a3dafe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_bb267017-107a-41b3-938f-f17b7f4488ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d80ed6c7-bee5-4163-b03c-533191a3dafe" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_bb267017-107a-41b3-938f-f17b7f4488ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_42500afe-6e5f-4a61-be92-e94d3830d3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bb267017-107a-41b3-938f-f17b7f4488ab" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_42500afe-6e5f-4a61-be92-e94d3830d3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_c712a89f-418d-4faa-b90c-e6cf5833b93e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_42500afe-6e5f-4a61-be92-e94d3830d3b4" xlink:to="loc_us-gaap_CostOfSalesMember_c712a89f-418d-4faa-b90c-e6cf5833b93e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_df6d98f9-fada-4a10-9c69-fae38e199dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_42500afe-6e5f-4a61-be92-e94d3830d3b4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_df6d98f9-fada-4a10-9c69-fae38e199dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_426ea85d-b5cb-4582-a851-6e48e7b7a529" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_42500afe-6e5f-4a61-be92-e94d3830d3b4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_426ea85d-b5cb-4582-a851-6e48e7b7a529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d7176be8-719b-4188-a7f8-c4355d64f09d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d80ed6c7-bee5-4163-b03c-533191a3dafe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d7176be8-719b-4188-a7f8-c4355d64f09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_e32b7716-d654-4a7f-aa3a-822197365a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d7176be8-719b-4188-a7f8-c4355d64f09d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_e32b7716-d654-4a7f-aa3a-822197365a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#StockOptionPlanCommonStockReservedForFutureIssuanceDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_595ed84d-02f2-4257-99de-b36faf09f2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_55e1c30c-4c1e-4d92-90e8-b4f43a0374b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_595ed84d-02f2-4257-99de-b36faf09f2f7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_55e1c30c-4c1e-4d92-90e8-b4f43a0374b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2c9458a3-a9ca-4052-a1eb-dd67e14f5ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_55e1c30c-4c1e-4d92-90e8-b4f43a0374b7" xlink:to="loc_us-gaap_AwardTypeAxis_2c9458a3-a9ca-4052-a1eb-dd67e14f5ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dc31e046-7401-45da-95d8-8bf84b71b756" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2c9458a3-a9ca-4052-a1eb-dd67e14f5ab0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dc31e046-7401-45da-95d8-8bf84b71b756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_8fceb7e5-c1ae-47c7-8671-6cbb490a8064" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dc31e046-7401-45da-95d8-8bf84b71b756" xlink:to="loc_us-gaap_WarrantMember_8fceb7e5-c1ae-47c7-8671-6cbb490a8064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_db6874f0-1045-4072-a343-23be7c3e1227" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dc31e046-7401-45da-95d8-8bf84b71b756" xlink:to="loc_us-gaap_EmployeeStockOptionMember_db6874f0-1045-4072-a343-23be7c3e1227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_77b51425-b163-4ad9-91df-947d7148c498" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dc31e046-7401-45da-95d8-8bf84b71b756" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_77b51425-b163-4ad9-91df-947d7148c498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember_619c4577-ae67-401b-8ecf-905ee00a44d5" xlink:href="exdx-20231231.xsd#exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dc31e046-7401-45da-95d8-8bf84b71b756" xlink:to="loc_exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember_619c4577-ae67-401b-8ecf-905ee00a44d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_ec775fe3-c450-4254-a15d-c57bba8e8ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dc31e046-7401-45da-95d8-8bf84b71b756" xlink:to="loc_us-gaap_EmployeeStockMember_ec775fe3-c450-4254-a15d-c57bba8e8ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a05dc3e-b331-4232-92ef-c831e2f39abc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_55e1c30c-4c1e-4d92-90e8-b4f43a0374b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a05dc3e-b331-4232-92ef-c831e2f39abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8392c50a-2107-4a7f-b2ab-80acd59a3ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0a05dc3e-b331-4232-92ef-c831e2f39abc" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8392c50a-2107-4a7f-b2ab-80acd59a3ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7ee8dca2-be72-407b-9e18-9a458f72fbf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_5cf86ffb-9e3b-435f-a9d4-0d8d8f1d59af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7ee8dca2-be72-407b-9e18-9a458f72fbf8" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_5cf86ffb-9e3b-435f-a9d4-0d8d8f1d59af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_0c40e241-c7c6-47dd-96ff-6d253f755072" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_5cf86ffb-9e3b-435f-a9d4-0d8d8f1d59af" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_0c40e241-c7c6-47dd-96ff-6d253f755072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_9fbaf4bf-3532-40f0-940d-4b94c4cd1ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_5cf86ffb-9e3b-435f-a9d4-0d8d8f1d59af" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_9fbaf4bf-3532-40f0-940d-4b94c4cd1ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2389920b-91bf-4585-baba-40f4de29c63b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_5cf86ffb-9e3b-435f-a9d4-0d8d8f1d59af" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2389920b-91bf-4585-baba-40f4de29c63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_0308a505-8d37-41d5-bd2b-50963c76fc8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7ee8dca2-be72-407b-9e18-9a458f72fbf8" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_0308a505-8d37-41d5-bd2b-50963c76fc8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_98b8eb94-5151-40b9-b059-a637affc44fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_0308a505-8d37-41d5-bd2b-50963c76fc8b" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_98b8eb94-5151-40b9-b059-a637affc44fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_5347d996-7419-4121-a0d0-64fcfa66714b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_0308a505-8d37-41d5-bd2b-50963c76fc8b" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_5347d996-7419-4121-a0d0-64fcfa66714b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ac43b3ae-bcc9-4470-b0ae-52b27515c76b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_0308a505-8d37-41d5-bd2b-50963c76fc8b" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ac43b3ae-bcc9-4470-b0ae-52b27515c76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6950f4d8-f59e-4537-869b-e279977d5952" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7ee8dca2-be72-407b-9e18-9a458f72fbf8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6950f4d8-f59e-4537-869b-e279977d5952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_18f03cf1-6043-430b-8499-0412d00a2eba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1f2f0d5c-75db-4ffc-be61-79125e96a3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_18f03cf1-6043-430b-8499-0412d00a2eba" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1f2f0d5c-75db-4ffc-be61-79125e96a3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_b08a9b3e-70bd-489c-beaa-bdbc9498c205" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_18f03cf1-6043-430b-8499-0412d00a2eba" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_b08a9b3e-70bd-489c-beaa-bdbc9498c205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_8a204324-c6ef-463c-b459-2119ac236cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_18f03cf1-6043-430b-8499-0412d00a2eba" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_8a204324-c6ef-463c-b459-2119ac236cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_5aa261e6-dec3-4140-9cb6-5d92221b793e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_18f03cf1-6043-430b-8499-0412d00a2eba" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_5aa261e6-dec3-4140-9cb6-5d92221b793e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_518706ff-3986-4b5c-bfa5-0a575d536498" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_18f03cf1-6043-430b-8499-0412d00a2eba" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_518706ff-3986-4b5c-bfa5-0a575d536498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_0d76ff24-322b-4254-bca1-81855a6bae54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_18f03cf1-6043-430b-8499-0412d00a2eba" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_0d76ff24-322b-4254-bca1-81855a6bae54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_a6539507-b5b3-4b1a-b9ac-8f5a56ec2368" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_18f03cf1-6043-430b-8499-0412d00a2eba" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_a6539507-b5b3-4b1a-b9ac-8f5a56ec2368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d6d478ad-d332-4a3f-b882-b9710d5c14c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_18f03cf1-6043-430b-8499-0412d00a2eba" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d6d478ad-d332-4a3f-b882-b9710d5c14c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ddb7ba01-cba6-48de-b05b-bb18c6b06bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bc777664-5eff-4c69-821d-54334a10eb1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ddb7ba01-cba6-48de-b05b-bb18c6b06bfb" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bc777664-5eff-4c69-821d-54334a10eb1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2b946ed8-5166-49c7-b01e-7d487523cc62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bc777664-5eff-4c69-821d-54334a10eb1a" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2b946ed8-5166-49c7-b01e-7d487523cc62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_3716dafc-9ba8-4e2c-97c5-1c2103e2acb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bc777664-5eff-4c69-821d-54334a10eb1a" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_3716dafc-9ba8-4e2c-97c5-1c2103e2acb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_2b0e783d-c543-4d80-84ce-ee13edcc05d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bc777664-5eff-4c69-821d-54334a10eb1a" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves_2b0e783d-c543-4d80-84ce-ee13edcc05d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_d156e362-6cb6-4111-8dc1-3c4cf37fa867" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bc777664-5eff-4c69-821d-54334a10eb1a" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_d156e362-6cb6-4111-8dc1-3c4cf37fa867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_8ac28a7d-545c-4127-9936-03ea25e189c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bc777664-5eff-4c69-821d-54334a10eb1a" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_8ac28a7d-545c-4127-9936-03ea25e189c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_756e3d30-4a7c-48cb-b9e4-8ff4eca9a3a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bc777664-5eff-4c69-821d-54334a10eb1a" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_756e3d30-4a7c-48cb-b9e4-8ff4eca9a3a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredTaxAssetsLeaseLiability_5f4f2d5b-4f83-4d7f-ba88-3d8b6165a5c9" xlink:href="exdx-20231231.xsd#exdx_DeferredTaxAssetsLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bc777664-5eff-4c69-821d-54334a10eb1a" xlink:to="loc_exdx_DeferredTaxAssetsLeaseLiability_5f4f2d5b-4f83-4d7f-ba88-3d8b6165a5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts_aa8bc647-0ea4-49e3-a724-b38d0c9fb4ff" xlink:href="exdx-20231231.xsd#exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bc777664-5eff-4c69-821d-54334a10eb1a" xlink:to="loc_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts_aa8bc647-0ea4-49e3-a724-b38d0c9fb4ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_9e59dbd9-642d-4935-ae02-7304cc7b088c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bc777664-5eff-4c69-821d-54334a10eb1a" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_9e59dbd9-642d-4935-ae02-7304cc7b088c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7ddbe209-fb74-4278-93cf-1ae84f68bf6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bc777664-5eff-4c69-821d-54334a10eb1a" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7ddbe209-fb74-4278-93cf-1ae84f68bf6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_c9d21ec2-0eb2-4930-a277-77be36d8e711" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bc777664-5eff-4c69-821d-54334a10eb1a" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_c9d21ec2-0eb2-4930-a277-77be36d8e711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_4ebd5a0a-1f7e-4d3a-bca9-cd7d79001ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ddb7ba01-cba6-48de-b05b-bb18c6b06bfb" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_4ebd5a0a-1f7e-4d3a-bca9-cd7d79001ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredTaxLiabilitiesRightOfUseAssets_7c7a4db2-d117-4beb-a018-98d45f185988" xlink:href="exdx-20231231.xsd#exdx_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_4ebd5a0a-1f7e-4d3a-bca9-cd7d79001ce4" xlink:to="loc_exdx_DeferredTaxLiabilitiesRightOfUseAssets_7c7a4db2-d117-4beb-a018-98d45f185988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_9b959285-2c1e-45e9-ba45-659b82c6ac58" xlink:href="exdx-20231231.xsd#exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_4ebd5a0a-1f7e-4d3a-bca9-cd7d79001ce4" xlink:to="loc_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets_9b959285-2c1e-45e9-ba45-659b82c6ac58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_ae266285-43d9-478e-8d67-087e9018d6fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_4ebd5a0a-1f7e-4d3a-bca9-cd7d79001ce4" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_ae266285-43d9-478e-8d67-087e9018d6fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_f14ffe77-d894-41c1-955c-83baa423907e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ddb7ba01-cba6-48de-b05b-bb18c6b06bfb" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_f14ffe77-d894-41c1-955c-83baa423907e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesChangeInValuationAllowanceDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#IncomeTaxesChangeInValuationAllowanceDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/IncomeTaxesChangeInValuationAllowanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d9284039-9592-4b65-bb84-9cac66f213e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward_328e9cec-11a0-4665-9d3b-2dd5d1560342" xlink:href="exdx-20231231.xsd#exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d9284039-9592-4b65-bb84-9cac66f213e2" xlink:to="loc_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward_328e9cec-11a0-4665-9d3b-2dd5d1560342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_88180f9f-b0e2-4041-b992-0174024d41b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward_328e9cec-11a0-4665-9d3b-2dd5d1560342" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_88180f9f-b0e2-4041-b992-0174024d41b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_45fecbc0-3924-436c-b978-c43c10466be1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward_328e9cec-11a0-4665-9d3b-2dd5d1560342" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_45fecbc0-3924-436c-b978-c43c10466be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_835068ca-a60b-48d2-accf-14f6cf89f223" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward_328e9cec-11a0-4665-9d3b-2dd5d1560342" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_835068ca-a60b-48d2-accf-14f6cf89f223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c7121dfd-81d9-4a30-b0d0-a0ed47607e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_7b3d3602-aad1-46d7-ab68-1eb46cc3dd44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c7121dfd-81d9-4a30-b0d0-a0ed47607e9f" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_7b3d3602-aad1-46d7-ab68-1eb46cc3dd44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_38781b52-05ba-4e75-96af-8f8751cb4730" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_7b3d3602-aad1-46d7-ab68-1eb46cc3dd44" xlink:to="loc_us-gaap_TaxPeriodAxis_38781b52-05ba-4e75-96af-8f8751cb4730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_1dbd121b-c84d-4659-903b-6c96e8e06521" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_38781b52-05ba-4e75-96af-8f8751cb4730" xlink:to="loc_us-gaap_TaxPeriodDomain_1dbd121b-c84d-4659-903b-6c96e8e06521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TaxYearsThroughDecember312017Member_e277c6e4-a375-4cf2-895f-80e07cc8ce54" xlink:href="exdx-20231231.xsd#exdx_TaxYearsThroughDecember312017Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_1dbd121b-c84d-4659-903b-6c96e8e06521" xlink:to="loc_exdx_TaxYearsThroughDecember312017Member_e277c6e4-a375-4cf2-895f-80e07cc8ce54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_fa3962bb-ab42-43e6-b9a9-ff2e7f972140" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_7b3d3602-aad1-46d7-ab68-1eb46cc3dd44" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_fa3962bb-ab42-43e6-b9a9-ff2e7f972140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_1159b48b-bb78-448c-aae2-0793faaddd09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_fa3962bb-ab42-43e6-b9a9-ff2e7f972140" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_1159b48b-bb78-448c-aae2-0793faaddd09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_d8117ca1-22d6-4bda-bab9-8f77b264fd90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_fa3962bb-ab42-43e6-b9a9-ff2e7f972140" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_d8117ca1-22d6-4bda-bab9-8f77b264fd90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_14a2aaa7-37e9-4546-8da3-1951d78fd013" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_fa3962bb-ab42-43e6-b9a9-ff2e7f972140" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_14a2aaa7-37e9-4546-8da3-1951d78fd013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_56259d70-f246-4e06-ba65-1934c55442ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_fa3962bb-ab42-43e6-b9a9-ff2e7f972140" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_56259d70-f246-4e06-ba65-1934c55442ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_a47a8c64-8e6e-4537-be12-caef670a1660" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_fa3962bb-ab42-43e6-b9a9-ff2e7f972140" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_a47a8c64-8e6e-4537-be12-caef670a1660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/A401kPlanDetails" xlink:type="simple" xlink:href="exdx-20231231.xsd#A401kPlanDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/A401kPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_764a78ad-4a21-4bfa-a3b9-e5b1b59f02ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_c080f956-2fc1-4fe0-b999-2eafb917e3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_764a78ad-4a21-4bfa-a3b9-e5b1b59f02ee" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_c080f956-2fc1-4fe0-b999-2eafb917e3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_2dd6bea8-e956-44b5-987a-183186f6e21a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_764a78ad-4a21-4bfa-a3b9-e5b1b59f02ee" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_2dd6bea8-e956-44b5-987a-183186f6e21a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>exdx-20231231_g1.jpg
<TEXT>
begin 644 exdx-20231231_g1.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" "1 8H# 2(  A$! Q$!_\0
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M&K]!J93POD--+&RYZCZ:W]4ELO7Y,^@AF7$6=5&\*N2'R2]&WN_3YGS9I?\
MP<I_\%';#Q7=>(;JV^'][9W"XBT&Z\,2K:6W&,HT=PDY]?GE;D^G%>Q? /\
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MG_"-Z]?:/'JEK8_\(WJ5YYEH\LL2R;[6VE09>"5=I8,-N2,$$^^5^#?_  =
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M+VRG5F6>>%0FVV<$AB<E>""2/L[_ (.NCE_@+C^[XH_]Q-?G3^PC^PC\7O\
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M4UZVMYNW8^1XLR^%;!_68KWX;VZIZ6?I>_WGE/\ P:_$_P##?WBS_LD.H?\
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MN($3Q37L=TDN&*O:KM )#I_1![&MN-LSG"K#+Z+M&*3:6E^R]$E?MKY&7".
MC.G+&U%>3;2O^+]6].^@M%%%?GY]R&>:Y7XQ_!SX:?M _#'6O@Y\8O!]GKWA
MO7[-K;5-+O%)25,@A@00T<B,%=)$(>-T5T9652.JH&?6G&4H24D[-:IKH1.$
M:D7&2NF?RM?MU_L<^/\ ]@_]I;7OV=/'M]_:']F^7<Z-KT>GRV\.L:?,NZ&Y
MC60?[T<@5G1)H9HQ(_EEC[#_ ,$%.?\ @K'\*/\ >US_ -,-_7W'_P '2_P&
M\/WOPD^&G[3EL;.WU32_$DWA>\6/3$^T7]O=6\MW#ON 0VRW:SGV1$,,WLC
MH=P?X<_X(*G'_!6+X4_[VN?^F&_K]AHYC+-.$ZM:7Q*$E+U2:_'?3O8_+*F!
M67<2TZ4?AYHM>C:?X;'[\?MA_M*^%?V//V9?&7[2/C&W-Q:>%M(:X@L=TB_;
MKQV6&UM=\<<AC\ZXDAA\S8RQ^9O;"J2/YC? /@OXU?MT_M3VGA32Y?[8\<_$
M[Q?)+>7S6;+&;N[G:6YO)DM8CY4";I9Y6CCVQQH[!0JXK]:O^#IWXN2Z)\!?
MA;\#$T9G7Q)XMO-;DU$7>WR1IUJ(/(\O;\XD.I[MVX;?L^-K;\K\F_\ !NUK
M_P "OAG^U]XD^-O[0'Q,^'_AC3M!\%2VFBWGC3Q%8V,R:C=7$(62S%TZL6%M
M%=QR21\HD^QCB;!\/ARD\KX=K9A&-YRNEZ)V7_DU[]]#UL^J?VAG=+!2=H1M
M?YZO\-OF?MA^QG^R/\+/V(OV>]"^ 7PJTBUBATZV1]8U2*V\N76M1,:BXOI\
ML[&25ES@LPC0)$F(XT4>K5XV?^"B'[ )'_)\/PB_\.3I?_R10O\ P41_8!Q_
MR>_\(O\ PY&E_P#R17P=6EC*U1SG&3;=VVGJV?:4JV#HTU"$XI+1*ZV/9**\
M<_X>(_L ?]'P?"+_ ,.3I?\ \D4?\/$?V /^CX/A%_X<G2__ )(J?J^)_D?W
M/_(T^MX7^>/WHU_VL?V3O@K^VG\%-4^!'QX\-?VAI&H8EM;JW8)=Z9=J&$5Y
M:RD'RIX]S8;!5E9XW5XW=&_F:_:=^!?Q+_83_:S\2?!:\\1WEKX@\ ^)%;2/
M$&GS"WN'C&RXLM0C,,KFW>2%X+A5$A>(N%)#J<?TG?\ #Q']@#'_ "?!\(?_
M  Y&E_\ R17Y&?\ !R;X[_9=^,OQ7^%_QD^ 7QQ\,>,]7N/#^H:/XB7POXIM
M-2AL[>UGBGM"ZV[L8G=[V\Y8_.(Q@?(V?L>#<3C,/CWA)Q?LYI[IV32O?7ND
MT^^G8^3XJH82OA/K-.2YX-;-7:;M;3LVFC]0_P#@E!^V>_[=/[$_A?XO:[?K
M-XITY6T3QOM4#.JVRH))CMABC'GQ/#=;(EV1_:?+!)C-?E=_P= 9_P"&_?">
M?^B0Z?\ ^G75*]8_X-6_B];0:K\7O@-JOC&X\R>WTO7M!\/R-(8PJ-/;WUT@
MQL5B9-.1SD,P$?4(=OD__!T#D?M_>$\_]$AT_P#].FJ5OE>!CE_&<J,-(J[7
MHU>WRO8PS'%RQO"L:DG=W2?JG:[];7/F'_@F)^PW??\ !07]K?1_@/<:K>:;
MH$%I-JWC'5M/\G[19Z;!M5C$)6 +R3206ZL%D,9N!(8W2-UK^ESX0?"'X;?
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M /"@U3_Y74?\0O\ ^W[_ -%8^$?_ (4&J?\ RNK]Y/PHQ[5\O_KAGG\R_P#
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MX->?^3"?&'_97M0_]-6EU^DE?FW_ ,&O/_)A/C#_ +*]J'_IJTNOTDKP<_\
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MZNG>$_$VL*=OB2$K^X@GN.GVT$&(-)M-P?*&Z6>1M_U/_P %,O\ @F/\*O\
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MK>*,/!YL[1EHT!G&U%S'N:?[*_X)B_\ !,?2/V7])M_C-\9+&WOOB+?6Y\F
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MG]E4T?*_+3T6AT^VI:KF6F^JT.SS35('%?)?[ ?_  4;\&?M'GXV2_$GXY>
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MK,X6-7+$JJLQP. I)X!H+EB\+"RE-*[:5VM6G;OWT]3O#GM16/J_CGP7X?\
M$FD^$-=\6Z;9ZMKGG_V+IMU?)'<7_DH'F\F-B&EV(0S;0=H.3@5@_#_]H[X
M_%?7)/#/PQ^-GA/Q%J$<#3R6.B>(;:ZE6($ R%8G9@H+*"V, L/44!+&86-1
M0E.*E>R5U=NR=K=[-?>CMJ***#H/S1_9_N_^"A7Q-_;/_:F_:8_8HT;X.6NF
MZM\3X?!.K67Q0U+59)DNO#EDEHMQ"+&$+Y<PG\PJS%@?D_AWO<_:1\ ?M?\
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M6PIWH&0X#DCSNIXM6IF6%SZM7AA95%.,(QDG!15G)N_-)26LM;1=TE:YY/\
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M)GPQ^-NF^(H)/"?PI^/SVOA_QW>7PGO'\$M?S:<[O(1N"OYBPM%&JJ888B$
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M\;X(-:=CGCD.(I2K4'3E)2M&,KP:Y>5+5RO)-.[>C;?O6=V>,ZQX+UG]I/\
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(H4444&<C_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>exdx-20231231_g2.jpg
<TEXT>
begin 644 exdx-20231231_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 2( Y,# 2(  A$! Q$!_\0
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M_156XCM=.T\!PV;:)#(SD?PLTT\H([B)#Z4<["R///"/Q=\:WWQH^(^@>(M
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MP[IO@>/4-+M=+30M-O%N6G>.221KJ=T14W?O-BX!. <GH*]+^*G_ "3#Q?\
M]@>\_P#1#T^;FU%R\NAJ^%?^17TC_KSA_P#0!6K65X5_Y%?2/^O.'_T 5JT
M)^-%+10 WFCFG44 )0:6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTZW8:U$H5;_,8_?@ D /][J?O4WR-7C^EOP!<T=W^#1T]%%% PHHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ%_S_P#BC_PK=5_^2:7_ (5#H7_/_P"*/_"LU7_Y)H [>BN(_P"%0Z%_S_\
MBC_PK=5_^2:/^%0Z%_S_ /BC_P *W5?_ ))H [>BN(_X5#H7_/\ ^*/_  K=
M5_\ DFC_ (5#H7_/_P"*/_"MU7_Y)H [>BN(_P"%0Z%_S_\ BC_PK=5_^2:3
M_A4.A?\ /_XH_P#"MU7_ .2: .XHKB/^%0Z%_P __BC_ ,*W5?\ Y)H_X5#H
M7_/_ .*/_"MU7_Y)H [>BN(_X5#H7_/_ .*/_"MU7_Y)H_X5#H7_ #_^*/\
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M7PRNA_V7H=K9_P!BPSV^GF/(\A)RIFQSR7**23DD]^35;_A4.A?\_P#XH_\
M"MU7_P"2:/\ A4.A?\__ (H_\*W5?_DFGR1%S2[F//\ L[> ;CP[::(VCSQ6
M-E>RW]HT&H7,4UK-*3YABE60/&K;FRBL%P>E2ZI^S[X"U30]"TA] 6VM-$D>
M73VL;F:VF@:3_6D2Q.KGS/X\L=QY;-:?_"H="_Y__%'_ (5NJ_\ R31_PJ'0
MO^?_ ,4?^%;JO_R31RH.:7<UO!/@70?ASH,6A^&]-ATC2HY))DM;?.T/(Y=S
MR<Y+,Q-=#7$?\*AT+_G_ /%'_A6ZK_\ )-'_  J'0O\ G_\ %'_A6ZK_ /)-
M42=MC%>'^/OV:4\9Z_XHGM/%VIZ!HGBY(H_$FC6<,3)J 2,1$K(REHB\2K&Y
M7.54=#S7=?\ "H="_P"?_P 4?^%;JO\ \DT?\*AT+_G_ /%'_A6ZK_\ )-%A
MCOB!\,=-^(7A&R\/3RS6%C:7UA?1_9=N0;2XBGC3D$;28E!]NE6K7P2MKJGB
MK4A?S"]USRT6=0 ]K$D(C2-#W ;S9!GO*U4_^%0Z%_S_ /BC_P *W5?_ ))H
M_P"%0Z%_S_\ BC_PK=5_^2:+(+GF_P ,/V8]8^%MCI&D6?Q6\27GAFP&PZ+-
M8Z>D<Z'.X/(EN),MNR7W;B><YJWX<_9KNM-U7PW_ &YX^UKQ7X>\+W'VK1-'
MU&&$>3*J,D3SSJHDN#&KL%W$<X)R1FN]_P"%0Z%_S_\ BC_PK=5_^2:/^%0Z
M%_S_ /BC_P *W5?_ ))I*-E:_P"(^;6]E?T1Q'C;]FJ/Q9X+\%Z';^+=4T:Y
M\,7HU--0M+>WE:ZN]CAII(YHW0DM+(_3AFR.0*74/V>]6UOP]!:ZS\2]>UG7
M=-U.'5M&UNZM+-)M.GC5D^5(HE61&5W5E<'(8\BNV_X5#H7_ #_^*/\ PK=5
M_P#DFC_A4.A?\_\ XH_\*W5?_DFIY$%_+\$>=ZQ^RK;>(?AQXB\.ZAXNU676
M?$6K0:SJ_B!88/.NI83%Y<?E,AC$2K!$HC((PO.<FIKG]G+6]:\/W>E:[\5O
M$VM'?;W.G7$EK8P/IMU!*LD4\?E0("05P4?*D$C%=]_PJ'0O^?\ \4?^%;JO
M_P DT?\ "H="_P"?_P 4?^%;JO\ \DT<GG^(7\E]R,;X;_!VZ\(^+-3\6>(_
M%-WXR\57]I%IQOKBVBM8X+6-F=8HXHA@99V9B223CH!73?%/_DF'B_\ [ ]Y
M_P"B'JE_PJ'0O^?_ ,4?^%;JO_R34-U\&/#MY;2V]Q<^))[>5#')')XIU1E=
M2,$,#<X((X.:M*Q)T_A;_D5]'_Z\X?\ T 5C^//A7X1^*$-E'XK\.V'B!+)V
MDMA?0B3R6888KGH2.*IQ?!WP_#&D<=YXFC1 %"KXKU50 .@ ^T]*?_PJ'0O^
M?_Q1_P"%;JO_ ,DT6ON-:.Z(-#^!O@#PWI<^G:7X1TJRL+BXANI;:*W CDEB
M;=&[+T)4\C/>F>)O@7X"\8:LVJ:MX7L;G4FF,[W:AHI'<QI&Q9D()!2*-2IX
M(1<@X%6O^%0Z%_S_ /BC_P *W5?_ ))H_P"%0Z%_S_\ BC_PK=5_^2:3BGN/
MFDMF>:>/?V7;74(=)L/!]OX=T;0;*6YN/[)O],DECAN9FR]Q \4T;QD_,#'G
M8P;D5U'AW]FOP1I?PO\ #_@C4=(AUG3]'=KB*:5/*<7+LS2S(8R#&6:1\A2!
MAL=*Z/\ X5#H7_/_ .*/_"MU7_Y)H_X5#H7_ #_^*/\ PK=5_P#DFERH.9FA
MH?P]\,^'5T@:7H=C8KH\,MOI_D0A?LT<I4RA,=-Q12>Y*\U>L/"VD:7H]QI-
MKIUO;Z;<//)-:QH DC3.SS%AW+L[D^I8U@_\*AT+_G_\4?\ A6ZK_P#)-'_"
MH="_Y_\ Q1_X5NJ__)--12Z"NREX@_9_^''BQ=*75_!FCZBFE6BV%B)[56^S
M6ZXVQ)Z*,=*ZWP[X7TCPCI$&E:'IEII&F0#$5G90K%$@]E4 5S__  J'0O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4U[_ %Y/^T%]WX;_ /8ZZ9_.2@#UBBBB@ HHHH **** "BBB@ HHHH ****
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MWXS7'B70I8X;S0](M] UQMRB&Y5;KS&CP</M;R258$'H1S6#XP\.^/O%&D_
MKQYKVB>*M)N_#VGZAI7B"Q\*I''J-I-(L48N(HBI#Q,;=N$!.V5<#&:7M(_:
M_1?CI\[L?LW;W=_G_7I9'T7)^T5X C\"V_BX:X9M)N+W^S8EAM)GNGN\D&V%
ML$\WS1M;*;<@*3C%;"_&#PJWA_0-;EOY;6PUZ_CTRP^U6DT$DER[,JQ-&Z!T
M;<C#Y@.E?.TOPW\,VWPHFNSX;^*CRW_BDZ\FJ+$C:W9WXMQ$MZL2G(0JNS!0
MYW'<N#FI?$FF_$[Q#^SW\/=>\2:+J&N>)?#?BZTUNYL(;>--1NM/@NI CM"A
MV>>8&1RBD<Y'7BCGI[_JOT%RS_J_ZGHW[27QR'@;X;^/E\+ZK'!XS\.VEC>2
MQ-#O\B.XN-B,=RE#N"2COC'TJ7P_^U#H6L?'S7?A>UCJ$5YIT%JT5Z+&Y:.:
M:0S;U8^5MC5?*7#EMK;C@\5X'\2?#OC/XM-\>=:L? >O:7;:]H6@6NCP:E $
MN+SR+N=I3Y8)*$!L[&.0-I(&<5[3IRZMX,_:X\07UQX=U>]T;Q5H&EVEKJUE
M:^;;6\UM)=F59W!_=\2H1D<]J?M(]&@Y7NTSV/0_'&A^)-<UW1]-U&*\U/0Y
MHX-1MX\[K9W0.@;(QRI!XKSC]KOXP:O\ _V>?%OCS0K>TO-6TI;<P0WP9H29
M+F*([@K \!R>".17=^&=<DU/Q1XILF\-7NC+87,4:ZE<QHL>I[HE;S(BI)(7
M[AW <K7DG[?7@G7?B/\ LF^._#OAG2[G6M<O%M/L]C:)NDDVWD#MM'LJL?PI
M<RCJ/EYM#B/A+^TO\3;3X]>%/AI\4=)\,SMXLT-]:TK5/"[S 1!5+&.9)23T
M1N01SCKV]!C_ &XO@O-XZ3PFGC. Z@][_9J7/V:;[&UUG'DBYV>5NSQ][\:H
M?!/]C_PA\+=/'B"U35KGQS?:*NGR:OKE_)>7%HK1C=%%O.(U#=E Z=:^/K7X
M2_$_5OV9-%_9H?X4:OI_B"SU_P VX\9L(O[*2 7;SFZ2;=N+[6V@8SC\J:JP
M?Q;_ "7X;7%[)_8_S_/H?=>C_M5?#GQ%\3)/ NF:M=:AK<5Y)ITDMOIUP]FM
MTBEG@-R$\K>H4Y&ZO _'W[>;?!'1/'NI:]J>D>-+BR\:2Z%INFZ5;7-J;.!&
M7>D\C1E7D16SE>&/0FN>\#^%O&_@[]JJT/PP\->//"OAK5->NKGQEIOB&&)M
M D0D[KJTDW$[Y.H"\_=' XKCOB%^SY\1=2^$'[1,-GX1U"YU"^^)I\0:99[
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M#?\ ['73/YR5ZQ7D_P"T%]WX;_\ 8ZZ9_.2@#UBBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "O/?&OP(\%?$+Q*GB#7=)FNM82
MT2P%U#?W-NWD*[.J$12*" SN>03\U>A44 >3_P##+?PW_P"@-?\ _@\O_P#X
M_1_PRW\-_P#H#7__ (/+_P#^/UZQ10!Y/_PRW\-_^@-?_P#@\O\ _P"/T?\
M#+?PW_Z U_\ ^#R__P#C]>L44 >3_P##+?PW_P"@-?\ _@\O_P#X_1_PRW\-
M_P#H#7__ (/+_P#^/UZQ10!Y/_PRW\-_^@-?_P#@\O\ _P"/T?\ #+?PW_Z
MU_\ ^#R__P#C]>L44 >3_P##+?PW_P"@-?\ _@\O_P#X_1_PRW\-_P#H#7__
M (/+_P#^/UZQ10!Y/_PRW\-_^@-?_P#@\O\ _P"/T?\ #+?PW_Z U_\ ^#R_
M_P#C]>L44 >3_P##+?PW_P"@-?\ _@\O_P#X_1_PRW\-_P#H#7__ (/+_P#^
M/UZQ10!Y/_PRW\-_^@-?_P#@\O\ _P"/T?\ #+?PW_Z U_\ ^#R__P#C]>L4
M4 >3_P##+?PW_P"@-?\ _@\O_P#X_1_PRW\-_P#H#7__ (/+_P#^/UZQ10!Y
M/_PRW\-_^@-?_P#@\O\ _P"/T?\ #+?PW_Z U_\ ^#R__P#C]>L44 >3_P##
M+?PW_P"@-?\ _@\O_P#X_1_PRW\-_P#H#7__ (/+_P#^/UZQ10!Y/_PRW\-_
M^@-?_P#@\O\ _P"/T?\ #+?PW_Z U_\ ^#R__P#C]>L44 >3_P##+?PW_P"@
M-?\ _@\O_P#X_1_PRW\-_P#H#7__ (/+_P#^/UZQ10!Y/_PRW\-_^@-?_P#@
M\O\ _P"/T?\ #+?PW_Z U_\ ^#R__P#C]>L44 >3_P##+?PW_P"@-?\ _@\O
M_P#X_1_PRW\-_P#H#7__ (/+_P#^/UZQ10!Y/_PRW\-_^@-?_P#@\O\ _P"/
MT?\ #+?PW_Z U_\ ^#R__P#C]>L44 >3_P##+?PW_P"@-?\ _@\O_P#X_1_P
MRW\-_P#H#7__ (/+_P#^/UZQ10!Y/_PRW\-_^@-?_P#@\O\ _P"/T?\ #+?P
MW_Z U_\ ^#R__P#C]>L44 >3_P##+?PW_P"@-?\ _@\O_P#X_1_PRW\-_P#H
M#7__ (/+_P#^/UZQ10!Y/_PRW\-_^@-?_P#@\O\ _P"/T?\ #+?PW_Z U_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MV/3/O7'6O[./P\TWP/%X1LO#J6&@PW[:I!!:7$L3VUTS%C+%(KAXVRS ;&&
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M/A70(8?#VH>(-&L]6\3WD\; 1W-^L#6D$'+&5EY:1@%16^4ER-OT73 ****
M"BBB@ HHJI?330V=Q);0?:ITC9HH=X3S& X7<>!D\9[4 6Z*^2[7Q]\9/AK\
M1?A+:^-?%6D>(M5\=W[VNH^!=.TN.+^R(OL\DTEQ;W"NSR1VY6-7:3<&W\$$
M@CZTH **** "BBB@!N*6EKS[XT-XU'A!(_ NHZ5H>H27<2W^M:N@DCTVQY,]
MRD9(6215'".0O.2<#!0'?\TM?/?[)?Q@U?XJ0>.K>[\26?CW0_#^KI8:5XUL
M;1;5-50P1R2@QH=N8I&9#(@"/P0.#7T+3 **** "BBB@ KP[]M;_ )-I\5_]
M=M._].%M7N->%?ML,R_LV^)P$9@UQIX)_NC[?;G/]* /7O$OAW3_ !AX=U30
MM6M_M6EZG;2V=U!N*^9#(A5URI!&0Q''-%QX;TV\\/2:#<V<5SI$EL;.2SF7
M>CPE=I1@>H*\'-:]%2XW&>8^'OV=_ WABVU**PTV[#7UI_9\EQ<ZG=3SI; Y
M$,,KR%X4!Y C*\@'L*MZ)\#/!OA^*R2UTN22>UU4:VMU=WD]Q</>"$P"9Y9'
M+R$1-L&XD 8XX%>AT4<H<S/.;SX$^"]2U37K^?3)FDUNXM[R_A%Y.L$T\+Q/
M'+Y0<('!@BRP )V8.>:UM+^%GA;1_'VM>-;/2(H?$^L6\5K?:AEBTT<8 52"
M<#A5!P 3M&<X%=A12Y4Q\S[GG_@WX(^$OA_JQO\ 0;.\L" ZQ6@U*Y>T@#G+
M"*W:0Q1@_P"RHQVQ7?4ZBJ^9(4444P"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *P_&'A'3/'GAG4- UF.:;2[^/RKB.WN9;:1ER#\LL3*Z=.JL#[UN44 > :I
M\*_%/P/7PVWP:T:TUGP]9S7DFK^&=>UJ=KFZ:9(Q'+;WUSY[QE"G,9(1@QZ'
MFMW]FWX7Z]\.-#\7W_B?[!!XA\7^);OQ->6&F2-+;6+3)$BVZ2,JF0JL*EGV
MKN9FP,8-.^+W[1F@?!;XD?#[PUXB1;'3_%B:BQUJXF6*WL3:I"P\TL0,.9MH
MYZ_6M#_AJ+X0_P#12O"__@UA_P#BJ /4**\O_P"&HOA#_P!%*\+_ /@UA_\
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MD:Y>WUYI\0BTV]BG,2K>0NTD@#9" )@GGEEXYH ^P**\O_X:B^$/_12O"_\
MX-8?_BJ/^&HOA#_T4KPO_P"#6'_XJ@#U"BO+_P#AJ+X0_P#12O"__@UA_P#B
MJ/\ AJ+X0_\ 12O"_P#X-8?_ (J@#U"BO+_^&HOA#_T4KPO_ .#6'_XJC_AJ
M+X0_]%*\+_\ @UA_^*H ]0HKR_\ X:B^$/\ T4KPO_X-8?\ XJK_ (#^.7@S
MXF^*-5T/PMK=IKDVFVEO>R75C<1S0,LKS)L1E8DNGE N,843P\G=P >@T444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV_3_ #,^V/+Q^->B5YO\'88E_P""A%W(+DM.WP[NE>VSPBB_L-K8]]S#_@%
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MNRS+(QA4=&;8V<\>FZ@#0HHHH **** "BBB@ JI;Q2K<W;22!XVD!B4?P+L
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M5=<>8V.O&:=0 ,Q;DG)]Z*** "BBB@ HHHH :N=BY.3@9-.IL>-BXZ8&*=0
M4444 %%%% !7DO[5?_)"?$.#_P MK+_TL@KUJO)/VK,?\*(\09_Y[66/_ R"
M@#UNBBB@ HHHH **** "O-?@_);M_P %"KR-8"MVOPZNFDF[/&=0L-BCGJI5
MS_P*O2J\[^$,EVW[?\Z/&BV*_#V\:*0?>:0W^G^8#ST $>..YY/8 ^U****
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M_(E 'UG17R9_PUM\:?\ HU'XA?\ @OO?_D2C_AK;XT_]&H_$+_P7WO\ \B4
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M_@OO?_D2C_AK;XT_]&H_$+_P7WO_ ,B4 ?6=%?)G_#6WQI_Z-1^(7_@OO?\
MY$H_X:V^-/\ T:C\0O\ P7WO_P B4 ?6=>=_"":9O^"@-Q$UN$MU^'MXR7'=
MV-_I^Y?^ @*?^!UXA_PUM\:?^C4?B%_X+[W_ .1*[C]C+Q#\2?B1^V)JWB_Q
M=\*O%7PZT6'P3<:?#_;5A<10/<->V;$++)%&N]ECSLY.(R>QH _0NBBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** $I::** '4444 %%-^HI: %HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI* /*/'?[4GPH^&/
MB2?P_P"*/'FCZ'K, 5I;*\GVRH&4,N1CN"#6[X8^-'@WQIXBLM#T/7(=3U&]
MTE==MQ;QNT<ED9/+$HDV[.6XQG/?&*\-^-^DV?CK]M?X(^''M(9X='L=4\2Z
MBKQ*WF+Y:V]N6..@D9NM?/O[0'QL\::?\:_'%GHOB*30/!]QXDTKPDM[-J;:
M=:644%FUQ=QK.$86[2NZ)YBJ2 OY-.#TEI\_TL1RSU:=_(_2[-0SW$=M"\TL
MBQ1H"S.S !0.I)/85\!7C>/;+X/?#+PEI'Q4N-2U3QY\0";+6M%U.6^-AI,8
M=Y88KJ4![@1F+[[C#;L8Q7UIKEOX-^$'P9ETOQQKYN/"D-NUC=ZAXJO/.:Z6
M0D%9I&QO+;L8].*-&[13^X?O+XK+YG2^!/B=X5^)EOJ-SX4UZQ\06NGW36-S
M/I\HECCG4 LA8<$@,IX)ZUU=?(W_  3-U#P_JO[/=YJ6C2V*76J>(-0U2_T^
MSVJ+*268^7&RKPG[E(B%[#%?7%)[Z*PU?J[BT444#"BBB@ HHHH **** "BF
M\UP?QDM?&DW@NXD\#:_IWA[6+8FX>XU/3S>1/$J,60('3!)VX;)QCIS0K"]#
MOJ*^&/!_QV^*-]^R#)\7_&/CVQTR'5#9?8O["\.))/9%K\6[AEEFV2!P5';:
M"2,FO9?%_P"V;X-\%^--0T*YT_6;RPTB^M=,U?Q#:V\;6&G7-P5$:2$N'/+I
MDHK!=W)J^7F^%W_#\R'/E7O+]?R/H*BO&OA3^TUH?QA^('B7PMH/A_Q"%\/7
M5U8WVM75D$T\7,$PB:!9=QR[9W@8^[UP>*Y/XC_%_P"(OA/]K/X6^#?)T6W^
M'_BF2_A#+OEOKAK>R\\LQ("Q 2,J@#)(5B2,@5.E[7_KY%7;5TCZ0I:\K_:4
M^*EQ\%_@OXF\4V$2W&M0PK;:7;NNX37LSK%;KMR"1YCJ2!VS7GGP)_:6U6[^
M!OCS7_B7!$OBKX=WFHVOB.'28MH<6P,BO$C,.'BVXR0"5/2GRW]0YO+0^EZ*
M^>/A]^VAX6^(6L:CIEEX7\76=Y#H!\2V$-]I?EOJUB"%WVJAB7)9E !QG.1Q
M6-XH_:P3Q-\+?C+%HVD:YX'\<^#_  U<:JMKKMM"LJ!H)6AG38\B, R<@G@]
M13Y?/\4+F\G]S/J"BOECX>_ML^&W^#O]L:_#JUQXBT4Z/IFI6*V\:W-[>7L,
M)BDA0.%*2;V8<KPK<<46W[:@TKXU?%?POXF\*:II/A3P5:073:\+;<L:&&1V
M:;YSQ(440[1EMW(%'+;=K[Q<]]D_N/J:EKYXT/\ ;4\'7ND>*KW6=(U[PO-X
M=T9?$$]EJMK&)Y[!R0DT0CD<')7;@D$'J!7I/PD^*'_"VO"HUR/P]J_AR!W
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MTTQ'">;,(BP,_P ICW*O#<]*S=*+]UV].OW;E*<K7L?5B:39I]FV6L"_9?\
M4;8P/*XP=G''''%/OM/MM2@,-W;174+<F.9 Z_D1BOGJS_::\0:A^TC_ ,*K
M&B:)I<ME:VMQ=OJ>IRQ3WXDA\R5M/7R=LZQ=#E@3M;@8KS+2_P!O3QUXBU/P
MC-HWPJAU#1/%>L:CHNBS?VRJ3WCV[2!9PACPD("KO<G(^? .!D]G&UKJPO:2
M[7^X^T-/TFTTJ-H[.U@M(V.XI!&J GU( '-7:^(!_P %$+N/PCH$-WX<TK3/
M&VJ:KJ6GM'=ZE)_9D$=D^V2X,J1,[JS?(H5"2V>177R?M@>,[KP]\'HM.^&D
MC>-?B#'J$G]AWUXUL+*.V4_OG=H]PC;*/RH.UN 3Q5*FH;-!S2?V3ZQHKX0U
MK]KSXK?$KP;\!KSP'H.E:3KGC37KR*[M)[[?%/%8R2":)':)B(I%1B9 -R_*
M .<U]R6K3M:PFX1([C8#(L;%E#8Y ) )&?:AI+J4KOH6Z***0PHHHH ****
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M#/YKB90^>2, 8]Z]<_X0'Q#_ -%*\2?^ FE__(='_" ^(?\ HI7B3_P$TO\
M^0ZJTEL_R_5$NS=W^IQW[1'[/H_:'/@O2M3U5[+PMI.J_P!J:G8VYDBGO62-
MEA5)4<&,*[;CU/ Q@BO.[']B.+PC-\7].\*>(IK'PS\0?#9TN6QU%YKZ6WOO
M+DC%R99)"SKMDY!.?? %>Z_\(#XA_P"BE>)/_ 32_P#Y#I#X!\0_]%*\2?\
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M$TO_ .0ZL@[JBN'_ .$!\0_]%+\2?^ FE_\ R'1_P@/B'_HI?B3_ ,!-+_\
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MZ*7XD_\  32__D.@#N**X?\ X0'Q#_T4OQ)_X":7_P#(='_" ^(?^BE^)/\
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MOXULW:[MY[>&2.%XI%D "'?\PQDC(!'6O9_^$!\0_P#12O$G_@)I?_R'2_\
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M=GX:SZC/,RVC+]N^TI*H"_.=FWS.^<XKVC_A /$/_12O$G_@)I?_ ,ATO_"
M^(?^BE^)/_ 32_\ Y#HY'_,Q\WD=Q17#_P#" ^(?^BE^)/\ P$TO_P"0Z/\
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MB$JLKQE^"&YYKZG_ .$!\0_]%+\2?^ FE_\ R'1_P@/B'_HI7B3_ ,!-+_\
MD.IY//\ !?Y%<[/.='_9GETWQM\&O$"7VDV$?@*QU.UFT_2=,^RVUP]W&BDP
MH'(B52K':2V=W6N$U[]B%Y/C1XB\7Z<_@_4M)\1:G%JEW;^)O#OV^[M)%"B0
M6\OF* &VY&X'::^@?^$!\0_]%+\2?^ FE_\ R'1_P@/B'_HI?B3_ ,!-+_\
MD.G[/S_+_AA<[/$&_8WO6\+W6D?\)+!F?XFGX@>9]D; C,XD^S8W_>QQOZ>U
M:7PI_9G\6_#5?$/A%_&=C>_"G49M1FBTD:85U!1=[BT;7'F%=JEV((7)[XKU
MW_A ?$/_ $4OQ)_X":7_ /(='_" ^(?^BE^)/_ 32_\ Y#II26S$Y7W1X?\
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MJU_?V&DZGLCNVTV58Y)8@X9HBQ4X5MNUL8)!(S1_P@/B'_HI?B3_ ,!-+_\
MD.C_ (0'Q#_T4OQ)_P" FE__ "'0!PGB#]D#X>:GXF\,Z_H>G_\ "$ZKX?CN
MXK6Z\,10V<C"XMS Q=ECR2JG*G/!YJAI?[(>FZ+'X@NK/Q[XR@\4:]<6\^H^
M)UO8?MMPD$;QQP,/)\LQA7;(V9)P2>!7I7_" ^(?^BE>)/\ P$TO_P"0Z/\
MA ?$/_12_$G_ (":7_\ (=9JFH[7^\OG;U>OR/)X_P!A_P (:+9^#X_"VO\
MB3P=?^&;6YLK?5-)NX_M%Q%<2^;,)C)&ZDM)EL@#!;CMCHOBA^RYI?Q=T_3]
M*\0>+?%$WA^"TM[.\T=+Y/L^IK"^]9+@E"_F,?O.C*37;?\ " ^(?^BE>)/_
M  $TO_Y#H_X0#Q#_ -%*\2?^ FE__(=')I:[^]BYM;V7W(XEOV6M%O/B5!XT
MU/Q+XCUF^T_[9_8]E>7<;6^D&Y0I(8 (PW"G"AV8*.@IW@[]E+PAX'N/AE)I
M]QJ++\/K*]M-)CFE0JQNE"S2RX09<C=C&!\QXKM/^$!\0_\ 12_$G_@)I?\
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MK4T#+;13&,R?ZN)&=F\J,;G+'Y:]7VCIGBB]]_Q%;EV_#_AD/HI**8Q:***
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MD*%9D*E%@_<A&4C8,$'K7JWA/P]<>&M'2RNM<U#Q!<!VD:^U,Q^:Y)Z8B1$
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M^CJ]+H XCX?_ /(V?$K_ +&"'_TU:?7;UQ'P_P#^1L^)7_8P0_\ IJT^NWH
M**** "BBB@ KAM-_Y+;XC_[%[2__ $IOZ[FN&TW_ )+;XC_[%[2__2F_H [<
MXI:6BEL W%&TTHHH XSXF?$S2_A9H%OJ6H0W=]-=W4=A8Z=81B2YO;F0G9#$
MI(!8[6)R0 %)) %5_"_Q,;4]'U"_\1Z!J'@-;!E$PU^6W$95AD.LT<CQD=C\
MV0>HKD_VB?#VN3S^ /%VAZ1/X@E\(:]_:5UH]JR^?<6TEM/;2&(,0#(@GWA<
MC.T@'.*X[XH:WJ7Q/A\$^(#\//$=SX5\/>(1=:GHNH62+<7T1M)T29+5F+2+
M%-)$V& )QE0=M',EU7S_ *V^0N5[J^O]?>>^)XOT2328-436+!],GSY-XMRG
MDR8!)VOG:<!6)P>BGTKB_BI\==%^'?@G3]?LYK'73JU];Z=IL:ZA%%!<2RRB
M/)F.5"+DEF . O2O!K7X.7WB>ZTRYE\%S6/A#4OB;'KT/AZ]ME7['9+I<D+R
MRP@E8UDN%9]A_P">BY&215S4_@C<S:;>Z8?!R2Z9#\5K;4[2T-FC11Z<WV=I
MI(U(($1;S2< #[W%+GC_ $_Z^\7LY/2_X?\ !_ ^B=%^(L$W]H'7(;?P^+,P
MH9YM0AD@E9[=9VV,&SA06'SJI(0L!MYK2'CSPWYUK'_;^F^9>.J6R_;(R9BR
MAE"#=\Q*LI&.H8'O7S/XT^"^H>*/B]>B]\+/?^&)?B#I6HE9(0;=[6'0S$7*
M]#&LVU#QC/&*I_%']GL:YIO[0,]MX)BN+^_ETQ/#\D=HOF&."SM !;$8*!71
MA\N.5]J;J0ZK^ON'RRZ/\/\ @GU?IOB;2=8M[BXL-3L[V"V=HYYK>='6)E^\
M'*G ([YZ5SGB+XT^"?#/@W4O%5SXCT^;0]/;;<75G.DZHV<;?D)^;VZUY))\
M/]6\!ZY\;Y/!W@FRGLKWPSIPTC26MU2QU"ZCBO$DC*#"DD>0K XR-H)KR2Y^
M$7B?Q9X7^-Q/A2_NX=6\-Z3_ &;;WVAV^F_:KR"2\,BQ6Z$@,JLB@MACN7DC
M!H4X;_J)QGJK_A_P3[*TOQK;ZSXB>PLHTN+#^SX[Z/5(;F&2&3=)(FP*K[^-
MF=V-IW8!R"*L:;XY\.ZQ#>S:?KFFWT-B3]KDM[N.1;? )/F%20N,=\=*^;?%
MW@#Q#XVF^(4W@OP_>>&8-8^&\6E:5'<6PLMET+B])@V\>6Q#J>V-ZFL#Q%X$
MN_&UOXEO/!OPWU+P58V_PYU?0;JSN+%+5[^[G2+[-;I&I/F^7LE_>=/WN 3D
MTN>&E_S_ "[CY9_TOSUT/KK2?$VDZY<74&G:G9W\UJVRXCM9TE:%CT#A22I^
MM<?HOQFT:_\ 'WBKPO?S6FDW>BZA;Z? ;F[16OFEM8I_D0X.1YNW S^M<%\-
MOA0O@7XR>&;S2/#BZ+HY\#_8;Z2UA$4;W2W$+(LN.L@!E()R?O<UY1\9/AOJ
M&K>+?CO91_#+4=9USQ>UC;^'/$D=I&\,,BV-N@<S%MT*Q2KOWX&2A )(Q3YX
MK5_F'++9/\#['_MW3EAFG:_ME@AE\B20S+MCDR!L8YP&R0,'G)KG_B9\3-+^
M%N@0:CJ,-U?SWEW'86&G:?&)+F]NI"=D,:D@;CAB22  I)( KYW\0>"]5'[3
M5K\/HXEF\)>(KFS\>:FRL,)+9+Y4J%/26X33W]#MDKU3]HCP[KDT_P /_%NA
M:1-XAE\'Z^-2NM'M=OGW%M);3VTAB#$ R()]X&1G:0.<4^:(<K.J\*_$W^TM
M-N[CQ)H-_P" Y+:01M%X@EMU60%"^Z.6.1T8 *Q/S9&TY%5=;^-OAWPOH?B3
M7M;E33_#VC-#MU,7$4T=VLD22*T2HQ;^/ # $XR 1@UYI\2HY?VA&^':3> M
M;BT'3O&-O=7D/B"S6+?"MG=9=H2Q;RP[1J=X );&"*Y[XE?!O5-8\(?M$Z99
M>%A<P:C+8RZ%9K;ILN%ATZV3$"G"Y4QL@QCE<4O:17;Y/_APY9/9M?(]G_X7
MIX<C^(EQX;GOK&VLDT>UU6'5Y+Z-8)_.GGB$:DD D& G@G.[IQ743>+HK?Q+
M>Z;<P?9;*TT^/4'U.6YB6(!G=2I4OO7:(\EBNWYN#D&OGC4OA)I?Q"\>^(M;
M?X?&+19?A['INF6VIZ8L1AN#<7I>%(B,1N0T9X .&'/-<3XJ^%?C75-'TN6?
MPWJ&JI;^"_"46JV! \R_^R:BT]]9_,0'D,6[*$_-NQWHYX=;+YCY)]'?Y'T1
M;?'S3M6USQ58Z-8QZY!H8TPK=V6H0>7="\D9,HS,$'E[23\V3T S@'O9_&&A
MVFN1:+-K%A%K$PW1Z?)<HMPXQG*QD[C^ KY%N_AWJNO?\+9U'PY\.]0\,Z;K
MFI>%;BQLY+-+=[D6]\K7$OE*3LVJNX@@'')'-7OC%X9\:^*OBO(D'A*XMTL_
M%^A7MG>Z;HT#)=644UHTUU-?,V\.H$J&-0"%3D%231SQM?3[Q<LMM?N_,^E?
MB!\0D\":EX.M9+,W?_"1:RFCJPD">06@FEWG@Y'[G&./O=:Z"#7M.N8[-XK^
MUE6\!:V:.96$X R=F#\V!SQVKSGXX^'=3\1:U\+I-.LY+M-.\5QWEV\:Y$$(
MLKQ"[>@W.@^K"O"?ACX;\:>7\$O"S^#];T:?P7;:C8ZEK%Y"JVL<QLIHHFB;
M<3(C':0X&!N )R<4^:.S#E>Z/J34OB%I$.G:_+IMW::UJ&C6\DUQIUI>0^:&
M12=C[F"QDXQER .Y%<O8_&LZA=>,((] G>?PY?:=8O$+N%3,;J&WEW!F8(-@
MN.1N.[9\N20*\1\&^$YE_9G\0>#(OACJ>C^.[/P->:3>ZE+81I]NO3!M=8IP
MQ:X,TO[P$9'J03BG:I\,_%<OA3XF6Z:%>//J&O>%;BTC5.9H[=-,$[+[)Y4N
M?38:7/!;_G<.2;_X:Q]1VOC#0[W7)]%@UBPGUB!=TMA'<HT\8]6C!W#\J>OB
MK1GUQM%75K(ZNJ>8; 7">>%]3'G=C\*^3]#\->-=:_:"\%:M>^$;C11I?BK5
MI;TV.BP6]FEI);7L<,QN@WF7#2[H6;L&;D @5%\/_A!K%K\38K;Q/#XF35;/
MQC>:[#J%EH]JUI<1O/*\3O?8\S88'6-HRV1MV@8 I<T/Z?\ 7W"Y9_TOZ^\^
MSJ***HH**** &Y-+2T4 -I:#12 .*6DS1F@!HXHVGKQ3A2T -'O1^-+033 6
MBBB@#BOB[\3+#X.?#S5O%^IV5YJ-GIXCW6NGH'GE:25(U5%9@"2SKW%4=%^-
M?AWQ)?>!H-+>:]@\8:?<:EIUU&HV"*)8F8/DY5OWH&,'!4@XK._:4\.ZCXH^
M$.HZ;I-G+J%])?:<Z6\(W,52^@=SCT"JQ/L*\?L/ASKWPE_:5L;G[$P^%&FV
M&L:Y;ZGQY6ER7(A:XM6]%WQ22KQC$I'\-)2BM&A<LGJCW2Q^)AU#XF>*?#R6
M\4>D>&].MKF_U)W(VW,WF/Y.,8^6%%<G/_+5*K? _P"-NC?'CPA+X@T6SOK"
M.&Z:VEM-1C$<Z'8DB,5!/#Q21./9Q7C2>%?%GBK]F'4VTJUFA\6?%34?M=[.
MR%O[.M+Z15W2 ,#B&Q5$P"#N4#(S74_"?X?^-OAE\<M7;5WL-7\.^)]'A=[O
M1=.>SMK.\L]L**Z-+(<R0.H!R 1;@8XHYX;!R2/H3FCGUI:2E88&D_G3J*H
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M$+N+CRR&WDJ2W 7&*R? ]]K_ (7_ &0VU:\\0R>)[B7Q-! D>K6EO*D"G7A
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M:V/&?_"7^&_%VI^!/!/BO_A$/#?A/P%::E:0PZ?!<NTR27,:*S2*?W96",,
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MM$M+D-V=CZ$HKR+P'^TYX$^(VH:1;:+>:A+'K#F'3KRXTV>"VNY%B>5TBE=
MKLJQ29 /!4BLOQ!^U1X<TGQ;X4T>PTW5M:M]<U&_TUKZPTZXE2&2T\Q9-NR,
M^9B2)E.#P%9LX%/E8<WE^![C17SY\,/VH=,UK7M4\/>(I[B'5!XLU+0+2YBT
MR86>Z*XE6W@><*8Q*8T'!8$_4BNG7]I[P&9O$V;^^^S^')9K;4;S^S;C[/'<
MQSB VRR;-KS,[*%C4EF# @<T<H<WD>N45YSX9^.7A/Q)IOB.^:ZNM&/AV(7.
MK6^M6<ME/9PE"ZRNDB@[&5&((R#M/<&JGA?]H3PIXJUC2=-C75M,N]6D,=@N
MK:3<68N<1/,"C2H 0421AS_ U*P[^1ZC17AOB#]JGP[I/B[PIH]CINK:U;ZY
MJ-_IIOK#3KB5(9+3S%DV[(SYF)(F4X/ 5FS@5TUO\??"%UXP7P\EW>>=)?OI
M<>H&QF%B]Z@):V6X*>69!M8$9ZJ5SD8IV%?R?W'IE%>1_'[XM3_"%? =XK$6
M.J>(X],OECMGN)GB:VN'"1H@+%R\48& 3V[U/%^TAX)F\(G7Q<W^!J9T;^S#
MIT_]H?;P-WV;[-L\SS-OS8Q]WYLXYI6T'?R/5:*\VL/CSX0U#P7=^)Q>7$%A
M9ZC%I-Y#=6<L5S:W<DT4*PRPLH=&W31=1T8'IS4_BSXY>#O Z^)6UK4FM$\.
MBR;4F%O(XA%W)L@/RJ<[FZXSCO1RL7,CT*BO*K/]H[P1<^&?$6M37E]IL.@2
M11W]KJ&FSV]TC2X\@+ Z!V\W<H3:#N)P.:S/@Y\;9?BI\3/B!I<,5Q:Z3H<.
MF^1:WUA)9W4,LR3&42)( W\"$<8QT)S1;J%_(]HHKPGPW\2OB-\3M8U?5/"%
MGX=MO!NF:O/I,:ZL9VNM1-O*8KB1'C.R)?,615RKYV9. :35_C[JC_M$>'/
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MC7; :M<W%S!/(86@EAE=W=U1XG897.TX.#SGTKPW\1O"OC&ZGMM \2Z1K=S
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MG@4<LNK*YH[V1YU\8_ >K_$[X5S:!$UG9:O<2V,\FZ5F@1HKF&:0!MNXC$;
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M0W,HQ@MM'<U[!H_@W0O#^AC1-,T73]/T<JRFPM;5(X,-]X;%&WGOQS5+P?\
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MG(CV[<YYZ=:P]2^"NAWWBKP%J5O##IVF^#FNI;#2+6U1(!++%Y2N,8V[%:7
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MHB:X>.-H_-3=C@ ':"P.<5]17WPU\*:G:ZK:WGAK2;JVU:87%_#-91LMW(
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M**8#=M+S2T4 -YHYIU% !1110 F/>C'O2T4 %%%% "8]Z,>]+10 A- -+12
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MN-7DT&#Q 8H_L,M\A=6A'S^9]]'3?LVEEQFGR^?]?,7,=3_PL#7O^B:>*/\
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MD3^TUH2Z\MN-%UL^'FUG_A'QXH%O'_9QOO-\CRL[_,QYW[KS-FS?QFI_@O\
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M10!Q'_"P->_Z)IXH_P# G2O_ ).H_P"%@:]_T33Q1_X$Z5_\G5V]% '$?\+
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M_HFGBC_P)TK_ .3J/^%@:]_T33Q1_P"!.E?_ "=7;T4 <1_PL#7O^B:>*/\
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M ,G5V]% '$?\+ U[_HFGBC_P)TK_ .3J/^%@:]_T33Q1_P"!.E?_ "=7;T4
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M0 4444 %%%% !1110 4444 %%%% '$?#_P#Y&SXE?]C!#_Z:M/KMZXCX?_\
M(V?$K_L8(?\ TU:?7;T %%%% !1110 5PVF_\EM\1_\ 8O:7_P"E-_7<UPVF
M_P#);?$?_8O:7_Z4W] '<T444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!Q'P_P#^1L^)7_8P0_\ IJT^NWKB/A__ ,C9\2O^Q@A_]-6GUV]
M!1110 4444 %<-IO_);?$?\ V+VE_P#I3?UW-<-IO_);?$?_ &+VE_\ I3?T
M =S1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '$?#__ )&S
MXE?]C!#_ .FK3Z[>N(^'_P#R-GQ*_P"Q@A_]-6GUV] !1110 4444 %<3KGP
M[GU7Q9<:_8>*M:\/W4]E#8RQ:>EF\3I%),Z$B>WD8-F=P<$#&.*[:B@#B/\
MA7^O?]%+\4?^ VE?_(-'_"O]>_Z*7XH_\!M*_P#D&NWHH XC_A7^O?\ 12_%
M'_@-I7_R#1_PK_7O^BE^*/\ P&TK_P"0:[>B@#B/^%?Z]_T4OQ1_X#:5_P#(
M-'_"O]>_Z*7XH_\  ;2O_D&NWHH XC_A7^O?]%+\4?\ @-I7_P @T?\ "O\
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M .(_X5_KW_12_%'_ (#:5_\ (-'_  K_ %[_ **7XH_\!M*_^0:[>B@#B/\
MA7^O?]%+\4?^ VE?_(-'_"O]>_Z*7XH_\!M*_P#D&NWHH XC_A7^O?\ 12_%
M'_@-I7_R#1_PK_7O^BE^*/\ P&TK_P"0:[>B@#B/^%?Z]_T4OQ1_X#:5_P#(
M-'_"O]>_Z*7XH_\  ;2O_D&NWHH XC_A7^O?]%+\4?\ @-I7_P @T?\ "O\
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MP!"1%<,,;L] :]_L[J*^M8;B!]\,R"1&]5(R#S0XN/Q#C)2V+5%%%24%%%%
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M"=*_^3J .WHKB/\ A8&N_P#1-?%'_@3I7_R=1_PL#7?^B:^*/_ G2O\ Y.H
M[>BN(_X6!KO_ $37Q1_X$Z5_\G4?\+ UW_HFOBC_ ,"=*_\ DZ@#MZ*XC_A8
M&N_]$U\4?^!.E?\ R=1_PL#7?^B:^*/_  )TK_Y.H [>BN(_X6!KO_1-?%'_
M ($Z5_\ )U'_  L#7?\ HFOBC_P)TK_Y.H [>BN(_P"%@:[_ -$U\4?^!.E?
M_)U'_"P-=_Z)KXH_\"=*_P#DZ@#MZ*XC_A8&N_\ 1-?%'_@3I7_R=1_PL#7?
M^B:^*/\ P)TK_P"3J .WHKB/^%@:[_T37Q1_X$Z5_P#)U'_"P-=_Z)KXH_\
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MOBW\#/%6A:G9>#]'\8Q:GX,TCP]J*W>JI!_9$]JNV3&4;S(CNW83DE:^K?\
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M_3W_  G^N?\ 1-?%'_@3I7_R=1_PG^N?]$U\4?\ @3I7_P G4<LM^9W%>/\
M*CP"Q^$/Q,M_VJ+SQ]I.B1^%](FAGBUUEUM;FW\3"* Q6#"VV#[/(OREF)X'
M SWY/X8_L9^(-#C^ =KK^C:;<6_ANZU;Q#XJE,L;M<:I,,VW_73:S=>@V+7U
M7_PL#7?^B:^*/_ G2O\ Y.H_X6!KO_1-?%'_ ($Z5_\ )U#BY;L:DH[11\-V
M?['GQ3T/_A7VO7&C2:Q?VLVN7FJZ3HGB4:5-:WE[<EEFCN I!4PA4;;@^E>U
M1?LQ7EC\0OA%/I_A/3;#PAX"\.ZA<6VD_;?M"KK-SL^3<X#28.]O.8#GG@U[
MU_PL#7?^B:^*/_ G2O\ Y.H_X6!KO_1-?%'_ ($Z5_\ )U+D?<.9=CY/\%_L
MP_$;P#I?[-$*Z#I^NCPC?:I>^);634$B$=Q>$[9E8J1((O-D.U1SM %?<O/I
M7%?\+ UW_HFOBC_P)TK_ .3J/^%@:[_T37Q1_P"!.E?_ "=5Q7*2VGT.WHKC
M_#?CYO$'B"\T2\\/:MH&HVUM'>>7J+6SB2)W= 5,$THX,;9#8_&NPJB0HHHH
M **** "N)\??\C9\-O\ L8)O_35?UVU<3X^_Y&SX;?\ 8P3?^FJ_H [:O%_"
M?[0R>)OCGXA\!MH[6VGV23+INM>=N349[80_;(E7;P8FN(UZG)5^/EKUC6)K
MN#2;V33[<7=^D+M!;LX022!3M4L>@)XS7RUH?[+OC7P;HOP[UNT\77^M>*M!
MU5=3O])NOLJ6;O>.PU/RY%A60Y$\KKO<Y*CVPN91W#E<MC=\!_ME0^,OA+K7
MBN7PT^FZSI.H65M-HLMWG=;W5Q''!<I)L&499&/3[T;KVS78_%[]H2/X8?$'
MPCX>_L=M1L]3='UC4!-L&DP2SQVUO*PP=V^>4+U& CG/%>+>)/V5?&C?"OX;
MQZ&EG;>*]-%IIGB"T>X BN].2]2YX?H7B>,,OL\@[UV?C3]E_P 1?%C5_BCJ
M&M>+=2\.#Q$L>EV-AIOV:6$V-O%_H[.TD32*QGDGD^1E(W+W&:/:K>P>S>US
MWKXA>*CX&\!>(_$8M_MATC3KB_\ L^_9YOE1L^W=@XSMQG%<7;_M*> 8/[%M
M-5\1V>FZUJ,5J?[/R\ACFGC61(2RKC>0V0#@D<XQ4NKZ!XJ\8?LXZAH6L6T$
M?C74O#,MC=0I,IA-X]L4;#]-I<]?2OC[P?J4O@_X@7-KKTHOM+T_QCIR'PW8
MZQ;Q73ZA';VEJEPMHT)FD167<=LH5@FX#'!I>EQ.+]#ZQUKXM>*=:\<Z[X8\
M >%]/UQO#QBCU;4M9U-K*VCGDC$BVT6R*1GD$;(Q. J[QR37IOAV\U#4-%LK
MC5-/72M1DB5KBS6<3B%^ZB0 !@.QP,^@KP#Q=\+_ !+X?\5>/([7P19_$?P5
MXRO8=7?3Y-12SN+*^6"*!]WF?*\;"")@0<J=PP1BO4/@#X+U?X=_!?P;X:UZ
M6.;6=,TZ*WNGBE,J^8!R Y +8Z9Q2YD.S/1**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /&OVD/V@5^ _A>*\
ML]&;Q%K,V^==.6?R0EK%@SSN^TX5=RJ.#EY$'?-8GC;]I35?#=WXPU33O"D.
MJ^"O!=W%::]JCZB8KE6,<4LQMX?+(D6%)D+;G7)R!TK)_:4_9O\ %'Q,L_&N
MK>&/%US;ZKK.CQ:4FCS6UNT'EQN6V++(I:,,S%FP1DA<]!C#U[X*_$:'P[\2
M/A[;6EKKFB^/+M+B;Q9-=QP/9K+;P07GF6X7);]R[)Y?&7 .W%+VBM8.3J>\
M_%CXD)\,_!HU>*Q;5KZZN[73M/T]9!%]INKB9(84+D81=S@EL'"@G!KSBZ_:
M4U3PW:^*=+\2>%8;?QOH]UIEI;:5INH&>VU!]0D\JT*3-&A12XD#[D^4(3SQ
M6O\ &3PAXO\ 'FAW5EIFC6<-QX<UG2M9T*6XOAMU1K>2.:6)P%S#G:\8))Y(
M/ K@?$WP;\>_$"^\4>/9](M-%\3R:AH-UI/A^XOEE#1:9.\Y269 45IC/.HQ
MD+\A)ZT^=('"YZW\+_B?J_BSQ)XG\*^)]$MM!\3>'Q:SSQ6%Z;NVGM[A7,4D
M<C1QMUBE4J5&"G4@UJ>)/B(?#_Q,\&>$A8B<>(8;Z8W7F[?(^SK$V-N.=WF^
MHQMKFOA/X4\23?$3QKX\\4:5'X?NM<M[#3K725N5N7AM[43,'D=/EW,]Q)PN
M<!1SG-)\8_"OB:3QIX$\;>%]+A\07?AQ[R&YT>2Z6V>XM[F)59HI'&W>K1H<
M-@$9Y!Q1S(.5CY_VB/#F@^*O&FF>)[JU\.6>@ZG:Z7!?74QQ>2S62W84#;PV
M"X R<[>.3BM-/C+HOB"P\+:CX9U72M2TW6-8.E-+<3O$VY8YF=$783YP,7W'
MV\;CG@9\GM?@IXP\1>,++QEK6E6>GWM]X[M?$-UI(N5G^Q6=OIDEG'E\!7E+
M;6.W(&[@G&:T8_@GXGC\5PWHM8!:K\39/%!Q,O\ QY-IK0;L?WC*W3KWI<\=
MK!R/>YUGAG]JGX?^)/\ A+V;5QIT?AF_:QNY+I&4.08U5DP#G<\H0*,L3T'(
MKTOPWXFT[QAHEOJVDW'VJPN-WER^6R$[6*L"K ,""I!!&>*\"O/AAXCCA^*.
MAZAX*/B+1M9\1)X@TZ[LM;2QG+%;?;Y;<-'-$\)<,2 =HYYKU7X)Z7XNT?X>
MV%MXXNS>:]'-<'=)(DLJP&9C DLB*JR2+%L#.H + GGK3YDPY6CT"BBB@#E?
MB=XR/PZ^'/BKQ6+7[?\ V'I=UJ7V7?L\[R8FDV;L'&=N,X./2O+=#_:6O-(N
MM5MOB#X>M?#ALO##>+DN=*U WT,EDA D#;HXV212RX&"&W<'@UZ'\;?"]_XX
M^#7CKPYI:+)J6K:'?6%JLCA%:66!XT!8]!EAS7 M^RQX<_X4WXG\+V5O)9:Y
MXCT Z1>:M>7<U[.I,150))79O+5F)"*0/:ESJ/0.5,@MOCSXST1_"^L>,/ E
MIH7A/Q%>VVGPW%KJQN+RPDN2%M_M4)B50&9D4[';:6'4<UM?##XS>(/BAXFU
MAK+P]IL/A33=3O=(ENFU8MJ,4UL[(6DM?*PBNR?*/,W;65L8-<GJ7AWXI?%K
M3_"'A7Q3X3L/#6G:3J=AJ6L:Q#JJ7*7ILY5F1+:)5#@22Q1DF3;M7(Y-,;X:
M>*?$/QYT#Q9;^![3P)<:?=SG6=?LM624:Y9F&2..!H44%R7:)]TH!39@$YI\
MZZAR=5^?_!$US]I3QG'\'_#GQ&T7P5H][I&IFT@E@O-<D@GAGN+U;5 H6V8,
M@+HQ.0<9XXY[;4/BIXIT'6O"7A[5_#6GKXCUZRU.X$-EJ;RV\3VJHT:"1HE+
M;_,7)VC;[UQ<'P3\4Q_LH>&O 1M[?_A(K"_TNXFB\]?+"0:I#<R8?H<1HQ'J
M>*]%\8>!]5UKXU?#GQ);1QOI6BVVIQWKLX5E:=(1'M7J<E&SZ4<X<J[?F8EM
M^T1#JGPU^'7B;3M):YU'QE?6EA#I+3;6MY&W-=!FVDY@2*<G@9,6.,T_X!?%
MKQA\8M!TGQ+J'AW0]%\.ZI9"[MS::U)=7:Y(VK)$;=%'&<X<X]ZY7X<_ KQ'
MX;^.FLWVH+;?\(%I4^H:CX9C64-(+K4?*:YW)_ (V6Y"^HN3Z5!^R/\ "O5/
MA+X?TC1-5^%>G^&M5M]-%K>^*+.[M96O74@X81_O"&//S?W>:7M%+9![.VK9
M]+4444P"BBB@ HHHH *IZAJ%OI=G/=W4@B@A1I9'.>%49)P.>!Z5<KR73O#?
MB#P/K6M:[J-DWCFZ$%Q-97\4^R\4?>6T2W<^6F?NAXRN<?,.]*ZZ@=/_ ,+9
M\*_V9]O_ +4_=&Y-GY7V>7[1YP3>8S#M\S<%^;[OW>>G-=-I.K6>N:7:ZCI]
MQ'>6-U&LT$\1RLB,,@@^]>'>&;#6]+\0Z=XSNO#NK7E]<O?#6+1(41TFG2T$
M3Q(SC='&EFD.<ACG<1R:[[P+X9U[1_AU96$=Q#HVK-+-=.DT N5MQ+,\ODX5
MU!VA]N0<?+Q1S0E\+_$$GU.G\0^+-(\+MIBZMJ$&GMJ5XEA9^>VWSKAP2L:_
M[1"MCZ5:LM6M-1N;ZWMKA)9;&<6]RBGF.0QI(%/OM=#]&KA?BYX!;X@?\(CI
M]Q;O<6$6J2RWLT3!'@4Z?=QK*ISD,))(]I&2#@]LUX>OP[^)>H>)_$$^OI?6
ML5Y<&.WO-*A6=O/2VM8/MJJ+B,1F3R-R[@VS:00,_,<T-F'++='US52\O;?3
M8EEN9D@C9TB#2,%!=V"HN3W+, /4FOF&VNKN]^,M_>SVTMU-'K%]!I4RS#==
MS+9LBVLA\[='$I1VSY0 90<X^9K%K\/?$6L>'M>BU3P[=2:9]JT+4(=,,?E;
MI(+PO>>6C7$A+>4JC)9=^U<#N7[O<6O8^E;6^BNI[J.-F9[>3RI-T;+ABH;@
MD $88<C([9R#5RO#/$FA>,]/FUW6_#5G<-?)JZKI]C+*%5[2;3;:W.5+;0L5
MPHD/?$3XSNYI_#OX=^(?#GQ&@&H7FJ26VGW$BP7?EF2*ZLA;F.&.68SGA?E)
M7R@?,3.<$DEX]P][L>V3ZY9V^O6FD.[?;KJWFNHDVG!2)HE<D].#.GY^U9^L
M>.M%T'6;/2]0OOLU[=,BQ*T3^7N=BL8:0+M4LRX4,02>!FLG5O\ DLWA?_L!
M:K_Z/L*Q?B+=:CKGC#1=!?0]3F\.PSV^HW.H6D:NLL\<VZ&'.\%51T21VQ_"
MH&<M@O'JPU['6:/\0_#VO:Y+I%CJ27%_'YA\L(X5_+8+)Y;E0LFUB VTG!ZX
MKI68*,DXKQ+P/X;\0;? .C3Z/<:7+X2MYHKG5+C8T-RX@,"&/:^YQ(6\TY Q
MMP<&M;6? /B>Z\2:?J6J7UOXPT^(INTAMUA% X?/GHJLRRL!CY)>FW*D=*.:
M+"TCN+?QSHMWKEUI4%YYMY:Y^T;8G,41 !*M+MV!@""5W9]JC\+?$#0/&<EQ
M'H^HK>20HDK+L>,F-\[)%WJ-R-M;#KE3C@UXE'\._&4UIXB\-V+:M9'4;C7C
M=W-W-&VGM!=-</;&$ [A(&E@)X& LH)^[7H?@Z#4]>\;VNNW&@77ARUL=%.G
MM#=>7F29Y(V*IL8Y2,18#< [^.]+F@]@Y9+<[_6-6M-!TJ]U._G6UL;.%[BX
MN)/NQQHI9F/L ,U1\,^,M'\80W$FD7R7?V=Q',N&1XF(R Z, RY'(R.:YKXC
M>']?U;X2^.M)-U%JVI:AI5[!91VUMY!R\#*D>"[ G/?CZ5R?B;X;7NEZY8ZM
MJ U;QI:768]6AM_+BD.Q"+7$<9C!C0M+E<D[I0QR%&'=;,+/<]OK&7Q1IC6]
M[-]IR+)&EN(@C>:BJ[J6\O&[!,4@&!\VTXS7D:^&_$]C;_#R66QU'4;^QN)$
M>TGE$L,%O)<QE3-*)0?.A@& ^'#8<<[LUSR_#C7K6\^)5\=$O&US6=&U&WTS
M4$E!*N+W4FC4MORI,4]MLXZ>F#1S0[A[W8^E?>EKY\^('@GQ[J&I:]IVBO=1
MZ3 )-8L;F.XVM)-,JQR6B_.K9 ^V/R5 ,\."-N1Z!\&]#N]!\/7J737RK<7K
M30VUY;^1]G3RXU*1IYLA"%E9N6^\[< 8HO'N/7L=9IGB33]7TNXO[><+:03W
M%O+)+\@5H97CDSGL&1N?3FKS7L$=H;IID6V5/,,Q8; F,[L],8K@OAY)+#\/
M];DAM5O95U;7&2U;I,PU"YPAX/7IT_"N T?P+K.L?#7XC:7;6FH:1J&MZ3/;
M6VE&W%GIMM*\4J@6ZL[D%F;YGX!X.T4N9)V?_!%J>H_\+:\+?V:E^-2D-M+*
M(8"+2?=.Q4M^Z79ND&U6.4!&!G-=/I.K6>N:7:ZCI]Q'>6-U&LT,\1RLB,,@
M@^]>$:'9^*](^(5EXEDTCQ%J7ABULI;"+3]1>&6_AGF\MI)U4.!Y0\B- ,D@
MNY VUZ)X%\-:]H_P[LK".XAT;5FEFNG6: 7*VXEFDE\G"NH.T/MR#CY>*?-%
M[#M+J=!X@\::-X5O+&UU*\:*YO-Q@ACA>5V52H9B$4D*I= 6/ W+D\UJVU_;
MW4US%!-'*]N_E3*C F-RH8*P'0[64\]B*\T^,6GZK-]AU#PY8:K+XPM()H]-
MU"P\K[,'?83#=*[C]R[)&6X) 7*D'&>:UKX9W%QJ7CVW@T6ZAEUKQ'I-^U]:
MS&);BS5[ 7"[U<,/]3<;EXROKFCFB+4][HKP:W\&ZU9^*(X;;2=2@U2#65DA
MUI;G_0DTI<8@"^9T\G]WLV_?^?\ VJYF3PKK_P ._A%K61>V4]QX3TFWE::]
M:1GU(O+'/EFD^^=\0)W*",?.H&0<T'U_K[P][L?1^L:M::#I-YJ=_.EK86<+
MW%Q<2'Y8XT4LS'V &:H^&?&6C^,(;B32+Y+O[.XCF7#(\3$9 =& 9<CD9'->
M(^%M#EUKX(?%;1]+LY(M>O8[V!M-B5?+@GDLD$<43"612"&5OO\ WG/"]*ZO
MQ1\.=1TW3FU W.I>)[J\O;4ZRD+1P3W%E$'VP1*FQ=JO)O*YRPWC)R!3NOD+
M7<]AK&7Q1IC6][-]IR+)&EN(@C>:BJ[J6\O&[!,4@&!\VTXS7BMGX8\1V.K>
M'KRVT?5#91:Q(]CI-Y()(K.RDDMP[2N)LQR)LEDC'S@*[1X&<#,7X<:]:WGQ
M*OO[$O&US6=&U&WTS4$E!*N+W4FC7=ORI,<]MLXZ>F#2YH=Q^]V/I7WI:^?/
MB!X)\>ZAJ6O:=HKW4>DP"36+&YCN-K233*L<EHOSJV0/MC\E0#/#@C;D>@?!
MK0[O0?#UZETU\HN+UIH;:\M_(^SIY<:E(T\V0A"RLW+?>=N ,47CW'KV/0Z*
MY_Q;X)TGQS916>L17$UO#*)E6WNYK<[@".6B=21ANA./:O#]3TNWT7X)_M&Z
M9:^;]CLQJ4,*33/.RI_8ML<;G8L>O<T ?2%%<!_PS[\+O^B;>$?_  16O_QN
MC_AGWX7?]$V\(_\ @BM?_C= '?T5P'_#/OPN_P"B;>$?_!%:_P#QNC_AGWX7
M?]$V\(_^"*U_^-T =_17 ?\ #/OPN_Z)MX1_\$5K_P#&Z/\ AGWX7?\ 1-O"
M/_@BM?\ XW0!W]%<!_PS[\+O^B;>$?\ P16O_P ;H_X9]^%W_1-O"/\ X(K7
M_P"-T =_17@_Q.^$O@?PA-X)U+0O!GA_1=13Q5IB)=Z;I4$$JJTV" Z(#@CK
MS7O% '!6G_)=M4_[%NT_]*KFN]K@K3_DNVJ?]BW:?^E5S7>T %%%% !1110
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M-92:\TNTTA#)J"ZUI\]A);1A"^]TG1&V[><@$4P&?\+V\%_]!&[_ /!5=_\
MQJC_ (7MX+_Z"-W_ ."J[_\ C5:WP]^(FA_%3P?8>*/#=R]YHU]YGD320O$Q
MV.R,"C@,"&1AR!2^#_'FG>-KCQ!#IZS*VB:G)I5R9D"YF1(W.S!.5Q(O/'TH
MLPN9'_"]O!?_ $$;O_P57?\ \:H_X7MX+_Z"-W_X*KO_ .-5W;-M!.< =>*\
MY^&_QX\+?%F:$>'$UF>VFA-Q#?76B7=M:RH"!E)I(E1LYXP>>U(+EO\ X7MX
M+_Z"-W_X*KO_ .-4?\+V\%_]!&[_ /!5=_\ QJN\STK.OO$&FZ;J6FZ?=WT-
MO>ZD[I9V\C@/.R(7<(.^%4D^U&H71RG_  O;P7_T$;O_ ,%5W_\ &J/^%[>"
M_P#H(W?_ (*KO_XU6OX)\=:=X^LM2NM,698]/U.[TJ43H%/G6\K128P3\NY3
M@^G:NFYIV8'!?\+V\%_]!&[_ /!5=_\ QJC_ (7MX+_Z"-W_ ."J[_\ C5=[
MD=J-PZU(S@O^%[>"_P#H(W?_ (*KO_XU1_PO;P7_ -!&[_\ !5=__&JZN_\
M$&FZ9J>FZ==WT-O>ZB[I9V\C@/.R(7<(.^%4D^U:-/45T<'_ ,+V\%_]!&[_
M /!5=_\ QJC_ (7MX+_Z"-W_ ."J[_\ C5:WB[QYIW@V^\-VM^L[R:]J:Z5:
M>2@8"8Q2R@ODC"[8F]><<5T^[C.>*=F%T<%_PO;P7_T$;O\ \%5W_P#&J/\
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M$4506);>N !GFA1;V0-I$/\ PO;P7_T$;O\ \%5W_P#&J/\ A>W@O_H(W?\
MX*KO_P"-5G^)/VAO"'AG5].TR5]6U"_O]/CU6"'2=%N[YOLSL525O)C;8"5(
M^;%=;H?C;2?$6N:WH]C<M)J.C/#'>PM$Z&)I8Q(@^8 '*,#QT[T6:'?R,'_A
M>W@K_H(W?_@JN_\ XU1_PO;P9_T$;O\ \%5W_P#&JZCQ/XCT_P &^&]5U_5I
M_LVE:7:RWMW-L+^7#&A=VPH). I/ )KDO OQY\&_$&XOK;3K^XM;NRM%OY[;
M5K&>PE6V;.)@LR(3'P?G&1[T)-A>Q)_PO;P7_P!!&[_\%5W_ /&J/^%[>"_^
M@C=_^"J[_P#C58_AG]I?P%XLU[3--L[^]B_M5S'IE[>Z7<V]GJ#@$X@N)(Q'
M(2%)&UOF'3-:V@_'#PIXH\77'AS3)[Z\NX)YK1KN/3;G["9X<^;"MSY?E%UV
ML" W52.HQ18!_P#PO;P7_P!!&\_\%5W_ /&J/^%[>"_^@C>?^"J[_P#C5<[K
MW[4_@+P[X?TK7KF?6)=%U...2WO[/0KVX@/F3>4BL\<1"N9/E"'!)8<<BN@C
M^-WAAK7299GU&RDU2WO+JUM;W3;B"X>.U ,Q,3QAP0&! (&[MFE8+^0[_A>W
M@S_H)7?_ (*KO_XU2_\ "]O!?_01N_\ P57?_P :JY<?%CPQ:^#]!\4G4P^B
M:[)9Q:=<1QNYN&NF18 J@%N=X)XX&2<8-9/PV^/'A;XL30#PXFLW%M/";F&^
MNM$N[:UE0$#*321JC9SQ@\]J?+W%?L6O^%[>"_\ H(W?_@JN_P#XU1_PO;P7
M_P!!&[_\%5W_ /&J[^BD4<!_PO;P7_T$;O\ \%5W_P#&J/\ A>W@O_H(W?\
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MXAT :ROVF.VC5OD3R5=OD&[#/@U]K_A1^%-2FMF.T.Q\<V7VZ'PW\<YO@O\
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M'/%+P_\ %#QGJ?AO1I]0UOP]I5]=^'(_$CW%Q8NL#!U'^CH#,#A.KODG]XF
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MU#(P((/<5XW\/O@/KOPU:RTC2/B%J"> ]/F9[3P_)80-)%$22+;[21O,*EL
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MOE"%?,WXZ<8SQ5G0_P!G&.QETW4-2\1W6JZ_'XJ_X2W4-0-JD0O+@6C6JQA
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M^%__  F;G_Y85V]% '$?V3\1O^AK\+_^$S<__+"C^R?B-_T-7A?_ ,)FY_\
MEA7<44 </_9/Q&_Z&KPO_P"$S<__ "PH_LGXC_\ 0U^%_P#PF;G_ .6%=Q10
M!P_]D_$;_H:O"_\ X3-S_P#+"C^R?B/_ -#5X7_\)FY_^6%=Q10!P_\ 9/Q'
M_P"AJ\+_ /A,W/\ \L*/[)^(_P#T-7A?_P )FY_^6%=Q12 X;^R?B-_T-7A?
M_P )FY_^6%']D_$;_H:O"_\ X3-S_P#+"NYHI@<1_9/Q&_Z&KPO_ .$S<_\
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MQ#/Q6^&FA>+&L1IQU.(R_91)YGEX=EQNP,_=]*7*X[AS(/[)^(W_ $-7A?\
M\)FY_P#EA1_9/Q&_Z&KPO_X3-S_\L*[>BD4<0-)^(W_0U>%__"9N?_EA1_9/
MQ&_Z&KPO_P"$S<__ "PK3^(/BEO O@/Q)XC%N+S^R-.N+_[/OV>;Y4;/MW8.
M,[<9P:\G\$_M10^,_!?@;5UT)['4M;\0+X=U+2Y9_GTRY\J61LD+\X(C5EX&
MY9%-4HMDMV/0_P"R?B-G_D:O"_\ X3-S_P#+"C^ROB-Q_P 55X7_ /"9N?\
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M'8VX21@J"RD<$?.O_?5(#E_[)^(W_0U>%_\ PF;G_P"6%']D_$;_ *&OPO\
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M:3+<6LZ+)%+&<JZD9!'L:0SDO[)^(_\ T-?A?_PF;G_Y84?V3\1_^AJ\+_\
MA,W/_P L*ZR_OX-+LI[RZE6"V@1I99&Z*H&23]*L4 <5_9/Q'_Z&KPO_ .$S
M<_\ RPH_LGXC_P#0U>%__"9N?_EA7;TF: .)_LGXC?\ 0U>%_P#PF;G_ .6%
M']D_$;_H:O"__A,W/_RPK:?QAI$7A[4M<:[!TK3_ +3]IN%1CY?V=G6;C&3M
M:-QP.W%;JL&4$=*=A'$_V3\1O^AJ\+_^$S<__+"C^R?B-_T-7A?_ ,)FY_\
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M5X7_ /"9N?\ Y85V]%'F!P_]D_$;_H:O"_\ X3-S_P#+"C^R?B.?^9J\+_\
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MB665(S(^Q Q WM@G SU. :?*WU8<T8[11\D>'OV5/%UUX.^)7AK6+NVM8/[
MNO!_@ZY28OY>G22S2*\H'*$A[:(@=K;/>O2?@5\-]2T3Q1<:]KOAG5-)U:+3
M$TQ;O4O$QU173>&9(D_A0%<@M@]L#FO=>**$FGNQZ=AU%%%62%%%% !1110
M5YGX2\+^(-%\:7EYXC:3Q%)()39ZQ'<[([>,G(A^R<+&<<;UWEMO)'2O3**
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MKR+4/#NEW4$30P3VL4L<3')160$ D]2*U:@M[>.UMXX88UBAC4(B*N J@8
M]*GIB"BF[:=0 4444 %%-_"ES[4K@+1113 **;12 =13%:E-,!U%)12N M%,
M_"EI@.HHHH **** "BBB@#Y[^*/A.PM/VHO@WX@'VA]3O+K4K9WEN'=$C73I
MB%CC+;4!/)V@$GJ3Q6O^U9<^9\/='TQYBFEZKXGT;3-5V.5S9S7L2R(Q!!"N
M/D/(X<UU'B[X"^!O'?BBW\1ZYHC7VM6Y!ANOMMQ&8B%VY0)(%&1P<#D=<UIZ
MI\*?"6O1^)$O]"M;U/$@B&JK,"PNO+4+'N!/!4*,$8((SUI<SZ#M$\U^"N@Z
M;X)^/OQ6\,^&[2'3/#$%CHU\NFV:!+:WO)1=+-L0?*A9(H&( '8]ZT?B9,(?
MVE/@T7?RXY;;6XEW' 9S# P7ZX5B/]TUZ#X%^&_ASX;:?<6?AO3(]-@N)3/.
MP=GDF? &Z21R7<@  ;B< 8H\>?#?PY\3-+AT_P 2Z7'JEM!,+B'<S(\,@! >
M.1"&1L$C*D'!HYGN*R/G3Q)XNO= UC]H@:)/_P 3O6->TKP]I$BG=MO;C3K2
M$$8_YY;_ ##Z!#FM3Q5=>-?!'B*]^'W@+7=/\->'_"'@.UU.W\_35NI9)4>Y
MB5"2P 0B!=W!/H1DFO4;/X ^&](U;P?)H\"Z5H_AN\N=2CTN%,K<WDL1B%Q*
M[$L[JKR\L227SG@5V%YX*T2^UC4-5N-.CEO[_3UTRYG;.9;56=A&><8!ED/_
M  *CFET':*/$_@Q\3O&^O>-_#EEXHU/3]1LO%?@W_A*(;:RLO(&G2"2!3 K;
MRTBE;A>6YRAZ X'3?L?R-)^S=X'+,68VCY)_ZZO7H&E_#WP]HM]I5Y8Z7#;W
M.EZ;_8]G(F<PVA,9,(R?NYBCZ\_+UK$\ _ KP/\ ##5)=1\,:(-(N9(VA;R[
MF9H]C,&8"-G*C)&> *.:3^(+16QZ#1113$>?_M $CX$_$4@E2/#VH8(_Z]I*
M^3?">H7GP[U/X/\ PKU2XFEAA\16.M^'+F9RQGTV6SN?,M\G.3;S-LY/W)(:
M^X=:T>S\0Z/?:7J,"W6GWT+VUQ;MG$D;J593CL0<5B:E\+_"VL7_ (9O+W1;
M:YNO#3F31YI%):R8IY9V'.>5X.<]O2IYI+;8+1>^YX!X&^-'Q0\=>-(=3T[1
M[^X\.?\ "3WFC7-@;"W2TM[*"XEMS/\ :3+YOG!H@Y!3;ABH'1JC^&_QH\?_
M ! ^)%@\>JM%X;CO]776;3^P&CM+&UMI9([9H[U\+*9=BD[2?O' 4*:]RC^"
M?@JU\7R>*(-"A@UN2<W+SQ2R*C3$8,K1!MA<_P!XKGWKR#X>_LCW7@WQEH^J
MRZMHZP:;J5UJ$M]IVG2P:CJOG>=F*[<S&,IF;) 3DHN M5[67VK+Y?U^@O9Q
M^S<Y.P^,_C/Q3?:IHUGXFOKS2->\%:EKVF:Y=>'TL C0O;A'M5#EWB=+GCS!
MN&U2"<UL:?J/B>Q^"GP %[J]GXAUS6K^R2'4M1TY':U,FDW#HZ@DYD5EYDSE
M@S9ZU[9X1^ ?P_\  NI?;]"\,6=A=BUDL5==[[+:0J7@4,Q C)1?D&%&. .:
MM^'_ (,^#?"^DZ/I>F:)%!8:/>_VAI]N99'6UG$;1ADW,< 1NR@= &X%+GD]
MT/EC'9GS[#^UAXFO/!.H:]:V4$MSX1\%WFJ^)['R_P#F+I(UO'; @Y11):WC
M-WV[*]%^!OBSXD:KXHNK3Q39ZA<^'Y=,CNX=5U#3[>R*76_#PQK#*^^,JRL"
MPR-IR3FO1]$^%OA/P[)XD?3]!L[<^)+A[G5P(MPO9&7:QD!X.1U&,<GCDU%X
M%^$7A/X9R3R>&](73GF01']_+*%C!X1 [$(H[*N![4<U1Z627X_(7)#HV=G2
MT44QA1110 4444 %>?Z#\0&^(MUJ5MX>ADMM-M3+:R:S,R*Z7"G&([=@6.#U
M,@4'L&!S7H%8[>%]*;71K0L(8]6\HPF\0;9&C/\ "Q'4>F>G:@#E/AKK&KW:
M^)KK5M:&JZ1:7[VEE=R01P%EA7;.QV # F\Q!_URSWJO\4/'%_'\,SK'@?4+
M"?49]0L;*SN9AYMN6FO88&# $<8=AP<BNU\.^'[+POH=CI.GQF.TLXEAC5F+
M,0!U9CR6/4D\D\FEUW0++Q'91VM]$SP1W,%VJJ2O[R&99HSQZ.BGWQ2N]PLM
MCR+_ (:+MK6ZN[JYA$=LUEIJ1:?,Z120WTL]['<0RR,=H\O[+@_[C8SD5-K/
M[2EE8Z'8W]IH[74]Q:W5XUK->1P$K!/Y+K"3GSF9_NA!\PP?X@#V%]\&_"]W
MJNMZJ+.:TU+5Y;:XN+JUN'CD66#=Y4D9!^1AO;.W&[<<@Y.>3\??!'4->UBQ
MOM+U:1)[:Q-G!=WE[<K<6TA<O]H#1L/.(W<))P-O! )%'M$M9(7)TBS?N?C%
M;VWCJ'PL;.%]0N/,BMTCU")W,RP--MDC4EHU*HV&/MD#(KG_  [\;;V33_AO
M?^(-.:P?Q-IHN)HK25)((3(]HD<C$C=S)=1J%&<!R23BNPT_X3Z)8^((=9#7
MKW4-U)>I$UW)]G6XDC:.6019V[F#MGW8XQ4+?!?PU)H,.D217<EC!I\^EVZO
M=ONM[:4Q$I&V<KM,$6P@Y7;P:.=?RL?*^YS.O?M*:+H<-K*;":7SK>:_\MIH
MT=K1)GCCEB4G,AE"%T1>2.I!P#V_Q(U:ZT?PW9W%C,UO*^KZ7 S+C)CEOH(Y
M%Y]5=A^-,N?ACHLTFE/:_;-*?3;5;& Z;=O 3;KC;$VT_,HV\9Y'.",G-_QI
MX=D\4:1;V4<RVYBU"QO=[ ME8+J*<K]2(L?C1S!8B\?W$VG^&;S48]=D\/PV
M$;W5Q=1V\<_[M$)8;7!'OQS69X+\1:A<>&[#2]7U.S;QRVGBYN+61 /+=AD;
MT0]%+*#M(SCC&:Z/Q!H-GXGT_P"P7ZM+;&6&9HU<KN,<BR*&QU4E1E>A'!X-
M7KNV^U6LT/F20^8A3S(FVLN1C*GL1VH \=\.^,?%/BC^PM!?68K+5+BYUPW.
MK6UFF6BL;[[,BQQON4%MZ$YW<(W<Y'7^"_'\<GP_M-:\27MK93)++9W%P?W<
M4DL4SPEE!)P&,>X#/\55K/X*Z'8Z?%;0WFKI)#>7%[!=K?R"XBDG9FGVN#G:
M[.Q*G(SSV&.QT/0[+PWI-KIFFP"WLK5!%%'N)PH]2223ZDG)/6A2;Z6%9(XG
MXP>+M2\.Q^$H]+N[FV&K:O\ 9)YK"P^V3>6+.YF&R/!ZM$F3C@9JOJ'Q8GT*
MZM[)=)O=:@M;G3=/U#4BT=NT4]W)$B$PG!X\U&8#& V #SCK?%G@NT\91Z<+
MNXO+6;3[K[9;7%A.T$D<AB>(D,.Q260$'UKE_%7P6L]>FLKJVO[^WO(;W3;J
M=GNY"EW]DN8I5:500'<JA7<?;(.!@YK;H.7I<AUSXS6T'AW5;F*WNK:2"SUR
MX$L>QF3^SI_)<@-E26/S+GCUJ37?CGIGAZ2:"73;J?48M1ET^2RA*F0%8T>.
M09(&V0S6JCIAKA<]#5Z7X)^%YKO5)Y8;R0:A;7UI) U[*8HX[QP]R(TW84NX
MW$CG/3%7M8^%'AK7M:U/5;W3S+>ZA8KI\T@F=?W:MN!3!^1\JGSKAOW:<_**
M.;^Z/E\S(D^+DMI//I=WX>N(/$JW%O!#I2W,;K.)ED9'67A0H$$Y.0"/*; /
M&4UCXR0^&=>T72]6T];.XU"6V@>(ZA \\,D\GEIB)6W,FXJ"_''.#@UH#X1Z
M(UC<023:A/=37$=TVIRWLAO%DC&(RLN<@*,@ <89L@[CF-O@SH$FI17DDNI2
MRK-;7,BR:C,RSS6[!HI906^=@57KQ\HXX%/F7\K)L^YCS^,-6_X4CXXUD7;C
M5+ Z\+:Y"J#&+>YN4AP,8^540=#]WFO2-2N+R'2YIK&VCO;U8]T4$LOE+(V.
MA?:<9^E<]KW@&WO/AYXC\,Z:_P!D75H;]1)+EPDMTTKNQ[XWRL<?A70ZGI-K
MK6F3:??1">TG3RY8R2 RGJ#@YP:6I>AY9XJ^+5WK'PN\9:QX7F72M;\-P3R7
ML-];BX$3Q0M)L1D?RW)PHW!F &<C/%-\7>./$5N_C/6-/U&.TT_PE+!&^FFW
M1_MW[B&XFW.?F&Y)U1-I&&4D[NE=SXE^'FD^(O!\WA=EDT[1)HFMWMM+?[,#
M$RE6C^0#"D-SBL^X^$>A7E_'=7#ZA.^(!<1M>R>5>-"<Q-.@($C#CDCD*H.0
M *.=]B>4Z_4-4M-)T^6^O9X[2TB7?)+*VU5'J37G?Q7\?2:/I_@Z;2]9_L^Q
MUK5/LTFHVUG]L;ROL=Q,NQ #G+11CITS7J%96J:#9ZS?:3=7*,TVE737=L0Q
M&V0PR0DD=QLE<?C0,\OT+XU:M;^'IKO5_#US,-(16UJ^CVV_D(Q)1Q Y+9\G
MRY73JH? W$8K8\2_%B.Q'CNU6"2TE\.:9)>^>)8_/E"P+)OBA?JGS[0Y!7<K
M ^^UKGPOT/Q!K4NHW2W2O<>7]KMH;J1+>[\LY3S8P=KXZ<]1P<@8HUCX7Z)K
M^I:I=ZC]LNWU#3Y]+>*6Z<Q16\P02K&N<)NV)G'=>,<T<_D'+YG):'\5M=U#
M2].O-0T=K>YN->U/2[>TL9T<70MEO2H8LHV$_95&0>6] 2*BUC]I70;.XLHK
M*W:]^W6L-S;S37$=O$?,B,K(S/T98S 2,'/GI[D=OI_PWT;3+R"XA6Y/V?4I
MM6@BDG9DAN)4F64HI/ ;[1*2.F6S6;!\%_#5C:B+3X;O3)5OIM02ZL[N2.=9
M)>' <'.S;M4)]T*B  ;1A\W]T.7S.J\-:]#XH\.Z5K-O'+%;:A;17<4<Z;75
M9$# ,.Q /-:U5K6W6QM88%>1UC0(&E<NYP,99CDD^I-6: "BBB@ HHHH *^>
M_%7_ "2?]IK_ *Z:G_Z9+:OH2OGOQ5_R2?\ ::_ZZ:G_ .F2VH ^A**** "B
MBB@ HHHH **** /-/CE_QY^"_P#L;-+_ /1U>EUYI\<O^//P7_V-FE_^CJ]+
MH X*T_Y+MJG_ &+=I_Z57-=[7!6G_)=M4_[%NT_]*KFN]H **** "BBB@ KB
M?'W_ "-GPV_[&";_ --5_7;5Q/C[_D;/AM_V,$W_ *:K^@#MJ\8\)?M#1^*/
MCIXA\!MI#6FG6:3+IVM&;<FH3VPA^V1JN./*-Q&O4Y*OZ5ZMK$MW!I5Y)86Z
MW=^D+M! SA!)(%.U2QZ G S7RYH?[+GC7P;HOP[URT\7W^M^*M!U4:G?:3=?
M94LW>\9AJ?ER+"LAR)Y77>YR5'M@YE$.5R/:O#7[1/PX\87YLM$\6V&IW/V5
M[U5MRQ\R) "Y0XPY4,,A22.X%<[X9_::\/\ Q$^&-QXN\,7-HBP:A%8RQ:S(
M]LD9>\%N-SJC<L.4 !R64';SCFOAK\#?$7A70_@#;7-E:P3>#X[M=6\J5?W9
MELY8_EQ]_,C+G'UJC8_"3QM)\ =0^'UQHEO;WUCXCAO+.\%Y&T5];_VR+QI
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M><YI/C)X5\32>-/ GC;POI</B"[\./>0W.D272VSW%O<Q*K-%(XV[U:-#AL
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ME:-L=0L?]VESJ.C0<M^I[;#\9O!-QXR;PI'XAM6U[SFMQ:C=@S*NYHA)C89
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M9GC/X&^!?B#<6EQKWARUOI[2#[)%(&>(^1G/DML8;H_]ALK[5+\7OB1#\)_
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MCNZ*** ,[6M'L_$&CWVE:C MUI]]"]M<6[9Q)&ZE64X[$$BL/4OACX7UF_\
M#-Y>Z+:W-UX9<R:/-(I+V3%-AV'.>5XYSV]*F^(_BB3P+\/O$WB*&!;J32-,
MN;]+=SM$ABB9PI/8';BO(? O[44WC#P?X'U"70TT_7-6\1IX<UG2Y)B3I\Q@
MEEW(<?.K*D;IG&5E4TN52U%S-'I,7P3\%6OC"3Q1!H4-OK<DYNGGCDD5&F(P
M96B#>67/=BN?>O'_ (>_LCW?@WQEH^JR:MI @TW4;K4);[3M.E@U'5?.\[,5
MVYF*%,S9("<E%P%KUJ+XZ>"KCQF/#,>KEM4:[;3U;[+-]F:Z52S6ZW&SRC*
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MRUU#Q!%:QI?W=G$8H)9PHWM&A^ZI/04E)/;\G^H<MN_X?H;U%%%,!%H:EHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HI#0* %HIO-&?:@!U%%% !1110 4444 %%)P:#2 6BD%(
M?I3 =1110 4444 %%%% !1110 4444 %%%% "#ZT4M%+< HHHI@%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MF:E<:??ZBCV.L0Z3;".'R5+R3R*2S*95VQJ#G+%A@4[=$*^C=T>H?V5\1O\
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M]/M;Z^82W36RQ0S*'8 ;V7S64'&2%%&G0/>1V/\ 9?Q&_P"AK\+_ /A,W/\
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M/\4:MXJOKKX;W/B5%U4)*(=0B=!YD2*@"IB7)C (^0>]+3J/WCZ1_LOXC?\
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M?'8@+H"[87+#FN$^+'B8ZI\8O%&@:_\ $&^^'>BZ+X:MM4TM[*\2T^US227
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MW_0U>%__  F;G_Y84?V3\1O^AJ\+_P#A,W/_ ,L*[>B@#B/[)^(W_0U>%_\
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M(W_0U>%__"9N?_EA1_9/Q&_Z&KPO_P"$S<__ "PKMZ* .(_LGXC?]#5X7_\
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MIEIH]G':6%K#96D8Q'!;H$1!G/"@8%7:*%",=D#E*6["BBBK)"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** ."M/^2[:I_V+=I_Z57-=[7!6G_)=M4_[%NT_P#2JYKO: "B
MBB@ HHHH *XGQ]_R-GPV_P"Q@F_]-5_7;5Q/C[_D;/AM_P!C!-_Z:K^@#MJ*
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X*T_Y+MJG_ &+=
MI_Z57-=[7!6G_)=M4_[%NT_]*KFN]H **** "BBB@ KB?'W_ "-GPV_[&";_
M --5_7;5YM\7O$6F>%M8^'>HZO>PZ?8Q^(9%>XG;:BDZ7?@9/N>* /2:*X'_
M (7Q\._^ART?_P "EH_X7Q\._P#H<M'_ / I: .^HK@?^%\?#O\ Z'+1_P#P
M*6C_ (7Q\._^ART?_P "EH [ZBN!_P"%\?#O_H<M'_\  I:/^%\?#O\ Z'+1
M_P#P*6@#OJ*X'_A?'P[_ .ART?\ \"EH_P"%\?#O_H<M'_\  I: .^HK@?\
MA?'P[_Z'+1__  *6C_A?'P[_ .ART?\ \"EH [ZBN!_X7Q\._P#H<M'_ / I
M:/\ A?'P[_Z'+1__  *6@#OJ*X'_ (7Q\._^ART?_P "EH_X7Q\._P#H<M'_
M / I: .^HK@?^%\?#O\ Z'+1_P#P*6C_ (7Q\._^ART?_P "EH [ZBN!_P"%
M\?#O_H<M'_\  I:/^%\?#O\ Z'+1_P#P*6@#OJ*X'_A?'P[_ .ART?\ \"EH
M_P"%\?#O_H<M'_\  I: .^HK@?\ A?'P[_Z'+1__  *6C_A?'P[_ .ART?\
M\"EH [ZBN!_X7Q\._P#H<M'_ / I:/\ A?'P[_Z'+1__  *6@#OJ*X'_ (7Q
M\._^ART?_P "EH_X7Q\._P#H<M'_ / I: .^HK@?^%\?#O\ Z'+1_P#P*6C_
M (7Q\._^ART?_P "EH [ZBN!_P"%\?#O_H<M'_\  I:/^%\?#O\ Z'+1_P#P
M*6@#OJ*X'_A?'P[_ .ART?\ \"EH_P"%\?#O_H<M'_\  I: .^HK@?\ A?'P
M[_Z'+1__  *6C_A?'P[_ .ART?\ \"EH [ZBN!_X7Q\._P#H<M'_ / I:/\
MA?'P[_Z'+1__  *6@#OJ*X'_ (7Q\._^ART?_P "EH_X7Q\._P#H<M'_ / I
M: .^HK@?^%\?#O\ Z'+1_P#P*6C_ (7Q\._^ART?_P "EH [ZBN!_P"%\?#O
M_H<M'_\  I:/^%\?#O\ Z'+1_P#P*6@#OJ*X'_A?'P[_ .ART?\ \"EH_P"%
M\?#O_H<M'_\  I: .^HK@?\ A?'P[_Z'+1__  *6C_A?'P[_ .ART?\ \"EH
M [ZBN!_X7Q\._P#H<M'_ / I:/\ A?'P[_Z'+1__  *6@#OJ*X'_ (7Q\._^
MART?_P "EH_X7Q\._P#H<M'_ / I: .^HK@?^%\?#O\ Z'+1_P#P*6C_ (7Q
M\._^ART?_P "EH [ZBN!_P"%\?#O_H<M'_\  I:/^%\?#O\ Z'+1_P#P*6@#
MOJ*X'_A?'P[_ .ART?\ \"EH_P"%\?#O_H<M'_\  I: .^HK@?\ A?'P[_Z'
M+1__  *6C_A?'P[_ .ART?\ \"EH [ZBN!_X7Q\._P#H<M'_ / I:/\ A?'P
M[_Z'+1__  *6@#OJ*X'_ (7Q\._^ART?_P "EH_X7Q\._P#H<M'_ / I: .^
MHK@?^%\?#O\ Z'+1_P#P*6C_ (7Q\._^ART?_P "EH [ZBN!_P"%\?#O_H<M
M'_\  I:/^%\?#O\ Z'+1_P#P*6@#OJ*X'_A?'P[_ .ART?\ \"EH_P"%\?#O
M_H<M'_\  I: .^HK@?\ A?'P[_Z'+1__  *6C_A?'P[_ .ART?\ \"EH [ZB
MN!_X7Q\._P#H<M'_ / I:/\ A?'P[_Z'+1__  *6@#OJ*X'_ (7Q\._^ART?
M_P "EH_X7Q\._P#H<M'_ / I: .^HK@?^%\?#O\ Z'+1_P#P*6C_ (7Q\._^
MART?_P "EH [ZBN!_P"%\?#O_H<M'_\  I:/^%\?#O\ Z'+1_P#P*6@#OJ*X
M'_A?'P[_ .ART?\ \"EH_P"%\?#O_H<M'_\  I: .^HK@?\ A?'P[_Z'+1__
M  *6C_A?'P[_ .ART?\ \"EH [ZBN!_X7Q\._P#H<M'_ / I:/\ A?'P[_Z'
M+1__  *6@#OJ*X'_ (7Q\._^ART?_P "EH_X7Q\._P#H<M'_ / I: .^HK@?
M^%\?#O\ Z'+1_P#P*6C_ (7Q\._^ART?_P "EH [ZBN!_P"%\?#O_H<M'_\
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MT]K<65\@6>UN()6AFBD"DC<KHPX)!ZBE9I#OY':4444AA1110 4444 %%%%
M!1110 WZ5Y)^U)X@U;0?@KKMKX=CDD\2:[Y>A:9Y2,Q2XNW$"R''01AVD)/
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MAQ)K<1:LJ6<MN+A<GRV/FNDH$N#\N3A@*.:(<K[GT!_PC>D>3YV^X\G&[?\
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M:7?72EC%;SES$LH4 $IOV_* -JBO/_B9\#_&^J:7J?B"*>SL?'%]J6FV5B=
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MWE6."=78HDAC=L ] X*GW!':O"/ /[,.H>#_ !)9SWDMKK>GK<:?J#R/J=[
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M5WRVIF+2#(^ZWF\=^M97@?X.^+=*^-!\9:_K<&I6T%OJMI JW$[.T=U=02Q
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M#;II&+%B22.RC&]X+^#%G\/_ (77O@O3+Z6Z@N9+N3S]6#7JYGD9RK1RN=Z
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M5C^#_P!H"P\;7&EK;6%SI*76OW^A,FK6TT+2-;+=$M$=FTD_96)#$!1D$[L
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M&,D92/X[>%&T/4=4>>_MQ87%O:S64^FSQW?F7#*MNJPLF]O,+ *0,'GD8..
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MZ^\7+W?]?<>.?#W]H;5].^'.C>*/&;:A,]YX4U'Q9<6*VMMGRH6MB%B>)Q@
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MM;*-)+M+DL_G32JIW&WQLP,';C.3CUWP+XNL?B!X+T+Q/I8D73M8LH;^W68
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MQ&2S1J#PJJ%R2<G'1R? 71]1L[J#6-8UO7I;K2;[1)+K4+M6E^RW8A$JC:@
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M&Q5BVR,I3>Q)0'YL 5[AX6\ Z+X+T^XL]*MYH[:?&]+B[FN"0!@ &5V( '
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M/P]KVD7^O&W\9^-KBUM[70W@^TMIMOIM[Y(A^T?NPLCVBW!/!(DQGM5GX?\
MC_Q9\4&\!>%;WQ-?^'[RXT_5[O5[RUA@2^DN+*\BM1:DLC1AD,K&0HN"4&T[
M37MFI_"'PGK/A?P_X=O=+\W2]"\LZ=''-)$UNT<+0*5>-E8'RW=>O(8U#?\
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M;;FWDNK*WN)YI4G!5XVNGS&RIQL(8\TW4OCYXPL_#MG96ZV.K:M+XNN/#?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
)HH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>exdx-20231231_g3.jpg
<TEXT>
begin 644 exdx-20231231_g3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 2F Y(# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ I-P'7BEKB_ MQ--XI^(B22/(D.NQ1QJS9"+_ &98MM7T
M&68_5C0!V>X4;A5'5M8L] TF\U/4+A+6QLX7N)YY#A8XT4LS$^@ )_"OFGP_
M^W?I.N:UX7:3X=^,M,\'>*-0CTW1_%EU9QBTN99"1&Q4.71&P<,1T!.,525_
M+YV);Z)-^FI]29%&:YK2OB5X2UR_@LM.\3Z/?WMP'\FVMKZ*22382'VJ&)."
M#G'3!JS9>-O#VIZ]=:+9ZWIUWK%J"T]C#=QO/$ <$L@.Y>>.10XR70GVD>YN
M;A2;A6':^-_#U]KT^B6VNZ;<:S;J6FTZ.[C:XC [M&#N Y[BN*\(?M >&O$$
M.LRZK?:?X96QU"ZM8?[0U6U/VN"%E0W2[9#MC+$C#8*D8(%')-] =2*ZGJ5&
M:PM/\<>'-7U1=-L==TV\U$P+<BTM[N-Y3"P!60(#G80P^;&.14<7C[PO-JE]
MI\?B'2WO[!&EN[5;V,R6Z+]YI%W94#N3C%'++L/GCW.AS1NKG=$^('A;Q)?"
MRTGQ'I.IWC0BX%O9WL<LAB.,2;58G:<CGIS704FG'<:DI;#Z***104444 %%
M%% !1110 4444 %)N%+7"^"[B:7X@_$&&2622*&\LQ&C,2$!LXB0!VR>>/6@
M#NJ3<*1C@5\BZY_P4(L]'A\5ZS%\+_%>I>"/#.L3:-J'BBQ:V>W5XI5C9PAD
M#E<LIZ=Q32OUL2Y6Z7/KO-)N%<O-\3/"=FVF)>>(M,T^?4XTEL[>\NXX99U8
M J51R&.<^E<9>?M+>#_MGQ(T_3+L:KJW@2V2?4K5)$A5WDC,D<4<LC!"3@*3
MG"L0&(JE"3Z$.I%=3UO<*6N/TWXF:')I_AYM8U"Q\/ZMK5K%/#I%_>PB?<Z@
M^6N&Q(025RF02.*LS?$SPA;ZE_9\GBC1X[[[1]C^RO?Q"3S^/W6W=G?\P^7K
MR*7)+L/VD.YT^X>M&:X*'XT>%)_B])\,X]0W^+H]+_M=[51E%@\SR\%^F_/.
MSKCGI7>YI-6*C)2V%HHHI%!1110 4444 %%%% !1110 4444 %%%% !1110
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M&K8)5JN,K<VMMWI]YQ_[3EHL_B7X02Q@"]7Q=:A"!\WE\M(,^F%'Y5[UQ_\
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N)\ _\C9\2?\
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MO$/BO2?"MK;7&JWJV<5S=P6,+,"?,GFD6.-  "<EV ]NIP :_/[4/B]X^O\
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MYQJ7P/\ 'VJ6GCOP/+'HH\'>+M=GU*^\0?:Y#>M93,IEM?L_E[?,V+Y(D\S
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MFM:BI5."V0<TNYB_\(?HID\PZ/8^;NW;_LR9)SG.<=:7_A$=%77/[:&CV/\
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M[>%[B1F;&$52S-]  :I>$_%EGXO\,:)KML)+>UU>TBO+>*Z 24)(@=0RY.&
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MNM:CH?C^S'A_3+J)KCQA>VPAMYIEC0V]O'"G[Y2%)+Y"C8N,D\+VBVEO\O\
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MQ%\']<U"[MO /AWPZNO:CI5I<O;MK%S),$CCD9"&,2*0V >IP:^K[6 65M%
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MPSX*L=%U^XTW5O"OVC[-J=S:0W@N/M'-P9H7&UB[X?(P0RCG&08]1_9D:?\
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MHN_X/_+\ Y'U2^]?Y_\ !/INN!\$?\E(^)'_ %^67_I%%7>*NU0/2N#\$?\
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M/?\ 8.M__12UO5@^ _\ D2?#W_8.M_\ T4M;U !1110 4444 %%%% !1110
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M9XHB\?ZQX[\17FA7>M>(]*:Z2:T>RCTZ68L(47]VPN#;1JPPS%B#GG%66_\
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MZWO<^@[74+6^1WM[F*=$=XV:)PP5D8JZG'=6!!'8@@UBZE\1?"NCZ;IU_?\
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M7)<DMS[/M;J*\MXIXF8QRJ'0LI4D$9'!Y'XU+N&<9YKXW^*7QBN=(^,FMO\
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M8/@K_P!_8/\ &@#[VHKX)_X1G]HS_HV#X*_]_8/\:/\ A&?VC/\ HV#X*_\
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M!'(P?KTK,A\):/:S)-!I-E%*ARKQVZ*P[\$#KP*^(O\ A&?VC/\ HV#X*_\
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M(S^T9_T;!\%?^_L'^-5RI[HF[/N?3]%LM)1EL;*WLU8Y98(E0'\A5TBO@O\
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M1]$LHK@LK7$<*@L05P0S'U^44E",=4AN3>[/N&C</6N*_P"%'_#G_H0/"_\
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M75GRW&7. !@5Z?2NMT/7J.HI,T9I@+129HS0 M%)FC- "T4F:,T +129HS0
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M_P"$]_\ :Z^P:*+ ?'__  J_]L[_ *+/X$_\)[_[71_PJ_\ ;/\ ^BT> _\
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MDT_^QEF>![JXN$B5'61HR&+$;<LC8SUQD<4^63V%SQZL^>O^%7_MG_\ 1:/
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M_P!R]_\ :Z/^%6_MF\_\7F\"_CX>_P#M=?8%+4#/C_\ X5?^V?\ ]%H\!_\
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MO[:S\@3W$<)FD\J(2,%WO@G:N>IP"<#T-%M0YM+GR!??"']L74[.>TN_B_X
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MO,D\$JAXY8FW*ZD9!!'!!!SFC4=T?(O_  J_]L__ *+1X#_\)[_[72_\*O\
MVS_^BT> _P#PGO\ [77UZ&7UYJM:ZI:7T]W#;SI-+:2B&=4.3&Y17"GT.UU/
M_ A0%T?)?_"K_P!L_P#Z+1X#_P#">_\ M='_  J_]L__ *+1X#_\)[_[77UY
MOZ\]LUE0^+M#N+&ZO(]9L)+.T.VXG6Y0QPGT=LX4_6A)O8+I'RQ_PJ_]L_\
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M#_\ ">_^UU]7:7K^F:\LC:=J%K?K&VUS;3+(%/H<'@U>S1J2I)['R'_PJ_\
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MO'6C_A-M._Y]]7_\$UYZ9_YY>GZ\=: -^BN?_P"$WT[C_1]6YQ_S!KSN,_\
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M7.8-6XS_ ,P:\[#/_/+TI3XWTX9_T?5N_P#S!KSL,_\ /+T_7CK0!OT5@?\
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MLD831M6T^-HUF>Z;<8WQ '"G E#*H'%?19\;:;_S[:M_X)KSTS_SR_STI/\
MA--.W8^S:N/^X+>8Z9_YY?YZ=:/>\OQ_S_X'D'N^?]?UZ^9X._@+Q#_PSK^T
M!HG]D71U77+SQ*^G6GEX>[$Z2"$H.^_(Q]:ZO4O"NK3?%;X+7ZZ=.UCI&D:E
M#?S;>+=W@ME16/8DJP_ UZ9_PF^G$X%OJY'_ &!KSTS_ ,\J3_A-=.X_T;5A
MG'_,&O!U'_7+T_+I3L]@T['SY\*OA?XETGXX2:!J6E3V_@#P5?ZCK/A^];!A
MN9+_ &M'&G_7N)K^/IQO2H_@#H2>#_B9XG35/#OCJVUF]\5:U<PW9>Z_L5K>
M:ZEDCDV"3R>493DIG)]:^A_^$UT[<H%OJW..NC7@ZC/_ #R__5T-*OC33F8$
M6VK9..?[%O!US_TR]OPXSUI6E$;<6CHJ6L!?&VG-C%OJ_..NC7@Z]/\ EE_^
MJA?&^G-C%OJ_.,9T6\'7I_RR_P#U59)OT5SX\<::<?N-6YQ_S!KSN<#_ )9?
M_JH_X3C3N/\ 1]7YQ_S!KSN<?\\O6@#H**P/^$VT[_GWU?\ \$UYZX_YY>OZ
M<]*/^$VT[_GWU?\ \$MYZX_YY?Y'/2@#?HK _P"$VT[_ )]]7_\ !->>N/\
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M#.R[2R*\JS2#Y>0V>]9OQF\%W?C^W^'^GW2M:WBZTUPUW8[I18SII]X8YE)
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MN>FC7AZ=?^67^>U'_"::<H;=;ZMQG.-'O#TZ_P#++_\ 75>]W#W>QP?P%O\
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M3H2T444 %%%% &#X#_Y$GP]_V#K?_P!%+6]6#X#_ .1)\/?]@ZW_ /12UO4
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M\+_M.>%?$VL/I_V'7=)?^QYM?BFU73'MXY["(H&N$8]5/F+@'#>H'%%B>?\
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M-0B:2 /VWJK!BI[X.:U..*K:EJ5IH^GW-]>W,=G9VT;333S,%2-%!+,Q/
MSFJU%IN?(7Q7^!_C.W\)^/\ Q7/'H]KXJ\177AZVCT[PS:2RVRM;ZG')]KF#
M -+)^\);@82,#)KK/$W[,/B;XH6OC#5?&&I:+'XDU;^R%LH+""62Q@33KAKB
M)9 Y#N)))) _3"D8R17OEKXU\/WVFZ-J-MK=A/8:PZIIUU'<(T=VSJ658F!P
MY*JQ '7!K=\P'.#G]:GEG:S>GH@4H[K?U/FFW_9N\0::-'\0Z'IG@SPSXOT7
M5UU&"'3XKAK.]C-K/:O'<2'Y\[+ARI"_*0.#DUJ?%']G'6_C9<^"]0\3ZM96
M.L:#:7Y6[TF-U-M?236TMK/ &)_U1MQG<?F],' ]_CNHIM_ERK(4;8VT@[6]
M#Z'FN/\ $7QJ\!>$=?BT/6_&6B:3K$NW;8WE_%%+\WW<JS9&>V>O:A4YO1?D
MA.<$[O\ -GC_ ,1/V9?$7Q9DNM2\0ZKI(UB;0]'M2L<#O:O?6-]+=EF0X)AD
M+A2,[@&;'059_P"&;]3NOA[JUC;Z;X4\)^)9-4T_5[.XT2"9X'FLKA)X1<,^
M&=2T>, # 8]:]SA\7Z1-XIG\.)>(VM0V<>H/:X.1 [NB/G&""T;C&<\5K[E'
M?%-QEW_(?-'I^;/*?A+\.?%F@>//&GBSQ=?Z3<WOB**QC6TTF*18K46ZRKMW
M.<OGS =V!U/ XKU<_7FDW"C>/6GKU=P]!V:,TTL.O3\*7(4>@]Z '45CZ#XL
MTGQ1+JD6F7:W;Z7>/I]V%5AY5PJJS1G(&2 ZGC(YK8I@%%%% !1110 4444
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MI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1N%
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MO!;7-KJ%G>V,L[V\EW;W4311%(WD;<=W. AR!DC.<8!-5RLGF7<S/[+^(O\
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MBM'/*,[@02"#7-P_LWZ];^"?$>BR^*-)UNY\0ZU-J^I2:[X>2YMI#+#'&46
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M $,7A7_P0W/_ ,FTO]G_ !(_Z&'PK_X(+G_Y-I@=U17"?8/B03@>(O"OI_R
M;G_Y-I?[/^)/_0P^%?\ P07/_P FT =U17"_V?\ $C_H8O"O_@AN?_DV@:?\
M2&Z>(O"I_P"X#<__ ";0!W5%<+_9OQ)_Z&'PK_X(+G_Y-H_L[XD_]##X5_\
M!#<__)M '=45PW]F_$G_ *&'PK_X(;G_ .3:3^S_ (D?]##X5_\ !!<__)M
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M>&_+J<!J?P3\1W&O^)/)72_[-U3Q'H?B!+IIF$R_8S8K-"4\O&"MFS*V[DL
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M)_Z&'PK_ ."&Y_\ DV@#N:*X;^S?B3_T,/A7_P $-S_\FT?V;\2?^AA\*_\
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MNK7<EKJ4UK'#,EY)<+LA\MO,3+*X4LOS%P<@UZO_ &;\2?\ H8?"O_@AN?\
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MYC548^6I)#-SG'!KI?[-^)/_ $,/A7_P0W/_ ,FT?V;\2?\ H8?"O_@AN?\
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M89%'M(+;\_T#EEU/8[7XR^';#P7H?B#Q5JVD>$UU6(21QWFK0/$2<9"2@[9
M,CE>.16WKWQ*\)>%ET\ZSXFTG2QJ&/LAO+V.(7&<8*;F&X<CD>HKY@L_ _Q(
M\._"7X5^&$\.7R6UOX>N;/5&TNWL)[Z"\/EB*%FNB4C@8>9O903E5Z"N6TOX
M%^,]%TOPU%K^F>*;JQO/AYI/AJ[M?#JZ9/+:W$*RBX@E%V& 5_,4AXV RO/1
M:.>"W_/\^WZBY9]#[LW XI:Q?!^CKX>\)Z+I4?VDQV5E#;#[8ZO-A$"C>R\%
MN.2."36U0,**** "BBB@ HHHH **** "BBB@ HHHH **** /)M)_:&T74OCQ
MKOPMELKJRU?3;9+F&\FV_9[T^7'))'&<YWHLL9(/9L]C4>H?'NU;]GJ3XG6.
MGR-]HL!/8:;<,-\US(WEP0DKQEY61>/[U<!XY^"OB77O%/Q/\1Z1:K:>)+75
M-.UKPK>2R*JW$T%A'')"2#D1R#S(&SV<GGBL;X9^&]8NM*^!'PSUVP?3KS1+
M(^*=?L796,+0'9:0N5)!8W$GF#&?^/8^E'/';J+D>]]#U7QY\?K3X9>+/ ?A
MG7-/EN=2\0[%O+RQQ]FTXL\4"22;CD))/,D:]^2>QQZ[FOE7XB_L^^/OC)KW
MQ6U)M=A\+6^K1P:-I5G<:<ES(]M:J)H9UE$@,1:ZDE;ID!4STKZ(^'>HZSJW
M@3P_>>(M/;2=?GL87U"R9E/DW!0>8N5)! ;/0XI<R>@[=3I:***8!1110 44
M44 %%%% #?TH_6G44 %%%% !1110 4444 %%%% !1110 4444 <_JGQ \,:&
MMNVH^(=+L%N))(83<WD<?F/&VV15R>2K<$#D'BM-M:L(]4ATUKR!=0FA:XCM
M3(!*\:E59PO4J"Z@G_:%>&^&_!OB";QGH$D+SZ*D,GBMI9Y;(2@K-J\,D2G>
M, .@W ]P#BCQ!H_B^X^)C^.;;0XI+/3-5M[&',LBWDFGJ&AN"(1'@KON)I<[
M_F$,1P<"ES1#ED>[7^HVNE6-Q>7MQ%:6=O&TTUQ.X2.-%&69F/   ))/2FQ:
MM93R6R17<$CW,1G@5) 3+&-N77U4;TY''S#U%<!\1+&76O@OX_L;!-1U&YN=
M/U2&*"ZA;SGD995$:*5!*;OE3 .5QC->,^-?#OC3P?XTT71=$L[\>%]+M+H1
M:I:1SN8=/GN+-A:CRCYF^-H67"8/D[<$D'#YHKXM Y9=#ZOW"C<*^3?'&K>)
M+>STG29]<UB>!-(NKJ?5+<ZA:/8*]T?)GFCC0RR".)"H$Q7?L)SDDCM8M0U[
M5OBU:0VUOK=MH\MU<6=X6FO7B>U^QR-','($,8:01%3&?,R>2"2 <T._X"Y:
MG8]T&J6;74-L+J(W$T331QAP6>-2H+@=P"Z\_P"T*L[A7SGX-\/>)+7X?^#=
M&T)];TZ\L_"=W'*+]K@+'J<+6)B1VEY*[EE4 95E\P#(K*U:Z^(/B&\CU22[
MUKPU9ZS#-=Z?#]DO)6L)MZ1Q++%!R/W:12;)?DW22@BAR@MV/EF_A5SZAI::
MGW1DY-.H *2EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBDW"@!:*** "BBB@#!\!_\B3X>_P"P=;_^
MBEK>K!\!_P#(D^'O^P=;_P#HI:WJ "BBB@#+UK4I='TN:[BT^ZU1X\$6=B$,
MSY(!V[V5>.3R1P/PKE%^)VH8X^'WBO\ []V?_P DUW3$!<L< 5XI\!_VA)_B
MUXD\4:;?Z5%I,-MB_P!#F24N=2TMIIH8[G!'!+6[-@9^5T]::5]27*VAV/\
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M2ZK%,\%AHZW%^+GRF4,8 D>]_EDC;&W(#'J%)I<M]@N_Z_JYI_\ "S-1W?\
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MTW&,JR@CT(%7A\3-0_Z)]XL_[]V?_P DUWM%*Q1P3?$S4#_S3WQ8?^V=G_\
M)-)_PLO43_S3[Q8/^V=G_P#)-=]13 X'_A9>H?\ 1/?%@/\ USL__DFE_P"%
MF:AT_P"%>^+,9_YYV?\ \DUWM%*R X'_ (67J/\ T3[Q9G_KG9__ "31_P +
M+U#_ *)]XL_[]V8_]N:[ZBBR X+_ (69J&/^2>^+/^_=G_\ )-'_  LS4/\
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M]0_Z)[XL_P"_=G_\DT?\+/U#_HGOBS_OW9__ "37=T4 <)_PL_4/^B>^+/\
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M'4(M0L;>ZCWI%,BR*LT;1N 1D95@"IQV(!%%F%T<;_PL_4/^B>^+/^_=G_\
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M_09TG_P52^G_ %\^OZ<>]'V'Q1_T&=)_\%4OI_U\^OZ<>] &_1FN?^P^*?\
MH,:3_P""J7T_Z^?7]./>A=/\3\?\3?2.V?\ B52^G/\ R\^O^>] '09HKGUL
M?%/&=8TGMG&E2_C_ ,O/Y>GO2K8^*.,ZQI!^[G&E2_C_ ,O/?MZ>] &_1FL!
M;'Q1QG6-(/W<XTJ7\?\ EY[]O3WI%L?%/&[6-(/3/_$IE]>?^7G\O3WH U;Z
M2XAL[B2UA6YN%1C%"[^6KMCA2V#C)XS@X]*\1^#GA[XE^#V^)5QJOA?1;6XU
MO4KG7--6'6FF4SO#%&D$G[E=JDQ$EQG&?NUZS]A\4\9UC1^V<:5+Z\_\O/I2
M?8_%''_$XT?L3_Q*I?7G_EY]./U]J5KAHNAX[XF\ _$S3/&?B/Q'X8TS0KRY
M\8^'[/3M1AO-1DA72[R$3@3(1$WG18GP5^5OW8]37KGPS\%1_#GX=^%_"D,I
MN(=#TRVTY9B,%Q#$J;L>^VI_L7BC_H,Z1_X*9?7_ *^?3]>?:E^P^*/^@SI'
M_@IE]?\ KY]/UY]J+/N/3L>5:UX0^(O@?XG>,O$/@O1]%\16/BR&U9DU+4GL
MVL+J"(P[F B?S(V78< A@5;UK"\*?"Z\T'Q!\'?AQ(9+_1? NE'6M0O_ "RD
M-S>A3;VZCMC<]Q+MSP8T)[5[C]C\4?\ 09TCO_S"9?[W_7SZ?KS[4W[#XHY_
MXG&D#KC_ (E4N.HQ_P O/ID?7GVI:]&&G8\;\?? ?7_$VC_'.VMOL/F^-)[.
M33O,D(&V&TMXF\W@[?GB;IGKGO5;XN? GQ7XJN_BC=:.NGS/K]EX?33H;FX,
M2M+8W<DTJN0AV JR@'#?I7MQL?%'\.L:0.N/^)5*>_'_ "\^G7^E#6?BCG;K
M.D _-C.DR_A_R\_GZ^U3RON5S>1#X$U+Q1JFERR>*] LO#]^LNR.WLM1-\KQ
M[1ARYBCP<EAC!Z=:Z>N>:S\3_P .L:2/O8SI4I^G_+SV[^OM0UEXGYQK&D#K
MC.E2_A_R\_GZ^U:$&Y-\T,BKR2"/TKY,^&'[/OC7X?:Q\)$L[6*UT:WTF&;7
M(?.0_P!G:K'I+V;.H!PZREX\[<@-"3_&:^F#8^*.<:QI'?'_ !*I?3C_ )>>
MQ_R*3['XH_Z#&D]\?\2J7TX_Y>?7_#WI:]&-6ZGQ1K7PX\2?#7X<V4NLVE[;
M:Q+-IFG:F=5-D-*U.9+@222S,DRF8-LDR\[1Y$@!RV%K8U;X?ZWXX_9]\/:1
MX%\+#4+==/UJ&.^,%HD]KJ1G"QM S3[(X6=9&6:,R, D>T\YKZZFTWQ).C1R
M:KHSJW5&TB4J>.,C[3SSS]./>G1Z?XFC"JNK:0J#^%=)E Q@=/\ 2>.>?IQ[
MT<U0+1['@]S\&M6M/&7C.XT_PHL5UJ_BG0=97687@02VL+V NHF.[?D&WG<C
M;A@_!).*P?$7P+^(=_9^)=.C60Z5HDT=MX?2*YC9[^PFU*.\NXMKD*-L,<5N
MHD(#"-@?E:OIC[+XH'75](Z_] F7TQ_S\^O/T_.C[+XGXSJ^D?\ @JE].?\
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M% =HU*JQQR0"3@>V3]: )Z*** "BBB@#!\!_\B3X>_[!UO\ ^BEK>K!\!_\
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M4'#/M!V(7PNYL#/?BNC^&/BB?QO\.?"WB*ZCCANM6TNUOY8X2=B-+$KD+GG
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M3=,+=8BSB,F*Y0RG]R[*F<C(\LE2#C/I]G;-)-KR0+>V%S-*H^U32>9&SF!
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M&\MRT3^6"X##& ><BE8=SU7[/XHW?\?^C_\ @%+Z?]=O7]*3[+XGW9^WZ/\
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M=UL)-Q4$Y&?-Z<Y'U:NCW#UJK'K%I-JMQIJ3JU];PQW$L.#E8W9U1OQ,;_\
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ME@YL=#TK4;?4)MRX@>2"W1%//.XHXXST^E>R[>GI1M]J?O=QZ=CYD^%WP?\
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MX2T6/4;QM0U!+.$7%V\!@::0(-SF,\H2<G:>E;6VDX]LT>\]WH%DMB2BBBF
M4444 8/@/_D2?#W_ &#K?_T4M5?B9-+:_#GQ7-"[PRQZ3=.DD;;65A"Y!!'.
M00*M> _^1)\/?]@ZW_\ 12U4^*?_ "3'Q?\ ]@>\_P#1#T ?!7[(O[&.D?'3
M]G+P3XZ\0_$[XGP:SK$$LEQ'8>)WC@!6XDC&U61B/E0=SS7L'_#M7P7_ -%3
M^+?_ (59_P#C5;W_  3PNC8_L*_#>Y5#(8=.NY B_P 6VZG.*^=M/TWQ+XW_
M &-]7_:/N_B9XILOB&4N]9MOLFKR1Z=:B*Y=4LUM1^[*%4VX(R2W>FK?:O\
M)7)?-T/:_P#AVOX+QG_A:?Q:QUS_ ,)6?_C5 _X)J^#",CXI_%LCU_X2L_\
MQJO'[SXU?&'XA:?^T;;ZU/I,7ABS\ 6^H_8XY)5FL3<Z7/)&8 %'SLP'F!FP
M"/E->G_LX_M'^,_#_P#PCW@_XA:!I5II<?PYA\5Z;?:7=R7%PUM"L<;+<!E
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MISA,19ZJYR>>1[T<JVN'-+L4_P#AVMX,QG_A:?Q;_P#"K/\ \:H_X=J^#/\
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M@/XJ^&/B9]K/AW4C??95C>7=;RQ?)("8W7S%7<C '#+D'!YX-+E8<R9\Y?\
M#M/P;_T5+XM_^%6?_C5'_#M/P;_T5+XM_P#A5G_XU7UY12*/D/\ X=I^#?\
MHJ7Q;_\ "K/_ ,:H_P"':?@W_HJ7Q;_\*L__ !JOKRB@#Y#_ .':?@W_ **E
M\6__  JS_P#&J/\ AVGX-_Z*E\6__"K/_P :KZ\I* /D/_AVKX,_Z*G\6_\
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M^-5]>T4 ?(7_  [3\&_]%2^+?_A5G_XU2_\ #M/P;_T5+XM_^%6?_C5?7E%
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M\!_\B3X>_P"P=;_^BEJYX@T"R\4:'J.C:I;B[TS4+:2TNK=F*B2*12KJ2""
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M%"02R1@X9T &,\<=.]/'_!-;]FK_ *)?9_\ @QO?_C]'_#M7]FO_ *)?9_\
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M/#M_H,MY)8ZQH^O+;WJ+=3---$9!PT9=B=I!Q3?^':W[-7_1+[/_ ,&-[_\
M'Z=_P[4_9K_Z)?9_^#*^_P#C]/D7=_B/G9[3X7N_#GA;PW8Z-%XGAOHK2(1"
MZU#4UN+B3'\3R,V68^IKPCP)^QW\%? MUH97Q!?ZWINA7/VS2]'UCQ(UQ86<
M^XOYB0;@FX,Q.2#U-7O^':?[-?\ T2ZS_P#!C>__ !^C_AVG^S7_ -$NL_\
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M/V4_@[X@CUY(==ET,ZKK=MXC1M'UB.V-AJ$"%$GMMO\ JR58[NN3@\$4R/\
M9/\ A!%\/M4\)1^)KY+>_P!>C\3-J7]OAK^+445%%PDQ).X[,DG.2S'O3_\
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M?#S?%3Q/=/=7*77]KS>*B;Z)E& (Y <*N."NW![@US'_  [3_9K_ .B76?\
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M?9_^#&^_^/T?\.UOV:O^B7V?_@QOO_C]/E?45SWK_A8WA/\ Z&C1O_!A%_\
M%4?\+&\)_P#0T:-_X,(O_BJ\%_X=K?LU_P#1,+/_ ,&-]_\ 'ZCN/^";_P"S
M+:6\D\_PTL88(U+O))J=ZJJH&223/@ #O5$W/?O^%C>$_P#H9]&_\&$7_P 5
M1_PL;PG_ -#/HW_@PB_^*KP"W_X)P_LRWEO%<6_PTL+B"90\<L>IWK*ZD9!!
M$^"".]2?\.V?V:O^B86?_@RO?_C] SWO_A8WA/\ Z&C1O_!A#_\ %4?\+&\)
M_P#0T:-_X,(?_BJ\&_X=J_LU_P#1+[/_ ,&-]_\ 'Z/^':O[-?\ T2^S_P#!
ME??_ !^@#VW4?'WAJZL+J&W\6Z+;SR1LB3&^A;8Q& V-PSCZUXS9_"GP79^'
MFTE/B!H[0G1-%\/AVGAW"TL9FDE7F3K.'92>W'WL5!_P[5_9K_Z)?9_^#*^_
M^/TW_AVO^S7G!^&%G_X,K[_X_4VN.]BKJ7PET+4?L#3?$+PAJ!T_6=6U*"'4
MH4EA>.^F:5ED5;E2TD98JK@@;<@KSFNTOI/#W@^#QOXA\/\ B'0;K6[K08=.
MTO3K6YMX$A6UBF,$*9?"@RS.>P (';-<K_P[8_9K_P"B7V?_ (,K[_X_1_P[
M8_9L/_-,+/UXU*^_^/T6?<=TRCX1^$.@VNF>%H/$7Q(\.WX\/V^F65K;V0BA
MB%M:3)<;&!F;=(\L4)9^G[E<*,FNJ\$^"_"'A'X@:_XA;Q;X1O5U"\N;^WGD
M6+^T+:28 ,HN#,5V@948C!VX!.!6)_P[7_9K_P"B7V?_ (,;[_X_0/\ @FO^
MS6W_ #2^S_\ !C??_'Z$F*Z,>;X-VDG@VQ\/Q_%[P[;1_P#"*KX2OKF**+S)
M+568AXLW'[N1U;$A.<X! 6NSN/"'AV\U[7II?B%X?_L?5/$&FZ\+1)(A+&;2
M*!%A\SS<%-]K$X^48.[K6)_P[7_9J_Z)A9_^#&^_^/T?\.U_V:O^B86?_@QO
MO_C]'*^X^9$%K\(]!D\,7FAZE\4M#N;>+1+_ $#2I(#%$]O!=NK32RGSCYLQ
M$:#<-H&&.,M7J7A&;P=X3\2>)-6C\7:+*=6:U2*!;N%%MK>"!8TB&'Y&[S&[
M8\S';->:_P##M7]FO_HE]G_X,K[_ ./T?\.U?V:_^B7V?_@ROO\ X_19]Q7/
M>?\ A8WA/_H:-&_\&$/_ ,51_P +&\)_]#1HW_@PA_\ BJ\&_P"':O[-?_1+
M[/\ \&5]_P#'Z/\ AVK^S7_T2^S_ /!E??\ Q^J$>\_\+&\)_P#0T:-_X,(?
M_BJ/^%C>$_\ H:-&_P#!A#_\57@W_#M7]FO_ *)?9_\ @ROO_C]'_#M7]FO_
M *)?9_\ @ROO_C] 'O/_  L;PG_T-&C?^#"'_P"*H/Q&\)_]#/HW_@PA_P#B
MJ\&_X=J_LU_]$OL__!E??_'Z/^':O[-?_1+[/_P97W_Q^@"2V^$/@6TE>ZM_
M'NC6FIWEKKEKJ>HV\T"3W@U&?SRQ;S.L3_=SGC(&,UE1^%-%\.>&?#W@^TU/
MPE.EYJNGW&I:QHY@LHDL[&6.=4F#W#O(SM'M 7Y1O;A1R=#_ (=K_LU_]$OL
M_P#P97W_ ,?H_P"';'[-?_1+[/\ \&-[S_Y&J+6V*YB+PW\'?!VB^ _$GA:7
MQKX1>/5+633QJL$,4=\UM+(6F6:0SMO+J0IVA!D;L9-="O@KP='\8+KQDWBK
MP??6ET;:0VNH)'-/;/!%LC\B3SPJ $*PRC%3NP><UA_\.U_V:O\ HE]G_P"#
M&^_^/TO_  [6_9K_ .B7V?\ X,;[_P"/T["N:,GPW\'7&GK:3?$+25W#7999
MH;B%9&N=2D+>>#YG!B1Y4 [AAR-H%9VN_#^P\4Z7X/76/B'X(U"]\-^;###-
M:+]A:%XHX^81=AO,7R\AM^,.P*XIO_#M?]FO_HE]G_X,;[_X_2_\.U_V:\9_
MX5?:?^#&^_\ C]*WF%SN/%VB_#_QDW@ZUO=?\,G0_#L[W TCS+<V\[&UEMT7
M9NVJJ"9B%P>B],5YMJ7P=TJ7PM::!8?%[1K2T_X1<>$[J>00RS-:*[%?*8S_
M +MF5@CDALA5(P1FM'_AVO\ LU?]$OL__!C??_'Z3_AVO^S7_P!$OL__  97
MO_Q^CE[:#N6/'?P\\(:_H_B95\<:83JNJ_VO-%9W-NLK+'IPM;>WC+2A04=(
MY S$#<#TR37'>#O!B^.O"?C6#Q?XMT;1Y=5L-+T;34E>V016MD6D :WCN9!L
M=Y&5E\W+ '[HP*ZK_AVM^S7_ -$OL_\ P97W_P ?H_X=K_LU\C_A5]GGWU&]
M_P#CU/7:X778].^&]_X1\">&TT__ (2'PC#<M(TT[:.\5I%(QQR5:5V+;0H+
M,Q)QVZ5UG_"Q?"?_ $,^C?\ @PB_^*KP7_AVO^S5_P!$OL__  8WW_Q^E_X=
MK?LU_P#1+[/_ ,&-]_\ 'Z9)[S_PL;PG_P!#1HW_ (,(?_BJ/^%C>$_^AHT;
M_P &$/\ \57@O_#M?]FKI_PJ^S_\&-]_\?I?^':W[-77_A5]G_X,K[_X_0![
MS_PL;PG_ -#1HW_@PB_^*H_X6-X3_P"AHT;_ ,&$/_Q5>"?\.U_V:ST^&%G[
M?\3*]_\ C]+_ ,.UOV:_^B7VG_@QO?\ X_0![U_PL;PG_P!#1HW_ (,(?_BJ
M/^%C>$_^AHT;_P &$/\ \57@W_#M7]FO_HE]G_X,K[_X_2?\.U_V:O\ HF%G
M_P"#&^_^/TP/>O\ A8WA/_H:-&_\&$/_ ,51_P +&\)_]#1HW_@PA_\ BJ\%
M_P"':_[-6,_\*PL\?]A&^_\ C]'_  [7_9J_Z)?9_P#@QOO_ (_2 ]Z_X6-X
M3_Z&C1O_  81?_%4?\+&\)_]#1HW_@PB_P#BJ\%_X=K_ +-?_1+[3_P8WO\
M\?H_X=K_ +-?_1+[3_P8WO\ \?H ]Z_X6-X3_P"AHT;_ ,&$7_Q5'_"QO"?_
M $-&C?\ @PB_^*KP3_AVO^S7_P!$OL__  97O_Q^E_X=K_LU?]$PL_\ P97W
M_P ?I@>]?\+&\)_]#1HW_@PB_P#BJ/\ A8WA/_H:-&_\&$7_ ,57@O\ P[6_
M9J_Z)?9_^#*^_P#C]+_P[5_9K_Z)?9_^#*^_^/T >\_\+&\)_P#0T:-_X,(?
M_BJ/^%C>$_\ H:-&_P#!A#_\57@W_#M7]FO_ *)?9_\ @QOO_C]'_#M7]FO_
M *)?9_\ @ROO_C] 'O/_  L;PG_T-&C?^#"+_P"*H_X6-X3_ .AHT;_P81?_
M !5>"_\ #M?]FKC_ (MA9\]/^)C??_'Z/^':_P"S7_T2^S_\&-]_\?H ]Z_X
M6-X3_P"AHT;_ ,&$7_Q5'_"QO"?_ $-&C?\ @PA_^*KP7_AVO^S4?^:86?\
MX,K[_P"/T?\ #M?]FK_HE]G_ .#*]_\ C] 'O7_"QO"?_0SZ-_X,(?\ XJC_
M (6-X3_Z&C1O_!A#_P#%5X+_ ,.U_P!FK_HE]G_X,K[_ ./TO_#M7]FO_HE]
MG_X,KW_X_0![S_PL;PG_ -#1HW_@PA_^*H_X6-X3_P"AHT;_ ,&$/_Q5>#?\
M.U?V:_\ HE]G_P"#*^_^/T?\.U?V:_\ HE]G_P"#*^_^/T >\_\ "QO"?_0T
M:-_X,(?_ (JC_A8WA/\ Z&C1O_!A#_\ %5X-_P .U?V:_P#HE]G_ .#*^_\
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M'A?4?#NMPO<:3J,?DW,"R-&9$R"4)7G!Q@^H)%0^(/A_HOB;5O#NI7UJ6O=
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M +1244 +36^932TR2/S(V1B<,,'!P?PH ^'_ (G))\,=9^).M_"W4]6M]/\
M#GA&\M=>U.XU*>\BDU:62(PD&5V!G@3S9'8=/,4''0>N>!_"UO\ "G]HS2?#
M&@WNI2Z)K'A"ZU"^M;[4)KL&ZM[FV1+@F5V*NZW$H;&,[1Z5T7@_]E?P5X+T
MZXTNSEUZYT.YAN+>?1]0URZN;*9)PPEWPNY4EMS'<1G))K7\+_L]^%?"=IJ\
M5J^K7-QJ5A_9<E_?:K<7%U#: $+##*[EHE&XD;2#G!ZC-+VC??\ KYAR+R/,
MO'GA^+XK?%_XG:;KNIZC:67A7PU82Z0ECJ$UHMM/.+MY+O\ =NNZ0&%%#-D
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M'BVR;<@)Y<: =-J@'/.>MM]'7[%<VMY,VJ13R2,XO$1@5=B1'@* 54$*,C.
M,DG)*YEV';S/._%OQ0UM-%TO4-(TF\TJSNM2^SR7VI:1->%+?[/+)Y_V:%A(
MJET107V_?Y'2NZL?$EA_PC=AJUSJUB]I<P1RK?JPB@EWJ"&0LQPK9R!D]>M9
M ^&L&FZ>]EX>U;4?#-LTOF&&Q>.2-,C!2-)E=8U[[4"@$9&.<[.D>%=-T/PW
MIN@V]JLFF:?;Q6L$-Q^\PD:A5R3G)VCO0Y76WZ$V[,XOXD?%*]\!^./"=FMI
M;W'AN]M[NYU:[)/FVD:26T<<R\XV![D;R>BY;/RG.9)^T1HV@V,LNNAEGBN=
M2,JVI0""TMKV6W$S!W!;(C!VIN)(? XKT#6/!6G:[K5OJ%]&;@0Z?=:9]E<*
M87AN&A:0,I'/^H0>F,\5Q6D?L[Z-X=M=,ATS5-2MI;))HFNI?(N9;F.2=YRL
MAEB;)#N^&&"-QY-+F:^R-Q4NMC5D^,5A_P )A%H,.DZI<^9>R:>-0C2'R/M$
M<!G>/F0/P@/.S!(P,UD:K\>8;?2[V2P\/ZA>:E9W^G6=QIIEMQ(B7=PL*2!A
M*4Z[OE+ @KA@!S6!8_ _6(?B3J^K/]F@M-6NKHWUY%+&9);26)D6) 8/-C<'
MRR6\TCY3@8PHZ;2_@'I6EZ;?VR:KJ+S72V"K<A+:)H/L<S36Y1(X53AVR0RG
M..:/:=HA[/S+#?&;3--U;Q78Z@MPD^BH+@6ZVX5W7R8',*$2,)90;B,<8!,J
M 9ZFW9_&C0-0\<+X7A,K7CW,EDDP,9C:XCB:1XL!_,!"HWS%-N5(SGBH]0^"
M^BZKKD&K7<]Y+>QZI'JKOO5?-D2&",(V%YC+6L$A48^:,=N*OZ+\,K/0?%5W
MK-E?7,4=U/)=/I_E0&+SG7#L'\OS0#RVT/C))[XHYG_*'+YES4-=NK?XE:'H
MZNHLKO2K^ZD0@9+Q2VBH0?0"9Q7.>)/'FJ:+\4;31Y;FUTG098+-DNKK2[F9
M;J>6::,PK<JZQ1-A(0 P)+2J!G(KIKWP[=77Q!T;7%=!:6>FWMFZ$_,7FEM7
M4@>F(&S^%0^)/ 8\4:I:S7FLZ@--@G@NCI,7DK!)-#*LL;,WE^9PZ(Q4. =H
MR,9!=PL9OQ*\<7>@_#OQ%KWA>72M3NM'MI[F;[1,7C011M(RD)R6.T#:2O7.
M>,'#\5?$?7[&X\5:CIJZ>-$\*2P17]O<0O)/=$Q13S;'#@)MAF0KE6RV<X%=
M;XW\ V_C+PGJ?A^*\N-"M-2BD@NI-,CA$DB2(R.OSHP&0W7&>*R+SX.VVH7D
MLMQKFJ207GV<ZG:9@6+4'AQM>0"+(+!45@A4,J $4E($N[.WDU:QANX+26\@
MBNYQF*WDD"R/]%)R:\\UOQ]JD?Q@'A2"^T^PLX["SO2L^FSW,UP9IKE'42(Z
MI$ L Y<'[Q/:O1FL;>2XBG>WB>>+B.1D!9,]<'J,US.H> 9+CQLWB6SU_4=+
MFFMK>TN;2W6W:&XBADF=0WF1,PYG<':R\?G3N!@-\>=%C6]FETS5HK&WTN^U
MF&^>!/)O+:T9%E:(A\Y^=2 P7<#D<<UHZY\3+73]36UA2XEE@U%K":".W#O.
MXT][S9&=XP=@7DYY&W'.1SO_  H1/[=6!]7O;KPL^@ZGHIT^:1%-K'=2V[A8
MBJ G"Q2*&8D@!!SS71:)\);32=034+C5=2U6_75?[7:XO'BR\WV(V>-J(JJ@
MB8_*H'S<^N3F?8.7S*\WQJT6;4+6PTJVO_$%Y=VT-Y;0Z:B-YL<BLX(9W51M
M158Y(QYD?7=5BS^+FG:N^FQZ5INIZK-=Q>?-%;PJ'LD$IB;SP[#:P=9%VC<V
M8GXXK.TWX$Z3X?A0Z+JNIZ1?17D]U%?021O(B2JJ&W =&3RE2.)%7;P(4.<C
M)O6?P@L](FTZ?2=8U32I[> VUS);O$[7R&5I3YQ>-OF,CR-N7:?WC=,\+F[1
M_K[PY//^ON,GQ=\9H['2/&5K9VEQ8>(-(T6]U.U6\$3I*(%^_M1V( 9H^'"D
MANG6NL\5:[=Z7KG@NWMW58=3U5[6X&,[HQ97,N!Z?-$GY5R5E^SOH=I#JD+:
MAJ$T%[IEYI(1_(4PP7+*TN&6(,SY5<,Y8\=3R3V7B;P[<ZOK'A&Z@:,1:3J3
MW<_F,=Q0V=S#A<=3NF0\]@:.:_02CR];D_BCQ(_A6UBNFTN^U&UW8N'L(Q(\
M"XR7*9#,/78"?:N8O?B+<7.N>!KC0Y--U#PIXBN)(#>*[M,Q%K<3J4'"@ P
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M_0[>+O\ P9#_ .(KOJ* .!_X5*W_ $.WB[_P9#_XBC_A4K?]#MXN_P#!D/\
MXBN^HH X'_A4K?\ 0[>+O_!D/_B*/^%2M_T.WB[_ ,&0_P#B*[ZB@#@?^%2M
M_P!#MXN_\&0_^(H_X5*W_0[>+O\ P9#_ .(KOJ* .!_X5*W_ $.WB[_P9#_X
MBC_A4K?]#MXN_P#!D/\ XBN^HH X'_A4K?\ 0[>+O_!D/_B*/^%2M_T.WB[_
M ,&0_P#B*[ZB@#@?^%2M_P!#MXN_\&0_^(H_X5*W_0[>+O\ P9#_ .(KOJ*
M.!_X5*W_ $.WB[_P9#_XBC_A4K?]#MXN_P#!D/\ XBN^HH X'_A4K?\ 0[>+
MO_!D/_B*/^%2M_T.WB[_ ,&0_P#B*[ZB@#@?^%2M_P!#MXN_\&0_^(H_X5*W
M_0[>+O\ P9#_ .(KOJ* .!_X5*W_ $.WB[_P9#_XBC_A4K?]#MXN_P#!D/\
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MM\;M$M=-EN=6,MDZ7>H12+;P27"PP6MW);F>4HI\M#Y>=S8'7T.'RW#F+?\
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MV>[KQ/INN7WAR*XOM2US7-,U/4[7[8MNYBM%5-ML[*55BJCB3(.6Z<4SP/\
M 75_$W@'4O#_ (\EOK*PM]5BO_#*QWD+:CHWEQJ%<3PHJ;_,\U@ &&U]I+9(
MKTC_ (47X%Y_XDOL?],G_P#CE'_"B? W7^Q#_P"!EQ_\<J>76]Q\VEK(K_#S
MX+Q^!O%&I^);[Q-K?BW7[^SATY[W67A!CMHGD=(U6&.-1\TKDD@DD]:](Q7
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ME'_"A_ W_0$/_@9/_P#'* ._HK@/^%#^!O\ H"'_ ,#)_P#XY1_PH?P-_P!
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M8 9\I6;G '))/ ]*ZVN!_P"%#^!O^@(?_ R?_P".4?\ "A_ W_0$/_@9/_\
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MR"B\>-50E&+DQ"1$1''S95>"IYJ]_P *(\#?] 7_ ,G)_P#XY1_PHGP-_P!
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MXU#PE_8=]8Z#H_AVY^TPZ='IV\.3#-"RAA(H4;)FZ#KSS1_PH?P-_P! 0_\
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MPM)KOB;P_?S7"_V?I)FN!:[3NDN601QN3G[JH\W'<LI_AHN.Q!\1O&TOP_\
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MHH **** ,'P'_P B3X>_[!UO_P"BEK>K!\!_\B3X>_[!UO\ ^BEK>H ****
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MZ8]QK^FPIJ8#6+-=(!<@XP8SGYA\R\CCYAZTN5]@YEW,C_A4.@_\_P#XH/\
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M ,++CO;:YMM4ATG;8QPPP3P"W-L92S(R7,^X^9NRP(QC%>E#X4S?]#SXN_\
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M5 '?45P/_"J)O^AY\7?^!\?_ ,:H_P"%43?]#SXN_P# ^/\ ^-4 =]17 _\
M"J)O^AY\7?\ @?'_ /&J/^%43?\ 0\^+O_ ^/_XU0!WU%<#_ ,*HF_Z'GQ=_
MX'Q__&J/^%43?]#SXN_\#X__ (U0!WU%<#_PJB;_ *'GQ=_X'Q__ !JC_A5$
MW_0\^+O_  /C_P#C5 '?45P/_"J)O^AY\7?^!\?_ ,:H_P"%43?]#SXN_P#
M^/\ ^-4 =]17 _\ "J)O^AY\7?\ @?'_ /&J/^%43?\ 0\^+O_ ^/_XU0!WU
M%<#_ ,*HF_Z'GQ=_X'Q__&J/^%43?]#SXN_\#X__ (U0!WU%<#_PJB;_ *'G
MQ=_X'Q__ !JC_A5$W_0\^+O_  /C_P#C5 '?45P/_"J)O^AY\7?^!\?_ ,:H
M_P"%43?]#SXN_P# ^/\ ^-4 =]17 _\ "J)O^AY\7?\ @?'_ /&J/^%43?\
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M?^!\?_QJJ).ZE4R1NN?O C]*^=/"/[*]_P"%=>^&6H0:W#%%H&B1:;K=O$K
M7MQ#8/:0W,1_A8++(&S]Y5B'\ KU'_A4\W_0\^+O_ ^+_P"-4G_"J9NG_"<^
M+O\ P/C_ /C52U?J-,^;_$7[.GB;P!X!T.WLHS<:EH\FGV%OK6GW=]?W$=M!
M*LAE^RN6$8S$GR1;N3_=S6]J'P5\<?$SX*:7X=LI%\+6DFG:MIMW87MU<PM,
M\TN(;U]@#MN4.YMY,#,W/W<5[A_PJF;_ *'GQ;_X'1?_ !J@?"F?@CQSXMQ_
MU_1#_P!I4O?_ )O\Q^YORZG'ZE\$]>O-:\0^7>:=_9>J>(=%\0J[[_.1[,V2
MRQ%<8(9+/*G/63D<9KF-:_90U+4I/%FW6X?LTE_;W?ARV4RPBRC6_&H7$3NC
M!E\V?Y0R'Y5CCP.,5ZS_ ,*KE_Z'KQ=_X'Q__&J7_A5,W_0]>+O_  /C_P#C
M5%GTD%UV)?A/X%D\"^'[FWGM(+2\O+R2]N5@O[B]#2,%&XS3_.S$*N> ./Q/
M<5P/_"J9N_CGQ</^W^/_ .-4O_"J)O\ H>?%W_@?'_\ &JI7ZLG3H=]17 _\
M*HF_Z'GQ=_X'Q_\ QJC_ (51-_T//B[_ ,#X_P#XU3 [ZBN!_P"%43?]#SXN
M_P# ^/\ ^-4?\*HF_P"AY\7?^!\?_P :H [ZBN!_X51-_P!#SXN_\#X__C5'
M_"J)O^AY\7?^!\?_ ,:H [ZBN!_X51-_T//B[_P/C_\ C5'_  JB;_H>?%W_
M ('Q_P#QJ@#C;?X+ZK#X;^(.C)IGA^VE\1QZL(]:A9Q=2-=S2R1K./*'RJ)
M#AS]WISQT,WPWN_&GBK0=:\8Z1HLXTNSO;5+2%VNDW2O:LD@,D:X(\AP1CC<
M,$Y.-#_A5,O/_%=>+O\ P/C_ /C5'_"J9?\ H>?%W_@?'_\ &JG4>G;\S"U3
MX*7VJ:U>^(1KMQ!KC:S#JEM&DA^RQI#LC6(KC/S0JZM@\&5\=>>WU#PK'XI\
M,:GHFO6L!M+YYDDCL9'C#Q-(Q4EAA@Y!!;'&2>HK%_X55+_T/7B[_P #X_\
MXU2_\*HF_P"AY\7?^!\?_P :H2?<-.Q%<?#K5H_ .H>%8-<$MG<;+2&:2!89
MH+-F59D!BPK/Y?F!6"KR1G-=7J7ANTU+28].8W%I:Q[0@T^YDM64+P%#1,I
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M(M(T'5(7L;*R$VHLRW5F89KEV>$B-ADBX&.5Y7K6A_PJB?\ Z'GQ=_X'Q_\
MQJF_\*JE_P"AZ\7?^!T?_P :HL^X:(\YF^$/B6YU"/PQ<FP72/\ A$M<T:VU
M:%)'EW7$UKY;39 "L54D@$[BCG(X Z[2OA?KEUKJZOKDVFF1]>.JR6EF':/R
M?[+:R\K<P&XDD,<@#!(Z\UK_ /"J9O\ H>?%O_@='_\ &J=_PJN;_H>O%W_@
M?'_\:J;/N%UV.-\-?!/Q#X-N;#5K6_T_6-7L)9;6"/4#(L7]GB)(;>/> Q$B
M+&&+8()EF'1LUK>'/A=K_@N^L+K3+G3+UY;1K6_6\5T2(M<R3LUNH!^4&5U"
M''"1\C%;G_"J9O\ H>?%W_@?'_\ &J/^%4S?]#SXN_\  ^/_ .-4[/N%_(X:
M7X'>*=7?Q!)JVMV]Q<7V@:GHL<[7$\@=[IXV64QG"0JHC V1CWR:]&\9:?<7
MGB+P#)! \T5GK$DMPZC(B0V%V@9O0;G4?5A5(_"F7_H>?%W_ ('Q_P#QJFGX
M4S;A_P 5SXMST ^W1#M_UR_SBA)]PT[&[XR\,WGBW2QIJ:E_9UG,2MX8[9)9
M)8BI&Q2^53)ZG:WMCK7)ZM\.=5TVY\!V'AFTT]/#_AJZ^T%;Z^F\\J;:XMRB
M_(^?EGW9+=B.,YK2_P"%4S?]#UXN_P# ^/\ ^-4?\*IE_P"AZ\7?^!\?_P :
MHL'R,KP7\,M;T6X\+6>I7-C)HGA2*2+3#;;_ #YAY9AB,H(PNR$LIP6W$Y^7
M&*[VT\.P6-]?7D4MVTUYRZ3W<LL:XS]Q&8JG_ 0*Y?\ X53-_P!#UXN_\#X_
M_C5'_"J9O^AY\7?^!\?_ ,:IZ]P.=T3X!6>@_":V\.6?D1:\NGV=O-J4IDG6
M66#8P4[VW>274Y0$#:Q  JIXB^%7BKQ ^I:OYNEV'B6ZE@-M-:7$R1Z<8H9H
MTG1@H,LG[YU964*R84],GK/^%4R]/^$Y\79_Z_H__C5'_"J9O^AX\7?^!\7_
M ,:I<KZ,+_,H6?PTU?2_BE=>*H+FSGM[R6X66WE+(Z0RV^GQ[EP""P:Q/RG
M(D'(QBN9D_9UO+JQ\-Z=+JT<.G6V@P:7JJ6ZG=<3V\#QV\L?3 5IY7.>28X?
M[M=J/A7*W3QUXN/_ &_Q_P#QJE_X53-_T/7B[_P/C_\ C5%GW#Y%7X2?#>Z\
M"K=RZA#!]NEM[:S:ZBU&ZNS+'#YFP8G/[M097(1<@;CR>*]'K@?^%53?]#SX
MN_\  ^/_ .-4O_"IYO\ H>?%W_@?'_\ &J>MM7<1WU%<#_PJB;_H>?%W_@?'
M_P#&J/\ A5$W_0\^+O\ P/C_ /C5,#OJ*X'_ (51-_T//B[_ ,#X_P#XU1_P
MJB;_ *'GQ=_X'Q__ !J@#OJ3(K@O^%43?]#SXN_\#X__ (U7:V=JUG:00&:6
MX,2*GG3$%WP,9;& 2>_ H LT444 %%%% &#X#_Y$GP]_V#K?_P!%+6]6#X#_
M .1)\/?]@ZW_ /12UO4 %%%% %#6-8M-!TF]U*^G2WLK.%[B>:0X6.-%+,Q]
M  "?PKY3_9/^-UYXD^(.IV&K^,(?$1\8:3_PE^G6*WR3MI.9W62QVJQV>7#)
M9G:<<^8?6OI/XA>!['XC^"]7\+ZE<7-OINJP&UNC:.$D:)N'0,0<!AE3QT8U
MD:K\%_#.H>(O#&MVMDFCZCX?N))[633HTBWK)"\+Q287YD*OG''*J<\4N=QT
MY?Z] MYGEWPU_:2\7>-F\"7.I>#M-TC3?&UE<R:0Z:LTTR7$,)EQ.OE +&ZH
M^"I9A@9'/&%\-?BUXS\1>"_AIJ?C>WA-SJWC*?3+>XT?5)(PZHM^#Y\8B171
M1!M"<AOE8X(KV'P[\"=!\,6'P]M+6ZOGC\$+(NG&6129 \#P-YORC/RN<8QS
M6=H/[..BZ!_9<*:WK%SIVDZ_)XATVQN)(C':3.+C?&A$88QDW4APS,1A0" ,
M4<[["]G'^KG)_&SQ]<>/M#M8_A]J6I:[9Z)K$9\5:?X4N/(U0V9CF7; YVG<
M)0C%5(9E1@#FN-\7>([C6?!_@'Q#X?UGQQXB^%=M#?QZU<Z+<R1ZY;W*R*(W
MN5PLSK#MG1HQ\V=I8-BOHSQYX)O/&%K:I8>*-9\*W-O(9%NM&>+<X((*NLL;
MHP[\KP>E<5#^SC#H_A^TTCP]XX\5>'(U>YEO;BSN8))-0EN)6EFFF\V)P)&=
MF.] I&<#C "YVK[_ -?-#Y(O>W]?)FWX1^+G@G4H/#VB:;XMBUB_U'3H[JQ:
M5B9[V$PEUE)"@$E 6)X^E?+O[,/Q,U^Y\2?!^6_UCQHL7B33+K^UKCQ7)))I
MVHW(A$D2V;/N"R?)(X *@HK=:^RO!G@O2_ /@_2/#.B0?9=)TNTCLK:+<698
MT4*H+'DG Y/7G->1:#^RU#X%T72(]*\3:UXAE\*P32>&-+UZXB%E971@DBBD
M810JSE1*R@N6P&/?FGSM6MM_7]=0Y(O5VT_KM_D<'\0O$FIZAI?Q9^)6EW\]
MD;;5M,\*:-<P.5*V]M?1+=LI']^>:=#W(A6O>OBUXZN?A]X7@U*TGT"UEDN4
M@,WB+46L[=<JQX*H[.Y*@! ,G)/:L.#]G[3KK]G_ $_X87^I744,=K;K<:E8
MLJSO<I*D[S@NK#+3*7.1SD\<TW4/V?FUK2](BU+QWXGO]7T;4VU33M<F>T%U
M;.T#0,@40")D*._WD)RQ(/2CG]?P#DOV_$V/@?\ %/\ X7)\,;/Q1]EBLI9)
M[NTECMY3-%YEO<2V[M&Y5=R%HBRD@'!Y%?-'@O\ :Z\1^&_A=HT0L].\0ZS8
MZ/9ZA=R:]K+6UWJ#75W-#&EL@B<RLHB))X^\H%?5?PS^&NG_  L\)+X>TNZO
M+NU^U75XUQJ$HEF>6XG>>1F8 9^>1L<=/SKY>UK]E7QAX(\4:BW@2&^=8M,M
M;/P_JZ:K:Q+9RQ^:?,NXI86+X>4G]V.54#&<DGM%'6PO9\VET>C>.=7U?Q]\
M6=<\,WVJ:YHOA_PKX<L]7O--\*RR)>ZE=74EPNU9$ D:.,6Q 5-I8R<],5Z%
M\ _$6D^(_A^LNCZKKNKVMK?75FTGB12M[%+'*R/#)N4,=C KELG Y)J#QC\#
MXO&.L:1XD3Q#JGAGQG8V7V&37-!>.-KB(D,T<D4B/&Z;\L RY4DX(S6_\+OA
MI8_"OPW)H]A>7NI>?>7&H7-[J,BO/<W$\K2RR.555!+L3A5 YZ4<W37]/S_0
M?*M]/U_+]3LZ*3-&:8"T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)
MFC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T 5-
M0CGN+&XBM;D6ERZ,L=P4#^4Q& VT\'!YQWKQ[]F2ZUKR/B1IVM^(=0\2SZ5X
MMN;*&]U)E,GEBWMWP H"JNYW(51@9XKV*^M7O+.>".YEM))$9%GA"EXR1@,N
MX$9'7D$?6O+/ O[/[> X_%J6_CSQ1?GQ(\T]S)=26JO#<R(J&YB,<"%9 J+C
M.5&/NTKCL<;X\CUGXE_%;XAZ+%XKUCPQ9>$?#]E<Z>NCW9MM]Y<"Y<W$N/\
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MHGP5_P! NX_\&5U_\<KOJ* .!_X43X*_Z!=Q_P"#*Z_^.4?\*)\%?] NX_\
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M\>K"..\N9M"U2+3(]'OM;M+XB(QWEM:M&LA0"3<&;S5*A@,@]JT]<^)L-GK
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M .%;^$?^A7T3_P %T/\ \32?\*Y\(=/^$7T3_P %T/\ \33U["+O_";>'?\
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M_0K:)_X+H?\ XFC_ (5KX1_Z%;1/_!=#_P#$T 6O^$V\._\ 0?TO_P #(_\
MXJC_ (3;P[_T']+_ / R/_XJJO\ PK7PC_T*VB?^"Z'_ .)H_P"%:^$?^A6T
M3_P70_\ Q- %K_A-O#O_ $']+_\  R/_ .*H_P"$V\._]!_2_P#P,C_^*JK_
M ,*U\(_]"MHG_@NA_P#B:/\ A6OA'_H5M$_\%T/_ ,30!:_X3;P[_P!!_2__
M  ,C_P#BJ/\ A-O#O_0?TO\ \#(__BJJ_P#"M?"/_0K:)_X+H?\ XFC_ (5K
MX1_Z%;1/_!=#_P#$T 6O^$V\._\ 0?TO_P #(_\ XJC_ (3;P[_T']+_ / R
M/_XJJO\ PK7PC_T*VB?^"Z'_ .)H_P"%:^$?^A6T3_P70_\ Q- %K_A-O#O_
M $']+_\  R/_ .*H_P"$V\._]!_2_P#P,C_^*JK_ ,*U\(_]"MHG_@NA_P#B
M:/\ A6OA'_H5M$_\%T/_ ,30!:_X3;P[_P!!_2__  ,C_P#BJ/\ A-O#O_0?
MTO\ \#(__BJJ_P#"M?"/_0K:)_X+H?\ XFC_ (5KX1_Z%;1/_!=#_P#$T 6O
M^$V\._\ 0?TO_P #(_\ XJC_ (3;P[_T']+_ / R/_XJJO\ PK7PC_T*VB?^
M"Z'_ .)H_P"%:^$?^A6T3_P70_\ Q- %K_A-O#O_ $']+_\  R/_ .*H_P"$
MV\._]!_2_P#P,C_^*JK_ ,*U\(_]"MHG_@NA_P#B:/\ A6OA'_H5M$_\%T/_
M ,30!:_X3;P[_P!!_2__  ,C_P#BJ/\ A-O#O_0?TO\ \#(__BJJ_P#"M?"/
M_0K:)_X+H?\ XFC_ (5KX1_Z%;1/_!=#_P#$T %]XH\-:A9W%M+K]@(YT:-S
M'J*1L PP=K*P(/H0<CM7G7A7X4_"CP9!XA@TO5-D/B"*6+4DN?$]Q<"?S%"N
MQ\R=L.54#>,-@=:]$_X5OX1[^%M$_P#!=#_\31_PK?PAT_X1;1/_  70_P#Q
M-3J]4.YY_P"*/A9\(_&3:>VJ7-E(UG8+I8:'7)(#/9KTMYRDH\Z/J=LFX<GU
M->AVOBOPS96T5O!K6DPP1((XXX[N(*B@8  W<  4S_A7'A#_ *%;1?\ P70_
M_$T?\*W\(?\ 0K:)_P""Z'_XFCE%<X/QU\-_A5\1]:;5]:O;3^T9;=;.XFL-
M=DLS=VX)(BG$,JB5 2V%?(&2.AJQ:^'O"=G\1M$\1Q>(]'@TW0M$?1]*T>":
M)(K3S'0R2*=^.4AA0# P%/\ >KM/^%;^$?\ H5]%_P#!=#_\345QX \%VEO)
M//X;T&&"-2[R26$*JJ@9))*X  [T<H<QSFJ>&?AKK5KXKM[V[TN>'Q0\<FK+
M_:('VEHXTC0\/\N$C0?+CI5?Q5X+^%_C1/$2ZO=:;/\ V_!:VVHE-5,;3);.
MTD !20%2C.Q!7!YKJK?P#X*O+:*XM_#>@W$$RAXY8["%E=2,@@A<$$=ZD_X5
MSX0_Z%?1?_!=#_\ $TN4KF9B^!;/P1\.]+FT[1_$*-;33&=CJ.O27S[BH7AY
MY78#"C@''YUT_P#PFWAW_H/Z7_X&1_\ Q55?^%;>$?\ H5M$_P#!=#_\31_P
MK7PC_P!"MHG_ (+H?_B:LDG?QGX=D5E.O:9R,?\ 'Y'_ /%5YGIWPM^%NEZE
MX$OX-4L_M?@S3#H^FR-J49WVWD^2$F&<284M@GH7<_Q&O1!\-_"/_0K:)_X+
MH?\ XFC_ (5OX0X'_"+:)Z?\@Z'_ .)J7%/<:=CPKQO\%?#MYX!M?#6A^-;>
MZTRTNK62#2=6U>-;>.WA;(@CEC4NG\.&;S#A<=\BS'\&/"WBCP3I6E>,/&T$
MM_:65_I;2:7J<2+]@N9 WV4LRY942.) X"L0G;<17MG_  K?PC_T*VB?^"Z'
M_P")H_X5OX0_Z%;1/_!=#_\ $U'L^EW8?,<'=^!? 5YK6I7[^*45-0OK#4Y[
M-=3A$!NK-H##*!USBVA##."$Z9.:I77PI^%]Q>>+;L:Q;0W7B:ZM;VYFBU2-
M6MYK=Q+$\'/R8EW2D<@L[$YSBO2?^%;^$.WA?1#_ -PZ'_XFC_A6_A#./^$6
MT3_P70__ !-5RI[AS,H>%]5T#PUI*V3^,(=68,SFYU"^MS*<]OD"K@>@':MG
M_A-O#O\ T'M+_P# R/\ ^*JK_P *W\(_]"MHA_[AT/\ \32_\*U\(_\ 0K:)
M_P""Z'_XFJ\B2U_PFWAW_H/Z7_X&1_\ Q5'_  FWAW_H/Z7_ .!D?_Q55?\
MA6OA'_H5M$_\%T/_ ,31_P *U\(_]"MHG_@NA_\ B:8%K_A-O#O_ $']+_\
M R/_ .*H_P"$V\._]!_2_P#P,C_^*JK_ ,*U\(_]"MHG_@NA_P#B:/\ A6OA
M'_H5M$_\%T/_ ,30!:_X3;P[_P!!_2__  ,C_P#BJ/\ A-O#O_0?TO\ \#(_
M_BJJ_P#"M?"/_0K:)_X+H?\ XFC_ (5KX1_Z%;1/_!=#_P#$T 6O^$V\._\
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MXW_LV[DM[>UN(+6^MO)N(X9)717#JQ',TF=I'!KHA\-_".?^16T3_P %\/\
M\31_PK?PC_T*VB?^"^'_ .)JM42>9?\ "N_""^(-S>+8+GPY+HFIZ,^ESZG'
MM@CNY8'*P[<$*!%(/F)(!4#@8KH-%\-^"M'O([U_%::E?+J?]K-<WNIQ.SS_
M &0V@R!A0HB)&U0!GFNN_P"%;^$/^A6T7_P70_\ Q-'_  K?PAT_X1;1<_\
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M_K^O4]$HI**8"T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E%
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MH^J21AU1;\'SXQ$BNBB#:$Y#?*QP14VMU"[['NH^"/PX_P"A \+_ /@FMO\
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M@>[LX]3OIM4,=Q-%/!!*QAB$9RZ"5B0S $  $DG$Z=PN^QZI_P *1^' &3X
M\+ ?]@:V_P#B*3_A27PX_P"A \+_ /@FMO\ XBO./VMO$%[H^D_#B&UN?$%O
M;:EXKBM+R'PQ,\=]<0&RNW,:%&5L;D0G!_AJY^R=XNU+Q-X.\26NJW^IW-SI
M6OW=E#:Z\"NIV=L"KP1W60,N4<,&YRK+R31I\PUOY'=_\*3^''/_ !0/A;_P
M36W_ ,11_P *2^''_0@>%_\ P36W_P 17SG+XRU[Q!J5Q9Z?K-UHMUXZ^)5]
MX=FU."0":RL-/@E0QP$@A&<V+X;&09W8<XKK_CYX=U#X-?L^^(Y-$\4>+-0>
M;4M)2(R:DT]]"DE_;12QP3,0^71V&&8X+<$4>ZG;^OS#WOZN>N_\*2^'!Z>
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M)"TY$^XW,V?[R6R7#@]B@[T[+<-=CWE/@G\-Y%#+X!\+,IZ$:-;8_P#0*/\
MA2/PX_Z$#PO_ .":V_\ B*\@\;?M#>(_AO/XYMM"\"V-]X4^'LMC;7DS:F89
MYX9;>%]MO%Y9&Y!+_&P! &#G.,[XE?&[Q@_@7X@:3J6GP>$O%'A^?0[B.?1]
M0:X5[:\O$11O,:$/B.9& !!'0D&C3N%WV/<?^%'_  Z_Z$#PO_X)K;_XB@_
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M!X/RL2%;-;%U\?O!5GIME>R:HWE7D$L\"+;2M(WEW$=LR; N0YFE2,(1N+'
M!P</E?0.;N:/_"D?AS_T('A?_P $UM_\12_\*0^'/_0@>%__  36W_Q%:W@S
MQKI?CO2I+[2GFV0SO:SPW,#P30S)C<CHX#*1D'D<@@C@UO@8J2CBO^%'_#G_
M *$#PO\ ^":V_P#B*/\ A1_PY_Z$#PO_ .":V_\ B*[:B@#B?^%'_#G_ *$#
MPO\ ^":V_P#B*/\ A1_PY_Z$#PO_ .":V_\ B*[:B@#B?^%'_#G_ *$#PO\
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M35TV[U":Z6TL;1Y$GN+H&%(S&Q5R2X'R@@_-T/4$B@#FO^%(_#C_ *$#PO\
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M8[%IF1) F;I4,3*&4,8R7^]CC:V<;3@LV*_D3_\ "D?AS_T('A?_ ,$UM_\
M$4?\*1^'/_0@>%__  36W_Q%:'A'Q]HWC9KE-,EN#+;I%,T=U:R6[F.3=Y<@
M#J"4;8^&'!VGTKIOQI6*.*_X4?\ #G_H0/"__@FMO_B*/^%'_#G_ *$#PO\
M^":V_P#B*[:B@#B?^%'_  Y_Z$#PO_X)K;_XBC_A1_PY_P"A \+_ /@FMO\
MXBNVHH XG_A1_P .?^A \+_^":V_^(KK;6Q@L+6&VM88[:VA18XH84"I&BC
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MHO)58A$@#QKD;/F[UO\ _"C?!_\ SY7W_@XO?_CU'_"C?!__ #Y7W_@XO?\
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M_P#'J/\ A1O@_P#Y\K[_ ,'%[_\ 'J .]HK@O^%&^#_^?*^_\'%[_P#'J/\
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M\3VVG6US-9RH&A^Q3/- \>Y" V^0[L@@XK6/P/\ !V/^/*^_\&][_P#'J/\
MA1_@[_GROO\ P<7O_P >HLA\S-?P+X1OO!^E36=]XGU;Q5+)*9!=ZSY'F(NT
M#8ODQ1C;QGD9R3S735P?_"C?!_\ SY7W_@XO?_CU'_"C?!__ #Y7W_@XO?\
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M ,'%[_\ 'J .]HK@O^%&^#_^?*^_\'%[_P#'J/\ A1O@_P#Y\K[_ ,'%[_\
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MXU5"48N3$)$1$<?-E5X*GFM#_A1W@[_GSOO_  <7O_QZD_X4?X._Y\K_ /\
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M/+W8D(./F8]#I?P+UNTM-9FN-;MY]4O#I,D3O]HF3S+&Z:X!D,LK,1(3@A2
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ML3@D<C*[=RY .*VM?\2/HNJ^&+00"4:QJ#6;,6QY>+6>?</7F$#_ (%7ES?
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M7Q._;%^/7PMT#Q[H$_P8L](UJ)Y;>#4H-42= LKQG<J%U!RAZ,>#7;FS_;=
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M#8Z5R5[^V=IJZGXBU_3;EM1\+Z?X,?Q%;Z"^BW<&IRNMY);B4NRX6%BF/NY
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M+O([VU\Z6#S8B2OF1R-'(OX.C#\* V/F V'[;K?\Q#X%X_ZYZO\ _$TAT_\
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M_P#Q-'V#]M[_ *"/P*_[]ZO_ /$U]8;AT!IU 'R;]@_;>_Z"'P+_ .^-7_\
MB:/L'[;_ /T$?@5_W[U?_P")KZRHH ^3?L/[;W_00^!?_?O5_P#XFC[#^V]_
MT$/@7_W[U?\ ^)KZRHH ^3?L'[;_ /T$?@5_W[U?_P")H^P?MO?]!'X%?]^]
M7_\ B:^LJ* /DW^S_P!MW_H(_ O/_7/5_7_=H^P_MO?]!'X%?]^]7_\ B:^L
MJ* /DW^S_P!M[_H(? O_ +]ZO_\ $T?8/VWO^@C\"_\ OWJ__P 37UE10!\F
M_P!G_MO?]!'X%?\ ?O5__B:3^S_VWO\ H(? L>OR:O\ _$_YS7UG11Z ?)OV
M#]M[_H(_ O\ []ZO_P#$T?V?^V]_T$/@7_W[U?\ ^)KZRHHZW ^3?L'[;_\
MT$?@5_WZU?\ ^)H^P_MO_P#01^!7_?O5_P#XFOK*B@#Y-^P?MO?]!'X%_P#?
MO5__ (FC[!^V]_T$?@7_ -^]7_\ B:^LJ* /DW[!^V__ -!'X%?]^M7_ /B:
M/L'[;_\ T$?@5_WZU?\ ^)KZRHH ^3?L'[;_ /T$?@5_W[U?_P")H^P?MO\
M_01^!7_?K5__ (FOK*B@#Y-^P?MO_P#01^!7_?K5_P#XFC[!^V__ -!'X%?]
M^M7_ /B:^LJ* /DW[!^V_P#]!'X%?]^M7_\ B:/L'[;_ /T$?@5_WZU?_P")
MKZRHH ^3?L'[;_\ T$?@5_WZU?\ ^)I/@+\:OC5=?M2:W\)/BTO@F62R\*CQ
M%%<^#X;H*2US'"J,T[>A<D!/3FOK.OD;P[_RE,\5?]DNM_\ TX)0!]<T444
M%%%% &#X#_Y$GP]_V#K?_P!%+5/XIL/^%9>+_P#L#WG_ *):KG@/_D2?#W_8
M.M__ $4M'CCP[/XN\%Z_H=O>_P!F3ZGI]Q91W@B$OV=I(V02;"0&VEL[21G'
M:@#P/_@G&N_]B'X8*.]E<C_R;GKS3X1?L%^(?@[IWP>UC0Y] LO'/ANZOK;Q
M->6YD6+5M.N9925+>7N>2-&CV;P,$=>!6E\-?V)_CE\(O!6F^$_"G[4L^E:!
MIJLEK9KX$LI1&K.SD!I)F8Y9F/)[UT__  S?^TG_ -';7'_AO=-_^+J'&[O<
MI.W0H_"W]D7Q5X)T7]G6SO-1TIY/AU/JDNJ- \A$XN4E5/)R@SCS!G=MZ=ZY
M_P"&/[#^M> _B!&M_I?ASQ!X:M=>N-:LM8NM5U!;ZW#M(R 6@/D>:F\C?G!!
M.0:Z[_AG#]I(?\W;W'_AO=-_^+I/^&<?VDO^CMKC_P -[IO_ ,7246MI?D-R
MONCCO@I^R3\6?!/BCX-6WB'4?"LGA3X9W>IBUDT]YS>7L-S%*JNZLH12I=!M
M'^T<]!6^O['_ (J_L5;,W^DF0?&'_A81;>^UK'S_ #/*^Y_KL<>GOBM+_AG#
M]I+_ *.VN/\ PWNF_P#Q='_#.'[29_YNVN/_  WVF_\ Q='+)JTI7^[_ "#F
M5]$<YXL_91^)ZWWBV[\/ZUI[6.N>.)?$5UHJZI=:<M_9/;+&(9;B%=Z,KKNV
MKE2.I[57T_\ 8Z\?>'_V<?#OA.POM!D\6^'O'"^+[5)9YS93!+EI5A:1E,@R
M&Y)!.1UYS75_\,X_M)?]';7'_AO=-_\ BZ!^SC^TF>G[6UP?^Z?:;_\ %T6G
MMS/\/\B?<Z17XG&>,_V1_BOXDM_B/X8M]2\*P>$_B5J%IJVMWDC3O>:=*HA-
MQ% I7;*I:+"%BN >1GFM;XE?L:^+/$VJ_%75=&U72H+S6=9\/ZWX?CNVD9!)
MIT"QM'<X7A7(;&W=US6[_P ,X_M)?]':W'_AO=-_^+H'[.?[2)Z?M;7!_P"Z
M>Z;_ /%T<LOYOR_R'=?R_G_F=1^SK\'_ !_X-^*GQ1\>>/I]!.H>-!I;+::"
M\K1VOV6*6(H3(H+?*T9W=SNX P*X3QO^P[J7QA\;?%?Q'XM\9:MIC^*-FGZ=
M8Z!?F.V^P11!85N4:/YCYA=RH.,L>>:U/^&<?VDO^CMKC_PWNF__ !=)_P ,
MX_M)=/\ AK:X_P##>Z;_ /%T[.WQ/\A75_A+?P!_9U\=>!_B7H/B[QEJ&DWU
MQ8_#^W\'SM92R222S0W;2"7YD7*M'LSSG=GC%<=8_LC_ !(;]E'Q+\&;V\\.
M"--8CNM$U&*:8F6W_M,7DAN 4^5L?* N?<UTW_#./[27_1VUQ_X;W3?_ (NC
M_AG']I/_ *.UN/\ PWVF_P#Q=3RR>\OR_P BDUT7YF=\;OV/_%7Q,UCXR7>G
MZAI,$/C2+P['9I<22#R_L$XDF\T!#C('RXSGOBNY\<_LYZSXP^-7C'Q2M_96
MVCZY\/'\'HOS&>.X:>1_,*XQL"R=CGVKF/\ AF_]I+_H[:X_\-[IO_Q=)_PS
MC^TE_P!';7'_ (;W3?\ XNGRON/F,WX?_LS_ !+LKCX(W7B)_"JR_#K1M4T,
MQ6\T\\5U%+:0V]LY5D&23&Q<9  (QGFNJ_97_9[\7_!GQ-XKO=4FTK0_#6I1
MPK8^$M O[J[L;692QEG3[0!Y6_(_=H,#'6LC_AF_]I+_ *.VN/\ PWNF_P#Q
M=)_PSC^TE_T=K<?^&]TW_P"+IQ4D_B(ERVV_/_,S/&W[#NI?&'QM\5_$?BWQ
MEJVEOXHV:?I]CH%^8[;[!#$%A6Y1HSN/F%W*@XRQYYKF+C]E3XX6?]D7=EJ_
MA.[U:]^'O_"!ZY/J$MPRQ!))"EU%M0&1S&R@AL#=D\UW?_#.'[27_1VUP?\
MNGNF_P#Q='_#./[21Y_X:VN,?]D]TW_XNBT]U-CO';E,32?V2_'OA_6OAI/:
M7NB3VEE\/1X \1"::57BB)1GGM<+\S94@!MO;WI_P>_99^).C>*OA)'XUU#P
MW_PC?PMM[N'2I-%,QNM3:6(PHTRNH6(*G)VEBS=>*U_^&<?VDO\ H[:X_P##
M>Z;_ /%TO_#-_P"TG_T=M<?^&]TW_P"+HM*_Q?E_D%X]OS_S#XN?L0Z?XPO-
M%TWPM=W?AO0+S78]:\372ZO=27<Q@$CVZVXD,B(1+*6)^7&U>N*R=/\ V,_%
M/@__ (7EH^B>*'UKP[\0_#C6\=QXBNVFOH]5,4D7F2,L>#&5<$D<Y X-:W_#
M-_[2?_1VUQ_X;W3?_BZ/^&;_ -I/_H[:X_\ #>Z;_P#%TWS-WYF%UM9"R?LF
M^(KO6]#FEU+3H+2U^%DW@2X:-G9_M3B,>:H*C=$-K'D@].*H_#/]FGXD:;JG
MP*O/%$_AV(?#G2=2T21-,GF<W,,MI!!;R#>@^;,3%AP -N,\U=_X9O\ VD_^
MCMKC_P -[IO_ ,71_P ,W_M)_P#1VUQ_X;W3?_BZGE?2073Z'F?@?]B/XJ7/
MA7X:?#[QGJWAF'P3X,ENKY;[13,=0N)IDE"QD.H4!3,_S \@+P#S70>"/V._
MB-J#_#O0?'.J^'H/"WP^TS4=.TRZT,S->:@;FW-NLDJNH6+:C$D*6RP]#76?
M\,W_ +2?_1VUQ_X;W3?_ (NC_AF_]I/_ *.VN/\ PWNF_P#Q='+/K)_A_D/F
MCTC^?^9RGPF_94^+>@^,O@U)XIO_  F?#_PSM=2TVU.E&?[3>Q7%J\*2/N7:
M"#Y>5';><DD"N=M/V"O&GA_PA\)WMYM#UW6_"FEWND:CIMSJE]8VMQ'-<M,D
MD4]N!(K*3@J5PV?;->F_\,W_ +2?_1VUQ_X;W3?_ (NC_AF_]I/_ *.VN/\
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M_%T ?5E%?*?_  S?^TG_ -';7'_AO=-_^+H_X9O_ &D_^CMKC_PWNF__ !=
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MS,0S/)M/3)BZ=,^5#]F3]H_C_C+6\_\ "#T__P".4?\ #,G[2'/_ !EM>?\
MA!Z?_P#'*KFFW=L=HK9'UC17R=_PS'^T?_T=O>?^$%I__P <H_X9C_:/_P"C
MM[S_ ,(+3_\ XY0!]8T5\G?\,Q_M'_\ 1V]Y_P"$%I__ ,<H_P"&8_VC_P#H
M[>\_\(+3_P#XY0!]8T5\G?\ #,?[1_\ T=O>?^$%I_\ \<H_X9C_ &C_ /H[
M>\_\(+3_ /XY0 NE_"/Q_I_B;_A)3'>:A=W<_B/5[72[R2$6VF:D[LFG3?*
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M ..4 ?65%?)W_#,?[1__ $=O>?\ A!:?_P#'*/\ AF/]H_\ Z.WO/_""T_\
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MV2+( =IVD'!]*S-'\00:UJ6MV<*.LFDW:V<V\  NT,<V5YY&V9>N.<TAG/\
M_" ZZ/\ FI?BC_P&TK_Y!H_X0#7?^BE>*/\ P&TK_P"0:UM%\<:1K_B#6-&L
M9Y)+W25C>Z5H71 )&D52K, '&Z&094D H12>#/'6D>/M/N;W19VNK6WN9+1I
M/+9 SIU*Y'*G@AAP0002*+=1&3_P@.N_]%+\4?\ @-I7_P @TO\ P@.N_P#1
M2_%'_@-I7_R#5NW^(^CR:]=Z3.+O3KFW@FN@]];201S0Q,JRR1NP 95+ID_[
M:D<$&CPC\1M(\974MM9"\@N%@2[2.]M9+=I8'+!94#@;E)4^XXR!D95@*?\
MP@&NX_Y*5XI_\!M*_P#D&C_A7^N ?\E*\48_Z]M*_P#D&NE\1:]9>%] U+6=
M1E\K3]/MY+JXD"EBL:*68@ $G !X S5;0_%5KKFGO>B"\TZ%9/*VZG:O:N6.
M,$"0 D'( /0GBG;2P7,3_A7^N]#\2?%&/^O?2O;_ *<J7_A ==_Z*7XH_P#
M;2O_ )!KL?M</_/5.BM]X="< _C@X^E5K75([FXO8L-&;20(YD&,Y17##/5<
M,1GU4CL:.5A='+?\*_U[_HI?BC_P&TK_ .0:/^$ UW_HI?BC_P !M*_^0:[+
M[5#YPB\Q/-(W!-WS8]<>E,.H6JJS&XB"JVPMO& WH??VHU#F7<Y'_A ==_Z*
M7XH_\!M*_P#D&D_X0'7?^BD^*#C_ *=M+_\ D*N@M_$%M=>)[[1$#_;+.T@O
M)6*_+LF>5$P?7,#Y_"C1_$$&M:CK=I"CJ^DW:V<V\  N88ILKSR-LR>G.:+
M<^/ &N_]%*\4?^ VE?\ R#1_P@.N_P#12_%'_@-I7_R#732:Q:+I<]_#)]LM
MH59R;-3,3MSD*J ECD$8 )S7)K\8M"DM24@U)M0%VUDVE"QE-XLJQ+*08\9
M$;H^[IAUYR0*+:A<F_X5_KQ_YJ5XH_\  ;2O_D&D_P"%?Z]_T4KQ1_X#:5_\
M@UTOA_7['Q/HMGJNG3?:+&ZC$D4FTKD'U! (/8@C((P>:H^+O&FG^#8;![]+
MN=[ZY^R6T-E:R7,LD@C>0@*BD\)&YSC^&BVMF%]#)_X0#7O^BE>*/_ ;2O\
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M-.!:2VYN2D\(6,F52MTX*-LY53G&:]Y_L/XAG_F<= _\)N7_ .3:/[#^(?\
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M.Y7C2WP<YRAX[UZWCBN(_L'XB?\ 0XZ!_P"$W+_\FT?V#\1/^AQT#_PFY?\
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MYHKAO[!^(G_0XZ!_X3<O_P FT?V#\1/^AQT#_P )N7_Y-H [FBN&_L'XB?\
M0XZ!_P"$W+_\FT?V#\1/^AQT#_PFY?\ Y-H [FBN&_L'XB?]#CH'_A-R_P#R
M;1_8/Q$_Z''0/_";E_\ DV@#N:*X;^P?B)_T..@?^$W+_P#)M']@_$3_ *''
M0/\ PFY?_DV@#N:*X;^P?B)_T..@?^$W+_\ )M']@_$3_H<= _\ ";E_^3:
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M4TK5/#MKIFGZA;/''J8BD:226S:/)MY3N0B&3Y2<949'3.[_ &%\1/\ H<-
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M"Q97MS9)INK-=W5Y:R)',D9LKJ'*[E(R7E0<#H3TJ7^P?B)_T..@?^$W+_\
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M&: 2!MJJRNP^7BJYM+V#DE>Q]*^ ]4\6:I972^+=#T_1+Z&78G]EZB;V"=,
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ME?7(%8?B'X9?%&ZL_$NG6YU!=/\ #\T=GH\D=SN?5+"?44N;D;?-3<8[:..
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M@NWN?M$DA6/[8[2_/^[W%BC$X";02,5VT/AFXT7PK8:+X=N8=*2QACMX9+B
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MW_DM%UT'KU*'A/XD>&O'+.NAZM%?NL2SE55D8Q-]V0!@"R''##(]ZZ/</6O
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M^A!N/_"@U+_Y(H#0^K=U&X5\I?\ #L']FO.#X"G!Z_\ (P:E_P#)%'_#K_\
M9K'_ #(-Q_X4&I?_ "10'H?5U)FOE(_\$P/V:UR?^$!N!CU\0:E_\D52M?\
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M-JQQJ H'H .E?*W_  ZX_9O_ .A)O/\ P?ZA_P#'Z/\ AUO^SA_T)-Y_X/\
M4/\ X_2Y5>]A\WF?5^W../>EV_A7R?\ \.M_V;_^A)O/_!]J'_Q^C_AUO^S?
M_P!"5>?^#[4/_C],D^L I!]J=7R=_P .M_V;^/\ BBKS_P ']_\ _'Z3_AUQ
M^S>/^9)O,=/^0_J'_P ?H'H?6=%?)G_#K?\ 9O\ ^A)O?_!]J'_Q^C_AUO\
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MA)O/_!_J'_Q^F(^L"M)Y9]*^4/\ AUO^S?\ ]"5>?^#[4/\ X_1_PZX_9O\
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M/@!_P48\5^%? ^G2:5H9^'$=X;62[FN#YKW\0+;I69NB 8S@?B: /O2BBB@
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MWQCH^AWNO6<>E7EK*5,T5M&V%)E^6V*\>4.02<-7L/\ ;G[*W]FO8?\ "P/
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M%^RX!"HS*<D@GCBM#Q)X9_8X\5P:'#?^,_ )31].CTBW\CQI%"7LH^$@E*7
M,J =GSUK;UZZ_9-\2>)-*UO4/'?@":ZTL6XM;=?&$*6B^1_J";=;@1,4Q\I*
MG''I1[6?;\$+V=/N_O9YAJG[6WQ=TVU\3>-3-X5D\&>&_B%-X0GT5;27[?>0
M"[$0D63S-JNJ.N!M.XJQ.!Q7)?"3XJ?$;X1ZWXEUC3)]"F\!ZM\;+[P_>Z9/
M;R-?.UU=!6F64,%78-F%VG)SDUUWPO\ AS^S)X=\8>(?%?B[XF?#CQ#XAN_%
MU[XDL)X_%<"10K)+YD DA\\(\D9+$$J<9XKU@:[^RM_9LE@?B!X!^RR>(_\
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ME3X,_M/2?"#]FWXHZ/X1UB/Q#+X#\46L&D7FKK*QETJ^O8Q&SJ^QR5$DZY.
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MAWJ5W>:!\0?!-B+B&6W^Q_\ ";QO:Q1RY\Q8X&N3'&#_ +*C':FISVLONO\
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MECX;^%?AOQ?I-W806_B*YLXK&ZUPM!!'',/,:24<, L2NV..169H/[35I:>
M=.UOQ/IUPEY<Q7M]Y>BVTMRATZWF:/\ M#! 98739(,_-AQ@-4&O_&;X$>)-
M4\+7EY\8O Q7P]<275O;CQ)I_ER2/;RV^77S,<),^ ,<GVQ7F.HVWP&O/#MK
MH5M^T3X;T[3%T >&KJ.#Q)IA:ZLE=F1"S,2F [(=N-RX!]:.9KH'(GN]>_\
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M#/'O^&/?@8?^:/\ @@?]R_:__&Z#^QW\#/\ HD'@?_PG[7_XBO8:*!;'C_\
MPQ[\#/\ HC_@?_PG[7_XBC_ACSX%_P#1'_ __A/VO_QNO8** /'_ /ACOX%_
M]$?\#_\ A/VO_P ;H_X8[^!?_1'_  /_ .$_:_\ QNO8** /'_\ ACOX%_\
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MEX=GU.WM6LGMKN2SFC\U98]Z8.Z.1>'0@@AAZ\BNV/TJ"SR'_ACWX&?]$?\
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M#D9?*Q<RZB_\,?\ P*'_ #1_P/\ ^$_:_P#QNE_X8^^!7_1'_ __ (3]K_\
M&ZG\/?&*^\8^)/"T.DZ3"^C:M8:C//<-=*9();6YB@8)@%74,[<CALJ1@#F#
M3_C]I=CX1L[_ %*&[,[6.FWO[P(LDUO<Q&0SX7@;%BN691V@;'49.4+^0?\
M#'OP*_Z(_P"!_P#PG[7_ .-T?\,>_ K_ *(_X'_\)^U_^-UO_#'XM6GQ,>_C
MM[%K1[6*"<_OTF0I*9 @+)P)!Y9W)DXR.3D5J>#]5N]2\1>-X+B8RPV.L);V
MRD8\N,V-K(5'_ Y'/XU(SC!^Q]\"CT^#_@?_ ,)^U_\ C='_  Q]\"O^B/\
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MGA1-/O;F&\NEDUF.22>6)U>)I)&E+MM9$(RQ QCIQ7KW]DV'3[';_P#?I?\
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MSG RY]36M_PN'P%_T._AS_P;6_\ \771_P!CV'_/E;_]^E_PH_L>P_Y\K?\
M[]+_ (4UH(YS_A</@+_H=_#G_@VM_P#XNC_A</@+_H=_#G_@VM__ (NNC_L>
MP_Y\K?\ []+_ (4?V/8?\^5O_P!^E_PI@<Y_PN'P%_T._AS_ ,&UO_\ %T?\
M+A\!?]#OX<_\&UO_ /%UT?\ 8]A_SY6__?I?\*/['L/^?*W_ ._2_P"% '.?
M\+A\!?\ 0[^'/_!M;_\ Q='_  N'P%_T._AS_P &UO\ _%UT?]CV'_/E;_\
M?I?\*/['L/\ GRM_^_2_X4 <Y_PN'P%_T._AS_P;6_\ \71_PN'P%_T._AS_
M ,&UO_\ %UT?]CV'_/E;_P#?I?\ "C^Q[#_GRM_^_2_X4 <Y_P +A\!?]#OX
M<_\ !M;_ /Q='_"X? 7_ $._AS_P;6__ ,771_V/8?\ /E;_ /?I?\*/['L/
M^?*W_P"_2_X4 <Y_PN'P%_T._AS_ ,&UO_\ %T?\+A\!?]#OX<_\&UO_ /%U
MT?\ 8]A_SY6__?I?\*/['L/^?*W_ ._2_P"% '.?\+A\!?\ 0[^'/_!M;_\
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M%GC54B4;R6/E@D\D5]&?V38?\^5O_P!^E_PH_LFP_P"?*W_[]+_A4^SZ7?\
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M>,<U<N=8^%5WJ.H7DOC31";^[M;^>$:]%Y;7%NT312A?,P&'D0@XZA!7I_\
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MG6TEW<2L<!(XT+,?P )KY"_9$^+4=Q\3+S3[KQ+)K-WXZTAO%+V<TSR?V;J
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M,@/GW3VS8G93G&S)**,=8RV2&6M[POXH\167BF/1O%4FFR-=:6=4BFL(7A2
MHZI-$V]VW >:F'^7/.0.*6'X#^![36I]2M?#EA9R3Z?+IDL=M;I&C0R$;\@#
MJ<$9ST-:'A/X;P^&;Y[RYU74->O/LBV$4VIM&QAMU.=B[$4')P6)!)P,DXI\
MWD%BQXP\6-IW@/5_$&@FWU9[*VDNHTB;S$F\L%F0%3U(# >Y%<!J7QTO8M<\
M8V-G:6DL5M9P_P#"/S%RPU"[81!D8C^ 27=HG&#EF]*]@BL8+:V-O!!'!!@C
MRXD"J,]>!]:\YT?]G_PYH6E^$=/MI;]H?#5W+=6QDE5FFWL7\N8[?F4/Y;#&
M#F&/G@Y.>W0.6^[+EM\:M!N?&7_"-1F:6]\^6R6:/RS&]S'$TDD*KOWY"HW)
M4+E2,YXK#\2?'K3[+PYJE\A;19M(O],34%U(Q$16US>1Q-)F-W493SL9.X%#
MD#BNAC^$.GPZQJ]W#?7D%IJAF>XL(UA";Y4VR.LGE^:I/+8#XR2<<XK(L?V>
M= M])U#3[RXNM4MKX:>D\=Q%;HACLYS-%'LCB5=I9B&R"6!-+G?\OXBY/[QH
M>/\ XD3:!\,XO$UH(M':XO+&W5]=B*I!'/=Q0F21 ZD820O@L",#..16'X:^
M.4MS9W<=SIL_B&\M7F<W7AV &">T3;BY59),[2Q= H9BQB<KD<UV?_"N[.7P
M?8^'9[V\N;.RNK:YBDGD#RD07*3Q1LQ'S*#&J<\E1R2>:C\4_#>+Q'JG]HVV
ML:EH=V]J;"XDTYHP;B#<6"-YB/C:2Q#+@C<W/-',ULOZ_/\ $?*GZ_U_6QD7
M?QFTN^T7Q5=Z3YSVVAZ<;Y]3\E)(,&W6=-J>8'?,;JPX4'D;L@XB'Q8NI-0\
M2VTVD76F0:/KMAI*7TBQS)=?:#:8"HLH923=8R> ,-@D%:FN_@?H]Y-J DO+
MU;2XT2;0(;6/R42UM)$165&$>YB!$NW>6"Y;'6M*\^&%E>:AJL[WU[]GU+4+
M/5)K0,GEBXMF@*.#MW<BVA##=C .,$YI\_D'+YF1JOQ\\,Z1:Z=+,+IYKY)
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MC_AS_P!"!X7_ /!-;?\ Q%=M14EG$_\ "C_AS_T('A?_ ,$UM_\ $4?\*/\
MAS_T('A?_P $UM_\17;44 <3_P */^'/_0@>%_\ P36W_P 11_PH_P"'/_0@
M>%__  36W_Q%=M10!Q/_  H_X<_]"!X7_P#!-;?_ !%'_"C_ (<_]"!X7_\
M!-;?_$5VU% '$_\ "C_AS_T('A?_ ,$UM_\ $4?\*/\ AS_T('A?_P $UM_\
M17;44 <3_P */^'/_0@>%_\ P36W_P 11_PH_P"'/_0@>%__  36W_Q%=M10
M!Q/_  H_X<_]"!X7_P#!-;?_ !%'_"C_ (<_]"!X7_\ !-;?_$5VU% '$_\
M"C_AS_T('A?_ ,$UM_\ $4?\*/\ AS_T('A?_P $UM_\17;44 <3_P */^'/
M_0@>%_\ P36W_P 11_PH_P"'/_0@>%__  36W_Q%=M10!Q/_  H_X<_]"!X7
M_P#!-;?_ !%'_"C_ (<_]"!X7_\ !-;?_$5VU% '#?\ "DOAQG'_  @'A?\
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MGQ_\??&GP_NOB"OA_P *:'<>%?A[-8V\R7%Y)'<WD,MM;R%(0%*HR"4X+9!
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M1_PY_P"A \+_ /@FMO\ XBNVHH XG_A1_P .?^A \+_^":V_^(H_X4?\.?\
MH0/"_P#X)K;_ .(KMJ* .)_X4?\ #G_H0/"__@FMO_B*/^%'_#G_ *$#PO\
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MF-BKDEP/E!!^;H>H)%(-#FO^%(_#G_H0/"__ ()K;_XBC_A2/PY_Z$#PN/\
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M((&F6,R-$)=NPR! S%0<_*WH:=F+F13_ .%)?#C_ *$#PO\ ^"6W_P#B*/\
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MK&-N1&3<RG:23DCG Q6Q_P *)^'W_0IZ;_WZ_P#KT?\ "B?A]_T*6F_]^O\
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M'0]%FTNV@3Q%-I=U%*\ZR^:\J1MYJ#:,*0-I).#FO:/^%$_#W_H4]-_[]?\
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M $*6F_\ ?K_Z]'_"A_A__P!"EIO_ 'Z_^O0!WM%<%_PH?X?_ /0I:;_WZ_\
MKT?\*'^'_P#T*6F_]^O_ *] '>T5P7_"A_A__P!"EIO_ 'Z_^O1_PH?X?_\
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M<;4[\:U_;+E+988RW]GFR$:J&)"[#NR23FK/_"A_A_\ ]"GIO_?K_P"O2?\
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M*D+PQ2/CH46:YP!WFS_"*W/^%$_#[_H4M-_[]?\ UZ/^%$_#[_H4M,_[]?\
MUZ=@YF/^&/PPA^&]M<Q1?V;*\J11&XL=+CLY)%C#;?-*$^8V68YX ).%&:[K
M;^%<'_PH?X?_ /0I:;_WZ_\ KT?\*'^'_P#T*6F_]^O_ *],D[VBN"_X4/\
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M,YQDM^]()]A7+V_[,=A#J@B_X2?6&\'KK9\1)X3(@^R"]\_[3GS/+\WRQ/\
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M/ . N3CBG-\4?#*QZ4T>I&Y74X_.MOLMO+-F/(4N^Q3Y:@L 6? !X-</X?\
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M*& W5A8M;R2I%NV>:6E?<?G8X&%!)P.:[TU-^P#J***8!1110 4444 %%%%
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M* .O_P"&B_A1_P!%.\&_^#^T_P#CE'_#1?PH_P"BG>#?_!_:?_'*Y#_AAWX
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MHOX4?]%.\&_^#^T_^.5P_P#PP;^SY_T27PW_ . Q_P :/^&#?V?/^B2^&_\
MP&/^- '<?\-%_"C_ **=X-_\']I_\<H_X:+^%'_13O!O_@_M/_CE</\ \,&_
ML^?]$E\-_P#@,?\ &D_X8._9[_Z)-X;_ / 8_P"- ';_ /#17PH_Z*=X-_\
M!_:?_'*7_AHGX4?]%/\ !O\ X/[3_P".5P__  P;^SY_T27PW_X#'_&D_P"&
M#_V>_P#HDWAL?]NQ_P :!'<?\-%?"C_HIW@W_P ']I_\<H_X:*^%'_13O!O_
M (/[3_XY7$?\,'_L]_\ 1)O#?_@,?\:/^&#?V?/^B2^&_P#P&/\ C0,[C_AH
MKX4<?\7.\&_^#^T_^.4?\-%?"CG_ (N=X-_\']I_\<KB/^&#?V?/^B2^&_\
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M &?.G_"IO#?_ (#'_&C_ (8/_9\Z_P#"IO#?_@,?\: .Z_X:+^%'_13O!O\
MX/[3_P".4?\ #1?PH_Z*=X-_\']I_P#'*X7_ (8/_9\_Z)-X;_\  8_XT?\
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M%.\&_P#A06G_ ,<H_P"&BOA1_P!%/\&_^#^T_P#CE<1_PP;^SY_T27PW_P"
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M<*<PM-A>"#@Y'%>M:?\ MQ?LCZ3K&G:K9>,]%M=2T[3QI-G=1:1=K)!9@J1
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MW[*/@/0;71/#GCO1]%TFU!$-G8Z3=Q1)DY.%$'<DGW-;9_X*3_LV?]%0L_\
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MYF_X>4?LV?\ 14+/_P %U[_\9H_X>4?LV?\ 14+/_P %U[_\9H ^F:*^9O\
MAY1^S9_T5"S_ /!=>_\ QFC_ (>4?LV?]%0L_P#P77O_ ,9H ^F:*^9O^'E'
M[-G_ $5"S_\ !=>__&:/^'E'[-G_ $5"S_\ !=>__&: /IFN'^,GC"_\ _#G
M5O$.GK$\NG&&>43J63R!,GGG (Y\KS,<\'%>/?\ #RC]FS_HJ%G_ ."Z]_\
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M/*/V;/\ HJ-G_P""Z]_^,T@/IFBOF?\ X>3?LV=?^%HV>/\ L'WO_P 9I/\
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MS9_T5"S_ /!=>_\ QFF!],T5\S?\/*/V;/\ HJ%G_P""Z]_^,T?\/*/V;/\
MHJ%G_P""Z]_^,T ?3-%?,W_#RC]FS_HJ%G_X+KW_ .,T?\/*/V;/^BH6?_@N
MO?\ XS0!],T5\S?\/*/V;/\ HJ%G_P""Z]_^,T?\/*/V;/\ HJ%G_P""Z]_^
M,T ?3-%?,W_#RC]FS_HJ%G_X+KW_ .,T?\/*/V;/^BH6?_@NO?\ XS0!],T5
M\S?\/*/V;/\ HJ%G_P""Z]_^,T?\/*/V;/\ HJ%G_P""Z]_^,T ?3-%?,W_#
MRC]FS_HJ%G_X+KW_ .,T?\/*/V;/^BH6?_@NO?\ XS0!],T5\S?\/*/V;/\
MHJ%G_P""Z]_^,T?\/*/V;/\ HJ%G_P""Z]_^,T ?3-%?,W_#RC]FS_HJ%G_X
M+KW_ .,T?\/*/V;/^BH6?_@NO?\ XS0!],T5\S?\/*/V;/\ HJ%G_P""Z]_^
M,T?\/*/V;/\ HJ%G_P""Z]_^,T ?3-%?,W_#RC]FS_HJ%G_X+KW_ .,T?\/*
M/V;/^BH6?_@NO?\ XS0!],T5\S?\/*/V;/\ HJ%G_P""Z]_^,T?\/*/V;/\
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MICE9@!;>:20,EI'/ Q7J?P_N+>SUOQC-X#L+/4O#A>R\B&RG2&T-SY;>>T3
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M .)KR#PO>ZJ8=+T]?$TNJ:M+XQUFS>2^A@DGT]1'J;0D ("@(2)AG^%L#Y6
MK'O?C5XQU9;"Y2XB\.:7++_9EW<S/# L&H00E[A!+.C)AI9#'R/^71\?>HLN
MX:]3W?\ X5KX/_Z%30__  70_P#Q-+_PK/PA_P!"IH?_ (+H?_B:L^#[R^U#
MPGHMSJDEK+J<UE"]T]BV^W,I12YC)ZINS@^E;E2,YK_A6?A#_H5-#_\ !=#_
M /$T?\*S\(?]"IH?_@NA_P#B:Z6B@#FO^%9^$/\ H5-#_P#!=#_\35S2/"&A
M^'[AI],T73].F9?+,EI:I$Q7(.TE0"1D _A6S2;AZT +1110 4444 8/@/\
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M-\/OB=J<.G>'/$4=[>W$+7-M#+;S6YN8E.&>+S442*,C)3/6K46]4B.8T/\
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M'_'[TIO_  FVL[0!\,O$H7.[ N-*Z_\ @;UKNMU&ZBR[#N<0OCK7%Y'PT\4
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M_P"B:^*/_ G2O_DZNMLY9+JVAFEMY+61T5S#,4+QDC)5MI9<CH=K$>A-6:*
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ML[1= T[PW8I8Z3I]KIEDA)6WLX5BC7/4A5 &36C1>^K ****8!1110 4444
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MZMH9!(D4K("RJRDA@#D9!(/K6Q4,,"6\*1Q1K'&BA510 % Z  =JFI@%%%%
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M_P#\ [+_ .2Z]4_"C\* /*_^%Y:E_P!$F\?_ /@'9?\ R71_PO+4O^B3>/\
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M_P#\ [+_ .2Z]4_"C\* /*_^%Y:E_P!$F\?_ /@'9?\ R71_PO+4O^B3>/\
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M_P#\ [+_ .2Z]4_"C\* /*_^%Y:E_P!$F\?_ /@'9?\ R71_PO+4O^B3>/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPB_Z)OX:_P#!;%_A1_PRY\(O^B;^&O\ P6Q?X5ZC10!Y=_PRY\(O^B;^&O\
MP6Q?X4?\,N?"+_HF_AK_ ,%L7^%>HT4 >7?\,N?"+_HF_AK_ ,%L7^%'_#+G
MPB_Z)OX:_P#!;%_A7J-% 'EW_#+GPB_Z)OX:_P#!;%_A1_PRY\(O^B;^&O\
MP6Q?X5ZC10!Y=_PRY\(O^B;^&O\ P6Q?X4?\,N?"+_HF_AK_ ,%L7^%>HT4
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MZDF4_B2.PKSG4/B]XQ\:>/?A_P"&$FTNQ@OK^RO[RXT;4)666VFL=1G6W+J
M0RFSW'!PP*=BU.RW;"[Z(^B2OB(=;G2Q_P!L)?\ XNDV^(?^?G2_^_$O_P 7
M7FWB3Q%>:M\8M5\/W7C"?P=I>DZ19ZC;+;FW0WLDLMPLCNTR-N2,0Q@JN/\
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M4OV>V4LJMY6P0O(9'4E,D0,0=K"BW<?-YH^E,>(>/])TOG_IA+_\71M\0_\
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M R,8HAA^DNX?=I:+J/WGT/4MOB+C_2-+YZ?N)?\ XNCR_$7_ #\:7_WXE_\
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M)'7H2*^;U^"?CW5-0TJ*Y2]LXHYE77[P:X^-;!U&WE\U K[D"P13#!VD"78
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M()?R3C)(R>I%8<G@'QQH\O@K2(Y[RSAU_4+ZPU*Q^VR3'3],%V]["/-!/S+
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M1RI&SO;J4!"82(DKD?=^E:NG^%]!T/3[NTL]*T_3[*XW/<PPV\<<4F1@EU
M.0.<]J\%T_POXCM?L^G3^%9M":^\>0ZI9>7-%(D5LL9DDSY+$1_) \?.,^<
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M52S.S'@  $DGL*YZ#XM>"[K0KC6HO%.DOI-O-';S7OVM/*BD=E5$=LX4LSJ
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M*,#.TGG@$UV'B?X::=XN\0Z%JU_<W9;1IEN+:V1D$7FJ3AS\I<'G!VL P #
MBN-N/V7_  G=^((]5ENM5=H]2;5$MS<(8DE-[]M('R;@OVC+X#<[BI)7 "Y[
M:<O]?>'(WKS?U]Q=3]H[P=YFHB5]0MTM([J5))K"55NQ;W"VTP@X_>%9I$3
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M>]<Y;_ '1;?6K6^.H:I-!:ZM/K5O822QF&&YFF>:0J=GF*IDD=BH;!W8.5
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MMVC''%;O@OX6VG@?4+Z]M=7U>^GU":2YO/MUR)%GF=($\QE"@9"VZA<8"AF
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MK )2T44P&%>V* F/QYI]% "=J6BB@!NVC%.HH ;CVHVTZB@!,44M% "44M%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.Q>HHHI@%%%% &#X#_Y$GP]_V#K?_P!%+6]6#X#_ .1)\/?]@ZW_ /12UO4
M9,GBW0XI"CZSIZ.#@JUR@/Y9IO\ PF&@_P#0;T[_ ,"X_P#&M(8]0.]/^II
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M:SMXYY&OGC:XD<;^&"PO;8!.,NV:25^I1[!_PF.@\_\ $[T[CK_I4?'ZT?\
M"8Z#_P!!O3O_  *C_P :\'U_]JZYF\ ?$'7/#7A&\NSX<TO4KNVNY[BW:%Y;
M1BK+/&DGF0\@NJN 71&Q@\5U/Q#_ &AE^&2V$FL^%KZ.T>UMKF^NVO+:-+8R
ML4\I T@,[H1EECS@$8R2 :Y'?EZD\ZM?H>G_ /"8:#Q_Q.].YY'^E1_XT?\
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M->5^(OVD-!U/X1_$;Q)X,O#=:WX4T6ZU)M/U2RGM98W6"22$R0RJC^6QC/S
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MP"J!(HXU Y^[R374>./ -KXZ^&FO>"[JZGMK'5]*GTF6XBQYJ1R1-$77(QN
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MZHGB"32VUC3X;&?_ (E\-S+$(F=D,,D@S&I+_,H^]C@KDFI_@K\)[WPWX_\
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MV>Q\T1_#'7O&OA?XQ:K;:'XU?4]4\$W7A[3I/&EW MW>RR1S-Y*0QJ J*S*
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M[7PWX9G\<PR>!?#]S;RVL5M8O#J5Q#;L&M[:>X$NTHI5 Q5 7"8/!.=3X?\
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MWS GN!BO8+?XJ>$[SQ58^'+;7+:ZUJ^M5OK>TM]TA>W9699<J" C!&PQ.#@
M=1GS[7OCOKP\:>+M&\->$K?Q!#X4DBCU& ZJ(=1N=UO'.3:VOE-Y@"2J 6=0
MS!E'3-'LY;-ASK>)I>(/@.-<L_$D/]L&$ZQXHL_$F[[.&\HP):KY7WOFS]F^
M]Q]_&.*BTWX,ZGX-T?PW/H>KI/K/ACP9/X:L?-M@5FF9;;RYV!< #=:KE<\[
MOO#%=ZWQ"\/1I<-)JD,?V?48M)F#9!2[E\ORX3Q]YO-CQ_OBN1O?VFOAII^H
M36,OBB$W<;S1^5%;SR%WB?9*B;4/F.C9W*N2 "2,#-/V<K]0YT;?CGP'<_$#
MPKI6FWUXMI=6VI:9JDTD<>]7>TNX;DH!D8#F';GMNSS7GOA/]EN'PMK-EJ"^
M();LV7B5]9M4DMP/(LQ:W5O!8*0WW(OM<K!N^<8YS76ZM^TA\-M#CLI+WQ;9
M117EI;W\4P5VC^S3DB&9F52$C<@@,Q XZU./V@/ 3^'9M;'B!/L,-[_9KJ;:
M83_:=@D\H0[/,+;&#X"_=.>G-$J<KA[1'"^ OV<?$FAZ!X(\->(_&MKK7A3P
MDUK+9Z;8:/\ 9)+B2V ^SF>5II-P1@KX55RR ^U>^8KAF^./@5(_#[?\))9N
MNO(TFF^668W*JRJ[  <!2P#$XV\YQ@XM>!/BWX2^)DEVGAK68]2>U2.611')
M&?+DSY<BAU&^-MK;77*G!P:.6<=6',GL=CN'K1N'K7EGQR^-B_!?_A"I)=*.
MHVNO:]%H]Q*LVS[%$T,LKW!X.X(L1)''&>:CF^."?\-#1?#"'2FF3^P9M8FU
M?SL(DB21+]GV8Y.R5')SP&7CFG;2XKZV/5MP-+NKY]\!_M#>*=;\.^"?%/B7
MP?I^E^%/%KVL-K>:=K#7<UK+<D"W$\;01X#.43*,V&<5] <'%&G1W'=]5J/H
MHHI#"BBB@ KF/B-X1N/'?@76_#L&HMI#:I;/:/>QIO>*-_E<J,C#;2V&SP3F
MNGHH \:L?V8?#.C:GK2:7YMGX?US0&T'4])DFEG69 2(9%>1V*&-'F7 X(D'
M3;S'X?\ V=IM'\,^#K"Z\3W&H:OHNM7&NWNLM;JDVH7$UO<PEB-Q"%1<C;]X
M 0J/<>TT5/+YE7/FGQ!^REK'C2UU&'6M>T6WN[C0[_16UC2-$-M>7WVFV:#S
M+PB7;*%W>9L  +@$$ 8KU'X:_#[6O!M[<R7\OAAH)(@@70M!.GR9!X+.9Y-P
MZ\8')ZUZ+14J-O\ AE_D',> ^*/V==>\1_$1/$4OB:WFMX=7;48([J&>22.)
M[5[=K=1YWE*%61F5@F20,]\V-0_9NNH_^$1O-)UZ&WU;PQINGV5DUS9%X)'M
M2XW2*) =KI(XV@@J2&!/2O=J*?*^XOD>,P_ _6E\ ZAI4VO6<^N7GB6#Q,UW
M]B9+=98[R&Y\H1^86V_NMN=V><]:S_$W[+L'B7P=:Z!)KKP);C52LT=OMR]Y
M<>>#@.#A&P.OS 'IFO=J*.5]PN>5_#/X1ZCX%TOQ+))J%I_;NL%<7=M'.\<.
MR/9&3Y\SNY!+-RPZX'J<GP+^S#HOPWUKP=J^@7UW!J.BVLUC?S7,TL_]IPRH
M#("KR%8V:9(Y25'52,<Y'M5%.S[A<\,D_9AM_*^*D,>MRB#QEI]SIUE"UN"F
MCQW'G/<;!N&\/-,TA!Q]U5Z 5#XZ_9XUGQM>36USK6CSZ7)/#-;WUWI&[5M,
M"! 5M;A9%V9*EE8J2I8_>KWFBER^8^;R/$? OP'UGP)XCGN[?4/#%Y93:U?:
ML99_#A_M$+=74MPT?VD7'5?-*!MG0#BH?BU\ ]>^(GBN75+;Q%!#:!]/GMK2
M]BGD6VDM9Q+A$29(R)"!EF4L,<=L>Z44*+C\+M]P-\WQ:GA/B+]F,:UX7TK2
MH]>^SRZ;+J-U!/\ 9 RF:YNA<H63?RJ.HR,_,,],UV7PY^'FM>'-<\5:[K^K
MV>HZGX@>W:2/3[-K>& 11>6H7<[,V0,Y)ZG%>B44[/N*Y\__  Z_9W\2_#OP
M78^&[/7?"T<5GHZZ1'JEKX7,5\56(1B5I#<LK/@;CE2">HK$US]D/4'\(KX/
MTCQ6(?"<-C>Z=9Z?>0S-]ECG(8,3',@G=&+@&4$;2O&02WTW7GGQS^),WPG^
M'=QXBMTL3(NH:?9;]2E:*VB%S>P6QED<#(5!-N/^[2Y6MG;[O\ARDY;GB*_!
MOQE?>+M+\*7ELR^$+;6KG6+O4$MT0OY^GSQ2>5+YS,099SM4QAE'4D*,]/X/
M_97GT1M.?4=;MIYM,?35M)H8;AG>*TN$F^;SKAPK.8T&$ 5<9 .>.BT#X_Z5
M8:#+J_BGQ)X<GTTW)MEU#P]+)<6L+B-I-DSG[K-M(7U.%^\0#N^)OCUX;\'M
M8_VQ#JFGP7$5M++=3:?*(+03N4B69\81BPP1DE?XL4^64K7=_P ">:R>GZ_D
M)>_!M;SX?^,O#(U0HOB*\N[LW(@S]G\]]V-N[YL9ZY&?:N0\6?LZZCXB76M)
MDUN%O".H:I+K;V4=L4OS</"4,8G+[0A?Y\E,X^7IS706O[2WA"X6]W#5;:>W
MAM+B.UN=+FCGNDN9'CMS"A7,GF,C 8'&#G'--NOVFO!UK:I)MU::58+NYN+6
M#3)GGM([9U2X\Y N4V%TX/7<",Y%5[.7<GF7;\&>7^#?A'X_\9:Y/KFN&/0-
M0TFRT:WTAKK3D5'FLY;EW\V)+ARRLLP&0ZC)^4?+SN:]^S#X@U?=>1>*+&RU
MZ]GN[F[U2ULIH9;66>1&W6S1S*VU511Y<I=&(W$=0?4/'7Q.B\)R^"9+>&.\
ML/$6IFS>XW$&.+[#<W0D48Y_X]P,'^]6)IW[2_@W4]/%U'_:J&:"UNK.WFTR
M99;^.Y8K"T"%<R;F4].@Y.!S4\LGJY6^X?,EHH_F4_CM\#M7^+RFWMO$"6.G
M3:5<Z;+:7"3-&KRXQ<!8I8P[ #&V3<O0XZYPM4_9CN[R"WOH=<M_[=BU5]4;
M,4\-NQDLH;61#Y,R2#_4JP;?QT([U[3X3\567C#0X=4L%GCAD>2(Q74#P2QO
M&[(Z.C $,&5ASZ9Z5Y5J'QTU_4?%EYIWAKPTNJ6=G-Y4C.[!V'VB6V#L0#Y:
M--!,JMA^$+,%7!HUOK(;=NAT-O\ !B&U^'/A3PLEZD8T._L]1::.$A)I(+@3
MMA2Y*AF!ZLQ&>2>M<)XH_97&O>)?$-S+J23Z%JE[-J<EFQN/M*S/!Y>R,^>(
M%&[Y@YCW ?+TYK0N/VDKRSFT;5KGP[%:>$M6F6&U>:]_XF<J?9_.>X6V"$>4
MA#(WSY&PMC&!4=E^T!XNU*XT^R'@O3]/O-2TZ+7(;B]UK;:6NGLKEGN7\G*2
M*512JJRYE4[L T_9^8<S[')>#O@WXU^(6J7]YXM*Z#';:?HMC:-)IT0,K65Q
M<2L&B$TBD$2("=VTDG"X'/3>'_V<=?T?POJ&EGQ)9KNO='O+.Q@M[@V-LUC=
M+<,RQR3.R>=M"E8V5%VC:O7,G_#3&J+I/A769?"<%KI&M26-NGVG5 ES<S7$
MWE%;.(1GSUC!60L2FY#D 8-==\??BU?_  G\,VESHNC+X@UZ]G9+73&F,1D2
M*)YYVS@\B*)@.Q<H.]'++^:U^VP<UEHCSN+]C\R6NIZ9/KL+Z8T%]#8R&"XD
MGB-TY8EP\YC^56*_(B;LY..0=#7OV3XO$'BK6Y;G58V\/:M?2ZE-;LMP;F.6
M2 Q%4_?>2 &^<-Y6X=/>NB\5?'Q=)\2>#+32;2#5-*\206MU%>^85Q'-=6T*
MLH Y&VXW<^GI61\5/V@;OP+\3-3\,)J?A#1(+'1+35Q/XFU![9KEIIKN,I&%
M!X46JDGD_/THY7M?^ON#G?3^OQ.E^&_PL\1>&_%T>O>(=?L-5FM]%BT."'3]
M/-LOEQOO\UR9&)=NX& .U5?"/P.O?#.MWNHG7D$S1ZU!:-;6VUXDO[X78<DL
M06C8E>!@X!P.E5= _:2L;NUTTZOIEY9ZIJ&EV&H)H5G:RW5[$T\,DLBLJKR$
M"?>X]P"0#'I7[4WAW4]<9%M[^3P_/8:7?VNJ0V4LB!+UY4C,WR_NQN11SZGT
M.#E?\WY"YO[IR>B_LK^)-)UNWUT>*=/DUFTAL3#)-:7,XDGM7F(>4RW#,PD2
MXE! *A3L*],$OOV3=7O+R[U5O$]G/K.I-?"_WVES%;!+F59/W<<5RI)0@CYV
M8.",@8Y[/P_^TYX?U"WA-WI.M65]->7\ LDL9+B5(;6Z-L\[A <)N R.2O(Y
M"DUI?';XL7/PJM/";6\VCV?]N:S_ &8]]KUPT%K;*+2YN-[,!U)MPH]WHY9/
M[5_N_1!S=5']#'T3]FVWT+0=.TF'6CY-CHNN:/'BUQ\NHW,4V_&[_EGY07'?
M.<C&*Y^?]F#79O$FEWTGBN"Z@TZ^2X@-W!</(L/V-K5H57S_ "D 5V8%4R3C
M)ZYO>#?VK-)O+'51K<<=[<:?=3(+SPJDNH6EQ:Q1PO)=JP3(C1IO+;/\2,!G
M!QWND?'+PMKWB"YTNPFNKE+?<)-32TD-BK+$)F7S\;01&P;DX_$4W3DMF+VB
M>Z.+UG]ENQU>W\)R#5FM]8\*Z%#I6CZDEN-UM<1/$Z7(7=@Y\K:R'[RNXSS6
MI\*_@MK'P_\ &U_K%QKUJVFSPW"'3=-MY;>">269)!</$TKQHZA67]TJ!M[$
M]@)_^&G?!0L6NW;580PM7MH9-+G66\CN)/+@D@0KND5WP!@9Y&0,BM*'X_>#
MY=)MM3>\FMK:73KK5)/.MW#V\5O*L,JR* 2KB1M@3DDJP .*.27<?M#$D^!N
MJ2>*)/\ B>6O_"*MX@_X27[(;-OM@N=G^K\[?M\O?\^=N['RYQS7?_#?P?\
M\*_^'_AKPPMS]L.C:;;:<+K9L,OE1JF[;DXSMSC)QFN1_P"&BO"Q B6#6&UD
MW/V;^PUTR8W^X1B7=Y.W.S80=W3)QG=Q70_"3Q]_PL[X=Z-XG^SBU744:5(O
MFX4.RCA@".%Z$9I6?5_D/FOTL=I1113 P? ?_(D^'O\ L'6__HI:WJP? ?\
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MJ\:^.7[+_A?XX7%MJD\UUX>\5V0'V37M+?9<1XS@/_>4'GL1C@COT5O^T!X
MO-/NKV'Q#%)!;^22%@FWRB5BL31)LW2J[ A6C# X.#6;:_M*^!+S5M2M$O[H
M0V5G:7AO/L,QBE^T2RQ)''A-S2!X6!3&<Y&,JV+IRJ4I<T'9DRY9*S/$K']E
M/XV^(;VXT?QC\9[J3P;]P#3)G^V3Q]E?<BA<C@_,_P"-?1_PN^$/AGX.>&(M
M"\+:>ME9K\TDC'=-.^,%Y'ZLQ ^@[ #BKDOQ0\,P^#XO%3:HG]AS;5CN%C<L
M[,XC5!&%WERY"[=N[/&*SK'XX>"=2NM(MK;7(Y;G5O.^R0>3*)&\F3RYMRE<
MIL?Y6W@;3UQ6M6O6K+EEMY:?D1&G".IVX7:?:G8-<IX-^*GA;X@37,6@:O'J
M$MO&DS*(WC+1.2$E3>HWQL5;#KE3C@U'>?%WPAINF1:A=:Y;P6<L=U*DTBNH
M9;=]DYZ?PMQCN>F:Y>5WM8UYH]SK^]&<]*\ZN/V@_ %KI\-Y+X@6..1I5*-;
M3B6+RMOF-)'LWQJN],LX"C<O/(JIXA_:"\*:1XHTGP]9WJ:IJE]J4.FM'#N\
MN)Y$W_ZW:4+!"K% V[# XHY)=4',CT^EKS'6OCMHGAWXB:WX:U..:QMM)TRT
MU"XU*6*4H[W,TD44,2B,^8Q,9^ZQ))P 2&VZVF?&SP7K%]HUE9:Y'<WFK>;]
MDMHX93(_EOLD#+MRA1R%;>!@D9I\K[!S*]CN<U3U;38=8TR[L+@9M[J)H9!T
M.U@0?YUR>I_&+PKI^O7F@_VK'+K=N)!]D5'PTJ0F8PB3&PR>6-VS=N YQBN=
M\,_M%^&M4\+V&M:K<+I*W\R06UK'YEU+)(UK'<F/:D>2X1S\H!&!G-'++L',
MC \'^#_BUH.C>%/!3RZ-9Z%H,MM#+XDMKMWNK^RM\;(?LS1;8WD5$21MY&"Y
M7DC'/3?LJZM)8GQ+_;US_P +$_X2C_A*!G4I_P"R_-^T8\OR<8Q]C_T?=MSC
MFO3/^&@/!JL\KZO;OI\L%K-9S6HEGEN1,LKC$*(6X6%SQG@'.,5:'QZ\$75T
MMGI^N0ZA=30^;;""-S#.?L_VA46;;Y98Q?/MW9V\XJ?9U.[_ "*4H+9',?#/
M]FGPSX7U'4]=USP]HVH>)[CQ#J.LPZF(?,DC6:[EEA(+#AU5QR!P1P3UK"^%
M?[.OB/PK\79O&&L^)M1OHPVJ,L$ES'(LOVBY58]X$0Z6UM:YYSN&!P#GTY?B
MYH6G_#O0/&&N7*Z+I^K06LD:R!I&$DZ*T<0VC)8YV@ <GI4VF_&3P=J]E+=V
MFMQ20PVEQ>RYCD5HHH'V3%U*@J48@%2 WM2]G+I<.==5_P  9\2/!>H>.+CP
MM9QS0QZ+:ZQ%J&JQR,V^>*%7DAC0 8/^D"W8Y(&U&Z]*\\NOAY\0]2^-$OB'
M6-*\/>(=!M]0C;2/M6LW$9TNV"JK21VHMS&]QDRMO9\\@!E KKK_ /:0^'6G
MZHVF2^(U;4%D\K[-#:3RNTGEB38 B'<VPA]HR=O., U>/QV\!_:=+A7Q';2'
M48H9H)(T=XMDS%8B\@4K'O8%5WE<D8'-5[.9/-$X#P7\'/%FE^(O".F:BNFK
MX5\'ZUJ.LV-]!<LUQ>&X2ZCAB>$H GEI>2!FWMN**0!DXU?$GP1U/Q!I/QBL
MA>VML_C&ZBNM.E&YA;M'8VT*&1<#_EK;DG!/RFNG_P"%^> O^)C_ ,5!%_H!
MQ(3#*!(?-\G$1V?OOWF$_=[OF('4TDWQ_P# -O;6%P_B&(17ID"8AE+1^7((
MY/-4)F$*Y"DR!<'@U/LY6L/VD3@KKX8>-_$-[XF\5ZOX?\*W.N7\>DVD'AZ_
MG>[LWM[&:>4EIC$-DK/<R%&V-LV)D'FIM-^">O7/PE^+6CSP:7H>K>./MLEM
MIMC,TEGIS36,=LJ[]BDY:/S'94'S.V!W/N=S=PV=K+<32".&-"[N>@4#)/Y5
MY_8_M#?#[4]-NK^V\1Q26MO%;S%C!,K2).VV%HE*!I0[#"[ V3Q24&]45S+8
ME^+5A-%\!_&%BJ--<KX=NX0L:DEF%LXX ]Z=X_\  =QXP\1?#V^0V_V/0=6F
MOKR&Y!S+$^G7=KM48.3ON$)!P, \]C%H_P </"_B3Q?H?A_29[J_GU:RN[Z&
MXCM)!"@MI8XI8Y&*C9(&DQM."-I#8)7-;_AH#PA;ZAXBM+V>\L)=&U4:/(LM
MC,6N)S;I<$0JJ%I $<D[1P%+'@@FN1[6)YCG_@?\"]5^$_B[QR;G48-1\,:@
MEG::%;MN::TLXO.;[/)N&"J&<JAR?D4 ]*B\+_!77OA_\ ;3P9X>CT%-3M+J
M2=K.X@#6%Y"UV\KV[@H2H>-BF[:2IP1G%=CXT^,V@>#_  AH?B?[0E_H6K7E
MK;0WMNQ9-LY^1Q@$M_N@9.:9<?M > +72K74)/$40MK@S ;8)6DC\H@3&6,)
MNB"$@,7"A<C/6E[.3\RN='D^F_L\>(;GPK\5[*TT70_ =OXK\.2:/9^'=*OI
M)[%+IHYU-V_[I%C)\Q%(C3E4R<G %GQE\!_''QPTW3]-\;R:)X:T_1K.?^SE
MT.ZEO96OGMV@CN':2*(!8U=SL .XL,D8KVW5/B5X:T77-*T:\U6*/4M4B:>S
M@57?S8U*AI,J" HW+EB0!N%85K^T!X!OM/N[V'Q#"T%J(2W[B4/*LK;(FB0I
MNE5V&%:,,&/0FCDF^KL',M[?F<E<>$OB5\1K_P ,:?XQT[0-&T71=1M]4N[G
M2[^2XDU&:W;?"L<;1)Y*>8J.=S,?EVCKNKD]9_8YTG6/AGXUL9] \,S>-M:U
MC5-2M=<FLU:6-;B_EN(=TICWAECD53C.", XYKU6;]H;X?0:+;:JWB*-K"X-
MP%FCMIGVBW?9.SJJ$QK&YVLS@ '@FK=]\<O ^G3ZO#/KT7FZ3+'!>+'#+)Y<
MLFW9&-JG<[;UPBY8YZ4.E.6X*:CM^IE_&?X/P?%S_A"+/4+>RO=(T?75U._M
M+T$K-$MI<Q!5 ')WRQG!P, \]CD>-/V:_#&LV/@C1=)\-:':>&=(\1'6=0TN
M2T7R;I?L=S#G9M(=]\T9RW9#ST%3>$_VHO WBBZN8&U1+&2/4&L(Q(DA!_>>
M6CR'8!"'D#(!)@EE(ZBM2T^/7A?6/B)I'A'1[G^T[N^:[5YXE=8XS;@[]K%=
MLN&&TE&.#UINF^PE4MLRGXV^!]M>:;X,TSPC:V'A73M%US^TY(M/B6W"*;>>
M(F)40KOW3*W(QQSFN8_9O_9_\0?"K5KW6/$&OWFI7EWI=G:26[W"21><&EGG
M;B-2?W]S-M.>C$]QCTZZ^+OA&R\5/X<GUF.+54=HFC>*01"18C,T9EV^7O$8
M+E=V=H)Q5KP3\2_#?Q#AN9?#^I"^6WV&0&&2(A7!*.!(JDJP!(8<'!P3BIY)
M+WM;#YT]&>)?'#]G_P 1?$#QCX@O['2M"U8ZMIMO8Z7K.J7+QW7AF:-Y&-Q;
M*(VR=SI(-K(2R#)QBK4_P6\9>,O'FE7_ (FLM!M'TU+^UNO%&F3L+[6+&:":
M&*VDB\M0BKYD<C9=ANA7;U..ZL?VA_!<DR6M]K%O9ZAYXA>"-994BW7#V\1D
MD$85 [QE06P,\5KWGQN\$:?I]A>W'B"%+?4()+FU_=R,TJ)+'"V$"[MWFRQI
MMQN+-@ FG[*?](7M(GAO@G]F3Q!H^GM92^'/".DQV/A&X\-;8'DFA\03.8=E
MQ>($1@H\@\;G<>?)AO7OO@'\%[[P#XF\5>)M3L+?1[W6K>RL5L(-4GU-DBMO
M.8/)<3@,[,T[ #&%5$'K753?'[P#;VMA</XAB$=Z9 F()2T?ER".0RJ$S"%<
MA29 N#P:S9/VB/#$/B#6-.G>33XM&U&73KZ[U*-[= T=F+IGBRA$@VG'!'0G
MH5W"I3C_ ,,'M%+^F>K9HW#UKSN/X_\ @2;39KV+6VDCAO!I[P+97!N!<>4)
M?+\D1^9N\L[_ +O"Y)X%9C?M%>%KGQ!_9=A*]PHM],O5U"9'BLY(+V21(F24
MH0Q'EYQP.>ORMC3DEV)YD<#>_LDV4O@SQ;+%HWAX?$&^\07VN:9X@:#;/"SW
MS7$&Z<)YBLJE5.,XQCD5] ::VKR7VHK?P6D5DDB"R>WF9Y'3RU+&0%0%8/O
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MUOM:G35_[0TRRU^ZTNWMGOK[[6HCFB3=(B$E75@-^ PQTKV;Q9\;M&\)>-M
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M5)(P.>*@TKXT:/KWPYUGQC8P7$5CIMS>6LB:I'):9>VG>%SDJ2%W(3D XZ$
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M6;: ,Y8] *W["^CU*QM[J$.(IXUE3S$9&VL,C*L 0?8C-6:5@;N%%%%,1@^
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M/F?8K-^R3K<DLEZWBR">]N(KBR:VN/MTEK:VT@BQ'#_I0D8*T;MMD=E/G,,
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M&U\96.GZC?6-_=:]9^$]+_LVT:ZG@S;175U=I$BLS2+#--C@C]RG')J/P_\
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M\QY /L*ZW7/%6O?#/5?'FEVWB2^\06/AS2=/\1K)J!22XB!GF$]HSJHW+)%
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M^07\CCY?V<=4L]#M=.TWQ0IA74?MMS!<0S10W"FTCM]K^3,CG'E!\;L')!'
M-><1_ ?QUX-M],\$Z2%U/2;BXT&6_P!5%D@BQ8W$1+*QGW1'R8(\J4?+9VD;
MN-CX::GXCM_ _P #]9N?&NM:M>^/+.V@U2RO)HWYFTV2X>X@P@:-HW0'.2N&
M((S@BSI\FO\ A&U^+/B(^,?$&J)X,UM8[>SO[E)(I+1+.RN9HV78,LPFF4-G
M(W#THZW3?X!:75+[_P#@'6Z_^S*FN>%]/TC^W6MWL'U.:*X6U##S;NY^T*Q7
M=R$;;D9^8 ],UG>(OV>?$/BFZO-:U'6]&E\17=W',[1V,\$,,<<!AC,+QSK-
M'(-[,7#X;.TC !KWF\M_[0T^>#SI+?SHRGFP-M=,C&5/8CM7RM<7'B[PS?>+
M;C2_%VMZM>:7X\TS0+*TU:]4VS6\T6GR.)=L>>3<2Y(YP< <"DER[-KY?YAK
MT2^9M7G[)NO+:Q+:>-T?570B379K.2._BD,-O$TT<D4R9),&XQR;HR6'R_+S
MZI\6OASJOCZ'1(].UE+&.RN'EN;6?SA%=JT3(-QADC8[2P8#=M/.1TQY;JW[
M4OB*PN)-'B\+V]WK]@-0DO4MUN[BWD6VG\I1$8H'93)C.7 5.Y-=#\=O%VMW
M6D?"A]#37K4^(M<$5U8:5-#;7LD)TJ^N/*+3$*A5XHV;)'W"*=O[WY"U>G*1
M>$?V8Y=!\"W/A^ZU^*>:?3M*TTW%O9E%5+&9W1@I<\NK@$9PIR><XK3\#? S
M6O"GB/PM+=>(K.[T'PM'>6^F6D.GM'<21SX $TAD()0 #*J-W4\UCZM\5M:^
M$NF^$].N-(U":Y\1WC:=:KXEU."2Z@NFD01O,T3,OD;6.2I)#&-<'>M'C3]I
MBY\%>/KG3IM,M[[0;>ZFLI;BS%Q),CQ6,ETVY_*\D-^Z9/+#E^0?:CE_O!=K
M[)6L_@GXO\0:QXH@OM8MM$\.W'BU]=MDCLMUZS1I'Y+++YFT)YB*YRF[Y2O0
MY%/2?V7?$>G37%R_B;3Y[V6+1P9)+>YE,LNGWRW:N[23NQ$GSJ57 7Y<=\OU
M3]ICQ-X7FELM7\-Z<=1NK/2;K3AIMS/=)_ITT\8654B+_NQ Q^16W=L9X<O[
M2'C"]M9X[/PG9PW]CINIZE=MJ<MQ:QR+9R1*!$KPB3]XLH(W*-I!!S@9MQE;
MX_R_R&G+^0C'[(+VVLW,L.O0W.GZE.DNHPW4-P&PMS)-B-4G6,Y60)^\5L%=
MPZXKH_$7[-)UCP0= AUP0.MEKMJDS6N5SJ+N^2H8<(7'&?FQVS7L>AZHFM:+
MI^H*AC2[@CG",<E0RA@/PS6C6?*^X[E33XKF.RMUNWCDNEC42O""J%\#=M!)
M(&?4U;HHJQ!1110!@^ _^1)\/?\ 8.M__12UO5@^ _\ D2?#W_8.M_\ T4M;
MU '.6OA_PY>:C-<V]G8SWEKJ+7DDD85GCO#!Y1=L=)/)?;SSM-<O<?!/X;>)
M))3_ &#I]SY!2WDCMI61$>)MZ!E1@-Z%L@D;ER,8KYY^+-SXU\/ZUX]@T6U\
M1Z=/-=:CJ6FW-@;J.&XF%K9I"%2"%C*X96PLC+'][.[!VNTN^\7VFL:W>^&G
M\4IXQU'Q(;RSTVZM)XM*GL)+:,R2.&01@9#?,2'W@#@<5G>C>Q5JV]M#ZCU+
MX8^$]8TK^S+O0+&:R"W"+"T0POGL6FQW!=N21SWKAO%O[,WAC5K55T18]!NF
MNA=7%PT;71N&$31Y<NX;=M8#<&&X#:VY<"O(],F\::Y'IMCH.L>-WL+E='&N
M76H1317%M=M=*+I8C(@V#RC)O"91,)C%7_$&L>)_^%TV^GPR>*(='.L'2+J.
M2>]D5[-K!T24;(A$B-.4(E+M(7/)49 /W7]?\.'[WL>S:!\ ? NDZ3X9M?[)
MAOWT*RM;*UNIC\TD< !A,@7"OM;+#<" 6) %=0O@/PTL:I_8MD%6&ZMP/)'^
MJN7#W"_21@I;U(YKY)\"W7BO1/ OA>PM[CQA9ZS9Z)H<7A_3U@N3;32\"]2Z
MW*1\K[E<2D!(U!3'6M^\/Q%\.V^@1_VQKT^I>.M3U'P_-'=7!W:63=R/!=0J
M<;!'90W)!Q\Q\KFC]R_^&_K_ (<7[Q'O\OPK\!V7B>TU.31M/AUB8E8-S%1(
MRP[,K%G:SB)<;MI8*.N*O:A\+_">K:?%97.AVK6T,-O;QJ@,9CC@D62!592"
M CJK+@\$5Y]^TBGB6#2]!;PU<ZI:-&;P7%[IEH]U) /L<H1]B_,</CH<\#&3
M3?@SKGB;4/A/XH:&#4)=9LY[F/2Y=5GFG6Z;[/&\;1-/''*8O,<K^]4D%6&2
M,&BU/:VH^:>]]#T+QE\+_"GQ FMI?$.BVVIRVZ/#&TQ8$QOC?&V"-\;;5)1L
MJ<#CBJT?P?\ !5IKT>M)X?LHK^,*JO@B,-Y8A5O+SL+;/D#8SCC-?-&J>(?$
MZ6>A+I&K>.+G1Y5@/B.?5H[RW,-V8)CLCDCA:= 9 N]8U\L$1 $!F!35?#?C
M?Q-X?M=0\7:CXIN(-/D\+7$<-K]HMD?_ (F>;F9XT4.SK"L;-D?*1DJO9WH]
M?Z_$+5DM-CW-?AC\'](T\P2:;X>BM;Y9(T^T3JP9(T='2-G8X6-7<;5P$RV
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M]LVF3"SE2>>2X*;9_,<LHPS>89 W.-P7[O\ K0+U.O\ F>U:#X1\,WWB^_\
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M/BK2VFL8IY[E3.%$20MMF8D\?(>&],C/6JTGQZ^'<.GP7TOC#2DMII7B5FG
M(9 I<,#RNT.A)8  .I[BN U[]F2XUCPKI>E0ZS!;SZ?)JMQ'(;8LCRW5V+E
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M4O\ %110 E-_0T45+TV#<DI:**H HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ;VH
M%%%1L[ &*.]%%, XJ/J3S]:**JR8KV']\9I:**D!FT9-2+115=!BT444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183360232720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 14, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXAGEN INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-0434866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1261 Liberty Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Vista<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(760)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">560-1501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">XGN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,235,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain information required to be disclosed in Part III of this report is incorporated by reference from the registrant's definitive Proxy Statement for the 2024 Annual Meeting of Stockholders, which proxy statement will be filed not later than 120 days after the end of the fiscal year covered by this Form 10-K.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001274737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183255358432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">BDO USA, P.C.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Diego, California<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">243<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183337400096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 36,493<span></span>
</td>
<td class="nump">$ 62,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">6,551<span></span>
</td>
<td class="nump">6,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,797<span></span>
</td>
<td class="nump">4,143<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">47,841<span></span>
</td>
<td class="nump">72,611<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">5,201<span></span>
</td>
<td class="nump">8,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">3,286<span></span>
</td>
<td class="nump">4,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">616<span></span>
</td>
<td class="nump">528<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">56,944<span></span>
</td>
<td class="nump">86,221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,131<span></span>
</td>
<td class="nump">3,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">976<span></span>
</td>
<td class="nump">1,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Borrowings-current portion</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">7,531<span></span>
</td>
<td class="nump">5,347<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">11,902<span></span>
</td>
<td class="nump">9,623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Borrowings-non-current portion, net of discounts and debt issuance costs</a></td>
<td class="nump">19,231<span></span>
</td>
<td class="nump">28,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">2,760<span></span>
</td>
<td class="nump">4,493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">357<span></span>
</td>
<td class="nump">867<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">34,250<span></span>
</td>
<td class="nump">43,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value per share; 10,000,000 shares authorized, no shares issued or outstanding at December 31, 2023 and December 31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value per share; 200,000,000 shares authorized at December 31, 2023 and December 31, 2022; 17,045,954 and 16,549,984 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">301,893<span></span>
</td>
<td class="nump">297,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(279,216)<span></span>
</td>
<td class="num">(255,527)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">22,694<span></span>
</td>
<td class="nump">42,460<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 56,944<span></span>
</td>
<td class="nump">$ 86,221<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183337334720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">17,045,954<span></span>
</td>
<td class="nump">16,549,984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">17,045,954<span></span>
</td>
<td class="nump">16,549,984<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183341936848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 52,548<span></span>
</td>
<td class="nump">$ 45,563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs of revenue</a></td>
<td class="nump">23,092<span></span>
</td>
<td class="nump">24,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">47,428<span></span>
</td>
<td class="nump">52,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">4,865<span></span>
</td>
<td class="nump">9,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,506<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">75,385<span></span>
</td>
<td class="nump">91,614<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(22,837)<span></span>
</td>
<td class="num">(46,051)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(2,335)<span></span>
</td>
<td class="num">(2,448)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">1,516<span></span>
</td>
<td class="nump">830<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Loss before income taxes</a></td>
<td class="num">(23,656)<span></span>
</td>
<td class="num">(47,669)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense) benefit</a></td>
<td class="num">(33)<span></span>
</td>
<td class="nump">282<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (23,689)<span></span>
</td>
<td class="num">$ (47,387)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (1.34)<span></span>
</td>
<td class="num">$ (2.77)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (1.34)<span></span>
</td>
<td class="num">$ (2.77)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares used to compute net loss per share, basic (in shares)</a></td>
<td class="nump">17,679,467<span></span>
</td>
<td class="nump">17,082,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares used to compute net loss per share, diluted (in shares)</a></td>
<td class="nump">17,679,467<span></span>
</td>
<td class="nump">17,082,348<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183255081056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,164,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 84,936<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 293,060<span></span>
</td>
<td class="num">$ (208,140)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares', window );">Issuance of stock from vested restricted stock units and payment of employees' taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue', window );">Issuance of stock from vested restricted stock units and payment of employees' taxes</a></td>
<td class="num">(239)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(239)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock under Employee Stock Purchase Plan</a></td>
<td class="nump">385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">4,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (47,387)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47,387)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">16,549,984<span></span>
</td>
<td class="nump">16,549,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 42,460<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">297,970<span></span>
</td>
<td class="num">(255,527)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Issuance of stock from vested restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">93,335<span></span>
</td>
<td class="nump">93,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock under Employee Stock Purchase Plan</a></td>
<td class="nump">279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (23,689)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,689)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">17,045,954<span></span>
</td>
<td class="nump">17,045,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 22,694<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 301,893<span></span>
</td>
<td class="num">$ (279,216)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Stock From Vested Restricted Stock Units And Payment Of Employees Taxes, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Stock From Vested Restricted Stock Units And Payment Of Employees Taxes, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183361786160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (23,689)<span></span>
</td>
<td class="num">$ (47,387)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,168<span></span>
</td>
<td class="nump">1,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="nump">363<span></span>
</td>
<td class="nump">551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(306)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposal of assets</a></td>
<td class="nump">189<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_GainLossOnDispositionOfLeaseAssignment', window );">Loss on lease assignment</a></td>
<td class="nump">1,470<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_NonCashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">939<span></span>
</td>
<td class="nump">967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Long-lived assets impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">3,617<span></span>
</td>
<td class="nump">4,704<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(474)<span></span>
</td>
<td class="nump">3,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(654)<span></span>
</td>
<td class="num">(505)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="num">(101)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(1,010)<span></span>
</td>
<td class="num">(854)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="nump">2,497<span></span>
</td>
<td class="num">(1,402)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(14,462)<span></span>
</td>
<td class="num">(32,144)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(828)<span></span>
</td>
<td class="num">(4,318)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from disposal of property and equipment</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(804)<span></span>
</td>
<td class="num">(4,318)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments of taxes withheld on vested restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(239)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from common stock issued under Employee Stock Purchase Plan</a></td>
<td class="nump">279<span></span>
</td>
<td class="nump">385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Principal payment on finance lease obligations</a></td>
<td class="num">(697)<span></span>
</td>
<td class="num">(667)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Principal payment on note payable obligations</a></td>
<td class="num">(241)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal payment on long-term debt</a></td>
<td class="num">(10,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(10,632)<span></span>
</td>
<td class="num">(489)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="num">(25,898)<span></span>
</td>
<td class="num">(36,951)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of year</a></td>
<td class="nump">62,591<span></span>
</td>
<td class="nump">99,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of year</a></td>
<td class="nump">36,693<span></span>
</td>
<td class="nump">62,591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest expense</a></td>
<td class="nump">1,737<span></span>
</td>
<td class="nump">1,732<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of non-cash items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Equipment purchased under finance lease obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">741<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_EquipmentPurchasedUnderNotesPayableObligations', window );">Equipment purchased under notes payable obligations</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Costs incurred, but not paid, in connection with capital expenditures</a></td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">$ 182<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_EquipmentPurchasedUnderNotesPayableObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equipment Purchased Under Notes Payable Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_EquipmentPurchasedUnderNotesPayableObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_GainLossOnDispositionOfLeaseAssignment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on Disposition of Lease Assignment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_GainLossOnDispositionOfLeaseAssignment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Prepaid Expense and Current Other Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_NonCashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Lease Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_NonCashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183252597520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization</a></td>
<td class="text">Organization<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Description of Business</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Exagen Inc. (the Company) is a commercial-stage diagnostics company which exists to provide clarity in autoimmune disease decision making with the goal of improving patients' clinical outcomes.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Liquidity</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has incurred recurring losses and negative cash flows from operating activities since inception. The Company anticipates that it will continue to incur net losses into the foreseeable future. At December&#160;31, 2023, the Company had cash and cash equivalents of $36.5 million and had an accumulated deficit of $279.2 million. Since inception, the Company has financed its operations primarily through a combination of equity financings, debt financing arrangements, and revenue from sales of the Company's products. Based on the Company's current business plan, management believes that its existing capital resources will be sufficient to fund the Company's obligations for at least twelve months following the issuance of these financial statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To execute its business plans, the Company may need additional funding to support its continuing operations and pursue its growth strategy. Until such time as the Company can achieve significant cash flows from operations, if ever, it expects to finance its operations through the sale of its stock, debt financings or other strategic transactions. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its programs, product portfolio expansion plans or commercialization efforts, which could have a material adverse effect on the Company's business, operating results and financial condition and the Company's ability to achieve its intended business objectives.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 250<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//250/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183250247888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Basis of Presentation and Use of Estimates</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of the accompanying financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Significant estimates and assumptions made in the accompanying financial statements include, but are not limited to revenue recognition, the estimated incremental borrowing rate for the determination of the Company's operating lease right-of-use (ROU) assets and the recoverability of its long-lived assets and net deferred tax assets (and related valuation allowance). The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Concentration of Credit Risk and Other Risk and Uncertainties</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its cash or cash equivalents.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Significant payors and customers are those which represent more than 10% of the Company's total revenue or accounts receivable balance at each respective balance sheet date. For each significant payor and customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accounts Receivable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the years ended December&#160;31, 2023 and 2022, approximately 88% and 84%, respectively, of the Company's revenue was related to the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is dependent on key suppliers for certain laboratory materials. For each of the years ended December&#160;31, 2023 and 2022, approximately 96% of the Company's diagnostic testing supplies were purchased from two suppliers. An interruption in the supply of these materials would impact the Company's ability to perform testing services.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Disaggregation of Revenue</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table includes the Company's revenues as disaggregated by payor and customer category (in&#160;thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Client(1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other(2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52,548&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,563&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes hospitals, other laboratories, etc.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes patient self-pay.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company considers all highly-liquid investments purchased with a remaining maturity date of three months or less upon acquisition to be cash equivalents. These investments are stated at cost, which approximates fair value.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has an arrangement with a financial institution with which it has an existing banking relationship, whereby in exchange for the issuance of corporate credit cards, the Company agreed to obtain a certificate of deposit with this financial institution in the amount of $0.2 million as collateral for the balances borrowed on these cards. The Company has classified the value of this certificate of deposit (including all interest earned thereon) within other assets in the accompanying balance sheets. The Company has the right to terminate the credit card program at any time. Upon termination of the credit card program and repayment of all outstanding balances owed, the Company may redeem the certificate of deposit (and all interest earned thereon).</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash, cash equivalents and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,493&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,391&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,693&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,591&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Property and Equipment</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment are stated at cost, net of depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between <span style="-sec-ix-hidden:f-288">three</span> and five years. Leasehold improvements are amortized on a straight-line basis over the lesser of the estimated useful life or the remaining term of the related lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operating expenses in the statements of operations in the period realized.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Long-lived Assets</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s long-lived assets are comprised principally of its property and equipment and operating lease assets. The Company amortizes all finite lived intangible assets over their respective estimated useful lives. Operating lease assets are amortized over the term of the leases. In considering whether long-lived assets are impaired, the Company combines its intangible assets and other long-lived assets into groupings, a determination which is made principally on the basis of whether the assets are specific to a particular test offered or technology being developed. If the Company identifies a change in the circumstances related to its long-lived assets that indicates the carrying value of any such asset may not be recoverable, the Company will perform an impairment analysis. A long-lived asset is deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset&#8217;s carrying amount. Management&#8217;s estimates of future cash flows are impacted by projected test volume and levels of reimbursement, as well as expectations related to the future cost structure of the entity. Any required impairment loss would be measured as the amount by which the asset&#8217;s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Goodwill</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company operates in a single operating segment and reporting unit for the measurement of goodwill. Goodwill was reviewed for impairment annually (during the fourth quarter) or more frequently if indicators of impairment existed. The Company would first assess qualitative factors to determine whether it was more likely than not that the fair value of the reporting unit was less than its carrying amount as a basis for determining whether it was necessary to perform a quantitative assessment. If, after assessing qualitative factors, the Company determined it was not more likely than not that the fair value of a reporting unit was less than its carrying amount, then performing a quantitative assessment was unnecessary. If deemed necessary, a quantitative assessment compared the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeded its carrying amount, goodwill was not considered impaired; otherwise, an impairment loss was recorded.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Leases</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company categorizes leases at their commencement as either operating or finance leases. The Company recognizes operating lease ROU assets and operating lease liabilities for each lease arrangement identified. Lease liabilities are recorded at the present value of future lease payments discounted using the Company's incremental borrowing rate for the lease established at the commencement date. The incremental borrowing rate is the rate of interest the Company would have to pay to borrow, on a collateralized basis over a similar term and in a similar economic environment, an amount equal to the total lease payments. The Company primarily considers industry data, its credit rating and the lease term to determine its incremental borrowing rate. ROU assets are measured at the amount of the lease liability plus any initial direct costs, less any lease incentives received before commencement. Lease expense is recognized as a single lease cost over the lease term on a straight-line basis. The Company has elected not to apply the recognition requirements to short-term leases and not to separate non-lease components from lease components for its leases.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Clinical Studies</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, the Company engages in efforts to scientifically measure and document the application and efficacy of its various testing products. These arrangements typically require the Company to pay a fee to a third-party scientific investigator (usually a physician or research institution) for each subject enrolled in a clinical study, and the Company accrues expenses based on estimated progress of services performed, including actual level of subjects enrolled and progress of the clinical studies. Payments made prior to the completion of clinical study services are capitalized as a prepaid expense. The prepaid amounts are expensed as the related goods are delivered or the services are performed, or when it is no longer expected that the goods will be delivered or the </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">services rendered. Expenses associated with clinical study activities are recorded in research and development expenses in the accompanying statement of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue Recognition</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (each, a payor) consist of commercial payors (healthcare insurers), government payors (primarily Medicare and Medicaid), client payors (i.e., hospitals, other laboratories, etc.) and patient self-pay. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes revenue in accordance with Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (ASC 606) and follows a five-step process to determine the amount and timing of revenue recognized: (1) identify the contract with the customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to performance obligations in the contract, and (5) recognize revenue when (or as) the performance obligation is satisfied. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Payors are generally billed at the Company's list price, unless a separate pricing contract is in place. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions. Adjustments are recorded in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, are recorded upon settlement. Included in revenues for the years ended December&#160;31, 2023 and 2022 was a net revenue increase of $3.4 million and a net revenue decrease of $2.4 million, respectively, associated with changes in estimated variable consideration related to performance obligations satisfied in previous periods. The transaction price is estimated using an expected value method on a portfolio basis.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Variable consideration is included in the transaction price only to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainties with respect to the amount are resolved. The Company's portfolios are grouped per payor (i.e. each individual commercial payor, Medicare, Medicaid, client payors, patient self-pay, etc.) and per test. Consideration may be constrained and excluded from the transaction price in situations where there is no contractually agreed upon reimbursement coverage or in absence of a predictable pattern and history of collectability with a payor. Accordingly, in such situations revenues are recognized on the basis of actual cash collections. Additionally, from time to time, the Company may issue refunds to payors for overpayments or amounts billed in error. Any refunds are accounted for as reductions in revenues in the statement of operations as an element of variable consideration. The estimated expected refunds are accrued as a liability on the Company&#8217;s balance sheet.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information, along with any requested medical or other claims-related information to the healthcare insurers. This generally occurs within 30 to 90 days of billing, however, the amount and timing of any reimbursements or collections for our billed tests may vary by payor and other circumstances. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounts Receivable and Allowance for Credit Losses</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We accrue an allowance for credit losses against our accounts receivable based on management&#8217;s current estimate of amounts that will not be collected. Management&#8217;s estimates are typically based on historical loss information adjusted for current conditions. We generally do not perform evaluations of the financial condition of our customers and generally do not require collateral. The allowance for credit losses was zero as of December&#160;31, 2023. There was no allowance for credit losses recognized as of December 31, 2022. Adjustments for implicit price concessions attributable to variable consideration, as discussed above, are incorporated into the measurement of the accounts receivable balances and are not part of the allowance for credit losses.  Accounts receivable was $6.6 million, $6.1 million, $9.7 million for the years ended December&#160;31, 2023, 2022 and 2021, respectively.  </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Research and Development</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense; materials; laboratory supplies; consulting costs; costs associated with setting up and conducting clinical studies; depreciation; amortization and allocated overhead, including rent and utilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Advertising and Marketing Costs</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $1.5 million and $3.0 million for the years ended December&#160;31, 2023 and 2022, respectively, and are included in selling, general and administrative expenses in the accompanying statements of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Shipping and Handling Costs</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs incurred for shipping and handling are included in costs of revenue in the accompanying statements of operations and were approximately $2.5 million and $2.7 million for the years ended December&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Stock-Based Compensation</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The fair value of stock options and purchases under the Company's 2019 Employee Stock Purchase Plan (ESPP) rights is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The BSM option pricing model incorporates various inputs, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. Volatility is based on the Company's historical calculated volatility since being publicly traded. The weighted-average expected term of options was calculated using the simplified method, as we have concluded that our stock option exercise history does not provide a reasonable basis upon which to estimate the expected term. The risk-free interest rate for periods within the contractual term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is zero, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of each restricted stock unit (RSU) is determined on the grant date using the closing price of the Company's common stock on that date. The Company's RSUs generally vest in equal annual installments over four years from the date of grant or, for grants to new hires, date of hire. Vesting of RSUs is subject to the holder's continued service with the Company. The Company issues new shares to satisfy RSUs upon vesting.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Comprehensive Loss</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Income Taxes</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized as an expense in the period that includes the enactment date. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would adjust the deferred tax asset valuation allowance, which would reduce the provision for income taxes. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company records uncertain tax positions on the basis of a two-step process whereby (i) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Net Loss Per Share</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. The weighted-average number of shares used to compute basic and diluted shares includes shares issuable upon the exercise of pre-funded warrants at a nominal price. Potentially dilutive common stock equivalents are comprised of warrants for the purchase of common stock, stock options, RSUs outstanding under the Company's 2019 Incentive Award Plan (the 2019 Plan) and shares of the Company's common stock pursuant to the ESPP. For each of the years ended December&#160;31, 2023 and 2022, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as the inclusion of the potentially dilutive securities would be antidilutive.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409,108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409,108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">986,819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,387,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,036,208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,828,086&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,925,262&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Segment Reporting</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent Accounting Pronouncements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012 (JOBS Act), the Company meets the definition of an emerging growth company. The Company has elected to use the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Unless otherwise discussed, Accounting Standards Updates (ASU) not included in the Company&#8217;s disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on the Company&#8217;s financial statements or disclosures.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2023, the FASB issued ASU No. 2023-07, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (ASU 2023-07), which requires public entities to disclose significant segment expenses that are regularly provided to the Chief Operating Decision Maker (CODM) and details of how the CODM uses financial reporting to assess the performance of a segment. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. This ASU will likely result in additional required disclosure when adopted. The Company is currently evaluating the provisions of this ASU and the impact on its financial statements and related disclosures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In December 2023, the FASB issued ASU 2023-09,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"> Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> (ASU 2023-09), which requires additional income tax disclosures in the rate reconciliation table for federal, state and foreign income taxes, in addition to more details about the reconciling items in some categories </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">when items meet a certain quantitative threshold. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 with early adoption permitted. The Company is currently evaluating the impact of this standard, but does not expect that it will have a material impact on its financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Recently Adopted Accounting Standards</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which requires the measurement of expected credit losses (based on historical experience, current conditions and reasonable forecasts) for financial instruments (such as accounts receivable) held at the reporting date which are carried at amortized cost. The main objective of this ASU is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. In November 2018, the FASB issued ASU 2018-19, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Codification Improvements to Topic 326, Financing Instruments-Credit Losses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which included an amendment of the effective date for nonpublic entities. The Company adopted this pronouncement on January 1, 2023. The adoption did not have material impact on its financial statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in ASU 2020-06 are effective for smaller reporting companies as defined by the SEC for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. The Company early adopted ASU 2020-06 as of January 1, 2023. The adoption did not have an impact on its financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183250256016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock', window );">Other Financial Information</a></td>
<td class="text">Other Financial Information<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Prepaid Expenses and Other Current Assets</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diagnostic&#160;testing&#160;supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid product royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid maintenance and insurance contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,797&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,143&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Property and Equipment</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment consist of the following (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture&#160;and&#160;fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,970&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,321&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,769)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,201&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,197&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Depreciation and amortization expense for the years ended December&#160;31, 2023 and 2022, was approximately $2.2 million and $1.6 million, respectively. At December&#160;31, 2023 and 2022, the gross book value of assets under finance leases was $2.5 million and $2.8 million, respectively, and is classified in "Laboratory equipment" in the table above.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Loss on Lease Assignment</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 24, 2023, the Company entered into an assignment and assumption (the Assignment and Assumption Agreement) of the Company&#8217;s previously executed lease agreement with Liberty Vista, LP (formerly known as Geiger Court, LLC) and Mindera Corporation (Mindera), pursuant to which the Company assigned to Mindera the lease of a building located adjacent to the Company's headquarters in Vista, CA. Under the terms of the Assignment and Assumption Agreement, Mindera assumed all obligations under the lease, effective October 31, 2023. As a result of the lease assignment, the Company derecognized the remaining balances related to the associated operating lease ROU asset of $0.7&#160;million, operating lease liability of $0.8&#160;million and leasehold improvements of $1.6&#160;million, resulting in a $1.5&#160;million loss on lease assignment. The loss was classified within selling, general and administrative expenses in the accompanying statements of operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Impairment of Long-Lived Assets and Goodwill</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December 31, 2022, the Company recorded an impairment charge of $0.4&#160;million related to previously capitalized equipment used in research and development activities that were halted in the fourth quarter of 2022. The impairment charge was classified within research and development expenses in the accompanying statements of operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December 31, 2022, the Company also determined that a sustained decrease in its market capitalization constituted an indicator of impairment of goodwill and as a result, instead of performing a qualitative test, the Company chose to proceed directly to performing a quantitative test during the fourth quarter. The Company determined the fair value of the reporting unit using the discounted cash flow (DCF) method, which is considered a Level 3 measurement. In applying the DCF method, cash flows are estimated for a five-year financial forecast developed by management. A terminal value, which represents the value of additional cash flows into perpetuity, is also calculated. Cash flows are then discounted to present value at a discount rate commensurate with their risk. Based on this analysis, the carrying value of the reporting unit was in excess of the fair value and the goodwill was fully impaired. During the year ended December 31, 2022, the Company recorded a goodwill impairment charge of $5.5&#160;million.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents details of the Company's goodwill for the year ended December 31, 2022 (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,506&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Goodwill impairment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,506)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued and Other Current Liabilities</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued and other current liabilities consist of the following (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued&#160;payroll&#160;and&#160;related&#160;expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,738&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued purchases of goods and services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued clinical study activity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-387"><span style="-sec-ix-hidden:f-388">Finance lease obligations, current portion</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Refund liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,531&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,347&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183250265088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Borrowings</a></td>
<td class="text">Borrowings<div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">2017 Term Loan</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2017, the Company executed a term loan agreement (the 2017 Term Loan) with Innovatus Life Sciences Lending Fund I, LP (Innovatus), as amended (the Amended Loan Agreement), pursuant to which the Company borrowed $25.0&#160;million. At December&#160;31, 2023, no additional amounts remained available to borrow under the Amended Loan Agreement. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 28, 2023, the Company entered into the Amended Loan Agreement. The Amended Loan Agreement was treated as a modification. In connection with the Amended Loan Agreement, the Company repaid $10.0&#160;million of the principal balance outstanding, for which the prepayment premium was waived. Pursuant to the Amended Loan Agreement, the interest rate on all borrowings under the Amended Loan Agreement is the sum (the Basic Rate) of (a) the greater of 8.0% or The Wall Street Journal prime rate (the Prime Rate), plus (b) 2.0%, which is paid-in-kind in the form of additional term loans (PIK Loans). Under the Amended Loan Agreement, an amount equal to 1.5% of the Basic Rate will be payable in-kind and capitalized to the principal amount of the outstanding term loan on a monthly basis until April 1, 2026, after which interest is scheduled to accrue at the Basic Rate. The maturity date of the loan was extended to December 31, 2026. The Company estimated the effective interest rate of this loan to be approximately 11.0% and 8.5% as of December&#160;31, 2023 and 2022, respectively. Accrued interest is due and payable monthly, unless the Company elects to pay paid-in-kind interest. The outstanding principal and accrued interest under the Amended Loan Agreement is to be repaid in ten equal monthly installments commencing in April 2026. Upon repayment of the final installment under the Amended Loan Agreement, the Company is required to pay an additional fee of $1.0&#160;million. This obligation is being accreted into interest expense over the term of the loan using the effective interest method. For the years ended December&#160;31, 2023 and 2022, the Company issued PIK Loans totaling $0.4 million and $0.6 million, respectively. At December&#160;31, 2023, $18.2 million in principal and PIK loans are outstanding, all of which is included in borrowings-non-current portion on the accompanying balance sheet.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Amended Loan Agreement currently requires a prepayment premium of 1% of the aggregate outstanding principal for any prepayments made prior to November 1, 2024.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Loan Agreement is collateralized by a first priority security interest in substantially all of the Company's assets, including intellectual property. The affirmative covenants of the Amended Loan Agreement require that the Company timely file taxes, maintain good standing and government compliance, maintain liability and other insurance, provide prompt notification of significant corporate events, and furnish audited financial statements within 150 days of fiscal year end without qualification as to the scope of the audit or as to going concern and without any other similar qualification.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The affirmative covenants require that the Company achieve a specified level of revenue, as measured quarterly on a rolling twelve-month basis, however the Company is not required to comply with the revenue covenant for any quarter during which it maintains a minimum aggregate cash balance equal to fifty percent of the aggregate principal amount of the Amended Loan Agreement (excluding any capitalized interest paid-in-kind) at all times during such quarter. The consequences of failing to achieve the performance covenants, when applicable, will be cured if, (i) within thirty days of failing to achieve the performance covenant, the Company submits a new Board approved financial plan to Innovatus under which the Company is expected to break even on a cash flow basis prior to the maturity date, and (ii) within thirty days of the submission of such financial plan, the Company issues additional equity securities or subordinated debt with net proceeds sufficient to fund any cash flow deficiency generated from operations, as defined in the Amended Loan Agreement. The Amended Loan Agreement requires that the Company maintain certain levels of minimum liquidity and maintains an unrestricted cash balance of $2.0 million.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The negative covenants provide, among other things, that without the prior consent of Innovatus, subject to certain exceptions, the Company may not dispose of certain assets, engage in certain business combinations or acquisitions, incur additional indebtedness or encumber any of the Company's property, pay dividends on the Company's capital stock or make prohibited investments. The Amended Loan Agreement provides that an event of default will occur if, among other triggers, (i)&#160;the Company defaults in the payment of any amount payable under the agreement when due, (ii)&#160;there occurs any circumstance(s) that could reasonably be expected to result in a material adverse effect on the Company's business, operations or condition, or on the Company's ability to perform its obligations under the agreement, (iii)&#160;the Company becomes insolvent, (iv)&#160;the Company undergoes a change in control or (v)&#160;the Company breaches any negative covenants or certain affirmative covenants in the agreement or, subject to a cure period, otherwise neglects to perform or observe any material item in the agreement.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023, the Company was in compliance with all covenants of the Amended Loan Agreement. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon an event of default in any of the Amended Loan Agreement covenants, the repayment of the 2017 Term Loan may be accelerated, and the applicable interest rate will be increased by 4.0% until the default is cured. Although repayment of the 2017 Term Loan can be accelerated under certain circumstances, the Company believes acceleration of this loan is not probable as of the date of these financial statements. Accordingly, the Company has reflected the amounts of the Third Loan Amendment due beyond twelve months of the balance sheet date as non-current.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">2022 Equipment Notes Payable</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2022, the Company purchased laboratory equipment using notes payable. At December&#160;31, 2023, the total notes payable balance related to this financed equipment was $0.8&#160;million, with $0.3&#160;million classified within borrowings-current portion and $0.5&#160;million within borrowings-non-current portion, net of discounts and debt issuance costs in the accompanying balance sheets. At December 31, 2022, the total notes payable balance related to this financed equipment was $0.8&#160;million, with $0.2&#160;million classified within borrowings-current portion and $0.6&#160;million within borrowings-non-current portion, net of discounts and debt issuance costs in the accompanying balance sheets. The financed equipment is subject to a 5.28% effective interest rate and will mature on October 1, 2026.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Future Minimum Payments on Outstanding Borrowings</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2023, future minimum aggregate payments, including interest, for outstanding borrowings are as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,949&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,166&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,558)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total borrowings, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,495&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Borrowings-current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(264)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings-non-current portion, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,231&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183252388016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Leases</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Operating Leases</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company leases office and laboratory space located in Vista, California. The lease expires in April 2027, with an option to extend portions of the lease for additional 5-year periods. The Company has not included the optional renewal periods in the measurement of the lease liability, because it is not reasonably certain that the Company will exercise these renewal options. The Company's payments under the lease are subject to escalation clauses.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company leases additional office space in Carlsbad, California, under a sub-lease which commenced in October 2021 and expires in April 2027. Monthly base rent under the sub-lease agreement is $70,042. The monthly base rent increases by approximately 3% annually, each October 1, through the remainder of the lease term.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Finance Leases</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has entered into various finance lease agreements to obtain laboratory equipment. The terms of the Company's finance leases generally range from <span style="-sec-ix-hidden:f-440">three</span> to five years and are typically secured by the underlying equipment. The portion of the future payments designated as principal repayments were classified as finance lease liabilities on the Company's balance sheet.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Operating and Finance Leases Balances and Costs</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating and finance leases consist of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.786%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Balance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-445">Property and equipment, net</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-450">Accrued and other current liabilities</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-455"><span style="-sec-ix-hidden:f-456">Other non-current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs associated with the Company's leases were included in the statements of operations as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease cost</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">679</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest on finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,147&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,299&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(1) Includes variable lease cost of $129,000 and $165,000 for the years ended December&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Supplemental cash flow information on leases is as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash out flows from operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,405&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash out flows from interest paid on finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financing cash out flows from finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Information regarding the weighted-average lease term and weighted average discount rate are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.06</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.94</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Future payments under operating and finance leases as of December&#160;31, 2023 are as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">997&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(541)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,736&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(976)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(490)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease obligations, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,760&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Leases</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Operating Leases</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company leases office and laboratory space located in Vista, California. The lease expires in April 2027, with an option to extend portions of the lease for additional 5-year periods. The Company has not included the optional renewal periods in the measurement of the lease liability, because it is not reasonably certain that the Company will exercise these renewal options. The Company's payments under the lease are subject to escalation clauses.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company leases additional office space in Carlsbad, California, under a sub-lease which commenced in October 2021 and expires in April 2027. Monthly base rent under the sub-lease agreement is $70,042. The monthly base rent increases by approximately 3% annually, each October 1, through the remainder of the lease term.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Finance Leases</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has entered into various finance lease agreements to obtain laboratory equipment. The terms of the Company's finance leases generally range from <span style="-sec-ix-hidden:f-440">three</span> to five years and are typically secured by the underlying equipment. The portion of the future payments designated as principal repayments were classified as finance lease liabilities on the Company's balance sheet.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Operating and Finance Leases Balances and Costs</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating and finance leases consist of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.786%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Balance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-445">Property and equipment, net</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-450">Accrued and other current liabilities</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-455"><span style="-sec-ix-hidden:f-456">Other non-current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs associated with the Company's leases were included in the statements of operations as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease cost</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">679</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest on finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,147&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,299&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(1) Includes variable lease cost of $129,000 and $165,000 for the years ended December&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Supplemental cash flow information on leases is as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash out flows from operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,405&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash out flows from interest paid on finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financing cash out flows from finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Information regarding the weighted-average lease term and weighted average discount rate are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.06</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.94</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Future payments under operating and finance leases as of December&#160;31, 2023 are as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">997&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(541)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,736&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(976)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(490)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease obligations, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,760&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183251426224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Acquisition-related liabilities</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the acquisition of the medical diagnostics division of Royalty Pharma Collection Trust (Royalty Pharma) (formerly known as Cypress Bioscience, Inc.) in 2010, the Company had royalty payment obligations of 2.5% on net sales of products which incorporate certain acquired technologies through December 31, 2023. These obligations no longer exist for products sold after December 31, 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Licensing Agreements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has licensed technology for use in its diagnostic tests. In addition to the milestone payments required by these agreements, individual license agreements generally provide for ongoing royalty payments ranging from 1.5% to 7.0% on net sales of products which incorporate licensed technology, as defined in such agreements. Royalties are accrued when incurred and recorded in costs of revenue in the accompanying statements of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Supply Agreements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2021, the Company amended a supply agreement with one supplier for reagents which includes minimum annual purchase commitments of $8.0 million and $9.2 million for the years ended December 31, 2024 and 2025, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Collaboration Obligations</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2021, the Company entered into a master research collaboration agreement with Allegheny Health Network Research Institute (AHN), pursuant to which the Company is required to pay AHN a collaboration fee of $0.4 million per year. Collaboration expenses under the master research collaboration agreement were $0.3 million for each of the years ended December&#160;31, 2023 and 2022. Collaboration expenses under the AHN collaboration are included in research and development expenses in the accompanying statements of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Contingencies</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications; including for subpoenas and other civil investigative demands, from governmental agencies, Medicare or Medicaid and managed care organizations reviewing billing practices or requesting comment on allegations of billing irregularities that are brought to their attention through billing audits or third parties. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made or that the Company believes to be immaterial. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Litigation</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, the Company may be subject to various legal proceedings that arise in the ordinary course of business activities. The Company does not believe the outcome of any such matters as of December&#160;31, 2023 will have a material effect on its financial position or results of operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2023, the Company resolved an investigation with the U.S. Attorney&#8217;s Office for the District of Massachusetts that was initiated by a </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">lawsuit. Pursuant to a Settlement Agreement, the Company made a single lump-sum remittance to the government in the amount of $0.7&#160;million in connection with specimen processing arrangements that Exagen historically had with physicians. The U.S. Attorney&#8217;s Office dismissed this &#8220;covered conduct&#8221; in the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">lawsuit with prejudice, while non-covered conduct was dismissed without prejudice. In November 2023 the complaint was unsealed and served on Exagen. Exagen filed a motion to dismiss the complaint. In December 2023, the Company's insurance carrier provided reimbursement for certain defense costs the Company incurred in the October 2023 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">qui tam </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">lawsuit. In February 2024, the relator filed a motion for leave to amend the complaint. Exagen opposed this motion, and all motions are still pending. The Company intends to vigorously defend against the claims being asserted in the complaint.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's participation in federal healthcare programs is not affected by the Settlement Agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183251426224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The carrying values of the Company's cash, cash equivalents and restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued and other current liabilities approximate their fair values due to their short-term nature and are considered to be Level 1 measurements. The estimated fair value of the Company's long-term borrowings is determined by Level 2 inputs and based primarily on quoted market prices for the same or similar issues. As of December&#160;31, 2023, the Amended Loan Agreement had a carrying value of $18.7 million and a fair value of $19.7 million. As of December 31, 2022, the 2017 Term Loan had a carrying value of $28.3&#160;million and a fair value of $26.9&#160;million. The estimated fair value of the Amended Loan Agreement was determined based on a discounted cash flow approach using available market information on discount and borrowing rates with similar terms, maturities, and credit ratings. The carrying value of the Company's other long-term borrowing as of December&#160;31, 2023 was $0.8&#160;million, which approximated its fair value.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The three-levels of the valuation hierarchy for disclosure of fair value measurements are defined as follows:</span></div><div style="margin-top:9pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 1 -&#160;&#160;&#160;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:9pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 2 -&#160;&#160;&#160;&#160;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span></div><div style="margin-top:9pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 3 -&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.432%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,386&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,386&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certificate of deposit, included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59,538&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59,538&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of the Company's money market funds is based on quoted market prices.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183250131072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Common Stock</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Shelf Registration Statement</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On November 17, 2023, the Company filed a registration statement on Form S-3, as amended (the 2023 Shelf Registration Statement), covering the offering, from time to time, of up to $150.0 million of common stock, preferred stock, debt securities, warrants and units. The 2023 Shelf Registration Statement became effective on November 29, 2023, and all $150.0&#160;million remain available for sale as of December&#160;31, 2023.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">At The Market Sales Agreement</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 15, 2022, the Company entered into a sales agreement, as amended on November 17, 2023 (the Sales Agreement) with Cowen and Company, LLC as sales agent, pursuant to which the Company may offer and sell, from time to time, shares of Company common stock having an aggregate offering price of up to $50.0&#160;million. The Company is not obligated to sell any shares of Company common stock in the offering. As of December&#160;31, 2023, the Company has not sold any shares of its common stock pursuant to the Sales Agreement</span><span style="color:#008080;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Outstanding Warrants</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following equity classified warrants to purchase common stock were outstanding as of December&#160;31, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.788%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237,169</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67,086</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83,778</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,944</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants (Exchange Warrants)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">804,951</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 22, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">None</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,214,059</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">No warrants to purchase common stock were exercised during the years ended December&#160;31, 2023 and 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183255579008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Option Plan</a></td>
<td class="text">Stock Option Plan<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">2019 Incentive Award Plan</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2019, the Company's board of directors adopted, and the Company's stockholders approved, the 2019 Plan. Under the 2019 Plan, which expires in September 2029, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. The options generally expire ten years after the date of grant and are exercisable to the extent vested. Vesting is established by the Company's board of directors and is generally four years from the date of grant or, for grants to new hires, date of hire. The 2019 Plan contains an "evergreen provision" that allows annual increases in the number of shares available for issuance on the first day of each calendar year through January 1, 2029 in an amount equal to the lesser of: (i) 4% of the outstanding capital stock on each December 31st, or (ii) such lesser amount determined by the Company's board of directors. As of December&#160;31, 2023, 1,831,107 shares of common stock remained available for future awards. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the evergreen provision, on January 1, 2024, an additional 681,838 shares of common stock became available for issuance under the 2019 Plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Restricted Stock Units</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">RSU activity under the Company's 2019 Plan is set forth below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,036,208&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,487&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">857,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards released</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(273,319)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(232,730)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,387,459&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2023, all of the outstanding RSUs are unvested. The fair value of RSUs vested in the years ended December&#160;31, 2023 and 2022 was $0.6 million and $0.7&#160;million, respectively. The weighted average grant date fair value for RSUs granted during the years ended December&#160;31, 2023 and 2022 was $2.39 and $5.89, respectively. As of December&#160;31, 2023, total unrecognized compensation cost related to RSUs was $4.4 million, which is expected to be recognized over a remaining weighted-average vesting period of 2.8 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Stock Options</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock option activity under the Company's 2019 Plan is set forth below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,235&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.09</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(93,335)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43,895)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(370,686)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">986,819&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.44</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest, December&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">986,819&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.44</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options exercisable, December&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">877,937&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The weighted-average grant date fair value per share of options granted during the years ended December&#160;31, 2023 and 2022 was $2.17 and $2.74, respectively. The aggregate intrinsic value of options exercised during the years ended December&#160;31, 2023 and 2022 was $0.2 million and $0.6 million, respectively. The intrinsic value is calculated as the difference between the fair value of the Company's common stock and the exercise price of the stock options. The fair value of the Company's common stock was $1.99 and $2.40 per share at December&#160;31, 2023 and 2022, respectively. As of December&#160;31, 2023, total unrecognized compensation cost related to option awards was $0.3 million, which is expected to be recognized over a remaining weighted-average vesting period of 0.8 years.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">2019 Employee Stock Purchase Plan</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2019, the Company's board of directors adopted, and the Company's stockholders approved, the ESPP. The ESPP became effective on the day the ESPP was adopted by the Company's board of directors. The ESPP permits participants to purchase common stock through payroll deductions of up to 20% of their eligible compensation. The number of shares of common stock available for issuance under the ESPP will be annually increased on the first day of each calendar year during the term of the ESPP through January 1, 2029 in an amount equal to the lesser of (i) 1% of the outstanding capital stock on each December 31st, or (ii) such lesser amount determined by the Company's board of directors. During the year ended December&#160;31, 2023, the Company issued 129,593 shares of common stock pursuant to scheduled purchases under the ESPP. As of December&#160;31, 2023, 449,332 shares of common stock remained available for issuance. Pursuant to the evergreen provision, on January 1, 2024, an additional 170,460 shares became available for issuance under the ESPP.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock-based compensation expense related to the ESPP for each of the years ended December&#160;31, 2023 and 2022 was less than $0.1 million. As of December&#160;31, 2023, total unrecognized compensation cost related to stock purchase rights granted under the ESPP was less than $0.1 million, which is expected to be recognized over a remaining weighted-average vesting period of 0.2 years.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Stock-Based Compensation Expense</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total non-cash stock-based compensation expense recorded related to options, RSUs and stock purchase rights granted under the ESPP in the statement of operations is as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,617&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,704&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Common stock reserved for future issuance consists of the following at December&#160;31, 2023:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.408%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,214,059&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock option grants issued and outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">986,819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock reserved for issuance upon vesting of outstanding restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,387,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common shares available for grant under the 2019 Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,831,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common shares available for future issuance under ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">449,332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,868,776&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183255116160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The provision for income taxes consists of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The effective tax rate of our provision for income taxes differs from the federal statutory rate as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.660%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal statutory tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State income taxes, net of federal tax benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Significant components of the Company&#8217;s deferred tax assets at December&#160;31, 2023 and 2022 are shown below (in thousands). A valuation allowance has been established as realization of the Company&#8217;s deferred tax assets has not met the more likely-than-not threshold requirement. If the Company&#8217;s judgment changes and it is determined that the Company will be able to realize these deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on deferred tax assets will be accounted for as a reduction to income tax expense.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accruals, reserves and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalization of research and experimentation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,047&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,043&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,979&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42,942)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38,567)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,101&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Right of use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(814)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basis differences in fixed and intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(287)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,101)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,412)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the valuation allowance for deferred tax assets during the years ended December&#160;31, 2023 and 2022, which related primarily to increases in net operating loss (NOL) carryforwards, research and development tax credits, capitalization of research and experimentation costs, and impairment of goodwill were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation allowance at the beginning of the year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,567&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increases recorded to income tax provision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation allowance at the end of the year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,942&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,567&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At December&#160;31, 2023 and 2022, the Company had federal NOL carryforwards of approximately $129.8 million and $118.4 million, respectively. At December&#160;31, 2023 and 2022, the Company had state NOL carryforwards of $91.0 million and $87.0 million, respectively. Approximately $43.5 million of the federal tax loss carryforwards will begin to expire in 2024, unless previously utilized. The federal NOL carryforwards generated after December 31, 2017 of $86.3 million will carryforward indefinitely. The Company&#8217;s state tax loss carryforwards will begin to expire in 2030, unless previously utilized. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At December&#160;31, 2023, the Company's deferred tax assets are primarily comprised of federal and state tax NOL carryforwards. The Company completed a formal study through the year ended December 31, 2019 and determined ownership changes within the meaning of Internal Revenue Code (IRC), Section 382 had occurred in 2003, 2008, 2012, 2017 and 2019. Based on the analysis, $61.1 million of the Company's tax attribute carryforwards through December 31, 2017 cannot be utilized under IRC Section 382. The Company's ability to utilize NOL carryforwards generated after December 31, 2017 will not expire under the Tax Cuts and Jobs Act of 2017. The Company adjusted tax attribute carry forwards and deferred tax assets accordingly. As the deferred tax assets associated with the tax attribute carry forwards were fully offset by a valuation allowance, a corresponding reduction in the Company's valuation allowance was also recorded, resulting in no income tax impact.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is subject to taxation in the U.S. and in various state jurisdictions. The Company&#8217;s tax years for 2004 and forward are subject to examination by the U.S. and state tax authorities due to the carryforward of unutilized net operating losses and research and development credits. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes interest and/or penalties related to income tax matters in its provision for income taxes. The Company does not have any material accruals for, and did not recognize any, material interest or penalties in these financial statements in any period presented. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Uncertain Tax Positions </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At December&#160;31, 2023 and 2022, the Company had no unrecognized tax benefits. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company does not believe that the balance of unrecognized tax benefits will materially change within the next twelve months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183250109024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">401(k) Plan</a></td>
<td class="text">401(k) Plan<div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company sponsors an employee savings plan that qualifies as a deferred salary arrangement under Section 401(k) of the Code. Participating employees may defer up to the Internal Revenue Service annual contribution limit. Additionally, the Company may elect to make contributions into the savings plan at its sole discretion. For each of the years ended December&#160;31, 2023 and 2022, the Company made contributions to the 401(k) Plan at 4% of qualified employee compensation. For the years ended December&#160;31, 2023 and 2022, these contributions totaled approximately $0.8 million and $0.9 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183333279472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Other Risk and Uncertainties</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Concentration of Credit Risk and Other Risk and Uncertainties</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its cash or cash equivalents.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company considers all highly-liquid investments purchased with a remaining maturity date of three months or less upon acquisition to be cash equivalents. These investments are stated at cost, which approximates fair value.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Property and Equipment</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment are stated at cost, net of depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between <span style="-sec-ix-hidden:f-288">three</span> and five years. Leasehold improvements are amortized on a straight-line basis over the lesser of the estimated useful life or the remaining term of the related lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operating expenses in the statements of operations in the period realized.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-lived Assets</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Long-lived Assets</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s long-lived assets are comprised principally of its property and equipment and operating lease assets. The Company amortizes all finite lived intangible assets over their respective estimated useful lives. Operating lease assets are amortized over the term of the leases. In considering whether long-lived assets are impaired, the Company combines its intangible assets and other long-lived assets into groupings, a determination which is made principally on the basis of whether the assets are specific to a particular test offered or technology being developed. If the Company identifies a change in the circumstances related to its long-lived assets that indicates the carrying value of any such asset may not be recoverable, the Company will perform an impairment analysis. A long-lived asset is deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset&#8217;s carrying amount. Management&#8217;s estimates of future cash flows are impacted by projected test volume and levels of reimbursement, as well as expectations related to the future cost structure of the entity. Any required impairment loss would be measured as the amount by which the asset&#8217;s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Goodwill</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company operates in a single operating segment and reporting unit for the measurement of goodwill. Goodwill was reviewed for impairment annually (during the fourth quarter) or more frequently if indicators of impairment existed. The Company would first assess qualitative factors to determine whether it was more likely than not that the fair value of the reporting unit was less than its carrying amount as a basis for determining whether it was necessary to perform a quantitative assessment. If, after assessing qualitative factors, the Company determined it was not more likely than not that the fair value of a reporting unit was less than its carrying amount, then performing a quantitative assessment was unnecessary. If deemed necessary, a quantitative assessment compared the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeded its carrying amount, goodwill was not considered impaired; otherwise, an impairment loss was recorded.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Leases</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company categorizes leases at their commencement as either operating or finance leases. The Company recognizes operating lease ROU assets and operating lease liabilities for each lease arrangement identified. Lease liabilities are recorded at the present value of future lease payments discounted using the Company's incremental borrowing rate for the lease established at the commencement date. The incremental borrowing rate is the rate of interest the Company would have to pay to borrow, on a collateralized basis over a similar term and in a similar economic environment, an amount equal to the total lease payments. The Company primarily considers industry data, its credit rating and the lease term to determine its incremental borrowing rate. ROU assets are measured at the amount of the lease liability plus any initial direct costs, less any lease incentives received before commencement. Lease expense is recognized as a single lease cost over the lease term on a straight-line basis. The Company has elected not to apply the recognition requirements to short-term leases and not to separate non-lease components from lease components for its leases.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_ClinicalStudyPolicyPolicyTextBlock', window );">Clinical Studies</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Clinical Studies</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, the Company engages in efforts to scientifically measure and document the application and efficacy of its various testing products. These arrangements typically require the Company to pay a fee to a third-party scientific investigator (usually a physician or research institution) for each subject enrolled in a clinical study, and the Company accrues expenses based on estimated progress of services performed, including actual level of subjects enrolled and progress of the clinical studies. Payments made prior to the completion of clinical study services are capitalized as a prepaid expense. The prepaid amounts are expensed as the related goods are delivered or the services are performed, or when it is no longer expected that the goods will be delivered or the </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">services rendered. Expenses associated with clinical study activities are recorded in research and development expenses in the accompanying statement of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue Recognition</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (each, a payor) consist of commercial payors (healthcare insurers), government payors (primarily Medicare and Medicaid), client payors (i.e., hospitals, other laboratories, etc.) and patient self-pay. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes revenue in accordance with Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (ASC 606) and follows a five-step process to determine the amount and timing of revenue recognized: (1) identify the contract with the customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to performance obligations in the contract, and (5) recognize revenue when (or as) the performance obligation is satisfied. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Payors are generally billed at the Company's list price, unless a separate pricing contract is in place. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions. Adjustments are recorded in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, are recorded upon settlement. Included in revenues for the years ended December&#160;31, 2023 and 2022 was a net revenue increase of $3.4 million and a net revenue decrease of $2.4 million, respectively, associated with changes in estimated variable consideration related to performance obligations satisfied in previous periods. The transaction price is estimated using an expected value method on a portfolio basis.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Variable consideration is included in the transaction price only to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainties with respect to the amount are resolved. The Company's portfolios are grouped per payor (i.e. each individual commercial payor, Medicare, Medicaid, client payors, patient self-pay, etc.) and per test. Consideration may be constrained and excluded from the transaction price in situations where there is no contractually agreed upon reimbursement coverage or in absence of a predictable pattern and history of collectability with a payor. Accordingly, in such situations revenues are recognized on the basis of actual cash collections. Additionally, from time to time, the Company may issue refunds to payors for overpayments or amounts billed in error. Any refunds are accounted for as reductions in revenues in the statement of operations as an element of variable consideration. The estimated expected refunds are accrued as a liability on the Company&#8217;s balance sheet.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information, along with any requested medical or other claims-related information to the healthcare insurers. This generally occurs within 30 to 90 days of billing, however, the amount and timing of any reimbursements or collections for our billed tests may vary by payor and other circumstances. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable and Allowance for Credit Losses</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accounts Receivable and Allowance for Credit Losses</span></div>We accrue an allowance for credit losses against our accounts receivable based on management&#8217;s current estimate of amounts that will not be collected. Management&#8217;s estimates are typically based on historical loss information adjusted for current conditions. We generally do not perform evaluations of the financial condition of our customers and generally do not require collateral. The allowance for credit losses was zero as of December&#160;31, 2023. There was no allowance for credit losses recognized as of December 31, 2022. Adjustments for implicit price concessions attributable to variable consideration, as discussed above, are incorporated into the measurement of the accounts receivable balances and are not part of the allowance for credit losses.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Research and Development</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense; materials; laboratory supplies; consulting costs; costs associated with setting up and conducting clinical studies; depreciation; amortization and allocated overhead, including rent and utilities.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising and Marketing Costs</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Advertising and Marketing Costs</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $1.5 million and $3.0 million for the years ended December&#160;31, 2023 and 2022, respectively, and are included in selling, general and administrative expenses in the accompanying statements of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Shipping and Handling Costs</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Shipping and Handling Costs</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs incurred for shipping and handling are included in costs of revenue in the accompanying statements of operations and were approximately $2.5 million and $2.7 million for the years ended December&#160;31, 2023 and 2022, respectively.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Stock-Based Compensation</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The fair value of stock options and purchases under the Company's 2019 Employee Stock Purchase Plan (ESPP) rights is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The BSM option pricing model incorporates various inputs, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. Volatility is based on the Company's historical calculated volatility since being publicly traded. The weighted-average expected term of options was calculated using the simplified method, as we have concluded that our stock option exercise history does not provide a reasonable basis upon which to estimate the expected term. The risk-free interest rate for periods within the contractual term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is zero, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of each restricted stock unit (RSU) is determined on the grant date using the closing price of the Company's common stock on that date. The Company's RSUs generally vest in equal annual installments over four years from the date of grant or, for grants to new hires, date of hire. Vesting of RSUs is subject to the holder's continued service with the Company. The Company issues new shares to satisfy RSUs upon vesting.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Comprehensive Loss</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Income Taxes</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized as an expense in the period that includes the enactment date. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would adjust the deferred tax asset valuation allowance, which would reduce the provision for income taxes. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company records uncertain tax positions on the basis of a two-step process whereby (i) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Net Loss Per Share</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. The weighted-average number of shares used to compute basic and diluted shares includes shares issuable upon the exercise of pre-funded warrants at a nominal price. Potentially dilutive common stock equivalents are comprised of warrants for the purchase of common stock, stock options, RSUs outstanding under the Company's 2019 Incentive Award Plan (the 2019 Plan) and shares of the Company's common stock pursuant to the ESPP. For each of the years ended December&#160;31, 2023 and 2022, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as the inclusion of the potentially dilutive securities would be antidilutive.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Segment Reporting</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements and Recently Adopted Accounting Standards</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent Accounting Pronouncements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012 (JOBS Act), the Company meets the definition of an emerging growth company. The Company has elected to use the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Unless otherwise discussed, Accounting Standards Updates (ASU) not included in the Company&#8217;s disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on the Company&#8217;s financial statements or disclosures.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2023, the FASB issued ASU No. 2023-07, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (ASU 2023-07), which requires public entities to disclose significant segment expenses that are regularly provided to the Chief Operating Decision Maker (CODM) and details of how the CODM uses financial reporting to assess the performance of a segment. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. This ASU will likely result in additional required disclosure when adopted. The Company is currently evaluating the provisions of this ASU and the impact on its financial statements and related disclosures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In December 2023, the FASB issued ASU 2023-09,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"> Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> (ASU 2023-09), which requires additional income tax disclosures in the rate reconciliation table for federal, state and foreign income taxes, in addition to more details about the reconciling items in some categories </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">when items meet a certain quantitative threshold. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 with early adoption permitted. The Company is currently evaluating the impact of this standard, but does not expect that it will have a material impact on its financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Recently Adopted Accounting Standards</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which requires the measurement of expected credit losses (based on historical experience, current conditions and reasonable forecasts) for financial instruments (such as accounts receivable) held at the reporting date which are carried at amortized cost. The main objective of this ASU is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. In November 2018, the FASB issued ASU 2018-19, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Codification Improvements to Topic 326, Financing Instruments-Credit Losses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which included an amendment of the effective date for nonpublic entities. The Company adopted this pronouncement on January 1, 2023. The adoption did not have material impact on its financial statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in ASU 2020-06 are effective for smaller reporting companies as defined by the SEC for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. The Company early adopted ASU 2020-06 as of January 1, 2023. The adoption did not have an impact on its financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The carrying values of the Company's cash, cash equivalents and restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued and other current liabilities approximate their fair values due to their short-term nature and are considered to be Level 1 measurements. The estimated fair value of the Company's long-term borrowings is determined by Level 2 inputs and based primarily on quoted market prices for the same or similar issues. As of December&#160;31, 2023, the Amended Loan Agreement had a carrying value of $18.7 million and a fair value of $19.7 million. As of December 31, 2022, the 2017 Term Loan had a carrying value of $28.3&#160;million and a fair value of $26.9&#160;million. The estimated fair value of the Amended Loan Agreement was determined based on a discounted cash flow approach using available market information on discount and borrowing rates with similar terms, maturities, and credit ratings. The carrying value of the Company's other long-term borrowing as of December&#160;31, 2023 was $0.8&#160;million, which approximated its fair value.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The three-levels of the valuation hierarchy for disclosure of fair value measurements are defined as follows:</span></div><div style="margin-top:9pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 1 -&#160;&#160;&#160;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:9pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 2 -&#160;&#160;&#160;&#160;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span></div><div style="margin-top:9pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 3 -&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_ClinicalStudyPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical Study, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_ClinicalStudyPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org//705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for ESOP transactions, including the method of measuring compensation, the classification of dividends on ESOP shares, and the treatment of ESOP shares for EPS computations. If the employer has both old ESOP shares for which it does not adopt new guidance and new ESOP shares for which new guidance is required, these disclosures are required for both blocks of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480489/718-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183252748816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Concentration of Risk, by Risk Factor and Significant Payer</a></td>
<td class="text">For each significant payor and customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:<div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accounts Receivable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table includes the Company's revenues as disaggregated by payor and customer category (in&#160;thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Client(1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other(2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52,548&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,563&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes hospitals, other laboratories, etc.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes patient self-pay.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash, cash equivalents and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,493&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,391&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,693&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,591&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Restricted Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash, cash equivalents and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,493&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,391&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,693&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,591&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409,108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409,108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">986,819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,387,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,036,208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,828,086&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,925,262&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-16<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183252503888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diagnostic&#160;testing&#160;supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid product royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid maintenance and insurance contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,797&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,143&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment consist of the following (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture&#160;and&#160;fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,970&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,321&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,769)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,201&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,197&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents details of the Company's goodwill for the year ended December 31, 2022 (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,506&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Goodwill impairment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,506)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued and Other Current Liabilities</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued and other current liabilities consist of the following (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued&#160;payroll&#160;and&#160;related&#160;expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,738&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued purchases of goods and services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued clinical study activity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-387"><span style="-sec-ix-hidden:f-388">Finance lease obligations, current portion</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Refund liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,531&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,347&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183344701088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Minimum Aggregate Payments for Outstanding Borrowings</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2023, future minimum aggregate payments, including interest, for outstanding borrowings are as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,949&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,166&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,558)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total borrowings, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,495&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Borrowings-current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(264)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings-non-current portion, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,231&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183255144640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Costs</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating and finance leases consist of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.786%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Balance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-445">Property and equipment, net</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-450">Accrued and other current liabilities</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-455"><span style="-sec-ix-hidden:f-456">Other non-current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs associated with the Company's leases were included in the statements of operations as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease cost</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">679</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest on finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,147&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,299&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(1) Includes variable lease cost of $129,000 and $165,000 for the years ended December&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Supplemental cash flow information on leases is as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash out flows from operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,405&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash out flows from interest paid on finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financing cash out flows from finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Information regarding the weighted-average lease term and weighted average discount rate are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.06</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.94</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Lessee, Operating Lease, Liability, Maturity</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Future payments under operating and finance leases as of December&#160;31, 2023 are as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">997&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(541)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,736&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(976)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(490)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease obligations, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,760&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Finance Lease, Liability, Maturity</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Future payments under operating and finance leases as of December&#160;31, 2023 are as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">997&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(541)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,736&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(976)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(490)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease obligations, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,760&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183250210192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Financial Instrument Measured on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.432%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,386&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,386&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certificate of deposit, included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59,538&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59,538&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183250243936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Outstanding Warrants</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following equity classified warrants to purchase common stock were outstanding as of December&#160;31, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.788%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237,169</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67,086</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83,778</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,944</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants (Exchange Warrants)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">804,951</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 22, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">None</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,214,059</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183255509856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Share-based Payment Arrangement, Restricted Stock Unit, Activity</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">RSU activity under the Company's 2019 Plan is set forth below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,036,208&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,487&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">857,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards released</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(273,319)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(232,730)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,387,459&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock option activity under the Company's 2019 Plan is set forth below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,421,235&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.09</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(93,335)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43,895)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(370,686)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">986,819&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.44</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest, December&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">986,819&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.44</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options exercisable, December&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">877,937&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Non-cash Stock-based Compensation Expense</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total non-cash stock-based compensation expense recorded related to options, RSUs and stock purchase rights granted under the ESPP in the statement of operations is as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,617&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,704&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Common Stock Reserved For Future Issuance</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Common stock reserved for future issuance consists of the following at December&#160;31, 2023:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.408%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,214,059&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock option grants issued and outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">986,819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock reserved for issuance upon vesting of outstanding restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,387,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common shares available for grant under the 2019 Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,831,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common shares available for future issuance under ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">449,332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,868,776&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183252781504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The provision for income taxes consists of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The effective tax rate of our provision for income taxes differs from the federal statutory rate as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.660%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal statutory tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State income taxes, net of federal tax benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text">If the Company&#8217;s judgment changes and it is determined that the Company will be able to realize these deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on deferred tax assets will be accounted for as a reduction to income tax expense.<div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accruals, reserves and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalization of research and experimentation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,047&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,043&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,979&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42,942)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38,567)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,101&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Right of use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(814)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basis differences in fixed and intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(287)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,101)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,412)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Summary of Valuation Allowance</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the valuation allowance for deferred tax assets during the years ended December&#160;31, 2023 and 2022, which related primarily to increases in net operating loss (NOL) carryforwards, research and development tax credits, capitalization of research and experimentation costs, and impairment of goodwill were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation allowance at the beginning of the year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,567&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increases recorded to income tax provision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation allowance at the end of the year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,942&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,567&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183255124656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 36,493<span></span>
</td>
<td class="nump">$ 62,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 279,216<span></span>
</td>
<td class="nump">$ 255,527<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183252723856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Revenue by Major Payers (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_MedicareMember', window );">Medicare | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_MedicareMember', window );">Medicare | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">42.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_MedicareAdvantageMember', window );">Medicare Advantage | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_MedicareAdvantageMember', window );">Medicare Advantage | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_MedicareAdvantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_MedicareAdvantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183343581328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>segment </div>
<div>installment </div>
<div>unit</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units | unit</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="num">(2,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest', window );">Allowance for credit loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">6,551<span></span>
</td>
<td class="nump">6,077<span></span>
</td>
<td class="nump">$ 9,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising and marketing costs</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments', window );">Number of annual vesting installments | installment</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember', window );">Shipping and Handling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Supplier Concentration Risk | Two Suppliers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">96.00%<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | AVISE CTD Test | Product Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">88.00%<span></span>
</td>
<td class="nump">84.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Annual Installments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of allowance for credit loss on financing receivable. Excludes net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-5<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 72: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 73: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 74: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-6<br><br>Reference 75: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 76: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 77: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 78: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 79: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 80: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 81: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 82: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 83: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 84: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 85: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 86: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 87: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 88: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 89: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 90: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 91: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 92: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=exdx_TwoSuppliersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=exdx_TwoSuppliersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exdx_AVISECTDTestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exdx_AVISECTDTestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183251876240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 52,548<span></span>
</td>
<td class="nump">$ 45,563<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_CommercialMember', window );">Commercial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">23,985<span></span>
</td>
<td class="nump">18,975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_Government1Member', window );">Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">18,002<span></span>
</td>
<td class="nump">17,687<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_ClientMember', window );">Client</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">9,949<span></span>
</td>
<td class="nump">7,928<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=us-gaap_OtherCustomerMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 612<span></span>
</td>
<td class="nump">$ 973<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_CommercialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_CommercialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_Government1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_Government1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_ClientMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_ClientMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=us-gaap_OtherCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=us-gaap_OtherCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183255389024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 36,493<span></span>
</td>
<td class="nump">$ 62,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 36,693<span></span>
</td>
<td class="nump">$ 62,591<span></span>
</td>
<td class="nump">$ 99,542<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183251877008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation (in shares)</a></td>
<td class="nump">2,828,086<span></span>
</td>
<td class="nump">2,925,262<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation (in shares)</a></td>
<td class="nump">409,108<span></span>
</td>
<td class="nump">409,108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation (in shares)</a></td>
<td class="nump">986,819<span></span>
</td>
<td class="nump">1,421,235<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation (in shares)</a></td>
<td class="nump">1,387,459<span></span>
</td>
<td class="nump">1,036,208<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation (in shares)</a></td>
<td class="nump">44,700<span></span>
</td>
<td class="nump">58,711<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183333621536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Prepaid Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Diagnostic&#160;testing&#160;supplies</a></td>
<td class="nump">$ 2,871<span></span>
</td>
<td class="nump">$ 1,795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidRoyalties', window );">Prepaid product royalties</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_PrepaidMaintenanceAndInsuranceContracts', window );">Prepaid maintenance and insurance contracts</a></td>
<td class="nump">1,860<span></span>
</td>
<td class="nump">2,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses and other current assets</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 4,797<span></span>
</td>
<td class="nump">$ 4,143<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_PrepaidMaintenanceAndInsuranceContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Maintenance and Insurance Contracts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_PrepaidMaintenanceAndInsuranceContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for royalties that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183252957664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total property and equipment</a></td>
<td class="nump">$ 10,970<span></span>
</td>
<td class="nump">$ 13,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(5,769)<span></span>
</td>
<td class="num">(5,124)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">5,201<span></span>
</td>
<td class="nump">8,197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture&#160;and&#160;fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total property and equipment</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total property and equipment</a></td>
<td class="nump">5,312<span></span>
</td>
<td class="nump">5,136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total property and equipment</a></td>
<td class="nump">2,185<span></span>
</td>
<td class="nump">1,482<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total property and equipment</a></td>
<td class="nump">3,316<span></span>
</td>
<td class="nump">5,223<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total property and equipment</a></td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 1,382<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183252990624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 24, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,286<span></span>
</td>
<td class="nump">4,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">976<span></span>
</td>
<td class="nump">1,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_GainLossOnDispositionOfLeaseAssignment', window );">Loss on lease assignment</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">1,470<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Long-lived assets impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,506<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization', window );">Gross book value of assets under finance leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_GainLossOnDispositionOfLeaseAssignment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on Disposition of Lease Assignment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_GainLossOnDispositionOfLeaseAssignment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183344108976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information - Goodwill (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(5,506)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183333449488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued&#160;payroll&#160;and&#160;related&#160;expenses</a></td>
<td class="nump">$ 4,738<span></span>
</td>
<td class="nump">$ 2,355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_AccruedPurchaseGoodsAndServicesCurrent', window );">Accrued purchases of goods and services</a></td>
<td class="nump">720<span></span>
</td>
<td class="nump">803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties</a></td>
<td class="nump">463<span></span>
</td>
<td class="nump">514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_AccruedLiabilitiesClinicalStudyCurrent', window );">Accrued clinical study activity</a></td>
<td class="nump">$ 118<span></span>
</td>
<td class="nump">$ 162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance lease, liability, current, statement of financial position</a></td>
<td class="text">Accrued and other current liabilities<span></span>
</td>
<td class="text">Accrued and other current liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease obligations, current portion</a></td>
<td class="nump">$ 490<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CustomerRefundLiabilityCurrent', window );">Refund liability</a></td>
<td class="nump">302<span></span>
</td>
<td class="nump">445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">561<span></span>
</td>
<td class="nump">226<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">$ 7,531<span></span>
</td>
<td class="nump">$ 5,347<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_AccruedLiabilitiesClinicalStudyCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities, Clinical Study, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_AccruedLiabilitiesClinicalStudyCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_AccruedPurchaseGoodsAndServicesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Purchase, Goods and Services, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_AccruedPurchaseGoodsAndServicesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183253193408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 28, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>installment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Prepayment of principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Borrowings-non-current portion, net of discounts and debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,231,000<span></span>
</td>
<td class="nump">$ 28,778,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exdx_AmendedLoanAgreementMember', window );">Amended Loan Agreement | Innovatus Life Sciences Lending Fund | Loan payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Term loan borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Remaining borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Prepayment of principal</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Term loan, interest rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DebtInstrumentStatedInterestRatePaidInKind', window );">Term loan, paid in-kind, interest rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Term loan, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DebtInstrumentNumberOfMonthlyInstallments', window );">Number of monthly installments | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Term loan, fee incurred upon payment of final installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DebtInstrumentPrepaymentPremiumPercentage', window );">Term loan, prepayment premium percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DebtInstrumentCovenantRevenuePerformancePeriod', window );">Term loan, covenant, revenue performance period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant', window );">Debt instrument, minimum cash balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet', window );">Term loan, covenant, number of days to cure covenant if performance measure is not met</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance', window );">Term loan covenant, minimum unrestricted cash balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exdx_AmendedLoanAgreementMember', window );">Amended Loan Agreement | Innovatus Life Sciences Lending Fund | Loan payable | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exdx_AmendedLoanAgreementMember', window );">Amended Loan Agreement | Innovatus Life Sciences Lending Fund | Paid in-kind note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DebtInstrumentPaidInKindLoansIssued', window );">Term loan, paid in-kind loans issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Borrowings-non-current portion, net of discounts and debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exdx_Term2017Member', window );">2017 Term loan | Innovatus Life Sciences Lending Fund | Loan payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease', window );">Term loan covenant, increase to interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exdx_EquipmentNotesPayableMember', window );">Equipment Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Term loan, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.28%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Number Of Days To Cure If Performance Measure Is Not Met</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentCovenantRevenuePerformancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Revenue Performance Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentCovenantRevenuePerformancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Minimum Cash Balance Required, Not Required To Comply With Covenant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentNumberOfMonthlyInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number Of Monthly Installments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentNumberOfMonthlyInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentPaidInKindLoansIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Paid In Kind Loans Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentPaidInKindLoansIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentPrepaymentPremiumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Premium Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentPrepaymentPremiumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentStatedInterestRatePaidInKind">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Stated Interest Rate, Paid In-Kind</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentStatedInterestRatePaidInKind</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exdx_AmendedLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exdx_AmendedLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=exdx_InnovatusLifeSciencesLendingFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=exdx_InnovatusLifeSciencesLendingFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_PaymentInKindPIKNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_PaymentInKindPIKNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exdx_Term2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exdx_Term2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exdx_EquipmentNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exdx_EquipmentNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183333431872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowings - Future Minimum Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 1,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2025</a></td>
<td class="nump">1,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2026</a></td>
<td class="nump">21,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_LongTermDebtIncludingUndiscountedInterest', window );">Total</a></td>
<td class="nump">25,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount and issuance costs</a></td>
<td class="num">(113)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_LongTermDebtUndiscountedInterestAmount', window );">Interest</a></td>
<td class="num">(5,558)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total borrowings, net of discounts and debt issuance costs</a></td>
<td class="nump">19,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Borrowings-current portion</a></td>
<td class="num">(264)<span></span>
</td>
<td class="num">$ (190)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Borrowings-non-current portion, net of discounts and debt issuance costs</a></td>
<td class="nump">$ 19,231<span></span>
</td>
<td class="nump">$ 28,778<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_LongTermDebtIncludingUndiscountedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Including Undiscounted Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_LongTermDebtIncludingUndiscountedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_LongTermDebtUndiscountedInterestAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Undiscounted Interest Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_LongTermDebtUndiscountedInterestAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183255671376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=exdx_OfficeAndLaboratoryMember', window );">Office and Laboratory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=exdx_OfficeMember', window );">Office</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_OperatingLeaseMonthlyBaseRent', window );">Operating lease, monthly base rent</a></td>
<td class="nump">$ 70,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent', window );">Operating lease, annual increase in base rent payment percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Finance lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Finance lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Annual Increase In Base Rent Payment, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OperatingLeaseMonthlyBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Monthly Base Rent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OperatingLeaseMonthlyBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=exdx_OfficeAndLaboratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=exdx_OfficeAndLaboratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=exdx_OfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=exdx_OfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183333417680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Lease Balances (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 3,286<span></span>
</td>
<td class="nump">$ 4,885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease, right-of-use asset, after accumulated amortization</a></td>
<td class="nump">$ 810<span></span>
</td>
<td class="nump">1,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Finance lease, right-of-use asset, statement of financial position</a></td>
<td class="text">Property and equipment, net<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">$ 976<span></span>
</td>
<td class="nump">1,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease obligations, current portion</a></td>
<td class="nump">$ 490<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance lease, liability, current, statement of financial position</a></td>
<td class="text">Accrued and other current liabilities<span></span>
</td>
<td class="text">Accrued and other current liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">$ 2,760<span></span>
</td>
<td class="nump">$ 4,493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Lease obligations, net of current portion</a></td>
<td class="nump">$ 358<span></span>
</td>
<td class="nump">$ 848<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Finance lease, liability, noncurrent, statement of financial position</a></td>
<td class="text">Non-current operating lease liabilities<span></span>
</td>
<td class="text">Non-current operating lease liabilities<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183337385392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Costs Associated with the Company's Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 1,463<span></span>
</td>
<td class="nump">$ 1,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of lease assets</a></td>
<td class="nump">556<span></span>
</td>
<td class="nump">679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on finance lease liabilities</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">2,147<span></span>
</td>
<td class="nump">2,299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">$ 129<span></span>
</td>
<td class="nump">$ 165<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183251872896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental Cash Flow Information On Leases And Weighted-Average Lease Term (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash out flows from operating leases</a></td>
<td class="nump">$ 1,405<span></span>
</td>
<td class="nump">$ 1,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash out flows from interest paid on finance leases</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash out flows from finance leases</a></td>
<td class="nump">$ 697<span></span>
</td>
<td class="nump">$ 667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_WeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted-average remaining lease term (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
<td class="text">4 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance leases</a></td>
<td class="text">2 years 21 days<span></span>
</td>
<td class="text">1 year 11 months 8 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_WeightedAverageDiscountRateAbstract', window );"><strong>Weighted-average discount rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance leases</a></td>
<td class="nump">12.20%<span></span>
</td>
<td class="nump">4.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Flow Information, Operating and Finance Lease Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_WeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-Average Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_WeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_WeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-Average Remaining Lease Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_WeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183255330144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Future Payments Under Operating And Finance Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 1,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">1,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">1,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">4,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(541)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">3,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(976)<span></span>
</td>
<td class="num">$ (1,040)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease obligations, net of current portion</a></td>
<td class="nump">2,760<span></span>
</td>
<td class="nump">4,493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(149)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(490)<span></span>
</td>
<td class="num">(700)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Lease obligations, net of current portion</a></td>
<td class="nump">$ 358<span></span>
</td>
<td class="nump">$ 848<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183251697024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>supplier</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers', window );">Number of suppliers in amended supply agreement | supplier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInNextTwelveMonths', window );">Purchase obligation, due in next twelve months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInSecondYear', window );">Purchase obligation, due in second year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=exdx_USDepartmentOfJusticeCaseMember', window );">U.S. Department Of Justice Case | Settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Settlement payment</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exdx_AHNCollaborationMember', window );">AHN Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_CollaborationAgreementCollaborationExpenses', window );">Collaboration agreement, collaboration expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_RoyaltyObligationPercentageOfSales', window );">Royalty obligation, percent of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_RoyaltyObligationPercentageOfSales', window );">Royalty obligation, percent of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=exdx_PrometheusLaboratoriesIncMember', window );">Prometheus Laboratories | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_RoyaltyObligationPercentageOfSales', window );">Royalty obligation, percent of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=exdx_AlleghenyHealthNetworkResearchInstituteMember', window );">Allegheny Health Network Research Institute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_CollaborationAgreementAnnualCollaborationFee', window );">Collaboration fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_CollaborationAgreementAnnualCollaborationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Annual Collaboration Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_CollaborationAgreementAnnualCollaborationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_CollaborationAgreementCollaborationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Collaboration Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_CollaborationAgreementCollaborationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Obligation, Amended Supply Agreement, Number Of Suppliers</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_RoyaltyObligationPercentageOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Obligation, Percentage of Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_RoyaltyObligationPercentageOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=exdx_USDepartmentOfJusticeCaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=exdx_USDepartmentOfJusticeCaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exdx_AHNCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exdx_AHNCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=exdx_PrometheusLaboratoriesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=exdx_PrometheusLaboratoriesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=exdx_AlleghenyHealthNetworkResearchInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=exdx_AlleghenyHealthNetworkResearchInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183252314672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total borrowings, net of discounts and debt issuance costs</a></td>
<td class="nump">$ 19,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,538<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money market funds, included in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">14,386<span></span>
</td>
<td class="nump">29,438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Certificate of deposit, included in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,538<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;1 | Money market funds, included in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">14,386<span></span>
</td>
<td class="nump">29,438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;1 | Certificate of deposit, included in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;2 | Money market funds, included in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;2 | Certificate of deposit, included in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;3 | Money market funds, included in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;3 | Certificate of deposit, included in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exdx_AmendedLoanAgreementMember', window );">Amended Loan Agreement | Recurring | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total borrowings, net of discounts and debt issuance costs</a></td>
<td class="nump">18,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt instrument, fair value</a></td>
<td class="nump">$ 19,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exdx_A2017TermLoanMember', window );">2017 Term Loan | Recurring | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total borrowings, net of discounts and debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt instrument, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exdx_DebtOtherThanAmendedLoanAgreementMember', window );">Debt Other Than Amended Loan Agreement | Recurring | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total borrowings, net of discounts and debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exdx_AmendedLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exdx_AmendedLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exdx_A2017TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exdx_A2017TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exdx_DebtOtherThanAmendedLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exdx_DebtOtherThanAmendedLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183251560016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 15, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet', window );">Exercise of common stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=exdx_ShelfRegistrationStatementMember', window );">Shelf Registration Statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_SaleOfStockAuthorizedAmount', window );">Common stock offering, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_SaleOfStockRemainingAuthorizedAmount', window );">Common stock offering, remaining authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=exdx_CowenEquityDistributionAgreementMember', window );">Cowen Equity Distribution Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_SaleOfStockAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_SaleOfStockAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_SaleOfStockRemainingAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Remaining Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_SaleOfStockRemainingAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrants Exercised, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=exdx_ShelfRegistrationStatementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=exdx_ShelfRegistrationStatementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=exdx_CowenEquityDistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=exdx_CowenEquityDistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183343615232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Warrants to Purchase Common Stock Outstanding (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">1,214,059<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationJan192026Member', window );">Warrant expiration January 19, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">237,169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationMar312026Member', window );">Warrant expiration March 31, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">67,086<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationApr12026Member', window );">Warrant expiration April 1, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationSep72024Member', window );">Warrant expiration September 7, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">83,778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 14.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationDec72025Member', window );">Warrant expiration December 7, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">20,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 14.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_NoExpirationMember', window );">No expiration</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">804,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationJan192026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationJan192026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationMar312026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationMar312026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationApr12026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationApr12026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationSep72024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationSep72024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationDec72025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationDec72025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_NoExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_NoExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183252945008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 01, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">5,868,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Employee options, weighted-average grant date fair value per share (in dollars per share)</a></td>
<td class="nump">$ 2.17<span></span>
</td>
<td class="nump">$ 2.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic value of options exercised</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Common stock, fair value per share (in dollars per share)</a></td>
<td class="nump">$ 1.99<span></span>
</td>
<td class="nump">$ 2.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,617<span></span>
</td>
<td class="nump">$ 4,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">986,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Stock options, unrecognized compensation cost</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock options, cost not yet recognized, remaining weighted average vesting period</a></td>
<td class="text">9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage', window );">Annual percentage increase in shares available for issuance under the Plan</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">449,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock options, cost not yet recognized, remaining weighted average vesting period</a></td>
<td class="text">2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum Employee payroll deduction percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="nump">129,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost related to stock purchase</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized', window );">Increase (decrease) in number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,460<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">1,387,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Grant date fair value of RSUs vested</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Awards granted (in dollars per share)</a></td>
<td class="nump">$ 2.39<span></span>
</td>
<td class="nump">$ 5.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Stock options, unrecognized compensation cost</a></td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock options, cost not yet recognized, remaining weighted average vesting period</a></td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Common stock, fair value per share (in dollars per share)</a></td>
<td class="nump">$ 4.24<span></span>
</td>
<td class="nump">$ 7.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=exdx_IncentiveAwardPlan2019Member', window );">2019 Incentive Award Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options, expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options, vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=exdx_IncentiveAwardPlan2019Member', window );">2019 Incentive Award Plan | Stock options | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized', window );">Increase (decrease) in number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">681,838<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=exdx_IncentiveAwardPlan2019Member', window );">2019 Incentive Award Plan | Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage', window );">Annual percentage increase in shares available for issuance under the Plan</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Increase (Decrease) In Number Of Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=exdx_IncentiveAwardPlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=exdx_IncentiveAwardPlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183333720160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Restricted Stock Units (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 2.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">$ 1.99<span></span>
</td>
<td class="nump">$ 2.40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number&#160;of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">1,036,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards granted (in shares)</a></td>
<td class="nump">857,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Awards released (in shares)</a></td>
<td class="num">(273,319)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Awards canceled (in shares)</a></td>
<td class="num">(232,730)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">1,387,459<span></span>
</td>
<td class="nump">1,036,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 7.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Awards granted (in dollars per share)</a></td>
<td class="nump">2.39<span></span>
</td>
<td class="nump">$ 5.89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Awards released (in dollars per share)</a></td>
<td class="nump">7.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Awards canceled (in dollars per share)</a></td>
<td class="nump">6.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">$ 4.24<span></span>
</td>
<td class="nump">$ 7.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 2,761<span></span>
</td>
<td class="nump">$ 2,487<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183249013184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number&#160;of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">1,421,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">73,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(93,335)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(43,895)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(370,686)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">986,819<span></span>
</td>
<td class="nump">1,421,235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">986,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options exercisable (in Shares)</a></td>
<td class="nump">877,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise&#160;Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 12.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">3.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">0.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">13.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in dollars per share)</a></td>
<td class="nump">16.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">11.87<span></span>
</td>
<td class="nump">$ 12.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">11.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Options exercisable (in dollars per share)</a></td>
<td class="nump">$ 12.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual Term&#160;(Years) and Aggregate Instrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">6 years 5 months 8 days<span></span>
</td>
<td class="text">7 years 1 month 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest, Weighted Average Remaining Contractual Term</a></td>
<td class="text">6 years 5 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">6 years 2 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 228<span></span>
</td>
<td class="nump">$ 483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest, Aggregate Intrinsic Value</a></td>
<td class="nump">228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Options exercisable, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183333395264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,617<span></span>
</td>
<td class="nump">$ 4,704<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">191<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">3,174<span></span>
</td>
<td class="nump">3,860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 252<span></span>
</td>
<td class="nump">$ 631<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183344118448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stock Option Plan - Common Stock Reserved For Future Issuance (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">5,868,776<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">1,214,059<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock option grants issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">986,819<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Common stock reserved for issuance upon vesting of outstanding restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">1,387,459<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember', window );">Common shares available for grant under the 2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">1,831,107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Common shares available for future issuance under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">449,332<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183333605056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense) benefit</a></td>
<td class="num">$ (33)<span></span>
</td>
<td class="nump">$ 282<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183252755584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Effective Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal tax benefits</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development tax credits</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="num">(3.40%)<span></span>
</td>
<td class="num">(1.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-deductible expenses</a></td>
<td class="num">(1.40%)<span></span>
</td>
<td class="num">(0.90%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(18.50%)<span></span>
</td>
<td class="num">(23.90%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183249089888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 32,479<span></span>
</td>
<td class="nump">$ 29,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">2,353<span></span>
</td>
<td class="nump">2,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves', window );">Accruals, reserves and other</a></td>
<td class="nump">1,119<span></span>
</td>
<td class="nump">349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Interest expense</a></td>
<td class="nump">2,547<span></span>
</td>
<td class="nump">2,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Indefinite lived assets</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">1,391<span></span>
</td>
<td class="nump">1,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">925<span></span>
</td>
<td class="nump">1,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts', window );">Capitalization of research and experimentation costs</a></td>
<td class="nump">2,929<span></span>
</td>
<td class="nump">2,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets</a></td>
<td class="nump">44,043<span></span>
</td>
<td class="nump">39,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(42,942)<span></span>
</td>
<td class="num">(38,567)<span></span>
</td>
<td class="num">$ (27,158)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">1,101<span></span>
</td>
<td class="nump">1,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DeferredTaxLiabilitiesRightOfUseAssets', window );">Right of use assets</a></td>
<td class="num">(814)<span></span>
</td>
<td class="num">(1,206)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets', window );">Basis differences in fixed and intangible assets</a></td>
<td class="num">(287)<span></span>
</td>
<td class="num">(206)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(1,101)<span></span>
</td>
<td class="num">(1,412)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Capitalization Of Research And Experimentation Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Fixed Assets And Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DeferredTaxLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Right Of Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DeferredTaxLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from loss reserves other than estimated credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183252362112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Change In Valuation Allowance (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward', window );"><strong>Changes In The Valuation Allowance For Deferred Tax Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance at the beginning of the year</a></td>
<td class="nump">$ 38,567<span></span>
</td>
<td class="nump">$ 27,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increases recorded to income tax provision</a></td>
<td class="nump">4,375<span></span>
</td>
<td class="nump">11,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance at the end of the year</a></td>
<td class="nump">$ 42,942<span></span>
</td>
<td class="nump">$ 38,567<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes In The Valuation Allowance For Deferred Tax Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183337316672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating loss carryforwards</a></td>
<td class="nump">$ 129,800,000<span></span>
</td>
<td class="nump">$ 118,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforwards</a></td>
<td class="nump">91,000,000.0<span></span>
</td>
<td class="nump">87,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Federal tax loss carryforwards, subject to expiration</a></td>
<td class="nump">43,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Federal net operating loss carryforwards, carryforward indefinitely</a></td>
<td class="nump">86,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=exdx_TaxYearsThroughDecember312017Member', window );">Tax Years Through December 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Federal tax loss carryforwards, subject to expiration</a></td>
<td class="nump">$ 61,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=exdx_TaxYearsThroughDecember312017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=exdx_TaxYearsThroughDecember312017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140183249186304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Qualified employee compensation, employer matching contribution, percent of employees' gross pay</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Qualified employee compensation contribution, amount</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>76
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" !42W)8N(/[2Q (  #O,0  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;+6;77/B.!:&_XJ*[=KMK@K!'P22GH0J&I)>=B89-O1T3\_47 A;@*IMB9'E
M$/[]'MF <4H6]I:X"=CXO+:>2.*\TN%VP\6/9$6(1*]QQ)*[UDK*]<=.)PE6
M),;))5\3!I\LN(BQA$.Q["1K07"8!<51QW.<7B?&E+4&M]FYJ1C<\E1&E)&I
M0$D:QUAL/Y&(;^Y:;FM_XIDN5U*=Z QNUWA)9D3^MIX*..H<5$(:$Y90SI @
MB[O6T/TX]F]40';%5THVR=%[I)HRY_R'.IB$=RU'/1&)2""5!(:7%S(B4:24
MX#G^WHFV#O=4@<?O]^H/6>.A,7.<D!&/OM%0KNY:URT4D@5.(_G,-_\FNP9=
M*;V 1TGV%VWR:[N]%@K21/)X%PQ/$%.6O^+7'8BC@&NG(L#;!7AO MQN18"_
M"_#K!G1W =V,3-Z4C,,82SRX%7R#A+H:U-2;#&86#<VG3/W?9U+ IQ3BY&#$
M7XA ;?3;;(S>O_N WB'*T".-(OBG)+<=";=0%W:"G=RG7,ZKD',]],B97"7H
MGH4D+ MTX-D.#^CM'_"39U0<D^ 2^>X%\AS/USS0R!S^B,4E<KM9>%<3/C:'
M_R=E<'='=_=2:_P#;C_3\XVX_QS.$RF@R_^E(YPK=/4*:A[XF*QQ0.Y:,- 3
M(EY(:_#/?[@]YR<='9MB8TMB)7+= [FN27TPYD$*\XU$7[9KHL-F#G>=]L\Z
M/L:HIGPLB97X7!WX7-7C,V0LQ1%Z)FLNI Z464>*5(=W9(QJ"LJ26 E4[P"J
M5P_4E C*0S51(9@ZM7WJA-)^:JJ<FXSQ3:%9$BM!ZQ^@]8U-':5"*&8/- F@
M<WTG6!C!F=7:;==K^ZZ.F#&P*3%+8B5BUP=BUS7G*X$A2\J2G.HQ:=9:X"C1
M#DIC6%-:EL1*M&X.M&Z,+;QGDLHM=*^(H*<TGA.AHV36<!RW[=\XW1L=*6-H
M4U*6Q$JD7*?(V)PZK)[)DJHL KK8$XZUH_"4T._#S_=/:/(TNM0A,T<W969+
MK0SM*,UUZT";L( +&(18C<<+-),P?R$NT(BG3(HMO(9ZDF;U\;T6H#&H,4!+
M:F6 7@'0JP/P"WY%DQ#F-;J@04;1,%Y/2'I.V^GZW>M>3TO/&-R8GB6U,KTB
M[7>-N?&>WC ,03VYV+]!O\!UZ%>F[W-F2=?KN1 /Z$'X&]YJ&5I-_VVIE1D6
M!L UI_!O&8[4$8S=+WS#M/S,<E]A]L1::%8]@2VU,K3"%;CF=/XMM,.,-Q7\
MA;) W_/,FJ.A%IM5AV!+K8RM\ BN.;5_BVW*H;-$Z ^ZKOZ*,"O>>,ZU-N,U
MQS7F=@Z7X!8VP3WA$S)J@N!J3&:!]_V>\T&+R:HSL*56QE1X ]><T/_"E8N:
MKC@SI;LG1*YZ3MN]<O2=RJHSL*56IE5X ]><V'^A$FP!7R#7>S__@&8D2 7T
M,RTRL]*(QS%D+#/)@Q\7: TF]@5'*4'OG$MP#VA-!$I66&B]EEFZ,=)S> BO
M\!">.?4'4QI2MD2S;3SGD8[D"8'?/S]I%V.M>@9;:F5(A6?PS%G]OJ.A^]=@
MA=F25!JM$T)/P]EX^%\M+ZL6P99:F5=A$;Q:%N$;B:+V#P99&0Q5G, <%Z))
MDJ3Z2>Z$YA/78K/J#6RIE;$5WL"KY0V^\@@\*!;Y*HC0;KZ<4*J 9=4$V%(K
MPRI,@%?+!.S7(_,5M6PF@\0VU4,S*WXGNJB1.:HQM7.X *]P 5XM%S!ADHA\
MIU6MW.(]1BTULV(5-:LFP)9:F5IA KQ:)B ;CF@$OFG)A3;K.*'SQ%D;!P$!
M&1 )<T$M/:M6P)9:F5YA!3QS)K^C-XMQ%*%/:0(?)_KQ:=:IVI RAS6&=0Y#
MX!6&P#/G\CM8]S$12S6;?08%N0(3%:\QT_<YLV E-:O&P)9:F5IA#+Q:NP;W
MK\>;+/FVGA:96:URE\4<UYC9.3)_O\C\?7/B/AD]/*-A&E+)!1I*21*9+^,^
M1'BI+4<PZU52,\<U+CTXAQ7P"RO@GUC@W^_F/5"&64#!O6<K:=FY>R&R+03X
M+LV*F;04S?K5%*T:!%MJ98J%0?!K&839"AR":6X[(5,-RZHML*56AG54*53+
M%DS3>40#&)T<:_,TLTKC<B&[]4*YVE6FIBH07P9^_]*_[;SHR!0>P*_G 4J+
M.3.U;I.@7U,)$QI3BQM:6C:S^M%.K7?4/K?O^5?]*_?0QAV)<^3_?I'_^_6*
M@Y*C#5!(1.=J%WE!P +H]P%.J(Z(D)@R1%E>?YJ7@OZ=4@':DJ,Y02%-@H@G
M< S73;&0:#*9J*4\N:()7*S<&X)W],UCB?UCH87@,5Q-X-1^O_M?B:KLI(QF
M1F8J^.OV:#:&9\FN5P5_^V*H1T(RDP@WSKK+BD<A6.P+M%G18(76F41RD-A0
MF)_@Z1>0J(>(<8DB^$C)8H9<ST$AWB8(+_)S!!$6YFU2(5F!S%85R 2JV"]O
M3]9<5:B*5"&:=KO=#+OQT#N'=?(+Z^37++(Z+AAZ@)-:!W!"K*JZRAS6F-@Y
M[))?V"7?;'/>$MM5IU4S,\L]?-<2L^J9;*F5B16>R3=;G"'@"G-D5:GK_UE6
M98YKC.D<)LDO3))?RR2- )2 ?C5A(7E%/Q-]XG6JPLIQO7ZW[_>UU*S:)%MJ
M.;7.486\\MC9+PT2F*%3)O-B^</9PZ\9AED-?Z>X//\IQ"-6%CU!$5E J'/9
MAYE6Y+\NR \D7V?U]G,N)8^SMRN"X?M&70"?+SB7^P-U@\-O/ ;_ U!+ P04
M    " !42W)8;C+=Y#<"  "V!0  &    'AL+W=O<FMS:&5E=',O<VAE970R
M+GAM;(V4VX[3,!"&7\4R$E=5DZ8'H"21>F#%2BQ46RU<("[<9)I8&]O!=C;+
MV^-#&HK41KU)//;,YW]LS\2MD,^J!-#HE55<);C4NEX&@<I*8$2-10W<K!R%
M9$0;4Q:!JB60W 6Q*HC"<!$P0CE.8S>WDVDL&EU1#CN)5,,8D7_64(DVP1-\
MFGBD1:GM1)#&-2E@#_JIWDEC!3TEIPRXHH(C"<<$KR;+]<+Z.X?O%%IU-D8V
MDX,0S]:XSQ,<6D%00:8M@9C?"VR@JBS(R/C=,7&_I0T\'Y_H=RYWD\N!*-B(
MZ@?-=9G@]QCE<"1-I1]%^QFZ?.:6EXE*N2]JO6_T :.L45JP+M@H8)3[/WGM
MSN$\(+H2$'4!D=/M-W(JMT23-):B1=)Z&YH=N%1=M!%'N;V4O99FE9HXG:Z:
MG&ITS_WUFG.* VVP=C'(.L3:(Z(KB$F$'@37I4*?> [Y_X# Z.E%12=1ZVB0
MN(5LC*:3$8K":#K F_9)3AUO>FN2Z.?JH+0T3^+7I7P];7:99LMDJ6J208)-
M'2B0+X#3MV\FB_#C@-99KW4V1/=:A41?"8-+VH:CU]MOZ&F_&J'=>#,>4#/O
MU<QO4O-%9%=?QS!A3SC:4BC$"&U(1<T5<$H&E"UZ98N;E-U1R=#]]I*P84 T
MN_BT@K-:8B +US$4RD3#M2^K?K9O2BM?B__<?4=[(+*@7*$*CB8T'+\S)R5]
ME_"&%K6KS(/0IL[=L#2-%:1U,.M'(?3)L!OTK3K]"U!+ P04    " !42W)8
M1/2=BJ,%  #A%P  &    'AL+W=O<FMS:&5E=',O<VAE970S+GAM;+58VW+;
M-A#]%8R:Z65&M@CP[MB:B97)M ]M/7'2/D,D9&%"$@H ^M*O[X*228H :25U
M'VSQLKL\NUCLV<7E@Y!?U)8QC1[+HE)7LZW6NXO%0F5;5E)U+G:L@C<;(4NJ
MX5;>+=1.,IHW2F6Q()X7+4K*J]GRLGEV(Y>7HM8%K]B-1*HN2RJ?KEDA'JYF
M>/;\X"._VVKS8+&\W-$[=LOTY]V-A+M%:R7G):L4%Q62;',U>X<O5B0Q"HW$
M7YP]J-XU,JZLA?AB;G[+KV:>0<0*EFEC@L+//5NQHC"6 ,?7@]%9^TVCV+]^
MMOZA<1Z<65/%5J+XF^=Z>S5+9BAG&UH7^J-X^)4=' J-O4P4JOF/'@ZRW@QE
MM=*B/"@#@I)7^U_Z> A$3P$'(PKDH$!.5? /"G[CZ!Y9X]9[JNGR4HH')(TT
M6#,736P:;?"&5V89;[6$MQST]/*:%K3*&+HU%A0Z0Y]OWZ.?W_R"WB!>H4];
M42M:Y>IRH>%C1F61'0Q?[PV3$</O67:.?#Q'Q".^0WUUNCHY5E^ BZV?I/63
M-/;\$7NK6DI6:425 C\O7/[L#01N V8[7:@=S=C5#/:+8O*>S98__H C[ZW+
MNU<R=N2KW_KJ3UE?KJC:(E@UE)D+]K7F][0 YYVKN#<5-Z;,GK]?^E&0PHK=
M]]VQI2+BI[B5.L(9M#B#29SOLDS4  O*0<8 X[I@<U0Q[8*YMQ3U 80A'J!T
M"'EQ[ 89MB##29 WDNTHSQ%[A,JIF&H"*_262=B>_9QRH0XM0$&<Q@/4#B$<
M^&[448LZFD3]26A:G  P<@!,@F%<;:F81'AD]>,68OQ"8(&+I'YJ FJ2= ?L
MH$<3(+8PA,0; K6%$IR.)$#2XDPF<?X)**GFU1TJ&/ %DH88SL3FK(:;\<@F
M%A2?)-$ KRT4)$GHQINV>--IO$UNC@-+[4V"A[ALF9 D;EC8ZYC&.R$GQX$=
MU(^^&J5!,,#F$$LB0D:R$?>($)_$$ 6G:UYPS9F;)@YF7HDG7LO:L=,=*^))
M(NI*\(X^F?KK=)C8J8S]X=9S27E!-+(J'97A:2X;[K[>ZCBQ^A:*-!YFMT,(
M>X$W K5C,SQ-9]="@@Y 56?/A7<GI&E6G4AMLB*1E>NV$$['@':,AJ<I#19=
MUBQW,-E+T;6I*@[M3+"E0C\8J<*X8S3\+93V$E*;LC!$C@RAVF)I1$:X%W?,
MAJ>IK9<)E:B&V=!0'!(;E'-UV'UF)7*VUH@K53?]>";42)6T.0ZGQ%X$6XPD
M<3Q6Q#LRQ--L^$?/'_&->]-F.Q)'WA"X@Q/[_>@Q[HX4\2FLV%^-E]#:'.B'
MP];-(91$(YE..J(DIQ#E"_B(38-^0,)A.!UB@1]'(VQ).K8DD\2T7(FRY-IT
M;/OLS41E,H%5V1C>[R ZY)RL_KNA8Y][(^3T#'FK1?9E*XJ<2?53T[+J)_<D
M^;JCY/\Q2Y*.@<DT \, M&&P97*DC/]S],8[]SP,'8-$,%?6#$$90&I+)7N+
ML#?WO.9O_P22H]9;(?D_+(>Z)YZ?FCH'%H5$HM9*0P:9,D(U@KF?E6LP^'QT
MT&37\"EQ1MVF=6LW3(D<QZ>C?3)-^V8GB.J4X!!O(CK?X#R$.9Y[03A/PZ"1
MP-$\#-)YF@2#^#8,_UT!GL-0KG:L.60KGISA=O0FP_HX+7,<\*Y](2^T+WG.
M#8]"C323^1FO4$9W'&JF$Z;=C?@>3JP3#H<<26%8'\N/KF\ATWT+=%MU61=4
M,\/Q&YYQYWQ+[%;DC,0IL68SIV 8AF0LL%W;0J;;ECWO*$>5<P)V=!@$YK4A
M7%LL($$T%M:N$2'3C8A%DDT>GPP^L0ZT7+.F0\PU:RYZYZ_F\/MW*N]XI: M
MVH">=QY#;LG]>?+^1HM=<R2[%EJ+LKG<,@J@C0"\WPBAGV_,*6][JK_\%U!+
M P04    " !42W)8MJ20(]4"  #V"@  &    'AL+W=O<FMS:&5E=',O<VAE
M970T+GAM;*U676^;,!3]*Q:;ID[:@B&0CRY!6E--V\.DJ-&V9Q=N@E6#F6V2
M;K]^MJ$,6I*P*7D(_KCG<([M:^[BP,6#3 $4>LQ8+I=.JE1Q[;HR3B$C<L0+
MR/7,EHN,*-T5.U<6 DAB01ES?8PG;D9H[D0+.[86T8*7BM$<U@+),LN(^'4#
MC!^6CN<\#=S17:K,@!LM"K*##:AOQ5KHGMNP)#2#7%*>(P';I?/1NUYY%F C
MOE,XR%8;&2OWG#^8SI=DZ6"C"!C$RE 0_=C#"A@S3%K'SYK4:=YI@.WV$_LG
M:UZ;N2<25IS]H(E*E\[,00EL2<G4'3]\AMI0:/ABSJ3]1X<J-@@<%)=2\:P&
M:P49S:LG>:P7H@7PC@'\&N /!8QKP-@:K9196[=$D6@A^ $)$ZW93,.NC45K
M-S0WV[A10L]2C5/1#6$DCP%M#(-$5VLB(%<I*!H3]A:]1Z^1BV2J1^7"5?J%
M!N;&-?E-1>X?(;^%>(3&WCOD8W_< U\-A_M=N*MM-E[]QJMO^<9'^-;ZA( 0
MD""]K/%#GY^*(.@G,"EU+0L2P]+1.2-![,&)WKSR)OA#G[L+D76\CANOXU/L
MD=Y'M">L!'1%<Y1PQHB0J !1;>;;/O,5X\PRFO3?1WB$L;=P]VU7YZ(Z<H-&
M;G!2[L:>,$1*E7)!?^LM,K*K<]>KM:*;M%1XN/H]DSL@L*,X;!2'0Q13*<OS
M:D]2_>NQ"E\X.F)ETEB9#+&B+WFI2)[0?'?.S^2$A$KDR3?^Y]F?-GZF)_-\
MQ;-,?R&.)OGTDKMQ(;*.T5EC=';Q))\-2O)S41VY\T;N_+))/G]QS'S<G^5#
M(CN:/?SW XDOE^@U5^>ZF>(@G(?!,\5]D9,PF,]GP1'%K4^Z=^%\K@F'R.Z)
M[)?MMHH24Q%^)6)'<XD8;#44CZ;Z'A-5D55U%"]LG7+/E:YZ;#/5A2D($Z#G
MMYRKIXXI?9I2-_H#4$L#!!0    ( %1+<EC7FLY4C@0  !P1   8    >&PO
M=V]R:W-H965T<R]S:&5E=#4N>&ULK9A9;^,V$,>_"J$NB@1((I$ZG=H&<O0(
MT&V#9+?[4/2!ML:VL)+HDK2=?ON.#DNV1*E;("^)CIGA[\\A.1I/#T)^51L
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M[<VER<SS!G80;4LC':U +6)2%DDCH=L;FOHTZ +VK2+7&<!K*Q@=+V%EJA>
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M018&^'XEA#[>% ,T/XC,_P502P,$%     @ 5$MR6/)DXI.B!0  N2,  !@
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M!KQPT[+%3PIR+(#SVMHP?K"#Z4?*YE]02P,$%     @ 5$MR6.'\."40(P
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M+HXX2H'J@$TLEF%M)NP4Y9W1?7-2JJZ8Q;"!7=CS)8XM:J]1IT$H9FKM-F)
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ME/N@YUZ,+.U'M+DT1N;V[XI1( 0N@/F%E*9Y00/;KZK3_P!02P,$%     @
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MQ%%4-7!B 7!K84U(Y\B[GGXEUZP<1/'2UG"QK58H.5>%\HJ-5I4U#PIS2IP
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M/! VGF3C@S=5.#W.C<=9--SF./R390%\7Q@$W3RP@^[?"5=_ U!+ P04
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M1OW8 S =  FN66#](^DQ XQVJ2#@K<-P:*_:OP@A)?.:RYTWJK9;+X2PU:H
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M!*#K1UPM6%7ZA]-&67J&^65.[U[4[@*=;Y6RK> ,="_IU=]02P,$%     @
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M0GBR,[.V=X=7?9NN6]__Y&RG"YZ<FY4W[7BL<J4I",\ZE>E=-WV1A]J3$'#
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M5O/):ZIV*8W&[%VK,#L5CRAD1IRQN2C%0EH@<S)/6#)-G+'$8B%<D7 $FN3
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M=VO2?OX8(=N0<XB):/:<:$&5H2/4Y\5>^LUS;2WH%/45S]MI @[[IK1!#-\
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M=@#S-.7.9D+4)VW>IEJ7P5]Y1U^P+3[ &^"R3?M@!ZA^UQE&"824FT2CBQX
M77Q EN1==34RVDATS0[4JEBLJ92N74EPZA;Q8T7I8Q&MA,,3(P7C5RY-=P[I
M_6$EQ$1CD-UK^D\MYD\!E@G"L;+4ZH[3<$-1P\MH<$XS1@@_+HF '.\[QPF-
M8%.B'Z*B'CS5[>'!&"I0;_RP-92ZDK:92+VWG^?S9HS=AS<?@VNF-YR$"LP(
M&@W>G0:@FP';&%:5?JBME:41Z9<Y?9-0NP!ZGREE.\,EZ+]RL]]02P,$%
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M;'JV86=EWWKOO+1]2\B*@&]+!O <)HD,.'T.8:&W@&Z7WE;8EL4T&=-\I@
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MQ C5>^EBY4S!"K?IU#M?6 F7H;QB,QV=R&NUQME[-M-GKSZ\?G_NN4867ZZ
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M3#^QP>3''X)T]/,1;^/>V_@8^F2.I5DV@KFLW2I9,(E^>I+CP ,WCP06&]^
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M"D"W#;*=6%7[IK12EEJ<'V[HFX+:&=#^6BF[F[@ _5=J_A=02P,$%     @
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M"N[23)H-L+X00F\'YH#V=C[]"U!+ P04    " !42W)8LMS\6PX#  !0!P
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MX W+Q1JBX7"&XYOVMT@_L&KG;FXK97$/=)];7+R%I@7XOU;*-@,RT%[EE_\
M4$L#!!0    ( %1+<EA#3<DI9@(  -0%   9    >&PO=V]R:W-H965T<R]S
M:&5E=#(X+GAM;*U474_;,!3]*Y:')I!8DSAI.[HV$K1"V\.TBH[M8=J#F]PV
M%HX=;*=E^_6SG1 5"*@/>XF_[CGWG.M<3_=2W>D"P*"'D@L]PX4QU20(=%9
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M8#@8#S%2S1O2+(RL?!NNI;%-[:>%?79!N0![OI'2/"Y<9W</>?H/4$L#!!0
M   ( %1+<E@]MVP%40,  /<.   9    >&PO=V]R:W-H965T<R]S:&5E=#(Y
M+GAM;+57VX[:,!#]%2N5JE9JR97+;@$)V%:M5"0$:OM0]<$D0W WL:EM8%?J
MQ]=V0B H1%!E7TCLS)S,.3XQGOZ>\4>Q!I#H*4VH&%AK*3?WMBW"-:18M-@&
MJ'JR8CS%4@UY;(L-!QR9I#2Q/<?IV"DFU!KVS=R,#_ML*Q-"8<:1V*8IYL]C
M2-A^8+G686).XK74$_:PO\$Q+$!^V\RX&MD%2D12H((PBCBL!M;(O9^X@4XP
M$=\)[,7)/=)4EHP]ZL&7:& YNB)(()0: JO+#B:0)!I)U?$G![6*=^K$T_L#
M^B=#7I%98@$3EOP@D5P/K)Z%(ECA;2+G;/\9<D)MC1>R1)A?M,]C'0N%6R%9
MFB>K"E)"LRM^RH4X27 [%Q*\/,$[3P@N)/AY@F^(9I496@]8XF&?LSWB.EJA
MZ1NCC<E6; C5R[B07#TE*D\.%]GR(;9""Q)3LB(AIA*-PI!MJ20T1C.6D)"
M0._1''9 MX"6SVB*?S..9O@9N$!O'D!BDHBW*F9B:@:.)HR&0"7'9KGF1#SV
M;:DJUN^UP[RZ<5:==Z$ZUT-31N5:H(\T@J@,8"NJ!5_OP'?LU2(^0-A"OOL.
M>8[G5Q0TN3[=JRG'+^3W#5YP 6\*D1*< _I[$+=*I%H,_:'?BPT.86"I+UD
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M5TWF?4?)9"6]2[30%5I;^B;3]>VIKM):I;CRVPG($ET2ZTT ?\U)IK4_ ;G
MBSP!"5F8PZ(=? "^8<1-N\C,WO-H$7]&(NPWF;!O3X5OT-.S7N\RH9TY10M=
MH;55:Q)D/WA=KW>4$5?2NT0+7:&UI6_2==^>K_]/K[>#CRQ>[RAOKT3\&56
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MK)D6K>439LJ^4$+O$HU3R:(I-^(%6I 5(P7),%/H,LMXS11A*S3GE&0$)/J
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MVB%XF%;!V!ZF/;C)M;%P[,QV6OCO9SMI5)J *K27QF????NY\]D>;[AXE 6
M0D\E97+B%$I5%ZXKLP)*+$]Y!4RO++DHL=*F6+FR$H!S&U12-_"\V"TQ84XZ
MMG-SD8YYK2AA,!=(UF6)Q?,54+Z9.+ZSG;@CJT*9"3<=5W@%]Z >JKG0EMNI
MY*0$)@EG2,!RXESZ%]/$^%N'GP0V<F>,3"8+SA^-<9M/',\  85,&06L/VN8
M J5&2&/\;36=[B]-X.YXJWYM<]>Y++"$*:>_2*Z*B7/FH!R6N*;JCF]NH,UG
M9/0R3J7]19O6UW-05DO%RS98$Y2$-5_\U-9A)\"/7@D(VH#@T("P#0AMH@V9
M36N&%4['@F^0,-Y:S0QL;6RTSH8PLXOW2NA5HN-4^ET5(- U89AE!%-TRYK.
M,"7^C.8"*DQR]/5)=XT$B8YGH#"A\D0O/MS/T/'1"3I"A*$?!:\E9KD<NTIC
M&7$W:Q&N&H3@%8099*<H]#^AP O"@?#IX>'!RW!7%Z.K2-!5)+!ZX3LJ\OMR
M(970K?=G*,U&-QK6-<?Q0E8X@XFCSYL$L08G_?C!C[TO0TG_)[$7)0B[$H1O
MJ:<S@E>,2T6R1E*!'K-58\BZJBB!P8UN9!,K:^Z/=1J<)?[87>]FUG?RD_-1
MY_2"..J(HS>)MXU:"9[7F4*"/V.J7J%LI.(=@'"TQ]AWB;QAPE%'.#J(T-RL
M"DQS =+G19\=60MK99S9WAID'O6 _+/8VZ/N.P5>$@QSQQUW_"9W<QRJEAZV
M%X%!YW8IJX4 IA"6$H;9XWZ]]WNB[Q*$\3!XTH$G!Q7\7<A)KT>CY#S9@QYP
M\J-PC]K=N9O-N_@-BY7><T1AJ<.\TT1OFFC>FL90O++7]8(K??G;8:&?9Q#&
M0:\O.5=;P[P W8.?_@-02P,$%     @ 5$MR6"B*3O[^ P  !10  !D   !X
M;"]W;W)K<VAE971S+W-H965T,S4N>&ULM5A=CYLX%/TK%ENM6FDZ8$A",DV0
MMID=[4A3;=1I=Q]6??# 36(5,+5-,K._OC80/A(/:B3RDO!Q[^'<P[&Y]GS/
M^'>Q!9#H.8E3L;"V4F8WMBW"+21$7+,,4G5GS7A"I#KE&UMD'$A4)"6Q[3K.
MQ$X(3:U@7EQ;\6#.<AG3%%8<B3Q)"'_Y"#';+RQL'2Y\IINMU!?L8)Z1#3R"
M_)JMN#JS:Y2()I *RE+$8;VP_L W2]?1"47$/Q3VHG6,="E/C'W7)_?1PG(T
M(X@AE!J"J+\=+"&.-9+B\:,"M>IGZL3V\0']KBA>%?-$!"Q9_"^-Y'9A32T4
MP9KDL?S,]G]!5=!8XX4L%L4OVE>QCH7"7$B65,F*04+3\I\\5T*T$O#HE02W
M2G!_-<&K$KRBT))94=8MD228<[9'7$<K-'U0:%-DJVIHJE_CH^3J+E5Y,OA;
M;H&C.YJ2-*0D1O=I:0TM\7NTXLHO7+X@DD;HSQ\YS=0;E.CM+4A"8_%.A7Q]
MO$5OW[Q#;Q!-T9<MRX6*%7-;*G+Z$798$?E8$G%?(7(+X37R\!5R'=<SI"]_
M/=WMIMM*DEH7M];%+?"\5_ .E5^A54Q4R5T!_GM0X>A>0B*^F4HML4=F;#TR
M;T1&0EA8:N@)X#NP@M]_PQ/G@ZGP@< Z,GBU#%X?>O"%266*K&T#.*A@*KQ$
M\PLT/8/L NS,?&=N[]H5&:(\S\5U5(?JJ*8ZZJ7Z $+<J&DAS),\)A(B-9J5
M(LK5Y7RAJ).$<4G_+RZ8V)</F+1XO1_[D]D1>U,4=D=F]N.:_;B7_<HH\15*
MP:CS^(3#V'7P$='3H"F>^6:>DYKGI)?G7<Y3*G,.I<44V_)@39_U5>/ [T4\
M=S0,!-8IWJ^+]R\X*?A#RC 06$>&:2W#=-!)87KBP]GTR*J](1V2LYKDK'\Z
M($^,$\GX2S^Y7I1SW\I 8)V"L=-\RIT+VK,"'TB)H="Z4K2Z&CRH12NXSH3J
M8??(I:8H[$W,1L5-JX%[/^'!DB59+E4;5E,L" NVEGO"P<AWT YC*+1N_4V/
M@;U+^K:W@SE;BH'0NE(T/0SN;V+.]NUI,^+BZ?C8MZ=1>#1U7_%MT[+@_I[E
M =3Z:<OB"-%$4=Z!9FEN_7N!SGY' Z%URVXZ(#RYI%T'[8:&0NM*T?1#N+?/
M.-^N_HD1/0]/CNUZ&C5V]:+0:->F:\'];<N2I4+RO-P^4(M517NC1#$;MA?J
M[+<T$%JW\*83PK-+&G;0#FDHM.ZBOFF1W-Z^XVS#5G#MI>KX>#UHB,'>R>QJ
MM_9H] ;9)\(W-!4HAK5*<ZY]-:GQ<L^I/)$L*[9MGIB4+"D.MT BX#I W5\S
M)@\G>B>HWOD+?@)02P,$%     @ 5$MR6(HE88M&!   #14  !D   !X;"]W
M;W)K<VAE971S+W-H965T,S8N>&ULM5A=;]LV%/TKA%8,+=!$'Y8E.[,-U%;;
M!6@7HUFWAV$/M$1;1"G2)2F[V:\?*<GRAV2F I276*3N/>0Y)*]..-DS_DVD
M"$GP(R-43*U4RNV=;8LX11D4MVR+J'JS9CR#4C7YQA9;CF!2)&7$]APGL#.(
MJ36;%'U+/INP7!),T9(#D6<9Y$]S1-A^:KG6H>,+WJ12=]BSR19NT".27[=+
MKEIVC9+@#%&!&04<K:?6._<N<D.=4$3\A=%>G#P#367%V#?=N$^FEJ-GA B*
MI8: ZF>'%H@0C:3F\;T"M>HQ=>+I\P']0T%>D5E!@1:,_(T3F4ZMD042M(8Y
MD5_8_G=4$1IJO)@14?P%^S(V'%H@SH5D696L9I!A6O["'Y40)PFN?R7!JQ*\
MRX3@2L*@2AC\[ A^E> 7RI14"ATB*.%LPMD><!VMT/1#(6:1K>ACJM?]47+U
M%JL\.7N0*>+@ Z:0QA@2<$_+O:37Y ;\ 3F'>F' ZPA)B(EXHWJ_/D;@]:LW
MX!7 %/R9LEQ FHB)+=5\-*H=5V,ORK&]*V.['OC,J$P%>$\3E)P#V(I(S<8[
ML)E[1L2'6-X"SW\+/,<;M$W(G!ZA^!8,W*OIT<^G>P8V@WIM!@7>X K>DJOC
MS>736[ DD$J@5 ;OO^=XJ\Z=!/]\4N'@7J),_-LRUWF)[;=CZW)R)[8P1E-+
MU0N!^ Y9LU]_<0/GMS;=^@2+>@([T]2O-?5-Z&J-%*C:Z67148+"C'&)_RLZ
MVF0TPG65L00+"S!=D7<S3Q7HB;T[E:<9I.".06>TAS7MH9'V@]I(BB+= ()4
ME01<E\,;MK[)50,*@63;^9T;0;N2+\&"$UX#;Q1<D&\&^:/1L)U\4),/.I$G
M&*XPP1*C5M)&L*ZD@P:?<7C)N1GC.OZ5!0]KSJ&1\R<F!%!;O&2L5AAOJ"X;
M;83#YH8;7N[*1=B<I!]>;MUFT!4:HYK&Z!D:='-#U <HJ78IP-D68GZ-BA&M
MZ]J-#&Q*OLV(P3AL9SRN&8^-C#\RENPQ(<\0-8)T)3I^EF@S8CAT@G:FKG/T
M'HYY=>&*J9/)^!- A^]:&UDS3%>VO:)%?:&=2WABW]P7] @5>%_"]HD6]85V
M+JQW%-8SGT.N*ZC^AP7L(,D18.M#"<J56^5@77AF5%;8U@^)>83.ZGI-\] H
MTU%;U.B:>W"/3M0UFK+9/,<D45_05IJ].LU>T:*^T,YE.YI-UW_)T]FK]^P5
M+>H+[5S8HYUU7\3/NDU[&3:<CGGHSD+UA'8NU-'ZNKUZ7[?I14=-@?ITR%%?
M:.<"'7VR^XQ1UK*DC"3:<'&V0_IHMFO3XI.#ICC&X3J+TQ-:*8Y]<D^4(;XI
M[ML$B%E.97G)4O?6=WKOBINLB_Z%ONLK[I^.,.5%X6?(-Y@*M=O6"M*YU3=K
MO+Q[*QN2;8O;J!63DF7%8XJ@^J#J /5^S9@\-/0 ]0WH[']02P,$%     @
M5$MR6 3I/LB1 @  " <  !D   !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL
MK571;M,P%/T5*TQHD]B2IFV&1AII;1GL86+:&#P@'KSDMK'FV,%VF_'W7-MI
MZ$:;@<1+8COWG'O.C7V=-E(]Z!+ D,>*"ST)2F/JLS#4>0D5U2>R!H%?%E)5
MU.!4+4-=*Z"% U4\C*,H"2O*1)"E;NU:9:E<&<X$7"NB5U5%U<\I<-E,@D&P
M6;AAR]+8A3!+:[J$6S!W];7"6=BQ%*P"H9D41,%B$IP/SF:)C7<!7Q@T>FM,
MK)-[*1_LY+*8!)$5!!QR8QDHOM8P \XM$<KXT7(&74H+W!YOV"^<=_1R3S7,
M)/_*"E-.@K<!*6!!5]S<R.8CM'[&EB^77+LG:7SLZ2@@^4H;6;5@5% QX=_T
ML:W#%F"0[ '$+2!^#MB78=@"ALZH5^9LS:FA6:ID0Y2-1C8[<+5Q:'3#A/V+
MMT;A5X8XDWTR)2ARP005.:.<7 J_,VR)C\D'*8N&<4X.YV HX_H(%^]NY^3P
MX(@<$";(YU*N-!6%3D.#<BQIF+>IISYUO"?U("974IA2D_>B@.(I08@^.C/Q
MQLPT[F6<0WY"AH,W)([BX0Y!L[^'QSURAEUMAXYON(>OJ]ZW&XE/W'8-5<7W
M797R1*/=1/8DG^F:YC )\*AJ4&L(LM>O!DGT;I?+_T3VQ/.H\SSJ8\^FL&1"
M,+'$P\5Q3\$NMY[BU%'8-K/.HC1<;UOX,V(\CI(NZ(FT<2=MW"NM^QVLJBE3
MV(K,+G'C%\7YB&0KXGB_NJ13E_2JPS/P0M5Z\?^Z1Y(>EUY_N-54*E!+UVLU
MR>5*&'\DN]6NG9^[+O9L?8IMWG?EWS3^CKBB"G>+)AP62!F=G&)EE>^[?F)D
M[5K7O338"-VPQ*L*E W [PLIS69B$W277_8+4$L#!!0    ( %1+<EA@2\:'
MB ,  ,(+   9    >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;*U6;6_;-A#^
M*X16#"V01>^2G=D"$@=%"VQ8D*S;AV$?:.EL$Z5$C:3B^-_O*,FJ;=&&4?2+
M38IW#Y][[GCD;"OD5[4!T.2MY)6:.QNMZSO75?D&2JIN10T5KJR$+*G&J5R[
MJI9 B]:IY&[@>8E;4E8YV:S]]B2SF6@T9Q4\2:*:LJ1R]P!<;.>.[^P_/+/U
M1IL/;C:KZ1I>0'^IGR3.W &E8"54BHF*2%C-G7O_;N$'QJ&U^(O!5AV,B0EE
M*<17,_E<S!W/, (.N380%/]>80&<&R3D\5\/Z@Q[&L?#\1[]8QL\!K.D"A:"
M_\T*O9D[$X<4L*(-U\]B^PGZ@&*#EPNNVE^R[6T]A^2-TJ+LG9%!R:KNG[[U
M0APXA),S#D'O$%SK$/8.81MHQZP-ZY%JFLVDV!)IK!'-#%IM6F^,AE4FC2]:
MXBI#/YW]H3<@R4=6T2IGE)//55<:1N)?R'V>RP8*\ANC2\:99J#(^T?0E''U
M =>_O#R2]^\^D'>$5>3/C6@4K0HU<S4R,_ANWK-XZ%@$9U@\0GY+0O^&!%X0
M6MP7U[L'Q^XNZC&($@RB!"U>^!VB_'._5%IB]?UK"[/#C>RXYDC>J9KF,'?P
MS"F0K^!D/__D)]ZOMJ!_$-B1!.$@07@)/>LSW^'5="<%Y]T$,]P-)'"J]R;P
MAHU%@37WW4YINY-I*Z]9E(:3F?MZ&.S8* CC># Z"B(:@HBN"0*+4P-*I&WD
M.H3D8%\_G)YPL]A$@9U:/%"+KZ)6-S+?8!M21*S(6HA"$128F'2RW"YG/&*3
M!MX)X['-Q OMC).!<7(58REVE)M.8..6C/:-DO"$V]@F]B,[MW3@EE[%+<<%
MEN.)5;HI=MT=P?3.QC0=U9OOG]:DQ28YD_?)P'1RD6G75(!PP*3?$-XWUMT-
M-GLIH=(WR!V/%=Z4VI3$:FA"M5#,="!;,)?WW*MC"DNTK:W?:]C>GLW%#X<]
MDFPZ2#:]7C(BEIRMVU:L!LU0&WE.FNFX^4Q/3\O8)O4\>YY][]O%ZEVD_0RK
M!I49,FR]%;W160B]X(2=Q2B*SG1&_^#>]R_2Z^XXVN?P<B$\]%A'9S;Q3WF.
MC8(@.</SVU7L7[SFOKMX'WK<HZS&X8CTV"H.H_2$M7OPP#*OV]^I7+-*84FN
MT,V[3;'?RN[!V$VTJ-LWUU)H?,&UPPT^LD$: UQ?":'W$_.,&Y[MV?]02P,$
M%     @ 5$MR6+3(;#SA!P  FD,  !D   !X;"]W;W)K<VAE971S+W-H965T
M,SDN>&ULM9Q=;]LV%(;_"N$-0P<DL47%CI,E!I)(P@JT19"LW<6P"T:F$Z+Z
M*DDG#= ?/U)61%%F: L[S44KV3P/*;W\?$WI_+GD7\4CI1)]S[-"7(P>I:S.
MQF.1/M*<B*.RHH7Z9E7RG$AURA_&HN*4+.N@/!OCR60VS@DK1HOS^K,;OC@O
MUS)C!;WA2*SSG/"7*YJ5SQ>C8/3ZP2U[>)3Z@_'BO"(/]([*S]4-5V?CEK)D
M.2T$*PO$Z>IB=!F<)>%,!]0IOC#Z+#K'2%_*?5E^U2?OEQ>CB2X1S6@J-8*H
M_Y[H-<TR35+E^-9 1VV>.K![_$I/ZHM7%W-/!+TNL[_94CY>C.8CM*0KLL[D
M;?G\)VTN:*IY:9F)^E_TW*2=C%"Z%K+,FV!5@IP5F__)]^9&= (P?B, -P%X
MWX"P"0A[ >'Q&P''3<#QOCE,FX!I+R (WPB8-0&UF./-S:KO=$0D69SS\AEQ
MG5K1]$$M5QVM;C K=,VZDUQ]RU2<7%R57$6PXD&@0_2)<$ZTTNA=1"5AF?C]
M?"Q5+CKM.&V(UQLB?H,8H(]E(1\%BHLE73KBHQWQV ,8J\*VUXA?K_$*>XF7
M%3]">'Z \ 2'Z/-=A-[]ZKPP/^:.5D<HG&A,<.+!1'Y,1%.%">S2(%8(2;),
MM5GI0,;[([&G9(D?\Y&\M!3/;0_;JA76N/#-4MU+]%Y=%U_KRT+_?% )T'M)
M<_&OHW!7&]JQFZ9[V#-1D91>C%07*BA_HJ/%;[\$L\D?+BDA81$D+(:$)4 P
M2]_C5M]C'WUQPVE%7FIIRQ6J."M25I',):T7-%1:2%BT@9W4,#T*/RV"R>;O
M?/S4E6T[82]% E0N2XMIJ\74JX7IQ@^+LCA,UYQK7:J2Z_'[ !6T%FG)1%JN
M"RD0*99J %8-E FQ)D5*45H**5SB>7,>*AXD+-K 9EWQ3G$8;(LWW1(/ST].
MYEL)$Z#B61K.6@UG7@TO55-2 Q[Z4)("73YP2NNV]4/UH47Y1.1:H ]L1=%=
MRJ@23)VI]$IRE*R5F#\V<:I%DON,NG3TYCY41TA8! F+(6$)$,RJ#R=M?3@!
M'3]/(/6%A$60L!@2E@#!+'WGK;YS;WO_B_(<9;K1WK>]MTM7+V6HKO/MGG#J
M&N\BR%QC2%@"!+,T.VTU._5J=DOU:EUWNJUF*"4J.R9?7-IY:4.U@X1%I[OF
M,S%D=@D0S!(MF)A%[@1JJMJ0=L\(K_UY#M4#E!:#TA(HFJU>QZ((]NLH#]0R
M65*5A42<2.<DIT'I$IN*?33!?>V\.0[6#I(6@](2*)JM'3;:X7VUJPA;*@$/
MO[)BN8^2&W 0V$H&T[Z4W@(,EA*2%H/2$BB:+:6Q<P*OF]"5DJY6M+:$]Y 1
MU-8!I44-K==9!$%O('Q-UJN)\V;BU/SUHA*HHMIJ&7,F\+LSG];Y/>5ZN,NU
MFYJ]="U&H9:+?L?QRH\?K!NH:=/0K(5_?_8"FF,"1;/%-.Y.X+=W.DUO176C
MJPV>)5I79;WD?YW9K%A!LIW*@AHZH+0HV'9J J<=!YIM D6SY37&3^!W?KJ#
MI)FIJL.<K7-449ZJ<_+@[E]!;1U06M30^I.QK?X5U+*!HME:&M,F\'H&72W3
M\HD6I) 'B%-UM*9:ROK'8.VWJF-6NGX?N_+G,%A24"MGQ]4'>#/<N(R,&+0D
M"13-UMF8-X'?O:G=.=:Z<P?ZQUF6J^::$O&([DFF17:J"^KG@-*BAM9KL--^
M>P6U<Z!HMH[&T G\CHZSO1;MY&E)7@22)5(#+FT3(+:RFG).B=#?,X&*4JI3
M][@+:@:!TJ(=-RF<U#?"V:A!;2(HFKU/P/A$V.\3&4O6U(77=KTN]#J'LU2J
MB=>N1N[/9ZC6H+0(;SM<V#G' LTV@:+9TAH3"?M-),A?U]3I#6<Y1;=O+'K]
M91DL/ZA9!4J+06D)%,VN(\:LPACT%S<,:>]<@](B4%H,2DN@:+;,QLC"?B/K
M"^&L;L9O>5;8Z0M-YCWGT9_-8,% =QF!TA(HFBV8\;*PW\OZOWWW3<=YUC,T
MM^B@AA<H+0*EQ:"T!(IFUPUCC>$I;)\-ZGZ!TB)06@Q*2Z!HMLS&(L/[6V3=
MUJP_$O4F-N=>XRL_=K#<H/980^O:V,?.>?AL:\(^<Z1+H$IG2V2<+^SW?G[F
M'D1_UH-E!+7$&IKE6<^Q4TA0 PR*9LMM###L-\#J7?!FP0RV3=&?[6"I0?TQ
M4%H,2DN@:'9U,#X:/H4=AT'=,%!:!$J+06D)%,U^I,,X9.%PAXP5*:=$4.V3
M[MP/X.</?LP#U!EK:/UUWW&O&P?--(&BV8(:7RST^V+QMS6KZA;[22V,A%HK
MO=DS^TF#I0-UM4!I,2@M@:+9"AM7*X1UM4)05PN4%H'28E!: D6S9>X\;?<S
MMF?YH8/%AGWL#O:Y.]@'[]Q[PJ;8F(2VCL;L"G=LW*J[8<\$V1\_6#)0HZJA
M==="<]=**-S>P>5*ET"5SM;"F$NA?]^5I05J5K1.34!=)5!:%&X_)A<Z-=E.
MYUK%)E"ELS4Q3E#H=X)L38JR\,D"ZOZ TJ)PV]69.F79T_V!*MU&EG'GE0(Y
MY0_URQ\$JIV;S9/W[:?M"R8NZ]<J]#Z/@K-X\YH(@]F\M>(CX0^L$"BC*X6<
M')VH>L4W+X+8G,BRJE]<<%]*6>;UX2,E2\IU O7]JE15H3G1&;2OXUC\!U!+
M P04    " !42W)82_:L@2L#  !H"P  &0   'AL+W=O<FMS:&5E=',O<VAE
M970T,"YX;6RMEEUOFS 8A?^*Q:JIE=KR#4F7(+6-IO6B4M2/[6+:A0-.8A5L
M9INDW:^?;:B;$$JJ;#<)!I_CY]A@OZ,U94]\B9  ST5.^-A:"E%>V#9/EZB
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M;H &($P#_7W%N7IY, ,4YW:+_P!02P,$%     @ 54MR6%,Q'?<@!0  KQH
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M<XVEIR/I@Z";Y(!A086@87*[)M@C+'Y!_KZD5!P>8@?Y&=7L?U!+ P04
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M#(%K _5\R9A\GN@-REYS_!=02P,$%     @ 54MR6*PEV8%_ P  ^P\  !D
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MBR>Z^065H6O%%]&<ZU^TJ6(="T4K+FA1@:6"(B/E%V^KC=@#N,$9@%<!O&-
MYPS KP"^-EHJT[:F6.!PR.@&,14MV51#[XU&2S<947_C3# YFTF<".])1 M
MSW@+'%VB"2V6E  1'-$$O4VBVZU,' ZH-08"22;:J#4%@;.<MR7L939%K8LV
MND 90<\I77%,8CZTA52HUK&C2LVX5..=4>-ZZ($2D7)T2V*(#PEL::WVY^W\
MC;U&QBE$5\AW?R#/\7R#H,G'X5Z#'+_>;E_S^6?X)BO&Y.X.3%M3(CMFI#K.
M [[$$8PL>5XYL#58X?=O;N#\--GZ(K(#DYW:9*>)/;R#&!C.31Y+8%<#U0VS
M#IVAO=X7WA1QH.:Z5G/=J&8FL "3EA(6[*UTZ?M':@PQ7L>L)ZCU!(UZGJG
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MUF<FK=MP_4W31OTMEB7A"E$H#&4P>F<4R38^VXD6M4N@E= FS]RP,E\<D+;
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M:9[;V@2-(#\2D!^9PP;MU(ES;: %:UF^T^%%(ZHC'C%W+]8YNP(EX3<M(M7
M[(9O2GK5HZ&,$#$K86JK2H=F)R%-(:8P:(!@*7B>?4;*$!&S(LZE=N)6EK42
MWR%XM>LZ$HQ'R2%BM\-&CPNC,\Q&J2%B=P.P@;&:"C$#TV(P2@<1LP\N3&XK
M)6[DS_Y[1DD@8K9 .HH.'CZ\"1-E@6B?&O@GQIB4!R)F$="8"1[]4C*(F65
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M'W!B#^6Y+/.9$\U/MQ:>9LU*UKPNRRF479IO5A;KS\G6G\)]_@]02P,$%
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MY2_+KYUXOV@O."?X=^?Q+U!+ P04    " !52W)8=-+&8MX!  !:(P  $P
M %M#;VYT96YT7U1Y<&5S72YX;6S-VEU/PC 4!N"_0G9K6.D7?@2X46_5"_]
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( %1+<EBX@_M+$ @  .\Q   8
M          " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " !42W)8;C+=Y#<"  "V!0  &               @(%4$   >&PO=V]R
M:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ 5$MR6$3TG8JC!0  X1<
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M965T-RYX;6Q02P$"% ,4    " !42W)8R<=+WZ<%  "P#   &
M    @(%O+@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @
M5$MR6.'\."40(P  9&H  !@              ("!3#0  'AL+W=O<FMS:&5E
M=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( %1+<EBR=US_E0@  ,L5   9
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M970Q-"YX;6Q02P$"% ,4    " !42W)8\!G9\X8$  !5"P  &0
M    @('M@@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (
M %1+<ECX(GHP[@@   \;   9              " @:J'  !X;"]W;W)K<VAE
M971S+W-H965T,38N>&UL4$L! A0#%     @ 5$MR6",0C'L "0  ]Q<  !D
M             ("!SY   'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"
M% ,4    " !42W)8S1N#TP\#  #Q!@  &0              @($&F@  >&PO
M=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( %1+<E@\FK+0BR$
M .=I   9              " @4R=  !X;"]W;W)K<VAE971S+W-H965T,3DN
M>&UL4$L! A0#%     @ 5$MR6);WTF4:!0  ) X  !D              ("!
M#K\  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " !42W)8
M#P?R\<0$  ":#   &0              @(%?Q   >&PO=V]R:W-H965T<R]S
M:&5E=#(Q+GAM;%!+ 0(4 Q0    ( %1+<EB(_E@^ 0,  +$&   9
M      " @5K)  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%
M  @ 5$MR6'I@O3]9!0  J0\  !D              ("!DLP  'AL+W=O<FMS
M:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " !42W)8LMS\6PX#  !0!P
M&0              @($BT@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+
M 0(4 Q0    ( %1+<ECO:_MS" ,  -\&   9              " @6?5  !X
M;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ 5$MR6+[G )TI
M!0  -0T  !D              ("!IM@  'AL+W=O<FMS:&5E=',O<VAE970R
M-BYX;6Q02P$"% ,4    " !42W)8<9NG<!H&  #6#P  &0
M@($&W@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( %1+
M<EA#3<DI9@(  -0%   9              " @5?D  !X;"]W;W)K<VAE971S
M+W-H965T,C@N>&UL4$L! A0#%     @ 5$MR6#VW; 51 P  ]PX  !D
M         ("!].8  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
M    " !42W)8DV8PP\D%  "K(@  &0              @(%\Z@  >&PO=V]R
M:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( %1+<EBC0B:A<@,  .(/
M   9              " @7SP  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL
M4$L! A0#%     @ 5$MR6#G<II2F @  ( @  !D              ("!)?0
M 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " !42W)8 I_#
MVJP#  #Z$   &0              @($"]P  >&PO=V]R:W-H965T<R]S:&5E
M=#,S+GAM;%!+ 0(4 Q0    ( %1+<EA8>=%YQ@(  /P'   9
M  " @>7Z  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @
M5$MR6"B*3O[^ P  !10  !D              ("!XOT  'AL+W=O<FMS:&5E
M=',O<VAE970S-2YX;6Q02P$"% ,4    " !42W)8BB5ABT8$   -%0  &0
M            @($7 @$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4
M Q0    ( %1+<E@$Z3[(D0(   @'   9              " @90& 0!X;"]W
M;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ 5$MR6&!+QH>( P
MP@L  !D              ("!7 D! 'AL+W=O<FMS:&5E=',O<VAE970S."YX
M;6Q02P$"% ,4    " !42W)8M,AL/.$'  ":0P  &0              @($;
M#0$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( %1+<EA+
M]JR!*P,  &@+   9              " @3,5 0!X;"]W;W)K<VAE971S+W-H
M965T-# N>&UL4$L! A0#%     @ 5$MR6/Q$? YD P  "1   !D
M     ("!E1@! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %1+<EB3 I'2QP4  *0N   9              "
M@<(J 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ 5$MR
M6)1G)%4R!@  ;3(  !D              ("!P# ! 'AL+W=O<FMS:&5E=',O
M<VAE970T-RYX;6Q02P$"% ,4    " !42W)8>IP)L(T#  ">#P  &0
M        @($I-P$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0
M   ( %1+<EC0AY+F"00  .$5   9              " @>TZ 0!X;"]W;W)K
M<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ 54MR6)LA +_P!P  0SD
M !D              ("!+3\! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q0
M2P$"% ,4    " !52W)8KC/X]CP$  ##$P  &0              @(%41P$
M>&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( %5+<EA3,1WW
M( 4  *\:   9              " @<=+ 0!X;"]W;W)K<VAE971S+W-H965T
M-3(N>&UL4$L! A0#%     @ 54MR6$[7^X5F P  =PX  !D
M ("!'E$! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " !5
M2W)8K"79@7\#  #[#P  &0              @(&[5 $ >&PO=V]R:W-H965T
M<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( %5+<EABG=@1_@(  !0*   9
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M970U.2YX;6Q02P$"% ,4    " !52W)8%+"A\IT"  #/!@  &0
M    @(%^:@$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    (
M %5+<EBXK64.2 ,  ,H4   -              "  5)M 0!X;"]S='EL97,N
M>&UL4$L! A0#%     @ 54MR6)>*NQS     $P(   L              ( !
MQ7 ! %]R96QS+RYR96QS4$L! A0#%     @ 54MR6%'SILFU!   CB<   \
M             ( !KG$! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( %5+
M<EB8&UJ>^P$  ,LC   :              "  9!V 0!X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( %5+<EATTL9BW@$  %HC   3
M          "  <-X 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !$ $0
*DQ(  -)Z 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>140</ContextCount>
  <ElementCount>365</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>71</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/BalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StatementsofOperations</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StatementsofStockholdersEquity</Role>
      <ShortName>Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StatementsofCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Other Financial Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformation</Role>
      <ShortName>Other Financial Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Borrowings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/Borrowings</Role>
      <ShortName>Borrowings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Commitment and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/CommitmentandContingencies</Role>
      <ShortName>Commitment and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Stock Option Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlan</Role>
      <ShortName>Stock Option Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - 401(k) Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/A401kPlan</Role>
      <ShortName>401(k) Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.exagen.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Other Financial Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationTables</Role>
      <ShortName>Other Financial Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/OtherFinancialInformation</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Borrowings (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/BorrowingsTables</Role>
      <ShortName>Borrowings (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/Borrowings</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/Leases</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/FairValueMeasurements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/StockholdersEquity</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Stock Option Plan (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanTables</Role>
      <ShortName>Stock Option Plan (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/StockOptionPlan</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/IncomeTaxes</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OrganizationDetails</Role>
      <ShortName>Organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/Organization</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Summary of Significant Accounting Policies - Revenue by Major Payers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Revenue by Major Payers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Summary of Significant Accounting Policies - Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Other Financial Information - Prepaid Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails</Role>
      <ShortName>Other Financial Information - Prepaid Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Other Financial Information - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails</Role>
      <ShortName>Other Financial Information - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Other Financial Information - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails</Role>
      <ShortName>Other Financial Information - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Other Financial Information - Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationGoodwillDetails</Role>
      <ShortName>Other Financial Information - Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Other Financial Information - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails</Role>
      <ShortName>Other Financial Information - Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Borrowings - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/BorrowingsNarrativeDetails</Role>
      <ShortName>Borrowings - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Borrowings - Future Minimum Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails</Role>
      <ShortName>Borrowings - Future Minimum Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Leases - Lease Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/LeasesLeaseBalancesDetails</Role>
      <ShortName>Leases - Lease Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Leases - Costs Associated with the Company's Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/LeasesCostsAssociatedwiththeCompanysLeasesDetails</Role>
      <ShortName>Leases - Costs Associated with the Company's Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Leases - Supplemental Cash Flow Information On Leases And Weighted-Average Lease Term (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/LeasesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails</Role>
      <ShortName>Leases - Supplemental Cash Flow Information On Leases And Weighted-Average Lease Term (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Leases - Future Payments Under Operating And Finance Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails</Role>
      <ShortName>Leases - Future Payments Under Operating And Finance Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Commitment and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails</Role>
      <ShortName>Commitment and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Stockholders' Equity - Warrants to Purchase Common Stock Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails</Role>
      <ShortName>Stockholders' Equity - Warrants to Purchase Common Stock Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Stock Option Plan - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanNarrativeDetails</Role>
      <ShortName>Stock Option Plan - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Stock Option Plan - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails</Role>
      <ShortName>Stock Option Plan - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Stock Option Plan - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails</Role>
      <ShortName>Stock Option Plan - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Stock Option Plan - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock Option Plan - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Stock Option Plan - Common Stock Reserved For Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails</Role>
      <ShortName>Stock Option Plan - Common Stock Reserved For Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income Taxes - Components of Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - Income Taxes - Reconciliation of Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - Income Taxes - Reconciliation of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954510 - Disclosure - Income Taxes - Change In Valuation Allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/IncomeTaxesChangeInValuationAllowanceDetails</Role>
      <ShortName>Income Taxes - Change In Valuation Allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954511 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="exdx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954512 - Disclosure - 401(k) Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/A401kPlanDetails</Role>
      <ShortName>401(k) Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/A401kPlan</ParentRole>
      <Position>60</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 4 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:LesseeFinanceLeaseTermOfContract1, us-gaap:NumberOfOperatingSegments, us-gaap:NumberOfReportingUnits, us-gaap:PropertyPlantAndEquipmentUsefulLife -  exdx-20231231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="exdx-20231231.htm">exdx-20231231.htm</File>
    <File>exdx-20231231.xsd</File>
    <File>exdx-20231231_cal.xml</File>
    <File>exdx-20231231_def.xml</File>
    <File>exdx-20231231_lab.xml</File>
    <File>exdx-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>exdx-20231231_g1.jpg</File>
    <File>exdx-20231231_g2.jpg</File>
    <File>exdx-20231231_g3.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="626">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>83
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "exdx-20231231.htm": {
   "nsprefix": "exdx",
   "nsuri": "http://www.exagen.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "exdx-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "exdx-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "exdx-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "exdx-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "exdx-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "exdx-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 327,
   "keyCustom": 38,
   "axisStandard": 29,
   "axisCustom": 0,
   "memberStandard": 36,
   "memberCustom": 32,
   "hidden": {
    "total": 14,
    "http://fasb.org/us-gaap/2023": 10,
    "http://xbrl.sec.gov/dei/2023": 4
   },
   "contextCount": 140,
   "entityCount": 1,
   "segmentCount": 71,
   "elementCount": 569,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 626,
    "http://xbrl.sec.gov/dei/2023": 39
   },
   "report": {
    "R1": {
     "role": "http://www.exagen.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.exagen.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.exagen.com/role/BalanceSheets",
     "longName": "0000003 - Statement - Balance Sheets",
     "shortName": "Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PrepaidExpenseAndOtherAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.exagen.com/role/BalanceSheetsParenthetical",
     "longName": "0000004 - Statement - Balance Sheets (Parenthetical)",
     "shortName": "Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.exagen.com/role/StatementsofOperations",
     "longName": "0000005 - Statement - Statements of Operations",
     "shortName": "Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.exagen.com/role/StatementsofStockholdersEquity",
     "longName": "0000006 - Statement - Statements of Stockholders' Equity",
     "shortName": "Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.exagen.com/role/StatementsofCashFlows",
     "longName": "0000007 - Statement - Statements of Cash Flows",
     "shortName": "Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.exagen.com/role/Organization",
     "longName": "0000008 - Disclosure - Organization",
     "shortName": "Organization",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "0000009 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.exagen.com/role/OtherFinancialInformation",
     "longName": "0000010 - Disclosure - Other Financial Information",
     "shortName": "Other Financial Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.exagen.com/role/Borrowings",
     "longName": "0000011 - Disclosure - Borrowings",
     "shortName": "Borrowings",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.exagen.com/role/Leases",
     "longName": "0000012 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.exagen.com/role/CommitmentandContingencies",
     "longName": "0000013 - Disclosure - Commitment and Contingencies",
     "shortName": "Commitment and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.exagen.com/role/FairValueMeasurements",
     "longName": "0000014 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.exagen.com/role/StockholdersEquity",
     "longName": "0000015 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.exagen.com/role/StockOptionPlan",
     "longName": "0000016 - Disclosure - Stock Option Plan",
     "shortName": "Stock Option Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.exagen.com/role/IncomeTaxes",
     "longName": "0000017 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.exagen.com/role/A401kPlan",
     "longName": "0000018 - Disclosure - 401(k) Plan",
     "shortName": "401(k) Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConcentrationRiskCreditRisk",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConcentrationRiskCreditRisk",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.exagen.com/role/OtherFinancialInformationTables",
     "longName": "9954473 - Disclosure - Other Financial Information (Tables)",
     "shortName": "Other Financial Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.exagen.com/role/BorrowingsTables",
     "longName": "9954474 - Disclosure - Borrowings (Tables)",
     "shortName": "Borrowings (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.exagen.com/role/LeasesTables",
     "longName": "9954475 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.exagen.com/role/FairValueMeasurementsTables",
     "longName": "9954476 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.exagen.com/role/StockholdersEquityTables",
     "longName": "9954477 - Disclosure - Stockholders' Equity (Tables)",
     "shortName": "Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.exagen.com/role/StockOptionPlanTables",
     "longName": "9954478 - Disclosure - Stock Option Plan (Tables)",
     "shortName": "Stock Option Plan (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.exagen.com/role/IncomeTaxesTables",
     "longName": "9954479 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.exagen.com/role/OrganizationDetails",
     "longName": "9954480 - Disclosure - Organization (Details)",
     "shortName": "Organization (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R29": {
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails",
     "longName": "9954481 - Disclosure - Summary of Significant Accounting Policies - Revenue by Major Payers (Details)",
     "shortName": "Summary of Significant Accounting Policies - Revenue by Major Payers (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-23",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-23",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "longName": "9954482 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:RestrictedCash",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
     "longName": "9954483 - Disclosure - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)",
     "shortName": "Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-35",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails",
     "longName": "9954484 - Disclosure - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)",
     "shortName": "Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R33": {
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails",
     "longName": "9954485 - Disclosure - Summary of Significant Accounting Policies - Securities (Details)",
     "shortName": "Summary of Significant Accounting Policies - Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails",
     "longName": "9954486 - Disclosure - Other Financial Information - Prepaid Expenses (Details)",
     "shortName": "Other Financial Information - Prepaid Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OtherAssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OtherAssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails",
     "longName": "9954487 - Disclosure - Other Financial Information - Property and Equipment (Details)",
     "shortName": "Other Financial Information - Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
     "longName": "9954488 - Disclosure - Other Financial Information - Narrative (Details)",
     "shortName": "Other Financial Information - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.exagen.com/role/OtherFinancialInformationGoodwillDetails",
     "longName": "9954489 - Disclosure - Other Financial Information - Goodwill (Details)",
     "shortName": "Other Financial Information - Goodwill (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails",
     "longName": "9954490 - Disclosure - Other Financial Information - Accrued Liabilities (Details)",
     "shortName": "Other Financial Information - Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AccruedSalariesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AccruedSalariesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.exagen.com/role/BorrowingsNarrativeDetails",
     "longName": "9954491 - Disclosure - Borrowings - Narrative (Details)",
     "shortName": "Borrowings - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-67",
      "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails",
     "longName": "9954492 - Disclosure - Borrowings - Future Minimum Payments (Details)",
     "shortName": "Borrowings - Future Minimum Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.exagen.com/role/LeasesNarrativeDetails",
     "longName": "9954493 - Disclosure - Leases - Narrative (Details)",
     "shortName": "Leases - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-81",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-81",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.exagen.com/role/LeasesLeaseBalancesDetails",
     "longName": "9954494 - Disclosure - Leases - Lease Balances (Details)",
     "shortName": "Leases - Lease Balances (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.exagen.com/role/LeasesCostsAssociatedwiththeCompanysLeasesDetails",
     "longName": "9954495 - Disclosure - Leases - Costs Associated with the Company's Leases (Details)",
     "shortName": "Leases - Costs Associated with the Company's Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.exagen.com/role/LeasesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails",
     "longName": "9954496 - Disclosure - Leases - Supplemental Cash Flow Information On Leases And Weighted-Average Lease Term (Details)",
     "shortName": "Leases - Supplemental Cash Flow Information On Leases And Weighted-Average Lease Term (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails",
     "longName": "9954497 - Disclosure - Leases - Future Payments Under Operating And Finance Leases (Details)",
     "shortName": "Leases - Future Payments Under Operating And Finance Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
     "longName": "9954498 - Disclosure - Commitment and Contingencies - Narrative (Details)",
     "shortName": "Commitment and Contingencies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-87",
      "name": "exdx:PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers",
      "unitRef": "supplier",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-87",
      "name": "exdx:PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers",
      "unitRef": "supplier",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.exagen.com/role/FairValueMeasurementsDetails",
     "longName": "9954499 - Disclosure - Fair Value Measurements (Details)",
     "shortName": "Fair Value Measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LongTermDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-107",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
     "longName": "9954500 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails",
     "longName": "9954501 - Disclosure - Stockholders' Equity - Warrants to Purchase Common Stock Outstanding (Details)",
     "shortName": "Stockholders' Equity - Warrants to Purchase Common Stock Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
     "longName": "9954502 - Disclosure - Stock Option Plan - Narrative (Details)",
     "shortName": "Stock Option Plan - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails",
     "longName": "9954503 - Disclosure - Stock Option Plan - Restricted Stock Units (Details)",
     "shortName": "Stock Option Plan - Restricted Stock Units (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-124",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails",
     "longName": "9954504 - Disclosure - Stock Option Plan - Stock Option Activity (Details)",
     "shortName": "Stock Option Plan - Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails",
     "longName": "9954505 - Disclosure - Stock Option Plan - Stock-Based Compensation Expense (Details)",
     "shortName": "Stock Option Plan - Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-133",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails",
     "longName": "9954506 - Disclosure - Stock Option Plan - Common Stock Reserved For Future Issuance (Details)",
     "shortName": "Stock Option Plan - Common Stock Reserved For Future Issuance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-139",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails",
     "longName": "9954507 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Details)",
     "shortName": "Income Taxes - Components of Income Tax Expense (Benefit) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails",
     "longName": "9954508 - Disclosure - Income Taxes - Reconciliation of Effective Income Tax Rate (Details)",
     "shortName": "Income Taxes - Reconciliation of Effective Income Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails",
     "longName": "9954509 - Disclosure - Income Taxes - Reconciliation of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Reconciliation of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.exagen.com/role/IncomeTaxesChangeInValuationAllowanceDetails",
     "longName": "9954510 - Disclosure - Income Taxes - Change In Valuation Allowance (Details)",
     "shortName": "Income Taxes - Change In Valuation Allowance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.exagen.com/role/IncomeTaxesNarrativeDetails",
     "longName": "9954511 - Disclosure - Income Taxes - Narrative (Details)",
     "shortName": "Income Taxes - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.exagen.com/role/A401kPlanDetails",
     "longName": "9954512 - Disclosure - 401(k) Plan (Details)",
     "shortName": "401(k) Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exdx-20231231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "exdx_A2017TermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "A2017TermLoanMember",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2017 Term Loan",
        "label": "2017 Term Loan [Member]",
        "documentation": "2017 Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_AHNCollaborationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "AHNCollaborationMember",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AHN Collaboration",
        "label": "AHN Collaboration [Member]",
        "documentation": "AHN Collaboration"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_AVISECTDTestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "AVISECTDTestMember",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AVISE CTD Test",
        "label": "AVISE CTD Test [Member]",
        "documentation": "AVISE CTD Test"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r716"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r227"
     ]
    },
    "exdx_AccruedLiabilitiesClinicalStudyCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "AccruedLiabilitiesClinicalStudyCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued clinical study activity",
        "label": "Accrued Liabilities, Clinical Study, Current",
        "documentation": "Accrued Liabilities, Clinical Study, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets",
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued and other current liabilities",
        "totalLabel": "Accrued and other current liabilities",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "exdx_AccruedPurchaseGoodsAndServicesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "AccruedPurchaseGoodsAndServicesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued purchases of goods and services",
        "label": "Accrued Purchase, Goods and Services, Current",
        "documentation": "Accrued Purchase, Goods and Services, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedRoyaltiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued royalties",
        "label": "Accrued Royalties, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r683"
     ]
    },
    "us-gaap_AccruedSalariesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedSalariesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued\u00a0payroll\u00a0and\u00a0related\u00a0expenses",
        "label": "Accrued Salaries, Current",
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r683"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r716",
      "r872"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r411",
      "r412",
      "r613",
      "r772",
      "r773",
      "r774",
      "r848",
      "r874"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r376"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdvertisingCostsPolicyTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advertising and Marketing Costs",
        "label": "Advertising Cost [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for advertising cost."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_AdvertisingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdvertisingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advertising and marketing costs",
        "label": "Advertising Expense",
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "exdx_AlleghenyHealthNetworkResearchInstituteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "AlleghenyHealthNetworkResearchInstituteMember",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allegheny Health Network Research Institute",
        "label": "Allegheny Health Network Research Institute [Member]",
        "documentation": "Allegheny Health Network Research Institute"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r413"
     ]
    },
    "exdx_AmendedLoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "AmendedLoanAgreementMember",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amended Loan Agreement",
        "label": "Amended Loan Agreement [Member]",
        "documentation": "Amended Loan Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt discount and debt issuance costs",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r505",
      "r699",
      "r700",
      "r766"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anti-dilutive securities excluded from computation (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r199"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r145",
      "r170",
      "r203",
      "r217",
      "r221",
      "r260",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r452",
      "r454",
      "r490",
      "r573",
      "r637",
      "r716",
      "r728",
      "r808",
      "r809",
      "r853"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r152",
      "r170",
      "r260",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r452",
      "r454",
      "r490",
      "r716",
      "r808",
      "r809",
      "r853"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets:",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.exagen.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r733",
      "r734",
      "r735"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.exagen.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r733",
      "r734",
      "r735"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.exagen.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r733",
      "r734",
      "r735"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404"
     ]
    },
    "us-gaap_BuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BuildingMember",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Building",
        "label": "Building [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Costs incurred, but not paid, in connection with capital expenditures",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets",
      "http://www.exagen.com/role/OrganizationDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r142",
      "r681"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents, fair value disclosure",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of year",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of year",
        "totalLabel": "Total cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r96",
      "r166"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r96"
     ]
    },
    "exdx_CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "CashFlowInformationOperatingAndFinanceLeasePaymentsAbstract",
     "presentation": [
      "http://www.exagen.com/role/LeasesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities",
        "label": "Cash Flow Information, Operating and Finance Lease Payments [Abstract]",
        "documentation": "Cash Flow Information, Operating and Finance Lease Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CertificatesOfDepositMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CertificatesOfDepositMember",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certificate of deposit, included in cash and cash equivalents",
        "label": "Certificates of Deposit [Member]",
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r723",
      "r724",
      "r725",
      "r726"
     ]
    },
    "exdx_ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "ChangesInTheValuationAllowanceForDeferredTaxAssetsRollForward",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesChangeInValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes In The Valuation Allowance For Deferred Tax Assets [Roll Forward]",
        "label": "Changes In The Valuation Allowance For Deferred Tax Assets [Roll Forward]",
        "documentation": "Changes In The Valuation Allowance For Deferred Tax Assets"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r149",
      "r150",
      "r202",
      "r335",
      "r336",
      "r337",
      "r339",
      "r342",
      "r347",
      "r349",
      "r607",
      "r608",
      "r609",
      "r610",
      "r701",
      "r741",
      "r768"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Axis]",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Domain]",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, exercise price of warrants or rights (in dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants issued to purchase redeemable convertible preferred stock (in shares)",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "exdx_ClientMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "ClientMember",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Client",
        "label": "Client [Member]",
        "documentation": "Client"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_ClinicalStudyPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "ClinicalStudyPolicyPolicyTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical Studies",
        "label": "Clinical Study, Policy [Policy Text Block]",
        "documentation": "Clinical Study, Policy"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_CollaborationAgreementAnnualCollaborationFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "CollaborationAgreementAnnualCollaborationFee",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration fee",
        "label": "Collaboration Agreement, Annual Collaboration Fee",
        "documentation": "Collaboration Agreement, Annual Collaboration Fee"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_CollaborationAgreementCollaborationExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "CollaborationAgreementCollaborationExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreement, collaboration expenses",
        "label": "Collaboration Agreement, Collaboration Expenses",
        "documentation": "Collaboration Agreement, Collaboration Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_CommercialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "CommercialMember",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial",
        "label": "Commercial [Member]",
        "documentation": "Commercial"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r73",
      "r574",
      "r624"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r287",
      "r288",
      "r676",
      "r802"
     ]
    },
    "exdx_CommonSharesAvailableForGrantUnderThe2019PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "CommonSharesAvailableForGrantUnderThe2019PlanMember",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares available for grant under the 2019 Plan",
        "label": "Common Shares Available For Grant Under The 2019 Plan [Member]",
        "documentation": "Common Shares Available For Grant Under The 2019 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock reserved for future issuance (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r719",
      "r720",
      "r721",
      "r723",
      "r724",
      "r725",
      "r726",
      "r772",
      "r773",
      "r848",
      "r871",
      "r874"
     ]
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock",
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r625"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheetsParenthetical",
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r82",
      "r625",
      "r643",
      "r874",
      "r875"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.001 par value per share; 200,000,000 shares authorized at December 31, 2023 and December 31, 2022; 17,045,954 and 16,549,984 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r576",
      "r716"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Loss",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "exdx_ComputerEquipmentAndSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "ComputerEquipmentAndSoftwareMember",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment and software",
        "label": "Computer Equipment and Software [Member]",
        "documentation": "Computer Equipment and Software"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r44",
      "r67",
      "r68",
      "r225",
      "r675"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r44",
      "r67",
      "r68",
      "r225",
      "r603",
      "r675"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r44",
      "r67",
      "r68",
      "r225",
      "r675",
      "r745"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk and Other Risk and Uncertainties",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r129"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r44",
      "r67",
      "r68",
      "r225"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r44",
      "r67",
      "r68",
      "r225",
      "r675"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Costs of revenue",
        "label": "Cost of Goods and Services Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r567"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServicesSoldDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Cost, Depreciation and Amortization",
        "documentation": "Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service."
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of revenue",
        "label": "Cost of Revenue",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r170",
      "r260",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r490",
      "r808"
     ]
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of revenue",
        "label": "Cost of Sales [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shipping and Handling Costs",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Costs and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r308",
      "r337",
      "r534",
      "r684",
      "r686"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "exdx_CowenEquityDistributionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "CowenEquityDistributionAgreementMember",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cowen Equity Distribution Agreement",
        "label": "Cowen Equity Distribution Agreement [Member]",
        "documentation": "Cowen Equity Distribution Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current:",
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r750",
      "r771",
      "r846"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total current",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r435",
      "r443",
      "r771"
     ]
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r750",
      "r771",
      "r846"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r225"
     ]
    },
    "us-gaap_CustomerRefundLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerRefundLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Refund liability",
        "label": "Customer Refund Liability, Current",
        "documentation": "Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.exagen.com/role/Borrowings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r168",
      "r304",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r320",
      "r327",
      "r328",
      "r330"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r77",
      "r78",
      "r121",
      "r123",
      "r174",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r506",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r769"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable rate",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term loan covenant, minimum unrestricted cash balance",
        "label": "Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance",
        "documentation": "Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term loan covenant, increase to interest rate",
        "label": "Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)",
        "documentation": "Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term loan, covenant, number of days to cure covenant if performance measure is not met",
        "label": "Debt Instrument, Covenant, Number Of Days To Cure If Performance Measure Is Not Met",
        "documentation": "Debt Instrument, Covenant, Number Of Days To Cure If Performance Measure Is Not Met"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_DebtInstrumentCovenantRevenuePerformancePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "DebtInstrumentCovenantRevenuePerformancePeriod",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term loan, covenant, revenue performance period",
        "label": "Debt Instrument, Covenant, Revenue Performance Period",
        "documentation": "Debt Instrument, Covenant, Revenue Performance Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, fair value",
        "label": "Debt Instrument, Fair Value Disclosure",
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r489",
      "r697",
      "r698"
     ]
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term loan, fee incurred upon payment of final installment",
        "label": "Debt Instrument, Fee Amount",
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term loan, effective interest rate",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r70",
      "r333",
      "r506"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term loan, interest rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r306"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r329",
      "r506",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r769"
     ]
    },
    "exdx_DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, minimum cash balance",
        "label": "Debt Instrument, Minimum Cash Balance Required, Not Required To Comply With Covenant",
        "documentation": "Debt Instrument, Minimum Cash Balance Required, Not Required To Comply With Covenant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r174",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r506",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r769"
     ]
    },
    "exdx_DebtInstrumentNumberOfMonthlyInstallments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "DebtInstrumentNumberOfMonthlyInstallments",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of monthly installments",
        "label": "Debt Instrument, Number Of Monthly Installments",
        "documentation": "Debt Instrument, Number Of Monthly Installments"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_DebtInstrumentPaidInKindLoansIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "DebtInstrumentPaidInKindLoansIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term loan, paid in-kind loans issued",
        "label": "Debt Instrument, Paid In Kind Loans Issued",
        "documentation": "Debt Instrument, Paid In Kind Loans Issued"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_DebtInstrumentPrepaymentPremiumPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "DebtInstrumentPrepaymentPremiumPercentage",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term loan, prepayment premium percentage",
        "label": "Debt Instrument, Prepayment Premium Percentage",
        "documentation": "Debt Instrument, Prepayment Premium Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_DebtInstrumentStatedInterestRatePaidInKind": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "DebtInstrumentStatedInterestRatePaidInKind",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term loan, paid in-kind, interest rate",
        "label": "Debt Instrument, Stated Interest Rate, Paid In-Kind",
        "documentation": "Debt Instrument, Stated Interest Rate, Paid In-Kind"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r51",
      "r54",
      "r69",
      "r70",
      "r72",
      "r74",
      "r109",
      "r110",
      "r174",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r329",
      "r506",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r769"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unamortized debt discount and issuance costs",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r316",
      "r331",
      "r697",
      "r698"
     ]
    },
    "exdx_DebtOtherThanAmendedLoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "DebtOtherThanAmendedLoanAgreementMember",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Other Than Amended Loan Agreement",
        "label": "Debt Other Than Amended Loan Agreement [Member]",
        "documentation": "Debt Other Than Amended Loan Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r771",
      "r845",
      "r846"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r116",
      "r132",
      "r442",
      "r443",
      "r771"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred:",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r122",
      "r429"
     ]
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes",
        "label": "Deferred Income Taxes and Tax Credits",
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r771",
      "r845",
      "r846"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite lived assets",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total gross deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_DeferredTaxAssetsLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "DeferredTaxAssetsLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Deferred Tax Assets, Lease Liability",
        "documentation": "Deferred Tax Assets, Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets, net",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r844"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r844"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal net operating loss carryforwards, carryforward indefinitely",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r844"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal tax loss carryforwards, subject to expiration",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r844"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development tax credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65",
      "r844"
     ]
    },
    "exdx_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalization of research and experimentation costs",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Capitalization Of Research And Experimentation Costs",
        "documentation": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Capitalization Of Research And Experimentation Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r844"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accruals, reserves and other",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Loss Reserves",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from loss reserves other than estimated credit losses."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r844"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesChangeInValuationAllowanceDetails",
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: valuation allowance",
        "periodStartLabel": "Valuation allowance at the beginning of the year",
        "periodEndLabel": "Valuation allowance at the end of the year",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Deferred Tax Liabilities, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Basis differences in fixed and intangible assets",
        "label": "Deferred Tax Liabilities, Fixed Assets And Intangible Assets",
        "documentation": "Deferred Tax Liabilities, Fixed Assets And Intangible Assets"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_DeferredTaxLiabilitiesRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "DeferredTaxLiabilitiesRightOfUseAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Right of use assets",
        "label": "Deferred Tax Liabilities, Right Of Use Assets",
        "documentation": "Deferred Tax Liabilities, Right Of Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/A401kPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Qualified employee compensation contribution, amount",
        "label": "Defined Contribution Plan, Cost",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "presentation": [
      "http://www.exagen.com/role/A401kPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Qualified employee compensation, employer matching contribution, percent of employees' gross pay",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r207"
     ]
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Disaggregation of Revenue",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option Plan",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r378",
      "r406",
      "r407",
      "r409",
      "r713"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Common Stock Reserved For Future Issuance",
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "documentation": "Tabular disclosure of share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r56"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r733",
      "r734",
      "r735"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r733",
      "r734",
      "r735",
      "r737"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r192",
      "r194",
      "r196",
      "r197",
      "r198",
      "r200",
      "r478",
      "r479",
      "r572",
      "r582",
      "r688"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r194",
      "r196",
      "r197",
      "r198",
      "r200",
      "r478",
      "r479",
      "r572",
      "r582",
      "r688"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Federal statutory tax rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r423",
      "r444"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r842",
      "r847"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-deductible expenses",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r842",
      "r847"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r842",
      "r847"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "State income taxes, net of federal tax benefits",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r842",
      "r847"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Research and development tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r842",
      "r847"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options, unrecognized compensation cost",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options, cost not yet recognized, remaining weighted average vesting period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost related to stock purchase",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee stock purchase plan",
        "verboseLabel": "Common shares available for future issuance under ESPP",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options",
        "verboseLabel": "Common stock option grants issued and outstanding",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOwnershipPlanESOPPolicy",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Employee Stock Ownership Plan (ESOP), Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for ESOP transactions, including the method of measuring compensation, the classification of dividends on ESOP shares, and the treatment of ESOP shares for EPS computations. If the employer has both old ESOP shares for which it does not adopt new guidance and new ESOP shares for which new guidance is required, these disclosures are required for both blocks of shares."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "exdx_EquipmentNotesPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "EquipmentNotesPayableMember",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment Notes Payable",
        "label": "Equipment Notes Payable [Member]",
        "documentation": "Equipment Notes Payable"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_EquipmentPurchasedUnderNotesPayableObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "EquipmentPurchasedUnderNotesPayableObligations",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment purchased under notes payable obligations",
        "label": "Equipment Purchased Under Notes Payable Obligations",
        "documentation": "Equipment Purchased Under Notes Payable Obligations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r136",
      "r156",
      "r157",
      "r158",
      "r175",
      "r176",
      "r177",
      "r180",
      "r188",
      "r190",
      "r201",
      "r264",
      "r270",
      "r351",
      "r410",
      "r411",
      "r412",
      "r438",
      "r439",
      "r459",
      "r461",
      "r462",
      "r463",
      "r464",
      "r466",
      "r477",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r533",
      "r593",
      "r594",
      "r595",
      "r613",
      "r664"
     ]
    },
    "exdx_ExpirationApr12026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "ExpirationApr12026Member",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant expiration April 1, 2026",
        "label": "Expiration Apr 1, 2026 [Member]",
        "documentation": "Expiration Apr 1, 2026"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_ExpirationDec72025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "ExpirationDec72025Member",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant expiration December 7, 2025",
        "label": "Expiration Dec 7, 2025 [Member]",
        "documentation": "Expiration Dec 7, 2025"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_ExpirationJan192026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "ExpirationJan192026Member",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant expiration January 19, 2026",
        "label": "Expiration Jan 19, 2026 [Member]",
        "documentation": "Expiration Jan 19, 2026"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_ExpirationMar312026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "ExpirationMar312026Member",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant expiration March 31, 2026",
        "label": "Expiration Mar 31, 2026 [Member]",
        "documentation": "Expiration Mar 31, 2026"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_ExpirationSep72024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "ExpirationSep72024Member",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant expiration September 7, 2024",
        "label": "Expiration Sep 7, 2024 [Member]",
        "documentation": "Expiration Sep 7, 2024"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r483",
      "r539",
      "r540",
      "r541",
      "r697",
      "r698",
      "r709",
      "r710",
      "r711"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r483",
      "r484",
      "r485",
      "r486"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level\u00a01",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r358",
      "r363",
      "r483",
      "r539",
      "r709",
      "r710",
      "r711"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level\u00a02",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r358",
      "r363",
      "r483",
      "r540",
      "r697",
      "r698",
      "r709",
      "r710",
      "r711"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level\u00a03",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r483",
      "r541",
      "r697",
      "r698",
      "r709",
      "r710",
      "r711"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r539",
      "r540",
      "r541",
      "r697",
      "r698",
      "r709",
      "r710",
      "r711"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r486"
     ]
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/LeasesCostsAssociatedwiththeCompanysLeasesDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/LeasesCostsAssociatedwiththeCompanysLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest on finance lease liabilities",
        "label": "Finance Lease, Interest Expense",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r521",
      "r715"
     ]
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/LeasesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash out flows from interest paid on finance leases",
        "label": "Finance Lease, Interest Payment on Liability",
        "documentation": "Amount of interest paid on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r517",
      "r524"
     ]
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Leases",
        "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease liabilities",
        "label": "Finance Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r528"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails",
      "http://www.exagen.com/role/LeasesLeaseBalancesDetails",
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease obligations, current portion",
        "negatedLabel": "Less: current portion",
        "label": "Finance Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.exagen.com/role/LeasesLeaseBalancesDetails",
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease, liability, current, statement of financial position",
        "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.exagen.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finance Lease, Liability, Maturity",
        "label": "Finance Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails",
      "http://www.exagen.com/role/LeasesLeaseBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease obligations, net of current portion",
        "label": "Finance Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.exagen.com/role/LeasesLeaseBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease, liability, noncurrent, statement of financial position",
        "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total minimum lease payments",
        "label": "Finance Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: imputed interest",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/LeasesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails",
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Principal payment on finance lease obligations",
        "terseLabel": "Financing cash out flows from finance leases",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r524"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/LeasesLeaseBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease, right-of-use asset, after accumulated amortization",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/LeasesCostsAssociatedwiththeCompanysLeasesDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/LeasesCostsAssociatedwiththeCompanysLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of lease assets",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r521",
      "r715"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross book value of assets under finance leases",
        "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization",
        "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.exagen.com/role/LeasesLeaseBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease, right-of-use asset, statement of financial position",
        "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.exagen.com/role/LeasesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance leases",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r527",
      "r715"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.exagen.com/role/LeasesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance leases",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r526",
      "r715"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r329",
      "r347",
      "r467",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r581",
      "r693",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r780",
      "r781",
      "r782",
      "r783"
     ]
    },
    "us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for credit loss",
        "label": "Financing Receivable, Allowance for Credit Loss, Excluding Accrued Interest",
        "documentation": "Amount excluding accrued interest, of allowance for credit loss on financing receivable. Excludes net investment in lease."
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture\u00a0and\u00a0fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnDispositionOfAssets1",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on disposal of assets",
        "label": "Gain (Loss) on Disposition of Assets",
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee."
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "exdx_GainLossOnDispositionOfLeaseAssignment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "GainLossOnDispositionOfLeaseAssignment",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on lease assignment",
        "label": "Gain (Loss) on Disposition of Lease Assignment",
        "documentation": "Gain (Loss) on Disposition of Lease Assignment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Goodwill",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r280",
      "r571",
      "r695",
      "r716",
      "r788",
      "r795"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r283",
      "r695"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationGoodwillDetails",
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/StatementsofCashFlows",
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill impairment",
        "negatedLabel": "Goodwill impairment",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r281",
      "r282",
      "r283",
      "r695"
     ]
    },
    "us-gaap_GoodwillRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillRollForward",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Roll Forward]",
        "label": "Goodwill [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "exdx_Government1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "Government1Member",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government",
        "label": "Government1 [Member]",
        "documentation": "Government1"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r733",
      "r734",
      "r735"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-lived assets impairment",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r46",
      "r104"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r105"
     ]
    },
    "exdx_IncentiveAwardPlan2019Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "IncentiveAwardPlan2019Member",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2019 Incentive Award Plan",
        "label": "Incentive Award Plan, 2019 [Member]",
        "documentation": "Incentive Award Plan, 2019"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income taxes",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r158"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r286",
      "r648"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r648"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r418",
      "r424",
      "r426",
      "r433",
      "r440",
      "r445",
      "r446",
      "r447",
      "r612"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails",
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income tax (expense) benefit",
        "negatedTotalLabel": "Income tax (expense) benefit",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r133",
      "r189",
      "r190",
      "r208",
      "r422",
      "r441",
      "r583"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r420",
      "r421",
      "r426",
      "r427",
      "r432",
      "r434",
      "r606"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable, net",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued and other current liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r748",
      "r765"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Current Other Assets",
        "documentation": "Increase (Decrease) in Prepaid Expense and Current Other Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "exdx_InnovatusLifeSciencesLendingFundMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "InnovatusLifeSciencesLendingFundMember",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Innovatus Life Sciences Lending Fund",
        "label": "Innovatus Life Sciences Lending Fund [Member]",
        "documentation": "Innovatus Life Sciences Lending Fund"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r126",
      "r159",
      "r206",
      "r504",
      "r649",
      "r727",
      "r873"
     ]
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "documentation": "The net amount of nonoperating interest income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest expense",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r164",
      "r165"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest",
        "label": "Interest Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of stock from vested restricted stock units and payment of employees' taxes (in shares)",
        "label": "Issuance Of Stock From Vested Restricted Stock Units And Payment Of Employees Taxes, Shares",
        "documentation": "Issuance Of Stock From Vested Restricted Stock Units And Payment Of Employees Taxes, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Issuance of stock from vested restricted stock units and payment of employees' taxes",
        "label": "Issuance Of Stock From Vested Restricted Stock Units And Payment Of Employees Taxes, Value",
        "documentation": "Issuance Of Stock From Vested Restricted Stock Units And Payment Of Employees Taxes, Value"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory equipment",
        "label": "Laboratory Equipment [Member]",
        "documentation": "Laboratory Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://www.exagen.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Contractual Term [Axis]",
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://www.exagen.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Contractual Term [Domain]",
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/LeasesCostsAssociatedwiththeCompanysLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.exagen.com/role/LeasesCostsAssociatedwiththeCompanysLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r715"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.exagen.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Lease Costs",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements, Gross",
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeaseTermOfContract1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeFinanceLeaseTermOfContract1",
     "presentation": [
      "http://www.exagen.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease, term of contract",
        "label": "Lessee, Finance Lease, Term of Contract",
        "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeFinanceLeasesTextBlock",
     "presentation": [
      "http://www.exagen.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Finance Leases [Text Block]",
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.exagen.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Lessee, Operating Lease, Liability, Maturity",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total minimum lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.exagen.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, renewal term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.exagen.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r170",
      "r260",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r453",
      "r454",
      "r455",
      "r490",
      "r623",
      "r689",
      "r728",
      "r808",
      "r853",
      "r854"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders' equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r124",
      "r578",
      "r716",
      "r770",
      "r784",
      "r849"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and Stockholders' Equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r141",
      "r170",
      "r260",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r453",
      "r454",
      "r455",
      "r490",
      "r716",
      "r808",
      "r853",
      "r854"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseAgreementTermsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LicenseAgreementTermsMember",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Licensing Agreements",
        "label": "License Agreement Terms [Member]",
        "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityAxis",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lender Name [Axis]",
        "label": "Lender Name [Axis]",
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r769"
     ]
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityLenderDomain",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Facility, Lender [Domain]",
        "label": "Line of Credit Facility, Lender [Domain]",
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r769"
     ]
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining borrowing capacity",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Axis]",
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Domain]",
        "label": "Litigation Case [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationStatusAxis",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Status [Axis]",
        "label": "Litigation Status [Axis]",
        "documentation": "Information by status of pending, threatened, or settled litigation."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_LitigationStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationStatusDomain",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Status [Domain]",
        "label": "Litigation Status [Domain]",
        "documentation": "Status of pending, threatened, or settled litigation."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_LoansPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoansPayableMember",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan payable",
        "label": "Loans Payable [Member]",
        "documentation": "Borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails",
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total borrowings, net of discounts and debt issuance costs",
        "terseLabel": "Total borrowings, net of discounts and debt issuance costs",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r123",
      "r317",
      "r332",
      "r697",
      "r698",
      "r863"
     ]
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets",
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings-current portion",
        "negatedTerseLabel": "Borrowings-current portion",
        "label": "Long-Term Debt, Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "exdx_LongTermDebtIncludingUndiscountedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "LongTermDebtIncludingUndiscountedInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Long-term Debt, Including Undiscounted Interest",
        "documentation": "Long-term Debt, Including Undiscounted Interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails": {
       "parentTag": "exdx_LongTermDebtIncludingUndiscountedInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r174",
      "r322"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails": {
       "parentTag": "exdx_LongTermDebtIncludingUndiscountedInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Long-Term Debt, Maturity, Year Three",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r174",
      "r322"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails": {
       "parentTag": "exdx_LongTermDebtIncludingUndiscountedInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Long-Term Debt, Maturity, Year Two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r174",
      "r322"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets",
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails",
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings-non-current portion, net of discounts and debt issuance costs",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "exdx_LongTermDebtUndiscountedInterestAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "LongTermDebtUndiscountedInterestAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest",
        "label": "Long-term Debt, Undiscounted Interest Amount",
        "documentation": "Long-term Debt, Undiscounted Interest Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes payable noncurrent",
        "label": "Notes Payable, Noncurrent",
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r47"
     ]
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.exagen.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Line Items]",
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r294",
      "r804",
      "r805"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.exagen.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Table]",
        "label": "Loss Contingencies [Table]",
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r294",
      "r804",
      "r805"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r225",
      "r704",
      "r811",
      "r865",
      "r869"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/LeasesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r373",
      "r566",
      "r590",
      "r615",
      "r616",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r677",
      "r678",
      "r692",
      "r701",
      "r712",
      "r718",
      "r810",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860"
     ]
    },
    "exdx_MedicareAdvantageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "MedicareAdvantageMember",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medicare Advantage",
        "label": "Medicare Advantage [Member]",
        "documentation": "Medicare Advantage"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_MedicareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "MedicareMember",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medicare",
        "label": "Medicare [Member]",
        "documentation": "Medicare"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/LeasesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r373",
      "r566",
      "r590",
      "r615",
      "r616",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r677",
      "r678",
      "r692",
      "r701",
      "r712",
      "r718",
      "r810",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds, included in cash and cash equivalents",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r225",
      "r704",
      "r811",
      "r865",
      "r869"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97",
      "r98"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      },
      "http://www.exagen.com/role/StatementsofOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows",
      "http://www.exagen.com/role/StatementsofOperations",
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "verboseLabel": "Net loss",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r98",
      "r125",
      "r139",
      "r153",
      "r154",
      "r158",
      "r170",
      "r179",
      "r183",
      "r184",
      "r185",
      "r186",
      "r189",
      "r190",
      "r195",
      "r203",
      "r216",
      "r220",
      "r222",
      "r260",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r479",
      "r490",
      "r580",
      "r645",
      "r662",
      "r663",
      "r690",
      "r727",
      "r808"
     ]
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r185",
      "r191",
      "r200",
      "r228",
      "r229",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r285",
      "r410",
      "r411",
      "r412",
      "r436",
      "r437",
      "r438",
      "r439",
      "r448",
      "r449",
      "r450",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r487",
      "r488",
      "r491",
      "r492",
      "r493",
      "r494",
      "r502",
      "r503",
      "r507",
      "r508",
      "r509",
      "r510",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r568",
      "r569",
      "r570",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r604"
     ]
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Standards Update and change in Accounting Principle [Table]",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r185",
      "r191",
      "r200",
      "r228",
      "r229",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r285",
      "r410",
      "r411",
      "r412",
      "r436",
      "r437",
      "r438",
      "r439",
      "r448",
      "r449",
      "r450",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r487",
      "r488",
      "r491",
      "r492",
      "r493",
      "r494",
      "r502",
      "r503",
      "r507",
      "r508",
      "r509",
      "r510",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r568",
      "r569",
      "r570",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r604"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements and Recently Adopted Accounting Standards",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "exdx_NoExpirationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "NoExpirationMember",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "No expiration",
        "label": "No expiration [Member]",
        "documentation": "No expiration"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_NonCashLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "NonCashLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash lease expense",
        "label": "Non-Cash Lease Expense",
        "documentation": "Non-Cash Lease Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes payable",
        "label": "Notes Payable",
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r123",
      "r863"
     ]
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes payable current",
        "label": "Notes Payable, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "us-gaap_NumberOfReportingUnits": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfReportingUnits",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reporting units",
        "label": "Number of Reporting Units",
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment."
       }
      }
     },
     "auth_ref": []
    },
    "exdx_OfficeAndLaboratoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "OfficeAndLaboratoryMember",
     "presentation": [
      "http://www.exagen.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office and Laboratory",
        "label": "Office and Laboratory [Member]",
        "documentation": "Office and Laboratory"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_OfficeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "OfficeMember",
     "presentation": [
      "http://www.exagen.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office",
        "label": "Office [Member]",
        "documentation": "Office"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r216",
      "r220",
      "r222",
      "r690"
     ]
    },
    "exdx_OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent",
     "presentation": [
      "http://www.exagen.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, annual increase in base rent payment percentage",
        "label": "Operating Lease, Annual Increase In Base Rent Payment, Percent",
        "documentation": "Operating Lease, Annual Increase In Base Rent Payment, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/LeasesCostsAssociatedwiththeCompanysLeasesDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/LeasesCostsAssociatedwiththeCompanysLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r715"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets",
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails",
      "http://www.exagen.com/role/LeasesLeaseBalancesDetails",
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "negatedLabel": "Less: current portion",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets",
      "http://www.exagen.com/role/LeasesFuturePaymentsUnderOperatingAndFinanceLeasesDetails",
      "http://www.exagen.com/role/LeasesLeaseBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current operating lease liabilities",
        "verboseLabel": "Lease obligations, net of current portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "exdx_OperatingLeaseMonthlyBaseRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "OperatingLeaseMonthlyBaseRent",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, monthly base rent",
        "label": "Operating Lease, Monthly Base Rent",
        "documentation": "Operating Lease, Monthly Base Rent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/LeasesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash out flows from operating leases",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r524"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets",
      "http://www.exagen.com/role/LeasesLeaseBalancesDetails",
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.exagen.com/role/LeasesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r527",
      "r715"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.exagen.com/role/LeasesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r526",
      "r715"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.exagen.com/role/Organization"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r117"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued liabilities",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diagnostic\u00a0testing\u00a0supplies",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r716"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Line Items]",
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Table]",
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCustomerMember",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Customer [Member]",
        "documentation": "Customer classified as other."
       }
      }
     },
     "auth_ref": [
      "r751",
      "r865",
      "r866",
      "r867",
      "r868",
      "r870"
     ]
    },
    "exdx_OtherFinancialInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "OtherFinancialInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Financial Information [Abstract]",
        "documentation": "Other Financial Information"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other prepaid expenses and other current assets",
        "label": "Other Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r762",
      "r786"
     ]
    },
    "us-gaap_PaidInKindInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaidInKindInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash interest expense",
        "label": "Paid-in-Kind Interest",
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PaymentInKindPIKNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentInKindPIKNoteMember",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paid in-kind note",
        "label": "Payment in Kind (PIK) Note [Member]",
        "documentation": "A payment in kind note accrues interest over the term of the note and is repaid at maturity or upon refinancing. A PIK loan is typically unsecured."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForLegalSettlements",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement payment",
        "label": "Payments for Legal Settlements",
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments of taxes withheld on vested restricted stock units",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://www.exagen.com/role/A401kPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "401(k) Plan",
        "label": "Retirement Benefits [Text Block]",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r356",
      "r357",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r711"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839"
     ]
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock",
        "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r335"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r625"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r335"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r625",
      "r643",
      "r874",
      "r875"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.001 par value per share; 10,000,000 shares authorized, no shares issued or outstanding at December 31, 2023 and December 31, 2022",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r575",
      "r716"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Financial Information",
        "label": "Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities [Text Block]",
        "documentation": "Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_PrepaidMaintenanceAndInsuranceContracts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "PrepaidMaintenanceAndInsuranceContracts",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid maintenance and insurance contracts",
        "label": "Prepaid Maintenance and Insurance Contracts",
        "documentation": "Prepaid Maintenance and Insurance Contracts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidRoyalties",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid product royalties",
        "label": "Prepaid Royalties",
        "documentation": "Amount of asset related to consideration paid in advance for royalties that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r682",
      "r694",
      "r786"
     ]
    },
    "us-gaap_PrimeRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrimeRateMember",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prime Rate",
        "label": "Prime Rate [Member]",
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term loan borrowings",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r607"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from disposal of property and equipment",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r14"
     ]
    },
    "us-gaap_ProceedsFromStockPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockPlans",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from common stock issued under Employee Stock Purchase Plan",
        "label": "Proceeds from Stock Plans",
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductConcentrationRiskMember",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product Concentration Risk",
        "label": "Product Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r223",
      "r567",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r680",
      "r702",
      "r717",
      "r749",
      "r806",
      "r807",
      "r811",
      "r865"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r223",
      "r567",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r680",
      "r702",
      "r717",
      "r749",
      "r806",
      "r807",
      "r811",
      "r865"
     ]
    },
    "exdx_PrometheusLaboratoriesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "PrometheusLaboratoriesIncMember",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prometheus Laboratories",
        "label": "Prometheus Laboratories, Inc. [Member]",
        "documentation": "Prometheus Laboratories, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation and amortization",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization",
        "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r743",
      "r747",
      "r800"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r747",
      "r798"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total property and equipment",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization",
        "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r742",
      "r761",
      "r799"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r130",
      "r131",
      "r579"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "exdx_PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of suppliers in amended supply agreement",
        "label": "Purchase Obligation, Amended Supply Agreement, Number Of Suppliers",
        "documentation": "Purchase Obligation, Amended Supply Agreement, Number Of Suppliers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligationDueInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PurchaseObligationDueInNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase obligation, due in next twelve months",
        "label": "Purchase Obligation, to be Paid, Year One",
        "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligationDueInSecondYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PurchaseObligationDueInSecondYear",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase obligation, due in second year",
        "label": "Purchase Obligation, to be Paid, Year Two",
        "documentation": "Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/LeasesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r356",
      "r373",
      "r401",
      "r402",
      "r403",
      "r542",
      "r566",
      "r590",
      "r615",
      "r616",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r677",
      "r678",
      "r692",
      "r701",
      "r712",
      "r718",
      "r721",
      "r801",
      "r810",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/LeasesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r356",
      "r373",
      "r401",
      "r402",
      "r403",
      "r542",
      "r566",
      "r590",
      "r615",
      "r616",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r677",
      "r678",
      "r692",
      "r701",
      "r712",
      "r718",
      "r721",
      "r801",
      "r810",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860"
     ]
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesPolicyTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable and Allowance for Credit Losses",
        "label": "Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable."
       }
      }
     },
     "auth_ref": [
      "r776",
      "r777",
      "r778",
      "r779"
     ]
    },
    "exdx_RentalPropertyByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "RentalPropertyByTypeAxis",
     "presentation": [
      "http://www.exagen.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rental Property, by Type [Axis]",
        "label": "Rental Property, by Type [Axis]",
        "documentation": "Rental Property, by Type"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_RentalPropertyByTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "RentalPropertyByTypeDomain",
     "presentation": [
      "http://www.exagen.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rental Property, by Type [Domain]",
        "label": "Rental Property, by Type [Domain]",
        "documentation": "Rental Property, by Type"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Principal payment on long-term debt",
        "terseLabel": "Prepayment of principal",
        "label": "Repayments of Long-Term Debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r610"
     ]
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Principal payment on note payable obligations",
        "label": "Repayments of Notes Payable",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r308",
      "r337",
      "r534",
      "r685",
      "r686"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r841"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r841"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r416",
      "r861"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r760",
      "r767",
      "r862",
      "r864"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units",
        "verboseLabel": "Common stock reserved for issuance upon vesting of outstanding restricted stock units",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets",
      "http://www.exagen.com/role/OrganizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r111",
      "r577",
      "r597",
      "r602",
      "r611",
      "r626",
      "r716"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r175",
      "r176",
      "r177",
      "r180",
      "r188",
      "r190",
      "r264",
      "r270",
      "r410",
      "r411",
      "r412",
      "r438",
      "r439",
      "r459",
      "r462",
      "r463",
      "r466",
      "r477",
      "r593",
      "r595",
      "r613",
      "r874"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r205",
      "r215",
      "r218",
      "r219",
      "r223",
      "r224",
      "r225",
      "r352",
      "r353",
      "r567"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r646",
      "r679",
      "r687"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment purchased under finance lease obligations",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r715"
     ]
    },
    "exdx_RoyaltyObligationPercentageOfSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "RoyaltyObligationPercentageOfSales",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty obligation, percent of net sales",
        "label": "Royalty Obligation, Percentage of Sales",
        "documentation": "Royalty Obligation, Percentage of Sales"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_SaleOfStockAuthorizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "SaleOfStockAuthorizedAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock offering, authorized amount",
        "label": "Sale Of Stock, Authorized Amount",
        "documentation": "Sale Of Stock, Authorized Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration received on transaction",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "exdx_SaleOfStockRemainingAuthorizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "SaleOfStockRemainingAuthorizedAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock offering, remaining authorized amount",
        "label": "Sale Of Stock, Remaining Authorized Amount",
        "documentation": "Sale Of Stock, Remaining Authorized Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r744"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued and Other Current Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash and Cash Equivalents",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Non-cash Stock-based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value, Financial Instrument Measured on a Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r483"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfGoodwillTextBlock",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Goodwill",
        "label": "Schedule of Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule."
       }
      }
     },
     "auth_ref": [
      "r695",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Minimum Aggregate Payments for Outstanding Borrowings",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restricted Cash and Cash Equivalents",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r119",
      "r864"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails",
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r377",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Payment Arrangement, Restricted Stock Unit, Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r57"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityWarrantstoPurchaseCommonStockOutstandingDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49",
      "r50",
      "r51",
      "r52",
      "r53",
      "r54",
      "r109",
      "r110",
      "r111",
      "r148",
      "r149",
      "r150",
      "r202",
      "r335",
      "r336",
      "r337",
      "r339",
      "r342",
      "r347",
      "r349",
      "r607",
      "r608",
      "r609",
      "r610",
      "r701",
      "r741",
      "r768"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Outstanding Warrants",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Concentration of Risk, by Risk Factor and Significant Payer",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r44",
      "r45",
      "r67",
      "r118"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r224",
      "r691"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative expenses",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SettledLitigationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SettledLitigationMember",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settled Litigation",
        "label": "Settled Litigation [Member]",
        "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.exagen.com/role/StatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual percentage increase in shares available for issuance under the Plan",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Percentage",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Authorized, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options, vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Awards canceled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards canceled (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning balance (in shares)",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r391"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number\u00a0of Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, fair value per share (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning balance (in dollars per share)",
        "periodEndLabel": "Outstanding, ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r391"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of stock from vested restricted stock units (in shares)",
        "negatedTerseLabel": "Awards released (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards released (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in number of shares authorized (in shares)",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Increase (Decrease) In Number Of Shares Authorized",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Increase (Decrease) In Number Of Shares Authorized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails",
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r377",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum Employee payroll deduction percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "exdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of annual vesting installments",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Annual Installments",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Annual Installments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Remaining Contractual Term\u00a0(Years) and Aggregate Instrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expired (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee options, weighted-average grant date fair value per share (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning balance (in shares)",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r383"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number\u00a0of Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning balance (in dollars per share)",
        "periodEndLabel": "Outstanding, ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r383"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Exercise\u00a0Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier [Axis]",
        "label": "Supplier [Axis]",
        "documentation": "Information by supplier."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier [Domain]",
        "label": "Supplier [Domain]",
        "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant date fair value of RSUs vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options, expiration period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intrinsic value of options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Outstanding, Weighted Average Remaining Contractual Term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable, Weighted Average Remaining Contractual Term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest, Weighted Average Remaining Contractual Term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "exdx_ShelfRegistrationStatementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "ShelfRegistrationStatementMember",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shelf Registration Statement",
        "label": "Shelf Registration Statement [Member]",
        "documentation": "Shelf Registration Statement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShippingAndHandlingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShippingAndHandlingMember",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shipping and Handling",
        "label": "Shipping and Handling [Member]",
        "documentation": "Packing and transport of product."
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r167"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r29",
      "r136",
      "r156",
      "r157",
      "r158",
      "r175",
      "r176",
      "r177",
      "r180",
      "r188",
      "r190",
      "r201",
      "r264",
      "r270",
      "r351",
      "r410",
      "r411",
      "r412",
      "r438",
      "r439",
      "r459",
      "r461",
      "r462",
      "r463",
      "r464",
      "r466",
      "r477",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r533",
      "r593",
      "r594",
      "r595",
      "r613",
      "r664"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r201",
      "r567",
      "r605",
      "r614",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r625",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r644",
      "r646",
      "r647",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r664",
      "r722"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r201",
      "r567",
      "r605",
      "r614",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r625",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r644",
      "r646",
      "r647",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r664",
      "r722"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of stock under Employee Stock Purchase Plan (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r81",
      "r82",
      "r111"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity",
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options (in shares)",
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r81",
      "r82",
      "r111",
      "r387"
     ]
    },
    "exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercisedNet",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of common stock warrants (in shares)",
        "label": "Stock Issued During Period, Shares, Warrants Exercised, Net",
        "documentation": "Stock Issued During Period, Shares, Warrants Exercised, Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of stock under Employee Stock Purchase Plan",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r81",
      "r82",
      "r111"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r29",
      "r111"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockOptionMember",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock options",
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.exagen.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets",
      "http://www.exagen.com/role/StatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r85",
      "r86",
      "r102",
      "r627",
      "r643",
      "r665",
      "r666",
      "r716",
      "r728",
      "r770",
      "r784",
      "r849",
      "r874"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.exagen.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r169",
      "r334",
      "r336",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r348",
      "r351",
      "r468",
      "r667",
      "r668",
      "r674"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r535"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r535"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r535"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "documentation": "Different names of stock transactions and the different attributes of each transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Valuation Allowance",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowElementsAbstract",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of non-cash items:",
        "label": "Supplemental Cash Flow Elements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.exagen.com/role/StatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplierConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplierConcentrationRiskMember",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier Concentration Risk",
        "label": "Supplier Concentration Risk [Member]",
        "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardLineItems",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Line Items]",
        "label": "Tax Credit Carryforward [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardTable",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Table]",
        "label": "Tax Credit Carryforward [Table]",
        "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Period [Axis]",
        "label": "Tax Period [Axis]",
        "documentation": "Information about the period subject to enacted tax laws."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Period [Domain]",
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": []
    },
    "exdx_TaxYearsThroughDecember312017Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "TaxYearsThroughDecember312017Member",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Years Through December 31, 2017",
        "label": "Tax Years Through December 31, 2017 [Member]",
        "documentation": "Tax Years Through December 31, 2017"
       }
      }
     },
     "auth_ref": []
    },
    "exdx_Term2017Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "Term2017Member",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2017 Term loan",
        "label": "Term 2017 [Member]",
        "documentation": "Term 2017"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r329",
      "r347",
      "r467",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r581",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r780",
      "r781",
      "r782",
      "r783"
     ]
    },
    "exdx_TwoSuppliersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "TwoSuppliersMember",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Two Suppliers",
        "label": "Two Suppliers [Member]",
        "documentation": "Two Suppliers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "exdx_USDepartmentOfJusticeCaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "USDepartmentOfJusticeCaseMember",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Department Of Justice Case",
        "label": "U.S. Department Of Justice Case [Member]",
        "documentation": "U.S. Department Of Justice Case"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r425"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.exagen.com/role/IncomeTaxesChangeInValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increases recorded to income tax provision",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.exagen.com/role/LeasesCostsAssociatedwiththeCompanysLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease cost",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r715"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Axis]",
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Domain]",
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanCommonStockReservedForFutureIssuanceDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants to purchase common stock",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r719",
      "r720",
      "r723",
      "r724",
      "r725",
      "r726"
     ]
    },
    "exdx_WeightedAverageDiscountRateAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "WeightedAverageDiscountRateAbstract",
     "presentation": [
      "http://www.exagen.com/role/LeasesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate",
        "label": "Weighted-Average Discount Rate [Abstract]",
        "documentation": "Weighted-Average Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average number of shares used to compute net loss per share, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r198"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.exagen.com/role/StatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average number of shares used to compute net loss per share, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r198"
     ]
    },
    "exdx_WeightedAverageRemainingLeaseTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.exagen.com/20231231",
     "localname": "WeightedAverageRemainingLeaseTermAbstract",
     "presentation": [
      "http://www.exagen.com/role/LeasesSupplementalCashFlowInformationOnLeasesAndWeightedAverageLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term (years)",
        "label": "Weighted-Average Remaining Lease Term [Abstract]",
        "documentation": "Weighted-Average Remaining Lease Term"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481047/942-405-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480489/718-40-50-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "250",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//250/tableOfContent"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-6"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-20/tableOfContent"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-9C"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//705/tableOfContent"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-4"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-6"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7B"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>84
<FILENAME>0001274737-24-000022-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001274737-24-000022-xbrl.zip
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M#2\)S'(%CGA$.1:\"E8B7G@%SBA&6_@?2TR_VMYXIZMA@#"BK.>?ODIAOM%
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M7D<4FOU*R3S>)\(*N!OYL)8[?00DO44H\1R)&*0\K)7.#RY;@! ;CN!((K
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MS?A*\D7-X<>Q\U)CD^GTZN(WU^A9E%>UQ_Y$LT(]:7 DR\B.1&+(6G#NF^^
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M(K-)LM6PX.+[G"?U*2(:(,<RS-TM.,@\KMX?]S&:F=OXM2Y<1O A5%T9]MV
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MC+QL]U8E T=9@H&^7?WCOH#Y3Y!B<?*Z$UG/L;91J<(2LF5=<6UA.,ZNCRH
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M!BH%JYS;"HQOEM:';VSFN3!-Y@'T#JKG-_P0\JP()TL;=!.$O>-#48@]'?O
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M-AQ$NBAU#/J[<T86?-S0M6PIDJO",6(AI&?B*X0[52S'R_[@5:F-^]K&T,Y
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MH=$]R7RW+YAH9V&AW)^6#&_'\@?W8A+MCI@!7.B'-CTD;[:Q)-2BQQ;_+HP
M,*_^PK#5O!Q7Y4((BH3X\1O!+$H*>CVA^F-<ZEN;3>WE0]9"J^C\03@P#^1;
ML=BCKSAIBZ7VO%TL3=Q4>B,E>U8KA:TQD!ATN$>A%=AHR$Q_8K7* ..>/Z(A
M*'2;[/SXX_EN]G8RJ:30\JH&M)SN8[[)SMM7?]S-I5]13O<T51J3@7#B-\,3
MKS!YEY]=XG47RGMNC9PD6C$2L"0_$FZE,1*TF^"O^F)0<8'>M-B)1=^_9/Y+
M$'.+P\:]7IU98W]AL[X\G/KG#8\5/IGB6Z_)^]%XU^O=QAP434I&PXX"G;%#
MU]*P2%.?@6(R9,+ZQ)S1F ?.0)_$W$Z'Z_TM(58L]0VW'L1"*2_ 6(90ZC]-
MMF-J%9Y_$7@!T<[ W$E"QXZ]N83&3$0A62JWATR.>8\D C6F'NG8I5_YKB&7
M*Z'7*:>3/,DO*WB?.:[L$O*T%V"S@D6X**^*Z<3<QO6'D=KBG'4[%Y+-1$J;
MWWPM(<^$>9>0]&"3Y NCO&W^)5"1SSPRR,)FBV+V*_3PQX3S?O9]*83]$C:Q
M?E%5"VSA-SY(JD)9V5)GZS>IIJ%INRNYG(ZE)I_4"HJQWP1N';2?7HC:V4+8
MR^@CA11-P#54W&@K>KS:/NMH.,R YZ7S.XW-+.2MK 6D<"3^R))S%%(!O,YF
M>[)DMD%&(X8B)9L83G@7<?.84]O+/VFIPQ)W00P--0)5H!"7$[5(]!O39=3(
M=';+<6R<'@0[Q?A".=\>'V1CEEGFDY A9H&?:JT12/^\\H\!5S-Y#ND_=L67
ML?1'VAOY]LTUBQTR:/O97_O9N(U?<GE1,[F;87Q28AP7,Q!SJ^38D*'5%*?/
M0-!<[HEY7^L^<NVC&_.4;FD-^##[Y%R)YW>'I)8E UQWB)Q%BF"!;Z@Q^$I3
M5RE.!A'>5B86_9$>D\_(_$2<)CNO.TAQO3ECYW_W4X?]SN&N=-<QJD +X0N*
M1[N)9!*3),2.QRW<%-6U?&;4A%4.C$T)50_P8P@Z=%>P08.^K 3C%&E'519U
M/_AX[1RI"B#$4HU4V1<$RY/ILJQ'8N;<Q4*4V($/U7@;'2%?V(;60PB=F39/
M=B7'WH-)6=H8PRZUAVU984CS%<^SG:-=[OR<-BL=:Y Q%M*4IT*.P]% 1%2;
M\1@>G\[B"K5XCB%#B&^*6R(&>L#CW= :E>"]5,1.3 (8%!3W-DY!>?+>\@#V
MJ'39A^EEE;5RRB6!*+1H-]/VT4>[SN>\Q>4$B(;-#U;9YK=S8WC;"M/J2#T,
M .$,CR/T0>)1\<Q(QG5#WJ\R"2;H>2VK:().]ZN2B4E@&.QD$J>9F ^$)#YI
MUZ7FQ$//KKGH4V,TY>2N"Q"6Z5&B2<C[VGA:&S^^KXVOE[FP"R3<T]UT<]7(
M,6)MPKP_NCN:_G786CQKY*31KO<].VNX2W4O%(4VG#QH.>%KHS; )U_93-"(
M?S=+\*\\:/KGS. 8T=L*SFPMYZ*N/Y!5[!^&0J$S)TPC16]L8C>6[66L0.==
M:YXZ"HG)&I5(8L-'UQ%L;CZ5DW>CP<9MA!J(2$4./]WFQ/%M#NU^]K8.IFH=
M-N7AQ&L#(04!7K/UGKXHG]1&C\*R+GZ1!7\&= IKBRHH#,>3&LHEB1Y])V5U
M X,#T8=\XU7!R6Y9)DY/6#OH^ _EA Z(A4M@#0^8X,T=WD2.&<UV24LP.1L,
M=?R'5M&7U1B[Q90-@Z9/Y=+IM@E0GS;.]0U@$\_%GC9+\ L+4Y&40.)ND&J(
MJZ*LP<'[%?*[KKT\ 83%0BJ.)R3QAKW@T&4@[6N=,$_C_,XU]RB\<F6*@N<\
M+KV7" O2W)/Q*X,DMU5]S,73"#8@_YI6^^SAM>O-O,XJYQNA:JNDN5HOBFP>
ML+:EEQE)*E^NB*6%JVV,:ZQ^$4JA 9)@*R*=L\+(!38!I,N/P!5JFK)8+- \
M(6ZC_$UJGMJI&&8:Y\3F,J$_D022;XB@C>,M&WC3<[*?*&4MB#&.M'_%X-@@
MZ9I#C5KTX '?$EG,#U)#7(6_Z>6XC%') ;/L>@E8; =-X/#]:C4V3A!]6J&J
MR"R3,4T+;:VU4>$XO'\D[6>O/U$"QD:?;)CP2&!=L 6ZT3J"()JE@K>.I?^U
M(=/;N*/X$(CT&F=VEITON7&-CE!.#DD["9ND>HE&E4'9 &08O>0KGXZ!%T--
MX+A=7BI=(XU+<UF-NJ3'*DD.6&X!EQ*V4TDQS92I4/*7\%#XUZPE:Z+!C0CX
MAG"3O#NH,FAU1J,F.MH6V'M(RX$XMIE3[%'21?#3O&'F#/P@2*&KBEM]"GQM
M-Q]H*XM'COI+.T9L4C.9:N+5=4I3LN!C#Y2!IMJ2$M@FI"<#5!B=^$X7J^1]
M6>='7SGZ.+JH=\U=8('.'C^(B16)SL-DHRQMMU%!HB<\.P"A1$ :VPPMR7^3
MZ,0+E?--'66.UN1>*"QD+]0D-R]P4FI6UK[M>V5N>K*:2HWNM<!O>[- W[PN
M#*6 @<'QB,,OA4TG+7OZYCRE_+P*@I.3D*(<$C\1E'#G.'X3GKP?7IP(X&<R
M(.#">6Y 4&*1[':!"#D-H=#J)2<XIP=-"T[9]N2/&F7AOJDZ9ZV%^^MNW/C2
MCU/C=R*[Y1B-N24F<:'#?,("AS81F4TX=CVPB9SXUC](MJUAZ8+($:Y+0QA!
M(]^82099$W7LW<V-PU^83OD,5RR! Q(@DD*='Z+(PA/,+S;78%:.XN 9,^%9
MM;W'AQ)(]>F5USSKI+FQ\7O24GTFW8ZIN@9&D7>C?%V[8$H<[+%=2.!&L>AN
M#'A%3'PBT<"',V^+)3-"2F.*H^4..;N$ZTG:R8I%I,%8P+]J/RSG/32(@X@B
MS*H%S">?#6Y$VM+I>( -QAR[:MWSXYDB?D,S%&[X0%8N[6;K;^<HG,(5F2I0
M-%2LPB3A0,Y8/F7F&-'3-3-)-4CJ#]B_<23Y,YR'?L ]D-X[<"G3\\DIQZR!
M]K5:E?2@$7*SEJ[FQ*E\-%25AMJK\=IZ/T7/8C@D.@VC)8=SF$>X>RCFU&,+
MB=PX!!Z ,& 3/]G&_N]B\-P$30RM1R\UYD6TRXNZZF(]VX)5U:HU[\$0CAZ$
MQK)<(6D.1S;*/;E37H1I^D.C/=UZ',CQ,\"K]KT:)5SEK&TFI4J9G#9C%D@:
M;L365^'4S905,@7MDH"._P#3BB;KD&[^W>$!=U'WNJ&E$=K0C6[;./HV69:V
M,6_IDW:;:C][PU._UG/]0'I:]_AJ#P(#;86SVU17#+HQL+Q">K\1RIP>NU1O
M7N-\;F4T_4K.4W?T "/'I-E:-NGS,V$W:2EY"$HW+CN*U"X,B9<E&]!YQT[R
M*Y990W? ,E&B<L?*((ME$#9&*X+C.K*047J8N AJ*S/MSG%7U9IV;G43"B<N
MFU;PMGFRRO-^97JM=G9[J3H/J1Y72V>/8+Y<&/4ZZQSG_:=5B31^-OS^2FIG
M8+X'V$!D9<B?JA6BI7E!\CBY'<;(E["-ENQG:^R<+H7<YEH90S9[-DZD3;Y>
M)@Y/9IHL@\[.M\)$\*I6H4!,S#N'"][&C0W3AU:^5A0AG(D,ZB<ZO^91ITSA
MB4210F-]?T*OP5B2L7(%#7M%OTR1 J @P/\J"X$FKZ)TV]UH" ;8!<(Z&VRY
MC^U08?*&VNM?<8RZ6 :Q#Z/P=P>M5.+%'\&ILL>\=JGPA?".#]P(^J>P,&L-
M<M-F!!O5[_[@B;HOK?K2ZL/[TNK:3C>),27$&>K !":=XA7Z6DV.7<L:Y.3L
M65U 6,=/SY0R]P\6M_L8#JMS)%^ME'MZ.^-13F?RR_A@BC8_QB 6X"(EN&6&
MV<.7#:X<$OA&_U.)38N%:Q@V;[), ;>0AB!Q)Q,F%ZXRF]^2)BUOK$D9S!:^
M$BNY$CF9%\IOHFE1 ;/H'#>3B9!^BR^J,QXSU[$Z70BT<VS@HJI>AJ43WKV!
MM;WD)P"4!]3QY D40&0.ZS<83;NF83JU<K)NT@8_V&QM;M=68]."4<(K3JF%
MRNWYR].09@_@F:H.PDH73?.A,Q:7=FR/SUE,X2BG<<"KF&JV5@U:>(K2_RY-
M71"^E8P?\*A6:?/*J/%R=O\!PGH(Z")7UA73(-,1IUS#,=&8E3;! #OL*PO/
MERV$E8PJGI:Z7U>\WF4$5!@50^#X.Y! QJ:@'7W!KGJ[2N#6V[JI&=$TQE*U
M*D^HETG1)N98>5!"B+OA14&.QAWM2KVV=CD^M4U EN:T;%L/"T9U#9-DEU[0
MJ&=0AU.I@.0AXKIRCS!NE.Y!XDYY# ?:[?PL?_*%1&BAG3<AE@L!=&K&C& E
M41+JA>I'^P<T/!1OZRJ&24$+MI@YU$RZ13/Z<-5,Q_B#F4^Y,3L\BT_?AXY;
MS@G(LAPF8_!D Y(Y"(YM6F4-2HM_II_'S<P-P%O(02C3.%_Z)6W+9E:-Z#S<
M>VO!"+[PPDE%HC#YO0XU$RYH-[#61_*!Y(4[))-4LV5NY$#^\WYFEP5691LW
MW=^8AGY=;#L)$YKE@L7B@Z?AE2XWA/!V2&U2-)>H.<IG]15X\T1]P*")7*'4
M?FYI"8TX42D->27&X5=IUW+4 AWJ7=A1Z\4 Z[9Q,.*RM4<$X\K L(DPB8U[
M(A3<]1H?D2:G)V%9E6Y<C2QX6N,#'% BS9P<K2NCFC5*A\S3.K?E7IB4IEV;
M()SOLS0 O7V= ,$ 5X(,P,ARJ*G\I U#%\L-=@Y_*RF$,VX+&PFPX[PD=X$]
MRE^SY_8SGU]Z6UGK<N.;;*,=^_'5V<E)1FN3(AG)EK%[V997/?U/<S BE^_<
MO69GKTE+6)4]G*>'-7]T</ LYV/BLI6S5FJWY\L+.G0IB'IARU\[@E\Y3_%]
M.;JJ&0^Q2H\GT$?8!M/O(6#[\=7[EZ<_[O:HV8"FF=$X<6X^H:=X5SK80&#'
M.'BVG\F5LF(F5309+A"M#('?R!X6^)S T]JROJ2_U_;%G.5.I9Y,3NJ""SBJ
M4NETDO)@1/E#*="];FKD[ZN T_4SQY^_$)H$J6"-K!;N2_3Z"@H+Y&!!!HZ5
M+/G0CFD9E)T%=['LU"0.8CC@Z@51^'4^8"!5K&T4T-ZV,>G>'2L4D6.QX@4B
MF+N7ZHNENGDQ1NT";BD$!&:- ZS71'E=QHJ7P+(3=1CNBY\VG8#V<W=M]FFU
M3\V+6OK8A;[^("C,#GS@0;9S]N.K776[9<AW0CWII.N:$0,+NEV3/M/UP?51
M76I:9],%"#XGAJ-R"56H%9(L(\J[>)Y;-R<]E&)0P_O+K?KCCF\./'!8/W+&
M2 TMP#%A(H"CD'[4,8H%&!0-KG1<>=4LE8_J4PLFO7:(P/VE(K!.EK$ :&Q]
MYIDK44;RHUA:9R /PYG=WD)R(.SV8 9P\DK9T-5%^NE_5I'N 1NVTXL%QADO
M&19)-/2^XN=EL].*2ZY98*TD+=A4XR<&4U\N<26KL?BK*(%*O/$<J>\RS-VH
M'"];L5 ACR"UQ+B<;]N"#(KNFDA&84EF8V%IE:Y64%Z39K3L^<L"N)EDHQ6'
M,W97 '.$^I(MX\!M$_ #;UGR[Z; F7%J(;T:1K'4<XUOK1=4&G707=!#O2!_
M'81DCW,ZEXZ.K2A[L:RF8V4O#(GU<$U@=W RJ"WYVU7%G"9LS?D[;XJ6KG%H
MET1 6&<_E!?MDCWG0[G90VE&!A1>R#CX64]1,7P':>YLY^WINP"9RWZR!WD5
M\JXTBN=A78$/*I[H.S^].G^_&Q!&2G4*V%$LK/:&S42 10%:V#2,48*G!6MZ
M*XO*<<>9B?96W,/_[>]JM6D*@8-PIYB9H[+HRB!PEBQ%NEN01T#6P%7?159=
M:\M)IZ1Q>W@U3P8WP,BV>!K;D=K#&*#RZZS<Z$?G6PG[Q$ASICCEXK-H*H[3
M@2JJ3'?)K5,2F=B8)*)7C6=W9P,DF4S[QE"TNI1T:'+N\U>UUP.S,NP_.:5[
M^&;NP3>!?0</5+$U \>JQ: "T,**UR>Q1]S&Q;SVCIY)0)X_S@\6VI6V?((A
MBNQQNYJK;'9$0V*7BVO D]Z.XX$<FFY"JI$"K%8ZMYE,B&S43O+;74XEZ7/@
MX2X,NRKMIEW30),Q- ^MK"=$Y.89$U<WV12$F4!C==5'ALHSGT&4B><EU1C@
M'TUMN"FS0$AZWNX]8U%;W@@ ". E@T>;IR^4:Q]>K\V4YR>]2YX42L?Q( !N
M>7]])8)=;NER!?>%5%](?71?2%W;Z3T)5-YHZAR3E0]]/2%I!FR4@P0/M,D4
M\8 CD\QYDW"Z!QZ;K3S!S]<$XU#(,CA5!/!+:B &\#8P&MVGC>LRFA'*H1T<
M:Z.FR=A&)66"2)-4%/S!.VYN:DY!<&-? !N% P>AIB'$V1;"TE91(SJT%L6^
M.KX5.]&K?77_XKO!E(S_ONP, ,Y55'7?:H'\HCE&&ATQ8,KJ@'[(,I133%6&
M@GF4-7"Q#4T6A8Z:.WH9E<E>_=2,(P\((D7<T+J2 E]9FAHY"7E<3('OQHZ=
M9X+.[WP$W>& ZZ,!Y>&D3$E'5E1T#J/F2$#BLO&%GMW X2SQ2FF\'J8 YQ6_
MFRD+'TG5%X2Y=>?RZZ&^31$J$Q\%8A)I#>$7F&@;I3;>N2*V# 23>14B>S[C
MK"@ZXQB%-W#&#,'>O1BXP80"XW 7:/UXN%G./;NLP*X4&BKB);;8P4_7$,W>
MU%S+T%XG24!'A2;^,6\OV>J%^14^WX5B'W<,+)GNEB>"7 ITRZH9 FNR-RMJ
M'C2UQ,%G#.Y%F(2],*1AUG33QDN)L"41B-H'5T(P97([?H[.5>[8+4:.LKRD
M0[RL31EN](%!]C _ZN22[5)7//5QMW$Z [VKFD5R4GP+#,2]%BZGF>9/T6_O
MV462Q!8NHF7N7O.8_Z";-9_M]:G%F*+*8X\@H,)VZHS)8UMIWJ^LJU^/F/76
MT7[)&QX*W[TM _!SOGY*_?#^-,?Q8+\K/I2)X!@=2',,Q8>RG ,*MB3[%D E
MP;#YY*X$((F0FN%Z]/B-?>-B#L6==VS'Z]CP<SW&'W&#B2$7WI]*A?N]_E!^
M1.M3!/D$7$/J(<WH++#DV$69.>J#ON :VB?4NDCVK&:'_)JO BTY<LI%+<W&
M)AD*6ML,8=#8!+&'P'8XV_)1LW" U80&K@"H;CJQ:=<T/7BV1=.('>,CKKEV
MJ3Q)9 "P>KV<\C$ U#2:'U]]3EZ^0@Z!JZE\&MG+EC)\ ANBE0E+R"<H0$>6
MIHS38.0"9??[@?-)\+Z .RGWI3_8?-;:A'GX4;B&C*=0FR<VM8A+2\"%XQ(]
M$=)WW5MK#L,C"R?,A1*T19J&K=S=Z[FOI#SATRS!T-%66-85ZCKFD3Z83)NF
M?2#A<:,,4B4Z5!U/A>2U:!NCD8J30?6E8OM-\LF?KI)>4&4,38WU<V!)5J[U
MB6A5=Y;L%C-C2*)G.*TED+RNF3 JIEM3*@A]'H.VR6#<X"''9E49,20GD"DZ
MU=R4NZ; 1NY0MMVSZH8/8 8>PS/@>/V;OOCBP 3@0>.Q-4L:*3PX0UP#/$.O
M29HC[1!K\OR+ N25*DD(1S5/PK(34X5,GEAG*_ H,<Q^]L-M'=S6 <7N:$3\
MYCV)6*L91+GG=55QW=\#48!8"O$$V>A=QN2MLI#3!3T_8])PAWJ@Y;[7RO=#
MG;UKHA^G33T1PUI,=36\T79E7X5'9?WTS2N&0AOG04BS7O>P-W:_7K8ZS;T.
M&/#U==>W^DF"N]];*E5);=]&N6E=I^34#CH#:B1R&*>"];:.$*$1:(SW_$]%
M+;41E$8.="@!,QW" XBGWZ$R#^,?S <9MTNU=1.C*3&VS=I5P83X"T@ JQ=H
MWK[Q[T3S@$%: _V%U#L-A4G4!]J)-(FN= <);F,A0VKOX8H$O<=!32@^3W"T
M-)$AT6MWBP5R \)$1Q9'6J]HI, 8,$=Q&N*0851[68HT-DJ0!9N#L8GEIT)"
MVVRP>&N!,D,"='_&^]V<B!EQ-D5)-KK!]E:7&&B&*RY)Q(WS:+VLL!8C& N!
MWW'IA0?Q'9X#[!5"207A2_D_D_*;E;Q=MR^7:(>.C[6L-I^0%%HY.8W>IK6]
MJA5'L45G4*ZY?8\>.QQ.8(BDE:)KYHQE/8S )<+X=+.:Q&&Z/.O(#*5#GH)M
MO6*XV1K=)CHV_'E,>[PD[KC$7WBW2UXU,:D .=!E<+7N [ZA55O9VRE7#" [
MX%Q-G&" A@!34EK+^=Q76FUX3(9*8*96;^V&IU/[Y.)T[0FM6P ]]RT),__P
M6[H)[H^X9!HC[_PX"IH$!L_K5-P$IB;=ED[,3C?H.+$_:V$?[R7GSN]_51;U
MH[M1E__R;.E_+5HD\[0?W)(ZIWQ3.D6!VT,>FH*9/'M!/B)3GN?9#_3W:DRK
MD(.THN9_-#?TWS?L\/*/;VE^&'3[OJRQ3TK^Y\>"%OG/BT)D/_Y:<4"" ]S1
M3LMAQ/PT-EUP97IB:GKR!I_!^MDU>J]4A5AT*-C-!_D;OYTX=KS"@^^9GE)I
MB-M#W<G)2GN0>0G%?^RB [F5P==/;(9 98:1FCBIFQ@HI!)S:KK<IAPFBG'1
MA6=](/>B*XU_)A?8G0N11CVOLQ^0&-_$!CQI[)$*F%)<(6K?K2T#MCA#;R '
M^D1.GCO!Z.P<=5U4 T?K?O8W2^>)3^K2^+5"7#3P+22KE?H98KPD#RPY$ZZ*
M),.Z*7$C2_O10<(CH3J%2N.8^.=)2K*(!2/4K9%4JSC/ ]O:5IS<99?)/:[6
MDR;F1X0UE7 14%@W7_@@0'NW"J.0XY-!>);O:]*^)OWXOB:]9M'0*S+;"*=8
MD[[QGGF"[Q'+YRU'<A0%$DV8C>4TM('PDHX>H&K411B)F!%SQQ:KN?AC&](Z
MY0J95H4Q132,STG8M>)F2=/":^[B<+ 4#&8(F5$(\J;2SMEA:C4S'$T:U"+
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M/XO#1E,"M'BNP7&B:C 6_HX93R%@G+=KTYBVZ4C-#[E7^E,U\U#%FCL_JX7
M);!*.\ME,1+S1MKOO3\2^IK3*6'<UF7;W.C*0]^N]MBR*2Y;):W ND*3/+WC
M92.[3)<YAB>.1Q&T26$_^00G PPQ3B ZV5PRQ!"]MG.TZ4JB0Y)H\VH.%)[X
M:Y*A"><OWYF&[GL5!U)LF;V.HQ?'0]27A:#,8"),!HJ1E'U$DW\03]:<['-
M&_7I-!W+E_12@\PPL,?.C,"XX._HCC420O: .9V#^=?%(!=RKEGO\70=YOI*
M;@$R]U E"3( V:![$JT8UIAHI"MRLZ5E,_Q]0<!)7IK]+YLTLX).6X-]TG)A
M- LS!AU%RG[+G5B>7P;2/86R4B8+\??9=1,D6,@5:+?61# \C<>D;JZ5NEX'
M+1=NN7%;,85C($N=(<6;(QJ =(H26%V15>XX),)"PB*O+#:R*?$;6&0*UG<O
M>2&V]2'1TLVMM1\4>$&/1LC&*2"[6(;<\84H:C;,)=779Y#.6 %$;N5<\-H6
M8>.1."Y9%#ANX-32N(0S'*8G0K]R@Z*OU'IA8Z26;,WF\YZ^5(<.$V$=T,Y4
M)2X$$/XU(V6F@7LTG.!LP 'U*T4$F3QB=<S]CK=MRHZ#/ TT-41G(?5DQE4+
MC:@8IM##*CRJ6S2C#PK(3G?L#4AX9?.O IR*2\GZ<0W6<#)<-#6'4?@."CS"
M\NNY[W$G,7*Z5RS(,V-GF6W0YJVD[2*,\YK'H+</F%8&9 :2#+&1AHPM1E=5
MJ<8]K@ X*,)L-%/VF4 E+]O-FS-+O;3EE09#?7MF1WK/S*Y]+) -%>0W33%\
M*5^;XZ-!MIL!I='FS\K01]_+4*M/H)Q.?)QV:VXA7II7E%/A*N4(X!R(?%A-
MLNO*Y+8.#77X$RJDE>XR8)7A-"2R#7*P)@2Y7,IFW[QB1+8Z"WE<QNX4BL^]
MC99&'%QHE$EC836BAV?=$4XJ!.^#3K7K<M6QK\99A(46SRR78MX3;[QN4H2F
M#Q''*68:''PH_5EIS-@J>7B!?;VP)4A60OP=,38&#(DJ79R:$-FL8M$_.\QE
MEYT$'0% KPU53$_/5I#BIE\M:-W(%C<<QGH^P1/(U?#&?!',(H@! T&YZ 6V
M6UD>X=F,M7=))'J61<9;E]8E/$Y>T#&PZPN"M/<CIY8W8Y%_BW6)XX-OIBZ!
M2"\..1^Z>QR7%_.N_,[^\9P3G]-B]5U5XV7QI>=Z+9VG@;8G3(?\.3[S_H$\
M]Z*E_S^V.^N?]^E/?UC__?'A_J.#H\$_'>P?#OY^TZ4>/]X_>O;TUDO] 8\F
MCT<CP./Y?Q\</XC3!OCA=T?SC]FA@3#]HEOK_L((_%)I-XSNG2W38OPMO^:9
M6H;D=3XQ?=PK<PFDQIX^'/F.="X^U\6/$V>^R,C45..,G_SY+4/!&-1?9B#N
MSF]*0R./2)%B(SF&[P ZDA;$+UH-_\2H'?"8W6%?K=]B@O_WN<-/C_)+G:A8
MA']JKM@I( >L^J*!_#;>\LQ 9WEV2K'09-VH* &S&)ZOLB.W?$C^7,RX17Q<
MW'S9Q'\;;RFS_4/0E?.S?=JTW)Q/$==Y.6K1NO[/3?RWL1?>TV P&T^19V=7
M^R_V_XVW?=SEIU=%Q;D:@R1\WS"&@FMGYFL,37TO"CA\)$[GE^V0<)+\L]__
M=M?E5_,"AF?M"\?CRP?VV["!W[=,=_I]U7[X-S;T;XI:&JC/BG91,R;KM-G[
MH<&:R;/S99V]8<@.)]7Z]?Q_8UM_0J;^QZ;Y4+;_QE;^O*R9+NBOW+:SYN@Y
M+AH]^W-.^HP6V?FHDHY^\P.^5BBVY</UM[(>KS+V^[O>"_][O:?,__=6M0ZS
M_ZZLRX9<GX+\@5&Y7"C:]%4]VO\MF(2S8CG-_ES-_HT-P@:G/\]^6$XA%<^J
M]/2 7V76OXW-\/*B!.7S&07Z!?J6OMSW_[(W_I<FV#[A$[P!/"YGDC):"55C
M+D"&3R@4YO7KT]_"_O^^96CRNX8&9-$Q.N/?/0@,J\""AO^?O7=M;AN[MD7_
M"BLWN6570=I^=;<[KG.KU'9[QSGNV+OEI,_Y= LB01$Q"#  *)GY]6?-,1]K
M+@"49&]UFCYAU:Z=MDCBL1YSS<>88V2S/YV^.?U/703W,/-?APUXW>;UQ]EY
M']S!_U;2]/ W_MX#X&7>]56(_LNF$^]OWQ'P'Z@2'1@>^17P3Z4 RM_4PCYS
MB)5:X.K;R[P6DHH((>VT=;1I>T5_+)(7*_7%&$ <(4@16#G$FBH")K_*RPI%
M08:?3H-<E!H.T2$1#BSTD@8V@\H$(0/V/9JV)'<&5!,XB3Z/4J]1VVO$5,T:
M("JW=83GN+=B;0B&YQSBK-Z,-__F^>FW?Q@CL8W<%'WZRV*=$\[LZ=/3[_\P
M^(P^8?3WZ3>W7HA;D"#?3DHBHIQ45,L3'>XA^^"S[^B6MUSVEU5)/8M/GIT^
M^0/]^T\E#6\YISN])2Q6D\T>?W/Z&!^>=64>CM"GI\_QSQ^JG%L=SI9@8CU1
M2E;Z"E^NOV[0.T&$NFU.X><#:DX:W^5A-GM$PQE^\Q=&O/\IO\Y+*-=H_]7[
MG&6BWG15SHD.&CS]F?'!OJD7\K.S*N\^YG+!T]FS.XS''8;Y('LWDF;@;';>
M&-$$BT/"]/Q$2*'#A+J\@2["(^Y:I,GMF^8C6OL@O*ZSEKYE%]_R,K[E@Q_/
M__,A-2GB92$>QMP3UX2-J@HFHM^V)DUSONW(LBK2^F<PP^OOGG!;(1#WU#LW
MN]-(OQ3[RT\3__DP OT$"1K,_-9LH^GH\9.@&YG>/QX!H#N-F'IM=,J&Y* $
M+)L7*:TA/0DCR!@HECP9D(;H-5RCERTG7H.<SA@5]<*%@4Y55+$]3FY88GHH
MRTIQW6E/!5(9 +0#19"=^79!TI?V6#+S%UK!B# G<(:<X>M^?(DUXQK<LJ"?
M?:WFQU-Z<E.I#B+&)1Y%82RQ2 @DR<]Y?7U]6@ Z=1H>[#_*.GR+'N$P3<'Y
M%K3H[6^F[GI[>PV1D!)-/:&9[&E5?FQ.$O+4F(F/9!=P2W0&O/3&*(/96EO3
MK#5Q;EG(R$##*FK&7P"PMQ22VB,C]1TF;=06P(XF^EZ8M80[0)J:U=,Z[D([
MCN\7CB]+=B-D@+WZ2(AR-*[2GCGA_H:X=4[#*;16!ANBV&7-X;8PUOU&-6%L
MMT&/4)NH#]*.Q8#6(WH/U*:MD5KCGH.4BSB<G>C+='TIX.^BMK7**P!UQ25W
M4L87WW]F^8XTM CRS91C(24?QB_JHF?.1;6SS.'%(@#&N*;A#:X&53+860*G
M-PS[YWLED='X5Z3*'.GFQ!3$]T)/JC4)O G_/7MN;!-G<#C4#3O(I1FQ-&YI
M'NC*!,$;F,WYD1>.U P$$H(184:=\ _"5?]4?"KG#:N5/0JS&7]2DY@-X\A]
M*5'<Y4?<AZURNNAXU.O&9S *87>K8*)>!5-]C1ZX7?!&VTMCNY"NJT;O^\J4
M!R2AE=$QU&VI7Y;<-72X#AX#SWW#)>CY57"*E<]NO@!^\PXNN/9V#3'W:5=V
M<#P>/_GV\>QM2;GHW>R7/,3H?RO#\%"BKBK#.JK+?/;]DT?/'_.5^Q"L;*A!
M4,DSPN9X\-VWCQ[.OOGVT<GC;Q[)]ZZ+BW#8%:Y+9."QLKM?WL6*_EMV #S^
M:CH _G66 ]0V)3-S@B.'2?T@\2Z-A=P+K:NO9'$ YGQ9"H<>_RVQ/A<[#JP*
MYFWIFVS*[(?])4$6M2Y!CZ+I+7*@AD$H$O@U77*[+0Z\$ 4R09)S4*7;<(UL
M9C/_>)A'RYFE= _X:'G"1\N22/22>4/;^FN*N1X_.OF?V>R_3)YHXO/_RDR"
M>/CI<_IQ<(8_:1XZ3G,7?8<8 OHO6(;EG'OM-2GRXR<VYYPM0+/V[,'YCR\?
MLA5=0BNC<S__\27S,=B,+%M.2+"(L#(;A>\9VZB9XMJT#G]G*_EW7N3);YW@
M374-+6O*U^3$%G51[32)PYUXT#@,)Q)Z?MNF9I(OG@'L!&/*I.?'AA6U:N),
MY4V&1^6S@-Z-N$QIBW<LST%Z,\%%Q -)F"P?LXO:W3XAV9X9B:XKTD^MJK2#
M@S%]H73T>QQD8=1.+YNKB?U:+O['[\KO%D^^R[];/"^>SK][]OTBO[AXO'SR
M])M@<//E\R=/GO__C[_]W<U;Y\EDS\R_=-O#!WY\=CK[N>P^SEXS#]?A=5SN
M2]Y>2?PJGKXWL^%O5TUUA0[H5?A1,-*7LH_:\*ZGL__=;-7&6S<JL8XP73%$
M?L+W5$5.*5QI5R^*;MX&=\KTLOOFDNT^NXU,E(.NV]&:],')^/P9F+$TDEI:
M'#.P1=I"31K>_)??1<B%V8A793??LOFAK[!F7 D_/$9(+YM:"%7I.S]'KO=W
M,?#[77CM):4VF5R"MS'-!/)C1CV1G('$0$+=QRN"Q;@>_'@JSMXL9Y'?S_6?
MRBR ."@LC'\2>XMG2LG<P,SU\;,;5'J".1&":V/M4RLFZ>8H^Y.#]Y<2NF]J
MMA[@YA+2\C9G2O&VG!=3+R4WD)H.FZE=6';\YXJX#MEO:771[+A H*,IG=48
M@<&J,XU<K+,:#DH14Y%$][O,YTH58Q4ZN1CXEOR:IBM]K)MKS-L67]!+Q<;?
M11&L1;DVFT\W46*;O&S'!#9"2V$C?IB^S_DVO!+1UCH;>&BNC_9ET_0I7^+D
MDLC#N<RO(SLI!HK);W.1K2P6&NSZ71RLTY;+-5TQ7FF\AL+2H!666E(SH+[#
MOTN?>V@P^^%[B=Q,OS(K*>?45RQG%5R";W]['13TUOQ2*,]Y&%HFE%LB1T?9
MNVOP4PLI8U@Y+H57&+>&[&NA!W-JM@P*:812CMABMI23*%D6*YA.S@HK5PJ3
M3K _2%9B2:QB*$)^Q1)#!S33;Y93K.2+AD-FX<H%WYX2>^6+XA];3AM[KGF5
MVAL69#(^*(K=C%(4\Q7.W7E9+QA^L2B7.R5T"R] D06.EH%\HM:0&U&ICV1
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MZ1%Y#)&CGZLPKE$4V^6@_#BP%TS7ON<'CK)=8[;$A"C6UGL#Q$_).!BYK!T
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MK.E,4SD,Q@1D5=8)P8L\&<3#7&$_)_,,K?>1:>$0&X@_5!.E03FL'8.6QW6
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M<6XNX%$J@[9/<X0GW%+38_@2,XRQV=A7#'F7F@ZAX3-$N+!=[STCX^*1G54
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M(27]'*D!Q#95P6VFI%5*2?=P=JZ:2I0/J:.+LIF<?"2]"^8"V%Z$=4\_)^H
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M)$7B(G1J](>1RCGE&6J+8/!JJHF  A$ 4BHW<V.RR:5:192)EU4[8].65/<
M5?*QN>Q7"NFM+:,U?B7T9@[;8C--S7,U18)M@<#*UU'RK\)5NWF^L92QPJU\
M!T,42L'" 9>+T$?B0M84P)7QP\S[?X!4T7HK79(,X'+P5LFJ2T&$L_,T8A45
ML]+T/,W$MI;LOAY+X@+<K;3 V&0H+$&Z&XU2@D2>KL(@_P_I(T"9::PSS;-H
M5T2$QJF+.-_-48%4-K!!Y16L8ZWB2<8W!7*(MW28LQ.1X+[(NS*!K!#<.OP,
M/0]OC,.T6V$DF6*" 7Z,GW D,"S9$=:<8WSV#8>1!^-0%U7)4Z.K8')II%RA
MLJ[PFF$/2[YL710,O$X+;,N(?VS:I *?5[NN=PRL-.2J8ZD*Z6]2=NIF:HY=
M;6_J]M,W(JDM_(3N1H7;>4[?2>M_D<M\U GZ.4+DV5Y1I$DJXJ\(R*+;(AA7
MK^"UU--7X%3!$[OD9JLT]\:V?9"!DY4U+:Z=\ZU\5BQLVF5954P5"-_4@*O2
MMCD)5-[+1V+$P1,JIV$>%Z";R5T(U;=A6(W/TQ-MQ!&AI3]ZSL-LHKYY6N>M
MB.MI2^SRSK.K^;0MBP2(:904:,(7TY;=/E$ZZP79ML$GZ-@7:&K,A5\^@.Z$
M1]%(RQ*N-%GD%+*U_E@J01"]ZXF :NR53V?G<1D3\HQ))]$<5?[#=$<2^3JZ
M2[!6"T -4_%=R1D2=96LDO!#NB7@T4S&J!2=ZT22+8ZBN[S7S+V(4BS7JT*H
M4O%@\;+:W!(9HQ7?Y]>L0-!, )II-.@M1+6*&WY6Q=JDJP&Q$?FZ>;#U8<R
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MA7\ZJ47I [AZLTDYQQ;J%.CF<18>M3 NO,@WA[JT#L@41I!4?AG6$*5$!2%
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MHEV[XVJ97S6M#L-VO#EHXF&2[&%P94''0(BP!FD<C@B150E3'HY:5OT8>,_
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M]SP()DX6V2J3<A7^0"X%<VG(K54?S]0T\L45F_54#4N(])IM5\6B)L?=2<:
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M<;73H<6K>#*3Q1@"2>FA1IG//X;PD#--Q >4MOU8KE^&45<S=.JBJ4/E@X0
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MZL8,54 ?@%JVJ8-'9[5L8T/I")R:.?<\ZK753%S 7X_-0.[>@]Q@K_+-KCZ
M,T??4"N:7N5!,]RJY)76'@<$"HE.AF8:<GJMIEXX#V.<G69X2A\I=D?#E,G9
MRAQCP\4ZMW9G+5%"FG<'/X+;5H@ZIO!/,88#)"C;FZ86J?^:R]9A=]B"=\"8
M*7,$.X5"M'5=7^R,31B6S=< T+,=3:B/)'$52O?][^"GI.E/*<3['E1FSU8O
M>@"W@S=EM&/.%;LH+NF/OWV=]ZY:=K;7B,PB#SM'M9K5_ C[7<''CG@PU'F>
M=])747SJ9X^?T';L5[0]$O /"Z%S!D!PTSDJ$9X:Z[J0PD1<YG+$J5?N<C&^
M'@$8^@062LHN^%47H=/!PR8)N>ER5.;X/5BC.HGX," :YLR(;RF'CCTO#WY\
MSVPS)/$97+YC#C!NIK7.8_=@*A@^YPI'[*XSF)/@]5C(CX8G[E1NPA9L HAH
M_P'4<.<>0JCW...O@:&[_V#LK.5F N^:0CUTHH9!9 )^'>P;H[62/-+![IMY
MWK8.M(;MP#E(C9TIHBA:%T_)JG-@WMA??[&E382(7J^H5AZ(+.11F)^F^TB)
MBZZ9EU@&&'BY,_?_Z4WD.>)-%/[H,5XJ#N J<O">KC0N,F 1)0L*[6.T GW2
M,LM5_*96_3?GXI1+:97]6A O[\:'9.2Y=]NN:S8K%(\Q&SB'3IKE2?C&";&2
MQ" :!D_<4%+%+>8EM*6J\J)UNP- L<[AU^";QLM$TAT"XH=I0E@K $>/J7(<
MBG:P3P-?8Y)AL@)RZ*?8@ !&)PM@S]CN($E+SFY2"M!X["6MJ2'+.IQHVU;!
M,Y8)<$3WBTB5<?:W-^<_WB.=\K=$C7P'/N51*94&_N0I?DW.&GEA4@XE]6BZ
M +$_/_[NV;^<_/EW_]_L[7:SY?/@.%YW&:^7'UZEF1908?^37-/($C=,IWO[
MXLW*"#SF0_3YO!$T9N/#9$Y2B04)VX9L-S*:B+>9H(V*[.%2%,FOR@H>Y-"9
M-* 3U7X<>EXHQD28N* F>W.BG>NAWA8LH'\RC,D1=N!A!\^.L(/1/K+F;W9[
MP,N24LH*3EXJ75)_I=\L4;=B/+\L?!65"^M4:0N[(LE5^2IS6YSH'D10M3Z=
MO8X=9,*_DWQI^"QSR?%="H^*/^/]H9Y&L#$VC9AX5#BBVQXA[N^'<@A0[LD7
MA31[2,5AV\&38]^\DJQ:N,.SY[,5Y:F5LY(/49'O7**P4"ZEPD:#RIWPS(P6
MW4WVDZN=B38C*!D8-RFE^B8\6 8_-4H2M1M737R=;,CE(>["2!HB]@_IK(8_
M+]M\[6:<LHPM-70(>"LIYG^E;;JZ3$ME$8YM3;Z=OR^J8K,2'*U,ZBZ$\FM]
M<9=$ =T(A]RI0SE)"CR&SD^R.QRB*_IF<K $%*KCI<,$E$E7,)TL"E=<4;HJ
MVY[;WG-0#J+9<APR.KBK.S(Y8N%N/HHK.8.=Q8R%@$^R&0< RE[GP-R ^"^,
MJY2KWHIL'+(L.J0CTI]Q8S$O:>9EE2%1E\56L'AC#G[Y=A1Y)0QJ55ETD=0Z
MCK .Y 5#6X_R7Y]YXVE9EK$A5*7Q$+*"6#BC=/C\H]@\S2 OQGK81]VO>YF1
M)(2/DT$5@N.H_WKJCFPZM8=!W1O)? ?+'#.=.B=LM1:6LU6@0T[=9)!//<[-
M_>P(JLJ?<%6>/(.J G>OE&L-7ZG1,+N8;+4BVI_V3_C7<4KNY]@(0;Q1DL,=
M]$>U:VGGGD&9H5+ALU3,BV0XX8?2]28"/X;Y'M.7>@2+NB7'.;U/5^!$N&5+
MA($",/6SJ_8/-7B:F14:F</T?2PV4$!<\B7RHT+T_<R,E_&.N"%77;C1X-$_
MC]-P+T8/XQP<XZ9=$"$:JKI=S!F %\!(_]( #MZ"QY1P>UO=#>%3T?J%_=:#
MS_<0@]]WR=M-RP+MB>852CC6!YJ5RTSZ'Y7]G9RR8ZQW+^OW"Q,\$.(F+[B5
M.@"E=F2U4Y:5Q5P*(HVH+_N5@F>.MO]>)LVYMQ7;%?&JOF FM?N.SVGNZSE.
MTV^YMWRN? C&4EB@P7P&EC5RLY @2 7C>W2)[U=B.N<>M(H4 ,'?H\@7Y&30
MO+(09B=.BQT%H^][[(F"B0\<*0OE,RIJ,M&(D%(?*(7&JZ+;E*:>2GEKH&C;
MG<).NHC$S#\6-5>HN.,#A=M%<UUW=Z_-."TBMB\9,6T);IW;; H&+N%C+; )
MFL#.]GU%,V0F ?>&4B;P2"GBJ&DC=%[05!,AO +@4QDJ>(-]H?6C.3.WM,S@
MHFEJ/P9W8 7Z3,?T:RG:G<NJEXU I1]M[L.NB>L@ @0[D['8MC.?41,'PY&A
M"IG3@$8M5C^)!*HK%=:^+^OCI7.&5'0YRDNT/(P3R%])^KL:6QV>G-.5OV^O
M)0YKX(=H)=[<J1V5N]OEE71J,O>2JLU\R^1*;IM)"M!\&6>3%D]FJH'O__1F
M]B#6'?U&?YA)F,I\W3YA-)Q';HHC!.W"?Q:I7O@A]E2 W2\R&"@\_)85V &X
MS?9W)B8_[H%T".=%6ZALN\F)6R\@@!!6T9]8FKX0RYB298J#SH1&6'# <29T
MR@3L7G,/U\+1"Y/1=7SE_#JTG1D/ALP.[<(+XGU07'$=EIHPI8<=MFC:$](&
M4@O/=P.9C@>3,:QXL%^%4Y,O['1:ARM(108'WT=)][8A4RO%^S\C?XKY XGX
M1HR^MJHEG^D/G#3?-#9Z<'293A8*,UM:B8RPO3)R_>GK<(\#C\X1>^:Q9]\<
ML6<C$TXI0>DR0TI$XX5@%*K@UC'2(2%4&^H'J@XKH/AHQ@QF44BY4@.MM9,I
MXS+>'YY=>%7$+FCEJ&'@M.7\"S$YR[(JA*DU[)9HNP[Q_ 1@!;4(]509$\,#
M* "40M7:%CP&0LO+J-<]EHNBCRMRRM1$#CS("?%1H4T(IU!#/8F3TN_L4?<>
M\)\<C)Y'&2UJ%BS$7^YQP80E;60XI5=$S&MV0S@AF07?K)C)619/.[_TM P[
MK)OK>9%IMO=J6]6%":KE?9_//T(;<D7H$G8[K\IV*VTG#M7'3J[%?Y9 !R$*
M7;]:AA%BJDQ-L$09N3"@<B]B[][WVCY%)HD5B5Z87TFD6^9ACF.VA7R@,OP.
M/-:N-41]'V;]@]N*\X?\G )>KY'D4%=CTE."<Y<EK,._+MMFN]%T#TF;+K8D
M%\TMX^%_%D325K.96#>@P#)VA+8ONQ'EQAJ6:<A$9?DG=W2"UX$8CWO07":-
MM<P[K1U*/A#_O) DA^QU[%3CUV@+3Y)EH4)<\NQ73FQ8K']^9F'(0Q^+LB$R
MF);H&O]!73> XQEV;7+?]$TF#"Y='@YMV!,#/H+AQT1]!/W!@N.:::6#X9*G
M<AL,+#$_;&LL9J7Y#L$Q$<+VTQP+L050F<OCXW,CD(JB:Q^TA%K<=:R6(^6W
M=MQHHVGC?<[D,6L>%6Z8L81_S/<SY8SK"%BH++W(VTE[/U97O.DB-N&S%8"R
M!NX/"#%_4AOS!2. P=',EJLN>EJ<W7YD[@1#OQ#-*'6-7<-PNSSCTJGLEX)H
M-&?"N>32$XML<-*'W38<4I.MG.^">6LJL3RLXYPO."R?<G6=.PSNVD7LD1:1
M IGJSB_6B42)=\!#3&?T\6OM$&>B" 1>Q0(-UO+H83+C38EKG?ML>8(F'Y.W
MN.[\B6P-K3^'6B\NP1&@)/PXOPMZ4@G1(JR=^\+I(7CP]" 4H5.,KYAD]. G
M Z A[9_>O#\[XV;Q-:_ABQVN\*<W'WY\^:?9V;S7TXZ,?D+=ZV@YV'L2/0<>
M/1@Y?0Y\K,L C\PE^7B!."/S8-0KM6A$Z1="V^"L5'QT_75J9?#PPI)VQ5JC
M03? T_!KOPYNR/"YUM&T\8!.>HUN::YXI76&^=5YQ%&WV11YY;M0%9$< BUB
M46+CPZ6MS! ]>T/Y>)QGZF7$^S(NM=CD;:'*S?M2"/HX29;B JT?GC[?90=D
M/V$"4^D>HO1RQ?MMSYM&Z;!5E98N?%U<6)AN$.ABR!&Q!_SMVJBU\W?49SW2
M2KR%+)VVL6SRR8V)6E1,^*G?YW,H>U(HR7#?^D13BF<'2828!&_*Z-QNB+/4
MEH#+WJ!E3XPI9]JD$XZTU,,QQK"J$XW.+-7CDBJP&S(5?ZT1))Z#]P+.!;L9
MP9=@55J6W@S34\Z-@C3\=EEM/X%4*T0R87B[$FZ%D$!W!=]#G Y[(7D>O(U*
M;RGX3F@<J#VV9M>WCWD7U21CME?6""['NK27%./6:T#-UJQI86HK7%T01(TE
MV:Z53C&]39(.4OYGXD&XO.ORBQOBI^ =T'-E?F3<29#,-D\!0G[N=S$Y1-[@
M*2$VR0JS)BKH2H,)!FT91_I$TCI[361^G_(U")I=]!'N$.:7;@<3-8'%TQ,'
M+A8A]O$XM&TWS/==V#*,PX[$&!1*2."-^^-R1HX1L4ME-!#AFE<ET<(L4WXH
M)HV8.-9T:84KU$!UGLY>@IH)5%B25^NH*35XCMN.+^*YJ+48- >]=I0E8F62
MQLBEE,LLK@JSEFYY6%#'O/0*G(ND4,GB5E6/0?WB,,W1A)2E%EE8,7ODV$_Y
MH8,@@K!HW3)G$T+=MPL:>TL_@+8L#-4\DBW:;<*4(8<4N>*HZ<_Y@OZ\BH<S
MDYYB?N '$=^$ND'1* @NSKRBH3&.20)_*M$N$3?4MR.+LSP/4W4Q8*OG2,?+
MNPM+BJ:1A?=IC1<<:^1PVZ4P,>PV(((,KW-!%O4B;+^OA(X9++KCZFCFB,U,
MR5F<G4B4-"RUKG)JV2IJ,XT(? =*"=-@0"0Z>V21I>LTQ+67,!RJJ7J0FY.<
M*WUP5#LFGCQSJ2JQ.RFEK_-^.PW96'_(!!Q]/^4^+2)/YW&.*"CYOEI?)4OS
MR1FF"*-V??EWVO3'/F$F;EQE;8E:(,JTCDPXIN!)N,J1YW0/3DMX4<\5Y+S0
M8DT<'%03Y1#3?./(>*3LZ/XOR_%#(4;7!QE&0B >CWV5FM& FV=:<B!'>/>W
M-Z].'G\_ R*+R&4'XYU-;YS]*(1YWJW0_\P[A<Z\$OSB3/#4RW'-GHS='IWK
MDZ0M@XV%+T;%%14F2=867YO.$E'",*]2GK 6^CG15=<2F0+]YU^+77OO:#&8
M>">S\J:!7W3I4X>+I8*+SCI65N4&N&^BA IKZ5= H63[6OAYOR=1NX7I22?4
MJ$GP, LW/W[:$#: 6=(JA@_8^))L3=<)&]6H_H*$)LPASI98(;\(-E7#I?=Y
M\$"KV;E,,8W>:W&&PZVA%O=26'YH=!\,/GR(A*<]F25U*%(-RR4,V0G^@PM*
MK!6QG& 6.):/??GXVV/Y>+019'D/)$2*>I4C76Z-/5%9;;C(PN'.<MZ#-9Q-
M[X5,%4_9 U%;)IX[*V6Z8R0+SS(GYCC09PD/V69D32W-REZ]HZDKA(&5$R.Y
M/;<3D$H]<2$$%[#3!%?'$%.(W4FWCUJ.G-F83)EQ;EG\]T6A_CN;$5]*&M"G
M+<6EF=3V2'4TK0Q73X24:02#<H@K%5N!C1@CU1Z"AFE$^6>S840/*O0NQ=*+
MG K2.?TI,_YYXYQ_\'EJ%@^S@9-:;$JX09(09I\(8HZL5=%;G1=>6G@K<CBP
MSI$6^0CB7RHT=F'?;: \3,6@9C</)HZYDI?F*#.5LGG#MPGX"(&!IRV86$M?
MR5F)@#\;;^\P.-.GG=;-HE#0D,8SVTMGE-!O1S9T<3>*B6/[IA-Q<@\+;Q#G
M,FN:P]F2,DV:3U8HJI0#N<:!>G>\=JP?2*(.5&@(Z^MF2/[D]'I,Z@<&#>Q^
MP0#2 E=>**72'SW.+627KTM1FP9!LOX.=GOTU''H)]0-G&["'?B'=6:F3)/*
M"B2JF/[-:__R@BS0(E\$<=PRNLCY87S-*:6$(=$G 2YA@G\]L\Z.1R/*#,D5
M%D(P&ASOH==&PS*YZEF$1OBI;?@73;B^XP9C"NWEZ+)[]Y)=P'.AVL42VBBO
M<<R[PZ+EB9?FD>-Q(I,H)45D.W$VLJ73@%\))FX+-F*F[?]*^/N;>EG=N05@
M\+(R( >9-XKOY62W4UXM)KU_\NC)$S$3O!Z3/*15'L/7GC*?DVPN*AWP'2BG
M4M179=MP18!R#SPT7/&A3$ A0;"E")3E,4<.@%,LK J*ZR^F*)W9CQI2/0YL
M5"87FA8$M'211VW'-FO\5&BKB!]>=]]BVUHIKK_+&##@I1ND/\@W\MM>$T+3
M.=+]B5#R^71ZA]<<+6 V>ZX2Q/78CB\:R4+5,'0>J!]^<VGH9L^;SNDO N_;
M)\K'00[JIC!F0ML\I>6,&.Q#I6-)!PIR(BTKA7E=4S6([3^A8IOU[@;46.+U
MRO!XK-E0<5U'?YCE;">VN*OI74^*_&YR@CRPDA7&-J\:P_Q%, "!APHZW<\X
MPLG2)82S [G)/4G:R02MCYY2"X52,1R1KR2M]@'95]&I6R;("R>\I1),^9S!
MB#,)* 5==2-(0':N./(B3#"1XK:FA<_<F8=X&+RK9S\!"O/X409+GLW.@RL1
MWF?VM^ )!'?KA[S^.'MP_K<?'LZN\V[&B#3=EDX XQ4A8WHE^WMM0_,^8@UH
M;-[4=7.5;,!\ V]>ZLCJ+;UBC;;P??4 TR3:JS<O'P)_SN%7>QJ>&VX-9)/M
MK9[$M[I$7%KP"]&CA!<-/[PD,_(RWP"!3?<X9?\5J)7NFGK8X<'JC2BF 0!/
M-Y".13H ])</+6J:NRQYLY\+.I *0Q#2J_#5!/Z<<S*=)>JPBL+HBQ_/VUZ!
M>*J$R.@!UJQ!)HN#'6K6C*2*^8ZEMP6<'2WY<DMDBZ#7 1(3<@$4G,L4$*$S
M\?FGF''?4PXH%*XBO]'D/3TX#[4??5A*+NBWR*U(;Q*J%!=YE2.MPH /KK%.
M;_:24*+*(&E#&=4.T/5 <^7L1AZ'=N>OQJ$\26_H%ZQHQ8=!''2&M5\%[Z*0
MR@K5D^E_R3V_RBL[%H?6QIWJT;.HRO"KA?H3\56=[?Y*3/2[-%Y4@G$!T_I7
M;E :;]M=>,-KTIWBX1*'2$A9\D_PT\J+;5\8?D@Z60[3FOX5Z-%S;4YX^IS]
MYZ?/G^H*?4.'40TKP([KRV:!=?GX^^??)I#1!["OX=.''/O/YL[^ :9ZV2 E
M.$,__:,7U)$'ZR1I-/SY\8O9@\BQO"B6:-(&(/Z2\F2JDO/-(UIOE+.GG#BG
M5P3V\B#8M["HM\5#8!3"TJ9E3L&FW3!\0Q[BFQ.YS*Q;Y6VQ:BKT<>NSY)T]
M@_@_](89HY3R6=N(-MJJ+8J3'6GPLD/X,!/?U(9 JKQ=LN#(=>NA@W$B#S^Q
M[A[\Y=W;<+WQ\M,TC/UXL )IZR^77='S38(OIU]4\%/X@72G I<%"Y]_$@B9
M%XX:+N9?&%%?LC@M0$2,D OK=KM@R4A22NDL\1KF;#CAF1_>,"6R#K$,M;*,
MT5[E"TU@+V+DY!I6)+)[%8X\-',^?4S'Z./O3X/Y1@9[@V^1;#(]7L;-2)P#
MU%-L^'1=>MLP_4\>/7I*UWWT'%?'4?WX.XP:W<PW! T,2S<4U (+6=3 "3,\
MF-^R\UI@&'>WD_8-%6\428WA\ BA*B6*!^^FNO.R+:<F9W@I*L%S1P<EWY>]
M)=RZOJ%>!?WYB%O<6]7Q>]YE'5LO@@I@:7=@7#.3MHM&Q-PL3DQU['0O!7E*
M-ZKRZ]@#0FM^-ZA#Z&89/[Q&]5@=$@F*/S-<BM_9'N*J$MI&KKG[&UN@[)%J
MW_8@U]>-22:E8R$U4,)/7OS)([XX?*B+(C;P\.9__N@/AE1.]CM"-S_'*&V%
MZ/"R0:L@)T?#$]0P2^F/LV,!-RG@?G<LX([<BPDS>),%V'M\??$Q]?6XH706
MA>,^KU52M4M19MP91>_%9U]5?"IE9*/&XHA=$?57[&*PU4U(PI+(67#@D[Z%
MYJ(2K'@GQPT2E?1P>7#"$$2R?U-!N-Y\76O/"Z%'Q6DSE59KKM'KIYJZB<XV
M_9K,#G/;R%E=P($@43;5-$44$A_M,#WJ<'*<AQ"<S3/;?;*A9)E4,@L#A\'T
M_5 VLNQ(P[/X0(OB;?CJ0YXPR45LN]G;<EG,SB&)&';*VX+K:Z])@O%--GO[
M?O; OOLPRL2[0YQ22>*XA_7SE[ *](F#'^/^^>0Q'O,L^!$5,A/\>&?R6WJX
MV9D^^D/.-T]_R*15%65!6T+*2I=O1+.+UH.61K5C+3*:I.C$2=J3&Q^ >578
MJ^H4*J\Y[>6RA#LIB0Z5G(D;)"'L,'_,-!F<G8N:ZL E@+"'G#&LYV"D@LLE
M\M8$-YDS<E\@)^C30C_7FGK<.6P71.*&<!O4[$QB$YFT SBM7?(D+H+=L_I.
M51:*IU1U\YAKU';I\.(5(< 9/ 95;C=.?HRBK4ADMG@@HY[%C+JWUMNU2Q0T
MRRB3^OLGIX_"5T+@!)#'?(6F6+V'_M;L!A4NZRWRUPA 8?,%>R^\_Q:%71?5
M57$"[54&+63BE5%'=&5B@9-997J'N+^DWALLELC&@V<P/!OE\N(ZJ!N-(^$R
M:6>*1(\/8ZQ"4T-H4UJ&4;-;4".2KT)J*RS"V!5OY5,VG'$>)'DK _\1S#D+
M+F>@XV]GVF7-MH=6-BLX4CO")J^F'+\N6>K:GJRW'"QX,@&",#(EJ&NN@^M*
M&Q]$L9%;3S:-YJ#=+KP"R_RJ83J$6*JT+D=7T4 >$!DZE^A&7HLSHRS0R]WE
M/EM.6R0YX6B@-WG)C6';"LT6X5&E^YW/R+J3+*FM$&=4)THH_&,,<_B1NNO_
M[__S^-M'+\1G?ZK@ 4I2__[Q-W%3()C0J4HF,)Z?T5W@I@QO!G[_]/2)7<O_
M/*P,ZB2MA8".CJ2P'\-J$>?JY",!7()19MY!+O?PR/!']AO1@Y;#;'*-:5XT
M2G#*$Z-]5]]CVE)GVL63BHF1_<NYB6#B?@S*QN3C<+&'):M")J'B_&FP!+([
M.(?3%[68#+85W,[!*RP,()]\/&??$FG&WNE4( EVJ'55L24AI0RSGC(BT^\.
M*QS!Y;H!]X%UK+#LQ,0,/,^]"IRW4[4P>%^N#F0/U>)\D;YQ-Z;!.K5;/YYR
MX-%&.E@?+$;OYDY&!"0?*D*D **?91X,8>9W]YAM.X-Y6P0OE<_(P7E+R$!4
MXG0[K=$GYEE"KO=GU].<>DL]U-(+S;K"OK?$-T= %9QL:]-^9/B]LWZ9_1.
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M(!]8%6,E/DN41/PT1Q'[@VUJ-AVC KS..+@<V!F43L$E)Y"]L"0QOG,7,*N
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MYVU<OUUZB\S!IP\,7/")9N*3-T=UF\="I%2D__#*0@TV^O$@H!33?U.;9(D
M5/:#I%73%;7B/DF-\?W7;TC8AK;U/!C433.E?_KOUU__^%W^'//#E?;3RI,
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MWXVK 1_*C-86!93-8"E0WI(; 0"#)3\4 9QH8L:3*]5K<FTK=/HBQT=?!QC
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MYP'A:AS;UHFJIF<[1W\U+]5E8DI,P3^1$$W^*I5@B!,O*PZ=J -], '2P/F
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M3?1*41GC_/DML3].BQIG2U^L"8=6@YXO/N'TC7WQUTJ^$-I.S!5H><@[.DM
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M&8=)LVV$BSOE(32^R8\$X_*_1P7KG"?B_@;5]QCVC](A27EBLIA8Q^QRTC2
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M'U=OV] EUV,X"XD/]BX)RI>"RS-X&.>(3"/&G<3:?<_G/4EM9$>R5=<J(;K
M[!@5GQUT69:U9X?5%?C3F.;:\%+XS_XLO\N5W1U+N'*7,[68G*H3)Z@/3R:I
MU$]HU!=#E\?0]H/020M1Q\+087>\4BB<+"_X#D#X5=OR+8K?O5&!Q$MN.'$W
M3%N=IQ.5E4FQX_,BP:01F@C_70??L<+9293WI)O*DQ$GD#V%B3ECTM2_]LMJ
MP3 7V4J<$;,?-$<8ED"2RH)VL8_Q0%+"-=Z"K4Z,L-_.=IMR(8R7#"@&L\V6
M)]FY8.-!.<\9_['/B,J.SX:R;4YJ2#C,7ANDIJ5GXX\GQ[J)?DHM7QKBT UO
M%6=B>'CVF896MBY[*?CBZQN \SR/)&.I?0IO0;(=U4*<!4'1]W1HX6QC*@[)
M'\\ZG"V4"21Z#$XB8X#LFZXDS+Y UNBN?+>+OHO.*+GN[HJP&8MUPSGW1&(B
MR:-$3N(3\?E--!.3D<9MF?'&\A"GU[^!"*I6@5N#%[$3B]0KC!]'@M&1,(@I
MWP[2LZG=('-<<E8NU#9NY72.T7_?_7;M3Z=MIYWM"OVO1@UO"HN8W&8YYQ29
M+%P1(/!\N!:MJ7A?30R;V<JY)\S)B.?EH*0#=*^7*%0\54^N(V>N+_"<I)7A
MO6\^"E'6[L.--N4:CL,A0 <,\/9N*)OHF VJ[%E?@CM?78H310J:%(T"CDX,
MK^KL#FCNGTRP3 UBJEB='L8/!;F8:PPAW#JD(GTN5LVXHV2HV7X;D45JU#I1
ME1F?_!:#(<'B6)*C>33-1;$A3F%0(KYUM7-\?#XEJ_8*^TN?S0"7TG/IM'2:
M#R )]A<V0"ZP*&=UOYV3R5]-!:*#*:(OJPS9/8C4^P<H:X%S\V]T*UF>%Q/_
M_+L_%;/_[X>?O\?F^<_O?F838BW $V] #] %<T\DV&_:@V9CG7%8QJU[$[B#
MVA9NX<GZXDS$C=K4W&3^'QE5WZ1&^U"%Z]0.T1Z(T5L4TWD"M>&)QYI\'IDM
M/A/OE)!M$*,,)#6<5=+1O^!KW@^ ]MP:N0< -,ZUI3B)]0;,*]6PMT@ND&07
MEKG[<[IH#7SL)D:SA*RWV9?6AG&,AN"$?^>*,466]3"(BTMSG :Z#+,%G) >
M1^/1Z6AT$;ORC7*FV06HO>[)E\\H7&-S3\7(ZL'BL+^VE?W>Z#[AE9\:*4;Z
MF+LFQG(11@<6LW<(-XC0?W ^J,@_Y*(%T)S&,?JZZG:]LBIR.70>]G>46>\3
M(BQ-%W-:W(MG<D'=I,W*PR]C]%"\C1PCJ6EF;-_R(@/P*C"55QI"\1M*@"&Q
MBV)*!%,=GXX-8C.(9+F<(^S=B5#IF-AMHA#Q"=ATT-$6=R.2/H1<C[X2CH.E
MS@<R ?>?HYH*24E#57YICWB>J4+<IZ*R>YR6&%N4$)XP XNPVPO#6+N5O%G"
M&"GG(V5&-"%+2L]C^D>KDC&DX6CZS.!"*)JPE^XH,*R3*V_:QR8X?IR.CE).
MZB5GP'EUE 9FZFGD3Q<*&U[\ALB2=W2]<YHAG7*%+H^SIRZL&I9%3"J%-L2R
M!YW6LEGTV(5Q58N]+8B@V-PAWP7@^JO9X1JP#SC=-7*PC"YU^DFMIC^)1M 4
MS=7P+3@X\P]SGN?#&]/AH2'0L5<DX:E!L^K(J*[EW/BI22S;P[')TTY)UUX7
MOZQF.TW. D[[J_C*S1*]C F[L0*#>30RX2X^,_]4UG4/G:\@KK&^)]\U>TNF
MO6:PX(";6[SLO/9,C47&9ACMG^72TJ@.6D1L  F,2:@*RM3M&7-X:^?/*J!G
M66S\B4?@L$,[ #0+3"W^"N"E^ 6I8)==6X9RN6%B!=+V4!D5&R%D1^,B7XHT
MWJ7"[2O<3R\5[I$E20LHF=/AJF2- 5IA]J<8>FPGUJ#LJ7PC4;!X9"\QK9$D
MRP@'W/:*:'^IR9X;<B;W8#RS^TAC&C3&7.>AT*W, B6WK[ [!9Q_&$!ZM9FK
M3"Y(_,:RA2B9[^YR15T^:2R0'V\]%@X;H& RN[,G!.6N"P/H^Q _R(Q-W'4M
M;EQ>*H$.U?V=8=P70*7:LN8&R%TW;$7CUQC<+5?WG&J09$SX@_LC$ZVQ[T>8
M.>:Q5@=U]DU/+FS\JNDD*Z95N>+_3HWQ[!&.-F'Y\ .OUW1A^.CSL&E2B>3X
M@X^"^K70J! 4G'(2:790@6RV.$= TK#H3<O'UE[)0%PZCEG8G8]$0K!SGQG6
M>N;7>.!*VV]"5SA\8Z(N3.D?+F&ICT [+JV(<AXGHC%V&%M7[KR?1'UI("!C
M*D1$,\ZAQ8!TCV*$IUG,.V GA;EA*WAYU9RT*H:$Z<+>YQGP:^4BD:P5V8R*
M&U_!)D'^8TH*YT*/BQ)X$\YI"EZ""LT))ZI109":Q9G@&_\N4@%71:E\([:3
M$(#PKY$GI7*24D?0E#1UJMIGJF0T0IDR5K5#<DX[S[D^P_9'TQE:%#E3/_T5
ME6Q!>:H1^&DXM;ZI1:\3Q0IZ<0Y.AQ25S1TV6'8H7)*P[Y>$_8.2"7"O%Y-"
M,@LW"[3E=)O2_LK\,PE^)K7MB68Q"%8. :N<I;]IF[N]Z=%::@X@-$G#<B"N
M)G2BVBBES,)M$33-=UJ '#^2)52RFJZC0727FG@AZ\S2_I32E, S.>[+HGS_
M13E ^.D<60>9XR%DE.%HF@K%[\W#D.QP+^3G-]6M9H#\"5HR\[7GG,B*V DE
MP)J_+P5)*0=RP@O(_EAZVBS7^8;X67 R@JUTL#O'QMD&A,=;[I-)+N\YG@-O
MUD,)+W>662N!DOR.-Q=1'^7B/#% U6Y+:3[V;19*GF(M/U!A;_D(N@$U=.L'
MF'P>R$]Q=R1HEB@Q0JA;\?,)6"$83V=0U#S<\_Q&HLQ2$N1PM\XNT(7V+#=\
MRW)#2MDQJC)>K,=[6X\?!BO"]:VGUIPC$E!(<?4^P*\H[_>W:#>B,[QV:XG6
MI*ZP17PNE*7N;SI<E#L^OLZV,7,@/Z9#QV1V\64"C1@WGL_]0$H3(4Y5)T3&
MU':903-WF:"'H6(@0.T)[;2V0ON%T@TL0[E)-=!T<-^S24^7J&IEO4OT=IS<
MX/<#O)!B^P3")H!EW]8IEW,;N&<Q>]HIF;4,-29'61J*=%J\P\,?TZIUI2GG
M*UULS*-S@Z3"W_T5/G(*Q>7UA;4/)49^X]:EMKV07.+QXG?&1N%%0Y'@WY2'
M420LY /G:1=%JD@14"J1HK7"88QRVU224LLY.0;UDBDO8MAR*0A,]HX\'+C<
M4IJ. 6E[J>@6K(<B'+.\4$]D_BC(&TI"/(#FYH0P2T$1T1VA->/_RR4TB?;2
M\;QS?"'HI%S3&O*2*(-T9+1D2NS)OC+!X%0)Q%]-.OA31IY"L)W:F5RF<DM=
MS.A-<Q<XS3GS?2C7AZO76THR/H]+(-JGZ/FS#,ESIK53:EIH<$AA,73#M\&<
MHCQY6\4/8@50=E_9J^FW?$L3CRF3\RP1K5Y[WC+S"BTIT 4849T_1720@X$[
M_63OG2*IM6:E;PSY64I)7+9"AC+B&[ H^\-+5OZICS-+A5>4"'QM=%QJG>TR
M%LY!:SL_!9W_1!0XE0 !$-- &^ $3"EI\1T<7]'EK/X[<(;=45M%@7E9BU8,
M(DF;XE;%KPO! 79O9R)OI-XP['QJR[YD)!_#M2)'X88%7#C#(\X&M^T<.4K=
MR<ERZ.?I0AP7<7>MF2-FD\M*>K^5A$1RI@%IZ/<TMHD5Q$&!K:WXKFRMUWMP
M!G#(Z.7>>VM>-9JUBQEX;WE@+MHJ;G^L#4;3DIV6278OQMR8.)2$4YNY^@',
MA2<B8=2IX+CF!QV'O;8AI4]<5)__KL.8VN1G7DJ'3]([TQ8SAPJ<"AWE\;/,
MB>(;FCI<+.9C;[JI;D=QQ:5 2!\<,E/RMD+7Q)!-@?PJ9528ZETGN 7D?;9D
M8@_1WV?1++*U)AO&9#8KKK@1"#).]).O""RX7_-F)L\-*#:A0!N8CV0:U&OW
M!N4"'O3@P4\OX,'13IED7; BU$:K3!(B3SD*ER/CO=TXJ:6/.XG%JT/BG6<#
M)TB.(F'R041S\GE3ZQ'0PO#BYQDZO#(8X%LP9 Q996$4\P"II2;_5+I(2:3J
M 1S670AO.6FF2K!_[6MCL^9,&I4LN!>F);V+57XN>%#B?-,LWMY;CZB#&?.+
ME_5W>5E?IR9$3AHJ,R<WK&U"UZ6U0.E,.M.%<X)A/Y.L$V@>TXZ3/!4-AN9.
MUA@#J4-PY5(F:,[2;2\'E!2E1][QOAT&_6F]FZ_"G9J,T,X>B(F2L^:Z-M!B
M50IE89!NVCH<K'$2..<$/5DQLS%*G13LL0_J) $R9U8NTCF1:='Q<$O[!.8-
M#=2N3QILJ<O !=2^G4U($0S0$&@I8M[8QKJ-LG$QW$ETG[CJP."4ZIC$<^H6
M%+$KK;BFE6 ZXUS_G#E^E&H_];G[:I?7LV_9.&S!.L&,:0*4GW=!A$9\T4/;
MAX,DX.8B'7H<7X@^NEMF5.W;1#K3M$/RC(LE>G]+)%@[[4)4")>G8+5)HM7C
MEP+:'IHCV !B.==J^PB"94LNA3&7ZO<CAHGNF!_'? [E1AH!#LQW%TZ@^33/
M;BX(0_<<<B]9.B2('X#<.Z++=XX.GH/=( +VQ][(VRM807+$ <L,S4+S0UR\
MTXQQQ[I81("7S]Z<I,I2;;B/@BQ'9S"MW8INB4#(EV\'M=94J 7J4824.:6O
M=.*>YAV"68-V&#PL:4!L=WL>,Q%+R,K$Q;C :KH.@VKL@-#7/Z99,L$,HEXJ
MSA( RJXY=/B>VBE"-&+<6,G^<ZZ$D;@$[A5<F.JCNMBR]T;RG &J]OT:5N;Y
M$MSE:BQ&J]I."+.(%FOPZ?01U7ZR\O.0M X+^)!7A&]END;NU$C.^WD:V+']
M2!F$+%!.$2Y0!BR)$Z1940I(YN!G61Z=$TX ,:GE0$[AGE%/G8)#G/F;9B9R
M2Z,P/SHY_7X=;>;?B"6D"\=0Z"!GGSA8;*JYV]0FFC='-M>9>,V8R948=236
MF6(*F\I'W&?L!BVD64\C4ZKN580RB>HH=7R3X*9E)PH,Y3'5R'-<M!D8MS)-
MC%3[2"M'3[^ED!][:Z">PZ#TDD@DK>QB9,'N'I>CY;U+F,)+Q5)'9$AE#XN+
M!3+<Y"'8X"/.O@S[>PP[@21/B8@@6E2=7,L?3%J$(I\\F[8,^&I4[^.;<:*S
M9 Z2;5.CC4=;N[4CN5;,V0U$M+I9OVL4!I;O5K+.HBGF&>8G;NF$:J]GKZ5!
MRFS!"-%7STSRS N_*3#BC0,(KAI"QX,_D G6F?A>N*#ST1@_%PFWUI)6XKGX
MR\"1I3FP:T FB+ET!OR'1\CL]XJ2K1OW2E@;1#(=1['(40,"?Y3EP#$#D3@&
M!N[?,7U**\LKT4^CB)T6!SXOAR#E.1I$M?D C<=G:K6XY 7(-.-+;4))Y ]X
M>,8=MNMRAS58#$!0N3S5Q7*_?];J-4,1!CWZ(]ZE8P#3#TGMY_MD!+V5L*0=
M>!)5LB+Y^,6 .^.8;F.'=C>, \M2#SB5M%0P3/DZD7-F-IY"O1.M-QV9A^3F
MPC^L:YDF.*'3WJ5/'N\3O!XX3U;=<:(B&?S LX=/:6I1?3$1CB>**)*6.^P&
MF>NQH'H;TE5!F4YDYG5\Y872T*V$(\*HYM:A!!(\3DIC-/V.#K#:9G.;9[@9
ME$/&K:VD\;[<'+J]</U3?Q.YE];ZI=QA?'<NC=1$78/0L-KG>R.;N!'^6M(]
M"S?0=%*2HNGB[8<2C/\A7ZI2+9,C4 XH/I6G"A9\CB$1:J0S[R2^*:[]!R#Y
M^'<-5-R"5,<+*=6/$D#F(E5&3YES^SU0?2@AO:]8BQ"]HQU,S=P*?J9O9(YZ
MJ=7*5F0R#+;8-+-UO#3:)1J#^\\#H/\L=.-6_@YE$88[8 >LF\TRB(#/)"8U
M;Q8<B_\^@#%SZB"C*/F>HVS*:G'ZH&:NW);)68^(#$DY5060VWQD0R8.=%2"
MWLWU":78:MBS/\PH\&HTZ9,CS6SQ*E1=R%BZ/;^IU7ZM#H*F%<[.NG88:E-)
MF7.BX-(UC;X7]""T_9+#014S+4T<GAI)*S!Y*E<>CD?E-6*;+6EP4HXE& >?
M9%C^Q(6 S06"0;DL%&8W]TFK_$NBX3[[UT3#O7<ZVO'ZZA96"V">7@%JA.@]
ME+4Z&4F\&-(_<5V2I8!5NB/F-<[<]1T3G(IS!>M\Q"\;MU">XX&HDI1M@&LU
M>)]A=ZA_OS&>86"2HWWA :?1K6ZK94_ ][MUP]$J654R 7%495X("^,[)&OA
M .5CA-NE/'7.D9E.HKWO.=^.*6YSR#/QU9;-\7LL!6B1C+0P_%,: "A^,<4E
M;8I+?%;=O3PU^$'H.)%5#ZB8HT,!2'*6Q< $TC-OJ/Y'WHKC9";FPGS(N*L)
M\\=8QE3UN70)/B9012EACBSO?'7PVO:R?>9G3A3GB5;4%HNY?QGOY'V.ZO7,
MA>N*D3!Z&532(8.0@H(@#K;L;'X5WW9M>D@ 1(%1-\@"?) IRF0[L!Q7@K$W
MP%B2!<\@#KL2BF*&0S/$GNRSD5P3>9E5K=F9>B3E^&[=O@.2J9SUS[U%-I3Z
M*BYU/,RG#C,AT@-!&4/)ALC[3^1$7#;D(>?5DZ?_L -K^J#_*<9&W>RGU"1%
MI @O.&9_31'+!Q*R_Z@1EF0?9"O=4J6W4J5Q:LZ<*'5"B*I;EZ(E-\Q:X!@E
MG'-S&UQ^@RY&_-OGZ8B /I=S37&%+B5GO@C&9)>](27*-%HB:4C'J+[BH]RA
M;G__T!=^MB/C4-]<;<)J__M/OXB_01A0P5'X_=63KW[E02&/X.D7O_KIE(_#
MD\_H!/VW_UWR00#>9\58,5-\PG0!7R_,- X89Y[-$8J:2<V*9Y=I>Y1IRS*W
M\P/XZMOA#-'0"VV(E(Z5B&X!%T*<!GQU4>[(S&%'5F">NLS5X\Q5](I >4*\
M7*':SBGY@I,Y3IMK,=TU>_&*\J[D0YS(RTP\RDP0@*H4D#_MBXGBA!JU-E ^
MCG<&YH_L&7H+ZJ58QI5/J5YFZ!]X'&4[R-0#&W0&481Q1'S\,B>/,B>^IB>Y
M$<Y'4.DDM*9W-)W@ML!S3$AVF9_'.5]@E19:H"G4$9!D#GY-JH8IMKP,_*,Z
M84LOP+#,:?:IQ">I 4X.9OW&QQRWRP0]T@0=8J3]5SO#-9A)V9'+0#^VBTO2
M*7VM\+@8%\9=<5G/CQ_UH?WB%P(X6CG"22I(3!XG0;A/+S/P*#,@M9>NW!S)
MTHEP;O@%H$[J)D1W%J6NEE6,(+BC,$G_.3C&,_S^,DV/,$TWH8; 8(S8ZF9;
M+5)F2B1ZB8N;P#."+QMHAC U4=;C7P+$Q\EXP1EI[*[5-@-[OVU+ZCE4&/ /
MU7*Y";-ORFY_GEG:(>9&EK(0-,6WDN$TC+G^B2)@_BRP5:O VL<+$4BV6F_"
MQ120:"2[U>*#2Q())JE0R0M#IK+9D"+V:M,O3%4+13)48IK5/M3,SMK72JLF
M44F,,!J@H@FE(C@:23W2<11:5)<D :""9/*<U[,_D-":OAK+(PF;IV6?'0/Q
M<(E1.^A&5*298(K%W-/"4P6W%H4UA5-:P8X2<QKI%L*5TDHMG=/B?NB/HAN'
M7!Q")HJH>FHHP&.:+^VJTXH%H..^7M$&DAP(J,$EQOI#3EE/4RZRUE9O8ZQ0
MRS0.J^$W/H!]83VWW;YP_0H[J+%BI-.8Z8<;R)QN_)J:FL+2;1#%ZQGL*^6H
M"I^O6FS*SH!6KFI(V\MM$2HQ5OL>84E><$SK_LT:4+:$C*Q64]_K490^79,4
M\I.<M27WN.W%J,&Z]L4"9G2)Z[%.,$'MX+9N&L<68N_<,(D(X[<[DZ/MPGZ_
M">D;*;>T7T-@@QB4)PJN*O:@DBMO0R:P(S*"'XP(W;<#ET5*C/-#ZCKU7HCV
MDYEZEZ]G @E JB3A NC+ 7V?_VL"^D[:S]>ZY'*X?JKJGJAVJ[GEXK%R14J3
M,[4,[!CN( #73A<X<[\WBP4N"#D,3QLB>N:X3%Z1GBRYDQ,0[635#CG&HH='
M )AE-!8XMJ5XIOJ#3!2R"8.H#,1F!V?&K\_^V(.41A:XC$,;A2$M%5 ?C0KK
M')E:DFH ;J/)): #QGU#:JLLQ?A3'P?KR2?SSZ^>F(SM+Y*T(1V$E4Y]W^X:
M!A()#QR9KV/1&)\ER?*EXQ.M-*??JCB^W)JTW$AMA!9;Q@=&30CU'G@F)R4W
M^?[%@U%&#UJRTQAT_9IXUI/[37CFF5>/PB-!CCL]=GWKWVK5ON/!]ZIM;JO.
M@QCB@FJ)Z&#9+/JM*2[P"OPZOCU:(.+_9$[0!M:WI-]5@DU6A.JIB<N?F)DJ
MVZJ\;5@%Q/S?4"Y%A8(H:];:2)%\HO-T?PG,5%*]4WA_*$KA<AS!+LFB[@.W
MGRZ:N"L9X,$.X-2WY@>0*9!Y*)E41&<'(WJ/L;XM-[VM7#DW"%CHRN8LTT7)
M=-,!:JW-PV4H 0UN-JFTVXWSPNCP:WK> C2WKOEEWL3PBML$Q8*(3O@#UEME
MS4:NZ?D"97J<["@'17'YT&H;39(J>;<A7!$A](ST[6\".$R8^BWQ@/'R85I
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M?\4#X\M/CA\8#V]+?/KTW\[NE#F7_L>GU_$4H$V&GN?[?']92N3^_]8GIE$
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MIOV%2900  D\58"GM6U&:Y$W66,E8(_!N E?E\BX=%U2&!@]0+S!;"8CC:1
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MEIT&+F8 B2+1G'*ETER5AB[%[/_L)I[[;Y-@^4U8*W3^[H9X'B(:VWPHSY9
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MRT+1%Y(<R L3;!>GB'3,N Q4=DN@PK'N.96_YPI._DYP';#]!$.%DL"FZ)G
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M;!%U>#A<?T$U53)@LN8>A_/7U0[\K+F/@^2@"/&V>7#N<7A!E!+9)3-P4Z/
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MU/%'=C7QF/['E3Z%/7[0[6?]U4<*3I(KT.H2Z)>AMAI]6^-^3V+/@#,S0)?
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M).9^(MX>Q*N+A32Z[<:XWP4#<^]P1MV)Y;#1>QI>5..D0C@IUA=#RU?+98J
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M5]2R%_-E%1M]0]Q<1Z@I>EXS'.)Y37?0JLW<<Z&F%>)X9R):+Y-'57.4SMP
MCH+,7"@O1YAKX_>0D0;B(<  9I(3SWSAX,]AC%$+IU375N[9D,0ZL;HE2>#@
M\GZ=&7$DVQ6/ :TG9HKX@&+-%[KEU?;KT>.RMQ'@P=( M'Q#K'#W[W^8;7YU
MO5\^*V!SC+2JV1PU#1TZB+ E#65I!3L CNKA)4?!-^86/ENVO:^HK:V0746M
MQ$#,+MDJC?6RM;R#K]ITK0K1; K0;D$TFR-)HUYCW%-[.6=@M7U[ /S7TTXK
M(7"ID_^GY5%LA7FG7ZTA:S7='%KFED0W6$ZI#EIE->6L[=NU^+\+9LRK+=JC
M"EB"^7?7P9@WS\>) FS;&[7#VJ@].[K9-IEK#0%E"66$Z> 5H9$S-V!O9KKS
MR'RL/A<!6BQ7LRU]8MEU_?E!Z\\[@\I1P[7!*YNP80&SGK#YI(IM"FIM>^C^
M-DMQ5L?P\!3K,^/_WCH2,S\BQ&0%I]9J85^/K!EZBMULSI%$#J%8MR.50@Z-
MUFJC(]P;G.,A:06E[KW'%KIERBP2KH)=-)@4(_0\AC7DNR=7O[/H0!EBF+()
MLHPE\"0,UVO'O.'8(=N6GX+E,9/6&/=SID,>O2:A)I@#U*X<@F"P\+'5>WN"
M.7-CE[!0EZU4Q,"- @2<159S1[<Q;K>R9<&UC7N"5+(IW61W*NFA)_3V1'+F
MENM=U+"0YT$GXD:UK7IHB;JU0QAAB3)COPD<%1T^I[6P8E!MM;-%*K4I>X+T
MM'N 824]94EFT!@/J^#[G+DI&\5M%_HK!GQJ<_:XJ=4K8W#W'!]YK#%LC"M3
MA5"3R,$SIW<AD5%C/,IQ=>H@[&%$J!=BF4HF]EH;M962JXBE;S%*KAV3G,+8
M*(F_*VKAMEO8C;E;F4*%FL+>TLP],*VUJ>2_I9V7<5S!%)?OVXQ9>$N+>;LQ
MZV?#D05F^V Y[[WG/EDF,S^]_O*Q&5C$?-<1\@KSG@:\UU6[_7V8KQ#R3L H
M?V=46&#0SJ&H$(LB-;7=+2%AYW!4>.KS>;8;0F@Y3\ROTN2=S0A]JYS( BL[
MS\&%]Z%GS'3,TW&GRL)#:R)X);^1_2>T%G6][?&/D^_U5YJU]=.]-@ ''KL7
M:+FW=2< L_V+Q$R>'.XVQD,M.X&G/E$^04+9V'E\>T(IJ,WQQ%GMM"M 1Z>N
MLE=E2;JP3%,H[&3GV1)E\#N+I)0I@@5ZO@)V'H W[J:%9#".8JU*_61-+ <?
M %&$6+8M,-3:Y76F/4YD[>WG06QWU7L+$.9Y@W6 \%0"A+<2>\G03%98#,'J
MSRG9KU#HI::R"@< <ZFLH,LP*LUEJ.-_^\7_IG+(7QW_J^-_A1Q1]L(\P_(9
M.J(^=H-2W 7R<%U2\H;^)^+ACJ/AB\"/F2. -<SWJ'/PSH9$BGB=VY)(NS'>
M?YYK'=A;)T]%3!8E* WL4YZM8#9CMHE33]#* J\,AT1ZEH&_<BF+=%#GXQU9
MQ@I,_6"V#ICXZ?[47_Z)N')M!,57U]NFH=K:&(Y6=Y4^#;(ZQ*E,<;K*TD\'
M5'K.P(=33:JKFJQ.V;Z&.Y^[CA#(EN]C_C3LB'G*E_G"=E\94TC/*O+(7,'P
M;FT8OZUAC#C(BXAI7;2&ZUDI9T,81<WAE82!4U6'V884E32"W_ZTY$!G*J=A
MRWN68U@+W<9*1-3I:,+SX!H3->+N!!:F[QXBJ>VLG57!5XX(*MN-,"6-KSS&
M[X/SFU,-4]=[GR!M;- &A6EC +214\!:&]J'$Z2.&S!9XKVW''UGAE.9<O0'
M$TCQ[Z;? 2=K:GBU(28VU>V*SH(L-HC0(F0Q K+8)TI11Y2+"D\;1Q$&S)L#
M#B=U=N@;BDR<'/<3$/$9\% T9Z+3PO9O*NSV[2V/FFP.':+8CFK6'BATVE4[
M4'@? 8RW7V"=VYJ7VYJ7Z53GMIY*;NM7B;W=LPX[&FG0?J<N?G^W5+AG[FLN
M%68)K=,8=X<E.#EU<NL.,I_F^J# 1^FO<AV M7%/@"5'C/E))-7@]V_I$[TS
M!MQ6#2#WX7]?8LS]B)"&7UP[9OJ#Q)7WL _7S#8V,NP0(?KEA1/)#SU@7Z93
M9A1WQO#$N*<.1_MDL!<B@!-PT]X9)6^K2BI.R7C$W5='O7TBM0>GY/,\ZKC9
M6D&IRH0]6HZ#WHL[55Z97L\!+3D@TUL?D-F+BPLS)1X_:VIO5)7\ZYJ^]D]6
M:U6)P :-\6BD]KI95[B2N4TGZH\4$? ,V^_N(=K7&'$[Z^VM;+<\.!^?%?]4
MFK&2V?2)"YYNE>3.D*S-_JA3TI'$UEA\(_^I9KWWS'J5LBE'9=F4QV"]4W?X
M\HOO'\+%PF9XK*O;V,C+L%T_]*B"VI!U^8KE<,0"9G8KQ-_&"-_B_@1^.X!!
MTPTQ^6X9P;L^_<BK.U_[4J$)ND R0#@!0[-2CM,]MAEYKNKJG#32QKD3G(3N
M@::^L\+!Q"[F**F#SAF-D:B)_O2)?N.$HOV(OLV)?N]0RFF5!1P2Y86M)X#Z
M%5E05L#F._8O*LDPJ=S]YVGZ1&TRE84HL985V$<KNJM5P^FKADW)V_C8N^DO
MG]' Y;M)H,/KS%M''KQ^=;UD_=B*$;-K\W2[Y]CXH^:-T^>-32GJN_-&E@<Z
MC?$@IUCLK"VHRFA,K*[TCU%>N?>Y[ZE)A;Q]G;A46*$QV8OY\B$B,=GVQOR%
M!)8L";R+J2M/#E!>7;;"Z62S'FJ*/WV*7Z$'2Z+X'G;CKDHKSO/T%6]</_ 5
MRZ&YQJ:J3,( =1Y%SE7*%'<=AW%"P Z,BJ$O+ PR4"#=M(+0*W\"<FTAG[YD
MV. ]WG R^I*@HEM!A)_" &3$OQ@%'?/$ F8 ]BMB#]?47E/[9G]P'VH?-,;M
MX8D$T-^^<K<N4Z[2 NMM5&F!]3:JM,!Z&U5:8(%M_#5 UQ7^-:VG\=_@A[QZ
MKGN/EL.S_K2TB68P/$@OV7JAQWQ P\(RUMLS&MHS/V=,T0W#G<,27K%:BL<V
M=0\^=BA#ZM&C[DA>0%WW9\QGLC,$?.X'>D GS+&[MPP \3JMVQST8)$+U[<H
M5<_#%M[6$_OX;)G!3)I7B1NY@?&A%=^B3WS7#H/5M^P!W)_6'/;]G3TK/]RY
M[JP <[NUR4HDJ'Z]ZJ?AD?R)ZT4[SAJ8VD ?F$/6,0;=D:E/)NVIUNG!MO3I
M4-.&_]?&1LOBKIDG-['0']G5Q&/Z'U?Z%/;X0;>?]5<?23%)=T!T8DU=C8-^
M&6H<-N._33RDXNQRUUY29!>#QMLQ1@9CF5R)=@^#_2\ 54<! [RYDI*KM6(*
MF2F!JWR-N/%A,S<N[>'H*U;:347X4-_#.3S'R(8(TF[2G?>H.]9_*2!XXSJ4
M-DU_?-)]R\=YH""2G(!_%/KP5M__S'S#LVAFR[5C7H-\"QV<P'8/-QL6\W_"
M^S[9KO%'[%$-N?=F.2$SKP/Q&:X&'J4O4+9X(6N,DZN1[I?8R!*#P'?B@71Q
M_")XZ#%1LE(AY",I 3H4^!*B&8(Z#.%DQ&E;2S.G<@$J2+GA^NI2L4!5*3A<
M .?R@&L*^NB1*::E/SJN#]ZJKPC5ICS/+&.FL!<+0YO -0O>J40Q;-VS@E>,
M:NIAX%KS>>C@$WS*AD'_W4=0S/4_4#M2M!-7\.CRB=+6G!X$7RT S<AZ?X%'
M6@XZRHH;!O!ZYF\M4MX8]]^L_X26"=#89KVC@TF/+!'TA*4B\*[,]#@\K7@,
M?T$4V*[O,UXNZ+!'LB[B.@$QB0*'!^M+$UL5H'$#6Z 8C B_J21?I@,38X](
M$K<S/5"L .C MB-Y@>1$JX&W!G(18#JY1"E3%P44HZ/B:8AAGJ9R'2B?F<'F
M$^;QD$VGK2I:2^NH2I#:)B]VI!UEJB*!^OZT>UU;+Z^X!H3E4M7,=7"C>QY:
MAO_0;1" 6^5Z]F.Q.L+ZM69V(H "=&'CBG%KN$\@([!#PWE(@UU@I5, >K#_
M)E<TF?C!>/;%%]W#)@'^=?SNS_S5.;OIT12X43,;>)/;:2H/:5):1J@OT^U,
M("-?4B.H-1!(L&H/N 7N\-SP<<8EVP0NE\(8L0^B*FK,YJO4H339J<WS,).$
M; !5U,T^,:11(GX?-N0+.UXNZB_X:M<,C<!O*C0X!WN@IB\@3G,"92*T@0(.
M$&P-[&2=OTR9,-N"-T4<XG-1BVN2AT/ !F[H&32U"[AGPA0_G"*H\7Y@EFD(
MRTV_-Y%:014;\&C,4H3+GYD-S#T'W,_P*QL8'-^%M^-X&4IH7.NO;"63CR[C
M7)P2:8"+0R!,@=M/D])<?P5Q \C"X"U""':'$"0HN #:Q<+U.":$G*)>&#&]
M(7$L0L\/^;L>/?<9=)L?P/?L\;6I_(*; & A:,T ?"-%]U/O-XAA9XATXC$+
M, F2<I6\=7']%I#P$_-4E*!X5&AP52P34)<80K(!OA4)E]0M7$)#A)8I'^[T
M%!<N]>06P+*$7QR?<RC0]K4=S*(')CERPL"X@(T":?K3T$93P--![2=HU^(<
ML0#:(S1X2&;@*P-4_-"CU:=4 Q%W\H$N97OA(PFB2:1%S(MLQ[RYCX(0I =I
M#*%$Q'()A/ :W;:YCN+7 V!P+_&3D#AT$T#M,Y G.C6ZH>>(.5D$+?R;(OLY
M$H%@C!?#(YK*;>IKW'GHR-7QC4G22],HF-VVB;  WD6)!Y>;X/7#-D!OA\BA
MG@)R8XXB#@ &IA)^ IN3J ;!].CI<R =(:(4)&I@=PL9!=Y!MAEQ!]X9&X+"
M0E?8%%Z-HI";?WQ!,QUH5@<@ ?10* A(X<4(IXSTDVRH)HP'$&:A+5H3Q.(%
M.(WCE3Y//T4D\R$0)-]8=,H>,,<$X$3,[D[^C6?K3QF[\:]++D4A)QS;(5?0
M'=2*NH,/L:S9QJ_KM;-^7:^=]>L>PCG XA4)+_$&)7Z%(M^QD]?'7YFS$*W*
MOB!YV B2I(]-I/V+CS'^ AH>V6BK>,,;.@Q_\7-M  IS+CRVT#W>\A8CH9Y)
MXIP\/3U&_X)WBD?["7Q1$ ,V2E82U/Q>Y/9?8)G"7Q2'(<!=$XWHRL5OU]?W
MEUQF\Q=&1EVP'('-7:F'MA]@(6ES@20!MQ3DEL0"H08UTGPA52@JBUC\PYM!
M'*+1,,=]<<V!R<C\5EMD' .5<T&^5')-Y/N(K\Z_"6T$L2,3);KX/6]#:B0A
M\]8DC5:\1A3G^HH9>M+$X_<06JC?&RAW(PBYC4EBF0MZ*>$!4Z8%4/"X20)F
M@)^ 6B4MP:006HW?N6XR27N;:<BB+GB,YW,AZ6-.%ZK?@.MF"75PJ%UX>^R^
MR 4@G1N>K"B;N)['K6ZTM\@^)\PS-$H27LN221^I4%YO1!;(E3N]"N&/BQ]W
MORZ3Q,61;;B@H*7^%*8!#6FP04N:R>O1 0?7D5%@(-!?Y'<7W!7BOB6XMD(Z
MZ^@W(+M?IEU^QB]!-QX]F97P)VD(/Q]=W-"$Q&5(AN,,G!_7HR@0$K '3H[!
MZ9D;J5,P2UU//-'\=TA1J31=9M[V/ ,[%6_D7QF6!SXKX-=!G\JT#,1TF9Q0
M2"_?N X&P;E<^V'Y?]P "L!/A]]B9:PMJ]WJZK[4?I#H^'X4W!"!_X[P&/WY
M"R[WT!1.M4FOD$2)CPDL!URDD,L$TA +L,1@W40>?DCF9\J.!]E@\-U[N%V@
M!"#T0*I$NDUTY%C1O$OH451C!H-OP'=H*@_A!(E7O!>M_J6@P\K(%\HNFOJM
MH[6>5#"X-2L("6>TM;P0!;=I9@ ;N:W_ ,> ;,$U@9=@,CIQ1/$*K@H\!/U?
MT%CL!:=@*E-F"O4/;PM1T) ,]=,B!!U+E*\Q]YODI(GP()J&@=@C>BY+6\RQ
M_),F9S4H*JFC%OJK%&<&"#-PY3R.)RYBN/L%:IL;DLK<I:]@I>W6G[-*(G!Y
MP(CK(_0)LP0$XM8F2PT0Q'1ZNK_@CE/TE3]CJ!!(+A9T,XP9N*A@[=U-4Y+@
M;HH<_^D5?WXE&9[C<W1R3/U.UN?XBNXOKMQ?!F0*CFIL#N%I!Y 3+@?/.1!N
M*4BMX+75-^9>[-$-/*B&M>'K_)U\GS1]]"_/G]_)T?]@]='_&QSBKW9(M5R'
MM--8?4]GS=$E%SX\:!5AD5H. >1M?>&S#_*7CS*#QG((?G331_$L@7K<ZG(1
M!&*8?QU#H=GBD!!I1.+-XNLF?/77[.>#=G/0&N1^U6JV"W[>Z^2_9-4=JQ;5
MAD7U>U5<U'#MHS8D<6W9G6'M9:/&$D4)&EG?,SN;GO'V'3E^<#F=2M#>$H"5
M3?'/SSG?&\>;FZ)7$<'_8KJG?*%XKCS@53IMM4;XNLXL!?HB5A'G>&Z_3;';
M-ML\?U!I17CA1.LG?P>GT@ SNI)C<I9)Y23[Q3LABM;EY ^MD\S^T#:&J.XC
MCZ@=97N@62SMW6YCW.E6OOOK$?'QYYJBCTS1W7(I&H?79.>LU12]JSHZB48V
M4ATIU^:33L11S\(IGU-[Y7)JOS%N5Z++1>752TV7:^FR7RY=8N5Y-IWW/='E
M>RM;K".[=62WCNQNB&Q<RX.T']%!6AWT.]<H;QW:W3=>>0I8WC>NNW=0]T2
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M$!X&-Y6OLHVJN+E0(D:R;CQV,*2=OAKCDJ57XSP)'Q$+(S+P$Y6\BSP,^LP
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M _0\K8&I#?2!.60=8] =F?IDTIYJG1YXN_ITJ&G#_VMW.HWC.SOK._ZYH/<
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MRUGK'NTB'UPM,=8R[QQVQI:Z;3+QI?/E)89+#-^O/.S$\)JJ ^U(9&BF( 3
M58>-<*PZ8$&WZUCG\OZ&[K]0NZEK>44_KQ-;1% ,Y?W-.C/%0SM> "B"!U/>
MWRR/$]CV/<US_E:LWTW/N7<^X2 U_O9K_+4\YJFBL=I> 6Y8G?'(/-DG+LU:
MB>17\HF7D;RF93M"R[9OB.+:N?V0^BE.\;<24-_C%!_T.^/[Z31,L'#"=_@
MY;2[1)4.(8/O,O)XM'O\ $5BH';&QNAD)BJ#ZQ+%K^(?/P3%-2R+%07%;]9)
M^F7=)TD$SX&\7^9Z2M6TFCZ5H&'OE93'-RV/C_->'=]&;(#]#;OF4!29+<E
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MH[1\O]9J]Z#MZ:NU8+7#0?5J<6XS9J;1@9(**:3.,.S6U2[.P]7IQC"-H*N
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M=Q3:5J+B835FLUR3"#^[<"@15LC?/X6$%%-\!**\GP5$CH!1X+KS9[NBAY/
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MP1[13=GKZ>LYMA%4\"/&2S9 \9[-97L(7@@;DL=?UE4^?W[ )Z9OH6]8YF;
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M5-% D5AW[OBEJ/WPOA_]]2WV) J\)-Y^2ZFX_'"=X\"FDWNU#PW7].E.ZV^
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M'!=P- Y .;(=H%GB=#-QM;Z:"IMYX#D$KULN0T!FASWRXX]OWYC0PM\ YZ>
MD0H!@4D9BQ(P6>G8J^QRR@WXVY3):N_*<H\'TEBX<:0L;32AW"5JGTAJR_1
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M*!D.-+:' _]]$C@K^&\>+[SQ_P=02P,$%     @ 5TMR6#MCD7ZI$0  9+T
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M/!?T"?O1"Z(NH?2'S*0,PP(P4^I6#'6KV/@R3L%#.4'#.N5RTM?>,%,O,TD
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MOTUQF'&^U"Q>.QBE&Q\:U(5N=*F908@XF/VT=SZ!+R&<]2Y?23CQ+7TYZ87
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MD1:43XJ0Z4C#I^V^D"7*6.N \&HT^_?;FBOO=I&2-I)OG0;\+L31N'[@^^6
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M44M+(/T1!"W8@7R_TKJ*_$HP!PO)M]+V[12&)E+OP%9>"NPB"K .M(Y"Z_?
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MR!/$G/9LJ3&59J-O:!N%9DRD_.9RG6VTXI-"B\?9@??/3;L<BY21#CR=K#T
MNFYY F+N(JP1ETCKF%B!;TA20$(#VF-$"&(4R1["3^2*4IDQ,R9L3(UU=D?C
M+YY!>P1N*<P]M@AC?=^R_NXT_U&F^F,09)5TI$ A2Y=&NKM7YH?-0DTM,5Q@
M1LC=I2C+#/>^P51H.9;(I[<AR(#<!G![]!.^*+K5$ /"?1O9"NSJT16!N2A#
M!F0I/@1D5Z<P2"QFUP+)#<S?*&9 MAL2R1$4$HT!^5Q%B&5 V#@M&9#4L07
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MND\XAQ!''.^6Y<_!0(Q3]>A%!2?KLZD%D:K[[_2%NM-U[31,XU_5R?&P55A
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M>F,M7+XAR4W;Q"^[RUL]]N8)KUX(F'SF_%A>&[:6@EPD80P4S!QJT9EHQ\7
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M?DF)35J_.ED2ETA6I1R> /W @'S^=R2:O1-#=P7FP'!>XY]%.0-&R^M-X@N
M0& Z1;&-?N8R^7EG^IW:/I$I^Y=GD]V>"EN<.-MD9+"4:FW]Z!6=()](4SS"
M9;BM,15O&-1=[6$@[946_X(!R;AVEZOL;A#B[.SE@/TU#.K>YQBY1:X2MO.?
M7VIS@JHEA"#F%#G P53\C 6[M,4H_KDXJ*#;52#B:4LG'V9R*JQW JZ]<N93
M?U;-;\V%/BCLH:CX=VH9&%S8&)!>*SH?T%P.K,;06\# &?Z1 ?$PENN0N$"
M;]C.&WM?%+WI3%2,4YC?EK*ZF!?7_I#W<GW:A326AB3<X^N.C;7>F&?3VRCJ
M*;,<LART+7&O9I!V"3NQ)JPM4@ -]^A%>-Y%7+15;)F@P@>>V]WV\#:6AE:=
M[U[QQ<X\W_CWJ3P'6%0GE!*-"@?F<G(.SS4D8@BFDK@ELB@.>\(-08BDA5/,
MZ#S--]>XU#<!MVTJJFK:N!'Z.,5_LZYWX8H&S124.Q,)IEMMK;18+1AQT("
MF:J!1B$5$S>GTJ>;,%_=U%=)01A_._E&O*"Q W^6=U*-5COB</N@$0O54B;
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MAUF;MV.9V7RL,8A=Y^D%5;H>!"_ZV9>'A? 4JB3HB\#]P]H\E,C'<FC MW-
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M+L^8'!WN$:1I^V.[DGZ>Q/[+F=O[G>]3;,8L/1WV\<Y*/C^9!)M;+^BFOG\
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M)P$UUX8!T^OF8V?9V16B3Q#0L07E"1!?M"CRR2S=OZV.+B/LG5ONV^9:8#.
MDZDI'O%,]EFZ5Z4TU?$><4^4JQ"4J3,#(11U<<]B$:T0?V6/05S\3/4H+$HK
M+D#9(^JZ!MS% XYXTI?%E<NM++RU)_7O*WZK<QGH0P9X)KDFUSM'0<F0I\ V
MUT2VTA7SXSYO]9LW.1*'=IA%5[)B'4O$@3X%&G\,>G@,$H45*5/*.I?-%:V
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M"MOV!&>A&KOC^45W3LK=BI)7)*M?57UGS;G=KBF0NJM0<XQG-^W+/;$"^A
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M-V_>#/$-/5CD7*)K=>\:#WU,G),-^TL Z/_F63GY&ZRS&3@.A=BB?2/P7 1
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M,3"_%?DGQ)6#LM'!B<!'&.)AY'&O?W].H[V;0D,R<L!01.RC*LORPY\T[8]
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MUYNMDB$ (B_(LDNJR1>A^3%#+*X"-.RB<5ZA%1KY'"R[WD9G'JN]6^E><=A
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M8HB1\K4;@X66&M8,52@(^W.=&ZJ5MW5^TH^EI#R[OORSK'TU\3SC=>;*;8H
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MS;LWT4JZC6..('%"T]IRVE/=-JMF'"Y>O30KQA%/2UZAT[.MFD].)]W@-HZ
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M*F+\^:"4(^B6HD7.>QKC"%-&U$1$B;BM^0+39MVW/K+D^5B&(\GW'%Y/+<\
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M6W(_K!PN@]2L2FT;&=7L-#?N3+K^Y8JBS($UUO3R*W<93+NN$>/)YRZ1J[M
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MZ'#%ND3.RTX?9E]X;1N:J-VD)Z!5R-8E*"O9:L^">"/)OL"5:80EXY(:.<T
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M(;-/R1'('3?[7R+ZS[MK_EEFB3Z^N@L9"^%29WY/]J+R(_"\2%+UXZ;!_=2
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M[B-%CWE7@Q.R:@W#$1SRT&@1QGZX+6X,$R1XJYJ/=WFIK%F=QV&Y>99C4;*
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MF=[NZ=* UD*!L\]RNQU<73U\=S/SI$RQSTYMG''3@&=4%-D>L^"JK#E1>FF
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M;Y]C.24Q.%WIFZ+WKE9[RC'\!O#X8C7(OR+S0C7C)X?]A%(H26D0?)@^'SI
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MV?>J$_F5PC LDL>;?SQ47K(;_@4% 72<??[=S"S1 !;)?^@B8^D'4L&CC]
M!ULOW&AX@\[]+MRR0"XII<ZV<NX53E;B.L-.+ ;5U7.K2T(Q[ET]:,R+%-BP
MC]R$<%K9+E;YN14MZAC9*NE6!MJJ&1XZL.-+5(^[*5RK/J,!E/SX_X9&OE8)
M^@DTD5ER;3>C@Z<-T<J(YZ(!"K\J""*$D$.I4>;/( 0N?1HPJUI^;/&76\49
MB.S[W&A.Q/395!KPT?OG)T&[YX+%:$"S@2P-2)AGK,FJ09 OPS5_Y_R?Y450
MHZ#_D/?S'>"@ORFJ_\^*IOY#T1"U*,F(OZ\URA_7&OGO:^W-,?S_O_0CHAF"
MNR2GD9@(.W(F_+*,M^"K4@4VN3:LXWDI'Y;V,)D2I=63J1P7YL$TX$<;V8O$
M061*)X;J$A^^Q6> C&QEVY4"!K#@#%&7U.=?RQ^S#J)R/40(W.<?Q]^07"@E
M7V[XI37W-PH\AOT.$+TIMG2E2Y_;3.E\Q4"7H7@:<!"F,]UN=YSX-=T!CXPH
M<[F%?(@>P 2ZOG?7N\1Q(N%X=R?X ==([1*"+.XSEXQ#'XA4H%>B2]23!,SB
MK8'29R@YGSM!AX:'4H]>US]=KAM&/O_(?P5J]C<?V?WJ(S #D<[D:;_B.56J
MJIX"*>V#DT8Z>L.H;#0@##$MS-<V99?.\JVE;%"GG-<W_=.9AAI-X>BDP;-U
M&%QJ\]^6!)TD'OXR9WU3O\Q-*2=HS_L7H:C3/WRT'F'IAO_.\ZXP/N@M,PB7
MNO:)3:9!_1\+U(CKQU:C<&C<WY[_^]PB_V/.S'^#J?=_"5,J:YC0Z<:NE2,$
M2+L=0_703/^[88,RZ[%3EXJ"S;Z8KK]YXO7=_OV2G1>1F72E@5B)['II3Q3C
MC<!;#!Z4&HG!WMD3.\<_N4'9J[IG?V*[]/ZOL2I^=_/O[ B_C)C[%9Y%$]9^
M-4-%,,=XB'V0>6>P(CGZ$CEK9+PU&-SG)M]HU5-T/=78T)7K3$,9F%!_Q>%N
MT3'?&='B*].(;S.F?51!\EJ;T@#Y_.>-=A&A]#:"2Z80 5>.Y-3^[) 14P05
MRY>HUW:=^ME#P._F+>EG;R#H3"7['\[03[6E :=KT?\/:>\=#^?3MHVO"))H
MD>@]>A>]$]$C2!"KBUX6J_?>NR!("*)'6*)WJ]<@.JNO%GT78;'6Z_NT^[WO
M[_-\GO?W^?T[.SO77#/G>9S',3/7.1"M7*A]<CB&/WD]^>!BW>R!AC!L(*KM
M79'R51NU;W/<S/NZ++EZ=?+@F:C%+RD7U5EI2C=QGKM_XHF?HM+Z]5HRXS>1
MRWD)GD;Q)M)]3CQ>O]0(O*J?N>E@82[9=\WD_V91NW+_.7FW@/^8/;>A=K--
MVA65D/W5ZJ=#R,)>4_ZIO*ZKC#0XKR:=]M%J[PK==>!R41RI*N_6*2E@T4T,
MNVX6VFNV8-F'84&E(*4,$3N)AVB9(M0M0"%< YKHN%QYN-,8I;KN4V0 >."-
M[J%B9B29;<_[5[16_QN/R%<:T+T%,+IU[(Q#<8,MLN^*1Y'W-(#O)ABUR%$.
M<L1#3NO+DNIV7[EJ"C6NAR@'?S*XLH1I^EN4(I(/O.'\[.LFT(0 8*E#Q@K>
MQ!\MXH@I1U-L=VMW>[*Z%ZD[1&&B+!MXW@"+]M-_M<T[/'N ]T]=*1V^QIAM
M\H&9NX+(,0,K7(CQ& P] [D/?-P$L=/3"BH'$QD:V-O O$\+3\*7)5+"/R:'
MD!+YBA0C5L_EVA!\:0CJ8:TG\EY!U./?QH5X"_D7.R93O^&?YF0'C%V.<</D
MU@'_[$30?P4^"893@5-?NKNH=1=C_Q4\_X[$LQ%/T0:(UWE/@LA1T.ZW)KP1
M6>?)WL60J1+DPRR*! GCA-!6\7$'Q"H^IN\'2JLWEV#:X\9F91(VUZ72E<O1
MV%AW<@MHL'Q\/\FSQYR%.*TYG-8UZ[SJ;P#-?N?&C#L8OG]X^^B [A3GJ^&!
MF*!1:/7R:F?P8_L38[6U9<V>5PU9L^,Z=8B=A?K8=U&D(Z[;9(.F1#,TK5EP
M(\S##??2WT$/_65 /5=CS>NKA^*L\;U9W*;V%RXFRT,NS3&O*JJH@AXX^U:5
M_8_AY!^&O><K?2<#,$KNM6,>P0NY)F+]J[AM+S)A&A%!]ZJG#VVFSG*$#AKF
MB+VI.9]_=6-ZQS5@SYNS#(J8@UI0I&VHQ+29E<J%_^%E[S7\8EB\#(UMDSJ_
M;E4CY?A@-++-@=6PZ8QG7_4U^'^-:KO7<G(C&$KC R3N3>*Q4?>%H0J:Y8=-
M<&PI'._SN7)GPAC+M:C8S8$KM+3>/H#SYC/:"#$3H+!.@<Q)/.[.4792MJM+
M*2&;)C4YXJ4Q]HWT*O-BC!PZCONS^K]'2GLUQ]ZMP(F[X%L+//#U1E#T&GHT
M$O\U#VJ-&;#_G(?T)AV1@2S@,Q\I7><C4#$JYYI]-X\\2!@DRS]7":D\,]'J
M>N(C?S;$&S[TM'[HDW%A6B07#3;@L>^H'Q#-?0OXFPO_L]\4#Q5GH^-VO%MD
M04BS ZT-.5(?L?6&Q&^H.;6Y341_HFN!\0!DMV;<GDL"GVS:]:'*\4;LR[#-
M,%]X X86T^>->93LV,'1V&R)6,0\%MJ""8:R9S/?%%ECCH\%:JM&9MMW_J>X
M\@^PS4[(33)+X=*;83ZM@@\<W&QH8:/.N[L7>\16^&6I$4F)17;7;3*NP:4@
M(/GU2'F=8,'B5R_CV)&DF_)=AEBSZNUR)#^<5HY$6^Y!26.%W6R#X5@\'/)X
M+V/V5!D:M)RARYCXLX@VC)3Z"N\_8?U_A+3B$?:[@"VULM&2W'.),4G*?C$Y
M)?_K[$92.$K\X'"C4;<Q1NGQH_P7BO<C3<6IQ,E*C<7^]C[)_S'W_R I#O)+
M$_]5,?-O%?]A) !O82#AWSI5]&_P(1.\;NWS#]KV_X'V@O]ZSCC:N.I_]L??
MV,W_4>]O[.J?J *0ZNY-^/^F:C+_-5B\5G'_BZ*$_/._Y?ZUOUC_WMJ_(939
M_U7MWK]46W[[_S3._SE\_V+C?T??7WC@R:;D! ;\LUM P@I@&DU7;K8Z;R^9
M.WBTJ)%NF:H?'F473R:NMUA?'2;/+/SW8?WOFGP()U[ 7M\NA8,)]J_H\^[Z
MH5F^CCJ"U[<@>M\L#';#ESK[%BR'N$JYW+NVO]D'U]!G%PS \<OEZ%'#Q*2@
M.?+3/5EVH_F@19</RL@!;&+V$8%(K\&%5!>U-6#QWV?LOXDI#EE)<]<C.V!@
MU>")SYU0O>N"74,0<7(W[!80*TT7O)YME,T=J*/6FGQ(06*LOOV335!Y3UTM
M8Q ;I^DP*1X>?=!<C#:9.KOA[J7G12JN,(1-KHR=JJAO7LN6_.CXD[KVD7];
MX'HLH6C.Z6]&6HAY3/S/ZHXMH_5ZOKF^/7,IB15J#2$_A>O2"T^CU>$R-M=:
MU[;G,NE;2T[@(IJ/G,]"'O2XE#ZB^\3QFW.%Z.9CV[,U_^0H;?L+ZGC^GGWN
M10TVB>*7%<X?>29'(JC<Q"PI&03@K5K_'<3^L[T%Y%IN!Q(S5=]$M7%^W<4\
MT2)"E?;)4L\$2! NUTF.Y7D3PRHMFK^,"XYVL.ED2MSG8&HGVEBC3_;?,*'H
M THV5+E7V,LR9/?,UFJX5"JZI:^Z]):\WK'8.DUVN!O1".S_;:&EZ&LF\"+^
M\RU C=X)=$WKHZ56C](B2JO8OU) BPDE\OE+%:GDL WDI@5$/$]S)OI52C O
M/0>]$:]D_W]811%X.Z_M;'0GDWL#)-IG#$_[6DQ+OR^!- KW1FQQMJ9=BD9I
M# S'HTF8V!1>KYFK4([YS8%U&?]SD["21N,6D+H(E[NFJ(/><$(KMYN<Q##J
MX)A;P('IW0/.2C A4A9>E5JO4,?KWH?W8 .'M.!-)*2A=!U*N>)@R)>]?M:1
M>!>[5@;NK9@_MA@Z#\792'TQ]ONF?-_)M',/]FXY&<96)_:\3<ZN\3UKLEM*
M\\/[N%2#:W-?1J_%44*8QZN$/FZS/=>"#$2CEK)Y@78IQ9,RY9POK>;=6YWG
M!B_#Q2!:0DEQ8L<WGD3O^%IIQ7K,8.I]':+@>TM[IG>J,%&L?Q;(7Z1&_WWR
M9^;C;NM[GB<A^DO<'X;U$PN9V;'QNV\!Y&VVY4$_C^%YM$;=<X151C %T>BR
MH?N3G+,XT+&1)P?X)PD$Q^]Z+-G:HWN@]X2)\><#9.KJFCM\T$0U)5^L/=GD
M68BQ?9M,@X".EK2SGID'NX6&/NRZB+1]O[Z!Z*,_=G_L>%E]H+],^'%V,O$?
M]#@*_EG1WPA1DO7U(E*]0 ^BG:Z54/ZJB,HRW_78-:1F(^B;P2[);O7P!'&#
MB3%O&R=SNA30W^H#T;VLDVS^>%,Q!'N"K- ^/>,O\VS=*8M?S]1I:'8K'2W4
M#*W\(=V\N]3EX#22C%[;*MR.:%0RXN(U*F>=)H]XS\UX48'EQY*2NP7&^/RT
MATN=H+KA 5%27 ]CDL1]X+-\S'B*'3%<?=^,QN<K*MKL^EG[[&93Z)$0N(UM
M^OFEN:J7=K;HQ@\)UM/ZXO!T=3T7>J99$8;XO,>R=\S0)]=)[/6L1X[S^;;6
M_?W4>%!FY,$LN4&Z;M,]97'FL)]$KL9X26UOD6P:[&]0@04^LW^D%?+1+^HG
MSHY)U.K4/.]GV;='X4.^\GRRU4T+;0:F9)T7WZ2?^5-*"WN R5!I\M-UHM,F
M(MQ43NCK3&BZ38M@[#.KRQS2Q+BO'@"@?!%F/(AJHJ[]R>2*T46FQESP.G/J
ME7^RZ/85JK!03>H':PT#K266+@%67)*OR9U/SNW1IIQ@H KC0>1H?UE)5&)P
M^<J*1K$]>1!^U*G.I&UPIF9'W-&V5+WKPH?>82V7KV>5H',-U(PO'!R3E913
MCNIF(&&@W#5#9.PV< :DY3 +U0Q9UNM_7"!HL,5#M4WMF^:5!PUW$,V@E9!X
M!@:>W)QH=TNZJ&K"G$[5%1$Y"27N$^'PK6#3MB<:GEG1756$)CYIW5>']:F[
MDLG1E2RYLR:B'.LK-2^1TMKF059<EP.TWW-G3">-W*[N</V(-A;D/M;!%F#8
MCK)&^O<;1AQZ!N?_#L(R 5VS27@5_FS4"5M"/'SWQ@P/*[ \"4EQ*+*AH=.3
MR_VCIAYQGAV(6UAHEY'[;,)3=-JI(/-MKCAZ-8O5N+>J*4Q+2O Y:#)(-H P
M&XX;O4&GHN"&X9B5EFTA<!F72\>*M!5,K2!-_W#\GG)+OE\W88X?,;=F6E_V
M&\.+&$@X<(9T,#AD?% "%S@ 9R_$7)>Y:]5<THP*8@:N"MIJ<356>>DG8?HR
M62O;C2'!U=*$R%3BAWE/T"_:YO@<CUA(4'$&ME-_2!@^6F6(><Y3!<S? F;(
M&$0%3"^S3H+Q K"3>V2%IP(TOON,].;R3@N7JQUXK$,TL'GK="A_YNW!E;W
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MVT]--1'+?@9\#S-:GVSE64]SEN-BV,H":^7ZYBC=)-,K%LJA=?$N4G>9GO0
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M S;_'G7U322G':H8/H(CN'=(,;L!M@R)^&^D%^_(([5S/?%3UIR;C!RG$JW
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M-\8'22VH($;>SGJ.4]0G0J.EU>B*P 2"O(DM>$+DRX_ZN(Y70U,C[JGVR?I
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MG+$&7,"K+EEN 75S-Q[3MX"S(:<7#"__-0_=OY+RMJF-3+0OBA_3/WK'L56
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M!++L#T9DHL!]L+Q0Z:=P*$I16FQ=#LO00>]#3VF7VZ&@FCLUMW!<L)?>@QZ
MH!<"^&4VI#EW8%K.ZVM]6QAFF:TA2RK&V-HZMH>3OM?53!)-B@K?<%(?,*6H
M1_+'6,Y"I(W6\E!JF.&,MYU9 ?NL30**P&T.O0T&"<N/8\JN)L #;Z[&@]4U
M3R*JCL%+JIT;T&3@A_KF0^&W2DQQF7.S,.O6I>4E%2<PY8B&4(02U9%:GX)?
M W68:(X?[X[ZX )AQ:*^%OWS#?OKD:B=,(DJIIL:X44GT+D_$C?'FWK$UMN[
M5%[:MI#9;#$*;X_09S44K59VQZW'0S'TH&31_"H?FE>S&PU96ED:*AIVAUG#
M 1<6WR8$=G9B;^SY3#Y!>"?.K5R+!+B8(I4HW[T- ?P&E!$[H/S54)?(5+F(
M722CT;*Q?59T-%^]!+3^J:81MU3:8W]SNQ^#MBXT%]9L]W,?<KAQ3V 8T I(
MY9P[T,OE0<K%_X&B7IZURUA-B?#:*C8V-,?V\DP-,ZI.%#VZ?AE%Z?QE@^W2
M$MW=VC$PY?M=_;NA:-'YO>VG =4\HXZTOO%4+'C<7PY9];$3K*A1WG#V9&EW
M"%H*-;7>>@MXC(K7,J%1FJR/EVHW7.GF?<';VXC/)+9P$B:TR<SWPO74-@%8
MCLJX[K\")DK;%MA1M_F5Q@D? V .HI+%8WG@\_CR?&^?EZIO ?-=9**AH4T?
M!-4*EX^H:W>SN.&CWN=%2'!R_2CU<>>4"7^$Y^*AG&*8B2R-7K-1QH\LS&;O
M'([EJ6A]W3/C#X]&NM[C!)(AA-X@(1<1?&D#Y%,*949[3WN<6%<7,!,RWQA[
M3_&]['H_.97: P['<.WL^5K"G,YDV.(XRCC^*YM3!?@I*FZN6Y8!.G/,W)PQ
M.\8L' O"5^?$OO[>EH;1<*4PY6E'4O1<KSX=_ZZVKL&U3'_.61<?[[]0%/HF
ME;9.B](B.!3?O7]C\I.#7R19OX^M7@<"VG-#O]\O-JG^_1.S6!H/S?RK'E:O
MWI  J/>S%U+NH?IR--(:<"?<U6["]9=5OIX59%F3BMI@IXW:EB9_3]X+*G3Z
MHZ7W&])6VMC3=E5X\><Q\8>&:09,^V]7'.0]BIP015Z%FG5-;@<IK3L_\RBY
MOW00 <H-,P\IS6?J6J5DGI#PSG3DN?*6E'T+S#@2;AT:[MFJ9F*E^I":KQQ(
M:,;L_]1]\5L501OJ3_F>H<;O"6&(H(G>U)L)N./>$YF*AHM,"[H1]E2BXPSY
M[@_BC(VO?ENAFBFB_HR:TCF(1743OE17<UZQMH-L:HC2C'Z_QSFO,[K5O 0]
M!%!PTXUK%[0%=\G1LR"C8RL\H"CE(\>^7HB]D&\RLY$Q"YL:=BBE/'5-F__%
M9L-JYGV@>9D#\"U:#_$G3(MI0:MP3T@= $Y?9JMYT.L7<G*'4,7F.9%DVWFD
MT(;#X[JW^:BLZ]?0Z:K\ZJAN#MZBT! VM4U+EM>W ![.9^LAK+HN&NQ]592F
MAF@Y9.1X5#WXX,92OCKKQ(!^$+H4N\25B27!U2PGBGLD%$:(K3/%4<6+C"JK
MW)?EF?$(Y#;)["DK^NWJ8&'W-4ZK3H/[YS>&G\HWL,"<&HK[ESG*W,6_VCQ!
MONM:!'M9(2")/]EVK*KD[&G$3-Q.4KH;-*V_J'.<R+:HQV-$6O,2)^U<5O?U
MKI0J/YO?R8>&V7$L7]M6 ^F+%()0U5# O KR':>LC$F7K?>WT?7V%@4[R22H
MN4MC5RZ<6SG&R6->NL&5ZT>7(U$;4JGJ1[)50=NI,2IRJZ^\R&7<&>;<6K+[
M^E>+C5F=3/[XSR*<6X!:UP8+9]?],($B%(*]=?)LD9"P\D]V?RK,2*7E0<.<
MNI0B<\IY7GI;? D1UF!XB/>C@ H^ORVRK1:&OE&=7EF65L2?TJBT:UNUP)9>
M;0<LBP9ME0R+8)[+XNDC0&3_<U61<;0A:ETN^K!-O7"A@L2$4/:&Y_C@F*!6
MWIWL2R/V3RT>+M>GECOL4FX2:UOXN5M*KM G?]0A0CVB.C MUK:J\MTW=2E?
MGJ2:=29!E?7>!V9!?$Y[YTP))_K+R8HA,^FM-@?&II!RGJ!O8Z+DXS;6>+.E
M\CE*9%N-*Z+3GAJVZQV08E,-^_5#K]VU3,V6ZI,=%\?*'9P1]%#XH_<<=)>,
M<<,(_GAI>5_7-3J'"_U4S%3_XQ&6+".%)\5)YF(DOM:Z<H/E6PW;CAGC=%R0
M;5XMVX):'L]].O4W[=5A>O[9@N36 I*1["64(<1K&C[**4APKYYD.J;D@KJD
MU1*WZKN^R;Q&":2]@IONH&$6A#.0T;K\V4(AP_6.?"RJVD[H E/W&:A%B(E&
M9#+*UZ_]931AV\M\QGLX%5\;LR0,^.B#N;GPY5F"!0$T5.(2)7NW )+Z:S/J
M17L_F>+V,T&?O&NV_<,+4WW56T"-TMI)@Z*FT/AHVI>$]:BY8>[<9B7?)P$.
M)O3#*!,#XV5CYVEH+7HAS7-S]BK<,/"+TXNG? B<07;BL5>ISF@QU"\H2?V&
M/;AP%">AX=3$R R;F5-U4[$WN_"=LM/Z1V[9%XX;I!44,B_C.(J>_U<"\;]M
MMI3_?G5I"Z>[B(.@\:^5^XI^PY2.DL:_!7X_.05FK,!Y?L\NGK]LF.1>=U&V
M,LXE^B7VF+C,/:G.WS;K<N/\)Z)]/+%-:(WWWLB[E@F^>F*RQ1["FR^1] ]Q
MZD>4-^[;.L8EAG<MFMKF8R:\9X.8D+> A'HI\F 2E,HZ0L-6$2CU5+NAI?4)
MQYD*5P4DZ>WT#!]P.L^_0':JN"H=@I$-4$6,1Z#!Y?N2W'L9+<!H!F!=1_.O
MTDD+BCA5T58K+\&RX1]<"G05DBDZ/K8;M@E6O]#@[PX=7)/*X=9L>;:%H)%U
M4%/DZ/1!@>KDTD^KS],U!=]#,\Q3793HCT_Y>_GYMVRG/?I2##[AWJ^Z3[1J
MB.HQ1+4CV?M7*,)FIWI)?OM5)B(9-'^Q=F0K9LT<,Z;S%BOPUKZF EPK4PDJ
M1#)XBRS<S3"I2%5T2V9?H#,-'9<92D7DAA*4^0'6(K.<9F 8^-U-[(NPPT%/
MZKV^\-PZ^R6^J\+=*^ZM*O*@25/V=_SYL&<U<]*6<E%GZH/"N_PYO(=.5J#R
M9$Y:*OUQL"17& "_*2W<M!4AUI?+@0R.<*X,,"H>+740G3LU[..9U;("O]<F
M\*97J!7V#^W2UN*:WR#-R80!\4<N35K/J) C&&DTQ2W TN9.=Q:63^Z/RDH$
M#V2&W0(.'/_ZIL/3SX0IB?F.O*,3\YY #]Y'WP(T# .]_O0&R-T"4FKAP)N$
MQW<:MERK<N4?Z2K7ZU8O>3N8;P'5_NJW@,GLJR/0OVQ,_<:&3 LO!NKUP\=.
M2)OJFA(+,J@HN'[W$!3YD1AD=N#_^D/W:$ZQ99)G>Y+W-2%.?'?':V5RO8CO
M&]CF2LQTHG%S+<U)8RMJ6^]3%(N7DZVQ6>;B KA1L4AN>&)&\H91H%Q/@RSN
M[,.FNJE*@EL S,S"\5*G+N33Q0_8BND28'XU*U<?&B-1U/%T6O@6@.7CK1;_
M,FI*N;8Q_B6!<%\2(\XG*XX5LPNW"OESD3Q;1'R7U_.]7T8^MAIAA'I($?S?
M=V*WJ4GM?CDS479$GMA<%F(\!%JW$XMA0H5WZL&:$?V%Q/'"(XDO%GT"MZ[U
MDK>X?E!PC:V5.R_F96X/X+:#-_A[(0J=Y*8,4V?X#T3D2'VR=378U1M;/Q3A
M/TM2L\K2_MHP"(]3?N8K#K"4*%SH>ZBI06<;+TV1CSI53%-!$J6!*NS=:EIA
M*XIT8IS#/_#R\3ZH,-4*,T1@B!"SGTOMKX!19XOX,J+'A^<?NNY]B]LLY_SD
MO?)NWEEZO3P129'4YHZ KIO%B8Q3J'S=R^K+XK)_6,CS:\#?]1E)%W[_09_Z
MZXDJ(C>:>G<*N3K^F(V;+Y4!ACP>K6!:^ZLV689I'ILG(L7MN],6M1_6GKM]
M2OMI*L\U,BJK7Q\\$2U=6/SYX,0'N\==15 VWF9$M)B^BE& .!?YB/3++:"!
MP$XAN(:KH0P![39<O1.F^,=$NQ>&,C>+9L8+0P\$1EPF?2&<#*N" 8LM.UFG
MX_?0GFW5;:C(T@!Y)T&8%FY]X=+>%=?/\UH5E\B/OK;N17% '+<E0=I3X"W
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MW7ECN__3M+VSJ_@K'_6$IB^[S0KO_UZ$5VA,*A#LZN $)TH]!!F5_K6HV:*
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M8Z2K85NO9FN4>_SL?D(BQ8WUB5RL/1>J-!%V>NW(8+Y_-S 5N^Z]<M3HONX
M\C"4=J3S*2DY,N\P@F$L.^P=/\0^_X*W<FCC=0R+AI0E[O='O405J;,&S?X9
M),.L4(K@*G2:51#RZSHA[LS__'*X975[J77>Y%_M(:5]TC:B+*8MKV!$<A $
MH1Q\$BP-Y[]'OFY\(XB6"FOQ*N@KP":]FCC=I5NCXBS/<TCJK@:\M"Q_<)^0
M_<6AMG[9C<6:(.--^\AFC[NIJ=TMH ;6 Z:\ '\,ZNNKAW>G,. G3[37'#@Y
M;C31S )R0<[\ I%N2L</Y69:_/2FQ84)L%P[%J$(E1]]$8=EV96A%J3&:JX0
M>VOV$% "DY5[[BMWGEYB,/.P+V'<RB(Q_))N3'R85GOBQ*TTOVMZBCV8]#RT
MA]'[L$]"L_,60/)?ZF)?#<Y"/^ZG>/:'(7!OD&?E6'V[^5,TZL?B3%-Y_=%-
MFY(UB&O\IKV\H(?U@9^!G (L$P]=VK0)OR8WP,9?^H_4^'Y<T[Z/KT%9ZG#,
MIB-7C2A.[$C8V"QY=#XZ!Q#W<>X^D3G$<6PH,IKW71<OF>_&5 *C8<GWG)@?
MOL>3#_$Y*T/OPAG.T@OM$2EAM<V[I,JK^X:>,!K7_B?'EN02DT4DV \7<8H\
M&Q58KZY+M6_[+!,JXWLGZ0:6&\2,D%#1>>6U$(#MHYRM/T5O?,69JA;EWQX^
MPD:93I>?JM?%$6LC9P5_"=8>FRN]:-8%"MQW?+/Z*,#1_]#*XO$KENR\G?>[
MYP8W3"FO)@*>+TO.&_*6#W(TY4[O5"4VOR'\81SO9J7WM^*?GV>YY"B2_&OM
M(94F2M;BP9;GS=-$PXQ3=0]L\GJN5;+[4[/Y./=?:<R73R=*Y'+.PC TC>5^
M;#//IG#\BF&6]3.U$O69H%EN6@<(R+$Z?/9[[Y3B<U;?V6FU\!L^:+,&MM$?
MG2__H;>Q%!JL/2GNN\PKI9)=:P.L)%PLL#(Q[7YX/TY! 5N1*P%FZ3.KD4R+
M^45[EJ^^_GQ!E=DK)^Q5<,(/:UWY!\-NXSCAFB9L)WE<N1 #<-Z,OA:D:1#C
MV5'Q/-F0=#)Y[G&?9<%5;Y9X/$]!X['U><0-A_F\5+A@&_L.#9=S!*T"56BG
M@* Y@I&F+7F!293&^SV8;[U2\HO2IIA#($7+QYPY)63JS5,SH^MT5"#N606*
MOZ&L;8(S.LVU4=_-BN*0]%FA?\Z/M\'_KHWD6+,%&[[9G=UC\[W^PWXE:FE&
MNV3;JSCM= $['94N5T/1WNEK,K_726K 9EGU,L?3SG)SD^M$J3B=E+WQ^83G
M[$3\S];#N<\=>#;3)DTK?<!'"HXS$&U*[,"J,AH.[3TXV;*@H=*8:-%9?WDN
M3'3V>KSAA1*C!J.F@.]9P@_Z^\%F]RTHY3X"JM$2A]%.^Y9)*(*94"Z,8\)+
MF+U=LJ 7)0W/,\KF_7"%I0Q"%/^VOS#R/+164$IKHO8:7ZNZ<L)&BD9R^LPN
M8?[-*WP.!T+J<$]Z.D61S30SO3N-&@H9EGH_44>*K]4Z<?KP9L(;Y&K/V.,J
M!#CFT'U@TU7!8?MU6,C^T'D7US=(OGLY__<BB#5B2<#?0!@/%G,0&GTCEP0/
M[D6";\:G!_.N:_Z2KU\$.&==Q8DYHQ-BID HHAYM:C_^*2$<MRWJHN6#*VJ?
MCU^8: ?V$%_.YV?+%0<R6IUB".1ZOX#]QDA=?=="30O=WD7+0F5!/(C,8,.]
MR+72D-2Y_N[^*_QL?\1[>[KR5#BHB?D\LH6@" @GR\C'2I?G58X+@G6>4@[2
M?B\7B6FFSNO 3[S8XST>K9)+N$DY+4@X/@RO(W_L)XB-NE+"EFAC5$M*')I8
M0_8J]L6C*FIJ:2F)07_RXE69BI\L2%:.#B?Z>MX"""&'$09-H7GNGK VWC&N
ML9R6>MBDA)DD,+5"ZN@CR+\XOHD)=P&H($H[EQW%QP:^QW"87(]$%8R6J^";
MY.=Q5DMT=;G_A"<TVR\LV+**G!8O46%!2,5[6A"I,#F)W"W11:M1?\D!67<A
M<L9(GF&F\?E35@$O@ZLX +9*L@!5$6-!D*0W):Q 9[&TW81SRS64K%[X0II*
MH<9+SK+QJ"S^82^R<^TCE H5%J7 H0B_!1#OM$DU_7-T9L/<KX:F=0JBLHRO
M""X1\XZVJJ^7B<6'ZP+ +98V;5D8VSMC$NS.BS\8UK"31<\78SDJDV!*E^(>
M38(E,CR>;ZM7.>._IP-HL:^Z30@RPXJA%FJ3XB#!=NN) \=/B0\DHTG##1U6
M7#N>N&O8I:"8JCP#LX_OE$)[3";[I-\K] BI;S>%5IYY0:0@]V2NT9^H#S2&
MKFKV[O'W@OZ5M ]^\:(DE+&&"J.(8A0$U-#)O<M]AH@/!>%E.$W7P$+[ROG:
M&0K$TNOD&Z",:/Z4H],C-[&%-7^1<C\Q=%:$N"\S]P?T=%*1O2=)F;TMQ)HI
M?OX'G87@(Z3+BQ6/$I_ X%IF(4WNZK%2,$N/C:8>:35W?'6EO;(E:?9?@JK)
MT_P"^5*FJN43!5-T17<%+?2&-32 90H'<4?:'8KO>][168L:36C!)'=E2RR"
M8RC\;ZJJMRE?]/Z>F!Y.MF7FV2T@R <T8\[4 GYE9L9M[BL[KX*8T#A+K^:(
M%L:PE,1B>_P92_P$T0&M>2;;/G$A)[[7DM,V34'C&[V\SR(-/@WMY*F3:(IP
M0/K+AME5*O\YWHG\&EAEM?)0_5D5GVK>SYJ/^GC] MK,6D+V\N"/1SWVU_Z;
M23B).PGT,1M+WG49]DV@UG>.;5QN\9F\/)M4S>\PH:K5#2'XH>_I1MO[.%1H
MS8IV>"87!@X%==/<<6+A%KS2G11;G;$-=<L&8TOH)X(O0X_5*'O)\5+]S=NV
MT<M=<8305\"FJ1/%1UM-JD60+)FCWBX>ZR1N;H%B<NZD7:"7.>N$LP2>OWQ(
MZ<RRK:]V;0O?YR.CH+$#=EF-#QP>+[;?5U ?]#P=V^7V])M"YX]H*9X55P5I
MA].RR-G+$9ZS^,_!1%^;']Q3?_XG)N[\B[PL)?].Y/H=1H-=Y@3Q_<A#DFT9
MIA!C+_MZG0[/*H)0':5.OMQ;0),\?_&^8?GA<4/M7(#!HQZ,05@>-!U^GN8$
M<V9>2G%)=V)+C>S=C7=9B"5W@<J3@O&-$1M?_[N7KF%"PI<1K/>NT:S&Q/QU
M=<^SS1?6EDJL.F_)HT_J*\/.I-'6J9(8+-C/]3Y#J6:=I29518-U/-E]VW6B
M%XSNF7RL4<^W/;,HVM@Z"SA+S>\G =&ZH!*GXOKTX;6@%0W8>F?4WJ>W=_%>
MK,??^H\?&UHQ]"3CU9MQ.;;L[32;/\W. GLGV#^AZ]ZHUQ_P^H9\8D]!FG<?
MOCP57(J%90(GD3MG)X7W#6%*HY-7V]QVMM6U+WV8H%/AW%TF>T.4@F.#3>P'
MVHU&C6V)=-*$G3$_'JC_:(#G7[TYW&&1$IAT9K:(J6X,1,"0"[< RC8^/^$)
MC]WVO7T?Q*C1W5)["[@X:_MF(D<6.+?0\''1*/;TA#7$C_XWEDJ3P3G,PY>9
M7'O)8J_)OTF)975R_SVAEEG#V)ZS!"/PHG0E^6;,[&ECXO-QY8H8)%WT%\]R
MUVA4C*-@YF:GC%3?* 4TKGOI:?._LH,3X"$5M%E[K"XWR.YI8V4F\]/4_42-
M8P;IS.5!LHXU_[%$_F9LB-5J#!#I')S4$\ Y*0YLM@@WD*PT-UF8TW29CG/[
MP]4 7;7#32[& HCL!,A<+70L_"30^06@8L02%*315#^53TN+'K9F%%SX F!Y
M;TC6P7?D!LV_BS(5Z#C<,S R#JLJ'H=5HUNOS:I2.]/U<NJ/<UK8S,QP:"SV
MA/UN_+B[$R=V72;>4-YNTPK4;DZM4^?(T@PR=KJ7Y))_N4!Y]=+<=\4*T>:.
MJ5O?C%2@WEV^YYQF'(@T-]I)\8$/9BW;GR5?G7SI/A7UKA]=YII^<U6_"??Y
M<!#'DN!:8#*<U\O^T)J#[U]A=- 7-KJ+-T5,KK7Z8E"UUXU-4T*<XP*Y6?I?
MP17K( ]!"&4H,5,!/01O%N"F8*6R5L_:/'EA,OH&0U:$:>_:1EZSPM.Z(]#S
M;\6$PQ$JKRUJ-8=\V9W3=PA\9KK88*N;?7A?%"<\RHFN@U$5!G7H@Q1;OY1Z
M!*2L%34OF+:@]J@TB("C5.G+WY?>Q!.(W+HQ1T?A"N>RTI6@H],?Y4[LT0))
M/\R*S;X,6KJ(_=///?0E7Y1S/QNAO /RRY3"*)CZ3M<@+H53P.+IE 8W4[5=
M-98K+-]6KDF]:7N$0Q'+03<,.!6,:KM5/A;T!O.N[G=^V1\[,?%*$_L$LU?4
M"[%(=H+<B-SC!^\E>?I?<+5U3-6"F'W^S>U(NE@@G&/U2+N57R_%,C/>IX@?
M*)5_%*RW.-?I#Q*L&^)U=>:C6PO5)RG/M0PE"B)E6-IU^7?1CI*(^U9Z(^G'
M:/$PT,;((F62 -=DF/+8C'&/REGT20=%1-MP+0RO*O9TDZ(WX#&6MH>5V$D0
MIXAB-, &EIIN!0B,Y:@?+(W039G(]M!?I ]'1U#7_]7_A6]A##6\$[$XHC,X
M<O3A%H*BA='I78;5$Q:W2\DI>I:^R*B[)?&!'"G2J(['P_F!G8^^22)=A>Y(
M%T_( -/ZYT<Y;K\RR:EE2CB2,P/1BFR7[?";A\B;%^BE).^<FV&]!?MD]V%7
M%#'=>B+0PR9!-<XWY).J^H5AQ;G*9VA-AQBVQN#Z3ZDXG0$I2+-I#&)&_>GE
M?:_D^O>C3D](+&DB]%=K&"Z3 TFW#?&UC#UVC6G?QFM^+GN4X(A\1!@7%Q]B
MHQ/MTJU?W\259>7O[^ML?9\VI;0,(N<:XCU0/B7T\K^Q182P&$)+"$;CZK*H
M$3@OK"VF#U66;*$:U:&W)2/+,E]J?H ):TPTRE$X6S-L"1B5"2BQ0C*Z%[>'
MI"Z-S_;<=7ZQ1'E>,G 0/#*G\/.\?%<;K1966T$VBKR2I]*N^W= HY^B%3I%
MLZ02G_34K@/QRLEQS3W3(2OXYHXE(/=@HE"KKDO%L-S&]S62*5;,C?$D*R(J
M]'V.4[+]!<Z[Q]R:=F<WS1G63W0,_N?M.'S6'H8CJ 7\'%&:[)469/+:&@1\
M\+:F/_9O3E$%Y\P-%S3*[)^?"%?J$U\_E=+K$"KX>?RH.PDQ2![.KRG$;OPP
M& 0@^]=W_Q?#.=]&71Q@B^'$K<\[K\MO;GH]+_BYUD8A@H-2]54H/KN+=&??
M&Z%_QI 76K8])B&;7^3$RNR:>G,^Q>\FFT#6:!-4.+N'(#QE7)&&@%A%GX?O
M"NR)F/W%]&?*:HT%*=>%,LKS*-3.?#5L\>+.AQR4R3T[SDL%]9 6H75EM._&
MA3PNJ+0F%ED0B.D#.VIZ4YFJHT6OQP-T-/VC\J"26(D@"97%.E5"E-'J0J8]
M?TC"ZHT 9J,1Z1RC5PM+Q]$ZYVUCEA#?+4Z,RVV;7S<MQLR2DJC#7^"=N]9N
M,G8$LDJ8O1GM2N96:9H1XJ@:5RWP)Q&KH2__$Y&F<H04(5!ZZKFTV^OR8G-.
M&,>=ZS#NX.Q= '>#R*I4MAH;NF0N^@VIPO.)TKFO3T"2,\C T%*GVMTH,ZD]
MM^TS-*+SS#XWPJ\P])GA!\MJ@OT6)IVALTH3V4SO;+^ UAGA.F,J[7'DN..^
M4[Z4KL5@NO>S7RI,[BA*?(UCT6\"ZN9X*TE=BG1RFJO:X=,R<B;@'S^^/;8H
M_\WA/:Z:*%S9)*>LKE.UOB1,DL/M]1Y/JH7_2GYNRTNOS]^7^B:5LV7ZT)ZT
MN</I;2+_14WE]]"$-VNB?)95[,S-S%)WR(H#!WU+Y,7^-H7:-@!#&E*&[9EU
M3)M3%JZ^Z:R)/-W3F]09ZAMDO6-K&ZYMU-@IP8-TY""O^#;'E(2F&1=JS*9A
M8:+3G=[;[-=31I21$]T7:42&E&LV>G25=*;;S*6[C;6Q=MP6EK8S_]ZNG-HS
MMSBR_',(E7O8PGTG'/\:9M3,=H6<?-;<SNN]_7LUA2B[:1F/G]+U7X."HI(F
M'N3\R@K0TLB&<JN@1[(AWOF(NE*8P-Y.C?HG@G1WQ^BJUX-NGE^3M%/;OMKE
MR';2SM":<V'VW-\=]3B7J3WA&U*/(<NRZ='W9$R-FXIQ&5W=5PG@ >7H, RW
M!>>!#-(X6Y*=G03E^O?W%]_^U?@1I>E1$O^<$-XW!)JH924KOR/CD1@;T0SS
M"^<W"7$"4="/".G-ZW>!*Q\,=I&'80<MZDVX- >%8N;/QWY]B'&^?6-ZL<JF
M"KR_ D2O.O(\^=E_HFTCA3VD6UQ9PR&RB_8>PZZ"V8G,\KD0M>JZ%(>^1U2U
M<A7102]WM$VZL66H,HO.R[6F_.!B\QTIFC3(4DFAW7BQ1*UD%4)SW>6Q:+.I
M@-$@I5KZK.M6 !TV\ ]6X5RG:7RE(=)?54EP8M!;[@84\H@N@CG4LS@ZVN6W
M)_4]/Q'T20!7R\STN/7DH9'\('$_KC$\6E6JIWW0.=[J1X&G+/M 7:M%=P C
M9B88Q\8:Y5Q'[$S]FF%3-^'CL2"#A#?]GV?/B[EZ.Q[(>N(:)):QY-VT!CZ*
M$9^F*H3JU$_D=8$O#N\3&F^$<[@)&7 .5E\TDTWUSXU*E]0O$\FQ@?(7C%1R
MBN>'UT(7Y4JWGH'''BS4;W6QZ+/A^>*9D04CK\B)MZNV+\V*$8@<,>^/$9RI
M46(T'(G=R1Q)B=I<*6([I&K9/3@+C,I(!GI*PDQH\WV5%.WE9P7KLJ(KDQZ)
M/0IU2M['&>O,7PC<'FZG;;1(K2[3SV6\TM 2V('1)/07PH7#A6@&UDLUP>'J
M5:\-AVPT,/$-'Y07DLQ;2^S.?-:+@1;*L,>Y8Z;%]=!$7AKU^=B=K5Q_?NX>
M5O):<GHMDJ;6+TW)3Z ?I@W#:YUCQJI4&<<J16/B_7F:9TVK=KQ/-WOG)$CQ
M>PPU"]HR[$'(S6F/HPEQ0Z_XZS3IMPG!]"]_#U;&#WU(2?B;[[!,(??!IDTZ
M$:@I&^[1_G@;89/*7#:HPG_1U1T2__,O0JMS,?H7)>$+B673.V:V.+5^W8TP
MT>*\SDVF*DV4Y9Y;X(%.$8-?=M+* D;&,G]\<L;;,F0(6=RKYSNG35*2NP6T
M^%=K$K._7I<"+^3SW#C:/L#C>.0WOJ=@Q.+K?:7<PQ7;%)N2J^E-"C<RF:?:
MJ+KZT*TEEZ">H'H@5^A7+ZN?:$%'-^Q#]!6G!4&-/E(J6K)/VJ;5%2\\@SW8
M4M*@E\)[5@(&-X>N$X%(ONH$=M6@![9@/KKVCWNL(-"9HSZ*SUSKN<<DG=]#
MR9OCE>CVOP)]S./ .=MCLPC^LA;+D&-.>V"B!N>O9&Z%W#'?R'Y'-U9RB.";
MW96"4 AU8ZC9.RVRZ96%G7=+P+^6NB8&3"OG3O[>I838!-"J,_Z.3TC/=!&R
MX:2_6]=TFRPQ;^]G5UEISX-?--;X=O=A VKO?2O(L)*C*FBA'\BHO#C]ZJJJ
MT)ZVL<?6J58JIM5,L9Z;3./0G X9UN@R1_ I4"V9_V%(#VSN@!,FHOZDT-IN
M3ALO?/?-8>5>4Z;L+> A:PQM5]O3Z5.PDR_K8Z@NXP/K"7"WA6USPY4 +=4A
MHX8"Z.T8"45,EK!$%7D$I#\7AE$[&QX(P^AMV;Y"9-E>B2Y*5&@UG^/: J[G
M]L^A%2^3[F(L=WM-:\I;^P.P+L^X1CFG/XIKD2)>+('WU4#MUW"Y8+T^]#%\
M#!N/_6)?V%209G/LU;8LG@_G3FFV.6H7NFZNZK7;B#?ARCH[K4V;WU82:INN
MNLB+R6U[MVSON<<][^E?TG-Z2'_7R2:O;L5Z,[/VR)4)B+RM1BPZQ[[&!,YE
M95?/9FTWMF*HUFM<<XS?U'K4R!\8RD(?NJJ??B5HX_^&'ERN,,:1&$P2)JJ:
M/?M-5>['2[S56 *R:P+KR36<$@9H@5ZJ\;9VSS8:9<G*-S9;U&*^BA-%[7BO
MA-)]C3LXC'#;4\4_>5%X2A[%PEF)(:@(M8!?NF*>S(P!UR'<5T]#-8%%TUHW
M!OL=")GO\[@W[L%F73CY?PP#!^-:\K9!!^.RQ"$-7M\'[]'R1(]T_Z+__'13
M4<K$)@F]"4?P?D'8=UH'K2UQC ]R5%_T<H7YRE9]>NTT(/H.#Q5K.^L9=QIX
M+#?3G54KN)X<AFS.X%>M2]&9%O\P3=EUM#^5:W/4-:]2+2G,)N0:_WO_$G78
M<_AXUR#@.7HZY:-ON8G$=$+AHC<+:UVL5R**5V!:\.:3Z#<64-S/PHM&">?>
M93RPGYKK)X39>EL<:7Z:>"%%F;E!;9PTN=/NLR>N1T?S80,OF#;'%2L=;P&U
MI76T4<.3@H)K=9'(_@5V=WK7[6.Z'.YKA-"YDETF*-O/ $,^>S*? 52IH6%%
MB-AYP23/PT9I0[X)[=(,MQEEK;,J>.)F^YX$HS)S E&%XBF5<=J3M":9O;*2
MC1#/:*!YB][;,EJ1_C/PX'JB@E.C+KFC C,4XJ<.&<L7/DM-&15U]L]T&LZT
M36FV387%7'E9M4KV(=O#/*X_UAEY_(/@*R((AFHT^$L(?J@N#GD64@W=B^8Y
M9L1/D\Z;%:0:.E&,2KNN"/9C+]\UT#&W6,2:^'L>,!('KXN[IK.SW^=YF.1X
MH!Q$J"H]\NIT%"&*6@9..M9:D(R6O[+?&$H$"G:7>3UQ9'_&]D04L/$Y@_"H
MY.JW^['K=I/B%W%6\K)BH^U!2J"21.FCD0.V4.60U??=2/(?K ,O&%\"'N6P
M=ED\G)_=EO2\5$8 [=^G^[ZN23,B<4U\J/RWHRGQ=WQWD+?XQ5TKB3,2,P;(
M1#)[V_PQAKC$0 3HILDA\/)S?845)BS(PYEY%FY;;B*_7JL;D4#C_0P.4'5G
MY-W2UHL<L/AF3@-#&X;[<8,+^D%_=O\-$V8_,=2]2!2H?, 409RL>C3UDD^)
MT4UZXRMS'?7&+0"=X]%^2=]B?PL(T;H%W *8<VZ>.*7< EY)Q2BBB]IO :NU
M>-M/#-/O]%W,^"U@RP93<$,M=0O ><9A=9HLKDF6Q.^*\O^K&ON/*%?'W/D6
M\$A*\Q:0G=Z;A=5?O@5@$(I(U>W $S'HQ%W1G:,;V9<L"2K>[3B>1>&;4&>&
M0*1>X"V@S^ZN"8QYMX!_PZO:.+X[-]A]@-C_;TMS)KT3S:UDIOFNM7'*3ZM8
M,@O"O/9XQ_QI2\.W-V$\O5+Q19UKGQE.(@'_>YO35.U.D5TP*G &SG:2WZ35
M7NYO ?ZO7ITV"!2DCWLI9B$"E;UY]!"]V\=*A#/&D&O73-/TP6G? QT8/O_K
MA7W1XE-[$MEF,QYM$=R,-6G[]8LF]"41ISKKCP!M;,W9:VS6GYOA&T [&A9R
M&!8!T13&JN$LD"OI-E J'2D#&*<;X1I/L38WZ.N$N*]Z'TJIGQ<G<*W2CED.
M$R_[-*'>.E,[+V^RA^_\T=6+P50S,YV=VSW@7N,P\2HLR$\#P]Z=25 ] UZ^
M(Z3J)F?#/WE9/M4 OF7]*GS5S.K5QH\<C5F^+P<LAR:M*GSEAI-J=[>)8@)@
M'[V0SDPJ)&!P 9 [Z<L,9_#\!9#U*7DZQ!&GC\5'Z6&\5A?S0U9D(R!Q]%B;
MB2NB'LED5P$*4S5GOJ4<[?A/B2OU$]>HA5_NF@C=U@KL+<#D@GAN-'#BAFS)
M=A'!&NLGC_(%EL2PFDU C 2-<H_FS/KX7JN][S'ZHM8* IK"?9V9SHYRT>K9
MXT:SHI7R#]B#2/WDKT1PO#), 1+3=8H/L'"_)0HSEF-X6FBP;0YB^>)CW(_'
M7V\!OKR,\>HO_SK5G?9UR<J"%9&!(>!2G*S4MSNH+-5K&9,7.8.^T7V-???F
M1&ZB:?LBG\9U^<ANSSOO3^0K1K7I#!4 )UW>GY\$W.*UNG<3@??+]X#_;G1V
MC7S1(_@$\+U6Y^4#NR>UNGBUMDMWMI)Q7?_5>%*KA\>K\'V'!T_ZSL]+\6C=
M8$V5YU0LDY_^#WO?&=74VJT;1$&E2>\=1$5 D"8M(M)$0$#I$!$I(=*D!0@$
M04"Z@(!2I8DH14JH :0K2.]!2D+O"35 @!N_\^U]]G9_][CO&>.,<<>]WX_U
M)V-ES>>=\YGS?=ZRWI48;DA2GI48_O#BI7:$"$-!@'*RZ:6WIXF_7#WEJJ7*
M\%FW.]ST$LFEW*R$@#LJ:SI9 72)1*,_+>P#7N]EL_SCT&D]58"0Y.L\O?\X
M>3HCBF4O-RN /AG(1GP(H)5#_Q_G5&O\.+^:U+-_B_@/F>0;>?\\N#K&1_RW
M9UQ47&RO(S[@>2^5",./W6L/&?YYM,<?KW_QZE317\_DVOX=I1$5,>F_.N*X
MCR)0H.-74R-NYM+$Y!:L;('OBH'A!P;PFYR6^=[2&7D]KD2VYG>QS3F*F$HE
M&BR^4[_?<_B-O.YI S9C)6-;6T'O!/!,SN@$(&1DX>?-E&&G.-A5>LD:S%G'
M0)F,HPGRY\6_P:FH8$\ +?)IOIH#,)G"9W[,(<#2"*0GW:E'73VOV;N%$3&=
ME4)$MVDYB/AP!1$ESG'M">#V0"LWGCX7ONG!3315!T>;0K-/ *?<BX]UBF5[
M@6 (<:19?WY(TA=X 0J_/8QX?[6P:(=*0B3YK:]ODGV2A%/4_<9OKY<_5KH\
M&8")'QJ<*R3 ?3&ZYQU0@J$AB+(<LV_\T2K>_"SZ++2&M^ZN;UTB)7'I_++
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M3O_]5_L3P/-_3%R_^<UFO<-1'NPRALIZ]RW>"%U(@0%%P8#<D8_KDO1+^J5
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M0=(N$@_D#EY%JA-%R'#:Q1AO5\'"<MPY ?#C*!4-1D:MEV\#VUE89\,57YT
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MH>J#DG[\C<[9L7SQAU]B<_CFT2K7!-6_U75#)H%6G#(6O012#*?,?6PJ%]=
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M[/"M,QGE>/^]5LMS.,MJ2('P*+[X4()"CSMIL\>Q)#)$(MS SH8T?)7@C,W
MK ?A/LXH54YK\VLG<G/8,[F"#R:Z5AW<#VN-!6]&4>2+/A9K/,S.[SY;G-E
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M$@'AW:I4IWOEV?,*8$,NNY_<6MP\10OAXAK)&E*0][CX9K>0XE[H7?%]LYQ
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MRJF61!L.4I/)*_BO:!HR@N2/E>N/$/%FM'1ER)+4V;Y9.G5Q/5K5>\:)DU4
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M:K<$(H=> SK9I'#&EU=9:,*:JXE)$6DP7\JM#\RF&M!EZYA/^J'2W]+7971
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M.Z+DP>0''%<FO<!W8=+0XW!&5TFS&$+#&H]7$0/>1M2_K?/X3_SW/S8S7[S
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M=9W:R2]A_-Z=(F^ZZ/N(1<+N/N=>\[HDG49*J^QD5.47O-V 47J8YVV9\(V
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MS^1Y^YFW_2G!%Y'4'7(/<-SMCX] +%N?D?APM<;&J5V$0KZR.<2!SS$86#'
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MY_+I -A\-DP?EW0AS!YX=%MTN!K:;H1[@(>XUI?F#)A8_3AN]HFG>;0:JD[
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MD>\'WD+X!18?)[8RS-7U2I3%KK<?)Z7D960]SMS5^:$CE"3TX$.4^X-RG6N
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M%:0*C 8OCD06J-/-VP9;P[HSP5\>/F%,8,KV6IC4G.&#RMJ>#JRKM+:VSN&
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ME&7 H_VU88_,54="DVQQX)PHZ_1RO>[J,/E3@2QFF3E;'%JB3R02!_Y&&ZU
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M[D'GK16Z! X59!:@^M!&$P9#"X/$!9&'] 9\.SATMI+LU\GZ_P0SJG(P>G<
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MWKS"2*#"KFJG94S>EZS<IISH.8^R"+$#FI5B)=_V/E5G:Z*:0-M=9"#O 'W
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MNL["^J-*:COJ!GX2+J/-&>%I3F5H!-9>47;F+8A=_I&DIQ*KIM"#1_Z,D)3
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M7#='JY;6^S(2HCQ'AT1:URF-]K0/Y)<&7S?'O$HZ?6C7\J)WX(TK/_L+G&W
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MKRE::=?O&F82+ _PW+KF(Z2\_6CR^]DZ%=_< =:]9!$0F[;3>ZB$VT<2&7<
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MA,Q@!X6JNBFF&9:I<B&02DJ(67.\\G4- ,O*E9=HL7L+H*M[)0R?-;AV0O\
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M1Y%59)>7^J"Y?_+(^IQA@X1-=$%:QZG(C$"C\HLZRYF*C-<.*V!GR37ZC)+
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M$V)19<AY\5/R$9>@^BSW5]+A3#ZN-\0N\U_PI4X4>^;MPW_#*QG<S75-,7S
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MJB:+D?0$UVSP9/P&D]"2VVU77P&"YP0(Y-UJH,Y:Z8G2H4_YF[&%>E.#8E>
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MRWQ9>?%+.7OTOKK-N+GCJ-8 Y;L >Q-SGJ'R,Z%Y&#M;FHIT:6EV)J;S:-0
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M&OP[UX[OO77)2.C^M 13+CND,D/KUH2I"RKSK^K=D"!I:UL*IAE+[:LE]B]
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MBDO5,:CT#Z?;@#G.3[8OG4.;:@3Z^M,Y@,9XOH=]KE\=4 DU G3]%(LP1MT
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MO6OC8$!9MRNIP_ET3>G"@FFWN%^^UFN"\> TS-;R:-8VES/15"4:_=:MHPF
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M9N$_EWW]\,T/OKE0>HW(N$-?[B<K+^#Z(0Y#:M?4R7'FCX)$7E/[2<Z\R[D
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M7J95ZN:0?O>PLF/M$/_1>)>Z61I;(+HKK#^6&=V3_% "'N&3OM17MJ-% K:
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M5_Q3.C7_[,56@N[_\N0TXK<"0B'ZTON;G^2QH'>@P!*=2?R &4A+QB?MQ0W
MBT6-\QGW?8>>++<R'\^$E4+\3#<ER:4D2X1?LM[U,)A=X>*=G5]>]&QGN.A
MJ(>2:'@1_SJ;IREOV>Z:.V7T)7GA -9O%8G[/!H4MR7>E83_$+GRA.8-\$F3
MU2QG.T6E'_WXI3X!6'QI-'WY/*3<=(#$D58Z?X%*U.+E$%N^\I?-5B\JC1Z_
MFL4DVU^1_?5O:BJA%N-"$A5@5ME/+=Z3JQ,N1>IV:7I<6WN!M50Q2FV9:_F-
M[=RRC=6R-5?57OY8G$N-?XE3@&&T]Q+%(L23V6LGUD6H!898_:1TD9))(Z:1
MV/:X?3<@^<[U"$,^\2B4UO*JR;=\WL]5#S7%<8YA'&I-@P3&0S62<MYY$[$7
MZAJ?N^Y.U[<RU(W"+S6$YAE 3)-R_! N]%-1$].S.\:MUIF*+D5R]T<4U<0V
M(U*][8L(S=C[R<MYDG\.KXW7KT?SG"OW*JL6L8'EK\4BD\3O9>VJ6??<T>"/
M.[2@#9Y&*P=H)Q;CUO."0B0C,+ 9;$M339Z067N30=2K]W2V$(-W#XE]UK9+
M?]%V%Y"MX^D+(FTF)&!CQP7DIJ3QK-/UM-T:#6D+T^KQ9!4\56-AQ(XC].W5
MNT@V%L,8\8L0VN&??O'*3>-(G[0QY@T8)+X9UOB*Z<%(7J#T;/ASA(U5DHM9
MBD?9+?8 D\SI6G&M57")H862^DQ/]HQ)1@.Q+H^Z?J[G7']Z>?BT04)9Q#[X
MN"IK_ W@CPRLJLC18,))=!M=/*%('[Z5R0$5(NU,]Q^H>WY73%4#2O9,NDL7
MG[E[54H8T<8'(1>.["TF*[UUU\'%Y:X2/UYRWV.-I<KQGB]C)E-5,ZE95@@W
M:"7!<V16"4Y3+QC/FL_*L;S-@DD>7I6"[45JC##1L^\]-&11N,?KAQ3Z;<_U
M5H ]>V*8TAQLLZQX]FW*GTM&2#:=6-0,GHQU<W\I$GL=CR1B8B/[R8,3L.M9
MR8P4:1'YL9/HZ>OH7+*@9NM];RH!;UIY&).@_K.6^/^I#2B)CXON+KCO#'6X
M!HEN>YK<5@G^VOY-L_[1DKU1ZT0L(W]:\.0\6]!2P,AM71>EA EMO/?_3UW2
M*"-H16 V+(1#CMT;XOVB+7NA2K#:F_2[L#-OG ,7XK&P5-%C6]LCZS/W-";J
M5./SLCW^Y2!^DTSUM)UWV=NRGVMN "KC+G:JJ$#OQJ0%,^NG-@Y9SUYZ)K]>
M0[;->B/9Z84$Y11M,0.QB#TU]=9TU='"<.:]:KD"L8_@7F/BV96.M'E[[E*9
M*H5EK?R"'RI^$L9Y17@Z<T[TF(@H7VX]R,+\D_#E.5Y-]%K7HWI=Q,F"'?JD
MA"#9T^71]WW@ZWR7X)ZO:ZFINI!U#-8@]ZF=4#1G0ZCJ]$J$,1 W*LF8?1#S
M+TM0N-)F]'A/027M0 >9)P0G'S!9[MYA9DU&?W[,3QS%\V3($R1SE2[4XHB1
M#:$$TFB2AW=5*/+X,FBX1>]-?#%1?M5N8'0J6I&[_'R%#U5Q PCC.S*9+F/Y
ME[J%RJ\NV4FV/]&WTZS@=D[0:(0FU:>&/V^WD]Y34[ !J4SE641=\SHL"L](
MD(MI2F626QUVGH98?G$V5R\^7%/.K8;M)A^F/%P%*B4_)\1>Z#GFLT]SUXS]
MSF9J0TP?Z+36-6F^G'93'W^P_IY+J[:GYN0^]_KO7O@%9J0C3PUSM?C-&1C#
M<M21;KI@AM[R,/[QJR63\;[OPK./C0:^),^>L:;]O=]RT&E1FTZ(&S]XG=/-
M^)P ;:WFS0C_VX-:0-[+&5[@V^U#EEGEDE%0[']=7YMN[Z]NVDK$NW:X.W'P
M-L#V':QQ\T*2Y4&\E160CPP\&9\'#2TMV6*Z%/G))R+B&);86J0#2Q86P7,[
MG@/VXNY:93U%ICF(Q<BQ!)#Y<J1^#-0ZP5[.@#CNEJ? "BR$Y"ZI<WA%;8_Y
M&%S<>.^C$,-#GB1]Q59'*6K9GKI3V\_.9(J]E;%MML<%+QM^LN2GVHK[]OF*
M_)63I6.8B?DY0*49HX]_P@%YP;,L&M& !+ER>L W((P](_>&UC0YRGGJM8IZ
MJC5"V(N'G%UM>5QY/ 8>:=7L&^6&=@(SF?J8U:]E_701\FKO_0_VNB*[?E5.
MZVW5]?BNFXI6H2H%<^8&!?]+>>:_^F$E=$K!1DC6!+<4U2+K#6\<^^=,= 'H
M<[9*-3?M.C%LZ$R_WYZ\<2176TRLH[AGQE%PH5!:L!QD_Y*&X#DTB1:1-((^
M)]-1+Q_5).F[Z-ZGP" . 45?0AZ?&1ZQ[S>O5"A0$@)FC+('#!H;&DEK2;5$
M_??OKPD==7XW>T8L&]J^?-3E47VAZD=GX<B W_9E)'J/_/DK"LO*O'@WZD2)
MO:+OMJA8=I_$3L_I'X2<94V_",Q!Q*7(_SXQ&HSH6#2X2%2]XX4*5>< +G4;
M$5]<=&O<R7A+(2"@<I6%V&/L>.Y0L^,KJL*1\77KE1))^5S)O/CF7V+FE-8'
M>^A,"11I*J@T!QHTX:T09\Z!@\6SS:0NF2\9+UAHVHHJHM!/R,*9XSZE5);7
M_'Q+$?3TH,LUEN,1P;W<(?.9 RJX"+,SI-KS)B_QJ&0+MKZLE%5(G6')9.OY
M?WDR#U,=6D?P[69Y6W)[L<I'FVA0T?=M21;%.I6_,Z4&&>:F,+<J,>?E#VZ^
MWE5 EO_QI"Y>0 VOWQ97A$".?SO<^Y=3]=R%.TF5?S"/==!4?2PO-,4G884U
M1R"G%UJS[S8>/&$RU!H15-6'B=<KL_#S-;A5FC5SV3Z/>K [V\Y:8I2^E^7/
MUOO+_D2@/%QSSSN_F3]UVS.^Y^0'F;)%FIBY&538J^\\8J)/*&03O'JJ//)I
M"42!&-8!_STY?9Z*HK\+6]<<<1 Z@;(N]Z?JB_9#%]C6]PYMOB24[SS-U$*#
MF?LPCR^U/;\[+:%1(['"U[-!WNS?ZY/=PE_0J5%9(^[&!M3PK*;_!4'^,?+H
M)A=>CP??G4'(+IC/Z;: 90,#-4L86;P[M3WI)[+VLN_:D#].4[$Q"UUK_%?!
M"$0 /PF)Q\MNY+P[<O'F&TO7,A/%5*M@.^V>B=^1BCJ<">%F=?.,R-X G]C6
MF5&^KHOH9-19V#(!)98:+USE@6VR/ZX[V-OR$WNZ]4VP/]@!RU#^7MJ]<GT[
MXTWNHZ5FFMQ)ZQ=WB'&&/=ZW#Y*O_._I?U"$$;3%0^-)W^K8R-78(7@OQ,+=
M?.6D$,?^:Z_K:X%!8SY?LPHXB&%?4=:D;VT^)JY3Z4SKM#X];O/8-0'$.K8Z
M.GBX*)'T4R@17D2>,&)_G8(1ZABD*V2TTQ%5$Q1+B.L>N[YGO,4HXS7P8XBS
M[GH>S2)QUH: MXZ>;1 H^^4#9X0J@OM]SJMF/B7D<V?L_B,UXUA\85^K8219
M\.*+.9]03$+)>XU0#9)GJD^.1-88G[9U705U)WW#+YYJ$%[G/V^J^80B?-_T
MZ"#S> T-J\RAZ8V'.<K5- (HP U.VSW=!Z12D8(2J_F'ZB+5/!/.N^/==BV!
MWP?#U>42\^V.#TMXJ'^KRDO_J+ED1":W,RRRL>0NON?@YN"B/5-R=R_/N0&(
MW(H,],N_]1HYK0O)K5;.,:%*]#FS2Y6<DC^6U7=2D&9[:;!)S#5.W2ATD\&'
M*,7CAV?W$T]?I36SX=AK&3_MOE$7 \C&Q#$LZH7(S-N"W3Z>.O_G/8(YDMWK
M%NG65$IN+X<\S%FNBC)UIKVJ*&X RBTR2=_/MZ*PW=.&]8F"$D1.S7^)PCL@
MM+E/=A+_E$,L:JO@R$H'*:'*.;#)EKUVZD=G1-8XTRJR10I<]5ER+D0BA_+V
M=DD?;XDOA0'_!N1'!)7MC"OQY8#JUF.=#13E6!+_HF"<1^21QCK$&Y'2;#C/
MN:\>_),C!+T++8)G3SX=;FKXFR#:'%ENXEBKY2ST&:^R8<[M;\>7JKJ9K9Q*
M?Q3^GNQ0;-/@!D!U*>^.D=?N7'(U0@B)+Y#F;.EF<#.,RWE*<?/J%T*I4]Q3
MLP]#Z*^']8RASR:]]D@.@Y1,ZW$946$EKK,,<SE\_D(NFC0ON0P2DW4D?>$W
M@&NZZQR1=E6"RREM2<3FAD8@HB?7DZ,[D_]1D\+S88^ L<'\35,8P?C=P<II
ME.!'9_ML=@_I?>AZLK8SS<%>L.GK1)Y6[<RV 5U!?ZBU<)$T-E/EZIL<-5:;
MUF0SP+Q$?J]KLL^5?-)'+RAU+5#7)S7VQ#\P^_[B?0\5.R<@,53_NX4C:H[P
M3PT+D057O5CJ*>I9119?:]A09;[P=J"/V)>K^^_!;RJ"U(GSV"4II-C8$97W
MY^^6R51]E3-=#.D=BJSL@%=@N<28RK<R^#CIEH@,W^M6C'@(.K!#)BKVY&)(
MP70BW\QGYR42X?P4:PS??^3??CAES5M;O]]#M+:ISE5X"P=O_$(Z0*SX-^?*
M:69.Y\XE%\824[E;MK[>$-:6GSQSKV3Y>N9_S%[-W0K2BIX2@0.M^JMLH1YU
MRB!C'W/0HF(+.?E0F>S+/@J3"NKQ6_#9I;ASY^5&E<<UUU6&82=::SW"%UL1
M@6F7+/<O_5N5_5!PWW4<P^LIO-O[0WB#I)%IJ>\%7=/YG.ZAT.>VZL9C,T8L
M13J6DG8;=2\97=HVWE^U6CBNZ,H6R1TB,BSPLW766O:6$7;=\E\04@NALM%:
M09;[+4-O5V=GYV;1FM[B1_ZNPEWJ&3FR7)X30!$3+%0%EVF.Q/NTK0 I( ;U
M^8]:)G@F*HL8-&D> OL?RD_<YUKNJGM,$A$^D)[=C(_XO<B/=ZG!;8=0.CTI
M,]U$#69FRGQ*X:E@L_NSSI;U)=//+N-]Y*/$V;M6%5]<V%"SSUU"'"G_ Z-G
M%Q)?;V/'(<IM,.SB']^DX86%5-LF3@6WYC05D-TS:^B*8U<;+=1N#)$#9 U*
M4DW;^7/B86IN:HH>%BSTCK7].R%HPT"RV64H%+7,QN9V \#U/Y_;G#E7*8O;
M+YQ #@EY55,+PF(.G9Z?30QP=\]R*$FC<MGN Y[]OFM7+V=[(5N6<'S 8#&_
M4V 5;SXF[*46U]UG955;Z<23%X'U2>"C?43%'J4E['WYK6_QE8," I:)%9#5
MQ%CZE]SB_L=MDS=CVPR&I()M-DE;6;_O^ODHV/*$J]Y7]?W D6Q$&/G&(WD#
MF,U._#68!DKG=*2Q$&P/\5S]K9]*.3P')IU;$PKU-,ZF_-U1M'WNW+&3[&E9
MZA=UT<G@$S6EG[&_@C(N\IWW39QQ^;W\X6E2P+1K9(A=D-2??+K&,<YI83AW
M>B>#S*2>)LU!%*OTUT"(Q V@U &V'=$VV%->-C+S69K1$_S; B$2#759? ]#
M1T6[G<.*REZA\HI3*D?L>>(Y#6U)\VK$K*69/OCKO6_ENG0+$E,B^'MCXOU%
MB!-%, V(YIRWC?DOO@;Z"TNU.")K]9_=X6:-E7L"=\4:[NZ4[UA0'HM0.*(0
M=5?-G1L&B'QQ([X)KN8FG\GG?"OK=JSQ)4P S._3:F,\9:@SLKF-6#TMYW&+
MQ/>@U@=6BD@\1+Y1:1-0(!?BDV1W\NIV"=N_ORJZ)/TV4AY_]7J;%'*O>2EX
MFO8*9H@T@&1A,^WZ.)XE9[S3WE^"3\2W"A%BRZO_-%<S^>EI)6WLXC3]G+W_
MY;=G,TT-4)6*8I+&&CQ"%8<A47C&W2I@+")GB.2@RY"X(]SYW9%6#5B<QGA^
MJ>3/Z[W_#9,(__\=)OK=UB>XRV!^'+RB4$-,D>.;O5#.ZR)>HF^O7AXSEPP%
MI7C X1OY?J[8X[6J_$S/%:DQ+Z-]!&LUE>8).+;DT/G;!<BH3KF(A%^V></E
MS@8#_U51"R.$#O0156@^Y >CWHK6:+J #.):-N^"S"_%W9N)$J!EJ1%:>,/=
M&T")7]O;^HECTHNHNO@_,_D,7LJF+89 ^\$FZ3N9NP-AX2 7IX)/"O8#%N3;
M^<!)&]3X^('Z9")!!I1('SYO-Q[XH?:>E<9_F!SIG=\ EMM]EBJ4UU8M5D0H
MQ].^(P0!H_GJQAC?UTTBX^4EM]?!WZB0X/BLKP:DB+IZVU[3.Y$?4W_+!,L0
MTHN@+Z*UG"WA"=D98W5U#34(V+;C&K7&[6*8K/=1WBA]L6-LP=C*YM1&\V_A
MZ8 VGBX8F-2C6S^9EZ/-J&HLM)'D$"W<_-+A;"=EH0+<&4S,P3,-Y2PW7:R=
M]PL^UYQZG^#<Z(O(_QLN]KMSK?EJ7C?0B]0_*YB<<+Q\P-XCNSEC.*/!47!5
M02N9XU;@5+\Y G!HSW3\D_+E4<KSWA^90(1:Q%ZE56,J\GU3D-X%DV/;K)20
M_TE;W56Q\@?JS+[H#6*F]F&(J,CL-*DKN=&6Y")7*R)0@63!SUQ@P.OAT\HA
MZJ-VXBB+QQ\HS9'$H2%VS=I$3O4!,5/O-&/D7EX_>C:[M06YDXJ8L%S[<?\%
M:S T3<.E+%NZ!4FA,C^.H^S98^TT$6[VK%A0LO0L'"CO^YZ5BB;5!$-FEU4S
M<*^:>63K:=./J)Z_&[I0\Q.>?ORFUBDV4 )KI%8:8F-Z5;/N9V[S'U DF.7%
M0E@W2&_D_D_$[6ZP4)GP:F/9HMX^U2SUZV97]([7CWV9#?FREBK,*$W*XRB@
M-AK]_DTR#"''?0$R(4#>CTH\%$8@FL<EN(,IDHM4/C0PW]Y0P3"CU3"WH69Y
M/P"1FOQUKX?(NFSU@\N7XRW>PJ7B$=[B,D$=Z#Y/WN)4)9Z8 ]:8A<^".>92
M>HA<^E/Z+A,H].<$5+;"+]XB:I^<AEU/%QF.[=#.QUC6UWUN%SRJ%;AK\9SG
M8RZTV,U-R]F/&*.+TTZ0TZL&E68*P<5M*W=WNRH?Z*ZY2HP917]IF1?/,FMG
MY&JIN[7<DJ6D%NER0HC>]/V\4M[%)G94CA<J">S\*@01J\\<FN00W\=20TSD
MWO-H;&B!6.A?T_88U 67NRCC^I!W86P*=G0AU_#7[N)9D^2?5:6-W</3K&"W
MYKJX#EQ(SPZ0;=Y1P]7:L[AD)D;D'Q<*B1AMJ?K8H)P5JU5<4%O#&8,6?;@0
MZM*!>S7-'GBA??'6ZC8;TGJP"B(#3$>,VF 1$>G-5P<+,W(&-B%U0QE=70B3
M^A*.ZF]HPNT&IG+T-5#O-]D3_O2SMRO&>\F7^\GO[E'I'371:YTU,QLM?-W*
M22:N0G/R6[V&ZZ6BJSW[<D-2O^/72)Z4'EIM'DB]A(\A:6-"!NAS&U6K')C@
M,Z./P%VE.YT?1Y65;HE6#>HIVK*=9AK\O!<8QFS6W^#>I-_7LQ)G+G.5.]$Y
MPY(;P-<"%2K>1IG!4X/*T'^[MT?G- 0ZUFC4,J^14XW2IM:.S#\605<Y]OB>
M^&H)PN7K;/D)9.[/H'0MBVQ-R(#F]^R-C?]6("9/X:\RC-EL\&I2-B"5^2KL
M")JUDX,<5QVOLO&)LQF?'Q98,D?.-Z(CY!K$?M6O>#?US5@4L^!RE&Y4,OR!
M1!WD0L51)BH5F^<R_G?!X5PA>O>XET?M:F\&S>#!.9N<<?3 U,-7\GG7V[8[
M7<>E)<(U6-(\0[-)I+/ ^^;)(90RR5\S%7=RE'(+CW]L]#M/@=SLCIP3[=&U
MJ1:C#H-?6I2=V7FP(M^BLM[4>'_;W [:<K)8GD-$-'%$R@LY4*"CI8?PQM=+
M7OSJ$O4EK7.%^=:*QE11?J"0FA;-69LM*LH@[CUY6*/+FXBP#%OY'43U8US9
M']:EJ'P!2PR[\BS!XOWD</F/OPMU;W_'6_#TL#;97ZV&/WG(G_PD&C]3:9=Q
M'HFB*$QA,?E IZL"^'\/OJ6 =;F@E4"+Z&L.&>00LNLRV=W5UM7>L6&HL3%;
M/^[QC#N)Z'X33R@QS[*AKNE,4@MEV>5+W&ZV:A%OYW-F#"H..ZXM[, 7IP)[
M8OV1313UA/FNSZ.DQW^E7@"I@T='"?JN.3JXI ;J,<3:E/>Q8;WK;H5=FKZA
M!V_G%ZK7A&3WOTW</"3Y1R=AB 8\<B/:$C==[29TS%V8J&5RKR'MW]_XR4A?
M==;U^,2U5U&_^;/-+$Z\1X]GV9'D]N;-%[;9CN?PB_8; &V@=YH&@VP*G:TB
M3/?0^<RT^@W))AA#$8KNS$YE!#H&.7L?Q09;($F?.[SH63B,UC;WU'B_!]PY
M8!3YWXN))*C\U3=DD"QF.!&;S%S_36S13T\7;]L5AYZS[X^LBC'*YV<"O'E5
M\5^/[^#OL/PZLZO2F0Y?4<60904:-0GDK\2I?^Y7&>@Q$6';^GJRNTMB=2IY
M/]X2>:B2>TD!ZY8BA:%BUE]1BT'A(QV9' SQM)=+UCE]2^G);1>?.H+\UI&7
MBKAT13Q?R8\E<]((4 E''MVU:;/JG$!T8P2;^U'O[#&;[O -(//\HF=@W1U=
MMB=1Z!#, 1[2TT2-'UM7@<*]<N9R'+ZXP&BE%\0TUNX>!@?-M<60V6";7-F#
MI\(O,"=%Y7[<:I/5<.PX9E)81/^# V),\/!5^,OQ8-Q^E.F992AI\PMN4&85
ME'+4VU$83H.] 6A/\DQ3---?%??7@1=8O>NM<C[#IV-],CXHS@?59&!=9V>4
M\-;2K=/>RRX?+2>.*?G^J5U]HWLGE^K_U_S'>!.KSZHDA1K=V;E'^L!,UB;4
M&6_]!L<^/STS/:/71Q$1@B5^]G2E#_$LELXV>G@Q8*6!F$=? _3<J&^E44[@
M7D9O<\YK,],%#9['L;2Q/GNJ;H<I5A_F[I VB:IZ,&)]V[58L44OT1G[91^V
MK+U+U=%F(RGVB,;#RTVV/04!IB*Y#XDM'&_MIX*IMDQF8L7930Y/=3.\5+HR
MPKY 8U8/;:*'+II/Z3+"SNKS'S+3-:6%/-B]R!7I *(]>KK5.GR2BYS&^;Z>
MH )O_93,X,!?.#L3(U<C(+/.MP'X[B(:,*.RK)!LH$ %=?;$[+ SZH0_QC0U
M:KTR_N"P8-DHN??94)13N"IT^R'1]KWDA]<CB_0XE[P28\<!/\X)[P<2 B&B
M03W#4>T?]7S9DGD9N2_F9WAQ8LO:,2 Z NKD?$6WCL5YT%?!*6[:\/,V;=^+
M-.DO9L2I/_WCJ(W#EF;BY L#OQV&^"T0W%<HF?S.-:L9)(M*9OU4Y56OAX78
MC)H7Y"0G-(FS[(\ %",,NQ\?"5A72_1"@,A[1WZ\E^ 2@OV[ACCM!T[F?!/_
MJE0>&;1$W7'H$U.OHV7!+E]^<N'F#P> 4HLO&<>]@-2+3@$N995_9\WF1_R%
MX]F/2&GE9H]LJ*VEK08[[5W6%Q(F^ C4&$<$NY1JFFS9SY^XR6NZ.,F<=&O1
M/W"FL(%45^#0\4JV])*E!WR#FG^/N-(AA$;DXW$;N9.N@\4LB@U>D^-S/9A]
MN+^^Y)7 ,QCVY0-&ZH, A^S?204'C<I+X9W2K8#D6.^MM@:^1*%'4<"ZN;]F
MR.;^[4-G3N-"G3N"5V[21%4W@$CVPA'R\:7%[8#<4QW'Z5-&0[WJ'*Y94_G.
MNQDZ8JVJPX#>WS],"G8/,$.OIJ=9 _? K_W>%E>!"GS7-,6E3H$.J+ YUWE'
MR=0$T3TF[MS\B8NVF460Q4&(A?O@9AN"?#BOL-WW1[>W9AAF@5&W,7X069O(
MTZR9-K*A];1\WAE?1T3L(I:>;(83B:\,?N0G\@H/@O&8R1K51ETOV %>)+VG
M: [EL2<?D6AW4JC3CJR&>U5\W_?69%T01?>/3V^CUWR+?<9,58"+[XH_-^?2
MJ/K?_9 PHX([Q301 OIL[7\L:&(NA(0'U"?$FTQKYWI<X&3%!;\$#NXD$5/S
M_V(['>MN[Y]ND&8//,D=O12"$XI>3WH-(!I'_^7L?:ADE*QKP9F(0T1ZTV")
MR3G,NH],H_;"G[;%*CCD7"FTGY>66"XO*%U -/'W<PH7-D_K7M8^71AP87BY
MPZF4M<\(E")O9[H[-:M@N_1 T[T*T<""&-V&9>>E@R5Z#Y>3KO5A.P-_(F#>
M=QD$U11[Z,<)$<N+D5A2!9H.P4S80;6YB1,C[=P@@SI<Z!-(.37M&4F.7_*C
M<,-4-9E 96G9WB*,1;Q)< U6A&;3," #V18C> RL13O,>*C<7;V*6_2(C;9^
M?-]@(%0VX8,-+ICHZIL$*9#(PBE?2-0IF+\!-;$+OWQB6<(JL">SO6_YWQ_E
M\0R8&#>TSD;@GG7ZW Q4'G<#T,+-0=(4A3H;3+I^-Z-0&3>  %L&O&*3T1W$
MYTA*I@V^IGB%4!FN>=/;9B^MJ][V'"E[,W.>T8_HKS<$.M3'?-0W"W_5B8?-
M>VC3G2T=QF<.5BQ7HVF6NJZY)OZ57PI5.=B=[!^]T:PXX"R\<(8?R%"FJ5J'
M)BF%(?;DIGZ!5^H+B@GPG3<RPB62F?85Z$U#U&JPX6S5 5S9_(V*9NP#/NP]
MX1\O1>_D4TA6@F@V35Q*RLR53L) !17F$!T[<]"8%R_-JG7&U<6R#[;NF#(,
M=;]DY>%QGS"2-VY#IV$*[O6YJ2NC:_=I/'D'GY2+Q5/NT':-Q(=WXTP75JZ"
M5M8L!DT)0?A7(D PI&%L$QV54;R5V2"I\=V"*=RLA5:3;# .;O04H08CS<6;
MOUU"UG]9@;!+R#UIG5[?>3>6SVP+6W273QPNNM<2"9-FZESCO4B[9]G"9L,6
M6!!YR5I*4%#*5*\UA$C#X? %.^?57YT'XFU19V".\,8KX#)%=-%F?<"S*8GX
M7RS=V.% <M ZAD56H7:$#5=(%197H1RQ(>@#%],NR(!R]C?GYIWNQ2[OR.N]
MKV>8R91$0S-3D4,MTX<,%]P93=94Z8,J.FD_[7685-VG/"M61M">KW"@C*KM
MNJU,0Y.WR;X254.'"R9_DE<[Z&JSE&LK7AL.V:)#T\9>]+SY%Z#0G@A4;9Z:
M)MU3_!>D <\/(M&@KNPPK1-?)6_&#>[[P)Z2LMTQ+=G8S5F>JWZX%<RNF6>%
M[N__<Z'E:-5R/_"[")M\;\:L!N^LHF"CRVQ[%\=$-3>CP+5E Q#Q%7<UTBF;
M3+5)ZX@6B3H&:PF/'[L\N@&\2<,*&,2^W0*\&O(J$XK4OZ5LIY*9/5WK2C\?
M7]QTQ/?M\^6&2=ZT\6&PH\H/=$QGVA>Y)6&50;SS@\[Z_5PV'YF>W[^(P(UX
MLC2S;5T^I%#)/*[#C9ZKN9[Z@8OUF4?MXX9/WD]]/%IRVZN@=R>@BO>BYZ!*
MV/NMR/#U,203?/S)OA"<A/EK2N&]OV]T;QTRL84Z71/MM49AWM(-3 0]A2P"
MKW):I%:8^!.]AUXZZ&K)&B%']?R](63C@M0IP^UV'M]_O;W_A#():E$% ='@
M8/%5QAT_G$R<]VO\X4X!=*-TX<R%L=9@J50C:<=,WIS03ROK]'.0MH?_\@(Q
MW07+I8V_$!->-X"?.>!XX_!YY9.T+D$RMG!1#J:^7ND?+#WM8':G)>7  JJ=
M%?#XW3Y(M9)/S>*91XI-[!<=;DYT+OWU/7E5APU(V2I;P]^5=<($' S]@&N+
M8EEY7:"6,%2VD_W)7=P.\J\.$D7UQ+.&ZJD];ZWM7.ZWB@**8"DG"YK@QX[U
MH[<=GXC)N0&0UR-M9K8H7.E+8U1$/_O8],O:LMYU8:9O::MK"P6;CR++Y>0=
MA>N*>R?X2@0?GTK1B*N*'O4:>B5&Y*;GS4]<<T!)1Z]9(0SHR*BBBL4^^[(0
M&^.N[V9G->C9*%4C7;<79G%WI#]Z\R<H.)QW0LN]GUT_#9[(9OPC%!PD!9X0
M_L+=D.]0C&Q"IAEG"V@(9SV06Q(G8GL'V/WJ8FJ? E$$*1BK8?8"SH\Z4+^B
MRDN<?%!*#N-G0NX27;V?YN[:>G( ]ZA78:S!'__]"!:[RFSA7AGR-)B4T$P$
MNY2)9^JAE3QH@"!-OEI'XH%FD-*'_[H45\G645J^RXL16%)7*C791?! E3EZ
M6W1^;JC>2-CY$]=#KA?+Y>%BO8]2>Q]A,V5"[%UW&CV0)\D*R2L6L44$$7Q!
MURD#L?;4Y=/S(J.MT\W$U:O\(5[E] $K-I>^7A<E[THAD9,X/-?6XN.?-+/;
MJ*'6HF+';/VI]73WDK33PQCE=/#KBT'W>BR[.B7B^Z-PR-3'5N)-R6L WOY3
M6?-D=2541[@-*>RR[SO_>H8JQO8#X3>O80(9Q6^*I]^N\B^E@\IVW"&,J/HV
M_PHU9S(T[)M?\ 3-G+IMPV'VLT(QMDI3>L#^:KH:(JCMKO;3@[-<^V[*N'P)
M@M+R;)4"$F$6TI65_@X<834]VE[653<HJK9>OV$/,L%$^6X06]MK]X1PB.RU
MZ%D6$@(U6F'30)HM-%]1U5YDE?XZ]6M<J$7(>9/>!FDHF'GHXPZPSB)"SAC3
M/"3297#DUPHI>9YG"'X^;ZX<#>1Y1]?I)+E!0BS-SY.N9QH\ F)-[^RK4/(L
M_PN&?X/\N '8H$UC*A/G'[*Y]UN3SMCHEC//'6XPKR?YEJR<4:::G HXW  8
M2G"G$=>/MO,Y:2VJ/WE7Y$#*G5/U6P<NFC]]=%/PO??'ONFOMIZ!G-2%DI]G
M%^AQYLN)J@/>UF2SQM$OKQ^S?FMP+&X$2IVGZ!8M7%T_-UED)-C3)T5@AQ1,
M')!$6.=7)]N7J@]4DUP7BJ%'G:0TP'?%TX;A(?9 8C\BTY]3_QJK6<YG5&1H
M^CP]+ 8C2T1;DB=$Z\3LWI:)>_H8 D6^A-U.C_Y7-0C6-T>C*>[HE20?Q*L%
M\9FN.6\Y-M]HW2:>DO7@B.DC6SYR2Z8G\7[L<@A!@Z.]V**NQ\TY>,J5F?4$
M9^M_U\ALOO[R@YLV,Q8J=B&Y:4XY<5 E7@4QK8<TLVH)F@85\ODY.V?KT3TF
M"Y1,EGGI*\ PPI,/^3H)(G<P7"+[U_9?D9G))MH$32H5I;O1.3V<3.KR08EJ
MK%PVC+BQ;+AAE5%@+FOMFOUZ(@#8F><QHSGA-=>5NK>1[\C36"\ S)#OI*#]
M6#Q\%U9+/G8?($K;X0Y*O5 Q\HMH1S,@2S=9(O>68D02DS)*5-R=)H:Q#'GQ
M/S\7@W6!;A[,KU>8N<4<%.I@89B+/1:LD*%)DQG?_HX.,@J[9LRPO3QL6\!)
MY*+@D!GZZFKQ!5W-]? YFV127\6.0!6HZ@HAT9DOT:Q977>5X_;G <[R[,%C
MQ>&WVN*_"D.L;WVN?P9]W;I<>_552.*[E_*8G%0EA 5>W##"ETF9DFY<E?>[
M'G6DV4OK\<8'4.G+D4LV#4)>J#M>$Q-\%I].[95-?K1JG;+*M^2MRE%C+YFO
M>6:TFL7,='>93].YCT2=ONT&0$*LB&P837\SZ9U(<Z"A^1UVW7WDW-5OVL_;
M1%/W9-XF0_E3 M5\.7T!-GDV^D\PWX3U3]B& :+A\%B=5[*!T\3!^^'EQ?>_
M&2_(KD@PH2LOACC&T8<W  N_I@!/)A.+O?>P5HIK-%XDNF1L'86G/XDH>WE:
MWYNIY2KQ!R8J]XV[TV?7J ;00)H;-S[=YLBJ67U_*SLY\I^6-GA2PIGO]'W4
MXESO H2^YGW&JL@CU3GNPM#(AA *-8G:I;K]J/JJ>ZUE%;-G 2VHA82?PSF(
MBW+E?/=X#^IZ;9!9/R9ZI/M%5S4=E')"SO!^BO!QGA-I,ZELHG3UGLLG0T;)
MB:S!,?5V]ZCGJL$ZQ?1GZD5HW^CCTVA^QUNNSW/%_QGY$T(!I8;[50R+5#ET
MGX-[K?43-.E34:GJO>TV&NH ZU5Y :ZCD_2)XV12Q?)-@^S0U*A8,=5I?)U+
M&^I0I>B^]\/'<]$\ESF31^/-0-I+6MQ(?,N]0C\EW:1U,VXUB!ZDWHKGZL^N
MSE"2$M^J"\C6AWV[-/-"@:"G/N$-(35R25O2PY,%\Q5XK26CQ_U*=8J3N"EI
M,,1,(U5L-X %H,AI\M.)&X"3*_4-P([ VHE*_N0ZH3DE!PS!"JEI_0ST9Y&(
MK,S9(]E[=/:?EC"M;*QM;W4P7BJ^$'?P"2YQ7 _YRQW+^]X8&^%1 Z YDN$*
M:^;WI)#7IN_>N@V]*,0"A="C!:=, QV'AGR.!G#L5 *#%)\0GI,$M!GY7WH:
M\3O(=WQF1YY8]S55?$=#LN>]8AJP-MGT\-V:OKNQ/&\>WGO+3(?YW_0-!9DJ
MP>;$/D>?1(W"053),;K&IGUE5TC$28/QMS-^<)W#7,F17+7@ZX>B+G,-ZT/V
M?@,GQ;B>L.,*(3'=^BPS^41XD2_+ GI]6B#:)AG03S9(YJ(>'?S?1F["<8#%
M'W8%11Q9*]V$M]F[832X?'^UU3AUWURCU+%$T.PUU>!>BB&3O("8%N'.UTTQ
M1YK-S//Z**\]F1D-2UNWQN;Z!D%+#=\B&_B9M%G9AF5^EO3XS&=IBR-J/X65
MX^@$.1VO3Z/>SB!F!41DWE5O;&$SA#3U_Q#UEE%1<-_[]T@J*4JGDBHE+3"
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MX-GK#YGO ;,-CL2N\+^ ;W9 -=]<?:,PWAB-A++'R,6KQ)^%FA[ZSI_%H%N
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M#W.^7=@^TSJOO%<FF&H@@*ON+#*-#:PD[[4S]9"P[5(@<O6UF=&Q];2HF71
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MFM2Y/-^J[]MP98Y</FT11C/W[/%%^B[SH<[KAO0G_%C_7(([<K!O"1SV7E=
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MG08%^5'!9%=O\]") 5D]^8;B)).J5;U7CP18^EX.ONJ^2\3YE=3XZ;&Z+:F
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M;?D&)9(^SKDVQNGB33TQU ^5H>1=:U^R7Z(E^K2L&'2O>+FIZ9_3&J\E&>Z
M&1,5$'S?OTQQX\J:<@630DB_V@,_6.=NGP\Y'F?&\46JYM)R9[*0LB1MK> ,
M=ZG;R\GFRWZ'Y>3'^Q:"BL'D:EPJ]G$?1/L+(#89(AYIOPD\I4OV25= 7WTD
M9[+!V,42DZ-A#1G8NF6"1G$JLE;;A,CP.^##+,78B%#'1IXF7@,GIH5;E^F=
M1MQ#J E0V"51T@UJG=_]HS9K&<+;?[_U_ZL>NEA>:=I(35\.2M:39!0:00:R
M;@+5(7/CXSMR;W"EIO)V-3NJ'R.[QG1U1%=.R^VQY5]=C4AT%G2WM<9[H/+
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MDX\1G4L)?B,GHJ"#^/Q#+;C\MI?$"NXN!F%EK@Q'N9GM76U-NQ(%.[<IR;I
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MY^KN_@D;D.2B+\%2_P,9J\?,RYI\MO)&&8CDDU9:E%JHT[:JJ!D51W3@[\I
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M+M]J_+4^&[P!F,.5%*VN/#60D#AEJH4:/#OV\X0J:K*E/84C[ ]$CH'G:SB
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MOR"_6%#:/"+X!Z'#/2P#V?0%0)=9^?/#!2L,! >W2FT7A2+%6 PF9ZVUUA3
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MA!UE:@*[P9SHJ><2'!$3X6?E[0FL.]19W,U]TCP<3%[V-D5+U,&VL"93Y 8
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M@,LN\Y)<O.N(,9P3]@MF.?)TU+'0O ]+U5XQIO?GS9IO>@+Z-"#QS^OO[,Y
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MC)/'JA2X?I&N@L; @,#8FKP69K%[+[XL\\8%!QFNHCXP:Q2)RE1=^]/JN-X
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M.&X_"6I/Z%7F S-^'Q7+&*J%3&LOU4=BK]0T7+MKE3&G.C2NM?4KR9.? ++
M-R:W>6).M:N$\)K]E=D6,859VNW-'6-;J0Z&T(KKF6;1HCR_LN]=E^8+9#!$
MFUK_*4XO^4QNGX:7K<GE"_ZTV^!)!HS:*Q++9V.,U^U9<:&8X89&O,X G-5_
M6P7BG[\](ZT4[)D1,^->M;U<[Q+'PK"B-F+X+)-IW;Z\9)TD&=/'C>)-KBF9
M7V-D^;[EOH^*Q[*G1O[B>0WB64N8SD5I;TZN=H@176H(GM6N(3S?#I"L4+6A
M0/99R[4 _+!$!NVHBMZB\-G[3HG^&U/Z-TX+B9<^$(S!*&5Z3XUK'<!FKI"J
MZ-JGWQ:LA[Y6\3M?2ENYL5[KO'T2/8?*#<K'BN=@P.@>RRG_$QDO:T@X5^.$
MWQ?I?</!WCQH0DSVJH,..S.7E FJ.DSJ!6I?$VJ(;XC#>_;E 2>KVA3+";UN
M(=%IF<,:QV'%O+[H]5]S.A=E>I$=3QT+4GVT[DF@=351&[+Z'8U$EH Q,@"B
M27O4F^V14.$:+H)[>UR-+YT+BC&"6LI9W?_\.26]_O"*>TI],@MG"@:)GKV!
MIPF_V);5O2 ]KB3'-J<-+=D,B<Y+@"BEO[VA*IHXB!0Y^XHYN"^8;MMI>38E
MR9[*!<><^V'#VC@Z,\S>W4U3S<]*%HVV@5K*3+W4J.I8'?*)B+K]><2&8Q1
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M."YW+S=X[RKKB(C!^3,WZ!B$'1,3T]0B::<QHV[F#$F2873&=U2>CRC.$LF
MO*D[J_836P?J82JAWQTF/80S@]RM!G*DO;?9%!"FW$-WETL/#JK5/).U.!I/
MU/@2?GN(CXVTN3M,R-J[5AZFB69P*8QEHKL>1CA+WJ")OQY*I[ 6N-&T'1^F
MSY\@^CC:JT<D0)N8I.Y5\%U6U6/K^>V*E-'VX*PXI.LB+<&XS[HLQH.Y,>P#
MY FH4;]XS:+QBV<[3:P )NX56S&_2U/U1%>'TEC')8*-,9XE!E$T61=V$Z2R
ML'+53.W'\QZ -LT%;4#D.>'<W#J&'!OX#*F.<[-/_=JF'F9SV/C=,?.\H56(
M1RNT NP6T(#U5+S7Q#7QYI*?W8I2^@]GP+6>ZCMI5)\EA)X5O52? FQ<R1E
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M99=BDM"WZ[-L$C^MWM=\._/[+8Z['PHO":7SZ7EG>Q3N4@0B4J<>&.Z"5\D
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M"?5]O&!SV3#">M[*SKHD_<O%AKH8F7-6Z/F'36*!'M+0D@F_F38CO,-24L9
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M$JIARN\-*VTWN6H&I''KU@+;A#A''J-AQGL?;M,LO<6V6W?H$S)*!S'MT.7
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M^F[*&\MPSFEX]]?3.G6B$"$$M*.V2/1)NG%"FX@:&,!:;!>J46Z'D@'/I\F
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M5OVWJI?+.5G\G7!O<$?K@+K,;:F-$BC%@%CYKAY[*X>48]_X#OW_G1>IDX9
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MF9:_,=0\,FZB+:*!K4PO+(R_3/V/OX3H5M8'^BVN)4<&?-1<)<6&-/YCG?@
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M7VRVZ7)P4?!A__GJE7^%6.J_HI"8P@#G7]#_W\%9R/>-YK^K,IW8%M,3RS/
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M0GZ'T2%A_I\BS 6;US1<FM:9ESX#?!)?-HWZ/0C.)#^U#4]@\QJ&2U2@X#-
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MBB/=EET@NVRR).S>0]+$9E;^ BQ\7+)%PW&D>UICMK-6.!]\B-(I+R$/Z_$
M/"KHB>&O#*5V3:H47TTF,M*/J -/4/!O.<1^9-Y_))8_#Y$GSAC0XF3"/U)D
M5N%1V,W*9!/L\L<WF&*K\O']Z+:R<M"8X,(0QW ICC/0C-^'&2+(STTIXG]U
M 5 G2^Q8176JE0+K4*TBSWY2329H8O60OI4R?)*!E>L6E4CPV^*/+M*&1_F-
M[:QFL"$MH[&*D4+1?[IC&I0)W*4)*;.E&CO/O;/$#&;;<.J9G9O?FM*E01/(
MA0M;MDF&5&%6/B>*61707ZXW]AI-7F<L27A=[/@@-QCU!6T"]N)!<6(_,L%_
MKMCDZ+6[IZID=.6S!E^?#')/#[(4/HC_&)Y%;MW.9J_87B=)5(;D$L?EMSC.
M "UQF#T6H@000B"MF8F<XD,<COJ_3?AW7LZGZW[^_)A1Y@YG8=HIL(3:Q;(M
MI(-+NL$4>;F6P$?*C1IUSMI<,9_%!0F/46@;].(DCC ]2TAVSK>!50\9BD^&
MKBH%KV9.,2P]?W@2N<%1R"BKN&XTC>>-<T7,HW5FDH]\_E1X"/]S 26&G]\8
M_[ML:.B<SV?#6,$WZCFPS>HY$Q-ZDS!7V>EK'7$) T=8X43ZK^ ;I781JFWD
MD=*JGM]8<ZXP<DPV8"T_96"7(C*LXS;WJPU44BD2GP_<\>[I^F43L* 44+ :
M="\K(KQ@=J?@TK;'.8MHG6,2]!N37\\QF8RDZUNC]Z(:*6L9V2J5?V1SBNUX
M"V'#\5<#S"RTA&T>S)@&\-B+#$8OCYPV+_JLP A%N;#4MFI$Z%['&Q1743VF
M+^<,8 [F=4^I40DQ#: ELPYN7&#FLNP@35HN'7$),5.O'G:!W)A_T3!0FBBL
MUO J\E:D>H=OZTJMR5>W#H*JSE7IB:(9I_Y,X1"QP4MH3] =]EWRVF6NWYKI
M&U%QV+Z9UFDV.U?6;41E312E81Z55::_,)LT.KA/DB%BE6409<\':HNEM7[C
M+E]2_,!RZ"\2:90%'=PP1;>+9%:_6*+6O12DL+K-"0GLFZO /;3GT#1R-@YE
MP@3>2*4_KI!%+%' B,(0312&KW0JL6Q!61/Z&O)^V0(QD9\V)_= /6T;(6RS
M)P74*(<-IA WLZ&4=KC7<&E5:8"<J)M=$^+:8_'X-0V+G?R0[*MW[+LR;UQ[
MR7GX.@V3AKI+E18YJ9*.7BVI"+G5.FAM8ALYJ/389EDLZ&ZRA02S4:&]4W(4
M(_*M"=-JC^*)0H%H!>%U16(_XRGJ7&_Q8<L3?\N__H._M W!8W"1(L$R9!:[
M."SC['<_[B'-:;;-;,U[8?32$3R;Y]5%U],9">"A0>6*^>@>,+!Z?3P/=4OW
MN-=[''QH8";M*36.YHX\33MMI/5,*=2#KRDR.AAWGDO8! >B]G=MQZM!SQGO
MG/#%S@!'!R/8Y&/2OX1.Z>FF[U:!?P1<M&17N)YU[''&!!KF\]AO!>8W!Y(,
M$AJX^5G,]R%"PC,RF+:2=]MIT\#,>A!D1*5#(<7N<=DWH9=#Y$"P2I=JL^,P
M!X&) T^PEUB? 8@&:?^<!,\ ;)^WB:9BBJBSS5#GX0XE6H=\^7=^B33)<JPS
M=8@F! V<!CG9>QH:E@X^MO@61YV G52TTF9-BY?]FD9=E');)09YE]51AM6R
MQ>OV$/["X4]KIMZ1Z(*RVX4Z?GK;92">CYM!CBU/&N)KS&3>SXF3X<>0)N>3
M0H,1:$$DJ2&EV@U[Q&(L<OG)E,10[&_KT2<&:OXY\Y=K>+)DI+)U()>L6-80
M/R?I6V9D8&0P;(?E^7[O"I?OES4K2.0?VA5+G_2\WWWL<U^^-VV("X)\@YD]
M+5(?VV<U>UPT/ A.&1?,K*B8="+%ISQ37;>.U[RRF\X!K_4PQ68D?(N"Y,*K
M5E.-V1*)K3C:5"$2AZ/?Y&_OHO(/[Z);-R$_U4Z.H3\#F R;#EN,NJ@AY^ZC
MWU#X)O=ZS]]P1P>'MU9PM)^4D=W5V2^(^B&'RYT#8A$MQP+SA,88><]C+X;\
MF',?RSNM<^1(<VZ&-;5^)\41&\0-JSC/U@W,K[4(=3?A9/OU[U,6*GHCDNR3
MCJZ<-#AJ/E167DQ7>T#=%K( AYBC2O83VA;K2/^Y/=C<;,=;E6#X^3:O&@,)
MS9T+W*[DTC-8G93:JL]@976=$3F*U+48T5X'^H"#^,_HB;M:7'9&M[_FL]N;
MQ":M:'BXG1MF#T]0V/%?%/D"0=3V1'<5!M%C/R']NS%..TK:$%MSG*8RK?5_
MC)5?BG@;#C)>.[QE\"I_Q>/M3L?#ON[28OZN$E4%X\?+=4I8ZU'9,.H5R>/\
MF4'Q$(7M3=?B9E/>5&LAN:]<=SG)NKFX0X$?%S"*=,0)UV29:<>^,EY!?NZV
M_D;3YP[#7QWR#\8T6<XT$"_S>=SBHN:R2 1/KK%J61@-+/89SM-&/#0>NB0G
M@<IFG8T4TZAQ:^FE)V'5LW<*', *M@?(R69;QSDSM0>DCT!N3!.NK\#+XU@5
MXR_V;''=<[K]]G7+Y8&7P2Y(0R(O]7ISC%3]EA]$%]HOO#OHBRTX=X@-/<K
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M%BQ/*)[,$]!K#&< X*EU1&+Y0PYGWH@OCE< V&.LL7@:;J(7&^G)I8*EJC6
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M8[$M)O1OJX=K'^>L<NG%/Q[8?-).6I<[K3>M[JH?/O/EK=#-X"V2>-:+^F<
M/^CP5CW;VJC$,=17[LZ<OK@&4+>D<H#CZXQ[7L$-F%*S N-P*>P'*4F8P:$4
MW"1-8^XK7BHV8'Q8PF&-QL8G@K3FNX*#-X7R/&,_';)*!?["(1;1 1]8/2KI
M\KJ!E\9:?)CO9X*5M**.-7JW [X7A4#$OJ3IY2M5=]6X27<O]Y"[DK_X,5=G
M>.J>-L$W)0]>'YF0)[<('E*GK@->-?1E\YEZSZIDMJ(@, C7%LJF_^I: 4V?
M4DAVI=-SU[V:T\O8P<@AD_1 .O\?V?__A^,_^([V]ZDOW&AV[CK][[N/B"O!
M.S'L+<;4M2@"KS6;X+!S,DY#7.O6U,JN_EJ)RH%O>2BTY!>:$\@K$63V_A)#
M3WM"W+%3:+2/Y(=:H&1 E)$GK28$HGSKN411_(</'SY=W5K=UA9\%5=]<6$#
MOCR#8,<EMYK<+*/Q&QTO&U>?#:,S66,:&;8F\7_R(ZYM2.K'E-WUAX3%FL#=
M?E^9M#B:9B!966;8OBP?@0>6<: !,JAI" E-OG;+[9'46.QU+0'PU1L3.ZJ
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M?1JN55<\VE!B.]3"1.,CL,_X2BY1/$./:6O%;MXQ: (^+;2"DB,U>=HY>_I
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M3S3:NJ9H1RJ:15+Y8X)<JM>3YJ58+U.[TL?FS#'0KT<@A]!QGA"U'X8S)'T
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MYR7EN>68_3S#K#L#;>3O+[[MLMIR$WSW,#/EU(ZW]VB]D5](LW!8-7U6P0&
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M= LETI=<W9;[4+,#]F5J^=2QFYW*#JL/_J&8_(9WAA&_Q/^F:E<E(WG_!S(
M5HRR&?]5=HR(2A-+H+_(J]PO_L>34TU,;I53N+NP&1DG&15MLUQ$J)V#G$G[
MW'6Y/-*83?W%FOGK,S<YU?.*7UMIWQ]GQ#XHS%9;=/ (29*Q,$XV8;#;,JYV
M]#(4:C5JK6SG=6\@/SUL$33(S0#^[S)_K[ZT<>X < )_BS/FO7M38BQ3]^0
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M3R&:'$B:H;GW%]-OJTAC"[Q+5M"6LDO2M_/FR.Q!;_;I%R,%"C&71N1%<XV
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MNS5-#E5S^>UK])-/ ZGY],RTG9]"'\BQ7MVDJ7&ZDQ>F@1-$[S(2]]DP1L6
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M0P> NK8^^P. KS,J[P#P*O, \(T+@5./1.Q1K]*R[AH:$F9)D3 D:!B,' R
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M?.%S4QUS[)6B6X%> ,_TK?24/XGQ8\@Z^JY?PVPW1AP L@^CK>79 /8=YR_
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MG7;EK%>WBDWZ,*S5!F_1$0*RQB?U">4N;"\<OMWDW*48-X%!1^?\:4T92CB
M/1CVNAV ]7S-9M"]%S]-.YT^J2OP)US4OM]J1A/ 7>K($SK<OP!'T76> 1B]
M]@T\-6QKC1F;;@! P6]XG*-%DR&&RENY-4<?+ZI]#>4A:4V%\I,<)KX@AM\2
M@1;#^R6J.QPDHTE9%[Z1#_9VD+=7"(M]#CX7G$A@(G,YS(A0%.>GP<J R%X$
M@NVO_?G"^WG"LT*D,>+[!KOC3Y%3?6V_UE<I.-_/#:>Y-"1%9T3GB3W;W.QI
MM/&V7X7FA;AE<^<359,B$4.1>Z8&YTMZG*!B2ZL))(I)MR F?B7J&%;A?_$H
MK92XIQ^/O[._.QPMQ9N+L+@_R_NVCVL-K++8UL'$X9HC2@S 4E2;C5(+V#;C
M36'T_=MH=*F&L&FHGW[BT_,OK=._P=1/TQ?QAEOKI6N'9,&J&F+4-ZC_";"Q
M*<X>_?*=%([^SVRD_[.(OD5#]6"AW]M#GTERY2JQ,(D"L(#A6T@IMGDWP&NV
ME=IS:&G=01!?=)@SV?+$;T%"$[@H)<,$)/1D]Z!3 IV^917JT8>"KW=[LH4Z
M.)U?!H9#Q=Z"49K,^?.NH1>&]YL++@>X%>EY2N8_H[&>,&4:Y]EEFND[?#J*
MY":IX'\'H3_@EKA>^A;-SPU\!?K+'"7<?0OQJ9+H)'!11TP_6-EE=)1_#:]=
MC>-L;\/7&$:4#76V_,&>G#PZ [AE\1-/(#,M95G*Y#V7K#87+6AYA2%QJ)S8
MC.UM74QF<N5QGDQ;G&T&FYBN[%GM0HPRN5;V%A',RFN1W_.E-QNBJ8NTG3B[
M!./&8)?C%YZA^2J334#,BW\TGS?E!<H4,LW_B<1 /HC=)#5?FFW.GB[;B7.D
M(YDL001=Y=T$+M8.*VGQ/JP)=A2<W?A^G8/Y;J*B+$N$2-2(@X[,[BNH!\$L
M.\QQBL3L(_RP1[!6,*Z4S _%]/+0O-YO-1CJ5$&U(G,9R*6'@P2;9SO)'HS<
MGZ1@15SMOU<3&7265!)P!SJT;NJ8U[4EGJ#N=-LHW'O;T,J]7@[TI2_Z :ZL
M%U"W&:G: 7NC-5D4(GYCUEZ1B.3DP(>!B=]6NUG6BU?+ISC=L0P#)#5IA9RT
M44>8^N2VM@A)=/(!5V)RS,O^$]"A/,//W:YSHB,DN_S01[[)[RM<3O3T2F&J
M1&^LEH*Q"D]RP@Y.^NKH[P\E(*.3S#4%3[&;(E;G"3_B^9Z_6X3W8#A)1@2#
MTDHH1+<6WYM5ML&C,:]=)^RH,O,\E54(<:*-^?B6+S";R78%R4.B)8A%:VNZ
M'R?EU6/P$6XJG,<9T?E)C^WL-K0?VE],%A1*3%^0];!#%#PBRN!++(@A!*EN
MSJ;DSE:E[0-!%G?4ZU#%I-V)(A HZXU( OL9 '3$_2@Y[*[:NVDVF6;MC+S4
MN+^/%M('R+"]OW]NQ%@?X'LLF$Q)AWM&9F@6U&N[%&VT0D<?P9[ORUN^VVQL
M=<'H_"[#=7BW+*,CU&NU^XK[8;5K_8ZT#WJGVWVD,;'7S.ZF<%*+DQK[:A#G
M:YC-(H7MZO9/^E<G#Q@,+<E#8]N:[R >4YQ[M0H)XIZYSVPNW3"=6Z"V^^U(
M2[)9U))]-.J)DS[PE)=J%;2I?666_-V&9]+:TE5.)'&/JPSK_(-VX%/*C_Q,
M?OW^&ZO?^@CQG3Z\?CP)2(]=13"UC:DHK[_7\X3"W[HKAAF/.5<= MEGO 3J
ML/ KL@=P5A!J4UL0W_9&L8)CID]3W62,SB^V)O9'W#)]T=&-GQ^_?]_]\8!1
M8?W0?T $M7L+4<^I<#<?]]!XQ6#P\2T!-NF.1R]H%WU^]M&H79\RT#)A ($J
MAU_^V3G@;? H7;#?-5.X8"'PF^QHV]5$S%V,!]GS+-;II\H\Q> L&<[+WW6)
MN100'F?DB!83$X1:25$JCWXCE!HQL3(ES=N=&7%'9]9_MQ:A,NWQK?9&F,^C
M[%GS^@ N8?;NKL_@%-)UO+JU*_+:&,SO"S3X1/ZGD8!(-%VRY!7+WYR23^7U
MN'\+IC'Y C/%+3/TUK(GWGV%(@Q'ZTZE[K2,/ZZ?J-/_N.7QV\/XQ37:9R@-
M'/WE0T7<W2&+AA/NJK;HH6<1Y>?K>R%*P=](_;4G>_L56L0B_,I)GX#B<+DG
M[U:UV['IY\G,E Z.#'1(0OHJ]_E7RZK"N??;#_+6O32T8PK<FGK2J[SV9NRN
M=TLI5BH4OA!),DC2/XZQI%FW/$JV_6.UN!-."D*+Q%',:WIF4NP43TMF6HN_
M>TW9%\\PQ;W;HV\ZR_&KWKNS/D8TUU\HM-!H%WQUV,A8,DT]<6@=DT7]O'IC
M\>OM(U<'&QLO%:\[DLQW>QKD!"7^6*"9GINU3A]/AMQ&38*@A3FJ7QI\V<2W
MJ%(BTR4;-_Q+!#\KI@>]YGDM:L3]D;K%Q4<^^WN/]>/PH%=#H?G7D $CVH(;
MNX51 66NG 'UMH[Q#KN3X[W"4 ^XB2M"Q"$8YUB+Q#7_X!*C3BNS?]B!5#C1
MO&E;MC( N3^^WVIV*G81_=/>P":O@2: "R&?A_M3HPA[ K4;WM8)KMH!Q92Y
MZ);;SH&G,N755.K3\?-WLXS.J=E:W&8RK6Q;WG'0PX,ZR"(C)'._ *S$ 5-]
M66NW"FBQIVXN4;WZKH@"<I?=Z!;S[9)*H<=4<^LZNS8MYFLO960%C\CD^*(:
M@583PA(#,^D>6H GNQGLYN65T^,H+WWKJ[3ADPS3-C1-@=ZB#M]:CFH=.)L1
MCP%%6;'\D;]67?FS.MV\@7GN>2.#%["!K.2:P>RJGC#)@=(_+3T:[HYDE:YX
M3DA(/Y]=J3KT%+#S*)1S37TEC;&B<!V.RM2)D=DJDZF-)=WA6+$6-5,$1C$U
M]++= LA,6,?)\C?%C6)R41B8,7[[8X5^WKQC+4]"C4R+=VMM+H\!MP43PDUL
M$S=9"C7K4Q=,W$)MWFE5J?_)WK(C:C21%OVHV)DW@K]7W_<(I5Q2 L48AACH
MU*T?,[RS?Y.ORS./,>(1,@?R-PO;0)TB71Q";?N)*OD;MNR]N4[LR"KG15X0
M$!@B/V67]BQ'XN$ 2Y2:S/+K*U0-!Y8]G$GS>FA,[H9&^/EWX>I3:HLZ;P2X
M"6/J:[8MZJ^D@=H3]*5.D&8A>BKQX)M+Z(IU_Z;L%A7@5XQ>Z/;64U>9EL0W
M26RD@50MZ+'5:]>V2P<XP<6AB/(Z-3\3GS. V5BIAQ^# "L;B_YSX8=*+<'*
MZ=UOF#U_ :5!A@^XFC:T@@3U=_@''M1-E<J*6"\U."JU8*M4Q;>NA=VXS19N
M9"GDPO4G8]RERZ^"'AJM ZBJ'E6RT<SV N($;W_L;HCYX6QTPRR3MG=4H6DQ
M.>-#M?8#R<.8!<_;3 )$%[M)16!\(^XWX4)#(YJ_[/5Q7+][W\I)S@,DD^J?
M8&QR0$/K=E_=-$;OJTV''[5<]$N;*]7R+%^>.5N?4]TR</?<W'14UUMPC 5^
M)D(,JU-79G&HZPG'4>,(;F7;J"\T %(W7-G<G5&>MNN&V<"0(YZS2[TB!G?
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M6!5$DDKR*.=U0+ Y"O]SD'*1EU\H@D55$,7S_ZF(_5-P!C&;D(=9A,=JRA8
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M4-FKX%"=R8CM0^UKPZ&LQ+W.'&Z0#@N1CLS:/^^R2"G%$J?GZ82^@KE;-P)
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M@+T-[Y+1Q+6'@'ZR6\RG?-KA16$1J$&T$U(UK%86)8& TO44$1;K*Q@AW,,
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M-,TFLVSYR"(25R0UBJ[)2U\/[PJZ_GZ-N8VUP39,4#L?9FNG [4<*CUGWJ:
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MT==!L18H'B54>56VU5YF5L8GE:RQ"0-#68X\99Y<B1<3F)X^,8LLQMQ>O/K
M2D '%"M [*4IO 3O ?]<L+]Z=V#H8H*[+G$@T SH6\\2;JCH.N8B]&[%;8I-
MOG_GQ5JH_YN3%Y76R@\!N1PZZRM1O@T7\2.A*7XN)H=*#TMR, <61N(?91C>
MW)T# _O#@]7DY&C."+*O2UQ7ZE$6W% ]TEY<-VQ;&6\"D"9>AX"VK_]<6M84
M+@=OF#B#G1C=T<H8((+/\\N#>I3H&Y&"U)'B%3I5+#OHJ^['\MD[3I];4J:
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M:J7;@A\G7$.5[ZM0-NNZY5QM>M.^=)''PMFV(%5^:SX>X-#ZX!* 9P#OF<S
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M=S_("/NX"# MJBS+S]\PBAABUIU5:'R]C:H(AB--@9B@5==0PT&9 ; KS]+
M5&</366RU7GJ&\/*0I2? &>P/ O ,=DYLR^!TBS+6G3PX%D4.<H_"F\>W)*,
M*SHDK&XFC2B?>]=F$4L:8V'5)FVTDT]A)RJ[9.KU!7L5?YLL'+^+.7X7X*Q&
MRAYCK<$AP)?U$-"L'8L5.4BO-9@S1W+T9,Q\%E,<A-J9.7.^7,H5'N1HOA;O
M*/[M%J]]-N;J(W\B!4DCJ BF; Y(#A&83<Z8\[)4Z<F?N[D]X17*_#!2:CG8
MARSE4B!5_QWZVT[T"R;/N.V&W+W#;?'S\WU/6*,=8@-+2X:['([1),8%@&DL
M<(VRAX 7A2P'Z=)"EN.+X;.Y J20<.VJ,427"M[%-$;>C9W2D'.X=U>#5,FR
M9#-E5J2M84Z VGJZ6"!TAT?@XHJ6N2H%?\H;:^TH 71+='Q]187@)'E[O'Z/
M:$5WA?VZE54)#OX .CV*%=R&8:\Z 1==4>XXTH!# +D"_E*!2?3'I:$@<@NQ
M\0(KAV*;_>*WTX7'M4+ZQ(HN*##/V#AB4G\B(TW6N62_F/W9P^TMQ;6@K4/
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M6_NO DM ?A9X+PCP?^XFO)3C87',+.$'S6W?Q=@-+T:C>#$2PHN1,S6<H:#
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M--9,IY#2A85+XZ:>I=5VM17J>AV.\]F*<Q;&]\]\K02<5S[OF_ %JXI25A\
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M_:DJ=UYW<46.<LB#LMB[D6]$MI*)4=/9<Q%4&Y)%(8XPM2><O)4)'BC#JGL
M*OOK>?Z15;V@T9X3 !/8:J(K:D.XO^Q8HUE2"AJGB3Z739ZDSY2S4!T1D.\\
M%75EGFSSW>>/G]N\8?NE-A):%4!K=%[S#$LAXFSJ5\0)@&*S?!.L-;+'].Z:
M):)&M,*UA:#%B4,A8D"%']GY?/-!&7:L2.TX!:&0L:[#RE8\@-5'"E!5O/'^
M.*F$3.*J0)18A1HIRC=1E40W-)AY[Q6:-N(Y!*: [#V#,5EN82Q?#D0XSTTD
MU6\X&-XU?. *L>9XI>K5?VFBH^9JN.2'S<Z FXIV?7XT6"[P14>02LZTW<$T
MURA,WHME*37'5(G,<.R*\@--\1AM+4Y;P0#?;N;1%>9<N.GHDC<+]9MTX<\&
M-VXIVIRQR>AF>'\V+4[8ZBGMBWO]B8#_[8\O2B$/]E$8[7D@1@&QC5&I+]X&
MEV##O5)L=PP[)FK#MR=&$-O[GNBKB,2LRKFC38O66$P:J9U=;8% :RAC%_4]
M8QT]4#G)@S=&S(*+ .2G8--!1W=?QIV>0<VJ <=KX1F>(V$,\><V.EGTU:4;
MBF10,PT,WR*4FKV7TN=93 W0'L59$3=$QM(J0S?,3 5CS"+%&V]07''1HVSF
MA])G3!BXX1!-KZ2]3P F2G3S7?74V-N8S/ECTKOHH-PY'HWS-J*>'G:9A[*3
M)I.^J=B.RG2GB#N".7+ABSL:]'L:SV0$:S!AJ*@&F1MU$8\0(]\,I6_;])GK
MJ)CKFDF73.I>0?:.#6'BM!(TR]"%U:FFMHP@ ]9*Y\?QB^6JT(--SQF&RYV@
M,4%VB^UD<?H]X,456A.:/K<IIGN!#F6;DN-2JC9T&<Z*J0^4^F6IJPMI0<MS
MRR_<C77GB5NFKJWMJT: E:L'1QJG/M)./2Y1>E+%\C4.,_K: "LWBM4^8H6R
M7Q"1* 19S.<4E(EO[Q"E;C'$>S40/F,F%7[3QFKL[1E61S2Y;B(PC%"8VV:R
M,R%%C!2DE0^G#UI4ON*/9^MB*DIBHE\@V:@=?6L1R<U'-UNT3Q>%((F_V>0P
MFT*TXF( $6W5'"A?\#??9?8<(Z A4U=YM[H;]8H9'@ZVV52=>]<6;B]<!%#Y
M@+'^3&$)R9GASXGI1'4YD3UMN'S;N$]9B.'EI7H?+H+@9HVHY!M.!)B=1E\&
M+ VREV+2IJ1H;#M^TV1\9Y-&_3@LJ/%N^/M+4E0F"4B-IP8:+X1/ "'["9*!
M&Y#Y4+/XO?2QUZ <]L [,,]+N1*]!@7SVV.CJNB%9)%8-?QV23VEA;;&LFQ@
MXGQ'I>@M1#_(_&6 *OA*B7CZNWU<'=J%?[E L>&5N@^)NZO,6=1T\=P[;D-C
MZQ:Q:=YJ2%CFXMXG!%E8&;F_^1U-H0L=#(>?\K*Z;])OEHC:NS$4T6.TC]17
M3@ T;L!SMK2):DLIX)#"C'([G@I3T9;XX<*8C#9M:(!0S+C"09%U#*Q]"HX0
M_*[;6\=P_ H^QSCJQVA[<[V6..B;>%F$P;3XD\27,7J?\F_E]FY-Z>B?\YJL
ME3M*2Q"*C*?C\9[\EE,GB2'Q,9P(P:I9<^KX@!IK0\VV%U/#+82"X"^I)R_,
MNJHES-<_G45M1G[B"GFOQOZM8V'J=<;7._:TBDX)"]J<!-U/I1(/UYM32KE"
M8%2H$\#=X@'8)\5=U<3&'G)=-3H74P4[(G_L#-_64V+!+$W*-UP<_A45VS@
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M9W@UA0<ZB]EY+2^J+ST<(GN\+V*M.<B?A<F=VU2X8E52V;]'?S6II'U77T@
MR0$_6A@N\&P<P&_54,?84=+CE(PWA6<+!VM4X^68'=7]UM*[VUPZX4%AD<W
MRP@'@:83P'E;@YU5,<D:O8:K7Z(-)6_H]9.6"CX" &ZLIF2+A"(UPBA2UQBS
MX]*E<3%IB!MYMJ1/<AP29?-O*\K-E$A<GHAI(G,$:>$D,9ZN>3 9-%TP2!JD
M$[O^I-=)^/O;4J/\1WIC#"]I.2]'WPX@IHG(A?&.EBN.;*9H#\X-8)7-$O3]
M'=ZE>"LP"X7HU9-R/F#'?G[5X*C2PHQ>/Q1T*1VN#*@F9J\J4&T;O8^5DZ$K
M'9BOOCEN,&UDK.8=O:&2F7CS,DGL!BB(*UM[KS!RO6G?,S$S*YWM[91!KMZ+
MR?:0,\Q;L@V&.")R9^^VIJ3UJ!=PU*L)N32CMJL1[^+(;P]]:B9@*&0N$R+<
MB:?Z[BZGT&I?U-)+++V4;@.2@^Q'R$S[U+[D56PW,RM5OGBS,_QV,4.#^/I#
M.U;0@%M2AHH37X"2R\@H_\XKF[OCY1UG/-ZU==W_RA(JK<C3F8610-XH/P\3
M<_6QGV8Y 3S7->CG*]K<G.@)VZ0<][+2-"5KN%SCBWP>>\M_! (FV?,8Y1C>
M*[C;NC2[7C^^(P^Q[V#MW1@IV0E:?N0=S.O;*C6X%+5W B#C4?U^ @B6G#)%
M*@6Y,1!YUG27:;Y\H1"JXND>Y]?XX7U\^POYSR .UH!0'"?FT;0TM]+()HEM
M"&>IS0STS05"Z,1;?GW%^5;E)<1Z$YS0'7Y.U3IG-7&X8*3(4OBCK#NIE4V@
M?P1[ ,6K)L<[0;?J0:4JGV=:*X-Q-.LFY/4EM?WE/@S78L<*]CA\K+X4=CMS
M;G)REY"G" ]$9,1$O,4B"FU. *:H!@B3##NF/ U2!T2K;:6XTV;ZID(.Z';T
M'6W&%4+UWE)*,!C7)K QZXS4(Y7ZW4W)#,X3I>L-,7:_K@ A#'IEYM:_L,$_
MYW49SEZKS%$I4LG%Q$IU;'^35E50#27:D3AZ>.=./JMF:)E21,R'(O#3;V &
MB*?8-!N*<P155JRWMBW=1.:W=<O<D]YBL[K/3_@P0;9TS0[SK&5<(Y"C(D&G
MUI#4:V$G'FEI3EEIMAV1N_?H[./U9$E)L1<(L8P3@)61T?BZJ_"%7,[0A5;D
MA272\*U'.N=6;@I5@X:W::&.<&J]S!=KHP:62;'\@:_E.-'12O$L_E^E[T9,
M^=-TKJ60;=MO(2@@<W%9JW5 U-3H..W(G&6LXKEI*$F>(VYCL<3%17K5]?J6
ME%%2$Y@FQ718V#U!R8<%:*)BJCQD,&<T^=QXO>ZFC!IZRWT!A=@$Z:8*^VM5
M&KF:0&:W VNR_#WGNGPV=4:V[Z"^N+1DRI-7JX1<?Q3RI27DZA7>E.N'H5-M
M=[<<0-*0[!E3$[GE"]OGA=[P/W9O[Q'-$]0^ 3SUUT@\.IO_I(X$,TP<XN#
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MAMASK%K^:C*IG92#M6&( KML;!-I1@HH0"7)_OU';=Z;*FO<49$G  B+N@8
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MCHRBL_F2I!D**M)!$>B2<IA\^H*=/_KTT-@D=Y8>.[PT+AW':*ABU*Q$2EU
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M)1J,I:OV7S'EUI2]SS$U<"^:2:0/4G\6JT%>5^KNF3/>^\&8A54YWJXK[+F
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MD[YK_)3*4-F9IE];+@-!-[UN;T:O&UA:XN5]*5$!B>,O[]TU]"$OG>^%8&Y
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M]%/X*^N#]4%N1B)F4B_O<HB#\TBQ+1HY^18R6_KI@//)04;T2+9J1[H^7[&
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M1.W:V#>O8S&,QODXG<GI()Y%Y(**FC-F9_73=IO2<MIK;32/J_!I.E:3#IY
M_.)-75\>-8\>:1=9'-FW#>H)KSS7T1SNO +I&U_2O-W]R:1/P% F.]7R9"1S
MPHF>WN/4VG=IYM%7#@4Y'P&-?+2?6;6X<6 R)2>".1S*GM%I<N.$(YUD>#+L
M'/!!;H)%"7+#'KRFT5.IVH)(75DCT8Q8;(O(M-PS +$HOO+?5-.53P/?;02#
M7+B9H &HYX&[=M&?YAGH-IUV .OUK*/@'4CJWN>(I[6#2;WOW=2;;;_'$0M,
M=0"<CR/*;"5A/X92U[5.])JS>EV<+**;16:S+2$>[#WVTYVV<FZ!]U_LUM,
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M8NX]HYK<NG;A6%&J($5J4)I*DPY2HB)-I"J]1$&D@W200"@*T@4$% 14JD)
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M*$O2#(84RAB[B1*!90,?<N\P@-$IN&\T"H%^RZ"T'X>AGYNG1:.& J<Q-RP
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M+!T<G()>&B(-VC#7/S=;[)K9EI)Z#V:P3O[#2$+3/,M7_S"2D&<X=T;M/Z3
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M .->ZUS_UZWY;LK8+S8RPOVL<]Q%U^JKSV.,JU#B=O:\_&0#F!(]#=A<N/O
M3?5W3_FI5G<</68CSD"(/E4JF4[O*F<E? YIRK_Q-2+N@C\P[O@C_L,[(OB<
MDI2R",D, 1)21^='ZD#KPM#0O1TP=!)UP"-W/E_O:(;<P:K98A34/MV/UNO?
M9(2=U531;MN])7#:])5)+*MBE)BF:,?."2O[ #R Q$:&H3ZKJ&KU;?9B?.,$
MLHC7X&[,@[+RA';%_CPMK2.:XOV7,P$745F'\V%^V4CC[P[@*Z'9S*N_OBO1
MG*V/';HQ:.QIQ#?=2-3( AP0;O>E^1S3\"R7[7PM8DD@.?-\[.TS'C"8SK87
MF!)+I(UNJIA6.VMM^]X0,2;ZWD7J*&IL95;IW;J6"24K!<.,S4[%(![PAX.!
M?[JB##(Q+KGD26V+(]Y_-W%3Q:T1\24HO6?KV5:"0=A-)'?V^[--;#*W+Q*;
MR(LW.8WG\\/-)DX98:-1JD64U05EF.T7"&T8<V7;!:T'#SQ,-#,>A)ZC&O63
M=TBJXO^WK1W?E!5D6WX-#YEDK. GOQ9W%9;^&KW0,UJJY:$M=9.^'*"HKN*4
M=!8K8?YV[\1'K)F3<,2#^%,]=G;W6:5\WPJTLK(#7T9UMBQ:#?W;3CMR3C4R
MYW'=,E>+L4\_+":=*2[?D(\TS9AG*&1(JU0RYZBT>Z=<FA[4OM=Q>KVY(^4<
M4?S6OMLV%#>$8:_F[(,8Y;B#&N*?9HM^;1P*'*<)T1!XK^46;#%S;?'TD?Z3
M32?=:3X=AMKM6Z@W"*'6_ -C=S/UYMMFU\$.!>BUFGC[>N#Q^6KJGH:)$7V5
M?'V#_;=?6O,43B24[9UP#EPPI/L7@P8>,*_0U$+_#5RWR;>#)^%3\E@0#I(+
M1SL<,MG?&>?-_\YK;5\'5I?G B2#>-DCZ6E19RJFV4T=5X\_<)FAW,KE1?,O
MX\:/132^MY^&4X.3J0K[1EM=.#Y4B@E>>%L6E.)[JX6&CKXMU/F@Z=? D>,!
MR=P$L#..XP&814(WA)4\W-W^8/</-J#(;FS%MD/?GE8FR0Q&+4@X!!G&R7M6
MJ_1C6="# 5O3B4)5?=%ZW+I:HNC'#<;CKIO[='(%Z-4(TS3+3[RPIZ&G;>V/
MDK-]OZ+'$/JS,O^(SN^5V3%0('H:Y.,ZSHG13D$Q\S?*L**?XF"VS.F9PI?>
MWJT.EZXE"6+SRGG;MG8#%KY'*G8+RQ?/W\!_<E2WT=Y\<HW(0M/RJTQ2:-/-
MTN?OA,,B]\XT4*HZ0A:$U@I^5"JO7PODR0U<X%^"BT[4D.MHQNL8WK@&$H.*
MD)F(IOQ:OG>FD==EJ2EO5(/;'-8;RKH\.+.PT]N>GRK=QZ]$+:GW+Z=CI(L3
M;9U$7F<R_'%S3E'$0=]EBI/ZX<^#: (GUWX)YKL62,?0P84ZE?]VH8Z*(?#?
ML'TSL3^8/>S%EW.Y9PE990:CDQVL9K;26(Q3$7M2*/?I\S7?.W>#>(W'N5Z8
M?W;6,ZL%;GP*KZO@QVI4'Z)@;8_)^  $:C]@L?8=%7&,B\+=9S"@Y6BWJ0F
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M7XLA:]G).#18L0='BW07;%$P^:B/E-U_:VD7V;)Q_6.ST,5S#\>#1V?SM_
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M@4UX0*'W^ZF12MO,!18*AJ$G>^1++/#WQ:GG$W6O,S?4C3.'S>YHW,IV$WR
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M]JK$T$:C&%=.DE29S#4PS,9D6KD*M-OE<U1]^$!IQ\5R1^!4:O;(G>@)ZF[
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MT\6&.RI@D#$%ZPZ64GN[9'REN,=%K'>%G]>T6%D3L_IJQ8C]Z.VIN!9(\G:
MY&>GYJ_PG;-MN_%N$U0P9SP@*-[M"4LO6'!]N'U[.>+2PPORX4PNXPLGZG<)
M#1""IG]D293A:>40[="C[N."2M11;'Z9F#P=34\:5O^%X V5.Y-6B_%%V^6(
MSAECUCC=0"T_W;D7!O+G+P;1!WKWD@HLF_;'F0C$KVQ1D#2CDLD7&<2>397
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M#']M K*;_%2?;OC2S7Z3>!.S$EP?712CSYW/-I W?%Z=SA-_QBD%1]^\'4W
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ML2/&$!O6F]6H$QMY6WJ%ZLC)ZT7KL519#*GODRY?DL/R_6!F3NU=]'B%@17
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MTC?02W@W_/&I"=G;15.OA7'IT1[8*ZS<&2"U1P8O$W9&.)6O#O69.2*IRV<
MB@;S+3D$955IBEK%MV_5*-KQMQGQ#WK95'F:>VY=!WS9[6<@_M*FAMK97/DZ
MBU%MOV]8DFKI09<-A[AZ$;C82FK7C9B:15\ML:U46\IZ,R5KDHRK+SSU1U/C
M@E@(SP!7JF _1:-.R!' 4S)#X!^[IT<?T0L@QH$$."Y,,Y^K$67/0AY# 93
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M%$"$VJDA-?I>@B0_2HTH9CLR58&3%TYC&B=UEEV8ZA\F:RR:V'\WC5.5C1]
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MJ^$XD2[H[?=+<4P>UAHYOG+I#Y&3"N6O;Q?J.VFB3$[/;=H<-!=9H$1:S^^
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M76W:Q"0V'":2F0$F8;-7LV%;RL>K%?/>U=\%HS2($2_!/V.#XT K9KC(JP1
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MN!"G]03RI =J(1VR)4=?!W[@:1G=E8;H_P836=VDRZ)R) # VXJPP]>UWL
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M6NY!&0B =PTS8-R%W ;L.L G3.+E*;75X&W@/\2D$P"![[$"!( RK!&&O6L
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M;:WZ)G<K>WL> <'L-R#\NZ0V[K+^5[!(!=Y^5UN#9TV;*3@D@N 8 3"K:44
M=-C^FSSO8.ZG1INR9.*']QD:@AQ%=A,UABOKRN-T:>W*"QY&V#78>YE71E:?
MM"*?^B9-6EX&0KC.U.T^[RV&6J*$B+U6Y1R\==0H(C*L9:].V=NJONA WF#)
M*4,97=*$'%Y.4(17X.F<P"$FLKJ11(HP&-3< (U7+FO$=V2TQ"5Z6GQ:A]GU
M,O6,:>+#<O15K7*[T_2=GS&.\(91WA@(?7S\3)P'$D">GI+(\,DVA4-> >GD
M>FUPY[6$P$&8V8VG1F'($G-V1E<(K888NV-76!Q9$F9FKEEXH_ZD<>(%\*P_
M]J)ZKKN)QMW2 ^N\=.-T!S_1!-M@.9I6-74]\.5P&78]HSRH-58IP]!KS@"U
MUPX^KHT,,U/3$%!.:6.%NK1_4C[_Y!AP*_^; ?R^/C(KOJ'X:=Q!S\K;PUPH
M4#+Z7":L+*W00;] R"9:*\*O_((PW:0X"0MLJIL5)3-%WKE0YC:-X&F1C0O.
MK54L1R2Q9@QGCGV,'3O.%GDL::+J!/(JLZ!+# =%/P/2E+822_]NW,M?P0CS
M&)5<)?F2\0W$:L$KY.;+LQ4E$1IGSMX.O!II86W1S3R4.:FG.3/-":5 F87*
M7\U#0)U0;!VYQMH>*,F2C)<6L0\H(Q^R]5AU2M]Y*+9$2NT_P%2"/Y#U8\,4
M?"J0/PLI6)&EKLK*7?;V*H\<C_]JHD@&F"J?BHPY[_>H%3"AGB-E5GI/RC#N
M9>F!$.=6NX(PAZR<GR%^/ &A4=.N'$RJ?/;)X0X'M19FN2*%+:%_QA%/7XQ"
M'Z;72C&$^G.:47YY#57*R/GR.4TTC'E#3NWTQYY*88I>]VWLT(S):%V>J29Z
MNFEPW-YG/KP>X8UF?%/$7Q;,/* $F;QUF,#8M'0WO/0P#:]S".U8&]L&KW[U
M"<M:IYC5>*.R_[ENAW%T-*[BY?MNVRX'=XZT9]67&M".UB2I_:A%ACS4(G(A
M!*VH@=UY+T'I[8BLJ+0<%F+]DLPRDG#AC!2?OH"%M+Q>OZXKE 3>LE<MM+A^
M;-9/I:W4-X]$VT!>/3.[L+C*2NQ=C'G=9UZ'NN*'3S.U_/A;4M@52;U<6Q6Y
M1L]BNV>\A27BWT8.:M/KKS_G?L*M/T3G-YD#'E52%7,>I;Y75K6QHQ?W#]H%
MH49 )V%+!5@@ 7#*000O=^]_1=D,\]-_"E#]!U=\(@.FX0?C?,;:'0I.&U(Q
M;JJ7C^3O'+Q_6PFKT)^8,"I1]Y6ZIU^[N_7PX:./5Q4$E%K!9=8O"0!R8(A[
M >5GLQ5$;(P5Q-7.@2];IUI*$(V07I3CO,Z3)"G3P5U9L X?GYDP:IYFD^>)
M*1]U$CZG?<9NE>^C/7&=E(HX5)H-E*41.(MS0F6IHXCT4GO6' V?'<&\J*[+
M3'L_30 X+^N>D\[C#;=-H[VF^GJ35XV2_;XSAM0O;4W$NEIL&,=V<-/+8TZU
MVL00C_3ME;I1.P(1B=-TL#45T*5T+9.J(I5\F,5_^MZZX+'V8/R0*3T3PBII
M=+\NKW>GO).[JN@\*N0E-,<ZTC6&3NKB)7UJ_6.]WN"@ CS "]:XO_F,:2[N
MR?R NUI]SS4'V9MW<T]VV4[IG,V8S+T5U\_Y==$#Q(FC*,'F^<XY0,*2CZMO
MUF96E<49#,[SI85\O!,MQL)C\O;1!Y_0/1F9Z2VR$K,^'_<4(G*,-IG59Y=Z
MM[HY1GI#S-3M5VTP(5X]T<H+R13W[CR2GF/I9] A &S[J93>3=A'Z:^*&DW+
MYK^.UB^%O,]1&:3@.JUR]X$8W<1#T21GEJWE6N4#A2]VZ'%CJ"/JV2?RLHQH
M_,40P*!Z]D?+9..@V3C7#YB6I$6&-Q\<IDG=NT&GJ;0Q+U"ZV=E>?AD:1C5?
MM%5CP>?4!EC!O%'QAX,T!( 7.T;.=@&_] U<Z]/0V@"/563#ZLTV,"U+>= 8
M88,7^@38\AZ6TJBRM_38\;%?HJ2KL0A7MK8%EXYD9#UV6X>T[KLWFQJW^?K-
M+Y4/3KX=REL@]HW22U>LG@]9/@5+LM^7N%J L\;2(C7O-H_%I3#7GM9K&:,S
M,9J T]GAC:,4:LN_N6^+-M_$DK"G..J]7I&</E8@+^?PULA_0)%MJ+3M$UE@
M?MK3U@1SAQP^#\MK/:V9),4<E9.59*/AUM5DW+YUQ.G4D'/1^T#52Z7%..3&
M:_OS!^L\E5626EPEOJ^ QWO/SAH\87^DXMW&"EX'S7(\F-:IBK W=(I-S,@O
MXQM->X#JX(MFI.U[MM7T47)@+UQ6+QH[T9H"J-5,]PK@Q_;.',2-2/"/GJLP
M8UA&>P]2 HLZJ-<[["_F.E)?9CFVG# '9<J#BHSA).8$8!PX".I6U9A0Z;KB
M!/[B&V%OH;RUEUZ//ES7OUP3S<E\27Z7BWU_O%5&=AND#Y7!ODG':98,9PWQ
M5#\I72TH^J+D#8Q%=\VG/WZH)J-.@R).WN3<->RG4)LGH/Y8H9E-ZHEE&*JJ
M'C3YNIN>5W8JWCZ(-YGG97.^8HKA$G#]-LKH=X88F<H5<J)=N???\,S-_\4,
M\/_!6/%_1?[_(;(@LE:. +AP$ZUW&+4*.Y3F\_UGMQCK3Z&L=9]M> %&W35C
ML*]G1%/'($W$\ RO+AU6J-8%;W"LOE>M\FQOM;2TM.'A?JPX_#_\HD[U[J"3
M1)[LIO:PT+NZPIJ7J95EE5?0O6P7]'3OMARG.,$I:C#UQP,SAX_-1>([P"0\
M.K=1L"9>D;U2M@>PR_'B! #6HN$);$<51X3OL\," H#6M$E9X-A< XJXI1TG
M );@6!!Q73LPPTO=A&-4L%1BLEG-X.-5*I\GW-B4 E>?;KEC"E3162&"4,I9
M#H=6GU?)NF\R#'K]Y/9569D<?6?T.LV*@T* S_ 7A<)V6$<R]EJ%.'9[K]OO
MFXPDV>6E%VO*NX@/O']HGG1^/"5V2&'YH$ZYX+IO/TZ4 &C,C236%*SQ&P%0
MY#]& (0-N_IW$E/FA)"(GN5_PF/']H#TDQ/IPNJ3K4=>X!COK&:SX 9ZB<]X
M>GM# N#%SD0WY 6CU LG(;<B)@RT:$(<?1->&\????85.DHTU!6.2C%$2Z:@
M-F<Y.EZXY\"8ZK/FNG/4IF\7*O$E9&%>"X;KIXB=KX3,WKGG,EAJ).KP&6-]
M&%%_XEW4-#F4.O61AM</HSP:BK4;C9:>E1/C!*5PH5WF]:%*$UF@JX2%UXO#
M..WQQU&Q):D.R>RHV&SDY])U4\W;=YC=F9^7#4=>RY1A?CUE:WZ:>C*0)"G2
M9#%$'$Z!.XFB+G&952Y&B5=42$; U_+$)S<J8W6"^<('U.[R;'RNM>"ECRB3
M6_\6M%NXB;78?&*VHR;_5_[8/E2GK&4<@&W+Z:960*=J22QLR+_PM?4%V;';
M*FB<:2S@'\)+0S5&2C_7@AVR.RSRB?!LUC[U1MMPT$(=W[YO7CN%05==O5AT
M3(V+(R3BL@-H;O$%U!M9$&C&S!77%BN)4'W&7_(I7S!C\)/B^X6I03MGEI8%
M[G67K8LH23<9Y [^?HT?T!V.4<52BD>I@IJUC\NU7W$W(?T4TWG"YNM< '#N
MMCVH.&[M, UQF$FL/KW'CGE[Z=8.8:<&Z%T+E5DNA,:>5<WF\LP7:)UF*(.0
MKDPS:H4Y9(RO."'#R)3*AI/'YI6\(59,"&%RKN[Y;ZVAD<U/(@02L4W(@C.&
MR_[2**:7[J^A6N(Y*:=6RA&EN@Y.YXW>F-"FQM"L=TH>C &LS)*>).B&KS^?
M_[R[!+:$/ZZXT4O6;';\YH<VYHY4Q*73U.326JF8C#B,&I:2\CHO5F-&K2>O
M^!*"*E7X,S_)UZ\S]!UO"\1"D#8O<^5EL@RQ]DY,+1758VT<=UN&C-\HW'S
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MO=/5\SX[]G1-C56]>>@TB?U> KCEWF$RLBK>7?/!PH#XN"=(U(VR,V$%J:P
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M</XB5"(UW!7/!'S<L.2)6L13$0]CB4O40RPE/@A&#9M!3!, (?GPWRX!?<:
MMN<A/^#WI _6/(MB.J3&LQ, 364-! "3ZO]"/< U!54)):Y[2@U!8)0346@;
M\=6408UF.W)85P* =)0 P)FXP7Y1>1[?44@ I C #G8:9J^P+_ZAS>T?]IB
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MATG>DZSGI7$NKGXE9TB_R.@U<H>/K<MB/D";5V\@95SREXKI^KMB[J[MFQ
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M'']S=1Q\U/::2LO+Z:?79ZXCSS["O#!T;3C'Z\L[V7K.$J.,+IKZ4?_)(EU
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M2D?HH%":[1N3 C[6=_,I>CS?'=_<TAO*7TI%%_G$8N]-%'OD8V%?.^(%FS*
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MZ9$*].=]YVR8X!D)5Z?ZPZ@11\?L^0'KSY4Z3AZ.#2_T^0--3G?W(R5VF3)
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M6;1WHA0H9.H$*M(5@PQ P<,]=MAZ(^I H/ %_ %OZ;P3MU69$G.:2_<_/??
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MS<V2WD^T W]^_39*GC$WS6RL!>QR;ZCU7JKP4]O(-U'C-UCG3.DOOILU[/0
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M"37M) :",$X3Y@1'_%75&U45M><@AUTF;]LX!#C(=7PP6@4\0$V34* '=.)
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M^/OIOS1\#*W=?D.*HX9C^4(GGG]RWOP*V=S :*&BP6B^&BQ>\MI%=/.-1B7
M[3R3_0QQWZXFN>?F9V612GQB^PD(1/I+2>6FZ.C-5%.C1V2P4YET'JSKE"WV
M@H0&;>P-FS+$EZ_!9<NNJXU/I]A$_43LY"-)J4CGNPF&0?UUB_P)<DP)L8Y1
MFB]B1ID!FHH2-:EJGK;2&X@@:O%.MRP+#G8+>60YP[&=KVZ4G+]+EQV_H;5@
M4U/,^R8C"PS_712*G?[SKO-'__!W6_*WBFC\L7(9>+W?4O*/S?Y8V/=_#/Z_
MTB L$C/U[9IM6.-*HBD%L-@DG/8G&L!=RON)UCA(ASCA'%,846O:P1%T[&$
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M7WQCM@?*QSG;KLQLW*Y2OJY_NC E^6II9RSM>QNW&_MZ12[1-K)UP9N]BHI
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MMDEZO3Q!&1X],R_RXY2D;5:&Q^8=;V6T1+1;?Y$P!SR<ZEXG&/<]FX1B-UT
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M7QT=WT9Q(%IG;5[<=-#UZ5K^F"LF]I(Y(<ABVK#_5,URZN]3_Y7A0GQ-=)L
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M#!\1]7@3=2[ I42X]$!VXHZWY<S/?D\=,61_VRP'=A)IB @L=LT%(D9W"\!
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M_>Z4;T^X6$*3F*6?)@BEOF *]!#"83+XXBN/-%HKI_55$#LHBY-*PMQ(#L-
MUZH%&=I53CH=:D 3:=8!:C1H5+\<.R7>9A3UNM%?SV7.K.T=H6_75BQ ^D]5
M(-Q,KY0%;:,O8],CT>I==/GC=Y*E:M(+D*ZK<XB-EK/*[0MZQBR5#R;/Y5Z-
MD'UF_J#BU*+%+R3,@\TN_JCC7DNMT1'"6()@VV_H14S$Q6\E]SOE[+@:%R2K
M<KH,0RVEAG_//0U_KRA+R.8,+X>1771M2SV]]-;+6##.:\;-*5P4VWG#B!'O
MEZOT^!LPO^'AQGIEX8B,8L-4@,5[;O_H@^I%SY7-HM4,!53/UJ\+:M*W;#S,
MH8YI>!52*M*4XE%"X]X)SE_3]KBS.LQYQT]3RQ)5ID_G+Y;?)+Y*[&1DY[=%
MP[!AKY.VR(/T!M\![%3B\&ZHQAW=^P0M2)!%;F8,&IDT)MM<-I4@GDR>*B4R
M$M[7@[^^)BSVT^HMT_A*(3-@(R&M=!,VK58PB#RR.0UWS&G#IJ8A<MFUMT8U
ML)]@4ZO.)9G6&O?"S]K*W._0NS?&EV.U5..7V'E**5=+W,<CK@4'54H9JH^6
M1KAU /RHZL11-+W3#)WV5KY)@;TA*3\*@S9[6J@:9:R1;Z&YY#7A$IK9VA6Y
MSHYI:R*\U8^_(X"X6=(O;Z $XJG7#-Y?9#XCYV'.F9U7Y'RC^,::2VSA13\E
MU]?HS09I+*0U3./CC>LW4%IMO%>YH3%T-\V&S3G  7S E9_\:U68@$I;G\$N
MZS/3FJ6H*#,TR^KZ=D1MXJB5'KFFGZ):+49>4[@C3*(TO4>J(U@",U7MC$NZ
M60ACS%CT*LO4( !J*XQ)I=N/-;MTC:7JABD;"OQ0$!,%_-Q6VA)<R\+WQ85)
MX_;"./ U7DUS/VU ,&\6X)95D7JTZD*;%G)>%:Y.$ TTC(4Q@(JN9\7\G\ U
M(IU0C,C8*URC/.'D-Y(D)F:*-F(J?FFOV,^O*]=_>ZYSH#?;T6 1&(-UJQGN
M&57% F<[RL_+0R"*R!T2)EX<Y)2^)0O@8+3F? 'XM8\I8[LBC;^3@B]9\/&T
M"9A&6$5E515#V1WM91-Z70^PSL>$Z"?"/;LOTFR'BHW,MXT=N]*(37?&06#.
MA):6@9;;]B0FIH>,-J8VY'-]9+\A$RMW@*@;&N!WT]G.'[ODE0XI0G7G[T&N
MX/HZ/X^QDF<+I@=Z5<0]Z@JC7;PT1<9QIZ%_KI1E)*YNA6Y5UE8F=GKK)B>7
M#&$V&2E8A__L)#.KIZ)SOA?2&J.^TB5>\49SA@[&54G ["!MDWP]3KD75-:!
MZLKE&6^16@C1'+A?2\MWZ/SLGC3TT4'1%]:?-6*%Z?O#FZI\4=*+-]G'+@V/
MT,32MG[QD F'[,/J4G3%OEYM%OC\4 86PX!<Z]>&M3@VCJFX3(P#*Y:6IRP9
M15QM3UH4VS9]ANJ"3[FDE#/G%7_6^40D>QESV,@Q179W5J GXZG8E2D+4L$U
M/@YGTUW;IX'G<][LN3@RGI!^P?N"'[W>P)-U1'M6CC:.HO!52-0>WYSDQ&RY
M6@"Z&.\*B66K^/%-4P6;F51CR1KEQ1C2-4U^<:['P&HB#,O"]95?E::= U$D
M+$@(OP %ZRX72G0H,T\^3>[$&7PY#TCUS=E8C#UM +K=?#B3SO>F\16%[V?R
MIW<;4#NV##<P:;:G&.!4"G 0?2I/5OK-L-3ZWD^2'?? XA?HV]*2F7)>:U)^
M[HP!6HZ^(6EU$5,H[R?*DO:OOK/^S3-A<S=TR&*&&"L^$'$</M?1N8Z"(#G7
M;1+=;'.DKYT4T&PZQ!WJZ0;[H78MA?P!E&*2'$X_;Y'K6J+/4J^=E*[VBD$M
M%BJ%7_K&C"[,![Y\0FKI')1R7;Z#?231>K+3($ G!)/CGYT7K\YW.2!>[[,^
M'MAB\!E@YI\!T['C\W1XLWPD=09"Y6.S:-5M8\5!;C%ZOP\X'\02+/&).YO;
M$G:.$"/M?K4159=23SGE-$^2FST:/KY2U')RY"+76[)PR1+E-GS03NSU1 @T
MW+;ZZN;EI 3@W1%+HYK^A +BP4YX8Y7BNOD0A'E"^?FU*ZTE6K]N#W\DETKY
M.L=D39O.<K-X =*S4RPY3S"TZ^U)E_'7.I+^S2-0U.=PA;WXB3<FH?/S UMI
M2]."!](R=6%^LAM<;])@-(9S)V')1N0BD]9-XL]O0)VM=+Z,"(K@X10[X%LW
M")>O0<FNI_!#")-*E$\\9/K8<4&%[&05DY+PR\,+B3M U\B')5$$:S@WM5LC
M@C/L#J#26#W];7*Z=_^G#%\S D?8\>0AYN>#)PD/GQ1B)48:O^-0:S%N."TK
M+3'<%C/;+"@RZ[0NF.NXH! V(" 6L=;C'!Z$  #*K#_+O FCS'$;1\L$"YMU
M<EL3P0(>)^:WI1*%N1YZKSR&2:O$ @E-(T^44#3(VNMS&T1=,/>['#6'>P,F
MW6Z%1+E)E9\G8RD-[M/%FZ5FS)N 12]=7@X@/OYJ\80E;;84[J+H:R;>G=F-
M<FZ.Y3?$ZF<NC6B"HB+>LAT36R<EZ1+[ZR3V 38C%T1MSB5[=1%M'T]-)+6/
M-*??O7-TJ_Q^!8J8(IZM+'[^*3&TSXU1TI/0>/:$PEX\3"S8@L,0-7('(.+)
MGI(0_+$ 3!'CZ@UG;/93T<+:MS"<-^K&_S&$XV;-%D^4>MACR8H,]:G[=<O0
M14^+=/T.I&>)=Q*,$6*T8IX$Q[O2JEK'^MJL]%/G)#$E<<M+V9R3Y=:).SS_
M'A3Z?W:W77IG&$]L)A6\K*H$F%9L;K0 ]':[*LDK_1*2#/],W SI=VQ]YVN=
ML6"'U4!(Y3_E31^U.D(\D+L#S=L*=S,!YM=/L$SDZ]@/4(O11!,NYD18/[DB
M]J$%6_@/M9),2LC \,T]VKS.BDV:5$).VO5BU[O>SH<N)EC)"A-CO7@A4GBC
M=BV(M.ZFGHEP%P4+^E#=*&7JE]0:9!J;*:YW/LK!+]C ?1 ?35NU_JE+^SQK
M$=6*\!$_XMD[%,>7@Q&D%T Z5>%='[QJ?+;Q?_?2OOKQBD"8=Y^_EZK7UX L
M&S4NQI)MY^A:N$/=&H4_W2 52IKBT?8T4WRZ6J>> ?;I>?OPN-<*B=G'"!0U
M<(D;01!:;+&PF#R6;Q(%LK$A\OJA3GN3]VL+&P1H![1'KCE)V]X!'BXB/TCJ
MFY3J0265:U[5">.\458[FE=B8%EILQ]8$1:/3#  </L !V[]5ON6FI=G%LPT
MH.*_EMY^9_:37>1B;$QB2NO0,ZD OZ^=P!&Y737*?=6^:^:<-E1UFU,]+TG1
MW;C9E.] ;9Z4O5MNV5VRH$:J#,0X8OKM?XA7(C(L&VTG6%-X X"W%EG35;>]
MDP^C0;Y)$(^6>'MX2-/ I!-+9UL7\?E\/A9$8WZ;W,P!<V0Y'M!MFP9G7FWZ
M%!<7E4WE?=FLBUU2W1 JLXX 0-%,?7/=<KX$\)Q=Q,TM'P18.#<5WGC"#[.*
M'&J?+>LV9FDT1ZF#JV:5]B0GPRLYB6BMEJV+:=^C,<4'1RZ1(1>!/WQ%:Q#J
M!7;.3C/0O.ET8,'\?).I*F)1#<^>D?&]2[S3DQ4>II5'$Y,HO.W&F(Q]H.19
MS%!/,7UU2G(59C)N;L0SO) /O!5"GV0P^+TGK5<R8P@_[$N(8FX6/ !>!>\F
M-T8N'#9%;FPFZ"?Z/'C(Q1FX_ECNL:M&NHK)U75GXLC5=7CU'2!VB7:R!N2#
MJ?9Z=H0?JNCL;,WT/CTW(C]AWIGV=6'LZ\SM3E%M+.ZL:RV(L.8U/Z?Q5#,%
MKBW[B'.>&BV(;"WUP/8M1\?KE>^)PXHRTS5N;8%I+"D_Y"#0L%(?6@IB\VX[
M=S=ZLL8$\C"3:,?^^*3U8?6%OBZ &O-6.P.!J7W;7)]3//F <D5,\Z$LL*KZ
M//>KRZM83^]8D9STZ[:9)=JHR[;R^H[)-N (8?_J[)F9J%T86;I*IOY4J4TM
M@V7S5P7NQ/=4I@]QI(KZUNV,>\\_P?T+OID[3!];J-"53/\4K#067Q W_:GB
M5]C )$Y+J$J[AE5QPW/-M4WNCU,[>B/GXP=C0_W*GUU0<W__.K6D'[(:;4E$
M?O%I92/<R7#%NG#,_Q&0FCL8G)L^L#=@XC.@,MLZ.H:M4!MO3M3 :-9.2K68
MX+49![P=V1N5S+JXMW5K_OP'7,)?*:-&1=E)8K(F=D\C@=%50(>3I)-^!0VR
M[FZ $2@JVLYD,24-Y,$&IG%G_/@"+BLIYW1R9V3.^UQYFPE=G.)F3D=?)ZH*
MG#L5&1(VNTV_884]K)[;HH@W WI2ARXF=6F7(5F:FU2*%K"T"R[" 7@XT$$<
MT5)'DY6RT'+[8R T),63:.B[N3WQ0(O6$G2]Z'/&#U+AOA<O 3;1;U+$43(^
MDOY<TN7/"L)0PCO&,YV+ 3T&4*><[SMB7%.W+;W0;\QSCG8)%/%D+H8,S[^B
M?7(1?58\BQKS)VZ:HN[9<5=C7JM/'@<*<DD9/@N#',2,12R&H?ME&&M*-TI"
M2M,#0J@EI!XC&,*,85=F-*;U3?69V)])2$S[QE49'1O0<N/GL44XG8,"&:=:
M'R'!9JV-#:UAH*SJ7?"/(5R5\"6#B=BOOU^B"*LJ*%$7HCEIRW;.QP$^X+V*
M^Z+?J05A1!$M*IH06]#023#50:J9LT/C<XU2 ][_J$!=_%;@PRG[B*)0_$B^
MW"UL<MC:O?IM&4KQ#.MYGH*100,CX\\1K7C3VHIK=J3!/2%$R4_RG)D4B^0D
M8 Q^*L8Q9R11>-W%?YS5J@!7D,-+V^9!86R+U6Q%<(,W6YO\/-7]V/W&?UQZ
M''S]3J;IPM\I^J:^G?%KYL3UA_. 97R5M9'0ZG)R<Z2+$0^#YD^^V]*<:H](
MJ$AV7::R32*-'AGW2K_T$F.A8+SCM<8]EL)8JLRTSX^!R3CO'-\Q)</41IMW
M?U%(L\6R$:CS_@P.[K:'!)P'P)>BBD#&,5U7R75^)9W.F#?0C/9/PU6*8-K
M4#WT]>H0/+1H(;&I^_Z+:*Q9Z$I9I6EO(G?P;;4P/B5;*E,P\'E4_;NDRW>U
MSD/"TH<!%A"7 )^9JXH4T+4Z\MF><J*F2OKL*N_<D%,*.1AW2=%STR]-22ZH
MP>+WIP_O ;+JV(+,'P^85Q:USSMPE<&'VOM0ML;8'CG\)M/A:3A3>32'0-_8
MVE>B$0QJEC])RI)N:]_V+J+$[598O;K>2"\39U_UOCNT7<A3>;.I.?\Y##]:
M/Q7)FBWA\G"CJ=Z+02U!V6Q*13!FK#%P5??Y[2IS(."Q<S?MT27ZW!W Y^HZ
M.@O-?S1-.+;&_O3SN+N:M$["^=6<92:!D/%"O]-X8F9H#B,Z$ST!MN",[TM$
M%(1!L;+-Q+9)F+HL*__2]K?CM=J"_L9)<$:KT[Z/SXPH&(XM7S=="H[-_J&&
M658J50.V8JI(M6I(LTN3+;!+_6$3/UOXCFY65!.PB!#N%+<@AVA5<RSJ:!/=
MMDHJB/=M6E3+<7K*;G)%Z\84[F;+8&]HLKFR.:S=^JUM@%[= <KKN:78(?[S
MVM>XIJ^YI6MLQBK6:Z7&DQTA U_=CN-C_10X<#NDJX5#;FR+@6F..0[D%VFY
M6J9SBG[63%@0ID@C;;T%J1U#YAN# D9!V&WF:;W@^C2-\70YV+HQ4=/P\%"S
M8P9L,^TH_NS[1C2GHB7ADP?*(IDDM\D"0X3R<&0+ JO.&4;'/CP^+FE.\[-2
M]I.,@.SSRF8%^<&;QR:;.DWL./YCY@OE5Y=1\4=#MWZ]P)6VZ$PZ9%"AL;%]
MC+O;C)AC:R'S"])786[$\O69,NPR/2_$["0,)/T0AUS8O4O,8V?S/FH,ZF-K
MA Q0UL2#F6WKF)!:.$X%.T7B[TO33P-]5&05JUE!C10A9QIX2T8+%DH2HOF]
M><"?(^R5G8^Z*O!J1P^."U<J3$\"O0J;07"&5\B//_RJ+";OY0?L;=KOT84?
MW5:B9JUN(IJ_>D46!M$D'IGN@'Y+&2Q,P=NZ7B&$2HNA7!G=Z89&\XLT)K/F
M-)]/Z-TO)V/J!UDI66>RR=;)VVK1&I$,^<@!%-%72,*F%FTK_;7=XX($;M5\
MM2S7_<$$]+J2PA8U'\4P?UHHTNE:JU7L/A<<J$.K]>N$/8^+E9\IC%?Z30&L
MAZW:T0$&C(3[OU9\(!NO:AMU6#_"X!/"4,(;[YX?V1430Y;Q8;XVX3/C6=(F
M]Z!J()]AJ;C-\R4LE/LQ@'\S1)^%UK#PY(T3(W&XIRPVSY='A93]G/48CT%V
MJYY=0*EGTI$9U3NGLZ<QACMCO>XD\KP/H ^5W9T^N@V*K 3BK$RK?=P_6QT2
MEYER$[%K57MV^;K7H9SZ-N[BN]Z+QF^^Q:&V2T-U]KVT^D<?4.10"(-F:TO-
MU)G/SMG#W(;F:_>^>+LOXQ@G5+)!GVIW*2@?4052BCQ4OW*9]6UN;#!=DY!'
M#!C" \*;M?(=_!FJZL7\8EH.TH$S!RQ;F5O[Y_ %\@C?_/AP49I M'IQ+WGD
M:KGQKA:P;HFZ6J4)3-RYNO@:Y/>JF9?JVP=(;A1OF&]IQX=<[O'2?EC-09O=
MP3.: ))Y4Q#UU&U!N&V"3WV9$R/S6SL#(ZWI%ZLYSX/XNIYK F#I7M=2.S/3
M/W,@'\TC-]SEIYUXK.NCAIN:]&(8$TR[%/OBGQ5JYJ!C"US>!"=>-7$21MT!
M[)%#CBOI:B*FAK?)JUM3S?OLIEU/K1_D2SD6\54)O<=]ODN)9X@2V1VLO4+
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M*/Q[\NI_'V*D_S_&' %L^F&+!&R/I*H*<H(_E+H$HHSR[P =5M_N *-@]3M
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M"Q+VMNADP(BG;W*UO[:=/!H@>6)]8_19Z04$C?(,RC%7)FT)#G8!/AMG(%R
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MM]@+P,]*7@F!= ;LV,<]_,G90@PHM5(V5NMK;0: 4..-(#V\6A'^/9O"(=E
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MS#!]?O.CVO70>Z9J-RLSH/1[R>('TN_FR%&?0#H]\K2AZDI8!.E%ZP4@A3S
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M:J\GA7G->?+#/V]V+91_9&[X-/7KT94,62W*G30W &&U&XKS9;U=X4A$WQV
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MI:SJI)#T/E!_DK-]!R"7S^O)CK=%1A[A?A\$5L%*][/:)D=\@6L9/A4\.P$
M2QR1_?YR39'=?5 61D'9\#7CZ=!/I1?M=+V-BLM]XW6N>MF85R3*3/O'?W K
M>Q-\R\=[/Y%1MP] '4R..Z<+T4<H@=V&UIFJW5FQ]8;J-/'9#")TR0^ CTC+
M)IQOV\[SZR!6&YD.VR#_>@<@/AZ;+T&N/P4OZ\';[G'IO.HCW,:Q7J<+F._
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MFO14U.RT).H:"%R(JCR^8"/6"' O-E,I:?"GTE  /-6T8_\.("F/7]433ZR
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M6,$/TS!8[0*;6=WI2?1&?.I8]^"_M%JXM>!QRI0[)R<_!=LF@9T&DCP6RM.
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MR#_E^,T_AE?@CPO"?%A.,(NNM0BZYB<1N.J<ID;6,;9-$^@7421J1R@T*4/
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M_GVQ4^LY'^Z>LW%G@& 8A%W0O_G%TVQ!ST!X2'%E6@9SY88!][9R2*(%TIL
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MB8?L&G%25X?MGLO!SIYD[(C,\YH"$K]T541RJFA9]?I Z3XBP["U%53Y@M]
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MH8ZG>N4D/LQY2QSAF"ZG<\)%<S:=)#2QF^F<P(<.IK-O3%R-O_F/:YB^.=/
M69H6D$N[EV=YR@#.4V77/30 Y@A#2J7(,S9)J?TCS$UQ(;4MHO^UI9W<!T2Z
MC#(EGEZ49P)Z<O]*\T?2,1S?KS("C,]==?X8:W^,DO(]H$:K%]]'8X#_YI46
MJ[=5O5HVQV%7TZPM^/ANP:NZ]2+-1.%JKE %,IPU_4R@2S?!@&&5*2FU29GP
M=N1X$!Q9<7[1R[MD;LE=)?>[=5;=C^HFZ*:G,>0P!#V\.Y%Q"=-SCGBRI7[5
M%+>S/V@KL38L=/TU(P,3X/B)#- P#U $H,)\0@%2]SJ'?,:9SDL4(-6>NRCD
MO:%Y%>O&QI_MI_%0=PY*1"E!N- @+XBU,WG* 6?4 "&UEL:0++"R]'$R(RN^
MG3[8+=6! 0XG,/(S_"Z7/$RU#1!Z0/I#GTS1DAV.$IDXM:%/T,-$AMZGARW0
M;9W?#V9X"[J=DBHDYT0PY**M*<"9SMQ]N@1%B@5A4"M6!#5KB\S?V(?(W1HB
M;41R>Z[\I%WE*GN<>;-8)F_:>.2W73QRF+:(/6%^:N89IR'0]-HPZN;@\I:A
MHQ9\&0G52!HR-G>3JM:1H'VJD\<B,]2/?W>_U+>6=/E5M[UYVHN"I]=-5B6C
M/&<%(+EKODX9!4*E%- "<YBQG%$JP[SZ?H1']_'OL-%<T85Z^3WQ\_7YQT<E
M] 9@%Y"6!7O(:J_Q1KW."Y4]V@6!)]F)KPO"P#B\/ A\?X#GZO6W^[(-?_VL
M[XD%%J_SPR#A7"D![)DML[JB((!#34&A":1<$06-5\I)+Y61%</?^++I:*HW
MY!-+?]603LA5XA@)<,6<Q,K#,14#@3 E\'I/Z+6XY_/" N0.\#O%D'^8L^DX
M#I$<2^?$ZO4FG7QY.A?2.?[W_$9G'Q[H+%I4-\Z;[%HCU5W=KUG*<U+ IH\#
MPJZ;: HXTCF O! 4:@8%#\IX.T9D9.W3D$KN6UI)96<CI$1O+SJ>3J(+90[3
M-ZVXFX)Y[\_+&^XAZA$HEG_H&(EIO4,]0A[XAOJ>G;81R[NRTF_MUEK/4F:4
M3 T#A536<K"'#GO*D!I E4*6*XA8CJ=HQK+A:.QUKG_?[_VQRV'B8@?/M AQ
MC"8-IQ.U9=G.E9\BF70& K7.%.!/UJ3E +!G;M2RY></T:SE +Y8#5L.!YXX
M:JO-3MY>VM4?5K=Z^<5RW*6AV.W6Q2YI]6DQG[]9+-U+,T.IJVC.02I(#G">
M67.J,!H41E EM-&8!L5H3\O^V&K[P=FN_^.?89'^R]IG'%H8?=KI]%/6W^\D
MA6GV"%%C7:VV'9&21J9D987:YNQMY+)_;3Z*S1U"G?SF9$TZ86-69WB667KN
MH+1AS/\QPM8NFIAH@6V7<3%L5VM(N'O/<M60;+O^%4)I;#0$.82NH:N4@%)#
M 4.08Y5QF%&O>+=>*B/O$:VVV"$ZK'WB<8#\U/G%8H=IW7")@U5?KT21--1Q
M&I,JDEXQGZ[W_H<'&IOE356:4KK:NUN3UET=E+N=\!3F%!*! -30]4Y53>B&
M D@K1#@I-)1!J3Y^9,>.R'BXN^/+QV8CW_*S=P3L. JT^/PP];34HB,5:&'U
M(S-2L\$PJ6-9+'Y$I[4T@H XL!#"WA[IO'HRMN%)=83Z;5?I\V_:U?K6ZOJK
M7O(;O?Z]/6E+/4.YM0EHE@%-! 289MJ>5SD$!.*4D%38PRN)>EZ-RO[(*FV_
MFHNRUAM?UBY1J:WL$EK89=J9C71T?;;YBG]T[8\_ZZ\H<Y6LY4HZP39/)8UH
M$YY31YF2J<ZI<9G_OLZIHTQ,\#EU'"Z&[69O>+G\*Y\_Z+?5_<.J?J>_ZCGL
M0AFXM).@B$O,REV#!ZT!)ZD!BN1(<5444 5U:.NA-?(^T9!JW9HP;$_HP\=/
M@4>2.DS;.J))0_4J:>E>)0WE!(Y0!=E#Q$C:JX_2I*K&0^2G>L'GE8&9"]KH
MY5*K+_Q;TRRF?J]7,ZB0DJK(@<DE 5@5S96S/=+2@G&-L:82AS3P.D8D:-F&
MM]Q:DTQ6_%O"&Z(#^FT=1<=O[5XJ<]BBW8AKR;4MJIPC7C>%*]R'T]E+ZQH\
M$8/O>\2,%4%_C,2T8? ]0A[$LO<].R"BU([S7]H>3;[<+A</-[>OM&R6?091
M"DFWFU!",FF$ 5AR:K?<3 ".& 9&$"F*+$6$>86(^!(<><MUWW##0M+QD*R9
M2#+HX@TA"0BW] &P?TF/ 4O8\O9 9$@DJ@\T 4&ID2$:%I]ZR<<3%JP:(&YO
MW*K/.-.%L 9(M1?-&O+>,%/%E?WYO9S/9Z)(:4H1!LKD'&"M(!""9ZY] S8%
MI<Q:+[.VY,SG%5^N_(R4]? AG^A3(MY?Z0M]4U:5<P\+/@]/7]Q 88&0E"("
M8 JE/6<1"7@A$%!2,&28M(<MWD'QNO(LO3P<B#4)?R=<I2['P,\>&R)5F))>
M4XAG7#WE.9)!M1EV4B/JJ3!/#:>#WT=N3KV]3D((:PTU!+*  F"(7"^K0KGZ
M7(4N1(YA441I+OT<"=-[O88WG$1J,QQZ)1<7F;#E^*3-[Y,NOV,F)/M+/7:+
MW6>ZBO,'P+O%;;0K.&M.-I[4-K+'N5D7E7.L7G\KZQGE&<DQLSMI4Q.<(P18
MFB$@,%=%5B"<%T%NRUYJ8U]PM=%Z6YK);XYJ8*Q-/UZ>]U"Q4 A3 ,$ #&@@
MX"%8M%X!?;0F;@O@(?9A!P"?EP9F[,]Y77\P77[JAV73 'OOJF/SR[K[;0UG
M:4&%D%P!*7,*<*$)H*A  ''$"3;V'!%V/3Z(BY&50,.3,PM^[W)W%\MDZ2A?
M)7I]Q7GO6-MYIMX\5$>Y&Q\V.WZJ973,PU3.!NZ_;>'^U,*]?Z.\\TR]>>AT
M\%1XX8!+<(E516 0#].6%+@$IH/Z A<--DSS-9U_C=4+FW+(]CS]P;PI*WN@
M+OE\)W+9=3&HC_]JW46/I"H3D *M)+,*46K C(0 FA1B)"DT,"B_)29S(^O)
M#>&][(9AE>BBSHF?&GPNI,.TXT"0@Y7?&&A$THE169M458X!ZE,-.@J-@2:E
M/84V\: K1^:5OE_4Y6H=W*(A*9@4P+"4 \P4!CS7 N2<%S(7N10D*".[A];8
MYN&6LK-(5$OZ*BDK.7]0VI4A3B2O;QOG2?,7UV/X*Y\[G .MP!Y /6V].# %
M6G0[1!U$'=D1(F$\Q(MEF/50FM;\.B_R@9'E\<J 6_8/QHZIN\^Q4 CK(I6
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M(1G14#HQ5?2+F=AE&[E-X?=>LL<*ZC8\#FO;*$;[.>A5>X?G^OH8[K'@BP)
MV#+-[\'[+:,&S>I=_-R^>KXERZ %)PN-X4^/(*CEPPL8?KZ &>3:NF]/0<S2
M9K>I5MM*U,1:^YX65* ":LQ B8G)2"P; I66E987LH!9QC3W.JUX,4NF/@?I
MI"=[\0.,?M_9@W8[6_FG>'PA6Y-SL$'>_(Y,TDWUXH\J)NOCB]@Q/]7C2SZN
MJ_R.+ZK0S&3N/^]YU1BCFI4, Y*S'" J!2@S!($J((2JX!"67FVQXU6:^.TU
M>JM^!+5=A.?E\>Z:[2G,_!*:B&<O'F8OS0'\\\LP^,4#,!K_[N6= SNR.A;>
M'Y_W/_ZO2FW,C;X\_ZR^&5QMYQ%B&G&)$,B92@&"A0:\X)GY:R$ERV&II-=4
M4S>Q$P?,HS&<>]GU$OK]_7^$]6VY@>D6Z>)#Y!?-QJ#CW]WE96RL9B\WH?/V
M?GD!<=$*YG=U6,CXI';,1!_YAFWL^(WMO1!/7Y]J4J/72E>BVBUDF6$D,0:4
M"PD0XQBP7.:@$!!1J%B9*:\-AV&14^\,' 0FLI'H%QH<0"-$<0%+!K#&!C1$
M<E JQH#*,148%RD1>K&J<V['F1^18*,-;,>BORO@W.)IW.^07RSM9">=\.2'
M8V!:^;?KV;SCJ;NQD6*I@\!9XZ@[ .<QU./*0)*G]=>OU:YA>UM)._/0B%$K
M4:EM,$&SUSVG^YX?J=&,/C]69&H6YR ,8E$.><F>EVLH!)8+DJ&@FX1WGHOU
MYK%MV*H9C5ZMGU:[S?.KM50+S$61%R4%7&*S%B$Y XQ2#%2J29&;E8J03KPJ
MCO+FJ;(X4:$C\%IODE:1Q&KBWY/>!V-_8)D '+]0$@.7H&YU!VM'-:WWW7_V
MWG4'8Z^UL+M<%MAX=3R29/\2E&F1*K-F %G).4 4EX!QDQJ+O"!Y5BJ!I%/;
M>J^4B1V](^ECM6Q/*L/KL+CE!J.-]7/<L^D]D[SJ>TV*U2QU5<:\+5)]9EXT
M1O5^.,P;?UJOY9_5<FG>^>]6._.4*[Y4C:#NGYK^JT6IF<@TY2"#2@/$H0 <
ME04@'$&>FC\U1CX>ZBQY8J_MA/FYJSMN;BX\"1I^;MW)J?/Z@Q+[85W=O]\E
M;;_DI'V3WH!$"@KN<F<-%-YPG </_QN,8 [U)?D_O6BZKW@C9Y(7UG438M)I
MOA!W_G7#KA)KCN6V[VY65R(<+4A_WA\ADURF6N48Y!(K@+!( >=%#O+2O(&R
M+,.,*.^YC]<D3?S2:>J.CC=3PD_F;Z/EYGQ1,/#SPT#SP\9!]ID6<RKD53GS
M#X?L,_?JC,C>"T:3:[1L/ L("49::  9IP!!3 %#/ 502I,[TDPRXD4 >BEB
MZ@.B,PJ-KWL*#3&*0J,#R'&I-\ILSW7>D<6ML$EX,<X,B4^%T0EX*?:+,P-[
M""_./QE86R>^*/EDYT"]5EJ9Y:+\S/YJ<CU;]%XQ7BVK7:6V-9'.@;B%" T+
MKAD0J,P!2@FQ@_40$$(CG?*RQ"KU*J@+TV/J*KI6*TL^T>E5CT]H-&M:+ ZZ
M>9;)!4+OYOTS .H7(CRQ;*FTIEDQC@0G5N5;H!;SEKN-@^JBQFWD[4)/D>ZE
M--_-;;U!_6'S<;/^5AGS%YFBG,@2@KS(N!U)#0$K! 6\M/VY L%">+;G7A<T
MS[E1*_OH9*23[WM:= ,NUV.B\2 $G0\%V!]P*M1OW(CCH!LWGOD<J-^\RP.@
M@<_[#\VHSX_4YI%M=L_OV==F<D0.&_)_P(3" !7,_(2E AH5E!!.RB)W<M1;
M J8^[SD2F5B9WD,TKJ+2[X\Q;/7S0V\SO89J]-DR8K[&U=O.-FJCSZCCJ1N]
MGQLS@$/5^W'=F_>YFSWY^DDM=)[23)0*Y(S9!E&D "T)![H@A3+I/Z5(^@QT
M&A+HY82A<YZ^5JOJZ]/7=M[38RL]9"9'#W)N.7I,//P<M96<M).B]L+ODMTZ
MX2KYR*H(Q%N^=D:=V]$C[@4&> P;?WV2A\-U@86'2[;=?M#_8+:]9/=A\ZEZ
M^+)[O?[*JM5"8T8T0PP4.2\!(F:%SZ3,@"Y1CO,TATAZ;9WWR)KZO6LEVQ5G
M*]OFA+7TY/=&ON<&>A]J;CX?"0O/]W(X#/Z5E\,&QJJS[)$T;U7EL,D7-90.
MEX0Y]D?S'?AB8L8'OJP:,FP3+-ZMWINE].<_U?*;^F6]VGW9+B0595&D&:!Y
MO8-7IH!E0IMW/86:R(*@S*LEUE'NQ [?:9&L]VK<)?))U42R=BMI5^N2?*V5
M\7-^5V3= L$$>/D%A3U4'XZ@.KS^[Y+_H]@F^;"*N)/O:7.D..$J==:8X0G%
M>?SPO3SP=/U1V<+.U4.=A73)QR+E1!6I@D"G* ,HD]I.Z,L 9 )AD><BI5[U
M7=?%3'VNW@E-!-M^2=9/NT0OUW]N$_NLDO7^7^MU@F>DN(&;6V 8CX9?'#@
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M>8D%H3)5R*>!^E*$5S#P;Y3^;"]IQD6V8O]'HFK!OLY_@0U,68I*:-:'*90
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M[P?]VU;5#?4_*KW>J'LAGKX^+>UTV_NOZ\VN^J\F*RL)2Z'*"J!9;O+6$B'
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MLN0X8R5$H.""F21<$T"A60Z;13 G4"F<EUZ5%^/4F=BA.V&!Z?E(J-WR]_D
M](L.[MB-*+X:8W+T(JT@95ZHF&L,<+>+OD;=-6!-L9^F]M%\";]8#7ZSY\'O
MUSNU_<B>[6SF#WQ9/=1IX78A5)8)11$H2V2G)&IN?F("I$+E*9>TA-#IP"E
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MS^T]W^XV3.P6$G$)TQ("AB0%J"0"E-!64Q0L+V"F-!5^R5^/L*G#UKXRT++
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M0VD&#;X84#-\1>![@.VGR+UG7\V/GS=LM;5,$^M5=R*'<"F@+9XQ.2U F$G
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MRZ8KX$;?:*N^Z#%%/,.80I7GVHA!9E2$D"E,:2(9*AC.%7<Q8JY2''ESMM3
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MF#/T)DE[6K%%^84V'6*6LC(=VFF!3ZNU>]GV-1#=U<N-T-RD3SK:,["G/O+
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M)!O*&IXF).A3U'09+SO;(0@*;EK%&P#W\N1KPH4J4[Y(9]IRY6OBGI0M7WW
M\PJQJ-9&BO/]:+7*T#_*N10YHX00B&-%]?6=%) D7,!,*(RYB@E+K6H^W,B.
MO+WK_HK5.,F#R4[F6#'D'6\*=DA:WA."X^.V\<_VP=[W)IZ!MU<@<K\<.$D<
MZFI@1W3:BX$3$"?7 K>G/2X%KQ>E_@8T)B(5!28\QC!E)N2?I!1BG*<P-?G
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MMHW8)YO;ZB'/MI(E-[;#W9>UK+[NIFJD[7+,J<A2(3&,S>QY9#RS#,4YU-9
MFD2(8YDX=648H#7RUJXIFZK\CKCCOA["R6Y7!Y+>;4\W1/=B5YTEQ^@0;2%>
MJ/Z2 Y2F;3%Y7>23+I,6C_AMY \[\Y)[=?\D39;&\LMG^:7ZGL\+S@J2T **
M+*<0*7U:,YQR&)$,RSR22&3$91M?I#2V<Z&B:_()5BUEL&E(NVWFRUC9;>4@
M"+AMY+WP'5'P^9KPSIOXJF"!MO!E.I-NX*OB'F_?ZP]X=E,R#>4_U;,)/L@V
ML!9%,F,4$\A%(B$JD#:N8YY"RBE&7.I#6%K-S!VD,O*F_>0S<.$\''9[\V8A
MW?9E0PF\DDO^]9&N_QCA:!T4*52_GK,TINV[,R3F2?^<P0_?U@>G;A.A?VA_
MUSC8#D9M+T434MB\ID_EEBZZ;.I/<B,U[:]F((M^<%UVD>LJO7HN$<E15% H
M$I9 E!<Y)(E,82+TID:YBFA4./3;G(CML5,J#KBI1[74_-33G0XY<JG%F'AU
MA[74RUTS-[5WT/2F%F)6_=S]0Q><Z(M2K64KC/ZGPT6_5Z 5"-PMZU?T%_WU
MBUUTO[9%+V?Q W0^>AE? N\V2M.LA6TGII&Y>99F3M,@?*D?U$34_<S_-^6&
M?OFREE\Z:I5=<]1BLZ LTQ8#A9G@$42<*T@P*F J24YSD?,D=LHAL*(Z\K'?
M[[1YR(_YC=?EP0Y,N\M$<(@<3]E+B(S:5M1)Z$#7#SN:DUY'G& XOIZX/>PS
M2#N)XL)X#W];T;;BCJ9YEJ9"P Q'L1D.ET"*.84)CY$D,1&QW0S82P1&U@6&
M8#WXR)!T&?A\!@L+,_Q&"=VV\J%P/CG7YZ1TF6%]F[1^%J+EDCJ.I+XLR?#\
MZ3//33AL^C+7AY.E!S[G.4:Z:0OW;K7^32NDQ6>YW2[J&-@\P8)0F4>P4#35
M-D5!(<F*!*9)GF%,68S=FBX.T!K;DN@HM9TJ'0=!#Z!D9RP$DMU-K[1$@5JM
M0446].@&'.E\7;A0(YP'*$T[LOFZR"<CFBT>\8W3+^6]>JTO+N7V'>55PZ6J
M^E=OU(AAQF"$90*12@K(XA1!5G"1%3@IHMPI ^<2H;$C]'*IP:CFL_G-?+R$
MC]W>#2&UV\9U$-@C%C\L3;! _ 4R$T?AAX4]#<%?^;QG:<"_=N9%;%,-D+3-
M13]X:+PO6TU'?\\:2@&_:^=%")4 ?OCR:=.ZSPIVDJQ]_E-^WZ$NK'RNT^8G
M^4C+9?N/QD*,YRJ15%#%(>8IAR@J,LC,3RJF*2-Q1E)I%4KR96#D0V&?ZN#3
M<=<93;L].R9&;KMZ#\^EOKL=._4GJJM8N*WOBT0@Y>!,?E+UX0O.L8+Q?H_O
M=(/*4?5.R],.0_YGN?WZ>K?9KA[E^NT/OM@)3=#XT_7_C&M]'G'&$8L)-&T"
M(1*,:'W$B2D1D13)(F72J3K$@X>7F,7B Z6="AH9(#<MU+JDS1;H9IB#[YH?
MT#)D&GXT+(&6)Q,H##D9P!N18$,#W#F8>)Z -T2GHP;\7^73,^2KZ1RS>;]\
M^"I-'GP=K%LL5M]-S8N^:Y_$^3ZM%@O]^^]T+>8<99C)+(-9H?^#9*(5DX@P
M+#!62$:Y5E)6O8-O9V7L%)J:-_!^"31WH&,/=/P!S0@X$[4'OQLN0<.F4R.0
MFY;&PDD_&>!N2N_/A[5+EY:I,/=LZ^*-?:A6,"'P&>X=<Q.%"9O-A$#BL#M-
MD#=Z'#*'=O;?]+'V=?'3=,#Z9.8E$"P0XR*'0FH[%W&%(-.7:R@CPK(4T8+;
M]:2\3FK:*_4,/-;D@6ED!P;G*KAB9J'=@R%QX\6YH6QFMII+<T 0'-1N,##\
MU.H-H+BI3RLY!]7C\!NF4W]6DARH-[LG/$-$J^67;3/TZT&_H@I_\)QQ*@2&
M*16FAC/FD#&:0299EF22\BRWZK@]1&3LT% W;= 0G0%#UB]&= X@R_C0C6([
MQH8.YN?92>P>)!H0*52 Z!R):8-# T*>!(:&/NL^R>9.JV!AU/"[!?TRIU'&
M$(L2?0LEVH!(46SF)TM($%)4D!039N4C.WGSR)NOHP4,,?MY-8?2#V^RFV1R
MVUF6XCA-I3G+NM<TFL,W33:%YJP _>DSYS_@=TKI,T_^_!M=_R&W[W9+T=;0
MY[@0L2(IS/6?$#$50880AY%4F"0,JY0Y%2F?)S/R9JF(@L>**E"&[ R42^,,
MT]?0<@DXW=3E3-4/\E^[\AM=N)<O7X#0[B2['1BW'5=C4A,$%<41*B2'A0IT
MFET@,NEY-BSH\8EVY=,>M^3^8-GWR\;-^_=E.S5)BO?Z/_K;L)WK?9L)K#@4
M@A40R928S$("TR@NXB2GI%#I?'N]C:D;6:<-[M[.M.J ZG WM(?+XK(\"@@>
MAFG/%._8 'T^0,O(*$@YW*A'0<SO=AT*.;>KMC, @]=N^[=-=P5WEO#@.N[^
MM&>!U['3\J^KE?A>+A9W2T-"?U%,'\?ZG^8I31.%N(*8*J8U)U&0Z!L"U#?U
M+$X+AF/J-/_&A?C(!I*97*C*9;F58%%^,YT5A_WRMX-I9Q2-!9&;=CU;3]MR
M4MF->UZ"131N@2!4\9<+Z6EKP#Q .2D%\WF'YTPM?:W0;S5_O-U?+NZVK^EZ
M_5-KMJJ)W#R-%15Q)&!$$*V[\V-*"(SC/,4<)3%BV&F^E@W5L6/?86Y6=@#:
MZ93@L+@IDPZ1ZH<>!S- MZ!EHN[W&' 0EXO0H89R6=&<=D"7"PPGP[J<'O9-
M\VN*I#;WZL-J*S<?Z4]3FSH722P5CR0L<!I!1+A6#D3;(IG*.459'BE2>(SN
MN$3/ZOM_\^R.C^MRR<LGNFA+P\!J"9::#?/WJI!ZQ19E7:OKJ#$N FFG)&["
MQ3-=KZ5HZLDKFJ A&C(=;UBL8#EW%\A,G%@W+.QI]MR5S_MM:6U??)3K<B7>
MK$Q2\+Q@/(E55.@3/M?7"*1,:^8D@:Q@-$])AC/D5!MP]/Z1#W1C M?DP.\U
M0<=@WS$<=OOQ!B'=MJ&+?,[;[X(4@7;=\=LGW6P71#O>8Y<^YI-]NEKHGU?U
MZ-NN<>O=<KFCBX-_>R?E/$\S0910D&.6082C"%*9$4AR',6222*958\69\IC
MV]=]<D!)RU1X=P M_*!CP>)H7Q\@TK$Q S4CX/#?WXV'F$MBYTC(>>9Q!D/0
M,7W3 X7A;$V7%TZ8G.DAYV$NIL\+1JA\?-.X8\T8G&;4T3RCN1(1XI#2+(>(
MJA@2@A*(:9R+7&2<N T)=V5@9'T[8N7C.33MC*,Q,7)3OM<K'UMVJCE:(TS(
M\L5BBMK'<^1?3NWC #A.M8]#[_')_]Y^E>MZC$Y)%^^7:K5^K!6?74F_W4M&
MW!*&-.AH@QYQF[I_'T!<<IM# N.9WWP9H%")S;9"#B<W7WW+A G.MA(=)CE;
M/^5G++1!V8^T%!_D=EY(EHD429C)E$$41]H6X&8<59$J1'*&,;/J>W?A_5.$
M+IXTJ:J%4]G0;F=GN@[)/43&[ER_05XW'=42 H92ORBX:[?:2X&8]29=W)EY
MB.6V'#"$/&;GGI4ZV,S<P[=//"OWK&BG,W+/?\RK>S[;5MO^X2M=5NFB4I@&
M=MVMH6M1R5@L2 (+GB5ZJS(,J6"9F3"5XRPM8L:X0^][*Z(C[U_#!:@/%\,'
M:!BI^SQVK#BU+;?#TL(>&0$AMQUO!XY/.TQ;E)Q:LP='R[>Q^DU?*=<FZ$Y2
M7VEA;O>N*1N0.TEWU#[<[5D_:Z;._#@SXZ^SLTG*.4Z9A"AG.40J2B#FN8)<
MQH13F111K%SLFZL41]:8-?V_N)DVUV&R,W:""N^F#-N4KK.#-D=ISF8M;""K
MYSJ]2>T@:_&/+2/[!WWS04V^J7Y5=3B\HIMR\_EI+:FX7_Z#KDL3#39NC7B.
M$6(IEP3FF!(3Q,T@C60,BTPD7* \C:5368PMX9$U0$L+:/O>M;V_+71VZF ,
M0#Q,I#T+,U Q 6HN3*)*!]:G(; \$C[=) ^6[&E)=N)$3S<P3I,\'9_W;.6]
M-J,OMS\_ZF_0ULPB^=>N?#(4_[Z1:K?XK51RGA*9QU$N3)<CH:V%3$ FA( <
M11DJ%-7_[#0UT(+FR-JBY6 &G@P/]4"PEHL9V%5\@(5FQ+'EMP6:=EHD,$9N
M"F0/S\<.GK=[>&H6P&]#\+BW [<7.%1;< N*T[8'MX?@I$VXPZ/^O2#:PI8/
M6I[=>EUU(Q$T0RDAD$1FHC<ME-$2&4Q$G,8,H1S';A.]SY(961V\6JW7J^_E
M\LL&+E=+V! %3ZNUN63/P%)N36IC6\2SJ3:$,*=LN=GLJOY0#N,#KR!JIQ]N
MQ\E-)1PWD.AY6ANT_D:WNW5@C^JPE %[2IPA,GE7B<N"GNLK,?!ISW;C2DGC
M%)?OEWSU*!_H#V-??))&@G)1UJ/)JEY:[Y<G%2BGC;7F)$]PFN<13&.40R21
MA"PN)"S2*$MXA(J,9"Z:(3!_8\=@*DY,B?ZWKIL<;6F[Z8G0"V.G8)X1;C?-
MU#$*:DZK6C?#*SAD=@;V:W*NB^*9KG\C9'F,!&NH[OB!N9NVO?XXT)[TYQ^)
MC)_6KH/BTK8A?48B29#(8"8$,^%L?95+(P;S)(ZSF!&%F5.2FQOYD75NPXQ7
M@ILCCG8Z=#QTW%1D"\SS-/7W0R&01G,D/JG"\@/F6!]YON5V=?-;25DUZV9O
M@G[>:E5HKIWWJLO6^;C:E$;CO?VQE<N-J4S^K=QLYY0GF=8Y N:14%H3<0P)
MXP0F+,4)PZGDV&G*5##.IE12,[!H6=6WS([9&=BT[)I[I^HRS)X:COUUVVV+
MYJ[V)EN*FS3B;_M5^-!;A<_]5=CG^;7,@M_W[(*WR]VCK)/7 X;;@D,Y@EJ]
MC:]GT[A!X!Q2QF$(>'KK# -?5POQ_O%IO?I6#PQL\E=2H9(",0Y9I U!1 6%
M#&4QS+0ER+E*4&97469!:V1=VE$&98^THQ=N "E+5UP8^1W]<9WH?:HC-,*S
MD"Z4'VZ TK3.N.LBGWCD+![QV\E')MV'G7GGO7I3+G;ZMY^_4OTEN=]MM<&P
M-.[8>4()HU%*] TOPA E6$":90G$19ZBG.99DCJE]CC2'WG'M]Q VEQ=EA4_
MYGS>5*R8V)T VQ70=_,GS6'ENU^L-AOPI#]6?68&1,T\^*5<-H_]ZJ8T7!?%
M3I&,"+6;<CFY('[H4*ZY #TV9J!A,)S.\00BD!YRI3ZI;O*$YEA?^;[&3X=]
MWCT^TO7/>W7J_GJ0/[:OM(!_S*,DRD4A"YAE)EZ $84DC@441:1D1!F7J9-K
MRH;HR-JJ8<'LFS/>93>58X6AG9X)C8R;<AD&!?S^4&4F&49 Q4E 6\9%\$#*
MQ(KDI!K$!81CM>'TK&<?*:.8[M7?-W4#NWNVI>72M,U\^X-77O5WJ_796]8<
M)8(08N9%IBB%B E]P^&$02*B(A9Y'.?(R?+QYF1DK=+E=H G_8FOU!@\NVKT
MM^K[EF[H0.6]!';Z9Q)@W912Q1)<*:B9J@."H&7+Q M;QJJ"N@/?T=YU%+#7
MU:WXA&J&Y<W'M-VR;H7KI)W6S2^\K0JU#BR^K<LU/ZR6J[9JT11@XE05(DE2
M2 II[G=% 3'/,,0BP2E*),V(4\*5#=&1%5I7Q%E6//@5J Z"9J>70D/AIH(Z
M%)HTAE\:!GZM?-(=#_IO,F ^@HO,@0M9!TD^2W6K#0B72EZMG@T8=.OW%-=Z
M26XV=X_F;W,5$4G3B$!$&=)F$,>0IC(U8X)4SK4=Q'GBT6_3B0FK77)S$\[?
M-+V_&-=OY<PIKS6Z#X#M#?&OFZ *'.,Z&!!0,P-J;D:.7%T#8<SHU$7:SQ^!
MN@:+593IZDL\"T2:SJ(/JSNN+QYK>3'5?,YYGL588!A1GD&4,0X)HQAR5,09
M)BBC.6XUCYW2L2?NH7'<E,W'YJY5-;E]:M@X+!QQK!6Q!]9.[00&RZ]RI.T$
MO%V!A@MP5$TR.RPG"5A!XBQ_J$(2>\+3UI,X W)25N+^!L^2=2&J(#A=F-8A
M[Y=-^Y9VE!O+48*5@)1K=8(*4D"*"@R3A'.!B6!%Y.0:'J0V\F5G3[OJ60/?
M+]M>-8[5ZX.(V6F,8#BX*8EC",H.@A'BUU8RABI6'Z0U;:&ZC=@G1>I6#[D/
M+GW3]"RI&WU^DJ:P:JZO**;%5@(E,MW$288AR;7=D# F>((D1=BJ$/T2@9'W
M<4NR[2U;$[4?9WH6D^%M&T)2MYWJ**33D-,A2;QFG9Y]X60C3X?$Z4\^'?R<
M9WC5A&O-R&_Q>O5H_ ]U9&:]-K[*ZOQ^]7/_F>9,O_M.U^+^J0H/O/WQ5-:I
MBYOWR[K+^5& ^.T/N>;E1I__)9?S3-*,ZNT+BT*95KDIA82(!"H:Y8H2E2N>
M.H5J)Q9@[ "-X:9)+Q&FJ_&ZEWWBF&DR^=I:AI!?\(HYAJ,-E[!B$_1E 7UA
M /L)^A]L! *51*:M8"6(J8KMI#)AHUJN,P47K6R@$BY@@/N9EB54L'QJ]J<-
MO#_3XIP$\9^+CUNZF<TICU"4)SD4$AFW=EY '%$*"\$+)D5:<*)LIO\>OM;I
M)/"<[NLUDM)IV.388R1#3X8<9>;C<TQS')[3>-,$QF9>PG>Y-#Z6[<\WY6:[
M+MGN8')"<]N/,2U2Q07D22R-?R2%1!48"AKG6&49H5'B,"/&AN;()E3%!*BY
M 'TVO/J?6L(XO-E& L=M)UK@XM/ZU!(@I\$PH8'R'0GC_T5R'0+C(O&5\2]6
MKYIR\(N+;$<C7YP>]6U.M-F\7BU-N%TN>2DWOY5+^7XK'S?S@F-&219!GBNM
M&WF<0LKR")*"YE3E&4^X4YWI95(CJT1#&!Q0!K\;VJ B[CC+;@ P.Y,C# QN
MRL\7 8^V0]>$"]9ZZ"*AB=L/71/XM 71U2?<_<2O5_KZ8-E]]^3S8QZZFDS0
M;KH7F?=R?!Z^:3*/YUD!^J[.\Q^XP<?)!BZMS9V57;BS_D-NS/5T*4R&%C?Y
M1BOSJ^:B:DH.+O5.,-]R(\".+NK>'S02^CRA.4QBE$!$< PIH1PFV@8GB2!<
M95;6]LL3;>03K.$7R#UG@\U(>NP-MR1YZ=\8!Y_JBV#X>;VMML[66MXZFZ21
MV*2=_*.:]/(V]'?,SQ?[HI8SI)?V90@VO?_V9<@]Y-E]61SZI@/]QVZS;5./
MSF<EG!?VD\G&VY1;^5FNOY5<UNYITYWMR[)Z2]5^?UZ(G.4J2:%"B.I;H620
M9K&$G"2I)+Q 4>P4P1R;X9%/YL_;%?\#5KQ5A?,M<ZXI22.OFJ4W_ 6MA:.?
M_>/[U[/S9]]^#\],@<BZJCTSU6BO5YLMZ+$8,G-J&AR#)5^-S.[$^5O3@'^:
M C817;^#X8'^J-][]Z/<S/."RR3#!22)TEH\*Q D/!8P)IG6XHS'A732X@=O
M'UGEFLZS-3'PNR'GZ, [!,).,7J+YZ;%["5S5DEG)0BD/P[?/>EF/RO6\<X\
M_R'/X>AF!MG'M31#0IN2M::-^UQ2O:LR02 E!!G+R+0.RB2,"\4EIY3SQ,F[
M<9G4V-Z&:MK=4TVY'7Y:M^Y?5?_4MOGW"<\/ &BW%\/ XK8Q:T0:HJ"A.FL;
M^ ><9'Y5ME SRR\3FG8Z^56!3^:07W_"(UW@:F;/I<2>_4%?M_ZYVVV_KM9F
M>&[3 %W?]>9%%-,DI@BFM. 0Q9Q QA6&2L2)DB)/LMRJ;^#XK(ZL69IDZ*>.
MGBE<KRWRKJ$8H-]HN:A:V51#F-LY(76C#KWZ53&40XA^W+6U2'UX,2OFXW%D
MEAY'=L[CV*M7:=J?[47H1@1H(5[,:CKD:;R85?5+[W@)J^N6)C()X(/9)>-R
M,%U2RB1('N2R3$/1LTE$.UKT;_H@VJWK1%Y]^]961;G\TB1P,:$8*^(((H&Q
M_D^608II!KF2-%4YDT0XS>2Q(3KR8=Q1<^S[8 .7G2D?&@2W\VT_^G<&.J(C
MU%&Z2!FJC8,-R6F[-SB <-*TP>79&W5 G7E\MQ1M=XA2;AJRXG[9$=4?^+!:
MKMN_5D-&N\Y^#Y)_79;_VO5SPU**XI3'^@J0F08S)ML82XEARDE"BUS2/'9R
M#HS-\,BZIS=VN[>HX/WR:=<,"=QWN-QS=T/:WN@+[*CQ7L"R^6K+\"OFKU)'
MAC&T.AZ+W>=1Y2.#?_$8&)ON[;W&VM9FC25[O]PW^B1"4ED4'!8132'B)(,D
MD]JN1)D2%*&T0$Y3Y.W(CIZ?UK1L YQNOH+5;@O48O5] \RWI^LO!BKOJ=8/
M!]U6;Q@W-@"SI3H.#IZC4CUL--8U,FPOVAJK$;JDNDD]0F>Q :+/UE+L.A!#
MO<0LGKXAWM33<[UQQX@5N;YU$L@H9A#E+(8D105,9"2DB(I4"J<8[F52D\2;
M^O.C%WLN/*)+Y^%RB"[=#()/=*E'M#]+*W!P:5"TD,&E\X2F#RX-"GPVN#3\
MQ$B-1B[YO^KZK_?+S79=.7DW%8L/7^GR(//P0C7Y7_7[MV_H5G:VTSQ-DBRC
M,8<R3BE$*1,0)U$.$].!,,FE0+E3K_<7(]G8H2O#\P:L966T3-2B9+)OA9UR
M?#'\ON@T^Z9DMB<MJ#7\5LM[DH0_U.RD$AP8R<'^^CUASY.IEW.J9BB3R?6R
MNJ1,O9S.[5,F9]!W1.1F(V5WYSUL)MPV_GRCM6K$.:(J%S".F8)(F^009WFF
M+71BAC(I@63ATGG%EK#34>C;F^6Q7):/N\=F9,I30]UUA*0EDG;GTQCXN!T?
M-0>FU*IUB)SV$-^N )-5_\Z0LR;=) \V>-*2[,13*-W .!U)Z?B\GQIYO:H4
M&C<:3*NN]>J+_F*U U0+%.-(%!RFW"1H%S&&A"08*A9)K3[2.$7<Q4P?(C:R
MY=PG;<R=IX:XFZH81,M./83"P$TE'(O?TATATFPC8*"=/TAJTMUN(_3Q#K=Z
MQB.-=-_?[>YI'6O0\N8+BE&$69(P&.420402!*D4%$J"XSA.2*[WLW4&Z"4J
M(^_C?])U=1^1'7F@Z9<+$,^ 8<(AB>\B3L,;.9CT;COX[8' K;@^W:(NRNV0
M=QA"?K^4P?,X!,KNNR;68&+>Q8>GRZF[QO]!.MS5#_M.BV6;4I1T_?,S7<A[
M516G=O'-N6 2LT(;$:F(,FU38#/FL=":*$)IKI)$%FX#KH?)C:R-]L1GP)"O
M1BP;!FY($KF"GZ63+!@JCIZKVP#Q& EK(V>P8;"#Q"8> VLC^.D 6*NG;L\]
M.)K!>/>X6F_+_ZP/EB@G@N94PIS2'"*D#1(FF8+ZI87@:2R2S"V+U8[NV*[Y
M'BGSK:\]$C[%:;8XVFF"$=!Q4PE'Z06GHUIGH,_(.!D&%I*/D&(P1/79<@PL
MH!A*,K!YW'-4V;I\E)_H5C;F:,)$)E2>0)'1"*(HCB&E60HSGJ:"JSC)4J?6
MCT?O'UD?5-2 (><X5^P(!;M=?H-L;KMY+]8(KH,+4H2:\W7T]FF'>9T7[61B
MUX6/>3KWZ.:K^;\)77S3!WZ5L6Z:N)KF0.8?[I;B\!>]3]9AC+99R1M9_ZG_
MOMB)<OFE':9LF'VKE.3;N>*9WI;:JN=%U<\ADQ#G2L$T4C0N$(E9FKE$&J9E
M?^1XQ0>Y!<T4\G)992C.ZCQ%N>>YRF!>=Q)5_^[HH)QVQ2U=GB]V'1V=J-6B
MF?^"'H.F;J=;L?HC9AF/?GGX1--?H^L$]$LKUZ]5>Z!:M/W8^DK=UM(%]-,^
MRZJ$\OQ.R_RTON1G69@3[_3S<!$N&/Y)+N7WNI_='"%)N. <)BC.(.(YAP11
MI2U+''&6Q9@JIT#6%7ICIZIV<=U%?:=:UZ3!UKG+ZC7@[!1\0#C<-/+%2'=#
M/7!/4$LY1XQK]ZD]>SC[C.@V4>QSC_EM^SHEQ^3QK)9:[;Q9F7:6\SQA:9$(
M8:Z,.42YOD'22$8P2@N,19$:$]5ELY^E,O(6;]+W.J+@]YJLHR_Y/$!VF_IF
ML1WC6\X2.V_?08D";=KS-";=JH-B'F_0X0_?[@CN4E;:_EH(2X)$FD.9"V(:
M&9CX#\90IDD12<YQG#-?[^\QL9$WZ;M^!1E8L47YA39YM6T-B1D/ZMR(=1"_
M3*J,J A!D<L8HH)B2+*$09FHF$L:Q?HO\Z74G$@Q$8*D1K!/U.D$_\N(<+D[
MR6_Y$MWD&>]EYP7OZ68CX @.\!-2S^;UOB3TD*O[XC-^:O&-5%*_1SS0'W7Q
ML/[AM?Y[N7U-U^N?:K6NJCOTI4KJ=W^=YXPE69Q',),"0Q2+'%*48!AG,C>^
M[YRCPD53.M(?67FV9"IGB9#?Y&+U5!4P;.D/P"NV'.-FKOC:J88147/3%BTC
MP#1HK5F953_7W( #=BJG5,50.!WBB40@M>)*?5)-XPG-L?+Q?4T@?;2_IIGI
M4'V*\X@R1F6$H4B9UD4%%Y (?;%B""=1)@E6W,EJ<Z ]LAXR?OG5WJ%B9I3Q
M/OD;==  II[Z)PQ2 71/S^E237:S0NUVK7-=_K$TS@#EY]4VUR&YJFDL7N&K
M9=AV7S3U6Y?'AG.,$I+D,)?:L$%))B')<0XS2@E/B58LW"D/\ *=D;6'H=HK
MLKPA[>\23K9:XF;I736"A^ >FW]0K& ;_3R5B3?UH*BG&WCXXWZ;]:AH\</.
M)"'<J[KKY?UNN]EJ:[UI8\3GB>!*B"S5-Y*XFL*3ZBTL$<RB A="*E1()T>K
M$_61-W;+"Z1-&?2RXL9D]C4=HG>;>F"9&;BSV^H/:$.B,A^Z0OP98(;3JDJ_
M?LBQ--]M.>PTQ6@@N^F/DS+S#QV^31O?'B\S4'$33J]X@1!(V[C1GE0'><%R
MK)G\7N(^;?;M<KMWS7R2E>MP^>7SEFYWFWFA&(_UU00JAB1$J! 0RR*!'*42
M8YP516$5\+U&:.PP4$6Z=0>"CCBHJ=MIDZM@#2N.D! XAH0\I7>:XVLCFM=8
MW\$73S;EUT:\_M!?J\][EQJ;7MEUR=&G<O/'@WY/$Y(L2,YB$6=01H)!)(72
M^Q5ED"090XFD5"78L=+X$JV1M^P!96!( T/;,X [A)G=>1\(";>=ZPV"3[7Q
M-?'"%1M?I#1UK?$UD<^4&E]]Q+,U8.LW>+_4AK TWH.YI!DO$"(P4\HX"S-M
M1<>(0I5'7 @<T<AT%[7/ SY#PVD3NR?K5@ZMJFUHXQI<+5U[ )[!Q6[#WBBM
MVT;=^_!J:N 70^_R-<6]W]]E:4(U^CM#8=H.?Y=%/&GM-_#10(?JJY^OY))_
M?:3K/ZK9@B+25_0H0?HHE=P,6620I,P4U0B<YHAQQ)T:=%XC./WQVI'WFL1X
M%4#/8_8&6&X^:ZT1N?VXO2#F6&?N,;GG/7@O"'_U]+WTG$>SC_?-9+*FEO>=
M9KKN0[;/S:[^X>_+LNI6WO8&5F\?GQ:KGU*:&*/<U T82:IX&D4*RB(2$+&"
M0Y;$QD5?I#S'*$<I;W.+'BS[A(1DT",;Z<%=Q;0<5[Z^JG:]L@2^U:T2>^4Y
M]3_N#.-5%L-3VS!; =DR_V\FG\&V@7#X%1U67L^S0%Y:KEN4^[:A@&&T[5_9
M*[:I_[%B%FANN[Z8^KF.85!Q/+O2RG+DI7'HMO)<2^37H>49ELJMR\L8< YV
MA@E*<+IN,F/@=-"!9A0"?G9TZZ;N7%X5S;G(<$:B.(5QGC"(N)*0,LIA(6,9
MIQ&-*7**4I\G,W:*2Q=:67<NU.K4<K.4+T!D9Q_?+KC;>;&7>>\V_ON@S,ZV
M\+!(@2S@"T0FM7N'!3VV=J]\VK=U??GT5(_3^=_:U%KLA_SE44YC$9DN=D3O
M4,84Q#')(<."4,I5(0JG+-F+E$;>I"W=RI)L*;MV<K\$DMT>#2*ZVS8]*_4(
MG26NBA:LZ_<E.A-WX;XB[FE7[&L/W)9C6ON[]&G=FVLQ+W)$N"01)%%&]-9-
M(LA2CF"B%%8X2;#D>7?=M'<7#]'TN4&ZNX^[=$F3R^X]1F80.[L=?3,4MV>+
M'DR4^>MZ-=!RUSLW=$B\P,F@9TD]2_;GD-"7TCT'G_%U0&^VYK#_)I?Z4JNH
M*E*J,)09%Q"I/(<4"V9ZNPF2Y%&*W0KM#]X^NFMYLZV-Y(J:JQNY#X.MS]A3
M.%<'<2W7IRMR>3B#S_ ?S//;?_?$;MXS8IWZ=,]]R+?QF31#"=_^,.,HI#Z"
MJ\D2=5[VG(F4((40E))G$$F50EPD E)!F<!%D;(X=^N"=IG8R!NL(6UZ-QO:
MM=-T54VE:0M ??HE#L)GMQ-#@>*V,5L\&K(5'/60GKMA&#P:JUV7+UB7M0%2
M$[=<NR[T:?\UBV<\/4QR:[KD?%ROOI5"BE<__[XQ!W(7$K[CV_);=2*_7BWU
M+W;Z=_==]L$=VVS7E&_G2&%FABY"*<SH-$4Q9(6^^1*99+DB0F72JHE[6+;&
M/II-!ZW>,-=]P1;MV/N+HS<KS')8>K\F!]G16R:W=9>RED,S7>P7PR0HE[_V
M*KWVC,[ GE6PYQ7\WG(;\/8>%KY0GKDP3$WKR0L*Y(GG+^S;/3V%6WUI/RRA
MHGF>(A+',,L3KDVH/(6$9 642D@>)PEU=.*?DAC;-]@2O*6M_"DNEE[!FZ1U
M= >Z">KN!KPH2RC_WRF!:1U_%P4\\?A=_J3O+<:<RMN?'_6*;K7E9#H+51T=
M/JX6)?_Y(']L7VE6_]#;,1$\*_0FC/($HEQR2%5,8)YBG$0R,G6A;C<:.\*C
MWVYJ-BHSON/!]2ICB:'MM28\,JY7G)J#&:AX.,1&_[+B _S>_&D8 A5'09M*
MNX$0[!YD27;B.Y$;&*?W(\?G)YY4?3"*T_"G+W*\<N*;7_6JS^HHY5PB)AF/
M%$RR!$,D3,E)+DR+4)3EA!4"42?ORE2,CZS+FEP=LUMEPX@I=34I</[5K),M
MJFVT\^4ME6OP].8QT<>#H"O]W%MQ\^O982EN+=4+& #MN0[//=_9E>T_Q_AF
MS\4(-IW9E_[SG$]W0I3F![IX4V[X8K79Z6W>^9122J04"8-)JDSQ<II#G$4F
MZ8S'!8E83&+'E)81N1WY).KZ,+1] CY)4[5FG$[&B6 XV#5]GO_;?XWSZ'_^
M\N^2KC>_5IKL[LN7=17$KSN5E$O3C<$AZ7>:Y9[FN JVB,]W1NU% #T91O$X
M3H+V"SF)AGG]4QT_5K"'/G/LB%XZ:/K?V=_T3__KO[2_T?]AFN3_^B__'U!+
M P04    " !72W)8! )!WS&6  #;U 8 %0   &5X9'@M,C R,S$R,S%?<')E
M+GAM;-R]6W=;28XF^MZ_(D^=UX/*N%]Z=?<LV>FL]FI7VLMV=<V<%ZZX(&Q.
M4:2'I)QV_?I!D+I+E"@RMG8XN[-L6:+VQN4+!(!  /_V/[Z=SG[ZBLO5=#'_
M]S_Q/[,__83SM,C3^:=__]/?/OX*[D__XS_^Y5_^[?\!^)\OWK_YZ9=%.CO%
M^?JGETL,:\P__3Y=?_YI_1E_^OMB^8_IU_#3NUE8E\7R%. _-K_V<O'E^W+Z
MZ?/Z)\&$NOC8Q4^7_VJ"R\$5 ;FP @J-!^]1@Y>,^<)"]D+]?Y_^U3F!VG .
MLC &RA@%D3D'Z)+6PI50@M@\=#:=_^-?ZQ\QK/ G8F^^VOSSW__T>;W^\J\_
M__S[[[__^5M<SOZ\6'[Z63 F?[[X])_./_[MSN=_EYM/<^_]SYN?7GYT-;WO
M@_18_O/__.N;#^DSG@:8SE?K,$_U!:OIOZXVWWRS2&&]D?JC=/VT\Q/U7W#Q
M,:C? BY \C]_6^4__<>__/335AS+Q0S?8_FI_OVW]Z]OO!*_A4\X_W-:G/Y<
M?_SSRP7!@0C=_.+Z^Q?\]S^MIJ=?9GCQO<]++/_^)_R6O]$+A>1B^[K_=_N+
M/U^]]<L25P25#9=OZ!OGOU_?\E0*\-L:YQFW/%T\?[9(-SXTJQ)=7/[F+$2<
M;;X[R3B=;)YZ$E?K94CK28PF$QP%*(D1E' "0HP2A,7(>.+%Z5L,5X)71/%&
M 2M,?_ZT^/HS/?CG*H3ZQ48:&TG<>=U6*H?1?;'B/M)G)\X([F5RD#D1J[AD
MX!(&^D,*[5)62;*CR+[^MIM47]?FR3+]M%AF7)+)N'A=6*8[FKT)UO-/_/PE
M+.E!D#Y/9_GBM\MR<=I"5^M% \EMU4+D_NDGXKK@<HGYS58K.YG;<+8F0XJ;
M3[;0^,E\?A9F[_'+8KF>)%3"9\]!16=)"#Y!,#R0$$+*03.>I6VB^>MOW0L!
MHG\$'"S)3I#P#I?317XUS[_0GCO1-A15N +G:,]32']X$6GO##J&DHUV7C2!
MPHW7[H4%V3\6#I?ER&!X>;:LDOIUNDIA]K\P+"]X2"E+^JB &"KE3CJ(+C,P
MS/#LI8D"S7%[V8XW[P4)U2\DFDBT$Q/Q<1GFJVF5_;F9\P)3DM$!9XXV/"D4
M!$V2$9$9$Y1'H7@;5^'6F_="A>X7%4TD.C(J7LW7T_7W7Z<S_.WL-.)RPD1%
M;@@@M=1DYQ)Y/CDC(;H(@SY%5OQ1:+C]QKU08/I%P5$2[$+[[_'3M IAOOXM
MG))-*Q%ML(8"ZY1!*24AV)P@^E $%\5Q+AL@X.9;]T*![1T%1TBR"R2\GJ?%
MDDS81O ?2/[X<G$V7R^_OUQD<H%45DQ+"RS7S4XX5AD+H+RGF"@5X>QQ[N0>
M1.R%$]<[3MK)N0O8? S?7F<2W[1,MZFJ<TN((9?,@H7B#9&?F0.?+-(BT%S0
MCW2*+0"SX_5[0<7W#I46LNT")"<YDPI6YW^]F<Z13YS5!D56@$X3T@G>X LR
M$$GDY)-3O*0& +GGU?NEK%COZ#A6J#TAXR5]^7;Y<?'[?.*3TCXC0=JEFNHO
M!;PE<"N'QDEK>4ZA'2ZN7KP?*CK.9+80:$^8V.R-;Y?OEHNOTWG"B>$J8SW
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MTSGF5V$Y)Y=M=:.:MTS3=#T)@E#/%1E.5\OB@R/_K7@'Q6A$X1ESYJ'.6H<
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M-_2'/ P9#@A/N93_%*T<C+ ON)PN,JVEY7JH_OLN&5W( ZAC*>KL=LDALHR
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ML-X9Y@Y64C^8VU^BDQ2*QJ0<:%F(R^(424T8T"R$@,PPE9XI,7D/=>/>[.X
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M>[OMO'Z[W:!OM9JYPKZ/,3+M.#&E0]V@V;;2' 4Y#L;4VP[[I48&)'(<VS0
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MJCH1#*X3YTS4,BLOZ^Q'7;M(:8A>.;"H,6?K@Y"M$\S;TC;N74='"-Q942<
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MR]NXF8&7MZD. \\+V%0WK,J= KS+5,KOBVE:UQ&6C7>12LJ6@D4PF9/GJ[*
MZ$R"HL@3#J@--[UMK]VY'#?G<,(;;6! _?-LN8EST:0@,PDCTO%NLX,8R)]G
M+FM7$DM)=U.TO1MK+^;V<Q"$C[,A=X+;Z=R7/MK1>YMGJ+<%Q+37OI:?6U%O
M%#A:B"EXT"+H+)Q!D8]>D=..O1=SO]K%GAP)=J=P.CXGFDONMY-.4BHJ'PH8
M+!X4F2JR6I&#\\%J4;@('<V;V8?#%W,7?!+[<CCPO82M^<"]X9/R,8K9XED
M'>H8Y)1C+<:2(+3FH@15)V#VMCEWY/'%W$V?Q/8<$H O88,^<%'YI'RRM#:C
M<%!2J).9<@:G99VE:[1-/J1@NG-I=^3QQ5R&G\0&'1* I[!!&\7B/H2@5;&
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MN)'PR&@\0$?#'Z6;']0_8ECB__K__A]02P,$%     @ 5TMR6![6BC4E%
MA5X  !\   !X9VXM9&5S8W)I<'1I;VYO9G-E8W5R:71I97,N:'1M[5QM<]LX
MDOY^OP*7N9U-JF1'=E[7R:;*XW@RKIMSLK:SV6]7$ E)F) $!P"MZ'[]]0M
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MS1':K:+)49!H$U4!AAQ-#HS+P6AGWN @/#*Y(6<QEY=* ,QO"K XET0,/DS
MVNV*PPP,%TY7@)/!&><=<Q(H^PV.-WB"X+],X\$P5[3\\%'N,4\<H*.JEL.4
M@M6H^!<21%BE^[E=C*079@ 9T+@EN%:1S8UQ8"0,?&'1^_%JW13D$%.FX-<5
MPR$6BERF=JY1T7FF?-#*N^*\\YM(IFO O+020E[9U)/##WL:"6NW>(Y\PO2Y
MRG3.G@?GDM.I)I]PJ=I]1]U*]QZW$F61; O(-NQG;1:P3! @TY))Y^/\O7F
M?8?1(]!J5?@0'&^8C1 ,Z"J3O2O>7\?C!6\G"]B6VII+X(^ECXQT&Q+D:U5I
M+E7.0 ?%QNB'7"=^M44PJVKJ1:&05[\P.WZN;>XV"6:#_O9<UYH"XP8J\-7
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MRO @6BND20O/?(-OKI0GK5?.$_*??1 6>A6(\=KAVW"ND*R)>&&7'T+ZHB<
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M/LWRKW7&E>A'<;ZL$(0:XX(HQF,,M&(2Q.X]'\KD#$- <N10E: [+42G+?K
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M;G-E;G0N:'1M4$L! A0#%     @ 5TMR6 *V!-AE" , 4-(8 !$
M     ( !Z@(  &5X9'@M,C R,S$R,S$N:'1M4$L! A0#%     @ 5TMR6#MC
MD7ZI$0  9+T  !$              ( !?@L# &5X9'@M,C R,S$R,S$N>'-D
M4$L! A0#%     @ 5TMR6(:L+8>[(@  95H! !4              ( !5AT#
M &5X9'@M,C R,S$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( %=+<E@[\79I$$@
M (@F P 5              "  41  P!E>&1X+3(P,C,Q,C,Q7V1E9BYX;6Q0
M2P$"% ,4    " !72W)8X^=W'G%Q  "3=   %               @ &'B ,
M97AD>"TR,#(S,3(S,5]G,2YJ<&=02P$"% ,4    " !72W)8V7X0L*<J P!7
MD , %               @ $J^@, 97AD>"TR,#(S,3(S,5]G,BYJ<&=02P$"
M% ,4    " !72W)8/4[9ZYR:! !H1P4 %               @ $#)0< 97AD
M>"TR,#(S,3(S,5]G,RYJ<&=02P$"% ,4    " !72W)8;5D43/X! 0 \%@H
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MR&P- 'AG;C,Q,2TQ,C,Q,C,N:'1M4$L! A0#%     @ 5TMR6-R#\\<L"
MK2X  !$              ( !+W4- 'AG;C,Q,BTQ,C,Q,C,N:'1M4$L! A0#
M%     @ 5TMR6,Y[BF>V!   XAT  !$              ( !BGT- 'AG;C,R
B,2TQ,C,Q,C,N:'1M4$L%!@     .  X H ,  &^"#0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>exdx-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:exdx="http://www.exagen.com/20231231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="exdx-20231231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2024-03-14</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">exdx:TwoSuppliersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">exdx:TwoSuppliersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:Government1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:Government1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:ClientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:ClientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-24</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2023-10-24</startDate>
            <endDate>2023-10-24</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-28</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-28</startDate>
            <endDate>2023-04-28</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:EquipmentNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:EquipmentNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:EquipmentNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">exdx:OfficeAndLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">exdx:OfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">exdx:OfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:PrometheusLaboratoriesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:AlleghenyHealthNetworkResearchInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exdx:AHNCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exdx:AHNCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">exdx:USDepartmentOfJusticeCaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-23</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:A2017TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:DebtOtherThanAmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">exdx:ShelfRegistrationStatementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">exdx:CowenEquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-15</startDate>
            <endDate>2022-09-15</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationJan192026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationMar312026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationApr12026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationSep72024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationDec72025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:NoExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:IncentiveAwardPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:IncentiveAwardPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exdx:CommonSharesAvailableForGrantUnderThe2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:IncentiveAwardPlan2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-01</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-01</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">exdx:TaxYearsThroughDecember312017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="installment">
        <measure>exdx:installment</measure>
    </unit>
    <unit id="segment">
        <measure>exdx:segment</measure>
    </unit>
    <unit id="unit">
        <measure>exdx:unit</measure>
    </unit>
    <unit id="supplier">
        <measure>exdx:supplier</measure>
    </unit>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-33">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-34">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-35">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-36">0001274737</dei:EntityCentralIndexKey>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-43" id="f-288">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:NumberOfReportingUnits contextRef="c-1" decimals="INF" id="f-331" unitRef="unit">1</us-gaap:NumberOfReportingUnits>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-332"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-5" id="f-387">http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-4" id="f-388">http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:LesseeFinanceLeaseTermOfContract1 contextRef="c-43" id="f-440">P3Y</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-4" id="f-445">http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-4" id="f-450">http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-4" id="f-455">http://fasb.org/us-gaap/2023#OperatingLeaseLiabilityNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-5" id="f-456">http://fasb.org/us-gaap/2023#OperatingLeaseLiabilityNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-4">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-3">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-39049</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">EXAGEN INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">20-0434866</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">1261 Liberty Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Vista</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">92081</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">(760)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">560-1501</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">XGN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-19">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-20">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-22">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-23">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-24">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-25">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c-1" id="f-26">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-27">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-28">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-29">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="-5" id="f-30" unitRef="usd">37300000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-31" unitRef="shares">17235751</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-32">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Certain information required to be disclosed in Part III of this report is incorporated by reference from the registrant's definitive Proxy Statement for the 2024 Annual Meeting of Stockholders, which proxy statement will be filed not later than 120 days after the end of the fiscal year covered by this Form 10-K.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId contextRef="c-1" id="f-37">243</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-38">BDO USA, P.C.</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-39">San Diego, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-40" unitRef="usd">36493000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-3" id="f-41" unitRef="usd">62391000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-3" id="f-42" unitRef="usd">6551000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-5" decimals="-3" id="f-43" unitRef="usd">6077000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssets contextRef="c-4" decimals="-3" id="f-44" unitRef="usd">4797000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets contextRef="c-5" decimals="-3" id="f-45" unitRef="usd">4143000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-46" unitRef="usd">47841000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-5" decimals="-3" id="f-47" unitRef="usd">72611000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-4" decimals="-3" id="f-48" unitRef="usd">5201000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-5" decimals="-3" id="f-49" unitRef="usd">8197000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-50" unitRef="usd">3286000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-51" unitRef="usd">4885000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-52" unitRef="usd">616000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-5" decimals="-3" id="f-53" unitRef="usd">528000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-54" unitRef="usd">56944000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-5" decimals="-3" id="f-55" unitRef="usd">86221000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-56" unitRef="usd">3131000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-5" decimals="-3" id="f-57" unitRef="usd">3046000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-58" unitRef="usd">976000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-59" unitRef="usd">1040000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-4" decimals="-3" id="f-60" unitRef="usd">264000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-5" decimals="-3" id="f-61" unitRef="usd">190000</us-gaap:LongTermDebtCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-62" unitRef="usd">7531000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-63" unitRef="usd">5347000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-64" unitRef="usd">11902000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-65" unitRef="usd">9623000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-4" decimals="-3" id="f-66" unitRef="usd">19231000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-5" decimals="-3" id="f-67" unitRef="usd">28778000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-68" unitRef="usd">2760000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-69" unitRef="usd">4493000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-70" unitRef="usd">357000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-5" decimals="-3" id="f-71" unitRef="usd">867000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-72" unitRef="usd">34250000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-5" decimals="-3" id="f-73" unitRef="usd">43761000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-74" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-5" id="f-75" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-76"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-77"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-78" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-79" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-80" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-81" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-5" decimals="INF" id="f-82" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c-5" decimals="INF" id="f-83" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-3" id="f-84" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-5" decimals="-3" id="f-85" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-86"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-87"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-88" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-89" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-90" unitRef="shares">17045954</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-91" unitRef="shares">17045954</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-92" unitRef="shares">16549984</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-5" decimals="INF" id="f-93" unitRef="shares">16549984</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-94" unitRef="usd">17000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-5" decimals="-3" id="f-95" unitRef="usd">17000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-3" id="f-96" unitRef="usd">301893000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-5" decimals="-3" id="f-97" unitRef="usd">297970000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-98" unitRef="usd">-279216000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-3" id="f-99" unitRef="usd">-255527000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-100" unitRef="usd">22694000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-101" unitRef="usd">42460000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-102" unitRef="usd">56944000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-5" decimals="-3" id="f-103" unitRef="usd">86221000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-104" unitRef="usd">52548000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-3" id="f-105" unitRef="usd">45563000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="-3" id="f-106" unitRef="usd">23092000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-6" decimals="-3" id="f-107" unitRef="usd">24214000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-108" unitRef="usd">47428000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-6" decimals="-3" id="f-109" unitRef="usd">52018000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-110" unitRef="usd">4865000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-6" decimals="-3" id="f-111" unitRef="usd">9876000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="-3" id="f-112" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-6" decimals="-3" id="f-113" unitRef="usd">5506000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:CostsAndExpenses contextRef="c-1" decimals="-3" id="f-114" unitRef="usd">75385000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-6" decimals="-3" id="f-115" unitRef="usd">91614000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-116" unitRef="usd">-22837000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-6" decimals="-3" id="f-117" unitRef="usd">-46051000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense contextRef="c-1" decimals="-3" id="f-118" unitRef="usd">2335000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-6" decimals="-3" id="f-119" unitRef="usd">2448000</us-gaap:InterestExpense>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-1" decimals="-3" id="f-120" unitRef="usd">1516000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-6" decimals="-3" id="f-121" unitRef="usd">830000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:IncomeLossAttributableToParent contextRef="c-1" decimals="-3" id="f-122" unitRef="usd">-23656000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent contextRef="c-6" decimals="-3" id="f-123" unitRef="usd">-47669000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-124" unitRef="usd">33000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-125" unitRef="usd">-282000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-126" unitRef="usd">-23689000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-127" unitRef="usd">-47387000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-128"
      unitRef="usdPerShare">-1.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-129"
      unitRef="usdPerShare">-1.34</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-130"
      unitRef="usdPerShare">-2.77</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-131"
      unitRef="usdPerShare">-2.77</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-132" unitRef="shares">17679467</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-133" unitRef="shares">17679467</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="0" id="f-134" unitRef="shares">17082348</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="0" id="f-135" unitRef="shares">17082348</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-7" decimals="INF" id="f-136" unitRef="shares">16164994</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-7" decimals="-3" id="f-137" unitRef="usd">16000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-138" unitRef="usd">293060000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-3" id="f-139" unitRef="usd">-208140000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-3" id="f-140" unitRef="usd">84936000</us-gaap:StockholdersEquity>
    <exdx:IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares
      contextRef="c-11"
      decimals="INF"
      id="f-141"
      unitRef="shares">64064</exdx:IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesShares>
    <exdx:IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue contextRef="c-12" decimals="-3" id="f-142" unitRef="usd">239000</exdx:IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue>
    <exdx:IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue contextRef="c-6" decimals="-3" id="f-143" unitRef="usd">239000</exdx:IssuanceOfStockFromVestedRestrictedStockUnitsAndPaymentOfEmployeesTaxesValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-11"
      decimals="INF"
      id="f-144"
      unitRef="shares">245186</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-11" decimals="-3" id="f-145" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-12" decimals="-3" id="f-146" unitRef="usd">60000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-6" decimals="-3" id="f-147" unitRef="usd">61000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-11"
      decimals="INF"
      id="f-148"
      unitRef="shares">75740</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-12" decimals="-3" id="f-149" unitRef="usd">385000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-6" decimals="-3" id="f-150" unitRef="usd">385000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-12" decimals="-3" id="f-151" unitRef="usd">4704000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-6" decimals="-3" id="f-152" unitRef="usd">4704000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-153" unitRef="usd">-47387000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-154" unitRef="usd">-47387000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-14"
      decimals="INF"
      id="f-155"
      unitRef="shares">16549984</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-14" decimals="-3" id="f-156" unitRef="usd">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-15" decimals="-3" id="f-157" unitRef="usd">297970000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-3" id="f-158" unitRef="usd">-255527000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-159" unitRef="usd">42460000</us-gaap:StockholdersEquity>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-17"
      decimals="INF"
      id="f-160"
      unitRef="shares">273042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-17"
      decimals="INF"
      id="f-161"
      unitRef="shares">93335</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-18" decimals="-3" id="f-162" unitRef="usd">27000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-3" id="f-163" unitRef="usd">27000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-17"
      decimals="INF"
      id="f-164"
      unitRef="shares">129593</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-18" decimals="-3" id="f-165" unitRef="usd">279000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-1" decimals="-3" id="f-166" unitRef="usd">279000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-18" decimals="-3" id="f-167" unitRef="usd">3617000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-168" unitRef="usd">3617000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-19" decimals="-3" id="f-169" unitRef="usd">-23689000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-170" unitRef="usd">-23689000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-20"
      decimals="INF"
      id="f-171"
      unitRef="shares">17045954</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-172" unitRef="usd">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-173" unitRef="usd">301893000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-174" unitRef="usd">-279216000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-175" unitRef="usd">22694000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-176" unitRef="usd">-23689000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-177" unitRef="usd">-47387000</us-gaap:NetIncomeLoss>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization contextRef="c-1" decimals="-3" id="f-178" unitRef="usd">2168000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization contextRef="c-6" decimals="-3" id="f-179" unitRef="usd">1557000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-1" decimals="-3" id="f-180" unitRef="usd">156000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-6" decimals="-3" id="f-181" unitRef="usd">161000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:PaidInKindInterest contextRef="c-1" decimals="-3" id="f-182" unitRef="usd">363000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest contextRef="c-6" decimals="-3" id="f-183" unitRef="usd">551000</us-gaap:PaidInKindInterest>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-1" decimals="-3" id="f-184" unitRef="usd">0</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-6" decimals="-3" id="f-185" unitRef="usd">-306000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c-1" decimals="-3" id="f-186" unitRef="usd">-189000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c-6" decimals="-3" id="f-187" unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets1>
    <exdx:GainLossOnDispositionOfLeaseAssignment contextRef="c-1" decimals="-3" id="f-188" unitRef="usd">-1470000</exdx:GainLossOnDispositionOfLeaseAssignment>
    <exdx:GainLossOnDispositionOfLeaseAssignment contextRef="c-6" decimals="-3" id="f-189" unitRef="usd">0</exdx:GainLossOnDispositionOfLeaseAssignment>
    <exdx:NonCashLeaseExpense contextRef="c-1" decimals="-3" id="f-190" unitRef="usd">939000</exdx:NonCashLeaseExpense>
    <exdx:NonCashLeaseExpense contextRef="c-6" decimals="-3" id="f-191" unitRef="usd">967000</exdx:NonCashLeaseExpense>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-1" decimals="-3" id="f-192" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-6" decimals="-3" id="f-193" unitRef="usd">397000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="-3" id="f-194" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-6" decimals="-3" id="f-195" unitRef="usd">5506000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-196" unitRef="usd">3617000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-6" decimals="-3" id="f-197" unitRef="usd">4704000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-1" decimals="-3" id="f-198" unitRef="usd">0</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-6" decimals="-3" id="f-199" unitRef="usd">-36000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-200" unitRef="usd">474000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-6" decimals="-3" id="f-201" unitRef="usd">-3577000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets contextRef="c-1" decimals="-3" id="f-202" unitRef="usd">654000</exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets>
    <exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets contextRef="c-6" decimals="-3" id="f-203" unitRef="usd">505000</exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-1" decimals="-3" id="f-204" unitRef="usd">101000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-6" decimals="-3" id="f-205" unitRef="usd">47000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-206" unitRef="usd">-1010000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-6" decimals="-3" id="f-207" unitRef="usd">-854000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-208" unitRef="usd">67000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-6" decimals="-3" id="f-209" unitRef="usd">901000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c-1" decimals="-3" id="f-210" unitRef="usd">2497000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c-6" decimals="-3" id="f-211" unitRef="usd">-1402000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-212" unitRef="usd">-14462000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-6" decimals="-3" id="f-213" unitRef="usd">-32144000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-214" unitRef="usd">828000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-6" decimals="-3" id="f-215" unitRef="usd">4318000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-216" unitRef="usd">24000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-6" decimals="-3" id="f-217" unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-218" unitRef="usd">-804000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-6" decimals="-3" id="f-219" unitRef="usd">-4318000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-220" unitRef="usd">27000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-6" decimals="-3" id="f-221" unitRef="usd">61000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-222" unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-6" decimals="-3" id="f-223" unitRef="usd">239000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromStockPlans contextRef="c-1" decimals="-3" id="f-224" unitRef="usd">279000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans contextRef="c-6" decimals="-3" id="f-225" unitRef="usd">385000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-1" decimals="-3" id="f-226" unitRef="usd">697000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-6" decimals="-3" id="f-227" unitRef="usd">667000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c-1" decimals="-3" id="f-228" unitRef="usd">241000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c-6" decimals="-3" id="f-229" unitRef="usd">29000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-1" decimals="-3" id="f-230" unitRef="usd">10000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-6" decimals="-3" id="f-231" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-232" unitRef="usd">-10632000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-6" decimals="-3" id="f-233" unitRef="usd">-489000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-234" unitRef="usd">-25898000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-6" decimals="-3" id="f-235" unitRef="usd">-36951000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-236" unitRef="usd">62591000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-10" decimals="-3" id="f-237" unitRef="usd">99542000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-238" unitRef="usd">36693000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-239" unitRef="usd">62591000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-240" unitRef="usd">1737000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-6" decimals="-3" id="f-241" unitRef="usd">1732000</us-gaap:InterestPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability contextRef="c-1" decimals="-3" id="f-242" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability contextRef="c-6" decimals="-3" id="f-243" unitRef="usd">741000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <exdx:EquipmentPurchasedUnderNotesPayableObligations contextRef="c-1" decimals="-3" id="f-244" unitRef="usd">250000</exdx:EquipmentPurchasedUnderNotesPayableObligations>
    <exdx:EquipmentPurchasedUnderNotesPayableObligations contextRef="c-6" decimals="-3" id="f-245" unitRef="usd">807000</exdx:EquipmentPurchasedUnderNotesPayableObligations>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-246" unitRef="usd">66000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-6" decimals="-3" id="f-247" unitRef="usd">182000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="c-1" id="f-248">Organization&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Exagen Inc. (the Company) is a commercial-stage diagnostics company which exists to provide clarity in autoimmune disease decision making with the goal of improving patients' clinical outcomes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has incurred recurring losses and negative cash flows from operating activities since inception. The Company anticipates that it will continue to incur net losses into the foreseeable future. At December&#160;31, 2023, the Company had cash and cash equivalents of $36.5 million and had an accumulated deficit of $279.2 million. Since inception, the Company has financed its operations primarily through a combination of equity financings, debt financing arrangements, and revenue from sales of the Company's products. Based on the Company's current business plan, management believes that its existing capital resources will be sufficient to fund the Company's obligations for at least twelve months following the issuance of these financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;To execute its business plans, the Company may need additional funding to support its continuing operations and pursue its growth strategy. Until such time as the Company can achieve significant cash flows from operations, if ever, it expects to finance its operations through the sale of its stock, debt financings or other strategic transactions. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its programs, product portfolio expansion plans or commercialization efforts, which could have a material adverse effect on the Company's business, operating results and financial condition and the Company's ability to achieve its intended business objectives.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-5" id="f-249" unitRef="usd">36500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-5" id="f-250" unitRef="usd">-279200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-251">Summary of Significant Accounting Policies&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Basis of Presentation and Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of the accompanying financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Significant estimates and assumptions made in the accompanying financial statements include, but are not limited to revenue recognition, the estimated incremental borrowing rate for the determination of the Company's operating lease right-of-use (ROU) assets and the recoverability of its long-lived assets and net deferred tax assets (and related valuation allowance). The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Concentration of Credit Risk and Other Risk and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its cash or cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Significant payors and customers are those which represent more than 10% of the Company's total revenue or accounts receivable balance at each respective balance sheet date. For each significant payor and customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accounts Receivable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For the years ended December&#160;31, 2023 and 2022, approximately 88% and 84%, respectively, of the Company's revenue was related to the AVISE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; CTD test.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company is dependent on key suppliers for certain laboratory materials. For each of the years ended December&#160;31, 2023 and 2022, approximately 96% of the Company's diagnostic testing supplies were purchased from two suppliers. An interruption in the supply of these materials would impact the Company's ability to perform testing services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table includes the Company's revenues as disaggregated by payor and customer category (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Client(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt"&gt;Includes hospitals, other laboratories, etc.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt"&gt;Includes patient self-pay.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company considers all highly-liquid investments purchased with a remaining maturity date of three months or less upon acquisition to be cash equivalents. These investments are stated at cost, which approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has an arrangement with a financial institution with which it has an existing banking relationship, whereby in exchange for the issuance of corporate credit cards, the Company agreed to obtain a certificate of deposit with this financial institution in the amount of $0.2 million as collateral for the balances borrowed on these cards. The Company has classified the value of this certificate of deposit (including all interest earned thereon) within other assets in the accompanying balance sheets. The Company has the right to terminate the credit card program at any time. Upon termination of the credit card program and repayment of all outstanding balances owed, the Company may redeem the certificate of deposit (and all interest earned thereon).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash, cash equivalents and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property and equipment are stated at cost, net of depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between &lt;span style="-sec-ix-hidden:f-288"&gt;three&lt;/span&gt; and five years. Leasehold improvements are amortized on a straight-line basis over the lesser of the estimated useful life or the remaining term of the related lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operating expenses in the statements of operations in the period realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Long-lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s long-lived assets are comprised principally of its property and equipment and operating lease assets. The Company amortizes all finite lived intangible assets over their respective estimated useful lives. Operating lease assets are amortized over the term of the leases. In considering whether long-lived assets are impaired, the Company combines its intangible assets and other long-lived assets into groupings, a determination which is made principally on the basis of whether the assets are specific to a particular test offered or technology being developed. If the Company identifies a change in the circumstances related to its long-lived assets that indicates the carrying value of any such asset may not be recoverable, the Company will perform an impairment analysis. A long-lived asset is deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset&#x2019;s carrying amount. Management&#x2019;s estimates of future cash flows are impacted by projected test volume and levels of reimbursement, as well as expectations related to the future cost structure of the entity. Any required impairment loss would be measured as the amount by which the asset&#x2019;s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company operates in a single operating segment and reporting unit for the measurement of goodwill. Goodwill was reviewed for impairment annually (during the fourth quarter) or more frequently if indicators of impairment existed. The Company would first assess qualitative factors to determine whether it was more likely than not that the fair value of the reporting unit was less than its carrying amount as a basis for determining whether it was necessary to perform a quantitative assessment. If, after assessing qualitative factors, the Company determined it was not more likely than not that the fair value of a reporting unit was less than its carrying amount, then performing a quantitative assessment was unnecessary. If deemed necessary, a quantitative assessment compared the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeded its carrying amount, goodwill was not considered impaired; otherwise, an impairment loss was recorded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company categorizes leases at their commencement as either operating or finance leases. The Company recognizes operating lease ROU assets and operating lease liabilities for each lease arrangement identified. Lease liabilities are recorded at the present value of future lease payments discounted using the Company's incremental borrowing rate for the lease established at the commencement date. The incremental borrowing rate is the rate of interest the Company would have to pay to borrow, on a collateralized basis over a similar term and in a similar economic environment, an amount equal to the total lease payments. The Company primarily considers industry data, its credit rating and the lease term to determine its incremental borrowing rate. ROU assets are measured at the amount of the lease liability plus any initial direct costs, less any lease incentives received before commencement. Lease expense is recognized as a single lease cost over the lease term on a straight-line basis. The Company has elected not to apply the recognition requirements to short-term leases and not to separate non-lease components from lease components for its leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Clinical Studies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;From time to time, the Company engages in efforts to scientifically measure and document the application and efficacy of its various testing products. These arrangements typically require the Company to pay a fee to a third-party scientific investigator (usually a physician or research institution) for each subject enrolled in a clinical study, and the Company accrues expenses based on estimated progress of services performed, including actual level of subjects enrolled and progress of the clinical studies. Payments made prior to the completion of clinical study services are capitalized as a prepaid expense. The prepaid amounts are expensed as the related goods are delivered or the services are performed, or when it is no longer expected that the goods will be delivered or the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;services rendered. Expenses associated with clinical study activities are recorded in research and development expenses in the accompanying statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (each, a payor) consist of commercial payors (healthcare insurers), government payors (primarily Medicare and Medicaid), client payors (i.e., hospitals, other laboratories, etc.) and patient self-pay. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognizes revenue in accordance with Accounting Standards Codification Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; (ASC 606) and follows a five-step process to determine the amount and timing of revenue recognized: (1) identify the contract with the customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to performance obligations in the contract, and (5) recognize revenue when (or as) the performance obligation is satisfied. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Payors are generally billed at the Company's list price, unless a separate pricing contract is in place. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions. Adjustments are recorded in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, are recorded upon settlement. Included in revenues for the years ended December&#160;31, 2023 and 2022 was a net revenue increase of $3.4 million and a net revenue decrease of $2.4 million, respectively, associated with changes in estimated variable consideration related to performance obligations satisfied in previous periods. The transaction price is estimated using an expected value method on a portfolio basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Variable consideration is included in the transaction price only to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainties with respect to the amount are resolved. The Company's portfolios are grouped per payor (i.e. each individual commercial payor, Medicare, Medicaid, client payors, patient self-pay, etc.) and per test. Consideration may be constrained and excluded from the transaction price in situations where there is no contractually agreed upon reimbursement coverage or in absence of a predictable pattern and history of collectability with a payor. Accordingly, in such situations revenues are recognized on the basis of actual cash collections. Additionally, from time to time, the Company may issue refunds to payors for overpayments or amounts billed in error. Any refunds are accounted for as reductions in revenues in the statement of operations as an element of variable consideration. The estimated expected refunds are accrued as a liability on the Company&#x2019;s balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information, along with any requested medical or other claims-related information to the healthcare insurers. This generally occurs within 30 to 90 days of billing, however, the amount and timing of any reimbursements or collections for our billed tests may vary by payor and other circumstances. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounts Receivable and Allowance for Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We accrue an allowance for credit losses against our accounts receivable based on management&#x2019;s current estimate of amounts that will not be collected. Management&#x2019;s estimates are typically based on historical loss information adjusted for current conditions. We generally do not perform evaluations of the financial condition of our customers and generally do not require collateral. The allowance for credit losses was zero as of December&#160;31, 2023. There was no allowance for credit losses recognized as of December 31, 2022. Adjustments for implicit price concessions attributable to variable consideration, as discussed above, are incorporated into the measurement of the accounts receivable balances and are not part of the allowance for credit losses.  Accounts receivable was $6.6 million, $6.1 million, $9.7 million for the years ended December&#160;31, 2023, 2022 and 2021, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense; materials; laboratory supplies; consulting costs; costs associated with setting up and conducting clinical studies; depreciation; amortization and allocated overhead, including rent and utilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Advertising and Marketing Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $1.5 million and $3.0 million for the years ended December&#160;31, 2023 and 2022, respectively, and are included in selling, general and administrative expenses in the accompanying statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Shipping and Handling Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Costs incurred for shipping and handling are included in costs of revenue in the accompanying statements of operations and were approximately $2.5 million and $2.7 million for the years ended December&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The fair value of stock options and purchases under the Company's 2019 Employee Stock Purchase Plan (ESPP) rights is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The BSM option pricing model incorporates various inputs, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. Volatility is based on the Company's historical calculated volatility since being publicly traded. The weighted-average expected term of options was calculated using the simplified method, as we have concluded that our stock option exercise history does not provide a reasonable basis upon which to estimate the expected term. The risk-free interest rate for periods within the contractual term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is zero, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair value of each restricted stock unit (RSU) is determined on the grant date using the closing price of the Company's common stock on that date. The Company's RSUs generally vest in equal annual installments over four years from the date of grant or, for grants to new hires, date of hire. Vesting of RSUs is subject to the holder's continued service with the Company. The Company issues new shares to satisfy RSUs upon vesting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized as an expense in the period that includes the enactment date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would adjust the deferred tax asset valuation allowance, which would reduce the provision for income taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company records uncertain tax positions on the basis of a two-step process whereby (i) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. The weighted-average number of shares used to compute basic and diluted shares includes shares issuable upon the exercise of pre-funded warrants at a nominal price. Potentially dilutive common stock equivalents are comprised of warrants for the purchase of common stock, stock options, RSUs outstanding under the Company's 2019 Incentive Award Plan (the 2019 Plan) and shares of the Company's common stock pursuant to the ESPP. For each of the years ended December&#160;31, 2023 and 2022, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as the inclusion of the potentially dilutive securities would be antidilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;409,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;409,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;986,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,421,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,387,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,036,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,828,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,925,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012 (JOBS Act), the Company meets the definition of an emerging growth company. The Company has elected to use the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Unless otherwise discussed, Accounting Standards Updates (ASU) not included in the Company&#x2019;s disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on the Company&#x2019;s financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In November 2023, the FASB issued ASU No. 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; (ASU 2023-07), which requires public entities to disclose significant segment expenses that are regularly provided to the Chief Operating Decision Maker (CODM) and details of how the CODM uses financial reporting to assess the performance of a segment. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. This ASU will likely result in additional required disclosure when adopted. The Company is currently evaluating the provisions of this ASU and the impact on its financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In December 2023, the FASB issued ASU 2023-09,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"&gt; Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; (ASU 2023-09), which requires additional income tax disclosures in the rate reconciliation table for federal, state and foreign income taxes, in addition to more details about the reconciling items in some categories &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;when items meet a certain quantitative threshold. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 with early adoption permitted. The Company is currently evaluating the impact of this standard, but does not expect that it will have a material impact on its financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, which requires the measurement of expected credit losses (based on historical experience, current conditions and reasonable forecasts) for financial instruments (such as accounts receivable) held at the reporting date which are carried at amortized cost. The main objective of this ASU is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. In November 2018, the FASB issued ASU 2018-19, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Codification Improvements to Topic 326, Financing Instruments-Credit Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, which included an amendment of the effective date for nonpublic entities. The Company adopted this pronouncement on January 1, 2023. The adoption did not have material impact on its financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#x2019;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in ASU 2020-06 are effective for smaller reporting companies as defined by the SEC for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. The Company early adopted ASU 2020-06 as of January 1, 2023. The adoption did not have an impact on its financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-252">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Concentration of Credit Risk and Other Risk and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its cash or cash equivalents.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="c-1" id="f-253">For each significant payor and customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accounts Receivable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-23" decimals="2" id="f-254" unitRef="number">0.34</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-24" decimals="2" id="f-255" unitRef="number">0.39</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-25" decimals="2" id="f-256" unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-26" decimals="2" id="f-257" unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-27" decimals="2" id="f-258" unitRef="number">0.42</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-28" decimals="2" id="f-259" unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-29" decimals="2" id="f-260" unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-30" decimals="2" id="f-261" unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-31" decimals="2" id="f-262" unitRef="number">0.88</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-32" decimals="2" id="f-263" unitRef="number">0.84</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-33" decimals="2" id="f-264" unitRef="number">0.96</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-34" decimals="2" id="f-265" unitRef="number">0.96</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-266">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table includes the Company's revenues as disaggregated by payor and customer category (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Client(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt"&gt;Includes hospitals, other laboratories, etc.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt"&gt;Includes patient self-pay.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-35" decimals="-3" id="f-267" unitRef="usd">23985000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-36" decimals="-3" id="f-268" unitRef="usd">18975000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-37" decimals="-3" id="f-269" unitRef="usd">18002000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-38" decimals="-3" id="f-270" unitRef="usd">17687000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-39" decimals="-3" id="f-271" unitRef="usd">9949000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-40" decimals="-3" id="f-272" unitRef="usd">7928000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-41" decimals="-3" id="f-273" unitRef="usd">612000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-42" decimals="-3" id="f-274" unitRef="usd">973000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-275" unitRef="usd">52548000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-3" id="f-276" unitRef="usd">45563000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-277">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company considers all highly-liquid investments purchased with a remaining maturity date of three months or less upon acquisition to be cash equivalents. These investments are stated at cost, which approximates fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:RestrictedCash contextRef="c-4" decimals="-5" id="f-278" unitRef="usd">200000</us-gaap:RestrictedCash>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock contextRef="c-1" id="f-280">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash, cash equivalents and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="c-1" id="f-279">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash, cash equivalents and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-281" unitRef="usd">36493000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-3" id="f-282" unitRef="usd">62391000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash contextRef="c-4" decimals="-3" id="f-283" unitRef="usd">200000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-5" decimals="-3" id="f-284" unitRef="usd">200000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-285" unitRef="usd">36693000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-286" unitRef="usd">62591000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-287">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property and equipment are stated at cost, net of depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between &lt;span style="-sec-ix-hidden:f-288"&gt;three&lt;/span&gt; and five years. Leasehold improvements are amortized on a straight-line basis over the lesser of the estimated useful life or the remaining term of the related lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operating expenses in the statements of operations in the period realized.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-44" id="f-289">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c-1" id="f-290">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Long-lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s long-lived assets are comprised principally of its property and equipment and operating lease assets. The Company amortizes all finite lived intangible assets over their respective estimated useful lives. Operating lease assets are amortized over the term of the leases. In considering whether long-lived assets are impaired, the Company combines its intangible assets and other long-lived assets into groupings, a determination which is made principally on the basis of whether the assets are specific to a particular test offered or technology being developed. If the Company identifies a change in the circumstances related to its long-lived assets that indicates the carrying value of any such asset may not be recoverable, the Company will perform an impairment analysis. A long-lived asset is deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset&#x2019;s carrying amount. Management&#x2019;s estimates of future cash flows are impacted by projected test volume and levels of reimbursement, as well as expectations related to the future cost structure of the entity. Any required impairment loss would be measured as the amount by which the asset&#x2019;s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="c-1" id="f-291">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company operates in a single operating segment and reporting unit for the measurement of goodwill. Goodwill was reviewed for impairment annually (during the fourth quarter) or more frequently if indicators of impairment existed. The Company would first assess qualitative factors to determine whether it was more likely than not that the fair value of the reporting unit was less than its carrying amount as a basis for determining whether it was necessary to perform a quantitative assessment. If, after assessing qualitative factors, the Company determined it was not more likely than not that the fair value of a reporting unit was less than its carrying amount, then performing a quantitative assessment was unnecessary. If deemed necessary, a quantitative assessment compared the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeded its carrying amount, goodwill was not considered impaired; otherwise, an impairment loss was recorded.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-292">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company categorizes leases at their commencement as either operating or finance leases. The Company recognizes operating lease ROU assets and operating lease liabilities for each lease arrangement identified. Lease liabilities are recorded at the present value of future lease payments discounted using the Company's incremental borrowing rate for the lease established at the commencement date. The incremental borrowing rate is the rate of interest the Company would have to pay to borrow, on a collateralized basis over a similar term and in a similar economic environment, an amount equal to the total lease payments. The Company primarily considers industry data, its credit rating and the lease term to determine its incremental borrowing rate. ROU assets are measured at the amount of the lease liability plus any initial direct costs, less any lease incentives received before commencement. Lease expense is recognized as a single lease cost over the lease term on a straight-line basis. The Company has elected not to apply the recognition requirements to short-term leases and not to separate non-lease components from lease components for its leases.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <exdx:ClinicalStudyPolicyPolicyTextBlock contextRef="c-1" id="f-293">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Clinical Studies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;From time to time, the Company engages in efforts to scientifically measure and document the application and efficacy of its various testing products. These arrangements typically require the Company to pay a fee to a third-party scientific investigator (usually a physician or research institution) for each subject enrolled in a clinical study, and the Company accrues expenses based on estimated progress of services performed, including actual level of subjects enrolled and progress of the clinical studies. Payments made prior to the completion of clinical study services are capitalized as a prepaid expense. The prepaid amounts are expensed as the related goods are delivered or the services are performed, or when it is no longer expected that the goods will be delivered or the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;services rendered. Expenses associated with clinical study activities are recorded in research and development expenses in the accompanying statement of operations.&lt;/span&gt;&lt;/div&gt;</exdx:ClinicalStudyPolicyPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c-1" id="f-294">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (each, a payor) consist of commercial payors (healthcare insurers), government payors (primarily Medicare and Medicaid), client payors (i.e., hospitals, other laboratories, etc.) and patient self-pay. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognizes revenue in accordance with Accounting Standards Codification Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; (ASC 606) and follows a five-step process to determine the amount and timing of revenue recognized: (1) identify the contract with the customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to performance obligations in the contract, and (5) recognize revenue when (or as) the performance obligation is satisfied. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Payors are generally billed at the Company's list price, unless a separate pricing contract is in place. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions. Adjustments are recorded in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, are recorded upon settlement. Included in revenues for the years ended December&#160;31, 2023 and 2022 was a net revenue increase of $3.4 million and a net revenue decrease of $2.4 million, respectively, associated with changes in estimated variable consideration related to performance obligations satisfied in previous periods. The transaction price is estimated using an expected value method on a portfolio basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Variable consideration is included in the transaction price only to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainties with respect to the amount are resolved. The Company's portfolios are grouped per payor (i.e. each individual commercial payor, Medicare, Medicaid, client payors, patient self-pay, etc.) and per test. Consideration may be constrained and excluded from the transaction price in situations where there is no contractually agreed upon reimbursement coverage or in absence of a predictable pattern and history of collectability with a payor. Accordingly, in such situations revenues are recognized on the basis of actual cash collections. Additionally, from time to time, the Company may issue refunds to payors for overpayments or amounts billed in error. Any refunds are accounted for as reductions in revenues in the statement of operations as an element of variable consideration. The estimated expected refunds are accrued as a liability on the Company&#x2019;s balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information, along with any requested medical or other claims-related information to the healthcare insurers. This generally occurs within 30 to 90 days of billing, however, the amount and timing of any reimbursements or collections for our billed tests may vary by payor and other circumstances. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-1" decimals="-5" id="f-295" unitRef="usd">3400000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-6" decimals="-5" id="f-296" unitRef="usd">-2400000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="c-1" id="f-297">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Accounts Receivable and Allowance for Credit Losses&lt;/span&gt;&lt;/div&gt;We accrue an allowance for credit losses against our accounts receivable based on management&#x2019;s current estimate of amounts that will not be collected. Management&#x2019;s estimates are typically based on historical loss information adjusted for current conditions. We generally do not perform evaluations of the financial condition of our customers and generally do not require collateral. The allowance for credit losses was zero as of December&#160;31, 2023. There was no allowance for credit losses recognized as of December 31, 2022. Adjustments for implicit price concessions attributable to variable consideration, as discussed above, are incorporated into the measurement of the accounts receivable balances and are not part of the allowance for credit losses.</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest contextRef="c-4" decimals="-5" id="f-298" unitRef="usd">0</us-gaap:FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest>
    <us-gaap:FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest contextRef="c-5" decimals="-5" id="f-299" unitRef="usd">0</us-gaap:FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest>
    <us-gaap:FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest contextRef="c-5" decimals="-5" id="f-300" unitRef="usd">0</us-gaap:FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-5" id="f-301" unitRef="usd">6600000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-5" decimals="-5" id="f-302" unitRef="usd">6100000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-10" decimals="-5" id="f-303" unitRef="usd">9700000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-304">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense; materials; laboratory supplies; consulting costs; costs associated with setting up and conducting clinical studies; depreciation; amortization and allocated overhead, including rent and utilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="c-1" id="f-305">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Advertising and Marketing Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $1.5 million and $3.0 million for the years ended December&#160;31, 2023 and 2022, respectively, and are included in selling, general and administrative expenses in the accompanying statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense contextRef="c-1" decimals="-5" id="f-306" unitRef="usd">1500000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="c-6" decimals="-5" id="f-307" unitRef="usd">3000000.0</us-gaap:AdvertisingExpense>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="c-1" id="f-308">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Shipping and Handling Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Costs incurred for shipping and handling are included in costs of revenue in the accompanying statements of operations and were approximately $2.5 million and $2.7 million for the years ended December&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:CostOfRevenue contextRef="c-45" decimals="-5" id="f-309" unitRef="usd">2500000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-46" decimals="-5" id="f-310" unitRef="usd">2700000</us-gaap:CostOfRevenue>
    <us-gaap:EmployeeStockOwnershipPlanESOPPolicy contextRef="c-1" id="f-311">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The fair value of stock options and purchases under the Company's 2019 Employee Stock Purchase Plan (ESPP) rights is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The BSM option pricing model incorporates various inputs, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. Volatility is based on the Company's historical calculated volatility since being publicly traded. The weighted-average expected term of options was calculated using the simplified method, as we have concluded that our stock option exercise history does not provide a reasonable basis upon which to estimate the expected term. The risk-free interest rate for periods within the contractual term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is zero, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair value of each restricted stock unit (RSU) is determined on the grant date using the closing price of the Company's common stock on that date. The Company's RSUs generally vest in equal annual installments over four years from the date of grant or, for grants to new hires, date of hire. Vesting of RSUs is subject to the holder's continued service with the Company. The Company issues new shares to satisfy RSUs upon vesting.&lt;/span&gt;&lt;/div&gt;</us-gaap:EmployeeStockOwnershipPlanESOPPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-1" decimals="INF" id="f-312" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments
      contextRef="c-1"
      decimals="INF"
      id="f-313"
      unitRef="installment">4</exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c-1" id="f-314">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-315">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized as an expense in the period that includes the enactment date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would adjust the deferred tax asset valuation allowance, which would reduce the provision for income taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company records uncertain tax positions on the basis of a two-step process whereby (i) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-316">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. The weighted-average number of shares used to compute basic and diluted shares includes shares issuable upon the exercise of pre-funded warrants at a nominal price. Potentially dilutive common stock equivalents are comprised of warrants for the purchase of common stock, stock options, RSUs outstanding under the Company's 2019 Incentive Award Plan (the 2019 Plan) and shares of the Company's common stock pursuant to the ESPP. For each of the years ended December&#160;31, 2023 and 2022, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as the inclusion of the potentially dilutive securities would be antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-317">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;409,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;409,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;986,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,421,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,387,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,036,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,828,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,925,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-47" decimals="0" id="f-318" unitRef="shares">409108</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-48" decimals="0" id="f-319" unitRef="shares">409108</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-49" decimals="0" id="f-320" unitRef="shares">986819</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-50" decimals="0" id="f-321" unitRef="shares">1421235</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-51" decimals="0" id="f-322" unitRef="shares">1387459</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-52" decimals="0" id="f-323" unitRef="shares">1036208</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-53" decimals="0" id="f-324" unitRef="shares">44700</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-54" decimals="0" id="f-325" unitRef="shares">58711</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-326" unitRef="shares">2828086</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-6" decimals="0" id="f-327" unitRef="shares">2925262</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-328">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-329"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-330">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012 (JOBS Act), the Company meets the definition of an emerging growth company. The Company has elected to use the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Unless otherwise discussed, Accounting Standards Updates (ASU) not included in the Company&#x2019;s disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on the Company&#x2019;s financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In November 2023, the FASB issued ASU No. 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; (ASU 2023-07), which requires public entities to disclose significant segment expenses that are regularly provided to the Chief Operating Decision Maker (CODM) and details of how the CODM uses financial reporting to assess the performance of a segment. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. This ASU will likely result in additional required disclosure when adopted. The Company is currently evaluating the provisions of this ASU and the impact on its financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In December 2023, the FASB issued ASU 2023-09,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"&gt; Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; (ASU 2023-09), which requires additional income tax disclosures in the rate reconciliation table for federal, state and foreign income taxes, in addition to more details about the reconciling items in some categories &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;when items meet a certain quantitative threshold. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 with early adoption permitted. The Company is currently evaluating the impact of this standard, but does not expect that it will have a material impact on its financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, which requires the measurement of expected credit losses (based on historical experience, current conditions and reasonable forecasts) for financial instruments (such as accounts receivable) held at the reporting date which are carried at amortized cost. The main objective of this ASU is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. In November 2018, the FASB issued ASU 2018-19, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Codification Improvements to Topic 326, Financing Instruments-Credit Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, which included an amendment of the effective date for nonpublic entities. The Company adopted this pronouncement on January 1, 2023. The adoption did not have material impact on its financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#x2019;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in ASU 2020-06 are effective for smaller reporting companies as defined by the SEC for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. The Company early adopted ASU 2020-06 as of January 1, 2023. The adoption did not have an impact on its financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock contextRef="c-1" id="f-333">Other Financial Information&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Diagnostic&#160;testing&#160;supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid product royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid maintenance and insurance contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property and equipment consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Furniture&#160;and&#160;fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,769)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Depreciation and amortization expense for the years ended December&#160;31, 2023 and 2022, was approximately $2.2 million and $1.6 million, respectively. At December&#160;31, 2023 and 2022, the gross book value of assets under finance leases was $2.5 million and $2.8 million, respectively, and is classified in "Laboratory equipment" in the table above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Loss on Lease Assignment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On October 24, 2023, the Company entered into an assignment and assumption (the Assignment and Assumption Agreement) of the Company&#x2019;s previously executed lease agreement with Liberty Vista, LP (formerly known as Geiger Court, LLC) and Mindera Corporation (Mindera), pursuant to which the Company assigned to Mindera the lease of a building located adjacent to the Company's headquarters in Vista, CA. Under the terms of the Assignment and Assumption Agreement, Mindera assumed all obligations under the lease, effective October 31, 2023. As a result of the lease assignment, the Company derecognized the remaining balances related to the associated operating lease ROU asset of $0.7&#160;million, operating lease liability of $0.8&#160;million and leasehold improvements of $1.6&#160;million, resulting in a $1.5&#160;million loss on lease assignment. The loss was classified within selling, general and administrative expenses in the accompanying statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Impairment of Long-Lived Assets and Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the year ended December 31, 2022, the Company recorded an impairment charge of $0.4&#160;million related to previously capitalized equipment used in research and development activities that were halted in the fourth quarter of 2022. The impairment charge was classified within research and development expenses in the accompanying statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the year ended December 31, 2022, the Company also determined that a sustained decrease in its market capitalization constituted an indicator of impairment of goodwill and as a result, instead of performing a qualitative test, the Company chose to proceed directly to performing a quantitative test during the fourth quarter. The Company determined the fair value of the reporting unit using the discounted cash flow (DCF) method, which is considered a Level 3 measurement. In applying the DCF method, cash flows are estimated for a five-year financial forecast developed by management. A terminal value, which represents the value of additional cash flows into perpetuity, is also calculated. Cash flows are then discounted to present value at a discount rate commensurate with their risk. Based on this analysis, the carrying value of the reporting unit was in excess of the fair value and the goodwill was fully impaired. During the year ended December 31, 2022, the Company recorded a goodwill impairment charge of $5.5&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents details of the Company's goodwill for the year ended December 31, 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued and Other Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accrued and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued&#160;payroll&#160;and&#160;related&#160;expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued purchases of goods and services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued clinical study activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-387"&gt;&lt;span style="-sec-ix-hidden:f-388"&gt;Finance lease obligations, current portion&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Refund liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="c-1" id="f-334">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Diagnostic&#160;testing&#160;supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid product royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid maintenance and insurance contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:OtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-335" unitRef="usd">2871000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-336" unitRef="usd">1795000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidRoyalties contextRef="c-4" decimals="-3" id="f-337" unitRef="usd">35000</us-gaap:PrepaidRoyalties>
    <us-gaap:PrepaidRoyalties contextRef="c-5" decimals="-3" id="f-338" unitRef="usd">40000</us-gaap:PrepaidRoyalties>
    <exdx:PrepaidMaintenanceAndInsuranceContracts contextRef="c-4" decimals="-3" id="f-339" unitRef="usd">1860000</exdx:PrepaidMaintenanceAndInsuranceContracts>
    <exdx:PrepaidMaintenanceAndInsuranceContracts contextRef="c-5" decimals="-3" id="f-340" unitRef="usd">2072000</exdx:PrepaidMaintenanceAndInsuranceContracts>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c-4" decimals="-3" id="f-341" unitRef="usd">31000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c-5" decimals="-3" id="f-342" unitRef="usd">236000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-343" unitRef="usd">4797000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-344" unitRef="usd">4143000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-345">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property and equipment consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Furniture&#160;and&#160;fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,769)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-55" decimals="-3" id="f-346" unitRef="usd">98000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-56" decimals="-3" id="f-347" unitRef="usd">98000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-57" decimals="-3" id="f-348" unitRef="usd">5312000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-58" decimals="-3" id="f-349" unitRef="usd">5136000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-59" decimals="-3" id="f-350" unitRef="usd">2185000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-60" decimals="-3" id="f-351" unitRef="usd">1482000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-61" decimals="-3" id="f-352" unitRef="usd">3316000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-62" decimals="-3" id="f-353" unitRef="usd">5223000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-63" decimals="-3" id="f-354" unitRef="usd">59000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-64" decimals="-3" id="f-355" unitRef="usd">1382000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-4" decimals="-3" id="f-356" unitRef="usd">10970000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-5" decimals="-3" id="f-357" unitRef="usd">13321000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization contextRef="c-4" decimals="-3" id="f-358" unitRef="usd">5769000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization contextRef="c-5" decimals="-3" id="f-359" unitRef="usd">5124000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-4" decimals="-3" id="f-360" unitRef="usd">5201000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-5" decimals="-3" id="f-361" unitRef="usd">8197000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-5" id="f-362" unitRef="usd">2200000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-6" decimals="-5" id="f-363" unitRef="usd">1600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization contextRef="c-57" decimals="-5" id="f-364" unitRef="usd">2500000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization contextRef="c-58" decimals="-5" id="f-365" unitRef="usd">2800000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-65" decimals="-5" id="f-366" unitRef="usd">700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-65" decimals="-5" id="f-367" unitRef="usd">800000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LeaseholdImprovementsGross contextRef="c-65" decimals="-5" id="f-368" unitRef="usd">1600000</us-gaap:LeaseholdImprovementsGross>
    <exdx:GainLossOnDispositionOfLeaseAssignment contextRef="c-66" decimals="-5" id="f-369" unitRef="usd">-1500000</exdx:GainLossOnDispositionOfLeaseAssignment>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-6" decimals="-5" id="f-370" unitRef="usd">400000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-6" decimals="-5" id="f-371" unitRef="usd">5500000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="c-1" id="f-372">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents details of the Company's goodwill for the year ended December 31, 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill contextRef="c-10" decimals="-3" id="f-373" unitRef="usd">5506000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-6" decimals="-3" id="f-374" unitRef="usd">5506000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:Goodwill contextRef="c-5" decimals="-3" id="f-375" unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-376">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accrued and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.768%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued&#160;payroll&#160;and&#160;related&#160;expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued purchases of goods and services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued clinical study activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-387"&gt;&lt;span style="-sec-ix-hidden:f-388"&gt;Finance lease obligations, current portion&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Refund liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent contextRef="c-4" decimals="-3" id="f-377" unitRef="usd">4738000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="c-5" decimals="-3" id="f-378" unitRef="usd">2355000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:InterestPayableCurrent contextRef="c-4" decimals="-3" id="f-379" unitRef="usd">139000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent contextRef="c-5" decimals="-3" id="f-380" unitRef="usd">142000</us-gaap:InterestPayableCurrent>
    <exdx:AccruedPurchaseGoodsAndServicesCurrent contextRef="c-4" decimals="-3" id="f-381" unitRef="usd">720000</exdx:AccruedPurchaseGoodsAndServicesCurrent>
    <exdx:AccruedPurchaseGoodsAndServicesCurrent contextRef="c-5" decimals="-3" id="f-382" unitRef="usd">803000</exdx:AccruedPurchaseGoodsAndServicesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="c-4" decimals="-3" id="f-383" unitRef="usd">463000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="c-5" decimals="-3" id="f-384" unitRef="usd">514000</us-gaap:AccruedRoyaltiesCurrent>
    <exdx:AccruedLiabilitiesClinicalStudyCurrent contextRef="c-4" decimals="-3" id="f-385" unitRef="usd">118000</exdx:AccruedLiabilitiesClinicalStudyCurrent>
    <exdx:AccruedLiabilitiesClinicalStudyCurrent contextRef="c-5" decimals="-3" id="f-386" unitRef="usd">162000</exdx:AccruedLiabilitiesClinicalStudyCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-389" unitRef="usd">490000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-390" unitRef="usd">700000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent contextRef="c-4" decimals="-3" id="f-391" unitRef="usd">302000</us-gaap:CustomerRefundLiabilityCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent contextRef="c-5" decimals="-3" id="f-392" unitRef="usd">445000</us-gaap:CustomerRefundLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-393" unitRef="usd">561000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-394" unitRef="usd">226000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-395" unitRef="usd">7531000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-396" unitRef="usd">5347000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-397">Borrowings&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;2017 Term Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In September 2017, the Company executed a term loan agreement (the 2017 Term Loan) with Innovatus Life Sciences Lending Fund I, LP (Innovatus), as amended (the Amended Loan Agreement), pursuant to which the Company borrowed $25.0&#160;million. At December&#160;31, 2023, no additional amounts remained available to borrow under the Amended Loan Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On April 28, 2023, the Company entered into the Amended Loan Agreement. The Amended Loan Agreement was treated as a modification. In connection with the Amended Loan Agreement, the Company repaid $10.0&#160;million of the principal balance outstanding, for which the prepayment premium was waived. Pursuant to the Amended Loan Agreement, the interest rate on all borrowings under the Amended Loan Agreement is the sum (the Basic Rate) of (a) the greater of 8.0% or The Wall Street Journal prime rate (the Prime Rate), plus (b) 2.0%, which is paid-in-kind in the form of additional term loans (PIK Loans). Under the Amended Loan Agreement, an amount equal to 1.5% of the Basic Rate will be payable in-kind and capitalized to the principal amount of the outstanding term loan on a monthly basis until April 1, 2026, after which interest is scheduled to accrue at the Basic Rate. The maturity date of the loan was extended to December 31, 2026. The Company estimated the effective interest rate of this loan to be approximately 11.0% and 8.5% as of December&#160;31, 2023 and 2022, respectively. Accrued interest is due and payable monthly, unless the Company elects to pay paid-in-kind interest. The outstanding principal and accrued interest under the Amended Loan Agreement is to be repaid in ten equal monthly installments commencing in April 2026. Upon repayment of the final installment under the Amended Loan Agreement, the Company is required to pay an additional fee of $1.0&#160;million. This obligation is being accreted into interest expense over the term of the loan using the effective interest method. For the years ended December&#160;31, 2023 and 2022, the Company issued PIK Loans totaling $0.4 million and $0.6 million, respectively. At December&#160;31, 2023, $18.2 million in principal and PIK loans are outstanding, all of which is included in borrowings-non-current portion on the accompanying balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Amended Loan Agreement currently requires a prepayment premium of 1% of the aggregate outstanding principal for any prepayments made prior to November 1, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended Loan Agreement is collateralized by a first priority security interest in substantially all of the Company's assets, including intellectual property. The affirmative covenants of the Amended Loan Agreement require that the Company timely file taxes, maintain good standing and government compliance, maintain liability and other insurance, provide prompt notification of significant corporate events, and furnish audited financial statements within 150 days of fiscal year end without qualification as to the scope of the audit or as to going concern and without any other similar qualification.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The affirmative covenants require that the Company achieve a specified level of revenue, as measured quarterly on a rolling twelve-month basis, however the Company is not required to comply with the revenue covenant for any quarter during which it maintains a minimum aggregate cash balance equal to fifty percent of the aggregate principal amount of the Amended Loan Agreement (excluding any capitalized interest paid-in-kind) at all times during such quarter. The consequences of failing to achieve the performance covenants, when applicable, will be cured if, (i) within thirty days of failing to achieve the performance covenant, the Company submits a new Board approved financial plan to Innovatus under which the Company is expected to break even on a cash flow basis prior to the maturity date, and (ii) within thirty days of the submission of such financial plan, the Company issues additional equity securities or subordinated debt with net proceeds sufficient to fund any cash flow deficiency generated from operations, as defined in the Amended Loan Agreement. The Amended Loan Agreement requires that the Company maintain certain levels of minimum liquidity and maintains an unrestricted cash balance of $2.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The negative covenants provide, among other things, that without the prior consent of Innovatus, subject to certain exceptions, the Company may not dispose of certain assets, engage in certain business combinations or acquisitions, incur additional indebtedness or encumber any of the Company's property, pay dividends on the Company's capital stock or make prohibited investments. The Amended Loan Agreement provides that an event of default will occur if, among other triggers, (i)&#160;the Company defaults in the payment of any amount payable under the agreement when due, (ii)&#160;there occurs any circumstance(s) that could reasonably be expected to result in a material adverse effect on the Company's business, operations or condition, or on the Company's ability to perform its obligations under the agreement, (iii)&#160;the Company becomes insolvent, (iv)&#160;the Company undergoes a change in control or (v)&#160;the Company breaches any negative covenants or certain affirmative covenants in the agreement or, subject to a cure period, otherwise neglects to perform or observe any material item in the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2023, the Company was in compliance with all covenants of the Amended Loan Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon an event of default in any of the Amended Loan Agreement covenants, the repayment of the 2017 Term Loan may be accelerated, and the applicable interest rate will be increased by 4.0% until the default is cured. Although repayment of the 2017 Term Loan can be accelerated under certain circumstances, the Company believes acceleration of this loan is not probable as of the date of these financial statements. Accordingly, the Company has reflected the amounts of the Third Loan Amendment due beyond twelve months of the balance sheet date as non-current.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;2022 Equipment Notes Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In May 2022, the Company purchased laboratory equipment using notes payable. At December&#160;31, 2023, the total notes payable balance related to this financed equipment was $0.8&#160;million, with $0.3&#160;million classified within borrowings-current portion and $0.5&#160;million within borrowings-non-current portion, net of discounts and debt issuance costs in the accompanying balance sheets. At December 31, 2022, the total notes payable balance related to this financed equipment was $0.8&#160;million, with $0.2&#160;million classified within borrowings-current portion and $0.6&#160;million within borrowings-non-current portion, net of discounts and debt issuance costs in the accompanying balance sheets. The financed equipment is subject to a 5.28% effective interest rate and will mature on October 1, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Future Minimum Payments on Outstanding Borrowings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2023, future minimum aggregate payments, including interest, for outstanding borrowings are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.767%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,558)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total borrowings, net of discounts and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Borrowings-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(264)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Borrowings-non-current portion, net of discounts and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-67" decimals="-5" id="f-398" unitRef="usd">25000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity contextRef="c-68" decimals="0" id="f-399" unitRef="usd">0</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-69" decimals="-5" id="f-400" unitRef="usd">10000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-70"
      decimals="INF"
      id="f-401"
      unitRef="number">0.080</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-71" decimals="2" id="f-402" unitRef="number">0.020</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <exdx:DebtInstrumentStatedInterestRatePaidInKind contextRef="c-71" decimals="3" id="f-403" unitRef="number">0.015</exdx:DebtInstrumentStatedInterestRatePaidInKind>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-68" decimals="3" id="f-404" unitRef="number">0.110</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-72" decimals="3" id="f-405" unitRef="number">0.085</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <exdx:DebtInstrumentNumberOfMonthlyInstallments
      contextRef="c-73"
      decimals="INF"
      id="f-406"
      unitRef="installment">10</exdx:DebtInstrumentNumberOfMonthlyInstallments>
    <us-gaap:DebtInstrumentFeeAmount contextRef="c-68" decimals="-5" id="f-407" unitRef="usd">1000000</us-gaap:DebtInstrumentFeeAmount>
    <exdx:DebtInstrumentPaidInKindLoansIssued contextRef="c-74" decimals="-5" id="f-408" unitRef="usd">400000</exdx:DebtInstrumentPaidInKindLoansIssued>
    <exdx:DebtInstrumentPaidInKindLoansIssued contextRef="c-75" decimals="-5" id="f-409" unitRef="usd">600000</exdx:DebtInstrumentPaidInKindLoansIssued>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-76" decimals="-5" id="f-410" unitRef="usd">18200000</us-gaap:LongTermDebtNoncurrent>
    <exdx:DebtInstrumentPrepaymentPremiumPercentage
      contextRef="c-68"
      decimals="INF"
      id="f-411"
      unitRef="number">0.01</exdx:DebtInstrumentPrepaymentPremiumPercentage>
    <exdx:DebtInstrumentCovenantRevenuePerformancePeriod contextRef="c-73" id="f-412">P12M</exdx:DebtInstrumentCovenantRevenuePerformancePeriod>
    <exdx:DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant contextRef="c-73" decimals="2" id="f-413" unitRef="number">0.50</exdx:DebtInstrumentMinimumCashBalanceRequiredNotRequiredToComplyWithCovenant>
    <exdx:DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet contextRef="c-73" id="f-414">P30D</exdx:DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet>
    <exdx:DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet contextRef="c-73" id="f-415">P30D</exdx:DebtInstrumentCovenantNumberOfDaysToCureIfPerformanceMeasureIsNotMet>
    <exdx:DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance contextRef="c-68" decimals="-5" id="f-416" unitRef="usd">2000000</exdx:DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance>
    <exdx:DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease contextRef="c-77" decimals="3" id="f-417" unitRef="number">0.040</exdx:DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease>
    <us-gaap:NotesPayable contextRef="c-78" decimals="-5" id="f-418" unitRef="usd">800000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableCurrent contextRef="c-78" decimals="-5" id="f-419" unitRef="usd">300000</us-gaap:NotesPayableCurrent>
    <us-gaap:LongTermNotesPayable contextRef="c-78" decimals="-5" id="f-420" unitRef="usd">500000</us-gaap:LongTermNotesPayable>
    <us-gaap:NotesPayable contextRef="c-79" decimals="-5" id="f-421" unitRef="usd">800000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableCurrent contextRef="c-79" decimals="-5" id="f-422" unitRef="usd">200000</us-gaap:NotesPayableCurrent>
    <us-gaap:LongTermNotesPayable contextRef="c-79" decimals="-5" id="f-423" unitRef="usd">600000</us-gaap:LongTermNotesPayable>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-80" decimals="4" id="f-424" unitRef="number">0.0528</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="c-1" id="f-425">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2023, future minimum aggregate payments, including interest, for outstanding borrowings are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.767%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,558)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total borrowings, net of discounts and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Borrowings-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(264)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Borrowings-non-current portion, net of discounts and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c-4" decimals="-3" id="f-426" unitRef="usd">1949000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c-4" decimals="-3" id="f-427" unitRef="usd">1974000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c-4" decimals="-3" id="f-428" unitRef="usd">21243000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <exdx:LongTermDebtIncludingUndiscountedInterest contextRef="c-4" decimals="-3" id="f-429" unitRef="usd">25166000</exdx:LongTermDebtIncludingUndiscountedInterest>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="c-4" decimals="-3" id="f-430" unitRef="usd">113000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <exdx:LongTermDebtUndiscountedInterestAmount contextRef="c-4" decimals="-3" id="f-431" unitRef="usd">5558000</exdx:LongTermDebtUndiscountedInterestAmount>
    <us-gaap:LongTermDebt contextRef="c-4" decimals="-3" id="f-432" unitRef="usd">19495000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent contextRef="c-4" decimals="-3" id="f-433" unitRef="usd">264000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-4" decimals="-3" id="f-434" unitRef="usd">19231000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LesseeFinanceLeasesTextBlock contextRef="c-1" id="f-436">Leases&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company leases office and laboratory space located in Vista, California. The lease expires in April 2027, with an option to extend portions of the lease for additional 5-year periods. The Company has not included the optional renewal periods in the measurement of the lease liability, because it is not reasonably certain that the Company will exercise these renewal options. The Company's payments under the lease are subject to escalation clauses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company leases additional office space in Carlsbad, California, under a sub-lease which commenced in October 2021 and expires in April 2027. Monthly base rent under the sub-lease agreement is $70,042. The monthly base rent increases by approximately 3% annually, each October 1, through the remainder of the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has entered into various finance lease agreements to obtain laboratory equipment. The terms of the Company's finance leases generally range from &lt;span style="-sec-ix-hidden:f-440"&gt;three&lt;/span&gt; to five years and are typically secured by the underlying equipment. The portion of the future payments designated as principal repayments were classified as finance lease liabilities on the Company's balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Operating and Finance Leases Balances and Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating and finance leases consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.361%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Lease Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-445"&gt;Property and equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-450"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-455"&gt;&lt;span style="-sec-ix-hidden:f-456"&gt;Other non-current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Costs associated with the Company's leases were included in the statements of operations as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.794%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.785%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;679&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest on finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;(1) Includes variable lease cost of $129,000 and $165,000 for the years ended December&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Supplemental cash flow information on leases is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.794%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.785%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating cash out flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating cash out flows from interest paid on finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Financing cash out flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Information regarding the weighted-average lease term and weighted average discount rate are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.940%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.785%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.06&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.94&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Future payments under operating and finance leases as of December&#160;31, 2023 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.917%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(541)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(976)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(490)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease obligations, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-435">Leases&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company leases office and laboratory space located in Vista, California. The lease expires in April 2027, with an option to extend portions of the lease for additional 5-year periods. The Company has not included the optional renewal periods in the measurement of the lease liability, because it is not reasonably certain that the Company will exercise these renewal options. The Company's payments under the lease are subject to escalation clauses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company leases additional office space in Carlsbad, California, under a sub-lease which commenced in October 2021 and expires in April 2027. Monthly base rent under the sub-lease agreement is $70,042. The monthly base rent increases by approximately 3% annually, each October 1, through the remainder of the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has entered into various finance lease agreements to obtain laboratory equipment. The terms of the Company's finance leases generally range from &lt;span style="-sec-ix-hidden:f-440"&gt;three&lt;/span&gt; to five years and are typically secured by the underlying equipment. The portion of the future payments designated as principal repayments were classified as finance lease liabilities on the Company's balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Operating and Finance Leases Balances and Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating and finance leases consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.361%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Lease Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-445"&gt;Property and equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-450"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-455"&gt;&lt;span style="-sec-ix-hidden:f-456"&gt;Other non-current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Costs associated with the Company's leases were included in the statements of operations as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.794%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.785%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;679&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest on finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;(1) Includes variable lease cost of $129,000 and $165,000 for the years ended December&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Supplemental cash flow information on leases is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.794%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.785%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating cash out flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating cash out flows from interest paid on finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Financing cash out flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Information regarding the weighted-average lease term and weighted average discount rate are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.940%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.785%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.06&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.94&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Future payments under operating and finance leases as of December&#160;31, 2023 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.917%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(541)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(976)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(490)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease obligations, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-81" id="f-437">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <exdx:OperatingLeaseMonthlyBaseRent contextRef="c-82" decimals="0" id="f-438" unitRef="usd">70042</exdx:OperatingLeaseMonthlyBaseRent>
    <exdx:OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent contextRef="c-83" decimals="2" id="f-439" unitRef="number">0.03</exdx:OperatingLeaseAnnualIncreaseInBaseRentPaymentPercent>
    <us-gaap:LesseeFinanceLeaseTermOfContract1 contextRef="c-44" id="f-441">P5Y</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-442">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating and finance leases consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.361%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Lease Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-445"&gt;Property and equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-450"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-455"&gt;&lt;span style="-sec-ix-hidden:f-456"&gt;Other non-current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Costs associated with the Company's leases were included in the statements of operations as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.794%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.785%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;679&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest on finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;(1) Includes variable lease cost of $129,000 and $165,000 for the years ended December&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Supplemental cash flow information on leases is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.794%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.785%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating cash out flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating cash out flows from interest paid on finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Financing cash out flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Information regarding the weighted-average lease term and weighted average discount rate are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.940%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.785%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.06&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.94&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-443" unitRef="usd">3286000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-444" unitRef="usd">4885000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-446" unitRef="usd">810000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-447" unitRef="usd">1427000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-448" unitRef="usd">976000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-449" unitRef="usd">1040000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-451" unitRef="usd">490000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-452" unitRef="usd">700000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-453" unitRef="usd">2760000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-454" unitRef="usd">4493000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-457" unitRef="usd">358000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-458" unitRef="usd">848000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-3" id="f-459" unitRef="usd">1463000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-6" decimals="-3" id="f-460" unitRef="usd">1540000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-1" decimals="-3" id="f-461" unitRef="usd">556000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-6" decimals="-3" id="f-462" unitRef="usd">679000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-1" decimals="-3" id="f-463" unitRef="usd">128000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-6" decimals="-3" id="f-464" unitRef="usd">80000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-3" id="f-465" unitRef="usd">2147000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-6" decimals="-3" id="f-466" unitRef="usd">2299000</us-gaap:LeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-1" decimals="-3" id="f-467" unitRef="usd">129000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-6" decimals="-3" id="f-468" unitRef="usd">165000</us-gaap:VariableLeaseCost>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-3" id="f-469" unitRef="usd">1405000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-6" decimals="-3" id="f-470" unitRef="usd">1262000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c-1" decimals="-3" id="f-471" unitRef="usd">128000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c-6" decimals="-3" id="f-472" unitRef="usd">80000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-1" decimals="-3" id="f-473" unitRef="usd">697000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-6" decimals="-3" id="f-474" unitRef="usd">667000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-4" id="f-475">P3Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-5" id="f-476">P4Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-4" id="f-477">P2Y21D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-5" id="f-478">P1Y11M8D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-4" decimals="3" id="f-479" unitRef="number">0.080</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-5" decimals="3" id="f-480" unitRef="number">0.080</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="c-4" decimals="3" id="f-481" unitRef="number">0.122</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="c-5" decimals="3" id="f-482" unitRef="number">0.048</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-484">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Future payments under operating and finance leases as of December&#160;31, 2023 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.917%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(541)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(976)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(490)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease obligations, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-483">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Future payments under operating and finance leases as of December&#160;31, 2023 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.917%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(541)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(976)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(490)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease obligations, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-4" decimals="-3" id="f-485" unitRef="usd">1240000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-4" decimals="-3" id="f-486" unitRef="usd">574000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-4" decimals="-3" id="f-487" unitRef="usd">1277000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo contextRef="c-4" decimals="-3" id="f-488" unitRef="usd">248000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-4" decimals="-3" id="f-489" unitRef="usd">1315000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree contextRef="c-4" decimals="-3" id="f-490" unitRef="usd">147000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-4" decimals="-3" id="f-491" unitRef="usd">445000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour contextRef="c-4" decimals="-3" id="f-492" unitRef="usd">28000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-4" decimals="-3" id="f-493" unitRef="usd">4277000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue contextRef="c-4" decimals="-3" id="f-494" unitRef="usd">997000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-4" decimals="-3" id="f-495" unitRef="usd">541000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount contextRef="c-4" decimals="-3" id="f-496" unitRef="usd">149000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-4" decimals="-3" id="f-497" unitRef="usd">3736000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability contextRef="c-4" decimals="-3" id="f-498" unitRef="usd">848000</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-499" unitRef="usd">976000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-500" unitRef="usd">490000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-501" unitRef="usd">2760000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-502" unitRef="usd">358000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-503">Commitments and Contingencies&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Acquisition-related liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In connection with the acquisition of the medical diagnostics division of Royalty Pharma Collection Trust (Royalty Pharma) (formerly known as Cypress Bioscience, Inc.) in 2010, the Company had royalty payment obligations of 2.5% on net sales of products which incorporate certain acquired technologies through December 31, 2023. These obligations no longer exist for products sold after December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Licensing Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has licensed technology for use in its diagnostic tests. In addition to the milestone payments required by these agreements, individual license agreements generally provide for ongoing royalty payments ranging from 1.5% to 7.0% on net sales of products which incorporate licensed technology, as defined in such agreements. Royalties are accrued when incurred and recorded in costs of revenue in the accompanying statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Supply Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2021, the Company amended a supply agreement with one supplier for reagents which includes minimum annual purchase commitments of $8.0 million and $9.2 million for the years ended December 31, 2024 and 2025, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Collaboration Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In May 2021, the Company entered into a master research collaboration agreement with Allegheny Health Network Research Institute (AHN), pursuant to which the Company is required to pay AHN a collaboration fee of $0.4 million per year. Collaboration expenses under the master research collaboration agreement were $0.3 million for each of the years ended December&#160;31, 2023 and 2022. Collaboration expenses under the AHN collaboration are included in research and development expenses in the accompanying statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications; including for subpoenas and other civil investigative demands, from governmental agencies, Medicare or Medicaid and managed care organizations reviewing billing practices or requesting comment on allegations of billing irregularities that are brought to their attention through billing audits or third parties. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made or that the Company believes to be immaterial. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;From time to time, the Company may be subject to various legal proceedings that arise in the ordinary course of business activities. The Company does not believe the outcome of any such matters as of December&#160;31, 2023 will have a material effect on its financial position or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2023, the Company resolved an investigation with the U.S. Attorney&#x2019;s Office for the District of Massachusetts that was initiated by a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;qui tam &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;lawsuit. Pursuant to a Settlement Agreement, the Company made a single lump-sum remittance to the government in the amount of $0.7&#160;million in connection with specimen processing arrangements that Exagen historically had with physicians. The U.S. Attorney&#x2019;s Office dismissed this &#x201c;covered conduct&#x201d; in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;qui tam &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;lawsuit with prejudice, while non-covered conduct was dismissed without prejudice. In November 2023 the complaint was unsealed and served on Exagen. Exagen filed a motion to dismiss the complaint. In December 2023, the Company's insurance carrier provided reimbursement for certain defense costs the Company incurred in the October 2023 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;qui tam &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;lawsuit. In February 2024, the relator filed a motion for leave to amend the complaint. Exagen opposed this motion, and all motions are still pending. The Company intends to vigorously defend against the claims being asserted in the complaint.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's participation in federal healthcare programs is not affected by the Settlement Agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <exdx:RoyaltyObligationPercentageOfSales contextRef="c-84" decimals="3" id="f-504" unitRef="number">0.025</exdx:RoyaltyObligationPercentageOfSales>
    <exdx:RoyaltyObligationPercentageOfSales
      contextRef="c-85"
      decimals="INF"
      id="f-505"
      unitRef="number">0.015</exdx:RoyaltyObligationPercentageOfSales>
    <exdx:RoyaltyObligationPercentageOfSales
      contextRef="c-86"
      decimals="INF"
      id="f-506"
      unitRef="number">0.070</exdx:RoyaltyObligationPercentageOfSales>
    <exdx:PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers
      contextRef="c-87"
      decimals="INF"
      id="f-507"
      unitRef="supplier">1</exdx:PurchaseObligationAmendedSupplyAgreementNumberOfSuppliers>
    <us-gaap:PurchaseObligationDueInNextTwelveMonths contextRef="c-5" decimals="-5" id="f-508" unitRef="usd">8000000.0</us-gaap:PurchaseObligationDueInNextTwelveMonths>
    <us-gaap:PurchaseObligationDueInSecondYear contextRef="c-5" decimals="-5" id="f-509" unitRef="usd">9200000</us-gaap:PurchaseObligationDueInSecondYear>
    <exdx:CollaborationAgreementAnnualCollaborationFee contextRef="c-88" decimals="-5" id="f-510" unitRef="usd">400000</exdx:CollaborationAgreementAnnualCollaborationFee>
    <exdx:CollaborationAgreementCollaborationExpenses contextRef="c-89" decimals="-5" id="f-511" unitRef="usd">300000</exdx:CollaborationAgreementCollaborationExpenses>
    <exdx:CollaborationAgreementCollaborationExpenses contextRef="c-90" decimals="-5" id="f-512" unitRef="usd">300000</exdx:CollaborationAgreementCollaborationExpenses>
    <us-gaap:PaymentsForLegalSettlements contextRef="c-91" decimals="-5" id="f-513" unitRef="usd">700000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-514">Fair Value Measurements&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The carrying values of the Company's cash, cash equivalents and restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued and other current liabilities approximate their fair values due to their short-term nature and are considered to be Level 1 measurements. The estimated fair value of the Company's long-term borrowings is determined by Level 2 inputs and based primarily on quoted market prices for the same or similar issues. As of December&#160;31, 2023, the Amended Loan Agreement had a carrying value of $18.7 million and a fair value of $19.7 million. As of December 31, 2022, the 2017 Term Loan had a carrying value of $28.3&#160;million and a fair value of $26.9&#160;million. The estimated fair value of the Amended Loan Agreement was determined based on a discounted cash flow approach using available market information on discount and borrowing rates with similar terms, maturities, and credit ratings. The carrying value of the Company's other long-term borrowing as of December&#160;31, 2023 was $0.8&#160;million, which approximated its fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The three-levels of the valuation hierarchy for disclosure of fair value measurements are defined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:94.5pt;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Level 1 -&#160;&#160;&#160;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:94.5pt;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Level 2 -&#160;&#160;&#160;&#160;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:94.5pt;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Level 3 -&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.432%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Certificate of deposit, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair value of the Company's money market funds is based on quoted market prices.&lt;/span&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-515">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The carrying values of the Company's cash, cash equivalents and restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued and other current liabilities approximate their fair values due to their short-term nature and are considered to be Level 1 measurements. The estimated fair value of the Company's long-term borrowings is determined by Level 2 inputs and based primarily on quoted market prices for the same or similar issues. As of December&#160;31, 2023, the Amended Loan Agreement had a carrying value of $18.7 million and a fair value of $19.7 million. As of December 31, 2022, the 2017 Term Loan had a carrying value of $28.3&#160;million and a fair value of $26.9&#160;million. The estimated fair value of the Amended Loan Agreement was determined based on a discounted cash flow approach using available market information on discount and borrowing rates with similar terms, maturities, and credit ratings. The carrying value of the Company's other long-term borrowing as of December&#160;31, 2023 was $0.8&#160;million, which approximated its fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The three-levels of the valuation hierarchy for disclosure of fair value measurements are defined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:94.5pt;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Level 1 -&#160;&#160;&#160;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:94.5pt;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Level 2 -&#160;&#160;&#160;&#160;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:94.5pt;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Level 3 -&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:LongTermDebt contextRef="c-92" decimals="-5" id="f-516" unitRef="usd">18700000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFairValue contextRef="c-92" decimals="-5" id="f-517" unitRef="usd">19700000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:LongTermDebt contextRef="c-93" decimals="-5" id="f-518" unitRef="usd">28300000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFairValue contextRef="c-93" decimals="-5" id="f-519" unitRef="usd">26900000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:LongTermDebt contextRef="c-94" decimals="-5" id="f-520" unitRef="usd">800000</us-gaap:LongTermDebt>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-521">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.432%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Certificate of deposit, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-95" decimals="-3" id="f-522" unitRef="usd">14386000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-96" decimals="-3" id="f-523" unitRef="usd">14386000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-97" decimals="-3" id="f-524" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-98" decimals="-3" id="f-525" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-99" decimals="-3" id="f-526" unitRef="usd">29438000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-100" decimals="-3" id="f-527" unitRef="usd">29438000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-101" decimals="-3" id="f-528" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-102" decimals="-3" id="f-529" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-103" decimals="-3" id="f-530" unitRef="usd">30100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-104" decimals="-3" id="f-531" unitRef="usd">30100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-105" decimals="-3" id="f-532" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-106" decimals="-3" id="f-533" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-107" decimals="-3" id="f-534" unitRef="usd">59538000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-108" decimals="-3" id="f-535" unitRef="usd">59538000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-109" decimals="-3" id="f-536" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-110" decimals="-3" id="f-537" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-538">Stockholders' Equity&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Shelf Registration Statement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On November 17, 2023, the Company filed a registration statement on Form S-3, as amended (the 2023 Shelf Registration Statement), covering the offering, from time to time, of up to $150.0 million of common stock, preferred stock, debt securities, warrants and units. The 2023 Shelf Registration Statement became effective on November 29, 2023, and all $150.0&#160;million remain available for sale as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;At The Market Sales Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On September 15, 2022, the Company entered into a sales agreement, as amended on November 17, 2023 (the Sales Agreement) with Cowen and Company, LLC as sales agent, pursuant to which the Company may offer and sell, from time to time, shares of Company common stock having an aggregate offering price of up to $50.0&#160;million. The Company is not obligated to sell any shares of Company common stock in the offering. As of December&#160;31, 2023, the Company has not sold any shares of its common stock pursuant to the Sales Agreement&lt;/span&gt;&lt;span style="color:#008080;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Outstanding Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following equity classified warrants to purchase common stock were outstanding as of December&#160;31, 2023:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.432%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issuance date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;237,169&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 19, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 19, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67,086&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 1, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 1, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83,778&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 7, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 7, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,944&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 7, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 7, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants (Exchange Warrants)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;804,951&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 22, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,214,059&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;No warrants to purchase common stock were exercised during the years ended December&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <exdx:SaleOfStockAuthorizedAmount contextRef="c-111" decimals="-3" id="f-539" unitRef="usd">150000000.0</exdx:SaleOfStockAuthorizedAmount>
    <exdx:SaleOfStockRemainingAuthorizedAmount contextRef="c-111" decimals="-3" id="f-540" unitRef="usd">150000000</exdx:SaleOfStockRemainingAuthorizedAmount>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-112" decimals="-5" id="f-541" unitRef="usd">50000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c-1" id="f-542">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following equity classified warrants to purchase common stock were outstanding as of December&#160;31, 2023:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.432%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issuance date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;237,169&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 19, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 19, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67,086&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 1, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 1, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83,778&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 7, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 7, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,944&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 7, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 7, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants (Exchange Warrants)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;804,951&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 22, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,214,059&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-113"
      decimals="INF"
      id="f-543"
      unitRef="shares">237169</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-113"
      decimals="INF"
      id="f-544"
      unitRef="usdPerShare">1.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-114"
      decimals="INF"
      id="f-545"
      unitRef="shares">67086</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-114"
      decimals="INF"
      id="f-546"
      unitRef="usdPerShare">1.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-115"
      decimals="INF"
      id="f-547"
      unitRef="shares">131</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-115"
      decimals="INF"
      id="f-548"
      unitRef="usdPerShare">1.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-116"
      decimals="INF"
      id="f-549"
      unitRef="shares">83778</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-116"
      decimals="INF"
      id="f-550"
      unitRef="usdPerShare">14.32</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-117"
      decimals="INF"
      id="f-551"
      unitRef="shares">20944</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-117"
      decimals="INF"
      id="f-552"
      unitRef="usdPerShare">14.32</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-118"
      decimals="INF"
      id="f-553"
      unitRef="shares">804951</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-118"
      decimals="INF"
      id="f-554"
      unitRef="usdPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c-4" decimals="INF" id="f-555" unitRef="shares">1214059</us-gaap:ClassOfWarrantOrRightOutstanding>
    <exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet contextRef="c-1" decimals="INF" id="f-556" unitRef="shares">0</exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet>
    <exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet contextRef="c-6" decimals="INF" id="f-557" unitRef="shares">0</exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-558">Stock Option Plan&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;2019 Incentive Award Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In September 2019, the Company's board of directors adopted, and the Company's stockholders approved, the 2019 Plan. Under the 2019 Plan, which expires in September 2029, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. The options generally expire ten years after the date of grant and are exercisable to the extent vested. Vesting is established by the Company's board of directors and is generally four years from the date of grant or, for grants to new hires, date of hire. The 2019 Plan contains an "evergreen provision" that allows annual increases in the number of shares available for issuance on the first day of each calendar year through January 1, 2029 in an amount equal to the lesser of: (i) 4% of the outstanding capital stock on each December 31st, or (ii) such lesser amount determined by the Company's board of directors. As of December&#160;31, 2023, 1,831,107 shares of common stock remained available for future awards. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Pursuant to the evergreen provision, on January 1, 2024, an additional 681,838 shares of common stock became available for issuance under the 2019 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;RSU activity under the Company's 2019 Plan is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.378%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,036,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;857,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(273,319)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(232,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,387,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2023, all of the outstanding RSUs are unvested. The fair value of RSUs vested in the years ended December&#160;31, 2023 and 2022 was $0.6 million and $0.7&#160;million, respectively. The weighted average grant date fair value for RSUs granted during the years ended December&#160;31, 2023 and 2022 was $2.39 and $5.89, respectively. As of December&#160;31, 2023, total unrecognized compensation cost related to RSUs was $4.4 million, which is expected to be recognized over a remaining weighted-average vesting period of 2.8 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Stock option activity under the Company's 2019 Plan is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.122%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.911%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.888%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&#160;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,421,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.09&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(93,335)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(43,895)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(370,686)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;986,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest, December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;986,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Options exercisable, December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;877,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The weighted-average grant date fair value per share of options granted during the years ended December&#160;31, 2023 and 2022 was $2.17 and $2.74, respectively. The aggregate intrinsic value of options exercised during the years ended December&#160;31, 2023 and 2022 was $0.2 million and $0.6 million, respectively. The intrinsic value is calculated as the difference between the fair value of the Company's common stock and the exercise price of the stock options. The fair value of the Company's common stock was $1.99 and $2.40 per share at December&#160;31, 2023 and 2022, respectively. As of December&#160;31, 2023, total unrecognized compensation cost related to option awards was $0.3 million, which is expected to be recognized over a remaining weighted-average vesting period of 0.8 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;2019 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In September 2019, the Company's board of directors adopted, and the Company's stockholders approved, the ESPP. The ESPP became effective on the day the ESPP was adopted by the Company's board of directors. The ESPP permits participants to purchase common stock through payroll deductions of up to 20% of their eligible compensation. The number of shares of common stock available for issuance under the ESPP will be annually increased on the first day of each calendar year during the term of the ESPP through January 1, 2029 in an amount equal to the lesser of (i) 1% of the outstanding capital stock on each December 31st, or (ii) such lesser amount determined by the Company's board of directors. During the year ended December&#160;31, 2023, the Company issued 129,593 shares of common stock pursuant to scheduled purchases under the ESPP. As of December&#160;31, 2023, 449,332 shares of common stock remained available for issuance. Pursuant to the evergreen provision, on January 1, 2024, an additional 170,460 shares became available for issuance under the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Stock-based compensation expense related to the ESPP for each of the years ended December&#160;31, 2023 and 2022 was less than $0.1 million. As of December&#160;31, 2023, total unrecognized compensation cost related to stock purchase rights granted under the ESPP was less than $0.1 million, which is expected to be recognized over a remaining weighted-average vesting period of 0.2 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total non-cash stock-based compensation expense recorded related to options, RSUs and stock purchase rights granted under the ESPP in the statement of operations is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Common stock reserved for future issuance consists of the following at December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,214,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock option grants issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;986,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock reserved for issuance upon vesting of outstanding restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,387,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common shares available for grant under the 2019 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,831,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common shares available for future issuance under ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;449,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,868,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-119" id="f-559">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-119" id="f-560">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage contextRef="c-120" decimals="2" id="f-561" unitRef="number">0.04</exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-121"
      decimals="INF"
      id="f-562"
      unitRef="shares">1831107</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized
      contextRef="c-122"
      decimals="INF"
      id="f-563"
      unitRef="shares">681838</exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c-1" id="f-564">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;RSU activity under the Company's 2019 Plan is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.378%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,036,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;857,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(273,319)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(232,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,387,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-123"
      decimals="INF"
      id="f-565"
      unitRef="shares">1036208</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-123"
      decimals="2"
      id="f-566"
      unitRef="usdPerShare">7.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="c-123" decimals="-3" id="f-567" unitRef="usd">2487000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-124"
      decimals="INF"
      id="f-568"
      unitRef="shares">857300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-124"
      decimals="2"
      id="f-569"
      unitRef="usdPerShare">2.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-124"
      decimals="INF"
      id="f-570"
      unitRef="shares">273319</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-124"
      decimals="2"
      id="f-571"
      unitRef="usdPerShare">7.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-124"
      decimals="INF"
      id="f-572"
      unitRef="shares">232730</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-124"
      decimals="2"
      id="f-573"
      unitRef="usdPerShare">6.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-125"
      decimals="INF"
      id="f-574"
      unitRef="shares">1387459</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-125"
      decimals="2"
      id="f-575"
      unitRef="usdPerShare">4.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="c-125" decimals="-3" id="f-576" unitRef="usd">2761000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested contextRef="c-124" decimals="-5" id="f-577" unitRef="usd">600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested contextRef="c-126" decimals="-5" id="f-578" unitRef="usd">700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-124"
      decimals="2"
      id="f-579"
      unitRef="usdPerShare">2.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-126"
      decimals="2"
      id="f-580"
      unitRef="usdPerShare">5.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-125" decimals="-5" id="f-581" unitRef="usd">4400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-124" id="f-582">P2Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-583">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Stock option activity under the Company's 2019 Plan is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.122%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.911%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.888%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&#160;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,421,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.09&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(93,335)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(43,895)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(370,686)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;986,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest, December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;986,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Options exercisable, December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;877,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-5" decimals="INF" id="f-584" unitRef="shares">1421235</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-585"
      unitRef="usdPerShare">12.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-6" id="f-586">P7Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-5" decimals="-3" id="f-587" unitRef="usd">483000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-588" unitRef="shares">73500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-589"
      unitRef="usdPerShare">3.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-590" unitRef="shares">93335</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-591"
      unitRef="usdPerShare">0.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="INF" id="f-592" unitRef="shares">43895</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-593"
      unitRef="usdPerShare">13.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="c-1" decimals="INF" id="f-594" unitRef="shares">370686</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-595"
      unitRef="usdPerShare">16.88</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="INF" id="f-596" unitRef="shares">986819</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-597"
      unitRef="usdPerShare">11.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-598">P6Y5M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-4" decimals="-3" id="f-599" unitRef="usd">228000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="c-4" decimals="INF" id="f-600" unitRef="shares">986819</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-601"
      unitRef="usdPerShare">11.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-602">P6Y5M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-4" decimals="-3" id="f-603" unitRef="usd">228000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="c-4" decimals="INF" id="f-604" unitRef="shares">877937</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-605"
      unitRef="usdPerShare">12.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-606">P6Y2M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="c-4" decimals="-3" id="f-607" unitRef="usd">228000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-608"
      unitRef="usdPerShare">2.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-6"
      decimals="2"
      id="f-609"
      unitRef="usdPerShare">2.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-4" decimals="-5" id="f-610" unitRef="usd">200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-5" decimals="-5" id="f-611" unitRef="usd">600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-4"
      decimals="2"
      id="f-612"
      unitRef="usdPerShare">1.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-5"
      decimals="2"
      id="f-613"
      unitRef="usdPerShare">2.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-127" decimals="-5" id="f-614" unitRef="usd">300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-128" id="f-615">P0Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate contextRef="c-129" decimals="2" id="f-616" unitRef="number">0.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage contextRef="c-129" decimals="2" id="f-617" unitRef="number">0.01</exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-130"
      decimals="INF"
      id="f-618"
      unitRef="shares">129593</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-129"
      decimals="INF"
      id="f-619"
      unitRef="shares">449332</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized
      contextRef="c-131"
      decimals="INF"
      id="f-620"
      unitRef="shares">170460</exdx:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesAuthorized>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-132" decimals="-5" id="f-621" unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-130" decimals="-5" id="f-622" unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-129" decimals="-5" id="f-623" unitRef="usd">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-130" id="f-624">P0Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-625">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total non-cash stock-based compensation expense recorded related to options, RSUs and stock purchase rights granted under the ESPP in the statement of operations is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.075%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-133" decimals="-3" id="f-626" unitRef="usd">191000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-134" decimals="-3" id="f-627" unitRef="usd">213000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-135" decimals="-3" id="f-628" unitRef="usd">3174000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-136" decimals="-3" id="f-629" unitRef="usd">3860000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-137" decimals="-3" id="f-630" unitRef="usd">252000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-138" decimals="-3" id="f-631" unitRef="usd">631000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-632" unitRef="usd">3617000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-6" decimals="-3" id="f-633" unitRef="usd">4704000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="c-1" id="f-634">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Common stock reserved for future issuance consists of the following at December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,214,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock option grants issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;986,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock reserved for issuance upon vesting of outstanding restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,387,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common shares available for grant under the 2019 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,831,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common shares available for future issuance under ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;449,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,868,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-139"
      decimals="INF"
      id="f-635"
      unitRef="shares">1214059</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-127"
      decimals="INF"
      id="f-636"
      unitRef="shares">986819</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-125"
      decimals="INF"
      id="f-637"
      unitRef="shares">1387459</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-121"
      decimals="INF"
      id="f-638"
      unitRef="shares">1831107</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-129"
      decimals="INF"
      id="f-639"
      unitRef="shares">449332</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-4" decimals="INF" id="f-640" unitRef="shares">5868776</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-641">Income Taxes&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The provision for income taxes consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax (expense) benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The effective tax rate of our provision for income taxes differs from the federal statutory rate as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.660%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-deductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(23.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Significant components of the Company&#x2019;s deferred tax assets at December&#160;31, 2023 and 2022 are shown below (in thousands). A valuation allowance has been established as realization of the Company&#x2019;s deferred tax assets has not met the more likely-than-not threshold requirement. If the Company&#x2019;s judgment changes and it is determined that the Company will be able to realize these deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on deferred tax assets will be accounted for as a reduction to income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accruals, reserves and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalization of research and experimentation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(42,942)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(38,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basis differences in fixed and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(287)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Changes in the valuation allowance for deferred tax assets during the years ended December&#160;31, 2023 and 2022, which related primarily to increases in net operating loss (NOL) carryforwards, research and development tax credits, capitalization of research and experimentation costs, and impairment of goodwill were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Valuation allowance at the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Increases recorded to income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Valuation allowance at the end of the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;At December&#160;31, 2023 and 2022, the Company had federal NOL carryforwards of approximately $129.8 million and $118.4 million, respectively. At December&#160;31, 2023 and 2022, the Company had state NOL carryforwards of $91.0 million and $87.0 million, respectively. Approximately $43.5 million of the federal tax loss carryforwards will begin to expire in 2024, unless previously utilized. The federal NOL carryforwards generated after December 31, 2017 of $86.3 million will carryforward indefinitely. The Company&#x2019;s state tax loss carryforwards will begin to expire in 2030, unless previously utilized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;At December&#160;31, 2023, the Company's deferred tax assets are primarily comprised of federal and state tax NOL carryforwards. The Company completed a formal study through the year ended December 31, 2019 and determined ownership changes within the meaning of Internal Revenue Code (IRC), Section 382 had occurred in 2003, 2008, 2012, 2017 and 2019. Based on the analysis, $61.1 million of the Company's tax attribute carryforwards through December 31, 2017 cannot be utilized under IRC Section 382. The Company's ability to utilize NOL carryforwards generated after December 31, 2017 will not expire under the Tax Cuts and Jobs Act of 2017. The Company adjusted tax attribute carry forwards and deferred tax assets accordingly. As the deferred tax assets associated with the tax attribute carry forwards were fully offset by a valuation allowance, a corresponding reduction in the Company's valuation allowance was also recorded, resulting in no income tax impact.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company is subject to taxation in the U.S. and in various state jurisdictions. The Company&#x2019;s tax years for 2004 and forward are subject to examination by the U.S. and state tax authorities due to the carryforward of unutilized net operating losses and research and development credits. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognizes interest and/or penalties related to income tax matters in its provision for income taxes. The Company does not have any material accruals for, and did not recognize any, material interest or penalties in these financial statements in any period presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Uncertain Tax Positions &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;At December&#160;31, 2023 and 2022, the Company had no unrecognized tax benefits. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company does not believe that the balance of unrecognized tax benefits will materially change within the next twelve months.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-642">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The provision for income taxes consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax (expense) benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-643" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-644" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-645" unitRef="usd">33000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-646" unitRef="usd">24000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-647" unitRef="usd">33000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-648" unitRef="usd">24000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-649" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-650" unitRef="usd">-137000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-651" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-652" unitRef="usd">-169000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-653" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-654" unitRef="usd">-306000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-655" unitRef="usd">33000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-656" unitRef="usd">-282000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-657">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The effective tax rate of our provision for income taxes differs from the federal statutory rate as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.660%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-deductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(23.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="INF" id="f-658" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-6" decimals="INF" id="f-659" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="3" id="f-660" unitRef="number">0.022</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-6" decimals="3" id="f-661" unitRef="number">0.043</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-1" decimals="3" id="f-662" unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-6" decimals="3" id="f-663" unitRef="number">-0.015</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="3" id="f-664" unitRef="number">-0.034</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-6" decimals="3" id="f-665" unitRef="number">-0.014</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c-1" decimals="3" id="f-666" unitRef="number">-0.014</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c-6" decimals="3" id="f-667" unitRef="number">-0.009</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="3" id="f-668" unitRef="number">-0.185</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-6" decimals="3" id="f-669" unitRef="number">-0.239</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent contextRef="c-1" decimals="3" id="f-670" unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent contextRef="c-6" decimals="3" id="f-671" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-672" unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-6" decimals="3" id="f-673" unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-674">If the Company&#x2019;s judgment changes and it is determined that the Company will be able to realize these deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on deferred tax assets will be accounted for as a reduction to income tax expense.&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accruals, reserves and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalization of research and experimentation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(42,942)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(38,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basis differences in fixed and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(287)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-4" decimals="-3" id="f-675" unitRef="usd">32479000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-5" decimals="-3" id="f-676" unitRef="usd">29789000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-4" decimals="-3" id="f-677" unitRef="usd">2353000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-5" decimals="-3" id="f-678" unitRef="usd">2216000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves contextRef="c-4" decimals="-3" id="f-679" unitRef="usd">1119000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves contextRef="c-5" decimals="-3" id="f-680" unitRef="usd">349000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-4" decimals="-3" id="f-681" unitRef="usd">2547000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-5" decimals="-3" id="f-682" unitRef="usd">2236000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-4" decimals="-3" id="f-683" unitRef="usd">300000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-5" decimals="-3" id="f-684" unitRef="usd">362000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-4" decimals="-3" id="f-685" unitRef="usd">1391000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-5" decimals="-3" id="f-686" unitRef="usd">1606000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <exdx:DeferredTaxAssetsLeaseLiability contextRef="c-4" decimals="-3" id="f-687" unitRef="usd">925000</exdx:DeferredTaxAssetsLeaseLiability>
    <exdx:DeferredTaxAssetsLeaseLiability contextRef="c-5" decimals="-3" id="f-688" unitRef="usd">1374000</exdx:DeferredTaxAssetsLeaseLiability>
    <exdx:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts contextRef="c-4" decimals="-3" id="f-689" unitRef="usd">2929000</exdx:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts>
    <exdx:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts contextRef="c-5" decimals="-3" id="f-690" unitRef="usd">2047000</exdx:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-4" decimals="-3" id="f-691" unitRef="usd">44043000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-5" decimals="-3" id="f-692" unitRef="usd">39979000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-4" decimals="-3" id="f-693" unitRef="usd">42942000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-3" id="f-694" unitRef="usd">38567000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-4" decimals="-3" id="f-695" unitRef="usd">1101000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-5" decimals="-3" id="f-696" unitRef="usd">1412000</us-gaap:DeferredTaxAssetsNet>
    <exdx:DeferredTaxLiabilitiesRightOfUseAssets contextRef="c-4" decimals="-3" id="f-697" unitRef="usd">814000</exdx:DeferredTaxLiabilitiesRightOfUseAssets>
    <exdx:DeferredTaxLiabilitiesRightOfUseAssets contextRef="c-5" decimals="-3" id="f-698" unitRef="usd">1206000</exdx:DeferredTaxLiabilitiesRightOfUseAssets>
    <exdx:DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets contextRef="c-4" decimals="-3" id="f-699" unitRef="usd">287000</exdx:DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets>
    <exdx:DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets contextRef="c-5" decimals="-3" id="f-700" unitRef="usd">206000</exdx:DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-4" decimals="-3" id="f-701" unitRef="usd">1101000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-5" decimals="-3" id="f-702" unitRef="usd">1412000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-4" decimals="-3" id="f-703" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-5" decimals="-3" id="f-704" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:SummaryOfValuationAllowanceTextBlock contextRef="c-1" id="f-705">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Changes in the valuation allowance for deferred tax assets during the years ended December&#160;31, 2023 and 2022, which related primarily to increases in net operating loss (NOL) carryforwards, research and development tax credits, capitalization of research and experimentation costs, and impairment of goodwill were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Valuation allowance at the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Increases recorded to income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Valuation allowance at the end of the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-3" id="f-706" unitRef="usd">38567000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-10" decimals="-3" id="f-707" unitRef="usd">27158000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-1" decimals="-3" id="f-708" unitRef="usd">4375000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-6" decimals="-3" id="f-709" unitRef="usd">11409000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-4" decimals="-3" id="f-710" unitRef="usd">42942000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-3" id="f-711" unitRef="usd">38567000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="c-4" decimals="-5" id="f-712" unitRef="usd">129800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="c-5" decimals="-5" id="f-713" unitRef="usd">118400000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="c-4" decimals="-5" id="f-714" unitRef="usd">91000000.0</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="c-5" decimals="-5" id="f-715" unitRef="usd">87000000.0</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c-4" decimals="-5" id="f-716" unitRef="usd">43500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration contextRef="c-4" decimals="-5" id="f-717" unitRef="usd">86300000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c-140" decimals="-5" id="f-718" unitRef="usd">61100000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-4" decimals="INF" id="f-719" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-5" decimals="INF" id="f-720" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="c-1" id="f-721">401(k) Plan&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company sponsors an employee savings plan that qualifies as a deferred salary arrangement under Section 401(k) of the Code. Participating employees may defer up to the Internal Revenue Service annual contribution limit. Additionally, the Company may elect to make contributions into the savings plan at its sole discretion. For each of the years ended December&#160;31, 2023 and 2022, the Company made contributions to the 401(k) Plan at 4% of qualified employee compensation. For the years ended December&#160;31, 2023 and 2022, these contributions totaled approximately $0.8 million and $0.9 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent contextRef="c-1" decimals="2" id="f-722" unitRef="number">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-1" decimals="-5" id="f-723" unitRef="usd">800000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-6" decimals="-5" id="f-724" unitRef="usd">900000</us-gaap:DefinedContributionPlanCostRecognized>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
